#0
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	previously	O	['N']	[6]
7	healthy	O	['N']	[7]
8	,	O	['N']	[8]
9	postmenopausal	O	['N']	[9]
10	woman	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	anticonvulsant	B	['N']	[13]
14	hypersensitivity	I	['N']	[14]
15	syndrome	I-Adverse_Effect	['N']	[15]
16	while	O	['N']	[16]
17	taking	O	['N']	[17]
18	Bellamine	O	['N']	[18]
19	S	O	['N']	[19]
20	(	O	['N']	[20]
21	belladonna	O	['N']	[21]
22	alkaloids	O	['N']	[22]
23	;	O	['N']	[23]
24	ergotamine	O	['N']	[24]
25	;	O	['N']	[25]
26	phenobarbital	B-Drug	['Causes']	[15]
27	)	O	['N']	[27]
28	for	O	['N']	[28]
29	hot	O	['N']	[29]
30	flashes	O	['N']	[30]
31	.	O	['N']	[31]
#1
0	It	O	['N']	[0]
1	was	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	potassium	O	['N']	[4]
5	loss	O	['N']	[5]
6	occurred	O	['N']	[6]
7	by	O	['N']	[7]
8	a	O	['N']	[8]
9	non	O	['N']	[9]
10	-	O	['N']	[10]
11	renal	O	['N']	[11]
12	(	O	['N']	[12]
13	intestinal	O	['N']	[13]
14	)	O	['N']	[14]
15	route	O	['N']	[15]
16	in	O	['N']	[16]
17	phosphate	B-Drug	['Causes']	[20]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	hypokalemia	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#2
0	Atenolol	B-Drug	['Causes']	[3]
1	induced	O	['N']	[1]
2	memory	B	['N']	[2]
3	impairment	I-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	.	O	['N']	[8]
#3
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	acute	O	['N']	[2]
3	cardiomyopathy	O	['N']	[3]
4	and	O	['N']	[4]
5	pericarditis	B-Adverse_Effect	['N']	[5]
6	secondary	O	['N']	[6]
7	to	O	['N']	[7]
8	methylphenidate	B-Drug	['Causes']	[5]
9	use	O	['N']	[9]
10	has	O	['N']	[10]
11	been	O	['N']	[11]
12	rarely	O	['N']	[12]
13	reported	O	['N']	[13]
14	.	O	['N']	[14]
#4
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	highlights	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	drug	O	['N']	[6]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	dysphagia	B-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	receiving	O	['N']	[13]
14	haloperidol	B-Drug	['Causes']	[9]
15	for	O	['N']	[15]
16	obsessive	O	['N']	[16]
17	nocturnal	O	['N']	[17]
18	thoughts	O	['N']	[18]
19	and	O	['N']	[19]
20	auditory	O	['N']	[20]
21	disturbances	O	['N']	[21]
22	.	O	['N']	[22]
#5
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	Balint	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	with	O	['N']	[8]
9	irreversible	O	['N']	[9]
10	posterior	B	['N']	[10]
11	leukoencephalopathy	I-Adverse_Effect	['N']	[11]
12	on	O	['N']	[12]
13	MRI	O	['N']	[13]
14	following	O	['N']	[14]
15	intrathecal	O	['N']	[15]
16	methotrexate	O	['N']	[16]
17	and	O	['N']	[17]
18	cytarabine	B-Drug	['Causes']	[11]
19	.	O	['N']	[19]
#6
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	demonstrates	O	['N']	[2]
3	the	O	['N']	[3]
4	association	O	['N']	[4]
5	of	O	['N']	[5]
6	selective	O	['N']	[6]
7	IgA	B	['N']	[7]
8	deficiency	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	remission	O	['N']	[10]
11	in	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	induced	O	['N']	[14]
15	by	O	['N']	[15]
16	fenclofenac	O	['N']	[16]
17	as	O	['N']	[17]
18	well	O	['N']	[18]
19	as	O	['N']	[19]
20	aurothiomalate	B-Drug	['Causes']	[8]
21	and	O	['N']	[21]
22	sulphasalazine	O	['N']	[22]
23	.	O	['N']	[23]
#7
0	Two	O	['N']	[0]
1	heroin	B-Drug	['Causes']	[12]
2	addicts	O	['N']	[2]
3	,	O	['N']	[3]
4	aged	O	['N']	[4]
5	34	O	['N']	[5]
6	and	O	['N']	[6]
7	19	O	['N']	[7]
8	years	O	['N']	[8]
9	,	O	['N']	[9]
10	developed	O	['N']	[10]
11	ballistic	B	['N']	[11]
12	movements	I-Adverse_Effect	['N']	[12]
13	after	O	['N']	[13]
14	intravenous	O	['N']	[14]
15	heroin	O	['N']	[15]
16	overdose	O	['N']	[16]
17	.	O	['N']	[17]
#8
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	cutaneous	O	['N']	[5]
6	lupus	O	['N']	[6]
7	erythematosus	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	severe	O	['N']	[10]
11	dapsone	B-Drug	['Dosage']	[14]
12	reaction	O	['N']	[12]
13	after	O	['N']	[13]
14	low	B-Dose	['N']	[14]
15	dose	O	['N']	[15]
16	therapy	O	['N']	[16]
17	,	O	['N']	[17]
18	with	O	['N']	[18]
19	a	O	['N']	[19]
20	fatal	O	['N']	[20]
21	outcome	O	['N']	[21]
22	in	O	['N']	[22]
23	one	O	['N']	[23]
24	.	O	['N']	[24]
#9
0	Listeria	B	['N']	[0]
1	brain	I	['N']	[1]
2	abscess	I-Adverse_Effect	['N']	[2]
3	,	O	['N']	[3]
4	Pneumocystis	O	['N']	[4]
5	pneumonia	O	['N']	[5]
6	and	O	['N']	[6]
7	Kaposi	O	['N']	[7]
8	's	O	['N']	[8]
9	sarcoma	O	['N']	[9]
10	after	O	['N']	[10]
11	temozolomide	B-Drug	['Causes']	[2]
12	.	O	['N']	[12]
#10
0	Stevens	B	['N']	[0]
1	-	I	['N']	[1]
2	Johnson	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	boy	O	['N']	[6]
7	with	O	['N']	[7]
8	nephrotic	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	during	O	['N']	[10]
11	prednisolone	B-Drug	['Causes']	[3]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#11
0	Life	O	['N']	[0]
1	-	O	['N']	[1]
2	threatening	O	['N']	[2]
3	acute	B	['N']	[3]
4	hyponatraemia	I-Adverse_Effect	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	low	O	['N']	[7]
8	dose	O	['N']	[8]
9	cyclophosphamide	O	['N']	[9]
10	and	O	['N']	[10]
11	indomethacin	B-Drug	['Causes']	[4]
12	.	O	['N']	[12]
#12
0	Peripheral	B	['N']	[0]
1	neuropathy	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	cerebellar	O	['N']	[3]
4	syndrome	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	amiodarone	B-Drug	['Causes']	[1]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#13
0	A	O	['N']	[0]
1	56-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	scleroderma	O	['N']	[6]
7	developed	O	['N']	[7]
8	rapidly	O	['N']	[8]
9	progressive	O	['N']	[9]
10	glomerulonephritis	O	['N']	[10]
11	with	O	['N']	[11]
12	epithelial	O	['N']	[12]
13	crescents	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	hemoptysis	B-Adverse_Effect	['N']	[16]
17	after	O	['N']	[17]
18	27	O	['N']	[18]
19	months	O	['N']	[19]
20	of	O	['N']	[20]
21	D	B	['N']	[21]
22	-	I	['N']	[22]
23	penicillamine	I-Drug	['Causes']	[16]
24	therapy	O	['N']	[24]
25	and	O	['N']	[25]
26	a	O	['N']	[26]
27	cumulative	O	['N']	[27]
28	dose	O	['N']	[28]
29	of	O	['N']	[29]
30	1,200	O	['N']	[30]
31	g.	O	['N']	[31]
#14
0	Until	O	['N']	[0]
1	additional	O	['N']	[1]
2	data	O	['N']	[2]
3	are	O	['N']	[3]
4	available	O	['N']	[4]
5	,	O	['N']	[5]
6	if	O	['N']	[6]
7	intravenous	O	['N']	[7]
8	acyclovir	O	['N']	[8]
9	is	O	['N']	[9]
10	administered	O	['N']	[10]
11	concurrently	O	['N']	[11]
12	with	O	['N']	[12]
13	lithium	B-Drug	['Causes']	[24]
14	,	O	['N']	[14]
15	we	O	['N']	[15]
16	recommend	O	['N']	[16]
17	closely	O	['N']	[17]
18	monitoring	O	['N']	[18]
19	patients	O	['N']	[19]
20	for	O	['N']	[20]
21	signs	O	['N']	[21]
22	of	O	['N']	[22]
23	lithium	B	['N']	[23]
24	toxicity	I-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	measuring	O	['N']	[26]
27	serum	O	['N']	[27]
28	lithium	O	['N']	[28]
29	levels	O	['N']	[29]
30	every	O	['N']	[30]
31	second	O	['N']	[31]
32	or	O	['N']	[32]
33	third	O	['N']	[33]
34	day	O	['N']	[34]
35	.	O	['N']	[35]
#15
0	Fluoxetine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	akathisia	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	clinical	O	['N']	[5]
6	and	O	['N']	[6]
7	theoretical	O	['N']	[7]
8	implications	O	['N']	[8]
9	.	O	['N']	[9]
#16
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Infectious	B	['N']	[2]
3	endophthalmitis	I-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	potential	O	['N']	[6]
7	complication	O	['N']	[7]
8	of	O	['N']	[8]
9	intravitreal	O	['N']	[9]
10	bevacizumab	B-Drug	['Causes']	[3]
11	injection	O	['N']	[11]
12	.	O	['N']	[12]
#17
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	thought	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	clinico	O	['N']	[5]
6	-	O	['N']	[6]
7	pathological	O	['N']	[7]
8	features	O	['N']	[8]
9	and	O	['N']	[9]
10	chronology	O	['N']	[10]
11	of	O	['N']	[11]
12	this	O	['N']	[12]
13	case	O	['N']	[13]
14	bore	O	['N']	[14]
15	the	O	['N']	[15]
16	hallmarks	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	so	O	['N']	[19]
20	-	O	['N']	[20]
21	called	O	['N']	[21]
22	"	O	['N']	[22]
23	3-week	O	['N']	[23]
24	sulphasalazine	B-Drug	['Causes']	[33]
25	syndrome	O	['N']	[25]
26	"	O	['N']	[26]
27	,	O	['N']	[27]
28	a	O	['N']	[28]
29	rare	O	['N']	[29]
30	,	O	['N']	[30]
31	but	O	['N']	[31]
32	often	O	['N']	[32]
33	fatal	B-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	immunoallergic	O	['N']	[35]
36	reaction	O	['N']	[36]
37	to	O	['N']	[37]
38	sulphasalazine	O	['N']	[38]
39	.	O	['N']	[39]
#18
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	lepromatous	O	['N']	[3]
4	leprosy	O	['N']	[4]
5	with	O	['N']	[5]
6	erythema	O	['N']	[6]
7	nodosum	O	['N']	[7]
8	leprosum	O	['N']	[8]
9	who	O	['N']	[9]
10	were	O	['N']	[10]
11	on	O	['N']	[11]
12	high	O	['N']	[12]
13	doses	O	['N']	[13]
14	of	O	['N']	[14]
15	clofazimine	B-Drug	['Causes']	[24]
16	,	O	['N']	[16]
17	showed	O	['N']	[17]
18	discoloration	O	['N']	[18]
19	of	O	['N']	[19]
20	nail	O	['N']	[20]
21	plate	O	['N']	[21]
22	,	O	['N']	[22]
23	subungual	B	['N']	[23]
24	hyperkeratosis	I-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	onycholysis	O	['N']	[26]
27	.	O	['N']	[27]
#19
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	additional	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	isotretinoin	B-Drug	['Causes']	[31]
7	teratogenicity	O	['N']	[7]
8	in	O	['N']	[8]
9	which	O	['N']	[9]
10	the	O	['N']	[10]
11	patient	O	['N']	[11]
12	had	O	['N']	[12]
13	agenesis	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	cerebellar	O	['N']	[16]
17	vermis	O	['N']	[17]
18	,	O	['N']	[18]
19	multiple	O	['N']	[19]
20	leptomeningeal	O	['N']	[20]
21	neuroglial	O	['N']	[21]
22	heterotopias	O	['N']	[22]
23	,	O	['N']	[23]
24	hydrocephalus	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	abnormalities	B	['N']	[27]
28	of	I	['N']	[28]
29	the	I	['N']	[29]
30	corticospinal	I	['N']	[30]
31	tracts	I-Adverse_Effect	['N']	[31]
32	.	O	['N']	[32]
#20
0	Cyclosporine	B-Drug	['Causes']	[16]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	potent	O	['N']	[3]
4	inhibitor	O	['N']	[4]
5	of	O	['N']	[5]
6	simvastatin	O	['N']	[6]
7	metabolism	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	may	O	['N']	[10]
11	therefore	O	['N']	[11]
12	facilitate	O	['N']	[12]
13	simvastatin	O	['N']	[13]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	rhabdomyolysis	B-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#21
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	B	['N']	[19]
20	anti	I	['N']	[20]
21	-	I	['N']	[21]
22	nuclear	I	['N']	[22]
23	antibody	I-Adverse_Effect	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	O	['N']	[32]
33	(	O	['N']	[33]
34	CBZ	B-Drug	['Causes']	[23]
35	;	O	['N']	[35]
36	Tegretol	O	['N']	[36]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#22
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	thought	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	clinico	O	['N']	[5]
6	-	O	['N']	[6]
7	pathological	O	['N']	[7]
8	features	O	['N']	[8]
9	and	O	['N']	[9]
10	chronology	O	['N']	[10]
11	of	O	['N']	[11]
12	this	O	['N']	[12]
13	case	O	['N']	[13]
14	bore	O	['N']	[14]
15	the	O	['N']	[15]
16	hallmarks	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	so	O	['N']	[19]
20	-	O	['N']	[20]
21	called	O	['N']	[21]
22	"	O	['N']	[22]
23	3-week	O	['N']	[23]
24	sulphasalazine	B-Drug	['Causes']	[36]
25	syndrome	O	['N']	[25]
26	"	O	['N']	[26]
27	,	O	['N']	[27]
28	a	O	['N']	[28]
29	rare	O	['N']	[29]
30	,	O	['N']	[30]
31	but	O	['N']	[31]
32	often	O	['N']	[32]
33	fatal	O	['N']	[33]
34	,	O	['N']	[34]
35	immunoallergic	B	['N']	[35]
36	reaction	I-Adverse_Effect	['N']	[36]
37	to	O	['N']	[37]
38	sulphasalazine	O	['N']	[38]
39	.	O	['N']	[39]
#23
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	report	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	acute	B	['N']	[8]
9	severe	I	['N']	[9]
10	hepatitis	I-Adverse_Effect	['N']	[10]
11	resulting	O	['N']	[11]
12	from	O	['N']	[12]
13	erlotinib	B-Drug	['Causes']	[10]
14	monotherapy	O	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	locally	O	['N']	[19]
20	advanced	O	['N']	[20]
21	pancreatic	O	['N']	[21]
22	cancer	O	['N']	[22]
23	.	O	['N']	[23]
#24
0	In	O	['N']	[0]
1	our	O	['N']	[1]
2	patient	O	['N']	[2]
3	,	O	['N']	[3]
4	DIAN	B-Adverse_Effect	['N']	[4]
5	possibly	O	['N']	[5]
6	was	O	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	cefuroxime	B-Drug	['Causes']	[4]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	the	O	['N']	[12]
13	patient	O	['N']	[13]
14	did	O	['N']	[14]
15	not	O	['N']	[15]
16	experience	O	['N']	[16]
17	associated	O	['N']	[17]
18	allergic	O	['N']	[18]
19	symptoms	O	['N']	[19]
20	.	O	['N']	[20]
#25
0	Atrial	B	['N']	[0]
1	fibrillation	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	vardenafil	B-Drug	['Causes']	[1]
4	therapy	O	['N']	[4]
5	.	O	['N']	[5]
#26
0	Sixteen	O	['N']	[0]
1	of	O	['N']	[1]
2	33	O	['N']	[2]
3	patients	O	['N']	[3]
4	developed	O	['N']	[4]
5	significant	O	['N']	[5]
6	hyponatremia	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	hypoosmolality	O	['N']	[8]
9	during	O	['N']	[9]
10	oral	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	lorcainide	B-Drug	['Causes']	[6]
14	.	O	['N']	[14]
#27
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	child	O	['N']	[4]
5	with	O	['N']	[5]
6	fatal	B-Adverse_Effect	['N']	[6]
7	valproate	B-Drug	['Causes']	[6]
8	-	O	['N']	[8]
9	related	O	['N']	[9]
10	hepatotoxic	O	['N']	[10]
11	effects	O	['N']	[11]
12	despite	O	['N']	[12]
13	this	O	['N']	[13]
14	supplementation	O	['N']	[14]
15	.	O	['N']	[15]
#28
0	Cefuroxime	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	acute	B	['N']	[3]
4	renal	I	['N']	[4]
5	failure	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#29
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Replacing	O	['N']	[2]
3	valproate	B-Drug	['Causes']	[12]
4	with	O	['N']	[4]
5	lamotrigine	O	['N']	[5]
6	resulted	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	decrease	O	['N']	[9]
10	in	O	['N']	[10]
11	serum	B	['N']	[11]
12	testosterone	I-Adverse_Effect	['N']	[12]
13	concentrations	O	['N']	[13]
14	in	O	['N']	[14]
15	all	O	['N']	[15]
16	3	O	['N']	[16]
17	women	O	['N']	[17]
18	.	O	['N']	[18]
#30
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	four	O	['N']	[2]
3	cases	O	['N']	[3]
4	in	O	['N']	[4]
5	which	O	['N']	[5]
6	the	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	heparin	B-Drug	['Causes']	[13]
10	was	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	hyperkalemia	B-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	discuss	O	['N']	[15]
16	the	O	['N']	[16]
17	pathophysiology	O	['N']	[17]
18	.	O	['N']	[18]
#31
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	the	O	['N']	[3]
4	first	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	insulin	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	cardiac	B	['N']	[10]
11	failure	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	patient	O	['N']	[14]
15	without	O	['N']	[15]
16	underlying	O	['N']	[16]
17	heart	O	['N']	[17]
18	disease	O	['N']	[18]
19	.	O	['N']	[19]
#32
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	simultaneous	O	['N']	[4]
5	administration	O	['N']	[5]
6	of	O	['N']	[6]
7	ciprofloxacin	B-Drug	['Causes']	[15]
8	and	O	['N']	[8]
9	tazobactam	O	['N']	[9]
10	/	O	['N']	[10]
11	piperacillin	O	['N']	[11]
12	may	O	['N']	[12]
13	cause	O	['N']	[13]
14	marked	O	['N']	[14]
15	thrombocytosis	B-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#33
0	Severe	O	['N']	[0]
1	rhabdomyolysis	O	['N']	[1]
2	following	O	['N']	[2]
3	massive	O	['N']	[3]
4	ingestion	O	['N']	[4]
5	of	O	['N']	[5]
6	oolong	B	['N']	[6]
7	tea	I-Drug	['Causes']	[10]
8	:	O	['N']	[8]
9	caffeine	B	['N']	[9]
10	intoxication	I-Adverse_Effect	['N']	[10]
11	with	O	['N']	[11]
12	coexisting	O	['N']	[12]
13	hyponatremia	O	['N']	[13]
14	.	O	['N']	[14]
#34
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Stevens	O	['N']	[5]
6	-	O	['N']	[6]
7	Johnson	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	/	O	['N']	[9]
10	toxic	O	['N']	[10]
11	epidermal	O	['N']	[11]
12	necrolysis	O	['N']	[12]
13	(	O	['N']	[13]
14	SJS	O	['N']	[14]
15	/	O	['N']	[15]
16	TEN	B-Adverse_Effect	['N']	[16]
17	)	O	['N']	[17]
18	secondary	O	['N']	[18]
19	to	O	['N']	[19]
20	trimethoprim	O	['N']	[20]
21	-	O	['N']	[21]
22	sulfamethoxazole	O	['N']	[22]
23	(	O	['N']	[23]
24	TMP	B	['N']	[24]
25	-	I	['N']	[25]
26	Sx	I-Drug	['Causes']	[16]
27	)	O	['N']	[27]
28	therapy	O	['N']	[28]
29	for	O	['N']	[29]
30	presumed	O	['N']	[30]
31	community	O	['N']	[31]
32	-	O	['N']	[32]
33	associated	O	['N']	[33]
34	methicillin	O	['N']	[34]
35	-	O	['N']	[35]
36	resistant	O	['N']	[36]
37	Staphylococcus	O	['N']	[37]
38	aureus	O	['N']	[38]
39	(	O	['N']	[39]
40	CA	O	['N']	[40]
41	-	O	['N']	[41]
42	MRSA	O	['N']	[42]
43	)	O	['N']	[43]
44	infection	O	['N']	[44]
45	.	O	['N']	[45]
#35
0	Prominent	O	['N']	[0]
1	positive	B	['N']	[1]
2	U	I	['N']	[2]
3	waves	I-Adverse_Effect	['N']	[3]
4	appearing	O	['N']	[4]
5	with	O	['N']	[5]
6	high	O	['N']	[6]
7	-	O	['N']	[7]
8	dose	O	['N']	[8]
9	intravenous	O	['N']	[9]
10	phenylephrine	B-Drug	['Causes']	[3]
11	.	O	['N']	[11]
#36
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	B-Drug	['Causes']	[29]
3	(	O	['N']	[3]
4	SR	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	B-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	O	['N']	[34]
35	.	O	['N']	[35]
#37
0	Iatrogenic	O	['N']	[0]
1	hypercalcemia	B-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	vitamin	B	['N']	[4]
5	D3	I-Drug	['Causes']	[1]
6	ointment	O	['N']	[6]
7	(	O	['N']	[7]
8	1,24(OH)2D3	O	['N']	[8]
9	)	O	['N']	[9]
10	combined	O	['N']	[10]
11	with	O	['N']	[11]
12	thiazide	O	['N']	[12]
13	diuretics	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	case	O	['N']	[16]
17	of	O	['N']	[17]
18	psoriasis	O	['N']	[18]
19	.	O	['N']	[19]
#38
0	ARDS	O	['N']	[0]
1	is	O	['N']	[1]
2	rarely	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	rituximab	B-Drug	['Causes']	[30]
6	infusion	O	['N']	[6]
7	for	O	['N']	[7]
8	lympho	O	['N']	[8]
9	-	O	['N']	[9]
10	proliferative	O	['N']	[10]
11	disorders	O	['N']	[11]
12	,	O	['N']	[12]
13	but	O	['N']	[13]
14	it	O	['N']	[14]
15	should	O	['N']	[15]
16	be	O	['N']	[16]
17	considered	O	['N']	[17]
18	by	O	['N']	[18]
19	those	O	['N']	[19]
20	administering	O	['N']	[20]
21	rituximab	O	['N']	[21]
22	,	O	['N']	[22]
23	especially	O	['N']	[23]
24	when	O	['N']	[24]
25	a	O	['N']	[25]
26	patient	O	['N']	[26]
27	develops	O	['N']	[27]
28	severe	B	['N']	[28]
29	pulmonary	I	['N']	[29]
30	symptoms	I-Adverse_Effect	['N']	[30]
31	soon	O	['N']	[31]
32	after	O	['N']	[32]
33	infusion	O	['N']	[33]
34	.	O	['N']	[34]
#39
0	Leukaemoid	B	['N']	[0]
1	monocytosis	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	M4	O	['N']	[3]
4	AML	O	['N']	[4]
5	following	O	['N']	[5]
6	chemotherapy	O	['N']	[6]
7	and	O	['N']	[7]
8	G	B	['N']	[8]
9	-	I	['N']	[9]
10	CSF	I-Drug	['Causes']	[1]
11	.	O	['N']	[11]
#40
0	The	O	['N']	[0]
1	reported	O	['N']	[1]
2	cases	O	['N']	[2]
3	of	O	['N']	[3]
4	in	O	['N']	[4]
5	utero	O	['N']	[5]
6	exposure	O	['N']	[6]
7	to	O	['N']	[7]
8	cyclosposphamide	B-Drug	['Causes']	[37]
9	shared	O	['N']	[9]
10	the	O	['N']	[10]
11	following	O	['N']	[11]
12	manifestations	O	['N']	[12]
13	with	O	['N']	[13]
14	our	O	['N']	[14]
15	patient	O	['N']	[15]
16	:	O	['N']	[16]
17	growth	O	['N']	[17]
18	deficiency	O	['N']	[18]
19	,	O	['N']	[19]
20	developmental	O	['N']	[20]
21	delay	O	['N']	[21]
22	,	O	['N']	[22]
23	craniosynostosis	O	['N']	[23]
24	,	O	['N']	[24]
25	blepharophimosis	O	['N']	[25]
26	,	O	['N']	[26]
27	flat	O	['N']	[27]
28	nasal	O	['N']	[28]
29	bridge	O	['N']	[29]
30	,	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	ears	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	distal	B	['N']	[35]
36	limb	I	['N']	[36]
37	defects	I-Adverse_Effect	['N']	[37]
38	including	O	['N']	[38]
39	hypoplastic	O	['N']	[39]
40	thumbs	O	['N']	[40]
41	and	O	['N']	[41]
42	oligodactyly	O	['N']	[42]
43	.	O	['N']	[43]
#41
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	other	O	['N']	[2]
3	factors	O	['N']	[3]
4	or	O	['N']	[4]
5	drugs	O	['N']	[5]
6	(	O	['N']	[6]
7	e.g.	O	['N']	[7]
8	cresol	B-Drug	['Causes']	[14]
9	)	O	['N']	[9]
10	are	O	['N']	[10]
11	thought	O	['N']	[11]
12	to	O	['N']	[12]
13	induce	O	['N']	[13]
14	MH	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#42
0	Within	O	['N']	[0]
1	3	O	['N']	[1]
2	weeks	O	['N']	[2]
3	of	O	['N']	[3]
4	beginning	O	['N']	[4]
5	continuous	O	['N']	[5]
6	daily	O	['N']	[6]
7	isoniazid	B-Drug	['Causes']	[20]
8	and	O	['N']	[8]
9	rifampin	O	['N']	[9]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	pulmonary	O	['N']	[12]
13	tuberculosis	O	['N']	[13]
14	,	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	developed	O	['N']	[17]
18	acute	B	['N']	[18]
19	renal	I	['N']	[19]
20	failure	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#43
0	Although	O	['N']	[0]
1	vasculitis	B-Adverse_Effect	['N']	[1]
2	has	O	['N']	[2]
3	been	O	['N']	[3]
4	reported	O	['N']	[4]
5	in	O	['N']	[5]
6	the	O	['N']	[6]
7	course	O	['N']	[7]
8	of	O	['N']	[8]
9	hairy	O	['N']	[9]
10	cell	O	['N']	[10]
11	leukaemia	O	['N']	[11]
12	,	O	['N']	[12]
13	it	O	['N']	[13]
14	has	O	['N']	[14]
15	only	O	['N']	[15]
16	rarely	O	['N']	[16]
17	been	O	['N']	[17]
18	reported	O	['N']	[18]
19	as	O	['N']	[19]
20	the	O	['N']	[20]
21	consequence	O	['N']	[21]
22	of	O	['N']	[22]
23	cladribine	B-Drug	['Causes']	[1]
24	treatment	O	['N']	[24]
25	.	O	['N']	[25]
#44
0	Recurrent	B	['N']	[0]
1	hyponatremia	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	citalopram	B-Drug	['Causes']	[1]
5	and	O	['N']	[5]
6	mirtazapine	O	['N']	[6]
7	.	O	['N']	[7]
#45
0	After	O	['N']	[0]
1	taking	O	['N']	[1]
2	cholestyramine	B	['N']	[2]
3	II	I-Drug	['Causes']	[13]
4	sachets	O	['N']	[4]
5	twice	O	['N']	[5]
6	daily	O	['N']	[6]
7	for	O	['N']	[7]
8	two	O	['N']	[8]
9	months	O	['N']	[9]
10	she	O	['N']	[10]
11	presented	O	['N']	[11]
12	with	O	['N']	[12]
13	lethargy	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	confusion	O	['N']	[15]
16	and	O	['N']	[16]
17	drowsiness	O	['N']	[17]
18	.	O	['N']	[18]
#46
0	An	O	['N']	[0]
1	objective	O	['N']	[1]
2	causality	O	['N']	[2]
3	assessment	O	['N']	[3]
4	suggests	O	['N']	[4]
5	that	O	['N']	[5]
6	the	O	['N']	[6]
7	JHR	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	our	O	['N']	[9]
10	patient	O	['N']	[10]
11	was	O	['N']	[11]
12	probably	O	['N']	[12]
13	related	O	['N']	[13]
14	to	O	['N']	[14]
15	penicillin	B-Drug	['Causes']	[7]
16	.	O	['N']	[16]
#47
0	During	O	['N']	[0]
1	her	O	['N']	[1]
2	third	O	['N']	[2]
3	cycle	O	['N']	[3]
4	,	O	['N']	[4]
5	she	O	['N']	[5]
6	again	O	['N']	[6]
7	received	O	['N']	[7]
8	cisplatin	B-Drug	['Causes']	[21]
9	100	O	['N']	[9]
10	mg	O	['N']	[10]
11	/	O	['N']	[11]
12	m2	O	['N']	[12]
13	over	O	['N']	[13]
14	30	O	['N']	[14]
15	minutes	O	['N']	[15]
16	and	O	['N']	[16]
17	developed	O	['N']	[17]
18	palmar	O	['N']	[18]
19	pruritus	O	['N']	[19]
20	,	O	['N']	[20]
21	urticaria	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	edema	O	['N']	[24]
25	.	O	['N']	[25]
#48
0	Ciprofloxacin	O	['N']	[0]
1	is	O	['N']	[1]
2	among	O	['N']	[2]
3	the	O	['N']	[3]
4	standard	O	['N']	[4]
5	treatments	O	['N']	[5]
6	for	O	['N']	[6]
7	infected	O	['N']	[7]
8	ischemic	O	['N']	[8]
9	ulcers	O	['N']	[9]
10	;	O	['N']	[10]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	rare	O	['N']	[13]
14	case	O	['N']	[14]
15	of	O	['N']	[15]
16	ciprofloxacin	B-Drug	['Causes']	[20]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	hemorrhagic	B	['N']	[19]
20	vasculitis	I-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	it	O	['N']	[22]
23	might	O	['N']	[23]
24	be	O	['N']	[24]
25	interpreted	O	['N']	[25]
26	as	O	['N']	[26]
27	progression	O	['N']	[27]
28	of	O	['N']	[28]
29	infection	O	['N']	[29]
30	,	O	['N']	[30]
31	instead	O	['N']	[31]
32	of	O	['N']	[32]
33	a	O	['N']	[33]
34	complication	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	treatment	O	['N']	[37]
38	,	O	['N']	[38]
39	thus	O	['N']	[39]
40	leading	O	['N']	[40]
41	to	O	['N']	[41]
42	faulty	O	['N']	[42]
43	diagnosis	O	['N']	[43]
44	and	O	['N']	[44]
45	treatment	O	['N']	[45]
46	.	O	['N']	[46]
#49
0	High	O	['N']	[0]
1	-	O	['N']	[1]
2	dose	O	['N']	[2]
3	methotrexate	B-Drug	['Causes']	[8]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	acute	B	['N']	[6]
7	renal	I	['N']	[7]
8	failure	I-Adverse_Effect	['N']	[8]
9	may	O	['N']	[9]
10	be	O	['N']	[10]
11	an	O	['N']	[11]
12	avoidable	O	['N']	[12]
13	complication	O	['N']	[13]
14	.	O	['N']	[14]
#50
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	third	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	6-week	O	['N']	[7]
8	-	O	['N']	[8]
9	old	O	['N']	[9]
10	infant	O	['N']	[10]
11	with	O	['N']	[11]
12	Escherichia	O	['N']	[12]
13	coli	O	['N']	[13]
14	sepsis	O	['N']	[14]
15	who	O	['N']	[15]
16	received	O	['N']	[16]
17	ampicillin	B-Drug	['Causes']	[24]
18	and	O	['N']	[18]
19	other	O	['N']	[19]
20	antibiotics	O	['N']	[20]
21	and	O	['N']	[21]
22	subsequently	O	['N']	[22]
23	developed	O	['N']	[23]
24	TEN	B-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#51
0	The	O	['N']	[0]
1	association	O	['N']	[1]
2	between	O	['N']	[2]
3	heparin	B-Drug	['Causes']	[12]
4	and	O	['N']	[4]
5	priapism	O	['N']	[5]
6	is	O	['N']	[6]
7	often	O	['N']	[7]
8	recognized	O	['N']	[8]
9	;	O	['N']	[9]
10	abnormal	B	['N']	[10]
11	platelet	I	['N']	[11]
12	aggregation	I-Adverse_Effect	['N']	[12]
13	could	O	['N']	[13]
14	play	O	['N']	[14]
15	a	O	['N']	[15]
16	role	O	['N']	[16]
17	in	O	['N']	[17]
18	the	O	['N']	[18]
19	pathogenesis	O	['N']	[19]
20	of	O	['N']	[20]
21	this	O	['N']	[21]
22	side	O	['N']	[22]
23	effect	O	['N']	[23]
24	.	O	['N']	[24]
#52
0	Thalidomide	B-Drug	['Causes']	[13]
1	was	O	['N']	[1]
2	withdrawn	O	['N']	[2]
3	from	O	['N']	[3]
4	world	O	['N']	[4]
5	markets	O	['N']	[5]
6	in	O	['N']	[6]
7	1961	O	['N']	[7]
8	following	O	['N']	[8]
9	recognition	O	['N']	[9]
10	of	O	['N']	[10]
11	its	O	['N']	[11]
12	teratogenic	B	['N']	[12]
13	effects	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#53
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	5	O	['N']	[2]
3	patients	O	['N']	[3]
4	(	O	['N']	[4]
5	3	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	chronic	O	['N']	[8]
9	hepatitis	O	['N']	[9]
10	C	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	pegylated	B	['N']	[13]
14	interferon	I	['N']	[14]
15	alfa-2b	I-Drug	['Causes']	[33]
16	in	O	['N']	[16]
17	association	O	['N']	[17]
18	with	O	['N']	[18]
19	oral	O	['N']	[19]
20	ribavirin	O	['N']	[20]
21	and	O	['N']	[21]
22	two	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	chronic	O	['N']	[25]
26	myelocytic	O	['N']	[26]
27	leukemia	O	['N']	[27]
28	)	O	['N']	[28]
29	who	O	['N']	[29]
30	developed	O	['N']	[30]
31	local	B	['N']	[31]
32	cutaneous	I	['N']	[32]
33	reactions	I-Adverse_Effect	['N']	[33]
34	at	O	['N']	[34]
35	sites	O	['N']	[35]
36	of	O	['N']	[36]
37	injection	O	['N']	[37]
38	after	O	['N']	[38]
39	the	O	['N']	[39]
40	administration	O	['N']	[40]
41	of	O	['N']	[41]
42	weekly	O	['N']	[42]
43	subcutaneous	O	['N']	[43]
44	injections	O	['N']	[44]
45	of	O	['N']	[45]
46	pegylated	O	['N']	[46]
47	interferon	O	['N']	[47]
48	alfa-2b	O	['N']	[48]
49	at	O	['N']	[49]
50	different	O	['N']	[50]
51	doses	O	['N']	[51]
52	.	O	['N']	[52]
#54
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	niacin	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	visual	B	['N']	[6]
7	symptoms	I-Adverse_Effect	['N']	[7]
8	had	O	['N']	[8]
9	cystoid	O	['N']	[9]
10	maculopathy	O	['N']	[10]
11	without	O	['N']	[11]
12	leakage	O	['N']	[12]
13	on	O	['N']	[13]
14	fluorescein	O	['N']	[14]
15	angiography	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	fourth	O	['N']	[19]
20	patient	O	['N']	[20]
21	with	O	['N']	[21]
22	no	O	['N']	[22]
23	fundus	O	['N']	[23]
24	abnormality	O	['N']	[24]
25	experienced	O	['N']	[25]
26	cessation	O	['N']	[26]
27	of	O	['N']	[27]
28	visual	O	['N']	[28]
29	symptoms	O	['N']	[29]
30	upon	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	niacin	O	['N']	[33]
34	.	O	['N']	[34]
#55
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	60-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	erythema	O	['N']	[12]
13	and	O	['N']	[13]
14	erosions	B	['N']	[14]
15	in	I	['N']	[15]
16	the	I	['N']	[16]
17	axilla	I	['N']	[17]
18	and	I	['N']	[18]
19	groin	I-Adverse_Effect	['N']	[19]
20	while	O	['N']	[20]
21	on	O	['N']	[21]
22	PLD	B-Drug	['Causes']	[19]
23	for	O	['N']	[23]
24	breast	O	['N']	[24]
25	cancer	O	['N']	[25]
26	.	O	['N']	[26]
#56
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	fulminant	O	['N']	[6]
7	adult	O	['N']	[7]
8	respiratory	O	['N']	[8]
9	distress	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	(	O	['N']	[11]
12	ARDS	B-Adverse_Effect	['N']	[12]
13	)	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	pegylated	O	['N']	[16]
17	interferon	O	['N']	[17]
18	alpha-2a	O	['N']	[18]
19	(	O	['N']	[19]
20	pegIFNalpha-2a	O	['N']	[20]
21	)	O	['N']	[21]
22	and	O	['N']	[22]
23	ribavirin	B-Drug	['Causes']	[12]
24	use	O	['N']	[24]
25	for	O	['N']	[25]
26	hepatitis	O	['N']	[26]
27	C	O	['N']	[27]
28	,	O	['N']	[28]
29	complicated	O	['N']	[29]
30	by	O	['N']	[30]
31	subsequent	O	['N']	[31]
32	and	O	['N']	[32]
33	ultimately	O	['N']	[33]
34	fatal	O	['N']	[34]
35	sepsis	O	['N']	[35]
36	and	O	['N']	[36]
37	multiorgan	O	['N']	[37]
38	failure	O	['N']	[38]
39	.	O	['N']	[39]
#57
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	detailed	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	fulminant	B	['N']	[6]
7	hepatitis	I-Adverse_Effect	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	nevirapine	B-Drug	['Causes']	[7]
11	(	O	['N']	[11]
12	Viramune	O	['N']	[12]
13	)	O	['N']	[13]
14	and	O	['N']	[14]
15	treated	O	['N']	[15]
16	by	O	['N']	[16]
17	liver	O	['N']	[17]
18	transplantation	O	['N']	[18]
19	.	O	['N']	[19]
#58
0	Second	B	['N']	[0]
1	cancers	I-Adverse_Effect	['N']	[1]
2	including	O	['N']	[2]
3	various	O	['N']	[3]
4	types	O	['N']	[4]
5	of	O	['N']	[5]
6	hematological	O	['N']	[6]
7	malignancy	O	['N']	[7]
8	have	O	['N']	[8]
9	been	O	['N']	[9]
10	reported	O	['N']	[10]
11	in	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	hairy	O	['N']	[14]
15	cell	O	['N']	[15]
16	leukemia	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	or	O	['N']	[20]
21	interferon	B	['N']	[21]
22	alfa	I-Drug	['Causes']	[1]
23	.	O	['N']	[23]
#59
0	Heat	B	['N']	[0]
1	stroke	I	['N']	[1]
2	-	I	['N']	[2]
3	like	I	['N']	[3]
4	episode	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	child	O	['N']	[7]
8	caused	O	['N']	[8]
9	by	O	['N']	[9]
10	zonisamide	B-Drug	['Causes']	[4]
11	.	O	['N']	[11]
#60
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	needle	O	['N']	[5]
6	-	O	['N']	[6]
7	track	O	['N']	[7]
8	cutaneous	B	['N']	[8]
9	seeding	I-Adverse_Effect	['N']	[9]
10	of	O	['N']	[10]
11	hepatocellular	O	['N']	[11]
12	carcinoma	O	['N']	[12]
13	(	O	['N']	[13]
14	HCC	O	['N']	[14]
15	)	O	['N']	[15]
16	after	O	['N']	[16]
17	sonographically	O	['N']	[17]
18	guided	O	['N']	[18]
19	percutaneous	O	['N']	[19]
20	ethanol	B	['N']	[20]
21	injection	I-Drug	['Causes']	[9]
22	(	O	['N']	[22]
23	PEI	O	['N']	[23]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#61
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	myocardial	B	['N']	[3]
4	infarction	I-Adverse_Effect	['N']	[4]
5	may	O	['N']	[5]
6	develop	O	['N']	[6]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	high	O	['N']	[11]
12	-	O	['N']	[12]
13	dose	O	['N']	[13]
14	glucocorticoids	B-Drug	['Causes']	[4]
15	for	O	['N']	[15]
16	Graves	O	['N']	[16]
17	'	O	['N']	[17]
18	ophthalmopathy	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	increased	O	['N']	[21]
22	blood	O	['N']	[22]
23	pressure	O	['N']	[23]
24	may	O	['N']	[24]
25	herald	O	['N']	[25]
26	this	O	['N']	[26]
27	complication	O	['N']	[27]
28	.	O	['N']	[28]
#62
0	Sudden	B	['N']	[0]
1	death	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	an	O	['N']	[3]
4	infant	O	['N']	[4]
5	from	O	['N']	[5]
6	methemoglobinemia	O	['N']	[6]
7	after	O	['N']	[7]
8	administration	O	['N']	[8]
9	of	O	['N']	[9]
10	"	O	['N']	[10]
11	sweet	B	['N']	[11]
12	spirits	I	['N']	[12]
13	of	I	['N']	[13]
14	nitre	I-Drug	['Causes']	[1]
15	"	O	['N']	[15]
16	.	O	['N']	[16]
#63
0	Mitomycin	O	['N']	[0]
1	C	O	['N']	[1]
2	(	O	['N']	[2]
3	MMC	B-Drug	['Causes']	[21]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	an	O	['N']	[6]
7	alkylating	O	['N']	[7]
8	agent	O	['N']	[8]
9	that	O	['N']	[9]
10	has	O	['N']	[10]
11	been	O	['N']	[11]
12	recently	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	hemolytic	O	['N']	[16]
17	-	O	['N']	[17]
18	uremic	O	['N']	[18]
19	syndrome	O	['N']	[19]
20	(	O	['N']	[20]
21	HUS	B-Adverse_Effect	['N']	[21]
22	)	O	['N']	[22]
23	.	O	['N']	[23]
#64
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	acute	O	['N']	[5]
6	leukemia	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	Horner	O	['N']	[9]
10	's	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	and	O	['N']	[12]
13	a	O	['N']	[13]
14	severe	O	['N']	[14]
15	demyelinating	O	['N']	[15]
16	peripheral	O	['N']	[16]
17	neuropathy	O	['N']	[17]
18	leading	O	['N']	[18]
19	to	O	['N']	[19]
20	death	O	['N']	[20]
21	after	O	['N']	[21]
22	receiving	O	['N']	[22]
23	high	B	['N']	[23]
24	-	I	['N']	[24]
25	dose	I-Dose	['N']	[25]
26	cytosine	B	['N']	[26]
27	arabinoside	I-Drug	['Dosage']	[25]
28	.	O	['N']	[28]
#65
0	Dermatitis	B-Adverse_Effect	['N']	[0]
1	to	O	['N']	[1]
2	captopril	B-Drug	['Causes']	[0]
3	.	O	['N']	[3]
#66
0	Massive	O	['N']	[0]
1	CBZ	B-Drug	['Causes']	[11]
2	OD	O	['N']	[2]
3	may	O	['N']	[3]
4	produce	O	['N']	[4]
5	a	O	['N']	[5]
6	reversible	O	['N']	[6]
7	encephalopathy	O	['N']	[7]
8	that	O	['N']	[8]
9	includes	O	['N']	[9]
10	cortical	B	['N']	[10]
11	hyperexcitability	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	profound	O	['N']	[14]
15	burst	O	['N']	[15]
16	-	O	['N']	[16]
17	suppression	O	['N']	[17]
18	EEG	O	['N']	[18]
19	pattern	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	cranial	O	['N']	[22]
23	nerve	O	['N']	[23]
24	areflexia	O	['N']	[24]
25	.	O	['N']	[25]
#67
0	Tacrolimus	B-Drug	['Causes']	[3]
1	(	O	['N']	[1]
2	FK506)-induced	O	['N']	[2]
3	mutism	B-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	liver	O	['N']	[5]
6	transplant	O	['N']	[6]
7	.	O	['N']	[7]
#68
0	Amphotericin	B	['N']	[0]
1	B	I-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	seizures	B-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	AIDS	O	['N']	[9]
10	.	O	['N']	[10]
#69
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Patients	O	['N']	[2]
3	with	O	['N']	[3]
4	insulin	B-Drug	['Causes']	[24]
5	allergy	O	['N']	[5]
6	may	O	['N']	[6]
7	not	O	['N']	[7]
8	have	O	['N']	[8]
9	complete	O	['N']	[9]
10	resolution	O	['N']	[10]
11	of	O	['N']	[11]
12	their	O	['N']	[12]
13	symptoms	O	['N']	[13]
14	after	O	['N']	[14]
15	standard	O	['N']	[15]
16	desensitization	O	['N']	[16]
17	,	O	['N']	[17]
18	particularly	O	['N']	[18]
19	those	O	['N']	[19]
20	patients	O	['N']	[20]
21	with	O	['N']	[21]
22	concomitant	O	['N']	[22]
23	protamine	B	['N']	[23]
24	allergy	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#70
0	Systemic	B	['N']	[0]
1	lupus	I	['N']	[1]
2	erythematosus	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	penicillamine	B-Drug	['Causes']	[2]
5	therapy	O	['N']	[5]
6	for	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	.	O	['N']	[9]
#71
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	pulmonary	O	['N']	[5]
6	adenocarcinoma	O	['N']	[6]
7	complicated	O	['N']	[7]
8	by	O	['N']	[8]
9	the	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	of	O	['N']	[11]
12	inappropriate	O	['N']	[12]
13	secretion	O	['N']	[13]
14	of	O	['N']	[14]
15	antidiuretic	O	['N']	[15]
16	hormone	O	['N']	[16]
17	(	O	['N']	[17]
18	SIADH	B-Adverse_Effect	['N']	[18]
19	)	O	['N']	[19]
20	following	O	['N']	[20]
21	systemic	O	['N']	[21]
22	chemotherapy	O	['N']	[22]
23	with	O	['N']	[23]
24	cisplatin	O	['N']	[24]
25	(	O	['N']	[25]
26	CDDP	B-Drug	['Causes']	[18]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	vindesine	O	['N']	[29]
30	(	O	['N']	[30]
31	VDS	O	['N']	[31]
32	)	O	['N']	[32]
33	.	O	['N']	[33]
#72
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	patient	O	['N']	[2]
3	suffering	O	['N']	[3]
4	from	O	['N']	[4]
5	rheumatoid	O	['N']	[5]
6	arthritis	O	['N']	[6]
7	,	O	['N']	[7]
8	we	O	['N']	[8]
9	report	O	['N']	[9]
10	the	O	['N']	[10]
11	first	O	['N']	[11]
12	simultaneous	O	['N']	[12]
13	occurrence	O	['N']	[13]
14	of	O	['N']	[14]
15	two	O	['N']	[15]
16	side	O	['N']	[16]
17	effects	O	['N']	[17]
18	of	O	['N']	[18]
19	low	O	['N']	[19]
20	-	O	['N']	[20]
21	dose	O	['N']	[21]
22	methotrexate	B-Drug	['Causes']	[27]
23	:	O	['N']	[23]
24	an	O	['N']	[24]
25	acute	B	['N']	[25]
26	megaloblastic	I	['N']	[26]
27	anaemia	I-Adverse_Effect	['N']	[27]
28	and	O	['N']	[28]
29	a	O	['N']	[29]
30	pneumonitis	O	['N']	[30]
31	.	O	['N']	[31]
#73
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	neonate	O	['N']	[3]
4	with	O	['N']	[4]
5	a	O	['N']	[5]
6	seizure	O	['N']	[6]
7	disorder	O	['N']	[7]
8	who	O	['N']	[8]
9	acutely	O	['N']	[9]
10	developed	O	['N']	[10]
11	pupillary	O	['N']	[11]
12	mydriasis	O	['N']	[12]
13	secondary	O	['N']	[13]
14	to	O	['N']	[14]
15	lidocaine	B-Drug	['Dosage']	[16]
16	overdose	B-Dose	['N']	[16]
17	.	O	['N']	[17]
#74
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	adenosine	B-Drug	['Causes']	[18]
3	shortens	O	['N']	[3]
4	the	O	['N']	[4]
5	antegrade	O	['N']	[5]
6	refractoriness	O	['N']	[6]
7	of	O	['N']	[7]
8	accessory	O	['N']	[8]
9	atrioventricular	O	['N']	[9]
10	connections	O	['N']	[10]
11	and	O	['N']	[11]
12	may	O	['N']	[12]
13	cause	O	['N']	[13]
14	acceleration	B	['N']	[14]
15	of	I	['N']	[15]
16	the	I	['N']	[16]
17	ventricular	I	['N']	[17]
18	rate	I-Adverse_Effect	['N']	[18]
19	during	O	['N']	[19]
20	atrial	O	['N']	[20]
21	fibrillation	O	['N']	[21]
22	.	O	['N']	[22]
#75
0	In	O	['N']	[0]
1	one	O	['N']	[1]
2	patient	O	['N']	[2]
3	the	O	['N']	[3]
4	vasculitis	B-Adverse_Effect	['N']	[4]
5	resolved	O	['N']	[5]
6	after	O	['N']	[6]
7	termination	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	ciprofloxacin	B-Drug	['Causes']	[4]
11	therapy	O	['N']	[11]
12	;	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	other	O	['N']	[15]
16	patient	O	['N']	[16]
17	the	O	['N']	[17]
18	ciprofloxacin	O	['N']	[18]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	hemorrhagic	O	['N']	[21]
22	vasculitis	O	['N']	[22]
23	was	O	['N']	[23]
24	superimposed	O	['N']	[24]
25	on	O	['N']	[25]
26	a	O	['N']	[26]
27	severe	O	['N']	[27]
28	forefoot	O	['N']	[28]
29	infection	O	['N']	[29]
30	,	O	['N']	[30]
31	leading	O	['N']	[31]
32	to	O	['N']	[32]
33	progressive	O	['N']	[33]
34	gangrene	O	['N']	[34]
35	and	O	['N']	[35]
36	a	O	['N']	[36]
37	below	O	['N']	[37]
38	-	O	['N']	[38]
39	knee	O	['N']	[39]
40	amputation	O	['N']	[40]
41	.	O	['N']	[41]
#76
0	Valproic	B	['N']	[0]
1	acid	I-Drug	['Causes']	[3]
2	induced	O	['N']	[2]
3	coma	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	presented	O	['N']	[5]
6	in	O	['N']	[6]
7	an	O	['N']	[7]
8	adult	O	['N']	[8]
9	patient	O	['N']	[9]
10	without	O	['N']	[10]
11	a	O	['N']	[11]
12	history	O	['N']	[12]
13	of	O	['N']	[13]
14	metabolic	O	['N']	[14]
15	disease	O	['N']	[15]
16	.	O	['N']	[16]
#77
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	carboplatin	O	['N']	[5]
6	(	O	['N']	[6]
7	CBDCA	B-Drug	['Dosage']	[14]
8	)	O	['N']	[8]
9	hypersensitivity	O	['N']	[9]
10	after	O	['N']	[10]
11	weekly	O	['N']	[11]
12	low	B	['N']	[12]
13	-	I	['N']	[13]
14	dose	I-Dose	['N']	[14]
15	paclitaxel	O	['N']	[15]
16	(	O	['N']	[16]
17	60	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	m2)/CBDCA	O	['N']	[20]
21	(	O	['N']	[21]
22	area	O	['N']	[22]
23	under	O	['N']	[23]
24	the	O	['N']	[24]
25	concentration	O	['N']	[25]
26	curve	O	['N']	[26]
27	=	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	therapy	O	['N']	[30]
31	in	O	['N']	[31]
32	patients	O	['N']	[32]
33	with	O	['N']	[33]
34	recurrent	O	['N']	[34]
35	ovarian	O	['N']	[35]
36	cancer	O	['N']	[36]
37	receiving	O	['N']	[37]
38	multiple	O	['N']	[38]
39	platinum	O	['N']	[39]
40	-	O	['N']	[40]
41	based	O	['N']	[41]
42	chemotherapy	O	['N']	[42]
43	.	O	['N']	[43]
#78
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	for	O	['N']	[2]
3	diabetic	O	['N']	[3]
4	coma	O	['N']	[4]
5	with	O	['N']	[5]
6	insulin	O	['N']	[6]
7	(	O	['N']	[7]
8	containing	O	['N']	[8]
9	the	O	['N']	[9]
10	preservative	O	['N']	[10]
11	cresol	B-Drug	['Causes']	[24]
12	)	O	['N']	[12]
13	and	O	['N']	[13]
14	electrolyte	O	['N']	[14]
15	solutions	O	['N']	[15]
16	was	O	['N']	[16]
17	started	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	complained	O	['N']	[21]
22	of	O	['N']	[22]
23	increasing	B	['N']	[23]
24	myalgia	I-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	developed	O	['N']	[26]
27	a	O	['N']	[27]
28	high	O	['N']	[28]
29	fever	O	['N']	[29]
30	and	O	['N']	[30]
31	respiratory	O	['N']	[31]
32	and	O	['N']	[32]
33	metabolic	O	['N']	[33]
34	acidosis	O	['N']	[34]
35	and	O	['N']	[35]
36	lost	O	['N']	[36]
37	consciousness	O	['N']	[37]
38	.	O	['N']	[38]
#79
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	patient	O	['N']	[2]
3	is	O	['N']	[3]
4	undergoing	O	['N']	[4]
5	hemodialysis	O	['N']	[5]
6	and	O	['N']	[6]
7	,	O	['N']	[7]
8	though	O	['N']	[8]
9	responding	O	['N']	[9]
10	to	O	['N']	[10]
11	sunitinib	B-Drug	['Causes']	[16]
12	,	O	['N']	[12]
13	is	O	['N']	[13]
14	having	O	['N']	[14]
15	significant	O	['N']	[15]
16	fatigue	B-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	hypertension	O	['N']	[18]
19	.	O	['N']	[19]
#80
0	That	O	['N']	[0]
1	review	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	patients	O	['N']	[4]
5	receiving	O	['N']	[5]
6	anti	B	['N']	[6]
7	-	I	['N']	[7]
8	D	I	['N']	[8]
9	IGIV	I-Drug	['Causes']	[19]
10	be	O	['N']	[10]
11	monitored	O	['N']	[11]
12	for	O	['N']	[12]
13	those	O	['N']	[13]
14	and	O	['N']	[14]
15	other	O	['N']	[15]
16	potential	O	['N']	[16]
17	complications	O	['N']	[17]
18	of	O	['N']	[18]
19	hemoglobinemia	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	particularly	O	['N']	[21]
22	disseminated	O	['N']	[22]
23	intravascular	O	['N']	[23]
24	coagulation	O	['N']	[24]
25	(	O	['N']	[25]
26	DIC	O	['N']	[26]
27	)	O	['N']	[27]
28	.	O	['N']	[28]
#81
0	The	O	['N']	[0]
1	literature	O	['N']	[1]
2	of	O	['N']	[2]
3	vincristine	B-Drug	['Causes']	[6]
4	optic	B	['N']	[4]
5	nerve	I	['N']	[5]
6	toxicity	I-Adverse_Effect	['N']	[6]
7	is	O	['N']	[7]
8	reviewed	O	['N']	[8]
9	.	O	['N']	[9]
#82
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	investigate	O	['N']	[3]
4	the	O	['N']	[4]
5	concentration	O	['N']	[5]
6	-	O	['N']	[6]
7	side	O	['N']	[7]
8	effect	O	['N']	[8]
9	relationship	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	with	O	['N']	[13]
14	severe	O	['N']	[14]
15	acyclovir	B-Drug	['Causes']	[33]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	neurotoxicity	O	['N']	[18]
19	and	O	['N']	[19]
20	to	O	['N']	[20]
21	summarize	O	['N']	[21]
22	the	O	['N']	[22]
23	information	O	['N']	[23]
24	available	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	literature	O	['N']	[27]
28	about	O	['N']	[28]
29	central	B	['N']	[29]
30	nervous	I	['N']	[30]
31	system	I	['N']	[31]
32	side	I	['N']	[32]
33	effects	I-Adverse_Effect	['N']	[33]
34	due	O	['N']	[34]
35	to	O	['N']	[35]
36	acyclovir	O	['N']	[36]
37	.	O	['N']	[37]
#83
0	A	O	['N']	[0]
1	toxic	O	['N']	[1]
2	encephalopathy	O	['N']	[2]
3	characterized	O	['N']	[3]
4	by	O	['N']	[4]
5	depressed	B	['N']	[5]
6	level	I	['N']	[6]
7	of	I	['N']	[7]
8	consciousness	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	marked	O	['N']	[10]
11	irritability	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	ataxia	O	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	seven	O	['N']	[17]
18	children	O	['N']	[18]
19	,	O	['N']	[19]
20	5	O	['N']	[20]
21	years	O	['N']	[21]
22	of	O	['N']	[22]
23	age	O	['N']	[23]
24	and	O	['N']	[24]
25	younger	O	['N']	[25]
26	,	O	['N']	[26]
27	following	O	['N']	[27]
28	administration	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	antiemetic	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	pentobarbital	B-Drug	['Causes']	[8]
35	and	O	['N']	[35]
36	pyrilamine	O	['N']	[36]
37	maleate	O	['N']	[37]
38	.	O	['N']	[38]
#84
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	child	O	['N']	[6]
7	with	O	['N']	[7]
8	metastatic	O	['N']	[8]
9	osteosarcoma	O	['N']	[9]
10	,	O	['N']	[10]
11	who	O	['N']	[11]
12	experienced	O	['N']	[12]
13	an	O	['N']	[13]
14	anaphylactic	B	['N']	[14]
15	/	I	['N']	[15]
16	anaphylactoid	I	['N']	[16]
17	reaction	I-Adverse_Effect	['N']	[17]
18	to	O	['N']	[18]
19	methotrexate	B-Drug	['Causes']	[17]
20	.	O	['N']	[20]
#85
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	premature	O	['N']	[3]
4	infant	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	seizures	B-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	intraventricular	O	['N']	[10]
11	administration	O	['N']	[11]
12	of	O	['N']	[12]
13	nafcillin	B-Drug	['Causes']	[7]
14	and	O	['N']	[14]
15	discuss	O	['N']	[15]
16	the	O	['N']	[16]
17	need	O	['N']	[17]
18	for	O	['N']	[18]
19	electroencephalographic	O	['N']	[19]
20	monitoring	O	['N']	[20]
21	of	O	['N']	[21]
22	patients	O	['N']	[22]
23	receiving	O	['N']	[23]
24	intraventricular	O	['N']	[24]
25	antibiotics	O	['N']	[25]
26	.	O	['N']	[26]
#86
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	44-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	taking	O	['N']	[7]
8	naproxen	O	['N']	[8]
9	for	O	['N']	[9]
10	chronic	O	['N']	[10]
11	low	O	['N']	[11]
12	back	O	['N']	[12]
13	pain	O	['N']	[13]
14	and	O	['N']	[14]
15	a	O	['N']	[15]
16	20-year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	woman	O	['N']	[19]
20	on	O	['N']	[20]
21	oxaprozin	B-Drug	['Causes']	[31]
22	for	O	['N']	[22]
23	rheumatoid	O	['N']	[23]
24	arthritis	O	['N']	[24]
25	presented	O	['N']	[25]
26	with	O	['N']	[26]
27	tense	O	['N']	[27]
28	bullae	O	['N']	[28]
29	and	O	['N']	[29]
30	cutaneous	B	['N']	[30]
31	fragility	I-Adverse_Effect	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	face	O	['N']	[34]
35	and	O	['N']	[35]
36	the	O	['N']	[36]
37	back	O	['N']	[37]
38	of	O	['N']	[38]
39	the	O	['N']	[39]
40	hands	O	['N']	[40]
41	.	O	['N']	[41]
#87
0	Aseptic	O	['N']	[0]
1	meningitis	O	['N']	[1]
2	,	O	['N']	[2]
3	hemolytic	B	['N']	[3]
4	anemia	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	orthostatic	O	['N']	[9]
10	hypotension	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	trimethoprim	B-Drug	['Causes']	[4]
17	-	O	['N']	[17]
18	sulfamethoxazole	O	['N']	[18]
19	.	O	['N']	[19]
#88
0	From	O	['N']	[0]
1	1996	O	['N']	[1]
2	to	O	['N']	[2]
3	2002	O	['N']	[3]
4	several	O	['N']	[4]
5	medications	O	['N']	[5]
6	were	O	['N']	[6]
7	changed	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	their	O	['N']	[10]
11	adverse	O	['N']	[11]
12	effects	O	['N']	[12]
13	:	O	['N']	[13]
14	indinavir	O	['N']	[14]
15	(	O	['N']	[15]
16	renal	O	['N']	[16]
17	colic	O	['N']	[17]
18	and	O	['N']	[18]
19	fever	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	nelfinavir	O	['N']	[22]
23	(	O	['N']	[23]
24	cutaneous	O	['N']	[24]
25	rash	O	['N']	[25]
26	)	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	efavirenz	B-Drug	['Causes']	[35]
30	(	O	['N']	[30]
31	nausea	O	['N']	[31]
32	and	O	['N']	[32]
33	temporary	B	['N']	[33]
34	memory	I	['N']	[34]
35	loss	I-Adverse_Effect	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#89
0	During	O	['N']	[0]
1	her	O	['N']	[1]
2	third	O	['N']	[2]
3	cycle	O	['N']	[3]
4	,	O	['N']	[4]
5	she	O	['N']	[5]
6	again	O	['N']	[6]
7	received	O	['N']	[7]
8	cisplatin	B-Drug	['Causes']	[12]
9	100	B	['N']	[9]
10	mg	I	['N']	[10]
11	/	I	['N']	[11]
12	m2	I-Adverse_Effect	['N']	[12]
13	over	O	['N']	[13]
14	30	O	['N']	[14]
15	minutes	O	['N']	[15]
16	and	O	['N']	[16]
17	developed	O	['N']	[17]
18	palmar	O	['N']	[18]
19	pruritus	O	['N']	[19]
20	,	O	['N']	[20]
21	urticaria	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	edema	O	['N']	[24]
25	.	O	['N']	[25]
#90
0	Among	O	['N']	[0]
1	12	O	['N']	[1]
2	thyrotoxic	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	arrhythmogenic	O	['N']	[8]
9	right	O	['N']	[9]
10	ventricular	O	['N']	[10]
11	dysplasia	O	['N']	[11]
12	,	O	['N']	[12]
13	who	O	['N']	[13]
14	had	O	['N']	[14]
15	been	O	['N']	[15]
16	taking	O	['N']	[16]
17	amiodarone	B-Drug	['Causes']	[23]
18	for	O	['N']	[18]
19	4	O	['N']	[19]
20	years	O	['N']	[20]
21	,	O	['N']	[21]
22	developed	O	['N']	[22]
23	thyrotoxicosis	B-Adverse_Effect	['N']	[23]
24	with	O	['N']	[24]
25	subacute	O	['N']	[25]
26	onset	O	['N']	[26]
27	,	O	['N']	[27]
28	accompanied	O	['N']	[28]
29	by	O	['N']	[29]
30	transiently	O	['N']	[30]
31	positive	O	['N']	[31]
32	thyrotropin	O	['N']	[32]
33	(	O	['N']	[33]
34	TSH	O	['N']	[34]
35	)	O	['N']	[35]
36	receptor	O	['N']	[36]
37	antibody	O	['N']	[37]
38	(	O	['N']	[38]
39	TRAb	O	['N']	[39]
40	)	O	['N']	[40]
41	,	O	['N']	[41]
42	or	O	['N']	[42]
43	thyrotropin	O	['N']	[43]
44	-	O	['N']	[44]
45	binding	O	['N']	[45]
46	inhibiting	O	['N']	[46]
47	immunoglobulin	O	['N']	[47]
48	(	O	['N']	[48]
49	TBII	O	['N']	[49]
50	)	O	['N']	[50]
51	.	O	['N']	[51]
#91
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	aseptic	O	['N']	[9]
10	meningitis	O	['N']	[10]
11	,	O	['N']	[11]
12	hemolytic	B	['N']	[12]
13	anemia	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	hepatitis	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	orthostatic	O	['N']	[18]
19	hypotension	O	['N']	[19]
20	simultaneously	O	['N']	[20]
21	during	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	trimethoprim	O	['N']	[24]
25	-	O	['N']	[25]
26	sulfamethoxazole	B-Drug	['Causes']	[13]
27	is	O	['N']	[27]
28	described	O	['N']	[28]
29	.	O	['N']	[29]
#92
0	It	O	['N']	[0]
1	was	O	['N']	[1]
2	highly	O	['N']	[2]
3	suspected	O	['N']	[3]
4	that	O	['N']	[4]
5	finasteride	B-Drug	['Causes']	[15]
6	was	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	anterior	B	['N']	[10]
11	subcapsular	I	['N']	[11]
12	opacity	I	['N']	[12]
13	on	I	['N']	[13]
14	the	I	['N']	[14]
15	lens	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	the	O	['N']	[18]
19	patient	O	['N']	[19]
20	therefore	O	['N']	[20]
21	discontinued	O	['N']	[21]
22	use	O	['N']	[22]
23	of	O	['N']	[23]
24	finasteride	O	['N']	[24]
25	.	O	['N']	[25]
#93
0	The	O	['N']	[0]
1	condition	O	['N']	[1]
2	should	O	['N']	[2]
3	be	O	['N']	[3]
4	suspected	O	['N']	[4]
5	in	O	['N']	[5]
6	patients	O	['N']	[6]
7	who	O	['N']	[7]
8	develop	O	['N']	[8]
9	unexplained	O	['N']	[9]
10	abdominal	O	['N']	[10]
11	pain	O	['N']	[11]
12	or	O	['N']	[12]
13	collapse	B-Adverse_Effect	['N']	[13]
14	following	O	['N']	[14]
15	vasopressin	B-Drug	['Causes']	[13]
16	treatment	O	['N']	[16]
17	.	O	['N']	[17]
#94
0	The	O	['N']	[0]
1	pro	B	['N']	[1]
2	-	I	['N']	[2]
3	arrhythmic	I	['N']	[3]
4	effects	I-Adverse_Effect	['N']	[4]
5	of	O	['N']	[5]
6	procainamide	B-Drug	['Causes']	[4]
7	may	O	['N']	[7]
8	be	O	['N']	[8]
9	explained	O	['N']	[9]
10	on	O	['N']	[10]
11	the	O	['N']	[11]
12	basis	O	['N']	[12]
13	of	O	['N']	[13]
14	both	O	['N']	[14]
15	its	O	['N']	[15]
16	vagolytic	O	['N']	[16]
17	action	O	['N']	[17]
18	on	O	['N']	[18]
19	the	O	['N']	[19]
20	atrioventricular	O	['N']	[20]
21	node	O	['N']	[21]
22	as	O	['N']	[22]
23	well	O	['N']	[23]
24	as	O	['N']	[24]
25	by	O	['N']	[25]
26	prolongation	O	['N']	[26]
27	of	O	['N']	[27]
28	refractoriness	O	['N']	[28]
29	in	O	['N']	[29]
30	the	O	['N']	[30]
31	accessory	O	['N']	[31]
32	pathway	O	['N']	[32]
33	.	O	['N']	[33]
#95
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Including	O	['N']	[2]
3	our	O	['N']	[3]
4	own	O	['N']	[4]
5	patient	O	['N']	[5]
6	,	O	['N']	[6]
7	a	O	['N']	[7]
8	total	O	['N']	[8]
9	of	O	['N']	[9]
10	26	O	['N']	[10]
11	cases	O	['N']	[11]
12	of	O	['N']	[12]
13	gemcitabine	B-Drug	['Causes']	[16]
14	-	O	['N']	[14]
15	associated	O	['N']	[15]
16	HUS	B-Adverse_Effect	['N']	[16]
17	were	O	['N']	[17]
18	identified	O	['N']	[18]
19	.	O	['N']	[19]
#96
0	A	O	['N']	[0]
1	noninvasive	O	['N']	[1]
2	method	O	['N']	[2]
3	in	O	['N']	[3]
4	the	O	['N']	[4]
5	differential	O	['N']	[5]
6	diagnosis	O	['N']	[6]
7	of	O	['N']	[7]
8	vecuronium	B-Drug	['Causes']	[17]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	and	O	['N']	[11]
12	magnesium	O	['N']	[12]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	protracted	B	['N']	[15]
16	neuromuscular	I	['N']	[16]
17	block	I-Adverse_Effect	['N']	[17]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	severely	O	['N']	[20]
21	preeclamptic	O	['N']	[21]
22	patient	O	['N']	[22]
23	.	O	['N']	[23]
#97
0	Occurrence	O	['N']	[0]
1	of	O	['N']	[1]
2	IDDM	B-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	interferon	B-Drug	['Causes']	[2]
5	therapy	O	['N']	[5]
6	for	O	['N']	[6]
7	chronic	O	['N']	[7]
8	viral	O	['N']	[8]
9	hepatitis	O	['N']	[9]
10	.	O	['N']	[10]
#98
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	occurrence	O	['N']	[5]
6	of	O	['N']	[6]
7	anaphylactoid	B	['N']	[7]
8	reactions	I-Adverse_Effect	['N']	[8]
9	to	O	['N']	[9]
10	intraperitoneal	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[8]
12	in	O	['N']	[12]
13	3	O	['N']	[13]
14	patients	O	['N']	[14]
15	.	O	['N']	[15]
#99
0	Ophthalmologic	B	['N']	[0]
1	and	I	['N']	[1]
2	neurologic	I	['N']	[2]
3	findings	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	children	O	['N']	[6]
7	exposed	O	['N']	[7]
8	to	O	['N']	[8]
9	vigabatrin	B-Drug	['Causes']	[3]
10	in	O	['N']	[10]
11	utero	O	['N']	[11]
12	.	O	['N']	[12]
#100
0	Acute	B	['N']	[0]
1	non	I	['N']	[1]
2	-	I	['N']	[2]
3	lymphocytic	I	['N']	[3]
4	leukemia	I-Adverse_Effect	['N']	[4]
5	occurred	O	['N']	[5]
6	in	O	['N']	[6]
7	eight	O	['N']	[7]
8	women	O	['N']	[8]
9	following	O	['N']	[9]
10	long	O	['N']	[10]
11	-	O	['N']	[11]
12	term	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	Treosulfan	B-Drug	['Causes']	[4]
16	(=	O	['N']	[16]
17	dihydroxybusulfan	O	['N']	[17]
18	)	O	['N']	[18]
19	for	O	['N']	[19]
20	ovarian	O	['N']	[20]
21	carcinoma	O	['N']	[21]
22	.	O	['N']	[22]
#101
0	Transient	O	['N']	[0]
1	trazodone	B-Drug	['Causes']	[5]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	hypomanic	B	['N']	[4]
5	symptoms	I-Adverse_Effect	['N']	[5]
6	occurred	O	['N']	[6]
7	in	O	['N']	[7]
8	three	O	['N']	[8]
9	depressed	O	['N']	[9]
10	patients	O	['N']	[10]
11	.	O	['N']	[11]
#102
0	Clofibrate	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	myopathy	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	diabetes	O	['N']	[7]
8	insipidus	O	['N']	[8]
9	.	O	['N']	[9]
#103
0	Delay	B	['N']	[0]
1	of	I	['N']	[1]
2	corneal	I	['N']	[2]
3	wound	I	['N']	[3]
4	healing	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	patients	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	colchicine	B-Drug	['Causes']	[4]
10	.	O	['N']	[10]
#104
0	Systemic	O	['N']	[0]
1	corticosteroids	O	['N']	[1]
2	in	O	['N']	[2]
3	the	O	['N']	[3]
4	phenytoin	B-Drug	['Causes']	[6]
5	hypersensitivity	I	['N']	[5]
6	syndrome	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#105
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	severe	B	['N']	[3]
4	cholestatic	I	['N']	[4]
5	jaundice	I-Adverse_Effect	['N']	[5]
6	induced	O	['N']	[6]
7	by	O	['N']	[7]
8	captopril	B-Drug	['Causes']	[5]
9	is	O	['N']	[9]
10	presented	O	['N']	[10]
11	.	O	['N']	[11]
#106
0	Both	O	['N']	[0]
1	the	O	['N']	[1]
2	longitudinal	O	['N']	[2]
3	melanonychia	O	['N']	[3]
4	and	O	['N']	[4]
5	the	O	['N']	[5]
6	multiple	B	['N']	[6]
7	skin	I	['N']	[7]
8	cancers	I-Adverse_Effect	['N']	[8]
9	first	O	['N']	[9]
10	appeared	O	['N']	[10]
11	after	O	['N']	[11]
12	approximately	O	['N']	[12]
13	6	O	['N']	[13]
14	months	O	['N']	[14]
15	of	O	['N']	[15]
16	hydroxyurea	B-Drug	['Causes']	[8]
17	treatment	O	['N']	[17]
18	.	O	['N']	[18]
#107
0	Cephalexin	B-Drug	['Causes']	[1]
1	rash	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	infectious	O	['N']	[3]
4	mononucleosis	O	['N']	[4]
5	.	O	['N']	[5]
#108
0	Cyclophosphamide	B-Drug	['Causes']	[1]
1	pneumonitis	B-Adverse_Effect	['N']	[1]
2	.	O	['N']	[2]
#109
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	Three	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	apparent	O	['N']	[5]
6	itraconazole	B-Drug	['Causes']	[10]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	liver	B	['N']	[9]
10	injury	I-Adverse_Effect	['N']	[10]
11	were	O	['N']	[11]
12	studied	O	['N']	[12]
13	.	O	['N']	[13]
#110
0	A	O	['N']	[0]
1	74-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	idiopathic	O	['N']	[6]
7	Parkinson	O	['N']	[7]
8	's	O	['N']	[8]
9	disease	O	['N']	[9]
10	was	O	['N']	[10]
11	evaluated	O	['N']	[11]
12	for	O	['N']	[12]
13	unintended	O	['N']	[13]
14	sleep	O	['N']	[14]
15	episodes	O	['N']	[15]
16	that	O	['N']	[16]
17	occurred	O	['N']	[17]
18	after	O	['N']	[18]
19	long	O	['N']	[19]
20	-	O	['N']	[20]
21	term	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	400	B	['N']	[24]
25	mg	I	['N']	[25]
26	/	I	['N']	[26]
27	day	I-Dose	['N']	[27]
28	of	O	['N']	[28]
29	L	B	['N']	[29]
30	-	I	['N']	[30]
31	dopa	I-Drug	['Dosage']	[27]
32	.	O	['N']	[32]
#111
0	2-Chloro	B	['N']	[0]
1	-	I	['N']	[1]
2	deoxyadenosine	I-Drug	['Causes']	[21]
3	induces	O	['N']	[3]
4	durable	O	['N']	[4]
5	complete	O	['N']	[5]
6	remission	O	['N']	[6]
7	in	O	['N']	[7]
8	Castleman	O	['N']	[8]
9	's	O	['N']	[9]
10	disease	O	['N']	[10]
11	but	O	['N']	[11]
12	may	O	['N']	[12]
13	accelerate	O	['N']	[13]
14	its	O	['N']	[14]
15	transformation	O	['N']	[15]
16	to	O	['N']	[16]
17	non	B	['N']	[17]
18	-	I	['N']	[18]
19	Hodgkin	I	['N']	[19]
20	's	I	['N']	[20]
21	lymphoma	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#112
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Interferon	B-Drug	['Causes']	[5]
3	(	O	['N']	[3]
4	IFN)-associated	O	['N']	[4]
5	retinopathy	B-Adverse_Effect	['N']	[5]
6	is	O	['N']	[6]
7	typically	O	['N']	[7]
8	characterized	O	['N']	[8]
9	by	O	['N']	[9]
10	retinal	O	['N']	[10]
11	hemorrhages	O	['N']	[11]
12	and	O	['N']	[12]
13	cotton	O	['N']	[13]
14	wool	O	['N']	[14]
15	spots	O	['N']	[15]
16	at	O	['N']	[16]
17	the	O	['N']	[17]
18	posterior	O	['N']	[18]
19	fundus	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	visual	O	['N']	[22]
23	function	O	['N']	[23]
24	is	O	['N']	[24]
25	usually	O	['N']	[25]
26	maintained	O	['N']	[26]
27	.	O	['N']	[27]
#113
0	There	O	['N']	[0]
1	is	O	['N']	[1]
2	evidence	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	angiotensin	O	['N']	[5]
6	II	O	['N']	[6]
7	receptor	O	['N']	[7]
8	antagonist	O	['N']	[8]
9	,	O	['N']	[9]
10	losartan	B-Drug	['Causes']	[14]
11	,	O	['N']	[11]
12	increases	B	['N']	[12]
13	urate	I	['N']	[13]
14	excretion	I-Adverse_Effect	['N']	[14]
15	by	O	['N']	[15]
16	reducing	O	['N']	[16]
17	reabsorption	O	['N']	[17]
18	of	O	['N']	[18]
19	urate	O	['N']	[19]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	renal	O	['N']	[22]
23	proximal	O	['N']	[23]
24	tubule	O	['N']	[24]
25	.	O	['N']	[25]
#114
0	An	O	['N']	[0]
1	elderly	O	['N']	[1]
2	man	O	['N']	[2]
3	with	O	['N']	[3]
4	procainamide	B	['N']	[4]
5	hydrochloride	I-Drug	['Causes']	[9]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	lupus	B	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	had	O	['N']	[10]
11	a	O	['N']	[11]
12	circulating	O	['N']	[12]
13	anticoagulant	O	['N']	[13]
14	against	O	['N']	[14]
15	factor	O	['N']	[15]
16	XI	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	biologic	O	['N']	[19]
20	false	O	['N']	[20]
21	-	O	['N']	[21]
22	positive	O	['N']	[22]
23	(	O	['N']	[23]
24	BFP	O	['N']	[24]
25	)	O	['N']	[25]
26	test	O	['N']	[26]
27	result	O	['N']	[27]
28	for	O	['N']	[28]
29	syphilis	O	['N']	[29]
30	.	O	['N']	[30]
#115
0	Pneumonitis	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	bilateral	O	['N']	[2]
3	pleural	O	['N']	[3]
4	effusions	O	['N']	[4]
5	,	O	['N']	[5]
6	echocardiographic	O	['N']	[6]
7	evidence	O	['N']	[7]
8	of	O	['N']	[8]
9	cardiac	O	['N']	[9]
10	tamponade	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	positive	O	['N']	[13]
14	autoantibodies	O	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	43-year	O	['N']	[18]
19	-	O	['N']	[19]
20	old	O	['N']	[20]
21	man	O	['N']	[21]
22	,	O	['N']	[22]
23	who	O	['N']	[23]
24	was	O	['N']	[24]
25	receiving	O	['N']	[25]
26	long	O	['N']	[26]
27	-	O	['N']	[27]
28	term	O	['N']	[28]
29	sulfasalazine	B-Drug	['Causes']	[0]
30	therapy	O	['N']	[30]
31	for	O	['N']	[31]
32	chronic	O	['N']	[32]
33	ulcerative	O	['N']	[33]
34	colitis	O	['N']	[34]
35	.	O	['N']	[35]
#116
0	While	O	['N']	[0]
1	the	O	['N']	[1]
2	introduction	O	['N']	[2]
3	of	O	['N']	[3]
4	carmustine	B-Drug	['Causes']	[34]
5	wafers	O	['N']	[5]
6	(	O	['N']	[6]
7	Gliadel	O	['N']	[7]
8	wafers	O	['N']	[8]
9	)	O	['N']	[9]
10	into	O	['N']	[10]
11	the	O	['N']	[11]
12	tumor	O	['N']	[12]
13	resection	O	['N']	[13]
14	cavity	O	['N']	[14]
15	has	O	['N']	[15]
16	been	O	['N']	[16]
17	shown	O	['N']	[17]
18	to	O	['N']	[18]
19	be	O	['N']	[19]
20	a	O	['N']	[20]
21	beneficial	O	['N']	[21]
22	therapy	O	['N']	[22]
23	for	O	['N']	[23]
24	malignant	O	['N']	[24]
25	glioma	O	['N']	[25]
26	,	O	['N']	[26]
27	it	O	['N']	[27]
28	is	O	['N']	[28]
29	recognized	O	['N']	[29]
30	that	O	['N']	[30]
31	clinically	O	['N']	[31]
32	significant	O	['N']	[32]
33	cerebral	B	['N']	[33]
34	edema	I-Adverse_Effect	['N']	[34]
35	is	O	['N']	[35]
36	a	O	['N']	[36]
37	potential	O	['N']	[37]
38	adverse	O	['N']	[38]
39	effect	O	['N']	[39]
40	.	O	['N']	[40]
#117
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	patient	O	['N']	[2]
3	,	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	cholestasis	B-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	receiving	O	['N']	[8]
9	trimethoprim	B	['N']	[9]
10	-	I	['N']	[10]
11	sulfamethoxazole	I-Drug	['Causes']	[6]
12	,	O	['N']	[12]
13	had	O	['N']	[13]
14	marked	O	['N']	[14]
15	duct	O	['N']	[15]
16	paucity	O	['N']	[16]
17	in	O	['N']	[17]
18	the	O	['N']	[18]
19	liver	O	['N']	[19]
20	biopsy	O	['N']	[20]
21	.	O	['N']	[21]
#118
0	Caution	O	['N']	[0]
1	with	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	cimetidine	O	['N']	[4]
5	in	O	['N']	[5]
6	tolazoline	B-Drug	['Causes']	[10]
7	induced	O	['N']	[7]
8	upper	B	['N']	[8]
9	gastrointestinal	I	['N']	[9]
10	bleeding	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#119
0	Both	O	['N']	[0]
1	colchicine	O	['N']	[1]
2	and	O	['N']	[2]
3	statin	B-Drug	['Causes']	[9]
4	therapy	O	['N']	[4]
5	may	O	['N']	[5]
6	be	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	myopathy	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	which	O	['N']	[11]
12	usually	O	['N']	[12]
13	occurs	O	['N']	[13]
14	after	O	['N']	[14]
15	several	O	['N']	[15]
16	months	O	['N']	[16]
17	of	O	['N']	[17]
18	therapy	O	['N']	[18]
19	.	O	['N']	[19]
#120
0	Severe	O	['N']	[0]
1	heparin	B-Drug	['Causes']	[3]
2	associated	O	['N']	[2]
3	thrombocytopenia	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	complication	O	['N']	[7]
8	of	O	['N']	[8]
9	heparin	O	['N']	[9]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#121
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	caution	O	['N']	[2]
3	that	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	alprazolam	B-Drug	['Causes']	[14]
7	may	O	['N']	[7]
8	be	O	['N']	[8]
9	complicated	O	['N']	[9]
10	by	O	['N']	[10]
11	the	O	['N']	[11]
12	induction	O	['N']	[12]
13	of	O	['N']	[13]
14	mania	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#122
0	Myoglobinuria	O	['N']	[0]
1	and	O	['N']	[1]
2	acute	B	['N']	[2]
3	renal	I	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	were	O	['N']	[5]
6	observed	O	['N']	[6]
7	in	O	['N']	[7]
8	two	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	vasopressin	B-Drug	['Causes']	[4]
12	-	O	['N']	[12]
13	treated	O	['N']	[13]
14	gastrointestinal	O	['N']	[14]
15	hemorrhage	O	['N']	[15]
16	.	O	['N']	[16]
#123
0	We	O	['N']	[0]
1	postulate	O	['N']	[1]
2	that	O	['N']	[2]
3	cyclosporin	B-Drug	['Causes']	[21]
4	,	O	['N']	[4]
5	possibly	O	['N']	[5]
6	together	O	['N']	[6]
7	with	O	['N']	[7]
8	ganciclovir	O	['N']	[8]
9	,	O	['N']	[9]
10	can	O	['N']	[10]
11	produce	O	['N']	[11]
12	transient	O	['N']	[12]
13	brain	O	['N']	[13]
14	stem	O	['N']	[14]
15	or	O	['N']	[15]
16	neuromuscular	O	['N']	[16]
17	dysfunction	O	['N']	[17]
18	with	O	['N']	[18]
19	eye	B	['N']	[19]
20	movement	I	['N']	[20]
21	abnormality	I-Adverse_Effect	['N']	[21]
22	in	O	['N']	[22]
23	occasional	O	['N']	[23]
24	patients	O	['N']	[24]
25	.	O	['N']	[25]
#124
0	Stroke	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	infrequent	O	['N']	[3]
4	but	O	['N']	[4]
5	recognized	O	['N']	[5]
6	complication	O	['N']	[6]
7	of	O	['N']	[7]
8	heroin	B-Drug	['Causes']	[0]
9	addiction	O	['N']	[9]
10	.	O	['N']	[10]
#125
0	INTRODUCTION	O	['N']	[0]
1	:	O	['N']	[1]
2	Although	O	['N']	[2]
3	gefitinib	B-Drug	['Causes']	[27]
4	used	O	['N']	[4]
5	for	O	['N']	[5]
6	the	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	non	O	['N']	[9]
10	-	O	['N']	[10]
11	small	O	['N']	[11]
12	-	O	['N']	[12]
13	cell	O	['N']	[13]
14	lung	O	['N']	[14]
15	cancer	O	['N']	[15]
16	is	O	['N']	[16]
17	a	O	['N']	[17]
18	well	O	['N']	[18]
19	-	O	['N']	[19]
20	known	O	['N']	[20]
21	cause	O	['N']	[21]
22	of	O	['N']	[22]
23	interstitial	O	['N']	[23]
24	lung	O	['N']	[24]
25	disease	O	['N']	[25]
26	(	O	['N']	[26]
27	ILD	B-Adverse_Effect	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	few	O	['N']	[30]
31	case	O	['N']	[31]
32	reports	O	['N']	[32]
33	on	O	['N']	[33]
34	erlotinib	O	['N']	[34]
35	-	O	['N']	[35]
36	induced	O	['N']	[36]
37	ILD	O	['N']	[37]
38	have	O	['N']	[38]
39	been	O	['N']	[39]
40	issued	O	['N']	[40]
41	.	O	['N']	[41]
#126
0	Hypersensitivity	O	['N']	[0]
1	to	O	['N']	[1]
2	carboplatin	B-Drug	['Causes']	[22]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	rare	O	['N']	[5]
6	but	O	['N']	[6]
7	real	O	['N']	[7]
8	complication	O	['N']	[8]
9	of	O	['N']	[9]
10	therapy	O	['N']	[10]
11	and	O	['N']	[11]
12	should	O	['N']	[12]
13	be	O	['N']	[13]
14	considered	O	['N']	[14]
15	in	O	['N']	[15]
16	patients	O	['N']	[16]
17	presenting	O	['N']	[17]
18	with	O	['N']	[18]
19	hyperacute	B	['N']	[19]
20	changes	I	['N']	[20]
21	on	I	['N']	[21]
22	ECG	I-Adverse_Effect	['N']	[22]
23	whilst	O	['N']	[23]
24	receiving	O	['N']	[24]
25	carboplatin	O	['N']	[25]
26	therapy	O	['N']	[26]
27	.	O	['N']	[27]
#127
0	Uncontrolled	O	['N']	[0]
1	headache	B-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	oxcarbazepine	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#128
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	trimethoprim	O	['N']	[4]
5	-	O	['N']	[5]
6	sulfamethoxazole	B-Drug	['Causes']	[20]
7	for	O	['N']	[7]
8	approximately	O	['N']	[8]
9	eight	O	['N']	[9]
10	days	O	['N']	[10]
11	when	O	['N']	[11]
12	he	O	['N']	[12]
13	revisited	O	['N']	[13]
14	his	O	['N']	[14]
15	family	O	['N']	[15]
16	physician	O	['N']	[16]
17	,	O	['N']	[17]
18	complaining	O	['N']	[18]
19	of	O	['N']	[19]
20	headaches	B-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	dizziness	O	['N']	[22]
23	,	O	['N']	[23]
24	difficulty	O	['N']	[24]
25	with	O	['N']	[25]
26	speech	O	['N']	[26]
27	,	O	['N']	[27]
28	weakness	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	itching	O	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	trunk	O	['N']	[34]
35	of	O	['N']	[35]
36	his	O	['N']	[36]
37	body	O	['N']	[37]
38	and	O	['N']	[38]
39	legs	O	['N']	[39]
40	,	O	['N']	[40]
41	where	O	['N']	[41]
42	a	O	['N']	[42]
43	maculopapular	O	['N']	[43]
44	rash	O	['N']	[44]
45	was	O	['N']	[45]
46	noted	O	['N']	[46]
47	.	O	['N']	[47]
#129
0	We	O	['N']	[0]
1	herein	O	['N']	[1]
2	described	O	['N']	[2]
3	an	O	['N']	[3]
4	additional	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	BCR	O	['N']	[7]
8	-	O	['N']	[8]
9	ABL	O	['N']	[9]
10	(	O	['N']	[10]
11	ela2	O	['N']	[11]
12	)	O	['N']	[12]
13	positive	O	['N']	[13]
14	acute	O	['N']	[14]
15	lymphoblastic	O	['N']	[15]
16	leukemia	O	['N']	[16]
17	who	O	['N']	[17]
18	developed	O	['N']	[18]
19	tumor	B	['N']	[19]
20	lysis	I	['N']	[20]
21	syndrome	I-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	10-day	O	['N']	[23]
24	treatment	O	['N']	[24]
25	with	O	['N']	[25]
26	imatinib	B-Drug	['Causes']	[21]
27	.	O	['N']	[27]
#130
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	exacerbated	O	['N']	[7]
8	mania	B-Adverse_Effect	['N']	[8]
9	potentially	O	['N']	[9]
10	related	O	['N']	[10]
11	to	O	['N']	[11]
12	an	O	['N']	[12]
13	interaction	O	['N']	[13]
14	between	O	['N']	[14]
15	lopinavir	O	['N']	[15]
16	/	O	['N']	[16]
17	ritonavir	O	['N']	[17]
18	and	O	['N']	[18]
19	valproic	B	['N']	[19]
20	acid	I-Drug	['Causes']	[8]
21	(	O	['N']	[21]
22	VPA	O	['N']	[22]
23	)	O	['N']	[23]
24	and	O	['N']	[24]
25	propose	O	['N']	[25]
26	a	O	['N']	[26]
27	mechanism	O	['N']	[27]
28	of	O	['N']	[28]
29	action	O	['N']	[29]
30	for	O	['N']	[30]
31	this	O	['N']	[31]
32	interaction	O	['N']	[32]
33	.	O	['N']	[33]
#131
0	Mean	O	['N']	[0]
1	time	O	['N']	[1]
2	between	O	['N']	[2]
3	initiation	O	['N']	[3]
4	of	O	['N']	[4]
5	gemcitabine	B-Drug	['Dosage']	[22]
6	therapy	O	['N']	[6]
7	and	O	['N']	[7]
8	onset	O	['N']	[8]
9	of	O	['N']	[9]
10	HUS	O	['N']	[10]
11	was	O	['N']	[11]
12	7.4	O	['N']	[12]
13	+	O	['N']	[13]
14	/-	O	['N']	[14]
15	3.5	O	['N']	[15]
16	months	O	['N']	[16]
17	,	O	['N']	[17]
18	or	O	['N']	[18]
19	21.9	B	['N']	[19]
20	+	I	['N']	[20]
21	/-	I	['N']	[21]
22	10.9	I-Dose	['N']	[22]
23	doses	O	['N']	[23]
24	of	O	['N']	[24]
25	gemcitabine	O	['N']	[25]
26	.	O	['N']	[26]
#132
0	Drug	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hepatitis	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	an	O	['N']	[5]
6	acromegalic	O	['N']	[6]
7	patient	O	['N']	[7]
8	during	O	['N']	[8]
9	combined	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	pegvisomant	O	['N']	[12]
13	and	O	['N']	[13]
14	octreotide	B-Drug	['Causes']	[3]
15	long	O	['N']	[15]
16	-	O	['N']	[16]
17	acting	O	['N']	[17]
18	repeatable	O	['N']	[18]
19	attributed	O	['N']	[19]
20	to	O	['N']	[20]
21	the	O	['N']	[21]
22	use	O	['N']	[22]
23	of	O	['N']	[23]
24	pegvisomant	O	['N']	[24]
25	.	O	['N']	[25]
#133
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	,	O	['N']	[2]
3	an	O	['N']	[3]
4	immediate	-	['N']	[4]
5	erythematous	-	['N']	[5]
6	macule	O	['N']	[6]
7	was	O	['N']	[7]
8	observed	O	['N']	[8]
9	on	O	['N']	[9]
10	the	O	['N']	[10]
11	photopatch	O	['N']	[11]
12	test	O	['N']	[12]
13	site	O	['N']	[13]
14	of	O	['N']	[14]
15	mequitazine	B-Drug	['N']	[15]
16	directly	O	['N']	[16]
17	after	O	['N']	[17]
18	UV	O	['N']	[18]
19	exposure	O	['N']	[19]
20	which	O	['N']	[20]
21	was	O	['N']	[21]
22	similar	O	['N']	[22]
23	to	O	['N']	[23]
24	the	O	['N']	[24]
25	immediate	O	['N']	[25]
26	erythema	O	['N']	[26]
27	noted	O	['N']	[27]
28	in	O	['N']	[28]
29	chlorpromazine	O	['N']	[29]
30	photoallergy	O	['N']	[30]
31	.	O	['N']	[31]
#134
0	Ten	O	['N']	[0]
1	hours	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	second	O	['N']	[4]
5	methotrexate	B-Drug	['Causes']	[15]
6	injection	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	patient	O	['N']	[9]
10	experienced	O	['N']	[10]
11	a	O	['N']	[11]
12	diffuse	B	['N']	[12]
13	pruritic	I	['N']	[13]
14	papular	I	['N']	[14]
15	eruption	I-Adverse_Effect	['N']	[15]
16	located	O	['N']	[16]
17	mainly	O	['N']	[17]
18	on	O	['N']	[18]
19	the	O	['N']	[19]
20	limbs	O	['N']	[20]
21	.	O	['N']	[21]
#135
0	The	O	['N']	[0]
1	hearing	B	['N']	[1]
2	impairment	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	tinnitus	O	['N']	[4]
5	were	O	['N']	[5]
6	gradually	O	['N']	[6]
7	reduced	O	['N']	[7]
8	after	O	['N']	[8]
9	PTU	B-Drug	['Causes']	[2]
10	withdrawal	O	['N']	[10]
11	and	O	['N']	[11]
12	corticosteroid	O	['N']	[12]
13	and	O	['N']	[13]
14	azathioprine	O	['N']	[14]
15	treatment	O	['N']	[15]
16	.	O	['N']	[16]
#136
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	glaucoma	B-Adverse_Effect	['N']	[5]
6	induced	O	['N']	[6]
7	by	O	['N']	[7]
8	doxetaxel	B-Drug	['Causes']	[5]
9	therapy	O	['N']	[9]
10	for	O	['N']	[10]
11	metastatic	O	['N']	[11]
12	breast	O	['N']	[12]
13	cancer	O	['N']	[13]
14	.	O	['N']	[14]
#137
0	Despite	O	['N']	[0]
1	a	O	['N']	[1]
2	very	O	['N']	[2]
3	low	O	['N']	[3]
4	complication	O	['N']	[4]
5	rate	O	['N']	[5]
6	,	O	['N']	[6]
7	several	O	['N']	[7]
8	severe	B	['N']	[8]
9	arterial	I	['N']	[9]
10	thrombotic	I	['N']	[10]
11	events	I-Adverse_Effect	['N']	[11]
12	have	O	['N']	[12]
13	been	O	['N']	[13]
14	reported	O	['N']	[14]
15	following	O	['N']	[15]
16	thrombin	B-Drug	['Causes']	[11]
17	injection	O	['N']	[17]
18	of	O	['N']	[18]
19	pseudoaneurysms	O	['N']	[19]
20	.	O	['N']	[20]
#138
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	mequitazine	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	photosensitivity	B	['N']	[6]
7	reactions	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#139
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	photo	B	['N']	[5]
6	-	I	['N']	[6]
7	onycholysis	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	doxycycline	B-Drug	['Causes']	[7]
14	for	O	['N']	[14]
15	acne	O	['N']	[15]
16	vulgaris	O	['N']	[16]
17	.	O	['N']	[17]
#140
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Prolonged	O	['N']	[2]
3	exposure	O	['N']	[3]
4	to	O	['N']	[4]
5	itraconazole	B-Drug	['Causes']	[19]
6	,	O	['N']	[6]
7	administered	O	['N']	[7]
8	either	O	['N']	[8]
9	continuously	O	['N']	[9]
10	or	O	['N']	[10]
11	intermittently	O	['N']	[11]
12	,	O	['N']	[12]
13	may	O	['N']	[13]
14	precipitate	O	['N']	[14]
15	severe	B	['N']	[15]
16	and	I	['N']	[16]
17	irreversible	I	['N']	[17]
18	hepatotoxic	I	['N']	[18]
19	events	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#141
0	A	O	['N']	[0]
1	45-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	thyrotoxicosis	O	['N']	[6]
7	developed	O	['N']	[7]
8	agranulocytosis	B-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	propylthiouracil	B-Drug	['Causes']	[8]
13	.	O	['N']	[13]
#142
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	priapism	B-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	the	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	olanzapine	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#143
0	Clinicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	that	O	['N']	[4]
5	an	O	['N']	[5]
6	erythematous	O	['N']	[6]
7	and	O	['N']	[7]
8	exfoliative	B	['N']	[8]
9	rash	I-Adverse_Effect	['N']	[9]
10	may	O	['N']	[10]
11	be	O	['N']	[11]
12	induced	O	['N']	[12]
13	by	O	['N']	[13]
14	temozolomide	B-Drug	['Causes']	[9]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	be	O	['N']	[17]
18	familiar	O	['N']	[18]
19	with	O	['N']	[19]
20	the	O	['N']	[20]
21	pharmacologic	O	['N']	[21]
22	and	O	['N']	[22]
23	supportive	O	['N']	[23]
24	measures	O	['N']	[24]
25	necessary	O	['N']	[25]
26	for	O	['N']	[26]
27	its	O	['N']	[27]
28	treatment	O	['N']	[28]
29	.	O	['N']	[29]
#144
0	The	O	['N']	[0]
1	typical	O	['N']	[1]
2	fluoxetine	B-Drug	['Causes']	[7]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	symptoms	O	['N']	[5]
6	of	O	['N']	[6]
7	restlessness	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	constant	O	['N']	[9]
10	pacing	O	['N']	[10]
11	,	O	['N']	[11]
12	purposeless	O	['N']	[12]
13	movements	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	feet	O	['N']	[16]
17	and	O	['N']	[17]
18	legs	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	marked	O	['N']	[21]
22	anxiety	O	['N']	[22]
23	were	O	['N']	[23]
24	indistinguishable	O	['N']	[24]
25	from	O	['N']	[25]
26	those	O	['N']	[26]
27	of	O	['N']	[27]
28	neuroleptic	O	['N']	[28]
29	-	O	['N']	[29]
30	induced	O	['N']	[30]
31	akathisia	O	['N']	[31]
32	.	O	['N']	[32]
#145
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	fifth	O	['N']	[2]
3	day	O	['N']	[3]
4	of	O	['N']	[4]
5	tocolysis	O	['N']	[5]
6	with	O	['N']	[6]
7	magnesium	O	['N']	[7]
8	sulfate	O	['N']	[8]
9	,	O	['N']	[9]
10	nifedipine	B-Drug	['Causes']	[16]
11	,	O	['N']	[11]
12	terbutaline	O	['N']	[12]
13	and	O	['N']	[13]
14	betamethasone	O	['N']	[14]
15	,	O	['N']	[15]
16	edema	B-Adverse_Effect	['N']	[16]
17	developed	O	['N']	[17]
18	in	O	['N']	[18]
19	both	O	['N']	[19]
20	labia	O	['N']	[20]
21	.	O	['N']	[21]
#146
0	Lymphoma	B-Adverse_Effect	['N']	[0]
1	developing	O	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	rheumatoid	O	['N']	[6]
7	arthritis	O	['N']	[7]
8	taking	O	['N']	[8]
9	methotrexate	B-Drug	['Causes']	[0]
10	.	O	['N']	[10]
#147
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	ophthalmic	O	['N']	[5]
6	features	O	['N']	[6]
7	and	O	['N']	[7]
8	clinical	O	['N']	[8]
9	course	O	['N']	[9]
10	of	O	['N']	[10]
11	two	O	['N']	[11]
12	cases	O	['N']	[12]
13	of	O	['N']	[13]
14	acute	O	['N']	[14]
15	syphilitic	O	['N']	[15]
16	posterior	O	['N']	[16]
17	placoid	O	['N']	[17]
18	chorioretinitis	O	['N']	[18]
19	(	O	['N']	[19]
20	ASPPC	B-Adverse_Effect	['N']	[20]
21	)	O	['N']	[21]
22	that	O	['N']	[22]
23	developed	O	['N']	[23]
24	after	O	['N']	[24]
25	intravitreal	O	['N']	[25]
26	triamcinolone	B	['N']	[26]
27	acetonide	I-Drug	['Causes']	[20]
28	(	O	['N']	[28]
29	IVTA	O	['N']	[29]
30	)	O	['N']	[30]
31	injection	O	['N']	[31]
32	.	O	['N']	[32]
#148
0	Amphotericin	B	['N']	[0]
1	B	I-Drug	['Dosage']	[2]
2	overdose	B-Dose	['N']	[2]
3	in	O	['N']	[3]
4	pediatric	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	associated	O	['N']	[7]
8	cardiac	O	['N']	[8]
9	arrest	O	['N']	[9]
10	.	O	['N']	[10]
#149
0	Fulminant	B	['N']	[0]
1	hepatic	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	rare	O	['N']	[5]
6	complication	O	['N']	[6]
7	of	O	['N']	[7]
8	disulfiram	B-Drug	['Causes']	[2]
9	treatment	O	['N']	[9]
10	for	O	['N']	[10]
11	alcoholism	O	['N']	[11]
12	.	O	['N']	[12]
#150
0	A	O	['N']	[0]
1	53	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	Greenlandic	O	['N']	[4]
5	male	O	['N']	[5]
6	was	O	['N']	[6]
7	admitted	O	['N']	[7]
8	twice	O	['N']	[8]
9	over	O	['N']	[9]
10	a	O	['N']	[10]
11	period	O	['N']	[11]
12	of	O	['N']	[12]
13	4	O	['N']	[13]
14	years	O	['N']	[14]
15	with	O	['N']	[15]
16	a	O	['N']	[16]
17	new	O	['N']	[17]
18	complete	O	['N']	[18]
19	right	O	['N']	[19]
20	bundle	O	['N']	[20]
21	branch	O	['N']	[21]
22	block	O	['N']	[22]
23	after	O	['N']	[23]
24	ingestion	O	['N']	[24]
25	of	O	['N']	[25]
26	10	O	['N']	[26]
27	g	O	['N']	[27]
28	and	O	['N']	[28]
29	4	B	['N']	[29]
30	g	I-Dose	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	B-Drug	['Dosage']	[30]
33	respectively	O	['N']	[33]
34	.	O	['N']	[34]
#151
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	polyserositis	B-Adverse_Effect	['N']	[9]
10	(	O	['N']	[10]
11	pericardial	O	['N']	[11]
12	effusion	O	['N']	[12]
13	,	O	['N']	[13]
14	pleural	O	['N']	[14]
15	effusion	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	pericarditis	O	['N']	[18]
19	)	O	['N']	[19]
20	after	O	['N']	[20]
21	being	O	['N']	[21]
22	started	O	['N']	[22]
23	on	O	['N']	[23]
24	clozapine	B-Drug	['Causes']	[9]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	whose	O	['N']	[27]
28	symptoms	O	['N']	[28]
29	remitted	O	['N']	[29]
30	upon	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	clozapine	O	['N']	[33]
34	.	O	['N']	[34]
#152
0	Sertraline	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	rhabdomyolysis	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	an	O	['N']	[5]
6	elderly	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	dementia	O	['N']	[9]
10	and	O	['N']	[10]
11	comorbidities	O	['N']	[11]
12	.	O	['N']	[12]
#153
0	Pheripheral	O	['N']	[0]
1	edema	O	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	in	O	['N']	[4]
5	five	O	['N']	[5]
6	female	O	['N']	[6]
7	patients	O	['N']	[7]
8	after	O	['N']	[8]
9	taking	O	['N']	[9]
10	proton	O	['N']	[10]
11	pump	O	['N']	[11]
12	inhibitors	O	['N']	[12]
13	omeprazole	B-Drug	['Dosage']	[30]
14	,	O	['N']	[14]
15	lansoprazole	O	['N']	[15]
16	,	O	['N']	[16]
17	or	O	['N']	[17]
18	pantoprazole	O	['N']	[18]
19	for	O	['N']	[19]
20	7	O	['N']	[20]
21	-	O	['N']	[21]
22	15	O	['N']	[22]
23	days	O	['N']	[23]
24	for	O	['N']	[24]
25	peptic	O	['N']	[25]
26	acid	O	['N']	[26]
27	diseases	O	['N']	[27]
28	in	O	['N']	[28]
29	recommended	O	['N']	[29]
30	standard	B-Dose	['N']	[30]
31	doses	O	['N']	[31]
32	.	O	['N']	[32]
#154
0	Concurrent	O	['N']	[0]
1	acute	O	['N']	[1]
2	megaloblastic	O	['N']	[2]
3	anaemia	O	['N']	[3]
4	and	O	['N']	[4]
5	pneumonitis	B-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	severe	O	['N']	[8]
9	side	O	['N']	[9]
10	-	O	['N']	[10]
11	effect	O	['N']	[11]
12	of	O	['N']	[12]
13	low	O	['N']	[13]
14	-	O	['N']	[14]
15	dose	O	['N']	[15]
16	methotrexate	B-Drug	['Causes']	[5]
17	therapy	O	['N']	[17]
18	during	O	['N']	[18]
19	rheumatoid	O	['N']	[19]
20	arthritis	O	['N']	[20]
21	.	O	['N']	[21]
#155
0	Late	O	['N']	[0]
1	lethal	O	['N']	[1]
2	hepatitis	B	['N']	[2]
3	B	I	['N']	[3]
4	virus	I	['N']	[4]
5	reactivation	I-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	rituximab	B-Drug	['Causes']	[5]
8	treatment	O	['N']	[8]
9	of	O	['N']	[9]
10	low	O	['N']	[10]
11	-	O	['N']	[11]
12	grade	O	['N']	[12]
13	cutaneous	O	['N']	[13]
14	B	O	['N']	[14]
15	-	O	['N']	[15]
16	cell	O	['N']	[16]
17	lymphoma	O	['N']	[17]
18	.	O	['N']	[18]
#156
0	Probable	O	['N']	[0]
1	enoxaparin	B-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	hepatotoxicity	B-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#157
0	A	O	['N']	[0]
1	33-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	recreational	O	['N']	[9]
10	benztropine	B-Drug	['Causes']	[18]
11	abuse	O	['N']	[11]
12	presented	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	emergency	O	['N']	[15]
16	department	O	['N']	[16]
17	with	O	['N']	[17]
18	confusion	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	abdominal	O	['N']	[20]
21	pain	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	distention	O	['N']	[24]
25	.	O	['N']	[25]
#158
0	It	O	['N']	[0]
1	also	O	['N']	[1]
2	highlights	O	['N']	[2]
3	a	O	['N']	[3]
4	current	O	['N']	[4]
5	major	O	['N']	[5]
6	etiologic	O	['N']	[6]
7	question	O	['N']	[7]
8	,	O	['N']	[8]
9	that	O	['N']	[9]
10	is	O	['N']	[10]
11	,	O	['N']	[11]
12	whether	O	['N']	[12]
13	and	O	['N']	[13]
14	to	O	['N']	[14]
15	what	O	['N']	[15]
16	degree	O	['N']	[16]
17	lead	B-Drug	['Causes']	[35]
18	exposure	O	['N']	[18]
19	contributes	O	['N']	[19]
20	to	O	['N']	[20]
21	the	O	['N']	[21]
22	development	O	['N']	[22]
23	of	O	['N']	[23]
24	hypertension	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	raises	O	['N']	[27]
28	the	O	['N']	[28]
29	issue	O	['N']	[29]
30	of	O	['N']	[30]
31	whether	O	['N']	[31]
32	lead	B	['N']	[32]
33	-	I	['N']	[33]
34	induced	I	['N']	[34]
35	hypertension	I-Adverse_Effect	['N']	[35]
36	constitutes	O	['N']	[36]
37	a	O	['N']	[37]
38	subset	O	['N']	[38]
39	of	O	['N']	[39]
40	hypertension	O	['N']	[40]
41	that	O	['N']	[41]
42	is	O	['N']	[42]
43	especially	O	['N']	[43]
44	amenable	O	['N']	[44]
45	to	O	['N']	[45]
46	therapy	O	['N']	[46]
47	with	O	['N']	[47]
48	dietary	O	['N']	[48]
49	calcium	O	['N']	[49]
50	.	O	['N']	[50]
#159
0	Comparable	O	['N']	[0]
1	adverse	O	['N']	[1]
2	effects	O	['N']	[2]
3	,	O	['N']	[3]
4	such	O	['N']	[4]
5	as	O	['N']	[5]
6	disorientation	O	['N']	[6]
7	and	O	['N']	[7]
8	temporary	B	['N']	[8]
9	amnesia	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	have	O	['N']	[11]
12	been	O	['N']	[12]
13	reported	O	['N']	[13]
14	in	O	['N']	[14]
15	patients	O	['N']	[15]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	analogous	O	['N']	[18]
19	agent	O	['N']	[19]
20	,	O	['N']	[20]
21	propranolol	B-Drug	['Causes']	[9]
22	.	O	['N']	[22]
#160
0	Basilar	B	['N']	[0]
1	invagination	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	mid	O	['N']	[3]
4	-	O	['N']	[4]
5	line	O	['N']	[5]
6	skeletal	O	['N']	[6]
7	abnormalities	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	in	O	['N']	[10]
11	utero	O	['N']	[11]
12	exposure	O	['N']	[12]
13	to	O	['N']	[13]
14	phenytoin	B-Drug	['Causes']	[1]
15	.	O	['N']	[15]
#161
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	diagnosed	O	['N']	[2]
3	with	O	['N']	[3]
4	Epstein	O	['N']	[4]
5	-	O	['N']	[5]
6	Barr	O	['N']	[6]
7	virus	O	['N']	[7]
8	-	O	['N']	[8]
9	associated	O	['N']	[9]
10	polymorphic	O	['N']	[10]
11	lymphoproliferative	O	['N']	[11]
12	disorder	O	['N']	[12]
13	(	O	['N']	[13]
14	LPD	B-Adverse_Effect	['N']	[14]
15	)	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	immunodeficiency	O	['N']	[18]
19	caused	O	['N']	[19]
20	by	O	['N']	[20]
21	MTX	B-Drug	['Causes']	[14]
22	administration	O	['N']	[22]
23	.	O	['N']	[23]
#162
0	Infliximab	B-Drug	['Causes']	[13]
1	and	O	['N']	[1]
2	its	O	['N']	[2]
3	serious	O	['N']	[3]
4	adverse	O	['N']	[4]
5	effects	O	['N']	[5]
6	are	O	['N']	[6]
7	discussed	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	other	O	['N']	[10]
11	cases	O	['N']	[11]
12	of	O	['N']	[12]
13	osteomyelitis	B-Adverse_Effect	['N']	[13]
14	with	O	['N']	[14]
15	infliximab	O	['N']	[15]
16	use	O	['N']	[16]
17	are	O	['N']	[17]
18	also	O	['N']	[18]
19	reviewed	O	['N']	[19]
20	.	O	['N']	[20]
#163
0	Hyperkalemia	B-Adverse_Effect	['N']	[0]
1	as	O	['N']	[1]
2	a	O	['N']	[2]
3	late	O	['N']	[3]
4	side	O	['N']	[4]
5	effect	O	['N']	[5]
6	of	O	['N']	[6]
7	prolonged	O	['N']	[7]
8	adrenocorticotropic	B	['N']	[8]
9	hormone	I-Drug	['Causes']	[0]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	infantile	O	['N']	[12]
13	spasms	O	['N']	[13]
14	.	O	['N']	[14]
#164
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	halothane	B-Drug	['Causes']	[5]
4	induced	O	['N']	[4]
5	hepatitis	B-Adverse_Effect	['N']	[5]
6	is	O	['N']	[6]
7	reported	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	middle	O	['N']	[10]
11	aged	O	['N']	[11]
12	woman	O	['N']	[12]
13	who	O	['N']	[13]
14	underwent	O	['N']	[14]
15	gastric	O	['N']	[15]
16	surgery	O	['N']	[16]
17	for	O	['N']	[17]
18	morbid	O	['N']	[18]
19	obesity	O	['N']	[19]
20	.	O	['N']	[20]
#165
0	Isoniazid	B-Drug	['Causes']	[11]
1	inhibits	O	['N']	[1]
2	the	O	['N']	[2]
3	conversion	O	['N']	[3]
4	of	O	['N']	[4]
5	tryptophan	O	['N']	[5]
6	to	O	['N']	[6]
7	niacin	O	['N']	[7]
8	and	O	['N']	[8]
9	may	O	['N']	[9]
10	induce	O	['N']	[10]
11	pellagra	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	particularly	O	['N']	[13]
14	in	O	['N']	[14]
15	poorly	O	['N']	[15]
16	nourished	O	['N']	[16]
17	patients	O	['N']	[17]
18	.	O	['N']	[18]
#166
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	previously	O	['N']	[8]
9	prescribed	O	['N']	[9]
10	alendronate	O	['N']	[10]
11	(	O	['N']	[11]
12	Fosamax	B-Drug	['Causes']	[21]
13	)	O	['N']	[13]
14	and	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	postoperative	O	['N']	[17]
18	hypophosphatemia	O	['N']	[18]
19	and	O	['N']	[19]
20	hypocalcemic	B	['N']	[20]
21	tetany	I-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	bowel	O	['N']	[23]
24	preparation	O	['N']	[24]
25	with	O	['N']	[25]
26	Fleet	O	['N']	[26]
27	Phospho	O	['N']	[27]
28	-	O	['N']	[28]
29	Soda	O	['N']	[29]
30	.	O	['N']	[30]
#167
0	While	O	['N']	[0]
1	40	O	['N']	[1]
2	mg	O	['N']	[2]
3	/	O	['N']	[3]
4	day	O	['N']	[4]
5	of	O	['N']	[5]
6	prednisolone	B-Drug	['Causes']	[15]
7	improved	O	['N']	[7]
8	hepatic	O	['N']	[8]
9	dysfunction	O	['N']	[9]
10	dramatically	O	['N']	[10]
11	,	O	['N']	[11]
12	her	O	['N']	[12]
13	diabetic	B	['N']	[13]
14	milieu	I	['N']	[14]
15	deteriorated	I-Adverse_Effect	['N']	[15]
16	seriously	O	['N']	[16]
17	.	O	['N']	[17]
#168
0	After	O	['N']	[0]
1	the	O	['N']	[1]
2	addition	O	['N']	[2]
3	of	O	['N']	[3]
4	citalopram	B-Drug	['Causes']	[10]
5	,	O	['N']	[5]
6	a	O	['N']	[6]
7	desmethylclomipramine	B	['N']	[7]
8	plasma	I	['N']	[8]
9	level	I	['N']	[9]
10	increase	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	an	O	['N']	[12]
13	8-hydroacy	O	['N']	[13]
14	-	O	['N']	[14]
15	desmethylclomipramine	O	['N']	[15]
16	plasma	O	['N']	[16]
17	level	O	['N']	[17]
18	decrease	O	['N']	[18]
19	were	O	['N']	[19]
20	observed	O	['N']	[20]
21	.	O	['N']	[21]
#169
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	use	O	['N']	[3]
4	of	O	['N']	[4]
5	fluorouracil	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	careful	O	['N']	[8]
9	monitoring	O	['N']	[9]
10	can	O	['N']	[10]
11	be	O	['N']	[11]
12	considered	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	patient	O	['N']	[15]
16	with	O	['N']	[16]
17	mild	O	['N']	[17]
18	allergic	B	['N']	[18]
19	reactions	I-Adverse_Effect	['N']	[19]
20	to	O	['N']	[20]
21	capecitabine	B-Drug	['Causes']	[19]
22	.	O	['N']	[22]
#170
0	Such	O	['N']	[0]
1	a	O	['N']	[1]
2	rapid	O	['N']	[2]
3	and	O	['N']	[3]
4	relentless	O	['N']	[4]
5	progression	O	['N']	[5]
6	of	O	['N']	[6]
7	methyldopa	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	liver	B	['N']	[10]
11	injury	I-Adverse_Effect	['N']	[11]
12	is	O	['N']	[12]
13	undoubtedly	O	['N']	[13]
14	rare	O	['N']	[14]
15	,	O	['N']	[15]
16	but	O	['N']	[16]
17	it	O	['N']	[17]
18	may	O	['N']	[18]
19	be	O	['N']	[19]
20	prevented	O	['N']	[20]
21	by	O	['N']	[21]
22	careful	O	['N']	[22]
23	supervision	O	['N']	[23]
24	of	O	['N']	[24]
25	patients	O	['N']	[25]
26	who	O	['N']	[26]
27	exhibit	O	['N']	[27]
28	liver	O	['N']	[28]
29	function	O	['N']	[29]
30	abnormalities	O	['N']	[30]
31	early	O	['N']	[31]
32	in	O	['N']	[32]
33	the	O	['N']	[33]
34	course	O	['N']	[34]
35	of	O	['N']	[35]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#171
0	Schneiderian	B	['N']	[0]
1	first	I	['N']	[1]
2	-	I	['N']	[2]
3	rank	I	['N']	[3]
4	symptoms	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	fluvoxamine	B-Drug	['Causes']	[4]
8	treatment	O	['N']	[8]
9	:	O	['N']	[9]
10	a	O	['N']	[10]
11	case	O	['N']	[11]
12	report	O	['N']	[12]
13	.	O	['N']	[13]
#172
0	We	O	['N']	[0]
1	are	O	['N']	[1]
2	concerned	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	macular	B	['N']	[5]
6	lesion	I-Adverse_Effect	['N']	[6]
7	was	O	['N']	[7]
8	a	O	['N']	[8]
9	retinal	O	['N']	[9]
10	toxic	O	['N']	[10]
11	effect	O	['N']	[11]
12	of	O	['N']	[12]
13	gentamicin	B-Drug	['Causes']	[6]
14	because	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	recent	O	['N']	[17]
18	description	O	['N']	[18]
19	of	O	['N']	[19]
20	similar	O	['N']	[20]
21	lesions	O	['N']	[21]
22	occurring	O	['N']	[22]
23	after	O	['N']	[23]
24	the	O	['N']	[24]
25	inadvertent	O	['N']	[25]
26	intraocular	O	['N']	[26]
27	injection	O	['N']	[27]
28	of	O	['N']	[28]
29	massive	O	['N']	[29]
30	doses	O	['N']	[30]
31	of	O	['N']	[31]
32	this	O	['N']	[32]
33	drug	O	['N']	[33]
34	.	O	['N']	[34]
#173
0	The	O	['N']	[0]
1	hepatic	B	['N']	[1]
2	enzyme	I	['N']	[2]
3	disturbances	I-Adverse_Effect	['N']	[3]
4	normalized	O	['N']	[4]
5	after	O	['N']	[5]
6	discontinuation	O	['N']	[6]
7	of	O	['N']	[7]
8	pegvisomant	B-Drug	['Causes']	[3]
9	.	O	['N']	[9]
#174
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	observation	O	['N']	[3]
4	of	O	['N']	[4]
5	"	O	['N']	[5]
6	on	O	['N']	[6]
7	-	O	['N']	[7]
8	off	O	['N']	[8]
9	"	O	['N']	[9]
10	risperidone	B-Drug	['Causes']	[22]
11	treatment	O	['N']	[11]
12	suggests	O	['N']	[12]
13	that	O	['N']	[13]
14	risperidone	O	['N']	[14]
15	may	O	['N']	[15]
16	have	O	['N']	[16]
17	worsened	O	['N']	[17]
18	both	O	['N']	[18]
19	psychiatric	B	['N']	[19]
20	and	I	['N']	[20]
21	physical	I	['N']	[21]
22	manifestations	I-Adverse_Effect	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	mitochondrial	O	['N']	[25]
26	disorder	O	['N']	[26]
27	in	O	['N']	[27]
28	this	O	['N']	[28]
29	adolescent	O	['N']	[29]
30	.	O	['N']	[30]
#175
0	Aggressive	O	['N']	[0]
1	management	O	['N']	[1]
2	of	O	['N']	[2]
3	doxorubicin	B-Drug	['Dosage']	[12]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	cardiomyopathy	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	'	B	['N']	[9]
10	low	I	['N']	[10]
11	'	I	['N']	[11]
12	doses	I-Dose	['N']	[12]
13	of	O	['N']	[13]
14	doxorubicin	O	['N']	[14]
15	.	O	['N']	[15]
#176
0	Cholestatic	O	['N']	[0]
1	liver	O	['N']	[1]
2	disease	O	['N']	[2]
3	with	O	['N']	[3]
4	ductopenia	B-Adverse_Effect	['N']	[4]
5	(	O	['N']	[5]
6	vanishing	O	['N']	[6]
7	bile	O	['N']	[7]
8	duct	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	)	O	['N']	[10]
11	after	O	['N']	[11]
12	administration	O	['N']	[12]
13	of	O	['N']	[13]
14	clindamycin	O	['N']	[14]
15	and	O	['N']	[15]
16	trimethoprim	B	['N']	[16]
17	-	I	['N']	[17]
18	sulfamethoxazole	I-Drug	['Causes']	[4]
19	.	O	['N']	[19]
#177
0	A	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[24]
2	hypersensitivity	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	,	O	['N']	[4]
5	consisting	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	nausea	O	['N']	[11]
12	,	O	['N']	[12]
13	vomiting	O	['N']	[13]
14	,	O	['N']	[14]
15	lymphadenopathy	O	['N']	[15]
16	,	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	,	O	['N']	[18]
19	hemolysis	O	['N']	[19]
20	,	O	['N']	[20]
21	leukopenia	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	mononucleosis	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	for	O	['N']	[35]
36	leprosy	O	['N']	[36]
37	.	O	['N']	[37]
#178
0	Previous	O	['N']	[0]
1	studies	O	['N']	[1]
2	have	O	['N']	[2]
3	demonstrated	O	['N']	[3]
4	the	O	['N']	[4]
5	interaction	O	['N']	[5]
6	of	O	['N']	[6]
7	MTX	B-Drug	['Causes']	[30]
8	and	O	['N']	[8]
9	a	O	['N']	[9]
10	variety	O	['N']	[10]
11	of	O	['N']	[11]
12	non	O	['N']	[12]
13	-	O	['N']	[13]
14	steroidal	O	['N']	[14]
15	,	O	['N']	[15]
16	anti	O	['N']	[16]
17	-	O	['N']	[17]
18	inflammatory	O	['N']	[18]
19	drugs	O	['N']	[19]
20	(	O	['N']	[20]
21	NSAIDs	O	['N']	[21]
22	)	O	['N']	[22]
23	with	O	['N']	[23]
24	various	O	['N']	[24]
25	clinical	O	['N']	[25]
26	manifestations	O	['N']	[26]
27	including	O	['N']	[27]
28	acute	B	['N']	[28]
29	renal	I	['N']	[29]
30	failure	I-Adverse_Effect	['N']	[30]
31	,	O	['N']	[31]
32	pancytopenia	O	['N']	[32]
33	,	O	['N']	[33]
34	vomiting	O	['N']	[34]
35	,	O	['N']	[35]
36	diarrhea	O	['N']	[36]
37	,	O	['N']	[37]
38	elevated	O	['N']	[38]
39	liver	O	['N']	[39]
40	transaminases	O	['N']	[40]
41	,	O	['N']	[41]
42	jaundice	O	['N']	[42]
43	,	O	['N']	[43]
44	mucosal	O	['N']	[44]
45	ulcerations	O	['N']	[45]
46	,	O	['N']	[46]
47	and	O	['N']	[47]
48	pyrexia	O	['N']	[48]
49	.	O	['N']	[49]
#179
0	Phenytoin	O	['N']	[0]
1	was	O	['N']	[1]
2	discontinued	O	['N']	[2]
3	after	O	['N']	[3]
4	admission	O	['N']	[4]
5	;	O	['N']	[5]
6	however	O	['N']	[6]
7	,	O	['N']	[7]
8	phenytoin	B-Drug	['Causes']	[33]
9	1	O	['N']	[9]
10	g	O	['N']	[10]
11	i.v	O	['N']	[11]
12	.	O	['N']	[12]
13	was	O	['N']	[13]
14	given	O	['N']	[14]
15	for	O	['N']	[15]
16	a	O	['N']	[16]
17	tonic	O	['N']	[17]
18	-	O	['N']	[18]
19	clonic	O	['N']	[19]
20	seizure	O	['N']	[20]
21	two	O	['N']	[21]
22	days	O	['N']	[22]
23	after	O	['N']	[23]
24	admission	O	['N']	[24]
25	,	O	['N']	[25]
26	after	O	['N']	[26]
27	which	O	['N']	[27]
28	swelling	B	['N']	[28]
29	of	I	['N']	[29]
30	the	I	['N']	[30]
31	face	I	['N']	[31]
32	and	I	['N']	[32]
33	legs	I-Adverse_Effect	['N']	[33]
34	and	O	['N']	[34]
35	pruritus	O	['N']	[35]
36	developed	O	['N']	[36]
37	.	O	['N']	[37]
#180
0	Gynecomastia	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	theophylline	B-Drug	['Causes']	[0]
4	.	O	['N']	[4]
#181
0	A	O	['N']	[0]
1	retrospective	O	['N']	[1]
2	review	O	['N']	[2]
3	of	O	['N']	[3]
4	TTP	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	quinine	B-Drug	['Causes']	[13]
8	-	O	['N']	[8]
9	associated	O	['N']	[9]
10	thrombotic	O	['N']	[10]
11	microangiopathy	O	['N']	[11]
12	(	O	['N']	[12]
13	TMA	B-Adverse_Effect	['N']	[13]
14	)	O	['N']	[14]
15	for	O	['N']	[15]
16	whom	O	['N']	[16]
17	ADAMTS13	O	['N']	[17]
18	was	O	['N']	[18]
19	measured	O	['N']	[19]
20	before	O	['N']	[20]
21	plasma	O	['N']	[21]
22	exchange	O	['N']	[22]
23	was	O	['N']	[23]
24	performed	O	['N']	[24]
25	.	O	['N']	[25]
#182
0	Prenatal	B	['N']	[0]
1	cytomegalovirus	I	['N']	[1]
2	(	I	['N']	[2]
3	CMV	I	['N']	[3]
4	)	I	['N']	[4]
5	infection	I-Adverse_Effect	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	severe	O	['N']	[8]
9	brain	O	['N']	[9]
10	damage	O	['N']	[10]
11	was	O	['N']	[11]
12	detected	O	['N']	[12]
13	in	O	['N']	[13]
14	an	O	['N']	[14]
15	infant	O	['N']	[15]
16	whose	O	['N']	[16]
17	mother	O	['N']	[17]
18	had	O	['N']	[18]
19	been	O	['N']	[19]
20	treated	O	['N']	[20]
21	with	O	['N']	[21]
22	prednisolone	O	['N']	[22]
23	and	O	['N']	[23]
24	azathioprine	B-Drug	['Causes']	[5]
25	for	O	['N']	[25]
26	systemic	O	['N']	[26]
27	lupus	O	['N']	[27]
28	erythematosus	O	['N']	[28]
29	(	O	['N']	[29]
30	SLE	O	['N']	[30]
31	)	O	['N']	[31]
32	.	O	['N']	[32]
#183
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	O	['N']	[32]
33	(	O	['N']	[33]
34	CBZ	B-Drug	['Causes']	[13]
35	;	O	['N']	[35]
36	Tegretol	O	['N']	[36]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#184
0	Metoclopramide	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	parkinsonism	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#185
0	One	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	subjects	O	['N']	[3]
4	who	O	['N']	[4]
5	was	O	['N']	[5]
6	using	O	['N']	[6]
7	extemporaneous	O	['N']	[7]
8	topical	O	['N']	[8]
9	minoxidil	B-Drug	['Causes']	[22]
10	had	O	['N']	[10]
11	hypertension	O	['N']	[11]
12	and	O	['N']	[12]
13	arteriosclerotic	O	['N']	[13]
14	disease	O	['N']	[14]
15	and	O	['N']	[15]
16	the	O	['N']	[16]
17	other	O	['N']	[17]
18	died	O	['N']	[18]
19	of	O	['N']	[19]
20	a	O	['N']	[20]
21	myocardial	B	['N']	[21]
22	infarction	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#186
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Patients	O	['N']	[2]
3	receiving	O	['N']	[3]
4	intravitreal	O	['N']	[4]
5	injections	O	['N']	[5]
6	of	O	['N']	[6]
7	bevacizumab	B-Drug	['Causes']	[19]
8	should	O	['N']	[8]
9	be	O	['N']	[9]
10	evaluated	O	['N']	[10]
11	for	O	['N']	[11]
12	potential	O	['N']	[12]
13	systemic	O	['N']	[13]
14	risk	O	['N']	[14]
15	factors	O	['N']	[15]
16	such	O	['N']	[16]
17	as	O	['N']	[17]
18	carotid	B	['N']	[18]
19	insufficiency	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	coagulopathy	O	['N']	[21]
22	and	O	['N']	[22]
23	poorly	O	['N']	[23]
24	controlled	O	['N']	[24]
25	diabetes	O	['N']	[25]
26	mellitus	O	['N']	[26]
27	.	O	['N']	[27]
#187
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	During	O	['N']	[2]
3	and	O	['N']	[3]
4	after	O	['N']	[4]
5	IFN	B-Drug	['Causes']	[23]
6	therapy	O	['N']	[6]
7	,	O	['N']	[7]
8	OCT	O	['N']	[8]
9	is	O	['N']	[9]
10	a	O	['N']	[10]
11	useful	O	['N']	[11]
12	examination	O	['N']	[12]
13	technique	O	['N']	[13]
14	for	O	['N']	[14]
15	revealing	O	['N']	[15]
16	macular	O	['N']	[16]
17	edema	O	['N']	[17]
18	in	O	['N']	[18]
19	patients	O	['N']	[19]
20	who	O	['N']	[20]
21	have	O	['N']	[21]
22	decreased	B	['N']	[22]
23	vision	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#188
0	Shortly	O	['N']	[0]
1	after	O	['N']	[1]
2	chemotherapy	O	['N']	[2]
3	and	O	['N']	[3]
4	an	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	pegfilgrastim	B-Drug	['Causes']	[19]
8	,	O	['N']	[8]
9	the	O	['N']	[9]
10	patient	O	['N']	[10]
11	developed	O	['N']	[11]
12	poorly	O	['N']	[12]
13	defined	O	['N']	[13]
14	,	O	['N']	[14]
15	rapidly	O	['N']	[15]
16	progressive	O	['N']	[16]
17	erythema	O	['N']	[17]
18	,	O	['N']	[18]
19	edema	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	pain	O	['N']	[22]
23	in	O	['N']	[23]
24	his	O	['N']	[24]
25	right	O	['N']	[25]
26	forearm	O	['N']	[26]
27	.	O	['N']	[27]
#189
0	In	O	['N']	[0]
1	three	O	['N']	[1]
2	of	O	['N']	[2]
3	these	O	['N']	[3]
4	patients	O	['N']	[4]
5	the	O	['N']	[5]
6	infection	O	['N']	[6]
7	was	O	['N']	[7]
8	clinically	O	['N']	[8]
9	unsuspected	O	['N']	[9]
10	;	O	['N']	[10]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	fourth	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	B	['N']	[15]
16	herpes	I	['N']	[16]
17	zoster	I-Adverse_Effect	['N']	[17]
18	developed	O	['N']	[18]
19	after	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	300	O	['N']	[22]
23	mg	O	['N']	[23]
24	of	O	['N']	[24]
25	cytarabine	B-Drug	['Causes']	[17]
26	daily	O	['N']	[26]
27	for	O	['N']	[27]
28	the	O	['N']	[28]
29	preceding	O	['N']	[29]
30	five	O	['N']	[30]
31	days	O	['N']	[31]
32	.	O	['N']	[32]
#190
0	Electrical	B	['N']	[0]
1	proarrhythmia	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	procainamide	B-Drug	['Causes']	[1]
4	:	O	['N']	[4]
5	a	O	['N']	[5]
6	new	O	['N']	[6]
7	ICD	O	['N']	[7]
8	-	O	['N']	[8]
9	drug	O	['N']	[9]
10	interaction	O	['N']	[10]
11	.	O	['N']	[11]
#191
0	Withdrawal	B	['N']	[0]
1	emergent	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	an	O	['N']	[4]
5	infant	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	maternal	O	['N']	[8]
9	haloperidol	B-Drug	['Causes']	[2]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#192
0	Intrahepatic	O	['N']	[0]
1	cholestasis	O	['N']	[1]
2	and	O	['N']	[2]
3	cutaneous	B	['N']	[3]
4	bullae	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	glibenclamide	B-Drug	['Causes']	[4]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#193
0	Methemoglobinemia	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	another	O	['N']	[2]
3	common	O	['N']	[3]
4	finding	O	['N']	[4]
5	among	O	['N']	[5]
6	patients	O	['N']	[6]
7	receiving	O	['N']	[7]
8	dapsone	B-Drug	['Causes']	[0]
9	therapy	O	['N']	[9]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	rarely	O	['N']	[12]
13	does	O	['N']	[13]
14	it	O	['N']	[14]
15	result	O	['N']	[15]
16	in	O	['N']	[16]
17	prominent	O	['N']	[17]
18	symptoms	O	['N']	[18]
19	other	O	['N']	[19]
20	than	O	['N']	[20]
21	transient	O	['N']	[21]
22	pallor	O	['N']	[22]
23	.	O	['N']	[23]
#194
0	When	O	['N']	[0]
1	the	O	['N']	[1]
2	acute	O	['N']	[2]
3	manic	O	['N']	[3]
4	state	O	['N']	[4]
5	is	O	['N']	[5]
6	characterized	O	['N']	[6]
7	by	O	['N']	[7]
8	marked	O	['N']	[8]
9	psychotic	O	['N']	[9]
10	symptoms	O	['N']	[10]
11	and	O	['N']	[11]
12	intense	B	['N']	[12]
13	anxiety	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	it	O	['N']	[15]
16	may	O	['N']	[16]
17	be	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	increased	O	['N']	[20]
21	vulnerability	O	['N']	[21]
22	to	O	['N']	[22]
23	the	O	['N']	[23]
24	development	O	['N']	[24]
25	of	O	['N']	[25]
26	severe	O	['N']	[26]
27	lithium	B-Drug	['Causes']	[13]
28	neurotoxicity	O	['N']	[28]
29	.	O	['N']	[29]
#195
0	Our	O	['N']	[0]
1	report	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	CBDCA	B-Drug	['Dosage']	[50]
5	hypersensitivity	O	['N']	[5]
6	was	O	['N']	[6]
7	correlated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	total	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	previously	O	['N']	[13]
14	administered	O	['N']	[14]
15	platinum	O	['N']	[15]
16	agents	O	['N']	[16]
17	and	O	['N']	[17]
18	that	O	['N']	[18]
19	CBDCA	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	excluded	O	['N']	[22]
23	in	O	['N']	[23]
24	patients	O	['N']	[24]
25	who	O	['N']	[25]
26	have	O	['N']	[26]
27	received	O	['N']	[27]
28	multiple	O	['N']	[28]
29	platinum	O	['N']	[29]
30	-	O	['N']	[30]
31	based	O	['N']	[31]
32	chemotherapy	O	['N']	[32]
33	,	O	['N']	[33]
34	even	O	['N']	[34]
35	in	O	['N']	[35]
36	platinum	O	['N']	[36]
37	-	O	['N']	[37]
38	sensitive	O	['N']	[38]
39	cases	O	['N']	[39]
40	,	O	['N']	[40]
41	because	O	['N']	[41]
42	CBDCA	O	['N']	[42]
43	hypersensitivity	O	['N']	[43]
44	can	O	['N']	[44]
45	occur	O	['N']	[45]
46	even	O	['N']	[46]
47	with	O	['N']	[47]
48	low	B	['N']	[48]
49	-	I	['N']	[49]
50	dose	I-Dose	['N']	[50]
51	CBDCA	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#196
0	Three	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	receiving	O	['N']	[3]
4	intravitreal	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	bevacizumab	B-Drug	['Causes']	[24]
8	(	O	['N']	[8]
9	1.25	O	['N']	[9]
10	mg	O	['N']	[10]
11	in	O	['N']	[11]
12	0.1	O	['N']	[12]
13	ml	O	['N']	[13]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	he	O	['N']	[16]
17	developed	O	['N']	[17]
18	acute	O	['N']	[18]
19	vision	O	['N']	[19]
20	loss	O	['N']	[20]
21	and	O	['N']	[21]
22	change	B	['N']	[22]
23	of	I	['N']	[23]
24	consciousness	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#197
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	use	O	['N']	[8]
9	of	O	['N']	[9]
10	pamidronate	O	['N']	[10]
11	for	O	['N']	[11]
12	significant	O	['N']	[12]
13	hypercalcemia	B-Adverse_Effect	['N']	[13]
14	secondary	O	['N']	[14]
15	to	O	['N']	[15]
16	acute	O	['N']	[16]
17	vitamin	B	['N']	[17]
18	D	I-Drug	['Causes']	[13]
19	poisoning	O	['N']	[19]
20	.	O	['N']	[20]
#198
0	Electrocardiographic	O	['N']	[0]
1	findings	O	['N']	[1]
2	and	O	['N']	[2]
3	laboratory	O	['N']	[3]
4	data	O	['N']	[4]
5	indicated	O	['N']	[5]
6	a	O	['N']	[6]
7	diagnosis	O	['N']	[7]
8	of	O	['N']	[8]
9	acute	B	['N']	[9]
10	myocardial	I	['N']	[10]
11	infarction	I-Adverse_Effect	['N']	[11]
12	due	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	L	B	['N']	[15]
16	-	I	['N']	[16]
17	thyroxine	I-Drug	['Causes']	[11]
18	therapy	O	['N']	[18]
19	.	O	['N']	[19]
#199
0	Purple	O	['N']	[0]
1	glove	O	['N']	[1]
2	syndrome	O	['N']	[2]
3	,	O	['N']	[3]
4	named	O	['N']	[4]
5	for	O	['N']	[5]
6	its	O	['N']	[6]
7	distinctive	O	['N']	[7]
8	purple	B	['N']	[8]
9	discoloration	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	swelling	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	hands	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	distribution	O	['N']	[17]
18	of	O	['N']	[18]
19	a	O	['N']	[19]
20	glove	O	['N']	[20]
21	,	O	['N']	[21]
22	is	O	['N']	[22]
23	an	O	['N']	[23]
24	uncommon	O	['N']	[24]
25	complication	O	['N']	[25]
26	of	O	['N']	[26]
27	intravenous	O	['N']	[27]
28	phenytoin	B-Drug	['Causes']	[9]
29	administration	O	['N']	[29]
30	through	O	['N']	[30]
31	small	O	['N']	[31]
32	dorsal	O	['N']	[32]
33	veins	O	['N']	[33]
34	of	O	['N']	[34]
35	the	O	['N']	[35]
36	hands	O	['N']	[36]
37	.	O	['N']	[37]
#200
0	High	B	['N']	[0]
1	-	I	['N']	[1]
2	dose	I-Dose	['N']	[2]
3	methotrexate	B-Drug	['Dosage']	[2]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	acute	O	['N']	[6]
7	renal	O	['N']	[7]
8	failure	O	['N']	[8]
9	may	O	['N']	[9]
10	be	O	['N']	[10]
11	an	O	['N']	[11]
12	avoidable	O	['N']	[12]
13	complication	O	['N']	[13]
14	.	O	['N']	[14]
#201
0	Fixed	O	['N']	[0]
1	drug	O	['N']	[1]
2	eruption	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	hands	O	['N']	[4]
5	caused	O	['N']	[5]
6	by	O	['N']	[6]
7	omeprazole	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#202
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	43-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	sore	B	['N']	[9]
10	throat	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	swelling	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	lips	O	['N']	[15]
16	and	O	['N']	[16]
17	oral	O	['N']	[17]
18	cavity	O	['N']	[18]
19	and	O	['N']	[19]
20	dysphagia	O	['N']	[20]
21	,	O	['N']	[21]
22	2	O	['N']	[22]
23	weeks	O	['N']	[23]
24	after	O	['N']	[24]
25	the	O	['N']	[25]
26	use	O	['N']	[26]
27	of	O	['N']	[27]
28	budesonide	B-Drug	['Causes']	[10]
29	spray	O	['N']	[29]
30	(	O	['N']	[30]
31	Budefat	O	['N']	[31]
32	)	O	['N']	[32]
33	for	O	['N']	[33]
34	treatment	O	['N']	[34]
35	of	O	['N']	[35]
36	bronchial	O	['N']	[36]
37	asthma	O	['N']	[37]
38	.	O	['N']	[38]
#203
0	Hence	O	['N']	[0]
1	,	O	['N']	[1]
2	hyperthyroidism	B-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	IFN	B	['N']	[5]
6	-	I	['N']	[6]
7	alpha	I-Drug	['Causes']	[2]
8	could	O	['N']	[8]
9	correspond	O	['N']	[9]
10	to	O	['N']	[10]
11	the	O	['N']	[11]
12	first	O	['N']	[12]
13	phase	O	['N']	[13]
14	of	O	['N']	[14]
15	silent	O	['N']	[15]
16	thyroiditis	O	['N']	[16]
17	,	O	['N']	[17]
18	to	O	['N']	[18]
19	Graves	O	['N']	[19]
20	'	O	['N']	[20]
21	disease	O	['N']	[21]
22	or	O	['N']	[22]
23	to	O	['N']	[23]
24	the	O	['N']	[24]
25	succession	O	['N']	[25]
26	of	O	['N']	[26]
27	both	O	['N']	[27]
28	.	O	['N']	[28]
#204
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	SJS	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	14-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	male	O	['N']	[11]
12	with	O	['N']	[12]
13	nephrotic	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	,	O	['N']	[15]
16	who	O	['N']	[16]
17	was	O	['N']	[17]
18	treated	O	['N']	[18]
19	with	O	['N']	[19]
20	oral	O	['N']	[20]
21	prednisolone	B-Drug	['Causes']	[5]
22	for	O	['N']	[22]
23	6	O	['N']	[23]
24	weeks	O	['N']	[24]
25	.	O	['N']	[25]
#205
0	Electro	O	['N']	[0]
1	-	O	['N']	[1]
2	oculography	O	['N']	[2]
3	,	O	['N']	[3]
4	electroretinography	O	['N']	[4]
5	,	O	['N']	[5]
6	visual	O	['N']	[6]
7	evoked	O	['N']	[7]
8	potentials	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	multifocal	O	['N']	[11]
12	electroretinography	O	['N']	[12]
13	in	O	['N']	[13]
14	patients	O	['N']	[14]
15	with	O	['N']	[15]
16	vigabatrin	B-Drug	['Causes']	[21]
17	-	O	['N']	[17]
18	attributed	O	['N']	[18]
19	visual	B	['N']	[19]
20	field	I	['N']	[20]
21	constriction	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#206
0	Lower	O	['N']	[0]
1	extremity	O	['N']	[1]
2	arterial	B	['N']	[2]
3	thrombosis	I-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	sonographically	O	['N']	[5]
6	guided	O	['N']	[6]
7	thrombin	B-Drug	['Causes']	[3]
8	injection	O	['N']	[8]
9	of	O	['N']	[9]
10	a	O	['N']	[10]
11	femoral	O	['N']	[11]
12	pseudoaneurysm	O	['N']	[12]
13	.	O	['N']	[13]
#207
0	Acute	B	['N']	[0]
1	interstitial	I	['N']	[1]
2	nephritis	I-Adverse_Effect	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	pantoprazole	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#208
0	Soon	O	['N']	[0]
1	after	O	['N']	[1]
2	its	O	['N']	[2]
3	introduction	O	['N']	[3]
4	in	O	['N']	[4]
5	1952	O	['N']	[5]
6	,	O	['N']	[6]
7	chlorpromazine	B-Drug	['Causes']	[16]
8	was	O	['N']	[8]
9	noted	O	['N']	[9]
10	to	O	['N']	[10]
11	induce	O	['N']	[11]
12	symptoms	B	['N']	[12]
13	resembling	I	['N']	[13]
14	Parkinson	I	['N']	[14]
15	's	I	['N']	[15]
16	disease	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#209
0	When	O	['N']	[0]
1	pilsicainide	B-Drug	['Causes']	[24]
2	is	O	['N']	[2]
3	prescribed	O	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	coronary	O	['N']	[7]
8	artery	O	['N']	[8]
9	disease	O	['N']	[9]
10	or	O	['N']	[10]
11	renal	O	['N']	[11]
12	dysfunction	O	['N']	[12]
13	,	O	['N']	[13]
14	close	O	['N']	[14]
15	attention	O	['N']	[15]
16	must	O	['N']	[16]
17	be	O	['N']	[17]
18	paid	O	['N']	[18]
19	to	O	['N']	[19]
20	avoid	O	['N']	[20]
21	life	B	['N']	[21]
22	-	I	['N']	[22]
23	threatening	I	['N']	[23]
24	arrhythmias	I-Adverse_Effect	['N']	[24]
25	due	O	['N']	[25]
26	to	O	['N']	[26]
27	high	O	['N']	[27]
28	plasma	O	['N']	[28]
29	concentrations	O	['N']	[29]
30	of	O	['N']	[30]
31	the	O	['N']	[31]
32	drug	O	['N']	[32]
33	.	O	['N']	[33]
#210
0	Acute	O	['N']	[0]
1	pulmonary	O	['N']	[1]
2	reactions	O	['N']	[2]
3	to	O	['N']	[3]
4	nitrofurantoin	B-Drug	['Causes']	[21]
5	are	O	['N']	[5]
6	an	O	['N']	[6]
7	uncommon	O	['N']	[7]
8	side	O	['N']	[8]
9	effect	O	['N']	[9]
10	of	O	['N']	[10]
11	therapy	O	['N']	[11]
12	and	O	['N']	[12]
13	can	O	['N']	[13]
14	cause	O	['N']	[14]
15	minor	O	['N']	[15]
16	or	O	['N']	[16]
17	life	O	['N']	[17]
18	-	O	['N']	[18]
19	threatening	O	['N']	[19]
20	pulmonary	B	['N']	[20]
21	dysfunction	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#211
0	Two	O	['N']	[0]
1	reports	O	['N']	[1]
2	of	O	['N']	[2]
3	spindle	B	['N']	[3]
4	coma	I-Adverse_Effect	['N']	[4]
5	are	O	['N']	[5]
6	noted	O	['N']	[6]
7	with	O	['N']	[7]
8	alcohol	O	['N']	[8]
9	and	O	['N']	[9]
10	imipramine	B-Drug	['Causes']	[4]
11	.	O	['N']	[11]
#212
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	is	O	['N']	[3]
4	presented	O	['N']	[4]
5	concerning	O	['N']	[5]
6	the	O	['N']	[6]
7	administration	O	['N']	[7]
8	of	O	['N']	[8]
9	ketanserin	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	treatment	O	['N']	[12]
13	of	O	['N']	[13]
14	pulmonary	O	['N']	[14]
15	vasoconstriction	O	['N']	[15]
16	and	O	['N']	[16]
17	right	B	['N']	[17]
18	ventricular	I	['N']	[18]
19	failure	I-Adverse_Effect	['N']	[19]
20	following	O	['N']	[20]
21	the	O	['N']	[21]
22	infusion	O	['N']	[22]
23	of	O	['N']	[23]
24	protamine	B-Drug	['Causes']	[19]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	patient	O	['N']	[27]
28	undergoing	O	['N']	[28]
29	coronary	O	['N']	[29]
30	artery	O	['N']	[30]
31	bypass	O	['N']	[31]
32	surgery	O	['N']	[32]
33	and	O	['N']	[33]
34	mitral	O	['N']	[34]
35	valve	O	['N']	[35]
36	replacement	O	['N']	[36]
37	.	O	['N']	[37]
#213
0	Ototoxicity	B-Adverse_Effect	['N']	[0]
1	as	O	['N']	[1]
2	a	O	['N']	[2]
3	result	O	['N']	[3]
4	of	O	['N']	[4]
5	cis	B	['N']	[5]
6	-	I	['N']	[6]
7	platinum	I-Drug	['Causes']	[0]
8	administration	O	['N']	[8]
9	is	O	['N']	[9]
10	well	O	['N']	[10]
11	documented	O	['N']	[11]
12	.	O	['N']	[12]
#214
0	Fulminant	O	['N']	[0]
1	hepatitis	O	['N']	[1]
2	with	O	['N']	[2]
3	severe	B	['N']	[3]
4	lactate	I	['N']	[4]
5	acidosis	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	HIV	O	['N']	[7]
8	-	O	['N']	[8]
9	infected	O	['N']	[9]
10	patients	O	['N']	[10]
11	on	O	['N']	[11]
12	didanosine	B-Drug	['Causes']	[5]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#215
0	A	O	['N']	[0]
1	review	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	literature	O	['N']	[4]
5	showed	O	['N']	[5]
6	no	O	['N']	[6]
7	previous	O	['N']	[7]
8	description	O	['N']	[8]
9	of	O	['N']	[9]
10	this	O	['N']	[10]
11	pattern	O	['N']	[11]
12	in	O	['N']	[12]
13	benzodiazepine	B-Drug	['Causes']	[14]
14	coma	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#216
0	Major	O	['N']	[0]
1	points	O	['N']	[1]
2	illustrated	O	['N']	[2]
3	are	O	['N']	[3]
4	,	O	['N']	[4]
5	(	O	['N']	[5]
6	1	O	['N']	[6]
7	)	O	['N']	[7]
8	occurrence	O	['N']	[8]
9	of	O	['N']	[9]
10	HIT	B-Adverse_Effect	['N']	[10]
11	with	O	['N']	[11]
12	any	O	['N']	[12]
13	dose	O	['N']	[13]
14	or	O	['N']	[14]
15	form	O	['N']	[15]
16	of	O	['N']	[16]
17	heparin	B-Drug	['Causes']	[10]
18	;	O	['N']	[18]
19	(	O	['N']	[19]
20	2	O	['N']	[20]
21	)	O	['N']	[21]
22	misperceptions	O	['N']	[22]
23	on	O	['N']	[23]
24	the	O	['N']	[24]
25	diagnostic	O	['N']	[25]
26	criteria	O	['N']	[26]
27	;	O	['N']	[27]
28	(	O	['N']	[28]
29	3	O	['N']	[29]
30	)	O	['N']	[30]
31	correct	O	['N']	[31]
32	(	O	['N']	[32]
33	thrombin	O	['N']	[33]
34	inhibitors	O	['N']	[34]
35	)	O	['N']	[35]
36	and	O	['N']	[36]
37	incorrect	O	['N']	[37]
38	(	O	['N']	[38]
39	platelet	O	['N']	[39]
40	transfusions	O	['N']	[40]
41	and	O	['N']	[41]
42	warfarin	O	['N']	[42]
43	)	O	['N']	[43]
44	management	O	['N']	[44]
45	;	O	['N']	[45]
46	(	O	['N']	[46]
47	4	O	['N']	[47]
48	)	O	['N']	[48]
49	influence	O	['N']	[49]
50	of	O	['N']	[50]
51	management	O	['N']	[51]
52	strategy	O	['N']	[52]
53	on	O	['N']	[53]
54	clinical	O	['N']	[54]
55	outcomes	O	['N']	[55]
56	;	O	['N']	[56]
57	(	O	['N']	[57]
58	5	O	['N']	[58]
59	)	O	['N']	[59]
60	severity	O	['N']	[60]
61	of	O	['N']	[61]
62	the	O	['N']	[62]
63	syndrome	O	['N']	[63]
64	;	O	['N']	[64]
65	and	O	['N']	[65]
66	(	O	['N']	[66]
67	6	O	['N']	[67]
68	)	O	['N']	[68]
69	potential	O	['N']	[69]
70	for	O	['N']	[70]
71	both	O	['N']	[71]
72	anamnestic	O	['N']	[72]
73	response	O	['N']	[73]
74	to	O	['N']	[74]
75	heparin	O	['N']	[75]
76	and	O	['N']	[76]
77	disappearance	O	['N']	[77]
78	of	O	['N']	[78]
79	HIT	O	['N']	[79]
80	antibodies	O	['N']	[80]
81	over	O	['N']	[81]
82	time	O	['N']	[82]
83	.	O	['N']	[83]
#217
0	Secretory	B	['N']	[0]
1	endometrial	I	['N']	[1]
2	adenocarcinoma	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	on	O	['N']	[6]
7	tamoxifen	B-Drug	['Causes']	[2]
8	for	O	['N']	[8]
9	breast	O	['N']	[9]
10	cancer	O	['N']	[10]
11	:	O	['N']	[11]
12	a	O	['N']	[12]
13	report	O	['N']	[13]
14	of	O	['N']	[14]
15	a	O	['N']	[15]
16	case	O	['N']	[16]
17	.	O	['N']	[17]
#218
0	Thirty	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	hepatic	B	['N']	[3]
4	reactions	I-Adverse_Effect	['N']	[4]
5	to	O	['N']	[5]
6	cyclofenil	B-Drug	['Causes']	[4]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	non	O	['N']	[9]
10	-	O	['N']	[10]
11	steroidal	O	['N']	[11]
12	drug	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	stimulating	O	['N']	[15]
16	effect	O	['N']	[16]
17	on	O	['N']	[17]
18	ovulation	O	['N']	[18]
19	,	O	['N']	[19]
20	are	O	['N']	[20]
21	reviewed	O	['N']	[21]
22	.	O	['N']	[22]
#219
0	The	O	['N']	[0]
1	newborn	O	['N']	[1]
2	manifested	O	['N']	[2]
3	a	O	['N']	[3]
4	four	O	['N']	[4]
5	day	O	['N']	[5]
6	course	O	['N']	[6]
7	of	O	['N']	[7]
8	lethargy	B-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	unexplained	O	['N']	[10]
11	high	O	['N']	[11]
12	lithium	B-Drug	['Causes']	[8]
13	levels	O	['N']	[13]
14	in	O	['N']	[14]
15	the	O	['N']	[15]
16	adult	O	['N']	[16]
17	toxic	O	['N']	[17]
18	range	O	['N']	[18]
19	.	O	['N']	[19]
#220
0	Carbamazepine	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	Oxybutynin	B-Drug	['Causes']	[1]
4	and	O	['N']	[4]
5	Dantrolene	O	['N']	[5]
6	administration	O	['N']	[6]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#221
0	Thrombocytosis	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	enoxaparin	B-Drug	['Causes']	[0]
4	has	O	['N']	[4]
5	been	O	['N']	[5]
6	reported	O	['N']	[6]
7	as	O	['N']	[7]
8	a	O	['N']	[8]
9	rare	O	['N']	[9]
10	adverse	O	['N']	[10]
11	effect	O	['N']	[11]
12	of	O	['N']	[12]
13	this	O	['N']	[13]
14	medication	O	['N']	[14]
15	in	O	['N']	[15]
16	adults	O	['N']	[16]
17	.	O	['N']	[17]
#222
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	B-Drug	['Causes']	[20]
4	hypersensitivity	O	['N']	[4]
5	reactions	O	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	considered	O	['N']	[8]
9	when	O	['N']	[9]
10	patients	O	['N']	[10]
11	receiving	O	['N']	[11]
12	phenytoin	O	['N']	[12]
13	have	O	['N']	[13]
14	unusual	O	['N']	[14]
15	symptoms	O	['N']	[15]
16	,	O	['N']	[16]
17	particularly	O	['N']	[17]
18	fever	O	['N']	[18]
19	,	O	['N']	[19]
20	rash	B-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	lymphadenopathy	O	['N']	[23]
24	.	O	['N']	[24]
#223
0	Successful	O	['N']	[0]
1	recovery	O	['N']	[1]
2	from	O	['N']	[2]
3	interstitial	B	['N']	[3]
4	pneumonitis	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	induced	O	['N']	[6]
7	by	O	['N']	[7]
8	bicalutamide	O	['N']	[8]
9	and	O	['N']	[9]
10	leuprorelin	B	['N']	[10]
11	acetate	I-Drug	['Causes']	[4]
12	given	O	['N']	[12]
13	as	O	['N']	[13]
14	treatment	O	['N']	[14]
15	for	O	['N']	[15]
16	prostate	O	['N']	[16]
17	cancer	O	['N']	[17]
18	.	O	['N']	[18]
#224
0	Nephrotic	B	['N']	[0]
1	range	I	['N']	[1]
2	pseudoproteinuria	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	tolmetin	B-Drug	['Causes']	[2]
6	-	O	['N']	[6]
7	treated	O	['N']	[7]
8	patient	O	['N']	[8]
9	.	O	['N']	[9]
#225
0	Total	O	['N']	[0]
1	blindness	O	['N']	[1]
2	with	O	['N']	[2]
3	a	O	['N']	[3]
4	transient	O	['N']	[4]
5	tonic	O	['N']	[5]
6	pupillary	O	['N']	[6]
7	response	O	['N']	[7]
8	,	O	['N']	[8]
9	denervation	O	['N']	[9]
10	supersensitivity	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	abnormal	B	['N']	[13]
14	visual	I	['N']	[14]
15	-	I	['N']	[15]
16	evoked	I	['N']	[16]
17	potentials	I-Adverse_Effect	['N']	[17]
18	developed	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	54-year	O	['N']	[21]
22	-	O	['N']	[22]
23	old	O	['N']	[23]
24	man	O	['N']	[24]
25	after	O	['N']	[25]
26	the	O	['N']	[26]
27	use	O	['N']	[27]
28	of	O	['N']	[28]
29	quinine	B	['N']	[29]
30	sulfate	I-Drug	['Causes']	[17]
31	for	O	['N']	[31]
32	leg	O	['N']	[32]
33	cramps	O	['N']	[33]
34	.	O	['N']	[34]
#226
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	clinical	O	['N']	[3]
4	diagnosis	O	['N']	[4]
5	of	O	['N']	[5]
6	fixed	B	['N']	[6]
7	drug	I	['N']	[7]
8	eruption	I-Adverse_Effect	['N']	[8]
9	owing	O	['N']	[9]
10	to	O	['N']	[10]
11	use	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	PDE5	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	tadalafil	O	['N']	[16]
17	(	O	['N']	[17]
18	Cialis	B-Drug	['Causes']	[8]
19	)	O	['N']	[19]
20	was	O	['N']	[20]
21	made	O	['N']	[21]
22	.	O	['N']	[22]
#227
0	A	O	['N']	[0]
1	2-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	mentally	O	['N']	[4]
5	retarded	O	['N']	[5]
6	boy	O	['N']	[6]
7	with	O	['N']	[7]
8	frontal	O	['N']	[8]
9	lobe	O	['N']	[9]
10	epilepsy	O	['N']	[10]
11	presented	O	['N']	[11]
12	with	O	['N']	[12]
13	an	O	['N']	[13]
14	episode	O	['N']	[14]
15	that	O	['N']	[15]
16	resembled	O	['N']	[16]
17	heat	B	['N']	[17]
18	stroke	I-Adverse_Effect	['N']	[18]
19	during	O	['N']	[19]
20	the	O	['N']	[20]
21	administration	O	['N']	[21]
22	of	O	['N']	[22]
23	zonisamide	B-Drug	['Causes']	[18]
24	.	O	['N']	[24]
#228
0	The	O	['N']	[0]
1	third	O	['N']	[1]
2	patient	O	['N']	[2]
3	had	O	['N']	[3]
4	been	O	['N']	[4]
5	suffering	O	['N']	[5]
6	from	O	['N']	[6]
7	serious	O	['N']	[7]
8	akathisia	B-Adverse_Effect	['N']	[8]
9	while	O	['N']	[9]
10	on	O	['N']	[10]
11	risperidone	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	was	O	['N']	[14]
15	cured	O	['N']	[15]
16	after	O	['N']	[16]
17	switching	O	['N']	[17]
18	to	O	['N']	[18]
19	olanzapine	B-Drug	['Causes']	[8]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	thereafter	O	['N']	[22]
23	the	O	['N']	[23]
24	patient	O	['N']	[24]
25	suffered	O	['N']	[25]
26	from	O	['N']	[26]
27	RLS	O	['N']	[27]
28	at	O	['N']	[28]
29	nighttime	O	['N']	[29]
30	.	O	['N']	[30]
#229
0	Evidence	O	['N']	[0]
1	obtained	O	['N']	[1]
2	indicated	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	Reye	B	['N']	[5]
6	-	I	['N']	[6]
7	like	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	might	O	['N']	[9]
10	be	O	['N']	[10]
11	caused	O	['N']	[11]
12	by	O	['N']	[12]
13	calcium	B	['N']	[13]
14	hopantenate	I-Drug	['Causes']	[8]
15	possibly	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	induction	O	['N']	[19]
20	of	O	['N']	[20]
21	pantothenic	O	['N']	[21]
22	acid	O	['N']	[22]
23	deficiency	O	['N']	[23]
24	.	O	['N']	[24]
#230
0	The	O	['N']	[0]
1	evidence	O	['N']	[1]
2	of	O	['N']	[2]
3	high	O	['N']	[3]
4	plasmatic	O	['N']	[4]
5	levels	O	['N']	[5]
6	of	O	['N']	[6]
7	CBZ	B-Drug	['Dosage']	[22]
8	and	O	['N']	[8]
9	the	O	['N']	[9]
10	absence	O	['N']	[10]
11	of	O	['N']	[11]
12	other	O	['N']	[12]
13	aetiologic	O	['N']	[13]
14	factors	O	['N']	[14]
15	lead	O	['N']	[15]
16	the	O	['N']	[16]
17	authors	O	['N']	[17]
18	to	O	['N']	[18]
19	conclude	O	['N']	[19]
20	that	O	['N']	[20]
21	the	O	['N']	[21]
22	overdose	B-Dose	['N']	[22]
23	of	O	['N']	[23]
24	CBZ	O	['N']	[24]
25	could	O	['N']	[25]
26	have	O	['N']	[26]
27	represented	O	['N']	[27]
28	the	O	['N']	[28]
29	precipitating	O	['N']	[29]
30	of	O	['N']	[30]
31	the	O	['N']	[31]
32	episode	O	['N']	[32]
33	of	O	['N']	[33]
34	acute	O	['N']	[34]
35	pancreatitis	O	['N']	[35]
36	.	O	['N']	[36]
#231
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	B-Drug	['Causes']	[43]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	B-Adverse_Effect	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#232
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	patient	O	['N']	[2]
3	developed	O	['N']	[3]
4	mild	O	['N']	[4]
5	nitritoid	O	['N']	[5]
6	symptoms	O	['N']	[6]
7	and	O	['N']	[7]
8	pain	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	band	O	['N']	[11]
12	-	O	['N']	[12]
13	like	O	['N']	[13]
14	distribution	O	['N']	[14]
15	,	O	['N']	[15]
16	corresponding	O	['N']	[16]
17	to	O	['N']	[17]
18	T10-T12	O	['N']	[18]
19	dermatomes	O	['N']	[19]
20	,	O	['N']	[20]
21	shortly	O	['N']	[21]
22	after	O	['N']	[22]
23	gold	O	['N']	[23]
24	sodium	O	['N']	[24]
25	thiomalate	O	['N']	[25]
26	(	O	['N']	[26]
27	GSTM	B-Drug	['Causes']	[8]
28	)	O	['N']	[28]
29	injection	O	['N']	[29]
30	.	O	['N']	[30]
#233
0	SLE	B-Adverse_Effect	['N']	[0]
1	receded	O	['N']	[1]
2	after	O	['N']	[2]
3	withdrawal	O	['N']	[3]
4	of	O	['N']	[4]
5	carbamazepine	B-Drug	['Causes']	[0]
6	and	O	['N']	[6]
7	treatment	O	['N']	[7]
8	with	O	['N']	[8]
9	anti	O	['N']	[9]
10	-	O	['N']	[10]
11	inflammatory	O	['N']	[11]
12	drugs	O	['N']	[12]
13	.	O	['N']	[13]
#234
0	Transient	O	['N']	[0]
1	phenytoin	B-Drug	['Causes']	[4]
2	induced	O	['N']	[2]
3	IgA	B	['N']	[3]
4	deficiency	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	permanent	O	['N']	[6]
7	IgE	O	['N']	[7]
8	increase	O	['N']	[8]
9	.	O	['N']	[9]
#235
0	Hyperkalaemia	B-Adverse_Effect	['N']	[0]
1	with	O	['N']	[1]
2	renal	O	['N']	[2]
3	tubular	O	['N']	[3]
4	dysfunction	O	['N']	[4]
5	by	O	['N']	[5]
6	oral	O	['N']	[6]
7	therapy	O	['N']	[7]
8	of	O	['N']	[8]
9	sulfamethoxazole	B	['N']	[9]
10	-	I	['N']	[10]
11	trimethoprim	I-Drug	['Causes']	[0]
12	(	O	['N']	[12]
13	co	O	['N']	[13]
14	-	O	['N']	[14]
15	trimoxazole	O	['N']	[15]
16	)	O	['N']	[16]
17	is	O	['N']	[17]
18	described	O	['N']	[18]
19	in	O	['N']	[19]
20	2	O	['N']	[20]
21	elderly	O	['N']	[21]
22	Japanese	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	lymphoid	O	['N']	[25]
26	malignancy	O	['N']	[26]
27	,	O	['N']	[27]
28	who	O	['N']	[28]
29	developed	O	['N']	[29]
30	Pneumocystis	O	['N']	[30]
31	carinii	O	['N']	[31]
32	pneumonia	O	['N']	[32]
33	and	O	['N']	[33]
34	improved	O	['N']	[34]
35	.	O	['N']	[35]
#236
0	Anhedonic	B	['N']	[0]
1	ejaculation	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	desipramine	B-Drug	['Causes']	[1]
4	.	O	['N']	[4]
#237
0	Oxcarbazepine	B-Drug	['Causes']	[9]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	Drug	B	['N']	[3]
4	Reaction	I	['N']	[4]
5	with	I	['N']	[5]
6	Eosinophilia	I	['N']	[6]
7	and	I	['N']	[7]
8	Systemic	I	['N']	[8]
9	Symptoms	I-Adverse_Effect	['N']	[9]
10	(	O	['N']	[10]
11	DRESS	O	['N']	[11]
12	)	O	['N']	[12]
13	.	O	['N']	[13]
#238
0	Interstitial	B	['N']	[0]
1	pneumonitis	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	alveolar	O	['N']	[3]
4	hemorrhage	O	['N']	[4]
5	complicating	O	['N']	[5]
6	use	O	['N']	[6]
7	of	O	['N']	[7]
8	rituximab	B-Drug	['Causes']	[1]
9	:	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	and	O	['N']	[12]
13	review	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	literature	O	['N']	[16]
17	.	O	['N']	[17]
#239
0	Emphasis	O	['N']	[0]
1	is	O	['N']	[1]
2	given	O	['N']	[2]
3	to	O	['N']	[3]
4	the	O	['N']	[4]
5	differentiation	O	['N']	[5]
6	of	O	['N']	[6]
7	diphenylhydantoin	B-Drug	['Causes']	[10]
8	induced	O	['N']	[8]
9	gingival	B	['N']	[9]
10	hyperplasia	I-Adverse_Effect	['N']	[10]
11	from	O	['N']	[11]
12	the	O	['N']	[12]
13	angiomatous	O	['N']	[13]
14	enlargement	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	gingiva	O	['N']	[17]
18	before	O	['N']	[18]
19	any	O	['N']	[19]
20	treatment	O	['N']	[20]
21	is	O	['N']	[21]
22	planned	O	['N']	[22]
23	.	O	['N']	[23]
#240
0	Autoimmune	B	['N']	[0]
1	thyroid	I	['N']	[1]
2	disease	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	common	O	['N']	[5]
6	side	O	['N']	[6]
7	-	O	['N']	[7]
8	effect	O	['N']	[8]
9	of	O	['N']	[9]
10	interferon	O	['N']	[10]
11	-	O	['N']	[11]
12	alpha	O	['N']	[12]
13	(	O	['N']	[13]
14	IFN	B	['N']	[14]
15	-	I	['N']	[15]
16	alpha	I-Drug	['Causes']	[2]
17	)	O	['N']	[17]
18	treatment	O	['N']	[18]
19	of	O	['N']	[19]
20	viral	O	['N']	[20]
21	hepatitis	O	['N']	[21]
22	C.	O	['N']	[22]
#241
0	The	O	['N']	[0]
1	fifth	O	['N']	[1]
2	patient	O	['N']	[2]
3	exhibited	O	['N']	[3]
4	paraesthesia	B-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	agitation	O	['N']	[6]
7	caused	O	['N']	[7]
8	by	O	['N']	[8]
9	olanzapine	B-Drug	['Causes']	[4]
10	that	O	['N']	[10]
11	was	O	['N']	[11]
12	misdiagnosed	O	['N']	[12]
13	as	O	['N']	[13]
14	psychotic	O	['N']	[14]
15	agitation	O	['N']	[15]
16	.	O	['N']	[16]
#242
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	In	O	['N']	[2]
3	our	O	['N']	[3]
4	reported	O	['N']	[4]
5	case	O	['N']	[5]
6	,	O	['N']	[6]
7	a	O	['N']	[7]
8	local	O	['N']	[8]
9	hyperproduction	O	['N']	[9]
10	of	O	['N']	[10]
11	TNF	O	['N']	[11]
12	-	O	['N']	[12]
13	alpha	O	['N']	[13]
14	from	O	['N']	[14]
15	macrophages	O	['N']	[15]
16	that	O	['N']	[16]
17	was	O	['N']	[17]
18	induced	O	['N']	[18]
19	by	O	['N']	[19]
20	the	O	['N']	[20]
21	injected	O	['N']	[21]
22	insulin	B-Drug	['Causes']	[29]
23	could	O	['N']	[23]
24	explain	O	['N']	[24]
25	the	O	['N']	[25]
26	dedifferentiation	B	['N']	[26]
27	of	I	['N']	[27]
28	the	I	['N']	[28]
29	adipocytes	I-Adverse_Effect	['N']	[29]
30	of	O	['N']	[30]
31	the	O	['N']	[31]
32	subcutaneous	O	['N']	[32]
33	tissue	O	['N']	[33]
34	and	O	['N']	[34]
35	the	O	['N']	[35]
36	reversion	O	['N']	[36]
37	that	O	['N']	[37]
38	was	O	['N']	[38]
39	induced	O	['N']	[39]
40	by	O	['N']	[40]
41	the	O	['N']	[41]
42	local	O	['N']	[42]
43	injection	O	['N']	[43]
44	of	O	['N']	[44]
45	dexamethasone	O	['N']	[45]
46	.	O	['N']	[46]
#243
0	The	O	['N']	[0]
1	objective	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	report	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	describe	O	['N']	[7]
8	a	O	['N']	[8]
9	case	O	['N']	[9]
10	of	O	['N']	[10]
11	fixed	O	['N']	[11]
12	drug	O	['N']	[12]
13	eruption	B-Adverse_Effect	['N']	[13]
14	that	O	['N']	[14]
15	occurred	O	['N']	[15]
16	during	O	['N']	[16]
17	omeprazole	B-Drug	['Causes']	[13]
18	treatment	O	['N']	[18]
19	.	O	['N']	[19]
#244
0	Herein	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	AIDS	O	['N']	[7]
8	who	O	['N']	[8]
9	presented	O	['N']	[9]
10	to	O	['N']	[10]
11	medical	O	['N']	[11]
12	attention	O	['N']	[12]
13	with	O	['N']	[13]
14	pancytopenia	B-Adverse_Effect	['N']	[14]
15	48	O	['N']	[15]
16	months	O	['N']	[16]
17	postchemotherapy	O	['N']	[17]
18	with	O	['N']	[18]
19	etoposide	O	['N']	[19]
20	,	O	['N']	[20]
21	prednisone	O	['N']	[21]
22	,	O	['N']	[22]
23	vincristine	O	['N']	[23]
24	,	O	['N']	[24]
25	cyclophosphamide	B-Drug	['Causes']	[14]
26	,	O	['N']	[26]
27	doxorubicin	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	rituximab	O	['N']	[30]
31	(	O	['N']	[31]
32	R	O	['N']	[32]
33	-	O	['N']	[33]
34	EPOCH	O	['N']	[34]
35	)	O	['N']	[35]
36	for	O	['N']	[36]
37	diffuse	O	['N']	[37]
38	large	O	['N']	[38]
39	B	O	['N']	[39]
40	-	O	['N']	[40]
41	cell	O	['N']	[41]
42	lymphoma	O	['N']	[42]
43	.	O	['N']	[43]
#245
0	Although	O	['N']	[0]
1	it	O	['N']	[1]
2	would	O	['N']	[2]
3	be	O	['N']	[3]
4	expected	O	['N']	[4]
5	that	O	['N']	[5]
6	,	O	['N']	[6]
7	like	O	['N']	[7]
8	other	O	['N']	[8]
9	type	O	['N']	[9]
10	IA	O	['N']	[10]
11	toxicities	O	['N']	[11]
12	,	O	['N']	[12]
13	diphenhydramine	B-Drug	['Causes']	[16]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	cardiotoxicity	B-Adverse_Effect	['N']	[16]
17	could	O	['N']	[17]
18	be	O	['N']	[18]
19	responsive	O	['N']	[19]
20	to	O	['N']	[20]
21	hypertonic	O	['N']	[21]
22	sodium	O	['N']	[22]
23	bicarbonate	O	['N']	[23]
24	,	O	['N']	[24]
25	this	O	['N']	[25]
26	finding	O	['N']	[26]
27	is	O	['N']	[27]
28	largely	O	['N']	[28]
29	unappreciated	O	['N']	[29]
30	.	O	['N']	[30]
#246
0	The	O	['N']	[0]
1	exact	O	['N']	[1]
2	mechanism	O	['N']	[2]
3	of	O	['N']	[3]
4	IVIG	B-Drug	['Causes']	[9]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	acute	B	['N']	[7]
8	renal	I	['N']	[8]
9	failure	I-Adverse_Effect	['N']	[9]
10	remains	O	['N']	[10]
11	unclear	O	['N']	[11]
12	.	O	['N']	[12]
#247
0	Linezolid	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	acute	B	['N']	[3]
4	interstitial	I	['N']	[4]
5	nephritis	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	drug	O	['N']	[7]
8	rash	O	['N']	[8]
9	with	O	['N']	[9]
10	eosinophilia	O	['N']	[10]
11	and	O	['N']	[11]
12	systemic	O	['N']	[12]
13	symptoms	O	['N']	[13]
14	(	O	['N']	[14]
15	DRESS	O	['N']	[15]
16	)	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	.	O	['N']	[18]
#248
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	53-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	acute	B	['N']	[10]
11	pneumonitis	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	bleomycin	O	['N']	[13]
14	and	O	['N']	[14]
15	moderate	O	['N']	[15]
16	oxygen	B-Drug	['Causes']	[11]
17	administration	O	['N']	[17]
18	is	O	['N']	[18]
19	presented	O	['N']	[19]
20	.	O	['N']	[20]
#249
0	The	O	['N']	[0]
1	goal	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	study	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	describe	O	['N']	[7]
8	three	O	['N']	[8]
9	patients	O	['N']	[9]
10	diagnosed	O	['N']	[10]
11	with	O	['N']	[11]
12	migraine	O	['N']	[12]
13	and	O	['N']	[13]
14	epilepsy	O	['N']	[14]
15	(	O	['N']	[15]
16	both	O	['N']	[16]
17	under	O	['N']	[17]
18	control	O	['N']	[18]
19	)	O	['N']	[19]
20	who	O	['N']	[20]
21	evolved	O	['N']	[21]
22	into	O	['N']	[22]
23	status	B	['N']	[23]
24	migrainosus	I-Adverse_Effect	['N']	[24]
25	after	O	['N']	[25]
26	the	O	['N']	[26]
27	introduction	O	['N']	[27]
28	of	O	['N']	[28]
29	oxcarbazepine	O	['N']	[29]
30	(	O	['N']	[30]
31	OXC	O	['N']	[31]
32	)	O	['N']	[32]
33	,	O	['N']	[33]
34	as	O	['N']	[34]
35	part	O	['N']	[35]
36	of	O	['N']	[36]
37	a	O	['N']	[37]
38	switch	O	['N']	[38]
39	off	O	['N']	[39]
40	from	O	['N']	[40]
41	carbamazepine	B-Drug	['Causes']	[24]
42	(	O	['N']	[42]
43	CBZ	O	['N']	[43]
44	)	O	['N']	[44]
45	.	O	['N']	[45]
#250
0	He	O	['N']	[0]
1	developed	O	['N']	[1]
2	fever	B-Adverse_Effect	['N']	[2]
3	,	O	['N']	[3]
4	nausea	O	['N']	[4]
5	,	O	['N']	[5]
6	diarrhea	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	malaise	O	['N']	[9]
10	and	O	['N']	[10]
11	stopped	O	['N']	[11]
12	taking	O	['N']	[12]
13	on	O	['N']	[13]
14	the	O	['N']	[14]
15	third	O	['N']	[15]
16	day	O	['N']	[16]
17	after	O	['N']	[17]
18	commencing	O	['N']	[18]
19	Pentasa	B-Drug	['Causes']	[2]
20	.	O	['N']	[20]
#251
0	Gynecomastia	B-Adverse_Effect	['N']	[0]
1	developed	O	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	epileptic	O	['N']	[4]
5	patients	O	['N']	[5]
6	some	O	['N']	[6]
7	months	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	addition	O	['N']	[10]
11	of	O	['N']	[11]
12	oral	O	['N']	[12]
13	fluoresone	O	['N']	[13]
14	750	O	['N']	[14]
15	mg	O	['N']	[15]
16	daily	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	phenobarbital	O	['N']	[19]
20	and	O	['N']	[20]
21	phenytoin	B-Drug	['Causes']	[0]
22	already	O	['N']	[22]
23	being	O	['N']	[23]
24	administered	O	['N']	[24]
25	.	O	['N']	[25]
#252
0	A	O	['N']	[0]
1	12	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	atrial	O	['N']	[6]
7	flutter	O	['N']	[7]
8	is	O	['N']	[8]
9	presented	O	['N']	[9]
10	,	O	['N']	[10]
11	in	O	['N']	[11]
12	whom	O	['N']	[12]
13	intravenous	O	['N']	[13]
14	adenosine	B-Drug	['Causes']	[22]
15	was	O	['N']	[15]
16	followed	O	['N']	[16]
17	by	O	['N']	[17]
18	acceleration	B	['N']	[18]
19	of	I	['N']	[19]
20	the	I	['N']	[20]
21	heart	I	['N']	[21]
22	rate	I-Adverse_Effect	['N']	[22]
23	to	O	['N']	[23]
24	a	O	['N']	[24]
25	potentially	O	['N']	[25]
26	dangerous	O	['N']	[26]
27	arrhythmia	O	['N']	[27]
28	.	O	['N']	[28]
#253
0	Diffuse	B	['N']	[0]
1	alveolar	I	['N']	[1]
2	hemorrhage	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	leflunomide	B-Drug	['Causes']	[2]
5	therapy	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	rheumatoid	O	['N']	[10]
11	arthritis	O	['N']	[11]
12	.	O	['N']	[12]
#254
0	INTRODUCTION	O	['N']	[0]
1	-	O	['N']	[1]
2	The	O	['N']	[2]
3	aim	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	is	O	['N']	[8]
9	to	O	['N']	[9]
10	present	O	['N']	[10]
11	a	O	['N']	[11]
12	15-year	O	['N']	[12]
13	follow	O	['N']	[13]
14	-	O	['N']	[14]
15	up	O	['N']	[15]
16	of	O	['N']	[16]
17	a	O	['N']	[17]
18	patient	O	['N']	[18]
19	with	O	['N']	[19]
20	phenytoin	B-Drug	['Causes']	[28]
21	(	O	['N']	[21]
22	PHT	O	['N']	[22]
23	)	O	['N']	[23]
24	intoxication	O	['N']	[24]
25	with	O	['N']	[25]
26	unilateral	B	['N']	[26]
27	gingival	I	['N']	[27]
28	hyperplasia	I-Adverse_Effect	['N']	[28]
29	(	O	['N']	[29]
30	GH	O	['N']	[30]
31	)	O	['N']	[31]
32	.	O	['N']	[32]
#255
0	The	O	['N']	[0]
1	diagnosis	O	['N']	[1]
2	was	O	['N']	[2]
3	supported	O	['N']	[3]
4	by	O	['N']	[4]
5	the	O	['N']	[5]
6	temporal	O	['N']	[6]
7	course	O	['N']	[7]
8	of	O	['N']	[8]
9	renal	B	['N']	[9]
10	deterioration	I-Adverse_Effect	['N']	[10]
11	during	O	['N']	[11]
12	exposure	O	['N']	[12]
13	to	O	['N']	[13]
14	cefuroxime	B-Drug	['Causes']	[10]
15	and	O	['N']	[15]
16	improvement	O	['N']	[16]
17	on	O	['N']	[17]
18	its	O	['N']	[18]
19	discontinuation	O	['N']	[19]
20	;	O	['N']	[20]
21	the	O	['N']	[21]
22	pattern	O	['N']	[22]
23	repeated	O	['N']	[23]
24	with	O	['N']	[24]
25	rechallenge	O	['N']	[25]
26	.	O	['N']	[26]
#256
0	Myoglobinuria	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	acute	O	['N']	[2]
3	renal	O	['N']	[3]
4	failure	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	intravenous	O	['N']	[7]
8	vasopressin	B-Drug	['Causes']	[0]
9	infusion	O	['N']	[9]
10	.	O	['N']	[10]
#257
0	Diclofenac	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	hepatitis	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#258
0	The	O	['N']	[0]
1	epivodes	O	['N']	[1]
2	of	O	['N']	[2]
3	NMS	B-Adverse_Effect	['N']	[3]
4	occured	O	['N']	[4]
5	under	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	clozapine	O	['N']	[8]
9	,	O	['N']	[9]
10	risperidone	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	amisulpride	B-Drug	['Causes']	[3]
14	.	O	['N']	[14]
#259
0	These	O	['N']	[0]
1	in	O	['N']	[1]
2	vitro	O	['N']	[2]
3	findings	O	['N']	[3]
4	and	O	['N']	[4]
5	clinical	O	['N']	[5]
6	course	O	['N']	[6]
7	suggest	O	['N']	[7]
8	that	O	['N']	[8]
9	TRAb	O	['N']	[9]
10	/	O	['N']	[10]
11	TBII	O	['N']	[11]
12	without	O	['N']	[12]
13	thyroid	O	['N']	[13]
14	-	O	['N']	[14]
15	stimulating	O	['N']	[15]
16	activity	O	['N']	[16]
17	may	O	['N']	[17]
18	develop	O	['N']	[18]
19	in	O	['N']	[19]
20	patients	O	['N']	[20]
21	with	O	['N']	[21]
22	amiodarone	B-Drug	['Causes']	[26]
23	-	O	['N']	[23]
24	induced	O	['N']	[24]
25	destructive	O	['N']	[25]
26	thyroiditis	B-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	as	O	['N']	[28]
29	reported	O	['N']	[29]
30	in	O	['N']	[30]
31	patients	O	['N']	[31]
32	with	O	['N']	[32]
33	destructive	O	['N']	[33]
34	thyroiditis	O	['N']	[34]
35	,	O	['N']	[35]
36	such	O	['N']	[36]
37	as	O	['N']	[37]
38	subacute	O	['N']	[38]
39	and	O	['N']	[39]
40	silent	O	['N']	[40]
41	thyroiditis	O	['N']	[41]
42	.	O	['N']	[42]
#260
0	Nephrotic	B	['N']	[0]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	interferon	B	['N']	[4]
5	-	I	['N']	[5]
6	beta-1b	I-Drug	['Causes']	[1]
7	therapy	O	['N']	[7]
8	for	O	['N']	[8]
9	multiple	O	['N']	[9]
10	sclerosis	O	['N']	[10]
11	.	O	['N']	[11]
#261
0	Theophylline	B-Drug	['Causes']	[1]
1	intoxication	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	viloxazine	O	['N']	[3]
4	induced	O	['N']	[4]
5	decrease	O	['N']	[5]
6	in	O	['N']	[6]
7	clearance	O	['N']	[7]
8	.	O	['N']	[8]
#262
0	Erosion	B	['N']	[0]
1	of	I	['N']	[1]
2	psoriatic	I	['N']	[2]
3	plaques	I-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	an	O	['N']	[5]
6	early	O	['N']	[6]
7	sign	O	['N']	[7]
8	of	O	['N']	[8]
9	methotrexate	B-Drug	['Causes']	[3]
10	toxicity	O	['N']	[10]
11	.	O	['N']	[11]
#263
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	B-Drug	['Causes']	[23]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#264
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	three	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	IFN	B	['N']	[5]
6	beta	I-Drug	['Causes']	[24]
7	induced	O	['N']	[7]
8	hepatitis	O	['N']	[8]
9	in	O	['N']	[9]
10	MS	O	['N']	[10]
11	and	O	['N']	[11]
12	discuss	O	['N']	[12]
13	the	O	['N']	[13]
14	pathology	O	['N']	[14]
15	findings	O	['N']	[15]
16	and	O	['N']	[16]
17	possible	O	['N']	[17]
18	mechanisms	O	['N']	[18]
19	of	O	['N']	[19]
20	drug	O	['N']	[20]
21	-	O	['N']	[21]
22	induced	O	['N']	[22]
23	liver	B	['N']	[23]
24	injury	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#265
0	Fatal	B	['N']	[0]
1	complication	I-Adverse_Effect	['N']	[1]
2	of	O	['N']	[2]
3	intravesical	O	['N']	[3]
4	formalin	B-Drug	['Causes']	[1]
5	during	O	['N']	[5]
6	control	O	['N']	[6]
7	of	O	['N']	[7]
8	intractable	O	['N']	[8]
9	hemorrhage	O	['N']	[9]
10	from	O	['N']	[10]
11	radiation	O	['N']	[11]
12	cystitis	O	['N']	[12]
13	.	O	['N']	[13]
#266
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	second	O	['N']	[2]
3	day	O	['N']	[3]
4	of	O	['N']	[4]
5	hospitalization	O	['N']	[5]
6	,	O	['N']	[6]
7	it	O	['N']	[7]
8	was	O	['N']	[8]
9	noted	O	['N']	[9]
10	that	O	['N']	[10]
11	the	O	['N']	[11]
12	patient	O	['N']	[12]
13	's	O	['N']	[13]
14	dyspnea	O	['N']	[14]
15	and	O	['N']	[15]
16	sinus	B	['N']	[16]
17	bradycardia	I-Adverse_Effect	['N']	[17]
18	could	O	['N']	[18]
19	be	O	['N']	[19]
20	related	O	['N']	[20]
21	to	O	['N']	[21]
22	a	O	['N']	[22]
23	recent	O	['N']	[23]
24	increase	O	['N']	[24]
25	in	O	['N']	[25]
26	his	O	['N']	[26]
27	timolol	B-Drug	['Causes']	[17]
28	dosage	O	['N']	[28]
29	.	O	['N']	[29]
#267
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	flucytosine	B-Drug	['Causes']	[32]
7	-	O	['N']	[7]
8	associated	O	['N']	[8]
9	ulcerating	O	['N']	[9]
10	enteritis	O	['N']	[10]
11	in	O	['N']	[11]
12	which	O	['N']	[12]
13	the	O	['N']	[13]
14	small	O	['N']	[14]
15	bowel	O	['N']	[15]
16	x	O	['N']	[16]
17	-	O	['N']	[17]
18	ray	O	['N']	[18]
19	demonstrated	O	['N']	[19]
20	severe	O	['N']	[20]
21	luminal	O	['N']	[21]
22	narrowing	O	['N']	[22]
23	,	O	['N']	[23]
24	ulceration	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	marked	B	['N']	[27]
28	separation	I	['N']	[28]
29	of	I	['N']	[29]
30	loops	I	['N']	[30]
31	of	I	['N']	[31]
32	bowel	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#268
0	Approximately	O	['N']	[0]
1	15	O	['N']	[1]
2	min	O	['N']	[2]
3	after	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	nebulised	O	['N']	[8]
9	morphine	B-Drug	['Causes']	[25]
10	the	O	['N']	[10]
11	patient	O	['N']	[11]
12	became	O	['N']	[12]
13	markedly	O	['N']	[13]
14	bradypneic	O	['N']	[14]
15	(	O	['N']	[15]
16	respiratory	O	['N']	[16]
17	rate	O	['N']	[17]
18	:	O	['N']	[18]
19	4	O	['N']	[19]
20	-	O	['N']	[20]
21	5	O	['N']	[21]
22	bpm	O	['N']	[22]
23	)	O	['N']	[23]
24	,	O	['N']	[24]
25	hypotensive	B-Adverse_Effect	['N']	[25]
26	(	O	['N']	[26]
27	BP	O	['N']	[27]
28	70/40	O	['N']	[28]
29	mmHg	O	['N']	[29]
30	)	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	responded	O	['N']	[33]
34	only	O	['N']	[34]
35	partially	O	['N']	[35]
36	to	O	['N']	[36]
37	command	O	['N']	[37]
38	.	O	['N']	[38]
#269
0	Atypical	O	['N']	[0]
1	neuroleptic	B	['N']	[1]
2	malignant	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	olanzapine	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#270
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	MRI	B	['N']	[3]
4	T2	I	['N']	[4]
5	abnormalities	I-Adverse_Effect	['N']	[5]
6	compatible	O	['N']	[6]
7	with	O	['N']	[7]
8	cyclosporin	B-Drug	['Causes']	[5]
9	neurotoxicity	O	['N']	[9]
10	.	O	['N']	[10]
#271
0	After	O	['N']	[0]
1	1	O	['N']	[1]
2	week	O	['N']	[2]
3	of	O	['N']	[3]
4	nefazodone	B-Drug	['Causes']	[16]
5	therapy	O	['N']	[5]
6	the	O	['N']	[6]
7	patient	O	['N']	[7]
8	experienced	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	confusion	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	"	O	['N']	[14]
15	gray	B	['N']	[15]
16	areas	I-Adverse_Effect	['N']	[16]
17	"	O	['N']	[17]
18	in	O	['N']	[18]
19	her	O	['N']	[19]
20	vision	O	['N']	[20]
21	,	O	['N']	[21]
22	without	O	['N']	[22]
23	abnormal	O	['N']	[23]
24	ophthalmologic	O	['N']	[24]
25	findings	O	['N']	[25]
26	.	O	['N']	[26]
#272
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	occipital	B	['N']	[3]
4	infarcts	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	was	O	['N']	[6]
7	found	O	['N']	[7]
8	to	O	['N']	[8]
9	have	O	['N']	[9]
10	extremely	O	['N']	[10]
11	elevated	O	['N']	[11]
12	levels	O	['N']	[12]
13	of	O	['N']	[13]
14	PPA	B-Drug	['Causes']	[4]
15	in	O	['N']	[15]
16	his	O	['N']	[16]
17	blood	O	['N']	[17]
18	and	O	['N']	[18]
19	dialysis	O	['N']	[19]
20	fluid	O	['N']	[20]
21	.	O	['N']	[21]
#273
0	With	O	['N']	[0]
1	the	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	optical	O	['N']	[4]
5	coherence	O	['N']	[5]
6	tomography	O	['N']	[6]
7	(	O	['N']	[7]
8	OCT	O	['N']	[8]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	two	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	IFN	B-Drug	['Causes']	[17]
15	-	O	['N']	[15]
16	associated	O	['N']	[16]
17	retinopathy	B-Adverse_Effect	['N']	[17]
18	who	O	['N']	[18]
19	had	O	['N']	[19]
20	developed	O	['N']	[20]
21	macular	O	['N']	[21]
22	edema	O	['N']	[22]
23	and	O	['N']	[23]
24	reduced	O	['N']	[24]
25	visual	O	['N']	[25]
26	acuity	O	['N']	[26]
27	during	O	['N']	[27]
28	the	O	['N']	[28]
29	clinical	O	['N']	[29]
30	course	O	['N']	[30]
31	of	O	['N']	[31]
32	IFN	O	['N']	[32]
33	therapy	O	['N']	[33]
34	were	O	['N']	[34]
35	observed	O	['N']	[35]
36	.	O	['N']	[36]
#274
0	Sulfasalazine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	lung	B	['N']	[3]
4	disorder	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	an	O	['N']	[6]
7	extremely	O	['N']	[7]
8	rare	O	['N']	[8]
9	entity	O	['N']	[9]
10	which	O	['N']	[10]
11	must	O	['N']	[11]
12	be	O	['N']	[12]
13	considered	O	['N']	[13]
14	in	O	['N']	[14]
15	all	O	['N']	[15]
16	ulcerative	O	['N']	[16]
17	colitis	O	['N']	[17]
18	patients	O	['N']	[18]
19	while	O	['N']	[19]
20	on	O	['N']	[20]
21	sulfasalazine	O	['N']	[21]
22	therapy	O	['N']	[22]
23	,	O	['N']	[23]
24	despite	O	['N']	[24]
25	the	O	['N']	[25]
26	absence	O	['N']	[26]
27	of	O	['N']	[27]
28	pulmonary	O	['N']	[28]
29	symptomatology	O	['N']	[29]
30	.	O	['N']	[30]
#275
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	reported	O	['N']	[3]
4	in	O	['N']	[4]
5	which	O	['N']	[5]
6	severe	O	['N']	[6]
7	hypocalcemia	O	['N']	[7]
8	,	O	['N']	[8]
9	with	O	['N']	[9]
10	a	O	['N']	[10]
11	low	O	['N']	[11]
12	plasma	O	['N']	[12]
13	parathyroid	O	['N']	[13]
14	hormone	O	['N']	[14]
15	(	O	['N']	[15]
16	PTH	B-Adverse_Effect	['N']	[16]
17	)	O	['N']	[17]
18	concentration	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	from	O	['N']	[21]
22	the	O	['N']	[22]
23	therapeutic	O	['N']	[23]
24	use	O	['N']	[24]
25	of	O	['N']	[25]
26	magnesium	B	['N']	[26]
27	sulfate	I-Drug	['Causes']	[16]
28	for	O	['N']	[28]
29	toxemia	O	['N']	[29]
30	of	O	['N']	[30]
31	pregnancy	O	['N']	[31]
32	.	O	['N']	[32]
#276
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	intrathecal	O	['N']	[5]
6	methotrexate	B-Drug	['Causes']	[14]
7	neurotoxicity	O	['N']	[7]
8	manifesting	O	['N']	[8]
9	as	O	['N']	[9]
10	left	O	['N']	[10]
11	arm	O	['N']	[11]
12	weakness	O	['N']	[12]
13	and	O	['N']	[13]
14	aphasia	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#277
0	Ciprofloxacin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hemorrhagic	B	['N']	[3]
4	vasculitis	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#278
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	the	O	['N']	[4]
5	syndrome	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	pulmonary	B	['N']	[9]
10	infiltrates	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	pleural	O	['N']	[13]
14	effusion	O	['N']	[14]
15	following	O	['N']	[15]
16	use	O	['N']	[16]
17	of	O	['N']	[17]
18	acyclovir	B-Drug	['Causes']	[10]
19	has	O	['N']	[19]
20	not	O	['N']	[20]
21	been	O	['N']	[21]
22	previously	O	['N']	[22]
23	reported	O	['N']	[23]
24	.	O	['N']	[24]
#279
0	Paralytic	B	['N']	[0]
1	ileus	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	patients	O	['N']	[3]
4	undergoing	O	['N']	[4]
5	bortezomib	B-Drug	['Causes']	[1]
6	treatment	O	['N']	[6]
7	has	O	['N']	[7]
8	been	O	['N']	[8]
9	reported	O	['N']	[9]
10	,	O	['N']	[10]
11	although	O	['N']	[11]
12	a	O	['N']	[12]
13	definite	O	['N']	[13]
14	attribution	O	['N']	[14]
15	to	O	['N']	[15]
16	bortezomib	O	['N']	[16]
17	administration	O	['N']	[17]
18	has	O	['N']	[18]
19	not	O	['N']	[19]
20	been	O	['N']	[20]
21	established	O	['N']	[21]
22	.	O	['N']	[22]
#280
0	Refractory	B	['N']	[0]
1	hypoglycemia	I-Adverse_Effect	['N']	[1]
2	from	O	['N']	[2]
3	ciprofloxacin	O	['N']	[3]
4	and	O	['N']	[4]
5	glyburide	B-Drug	['Causes']	[1]
6	interaction	O	['N']	[6]
7	.	O	['N']	[7]
#281
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	course	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	caffeine	B-Drug	['Causes']	[19]
6	,	O	['N']	[6]
7	which	O	['N']	[7]
8	is	O	['N']	[8]
9	present	O	['N']	[9]
10	in	O	['N']	[10]
11	oolong	O	['N']	[11]
12	tea	O	['N']	[12]
13	,	O	['N']	[13]
14	was	O	['N']	[14]
15	mainly	O	['N']	[15]
16	responsible	O	['N']	[16]
17	for	O	['N']	[17]
18	the	O	['N']	[18]
19	rhabdomyolysis	B-Adverse_Effect	['N']	[19]
20	as	O	['N']	[20]
21	well	O	['N']	[21]
22	as	O	['N']	[22]
23	the	O	['N']	[23]
24	delirium	O	['N']	[24]
25	,	O	['N']	[25]
26	although	O	['N']	[26]
27	severe	O	['N']	[27]
28	hyponatremia	O	['N']	[28]
29	has	O	['N']	[29]
30	been	O	['N']	[30]
31	reported	O	['N']	[31]
32	to	O	['N']	[32]
33	cause	O	['N']	[33]
34	rhabdomyolysis	O	['N']	[34]
35	on	O	['N']	[35]
36	rare	O	['N']	[36]
37	occasions	O	['N']	[37]
38	.	O	['N']	[38]
#282
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	34-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	acquired	O	['N']	[7]
8	visual	B	['N']	[8]
9	field	I	['N']	[9]
10	defects	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	severe	O	['N']	[12]
13	vision	O	['N']	[13]
14	loss	O	['N']	[14]
15	in	O	['N']	[15]
16	both	O	['N']	[16]
17	eyes	O	['N']	[17]
18	after	O	['N']	[18]
19	intravitreal	O	['N']	[19]
20	injection	O	['N']	[20]
21	of	O	['N']	[21]
22	triamcinolone	B-Drug	['Causes']	[10]
23	for	O	['N']	[23]
24	diabetic	O	['N']	[24]
25	macular	O	['N']	[25]
26	edema	O	['N']	[26]
27	.	O	['N']	[27]
#283
0	Development	O	['N']	[0]
1	of	O	['N']	[1]
2	persistent	B	['N']	[2]
3	late	I	['N']	[3]
4	onset	I	['N']	[4]
5	asthma	I-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	treatment	O	['N']	[7]
8	with	O	['N']	[8]
9	captopril	B-Drug	['Causes']	[5]
10	.	O	['N']	[10]
#284
0	Gabapentin	B-Drug	['Causes']	[5]
1	withdrawal	O	['N']	[1]
2	presenting	O	['N']	[2]
3	as	O	['N']	[3]
4	status	B	['N']	[4]
5	epilepticus	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#285
0	Myelodysplasia	B-Adverse_Effect	['N']	[0]
1	terminating	O	['N']	[1]
2	in	O	['N']	[2]
3	acute	O	['N']	[3]
4	myeloid	O	['N']	[4]
5	leukemia	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	hairy	O	['N']	[8]
9	cell	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	patient	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	2-deoxycoformycin	B-Drug	['Causes']	[0]
15	.	O	['N']	[15]
#286
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	B-Drug	['Causes']	[46]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	O	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	B	['N']	[42]
43	-	I	['N']	[43]
44	reaction	I	['N']	[44]
45	to	I	['N']	[45]
46	promethazine	I-Adverse_Effect	['N']	[46]
47	,	O	['N']	[47]
48	decreased	O	['N']	[48]
49	MED	O	['N']	[49]
50	to	O	['N']	[50]
51	both	O	['N']	[51]
52	UVA	O	['N']	[52]
53	and	O	['N']	[53]
54	UVB	O	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	photosensitivity	O	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#287
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	can	O	['N']	[2]
3	be	O	['N']	[3]
4	raised	O	['N']	[4]
5	that	O	['N']	[5]
6	M	B	['N']	[6]
7	-	I	['N']	[7]
8	CSF	I-Drug	['Causes']	[13]
9	accelerated	O	['N']	[9]
10	the	O	['N']	[10]
11	underlying	O	['N']	[11]
12	renal	B	['N']	[12]
13	disease	I-Adverse_Effect	['N']	[13]
14	in	O	['N']	[14]
15	this	O	['N']	[15]
16	case	O	['N']	[16]
17	through	O	['N']	[17]
18	enhancing	O	['N']	[18]
19	macrophage	O	['N']	[19]
20	accumulation	O	['N']	[20]
21	into	O	['N']	[21]
22	the	O	['N']	[22]
23	glomerulus	O	['N']	[23]
24	,	O	['N']	[24]
25	leading	O	['N']	[25]
26	to	O	['N']	[26]
27	the	O	['N']	[27]
28	development	O	['N']	[28]
29	of	O	['N']	[29]
30	nephrotic	O	['N']	[30]
31	syndrome	O	['N']	[31]
32	.	O	['N']	[32]
#288
0	Moreover	O	['N']	[0]
1	,	O	['N']	[1]
2	treatment	O	['N']	[2]
3	with	O	['N']	[3]
4	immunosuppressive	O	['N']	[4]
5	drugs	O	['N']	[5]
6	such	O	['N']	[6]
7	as	O	['N']	[7]
8	cyclosporine	O	['N']	[8]
9	,	O	['N']	[9]
10	cisplatin	B-Drug	['Causes']	[23]
11	,	O	['N']	[11]
12	tacrolimus	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	interferon	O	['N']	[15]
16	-	O	['N']	[16]
17	alpha	O	['N']	[17]
18	can	O	['N']	[18]
19	induce	O	['N']	[19]
20	a	O	['N']	[20]
21	condition	O	['N']	[21]
22	resembling	O	['N']	[22]
23	RPLS	B-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#289
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	colchicine	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	rhabdomyolysis	B-Adverse_Effect	['N']	[6]
7	is	O	['N']	[7]
8	reported	O	['N']	[8]
9	.	O	['N']	[9]
#290
0	Pseudomembranous	B	['N']	[0]
1	colitis	I-Adverse_Effect	['N']	[1]
2	readily	O	['N']	[2]
3	occurs	O	['N']	[3]
4	in	O	['N']	[4]
5	at	O	['N']	[5]
6	least	O	['N']	[6]
7	certain	O	['N']	[7]
8	population	O	['N']	[8]
9	groups	O	['N']	[9]
10	receiving	O	['N']	[10]
11	trimethoprim	B-Drug	['Causes']	[1]
12	-	O	['N']	[12]
13	sulfamethoxazole	O	['N']	[13]
14	.	O	['N']	[14]
#291
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	marked	O	['N']	[2]
3	QT	B	['N']	[3]
4	prolongation	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	torsades	O	['N']	[6]
7	de	O	['N']	[7]
8	pointes	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	setting	O	['N']	[11]
12	of	O	['N']	[12]
13	flash	O	['N']	[13]
14	pulmonary	O	['N']	[14]
15	edema	O	['N']	[15]
16	resulting	O	['N']	[16]
17	from	O	['N']	[17]
18	acute	O	['N']	[18]
19	myocardial	O	['N']	[19]
20	ischemia	O	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	patient	O	['N']	[23]
24	who	O	['N']	[24]
25	was	O	['N']	[25]
26	being	O	['N']	[26]
27	treated	O	['N']	[27]
28	with	O	['N']	[28]
29	dofetilide	B-Drug	['Causes']	[4]
30	for	O	['N']	[30]
31	atrial	O	['N']	[31]
32	fibrillation	O	['N']	[32]
33	.	O	['N']	[33]
#292
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	presented	O	['N']	[2]
3	with	O	['N']	[3]
4	dilated	B	['N']	[4]
5	cardiomyopathy	I-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	many	O	['N']	[7]
8	years	O	['N']	[8]
9	of	O	['N']	[9]
10	overusing	O	['N']	[10]
11	an	O	['N']	[11]
12	adrenaline	B-Drug	['Causes']	[5]
13	inhaler	O	['N']	[13]
14	.	O	['N']	[14]
#293
0	Nail	B	['N']	[0]
1	-	I	['N']	[1]
2	changes	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	penicillamine	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#294
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	ciprofloxacin	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	VBDS	B-Adverse_Effect	['N']	[9]
10	successfully	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	tacrolimus	O	['N']	[13]
14	.	O	['N']	[14]
#295
0	Nitrendipine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	gingival	B	['N']	[3]
4	hyperplasia	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#296
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	B-Drug	['Causes']	[39]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	B-Adverse_Effect	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	O	['N']	[42]
43	-	O	['N']	[43]
44	reaction	O	['N']	[44]
45	to	O	['N']	[45]
46	promethazine	O	['N']	[46]
47	,	O	['N']	[47]
48	decreased	O	['N']	[48]
49	MED	O	['N']	[49]
50	to	O	['N']	[50]
51	both	O	['N']	[51]
52	UVA	O	['N']	[52]
53	and	O	['N']	[53]
54	UVB	O	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	photosensitivity	O	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#297
0	Palpable	B	['N']	[0]
1	purpuric	I	['N']	[1]
2	skin	I	['N']	[2]
3	lesions	I-Adverse_Effect	['N']	[3]
4	on	O	['N']	[4]
5	the	O	['N']	[5]
6	anterior	O	['N']	[6]
7	surface	O	['N']	[7]
8	of	O	['N']	[8]
9	both	O	['N']	[9]
10	legs	O	['N']	[10]
11	appeared	O	['N']	[11]
12	on	O	['N']	[12]
13	the	O	['N']	[13]
14	55th	O	['N']	[14]
15	day	O	['N']	[15]
16	of	O	['N']	[16]
17	amphotericin	B	['N']	[17]
18	B	I-Drug	['Causes']	[3]
19	treatment	O	['N']	[19]
20	.	O	['N']	[20]
#298
0	Carbamazepine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hyperammonemia	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#299
0	Pneumonitis	O	['N']	[0]
1	with	O	['N']	[1]
2	pleural	B	['N']	[2]
3	and	I	['N']	[3]
4	pericardial	I	['N']	[4]
5	effusion	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	neuropathy	O	['N']	[7]
8	during	O	['N']	[8]
9	amiodarone	B-Drug	['Causes']	[5]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#300
0	Rhabdomyolysis	B-Adverse_Effect	['N']	[0]
1	caused	O	['N']	[1]
2	by	O	['N']	[2]
3	tocolysis	O	['N']	[3]
4	with	O	['N']	[4]
5	oral	O	['N']	[5]
6	ritodrine	B	['N']	[6]
7	hydrochloride	I-Drug	['Causes']	[0]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	pregnant	O	['N']	[10]
11	patient	O	['N']	[11]
12	with	O	['N']	[12]
13	myotonic	O	['N']	[13]
14	dystrophy	O	['N']	[14]
15	.	O	['N']	[15]
#301
0	Hyperglycemia	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	diabetic	O	['N']	[2]
3	coma	O	['N']	[3]
4	:	O	['N']	[4]
5	possible	O	['N']	[5]
6	relationship	O	['N']	[6]
7	to	O	['N']	[7]
8	diuretic	O	['N']	[8]
9	-	O	['N']	[9]
10	propranolol	B-Drug	['Causes']	[0]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#302
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	hyponatremia	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	a	O	['N']	[8]
9	grand	B	['N']	[9]
10	mal	I	['N']	[10]
11	seizure	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	28	O	['N']	[14]
15	month	O	['N']	[15]
16	-	O	['N']	[16]
17	old	O	['N']	[17]
18	child	O	['N']	[18]
19	after	O	['N']	[19]
20	intra	O	['N']	[20]
21	-	O	['N']	[21]
22	nasal	O	['N']	[22]
23	desmopressin	B-Drug	['Causes']	[11]
24	administration	O	['N']	[24]
25	for	O	['N']	[25]
26	high	O	['N']	[26]
27	fluid	O	['N']	[27]
28	intake	O	['N']	[28]
29	with	O	['N']	[29]
30	nocturnal	O	['N']	[30]
31	enuresis	O	['N']	[31]
32	.	O	['N']	[32]
#303
0	Flucloxacillin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	aplastic	B	['N']	[3]
4	anaemia	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	liver	O	['N']	[6]
7	failure	O	['N']	[7]
8	.	O	['N']	[8]
#304
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	suffering	O	['N']	[2]
3	from	O	['N']	[3]
4	heparin	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	thrombocytopenia	B-Adverse_Effect	['N']	[7]
8	(	O	['N']	[8]
9	HAT	O	['N']	[9]
10	)	O	['N']	[10]
11	,	O	['N']	[11]
12	recurrent	O	['N']	[12]
13	arteriothromboses	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	acute	O	['N']	[16]
17	renal	O	['N']	[17]
18	failure	O	['N']	[18]
19	after	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	standard	O	['N']	[22]
23	heparin	O	['N']	[23]
24	is	O	['N']	[24]
25	described	O	['N']	[25]
26	.	O	['N']	[26]
#305
0	In	O	['N']	[0]
1	one	O	['N']	[1]
2	instance	O	['N']	[2]
3	a	O	['N']	[3]
4	systemic	O	['N']	[4]
5	hypoglycemic	O	['N']	[5]
6	reaction	O	['N']	[6]
7	resulting	O	['N']	[7]
8	in	O	['N']	[8]
9	head	B	['N']	[9]
10	trauma	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	confusion	O	['N']	[12]
13	ended	O	['N']	[13]
14	in	O	['N']	[14]
15	an	O	['N']	[15]
16	emegency	O	['N']	[16]
17	hospital	O	['N']	[17]
18	admission	O	['N']	[18]
19	following	O	['N']	[19]
20	the	O	['N']	[20]
21	substitution	O	['N']	[21]
22	of	O	['N']	[22]
23	acetohexamide	B-Drug	['Causes']	[10]
24	for	O	['N']	[24]
25	acetazolamide	O	['N']	[25]
26	.	O	['N']	[26]
#306
0	The	O	['N']	[0]
1	toxic	O	['N']	[1]
2	effects	O	['N']	[2]
3	of	O	['N']	[3]
4	methotrexate	B-Drug	['Causes']	[13]
5	included	O	['N']	[5]
6	elevated	O	['N']	[6]
7	liver	O	['N']	[7]
8	transaminases	O	['N']	[8]
9	(	O	['N']	[9]
10	3/4	O	['N']	[10]
11	)	O	['N']	[11]
12	,	O	['N']	[12]
13	nausea	B-Adverse_Effect	['N']	[13]
14	(	O	['N']	[14]
15	2/4	O	['N']	[15]
16	)	O	['N']	[16]
17	,	O	['N']	[17]
18	abdominal	O	['N']	[18]
19	pain	O	['N']	[19]
20	(	O	['N']	[20]
21	2/4	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	bone	O	['N']	[24]
25	pain	O	['N']	[25]
26	(	O	['N']	[26]
27	2/4	O	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	mild	O	['N']	[30]
31	neutropenia	O	['N']	[31]
32	(	O	['N']	[32]
33	1/4	O	['N']	[33]
34	)	O	['N']	[34]
35	,	O	['N']	[35]
36	and	O	['N']	[36]
37	mild	O	['N']	[37]
38	pruritus	O	['N']	[38]
39	(	O	['N']	[39]
40	1/4	O	['N']	[40]
41	)	O	['N']	[41]
42	.	O	['N']	[42]
#307
0	The	O	['N']	[0]
1	most	O	['N']	[1]
2	likely	O	['N']	[2]
3	cause	O	['N']	[3]
4	of	O	['N']	[4]
5	liver	B	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	this	O	['N']	[8]
9	patient	O	['N']	[9]
10	was	O	['N']	[10]
11	,	O	['N']	[11]
12	therefore	O	['N']	[12]
13	,	O	['N']	[13]
14	clarithromycin	B-Drug	['Causes']	[6]
15	,	O	['N']	[15]
16	which	O	['N']	[16]
17	undergoes	O	['N']	[17]
18	hepatic	O	['N']	[18]
19	metabolism	O	['N']	[19]
20	and	O	['N']	[20]
21	has	O	['N']	[21]
22	been	O	['N']	[22]
23	reported	O	['N']	[23]
24	to	O	['N']	[24]
25	cause	O	['N']	[25]
26	fulminant	O	['N']	[26]
27	hepatic	O	['N']	[27]
28	failure	O	['N']	[28]
29	.	O	['N']	[29]
#308
0	Nine	O	['N']	[0]
1	eyes	O	['N']	[1]
2	from	O	['N']	[2]
3	6	O	['N']	[3]
4	patients	O	['N']	[4]
5	,	O	['N']	[5]
6	74	O	['N']	[6]
7	years	O	['N']	[7]
8	to	O	['N']	[8]
9	90	O	['N']	[9]
10	years	O	['N']	[10]
11	of	O	['N']	[11]
12	age	O	['N']	[12]
13	,	O	['N']	[13]
14	referred	O	['N']	[14]
15	by	O	['N']	[15]
16	ophthalmologists	O	['N']	[16]
17	for	O	['N']	[17]
18	repair	O	['N']	[18]
19	of	O	['N']	[19]
20	cicatricial	B	['N']	[20]
21	entropion	I-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	at	O	['N']	[23]
24	least	O	['N']	[24]
25	2	O	['N']	[25]
26	years	O	['N']	[26]
27	of	O	['N']	[27]
28	twice	O	['N']	[28]
29	-	O	['N']	[29]
30	a	O	['N']	[30]
31	-	O	['N']	[31]
32	day	O	['N']	[32]
33	application	O	['N']	[33]
34	of	O	['N']	[34]
35	dipivefrin	B-Drug	['Causes']	[21]
36	.	O	['N']	[36]
#309
0	Ticlopidine	B-Drug	['Causes']	[26]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	oral	O	['N']	[3]
4	antiplatelet	O	['N']	[4]
5	agent	O	['N']	[5]
6	frequently	O	['N']	[6]
7	utilized	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	treatment	O	['N']	[10]
11	of	O	['N']	[11]
12	cerebrovascular	O	['N']	[12]
13	disease	O	['N']	[13]
14	and	O	['N']	[14]
15	is	O	['N']	[15]
16	rarely	O	['N']	[16]
17	associated	O	['N']	[17]
18	with	O	['N']	[18]
19	severe	O	['N']	[19]
20	bone	O	['N']	[20]
21	marrow	O	['N']	[21]
22	suppression	O	['N']	[22]
23	,	O	['N']	[23]
24	typically	O	['N']	[24]
25	aplastic	B	['N']	[25]
26	anemia	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#310
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	rheumatoid	O	['N']	[3]
4	arthritis	O	['N']	[4]
5	developed	O	['N']	[5]
6	an	O	['N']	[6]
7	acute	O	['N']	[7]
8	intrahepatic	B	['N']	[8]
9	cholestasis	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	100	O	['N']	[11]
12	mg	O	['N']	[12]
13	of	O	['N']	[13]
14	sodium	B	['N']	[14]
15	aurothiomalate	I-Drug	['Causes']	[9]
16	.	O	['N']	[16]
#311
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Reproductive	O	['N']	[2]
3	endocrine	O	['N']	[3]
4	disorders	O	['N']	[4]
5	characterized	O	['N']	[5]
6	by	O	['N']	[6]
7	menstrual	O	['N']	[7]
8	disorders	O	['N']	[8]
9	,	O	['N']	[9]
10	polycystic	O	['N']	[10]
11	ovaries	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	hyperandrogenism	B-Adverse_Effect	['N']	[14]
15	seem	O	['N']	[15]
16	to	O	['N']	[16]
17	be	O	['N']	[17]
18	common	O	['N']	[18]
19	among	O	['N']	[19]
20	women	O	['N']	[20]
21	treated	O	['N']	[21]
22	with	O	['N']	[22]
23	sodium	B	['N']	[23]
24	valproate	I-Drug	['Causes']	[14]
25	for	O	['N']	[25]
26	epilepsy	O	['N']	[26]
27	.	O	['N']	[27]
#312
0	A	O	['N']	[0]
1	16-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	generalized	O	['N']	[8]
9	rigidity	O	['N']	[9]
10	,	O	['N']	[10]
11	leukocytosis	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	increased	B	['N']	[14]
15	serum	I	['N']	[15]
16	transaminase	I	['N']	[16]
17	and	I	['N']	[17]
18	creatine	I	['N']	[18]
19	kinase	I-Adverse_Effect	['N']	[19]
20	levels	O	['N']	[20]
21	while	O	['N']	[21]
22	receiving	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	O	['N']	[25]
26	and	O	['N']	[26]
27	lithium	B-Drug	['Causes']	[19]
28	.	O	['N']	[28]
#313
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	58-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	Graves	O	['N']	[12]
13	'	O	['N']	[13]
14	disease	O	['N']	[14]
15	who	O	['N']	[15]
16	developed	O	['N']	[16]
17	AA	B-Adverse_Effect	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	third	O	['N']	[20]
21	exposure	O	['N']	[21]
22	to	O	['N']	[22]
23	methimazole	B-Drug	['Causes']	[17]
24	(	O	['N']	[24]
25	MMI	O	['N']	[25]
26	)	O	['N']	[26]
27	.	O	['N']	[27]
#314
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	is	O	['N']	[2]
3	described	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	characteristic	O	['N']	[6]
7	features	O	['N']	[7]
8	of	O	['N']	[8]
9	phenytoin	B-Drug	['Causes']	[18]
10	hypersensitivity	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	(	O	['N']	[12]
13	PHS	O	['N']	[13]
14	)	O	['N']	[14]
15	including	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	erythroderma	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	tibial	O	['N']	[20]
21	and	O	['N']	[21]
22	facial	O	['N']	[22]
23	oedema	O	['N']	[23]
24	,	O	['N']	[24]
25	pinhead	O	['N']	[25]
26	-	O	['N']	[26]
27	sized	O	['N']	[27]
28	facial	O	['N']	[28]
29	pustules	O	['N']	[29]
30	and	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	liver	O	['N']	[32]
33	function	O	['N']	[33]
34	tests	O	['N']	[34]
35	.	O	['N']	[35]
#315
0	A	O	['N']	[0]
1	33-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	recreational	O	['N']	[9]
10	benztropine	B-Drug	['Causes']	[21]
11	abuse	O	['N']	[11]
12	presented	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	emergency	O	['N']	[15]
16	department	O	['N']	[16]
17	with	O	['N']	[17]
18	confusion	O	['N']	[18]
19	,	O	['N']	[19]
20	abdominal	B	['N']	[20]
21	pain	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	distention	O	['N']	[24]
25	.	O	['N']	[25]
#316
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Significant	O	['N']	[2]
3	weight	B	['N']	[3]
4	loss	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	potential	O	['N']	[7]
8	adverse	O	['N']	[8]
9	event	O	['N']	[9]
10	in	O	['N']	[10]
11	patients	O	['N']	[11]
12	with	O	['N']	[12]
13	rheumatoid	O	['N']	[13]
14	arthritis	O	['N']	[14]
15	treated	O	['N']	[15]
16	with	O	['N']	[16]
17	leflunomide	B-Drug	['Causes']	[4]
18	.	O	['N']	[18]
#317
0	Although	O	['N']	[0]
1	his	O	['N']	[1]
2	renal	O	['N']	[2]
3	function	O	['N']	[3]
4	recovered	O	['N']	[4]
5	completely	O	['N']	[5]
6	with	O	['N']	[6]
7	high	O	['N']	[7]
8	-	O	['N']	[8]
9	dose	O	['N']	[9]
10	leucovorin	O	['N']	[10]
11	,	O	['N']	[11]
12	hemodialysis	O	['N']	[12]
13	,	O	['N']	[13]
14	charcoal	O	['N']	[14]
15	hemoperfusion	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	carboxypeptidase	O	['N']	[18]
19	G2	O	['N']	[19]
20	,	O	['N']	[20]
21	we	O	['N']	[21]
22	present	O	['N']	[22]
23	this	O	['N']	[23]
24	case	O	['N']	[24]
25	to	O	['N']	[25]
26	emphasize	O	['N']	[26]
27	that	O	['N']	[27]
28	signs	O	['N']	[28]
29	of	O	['N']	[29]
30	renal	B	['N']	[30]
31	toxicity	I-Adverse_Effect	['N']	[31]
32	may	O	['N']	[32]
33	be	O	['N']	[33]
34	present	O	['N']	[34]
35	as	O	['N']	[35]
36	early	O	['N']	[36]
37	as	O	['N']	[37]
38	2	O	['N']	[38]
39	hours	O	['N']	[39]
40	after	O	['N']	[40]
41	the	O	['N']	[41]
42	completion	O	['N']	[42]
43	of	O	['N']	[43]
44	a	O	['N']	[44]
45	4-hour	O	['N']	[45]
46	MTX	B-Drug	['Causes']	[31]
47	infusion	O	['N']	[47]
48	,	O	['N']	[48]
49	and	O	['N']	[49]
50	to	O	['N']	[50]
51	suggest	O	['N']	[51]
52	that	O	['N']	[52]
53	monitoring	O	['N']	[53]
54	for	O	['N']	[54]
55	MTX	O	['N']	[55]
56	toxicity	O	['N']	[56]
57	should	O	['N']	[57]
58	perhaps	O	['N']	[58]
59	begin	O	['N']	[59]
60	within	O	['N']	[60]
61	a	O	['N']	[61]
62	few	O	['N']	[62]
63	hours	O	['N']	[63]
64	after	O	['N']	[64]
65	the	O	['N']	[65]
66	completion	O	['N']	[66]
67	of	O	['N']	[67]
68	4-hour	O	['N']	[68]
69	MTX	O	['N']	[69]
70	infusion	O	['N']	[70]
71	.	O	['N']	[71]
#318
0	Progressive	B	['N']	[0]
1	anemia	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	combination	O	['N']	[3]
4	therapy	O	['N']	[4]
5	with	O	['N']	[5]
6	interferon	B	['N']	[6]
7	-	I	['N']	[7]
8	alpha	I-Drug	['Causes']	[1]
9	and	O	['N']	[9]
10	interleukin-2	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	metastatic	O	['N']	[15]
16	renal	O	['N']	[16]
17	cell	O	['N']	[17]
18	carcinoma	O	['N']	[18]
19	.	O	['N']	[19]
#319
0	Three	O	['N']	[0]
1	diabetic	O	['N']	[1]
2	cases	O	['N']	[2]
3	of	O	['N']	[3]
4	acute	B	['N']	[4]
5	dizziness	I-Adverse_Effect	['N']	[5]
6	due	O	['N']	[6]
7	to	O	['N']	[7]
8	initial	O	['N']	[8]
9	administration	O	['N']	[9]
10	of	O	['N']	[10]
11	voglibose	B-Drug	['Causes']	[5]
12	.	O	['N']	[12]
#320
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	reports	O	['N']	[2]
3	on	O	['N']	[3]
4	delated	B	['N']	[4]
5	cutaneous	I	['N']	[5]
6	reactions	I-Adverse_Effect	['N']	[6]
7	to	O	['N']	[7]
8	captopril	B-Drug	['Causes']	[6]
9	have	O	['N']	[9]
10	been	O	['N']	[10]
11	seldom	O	['N']	[11]
12	reported	O	['N']	[12]
13	.	O	['N']	[13]
#321
0	Imatinib	B	['N']	[0]
1	mesylate	I-Drug	['Causes']	[7]
2	-	O	['N']	[2]
3	related	O	['N']	[3]
4	fatal	B	['N']	[4]
5	acute	I	['N']	[5]
6	hepatic	I	['N']	[6]
7	failure	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	chronic	O	['N']	[12]
13	myeloid	O	['N']	[13]
14	leukaemia	O	['N']	[14]
15	and	O	['N']	[15]
16	chronic	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	B	O	['N']	[18]
19	infection	O	['N']	[19]
20	.	O	['N']	[20]
#322
0	Cyclosporin	B-Drug	['Causes']	[6]
1	side	O	['N']	[1]
2	effects	O	['N']	[2]
3	included	O	['N']	[3]
4	hirsutism	O	['N']	[4]
5	,	O	['N']	[5]
6	hypertension	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	increased	O	['N']	[8]
9	blood	O	['N']	[9]
10	levels	O	['N']	[10]
11	of	O	['N']	[11]
12	urea	O	['N']	[12]
13	and	O	['N']	[13]
14	creatinine	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	abnormalities	O	['N']	[17]
18	in	O	['N']	[18]
19	liver	O	['N']	[19]
20	function	O	['N']	[20]
21	tests	O	['N']	[21]
22	.	O	['N']	[22]
#323
0	Postoperatively	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	1	O	['N']	[8]
9	to	O	['N']	[9]
10	2	O	['N']	[10]
11	cc	O	['N']	[11]
12	of	O	['N']	[12]
13	thrombin	B-Drug	['Causes']	[17]
14	were	O	['N']	[14]
15	slow	B	['N']	[15]
16	to	I	['N']	[16]
17	awaken	I-Adverse_Effect	['N']	[17]
18	;	O	['N']	[18]
19	one	O	['N']	[19]
20	had	O	['N']	[20]
21	evidence	O	['N']	[21]
22	of	O	['N']	[22]
23	vasospasm	O	['N']	[23]
24	by	O	['N']	[24]
25	transcranial	O	['N']	[25]
26	Doppler	O	['N']	[26]
27	ultrasound	O	['N']	[27]
28	studies	O	['N']	[28]
29	and	O	['N']	[29]
30	multiple	O	['N']	[30]
31	infarcts	O	['N']	[31]
32	on	O	['N']	[32]
33	cranial	O	['N']	[33]
34	computerized	O	['N']	[34]
35	tomography	O	['N']	[35]
36	,	O	['N']	[36]
37	while	O	['N']	[37]
38	the	O	['N']	[38]
39	other	O	['N']	[39]
40	had	O	['N']	[40]
41	a	O	['N']	[41]
42	moderate	O	['N']	[42]
43	-	O	['N']	[43]
44	sized	O	['N']	[44]
45	frontal	O	['N']	[45]
46	hematoma	O	['N']	[46]
47	with	O	['N']	[47]
48	intracranial	O	['N']	[48]
49	hypertension	O	['N']	[49]
50	.	O	['N']	[50]
#324
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	ciprofloxacin	B-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	psychosis	B-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	to	O	['N']	[12]
13	discuss	O	['N']	[13]
14	occurrence	O	['N']	[14]
15	rates	O	['N']	[15]
16	,	O	['N']	[16]
17	risk	O	['N']	[17]
18	factors	O	['N']	[18]
19	,	O	['N']	[19]
20	possible	O	['N']	[20]
21	etiologies	O	['N']	[21]
22	,	O	['N']	[22]
23	preventive	O	['N']	[23]
24	measures	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	treatment	O	['N']	[27]
28	courses	O	['N']	[28]
29	for	O	['N']	[29]
30	this	O	['N']	[30]
31	adverse	O	['N']	[31]
32	reaction	O	['N']	[32]
33	.	O	['N']	[33]
#325
0	From	O	['N']	[0]
1	these	O	['N']	[1]
2	data	O	['N']	[2]
3	,	O	['N']	[3]
4	acute	B	['N']	[4]
5	generalized	I	['N']	[5]
6	dystonia	I-Adverse_Effect	['N']	[6]
7	with	O	['N']	[7]
8	brainstem	O	['N']	[8]
9	and	O	['N']	[9]
10	thalamic	O	['N']	[10]
11	lesions	O	['N']	[11]
12	may	O	['N']	[12]
13	occur	O	['N']	[13]
14	in	O	['N']	[14]
15	WD	O	['N']	[15]
16	patients	O	['N']	[16]
17	after	O	['N']	[17]
18	an	O	['N']	[18]
19	initial	O	['N']	[19]
20	d	B	['N']	[20]
21	-	I	['N']	[21]
22	penicillamine	I-Drug	['Causes']	[6]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#326
0	Ophthalmologists	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	ocular	O	['N']	[6]
7	side	O	['N']	[7]
8	effects	O	['N']	[8]
9	of	O	['N']	[9]
10	IFN	B-Drug	['Causes']	[21]
11	therapy	O	['N']	[11]
12	and	O	['N']	[12]
13	carefully	O	['N']	[13]
14	monitor	O	['N']	[14]
15	patients	O	['N']	[15]
16	for	O	['N']	[16]
17	the	O	['N']	[17]
18	possible	O	['N']	[18]
19	occurrence	O	['N']	[19]
20	of	O	['N']	[20]
21	hypoalbuminemia	B-Adverse_Effect	['N']	[21]
22	and	O	['N']	[22]
23	thrombocytopenia	O	['N']	[23]
24	.	O	['N']	[24]
#327
0	In	O	['N']	[0]
1	each	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	three	O	['N']	[4]
5	reported	O	['N']	[5]
6	patients	O	['N']	[6]
7	,	O	['N']	[7]
8	alteration	O	['N']	[8]
9	of	O	['N']	[9]
10	eyelid	O	['N']	[10]
11	appearance	O	['N']	[11]
12	with	O	['N']	[12]
13	deepening	B	['N']	[13]
14	of	I	['N']	[14]
15	the	I	['N']	[15]
16	lid	I	['N']	[16]
17	sulcus	I-Adverse_Effect	['N']	[17]
18	was	O	['N']	[18]
19	evident	O	['N']	[19]
20	as	O	['N']	[20]
21	the	O	['N']	[21]
22	result	O	['N']	[22]
23	of	O	['N']	[23]
24	topical	O	['N']	[24]
25	bimatoprost	B-Drug	['Causes']	[17]
26	therapy	O	['N']	[26]
27	.	O	['N']	[27]
#328
0	Severe	O	['N']	[0]
1	erythroderma	B-Adverse_Effect	['N']	[1]
2	as	O	['N']	[2]
3	a	O	['N']	[3]
4	complication	O	['N']	[4]
5	of	O	['N']	[5]
6	continuous	O	['N']	[6]
7	epoprostenol	B-Drug	['Causes']	[1]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#329
0	She	O	['N']	[0]
1	died	O	['N']	[1]
2	within	O	['N']	[2]
3	six	O	['N']	[3]
4	weeks	O	['N']	[4]
5	of	O	['N']	[5]
6	developing	O	['N']	[6]
7	congestive	B	['N']	[7]
8	heart	I	['N']	[8]
9	failure	I-Adverse_Effect	['N']	[9]
10	coupled	O	['N']	[10]
11	with	O	['N']	[11]
12	liver	O	['N']	[12]
13	failure	O	['N']	[13]
14	due	O	['N']	[14]
15	to	O	['N']	[15]
16	haemosiderosis	O	['N']	[16]
17	despite	O	['N']	[17]
18	regular	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	desferrioxamine	B-Drug	['Causes']	[9]
22	.	O	['N']	[22]
#330
0	The	O	['N']	[0]
1	current	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	man	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	prescribed	O	['N']	[8]
9	zonisamide	B-Drug	['Causes']	[28]
10	for	O	['N']	[10]
11	epilepsy	O	['N']	[11]
12	and	O	['N']	[12]
13	subsequently	O	['N']	[13]
14	developed	O	['N']	[14]
15	widespread	O	['N']	[15]
16	skin	O	['N']	[16]
17	rash	O	['N']	[17]
18	,	O	['N']	[18]
19	acute	O	['N']	[19]
20	kidney	O	['N']	[20]
21	injury	O	['N']	[21]
22	,	O	['N']	[22]
23	high	O	['N']	[23]
24	-	O	['N']	[24]
25	grade	O	['N']	[25]
26	fever	O	['N']	[26]
27	,	O	['N']	[27]
28	eosinophilia	B-Adverse_Effect	['N']	[28]
29	,	O	['N']	[29]
30	liver	O	['N']	[30]
31	dysfunction	O	['N']	[31]
32	,	O	['N']	[32]
33	lymphadenopathy	O	['N']	[33]
34	and	O	['N']	[34]
35	an	O	['N']	[35]
36	increase	O	['N']	[36]
37	in	O	['N']	[37]
38	antihuman	O	['N']	[38]
39	herpesvirus-6	O	['N']	[39]
40	immunoglobulin	O	['N']	[40]
41	G	O	['N']	[41]
42	titer	O	['N']	[42]
43	.	O	['N']	[43]
#331
0	Clearance	O	['N']	[0]
1	rates	O	['N']	[1]
2	of	O	['N']	[2]
3	cerivastatin	B-Drug	['Causes']	[12]
4	metabolites	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	cerivastatin	O	['N']	[9]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	rhabdomyolysis	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#332
0	This	O	['N']	[0]
1	communication	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	Schneiderian	B	['N']	[7]
8	first	I	['N']	[8]
9	-	I	['N']	[9]
10	rank	I	['N']	[10]
11	symptoms	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	the	O	['N']	[13]
14	course	O	['N']	[14]
15	of	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	fluvoxamine	B-Drug	['Causes']	[11]
19	.	O	['N']	[19]
#333
0	The	O	['N']	[0]
1	noted	O	['N']	[1]
2	increase	B	['N']	[2]
3	in	I	['N']	[3]
4	the	I	['N']	[4]
5	theophylline	I	['N']	[5]
6	level	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	zafirlukast	B-Drug	['Causes']	[6]
9	administration	O	['N']	[9]
10	is	O	['N']	[10]
11	in	O	['N']	[11]
12	contrast	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	original	O	['N']	[15]
16	reports	O	['N']	[16]
17	by	O	['N']	[17]
18	the	O	['N']	[18]
19	manufacturer	O	['N']	[19]
20	.	O	['N']	[20]
#334
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	pulmonary	O	['N']	[5]
6	adenocarcinoma	O	['N']	[6]
7	complicated	O	['N']	[7]
8	by	O	['N']	[8]
9	the	O	['N']	[9]
10	syndrome	B	['N']	[10]
11	of	I	['N']	[11]
12	inappropriate	I	['N']	[12]
13	secretion	I	['N']	[13]
14	of	I	['N']	[14]
15	antidiuretic	I	['N']	[15]
16	hormone	I-Adverse_Effect	['N']	[16]
17	(	O	['N']	[17]
18	SIADH	O	['N']	[18]
19	)	O	['N']	[19]
20	following	O	['N']	[20]
21	systemic	O	['N']	[21]
22	chemotherapy	O	['N']	[22]
23	with	O	['N']	[23]
24	cisplatin	O	['N']	[24]
25	(	O	['N']	[25]
26	CDDP	B-Drug	['Causes']	[16]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	vindesine	O	['N']	[29]
30	(	O	['N']	[30]
31	VDS	O	['N']	[31]
32	)	O	['N']	[32]
33	.	O	['N']	[33]
#335
0	The	O	['N']	[0]
1	Naranjo	O	['N']	[1]
2	probability	O	['N']	[2]
3	scale	O	['N']	[3]
4	suggests	O	['N']	[4]
5	a	O	['N']	[5]
6	highly	O	['N']	[6]
7	probable	O	['N']	[7]
8	relationship	O	['N']	[8]
9	between	O	['N']	[9]
10	AIN	B-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	pantoprazole	B-Drug	['Causes']	[10]
13	therapy	O	['N']	[13]
14	in	O	['N']	[14]
15	this	O	['N']	[15]
16	patient	O	['N']	[16]
17	.	O	['N']	[17]
#336
0	Ibuprofen	B-Drug	['Causes']	[9]
1	overdose	O	['N']	[1]
2	is	O	['N']	[2]
3	usually	O	['N']	[3]
4	characterized	O	['N']	[4]
5	by	O	['N']	[5]
6	GI	O	['N']	[6]
7	upset	O	['N']	[7]
8	,	O	['N']	[8]
9	dizziness	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	mild	O	['N']	[12]
13	sedation	O	['N']	[13]
14	.	O	['N']	[14]
#337
0	The	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	systemic	O	['N']	[3]
4	lupus	O	['N']	[4]
5	erythematosus	O	['N']	[5]
6	(	O	['N']	[6]
7	SLE	B-Adverse_Effect	['N']	[7]
8	)	O	['N']	[8]
9	after	O	['N']	[9]
10	38	O	['N']	[10]
11	months	O	['N']	[11]
12	of	O	['N']	[12]
13	therapy	O	['N']	[13]
14	with	O	['N']	[14]
15	recombinant	O	['N']	[15]
16	human	O	['N']	[16]
17	interferon	O	['N']	[17]
18	gamma	O	['N']	[18]
19	(	O	['N']	[19]
20	rIFN	B	['N']	[20]
21	-	I	['N']	[21]
22	gamma	I-Drug	['Causes']	[7]
23	)	O	['N']	[23]
24	was	O	['N']	[24]
25	observed	O	['N']	[25]
26	in	O	['N']	[26]
27	a	O	['N']	[27]
28	patient	O	['N']	[28]
29	with	O	['N']	[29]
30	rheumatoid	O	['N']	[30]
31	arthritis	O	['N']	[31]
32	.	O	['N']	[32]
#338
0	Bromide	B	['N']	[0]
1	intoxication	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	pyridostigmine	B	['N']	[4]
5	bromide	I-Drug	['Causes']	[1]
6	therapy	O	['N']	[6]
7	.	O	['N']	[7]
#339
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	increased	B	['N']	[8]
9	cerebral	I	['N']	[9]
10	cortical	I	['N']	[10]
11	excitability	I-Adverse_Effect	['N']	[11]
12	following	O	['N']	[12]
13	intoxication	O	['N']	[13]
14	with	O	['N']	[14]
15	flupirtine	B-Drug	['Causes']	[11]
16	,	O	['N']	[16]
17	a	O	['N']	[17]
18	centrally	O	['N']	[18]
19	acting	O	['N']	[19]
20	analgesic	O	['N']	[20]
21	and	O	['N']	[21]
22	antispastic	O	['N']	[22]
23	drug	O	['N']	[23]
24	.	O	['N']	[24]
#340
0	Ciprofloxacin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	psychosis	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#341
0	Rapid	O	['N']	[0]
1	onset	O	['N']	[1]
2	of	O	['N']	[2]
3	muscle	O	['N']	[3]
4	weakness	O	['N']	[4]
5	(	O	['N']	[5]
6	rhabdomyolysis	B-Adverse_Effect	['N']	[6]
7	)	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	combined	O	['N']	[11]
12	use	O	['N']	[12]
13	of	O	['N']	[13]
14	simvastatin	B-Drug	['Causes']	[6]
15	and	O	['N']	[15]
16	colchicine	O	['N']	[16]
17	.	O	['N']	[17]
#342
0	The	O	['N']	[0]
1	increasing	O	['N']	[1]
2	prevalence	O	['N']	[2]
3	of	O	['N']	[3]
4	methamphetamine	B-Drug	['Causes']	[23]
5	abuse	O	['N']	[5]
6	and	O	['N']	[6]
7	the	O	['N']	[7]
8	severity	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	associated	O	['N']	[11]
12	ulcers	O	['N']	[12]
13	should	O	['N']	[13]
14	alert	O	['N']	[14]
15	ophthalmologists	O	['N']	[15]
16	to	O	['N']	[16]
17	the	O	['N']	[17]
18	problem	O	['N']	[18]
19	of	O	['N']	[19]
20	methamphetamine	O	['N']	[20]
21	-	O	['N']	[21]
22	related	O	['N']	[22]
23	keratitis	B-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#343
0	After	O	['N']	[0]
1	reviewing	O	['N']	[1]
2	the	O	['N']	[2]
3	literature	O	['N']	[3]
4	we	O	['N']	[4]
5	suggest	O	['N']	[5]
6	the	O	['N']	[6]
7	CPM	O	['N']	[7]
8	was	O	['N']	[8]
9	a	O	['N']	[9]
10	complication	O	['N']	[10]
11	of	O	['N']	[11]
12	lithium	B-Drug	['Causes']	[22]
13	toxicity	O	['N']	[13]
14	which	O	['N']	[14]
15	affected	O	['N']	[15]
16	the	O	['N']	[16]
17	lateral	O	['N']	[17]
18	geniculate	O	['N']	[18]
19	nucleus	O	['N']	[19]
20	which	O	['N']	[20]
21	produced	O	['N']	[21]
22	blindness	B-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#344
0	An	O	['N']	[0]
1	obese	O	['N']	[1]
2	patient	O	['N']	[2]
3	,	O	['N']	[3]
4	not	O	['N']	[4]
5	diabetic	O	['N']	[5]
6	,	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	metformin	B-Drug	['Causes']	[22]
10	for	O	['N']	[10]
11	some	O	['N']	[11]
12	weeks	O	['N']	[12]
13	,	O	['N']	[13]
14	was	O	['N']	[14]
15	referred	O	['N']	[15]
16	to	O	['N']	[16]
17	us	O	['N']	[17]
18	with	O	['N']	[18]
19	severe	B	['N']	[19]
20	inferior	I	['N']	[20]
21	digestive	I	['N']	[21]
22	hemorrhage	I-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	diagnosed	O	['N']	[24]
25	with	O	['N']	[25]
26	Meckel	O	['N']	[26]
27	's	O	['N']	[27]
28	diverticulum	O	['N']	[28]
29	.	O	['N']	[29]
#345
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	B-Drug	['Causes']	[18]
4	hypersensitivity	O	['N']	[4]
5	reactions	O	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	considered	O	['N']	[8]
9	when	O	['N']	[9]
10	patients	O	['N']	[10]
11	receiving	O	['N']	[11]
12	phenytoin	O	['N']	[12]
13	have	O	['N']	[13]
14	unusual	O	['N']	[14]
15	symptoms	O	['N']	[15]
16	,	O	['N']	[16]
17	particularly	O	['N']	[17]
18	fever	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	rash	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	lymphadenopathy	O	['N']	[23]
24	.	O	['N']	[24]
#346
0	Transient	B	['N']	[0]
1	acute	I	['N']	[1]
2	myopia	I-Adverse_Effect	['N']	[2]
3	resulting	O	['N']	[3]
4	from	O	['N']	[4]
5	isotretinoin	O	['N']	[5]
6	(	O	['N']	[6]
7	accutane	B-Drug	['Causes']	[2]
8	)	O	['N']	[8]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#347
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	in	O	['N']	[2]
3	detail	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	U.S.	O	['N']	[6]
7	case	O	['N']	[7]
8	report	O	['N']	[8]
9	,	O	['N']	[9]
10	of	O	['N']	[10]
11	a	O	['N']	[11]
12	4(1/2)-year	O	['N']	[12]
13	-	O	['N']	[13]
14	old	O	['N']	[14]
15	boy	O	['N']	[15]
16	who	O	['N']	[16]
17	experienced	O	['N']	[17]
18	angioedema	B-Adverse_Effect	['N']	[18]
19	during	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	oxcarbazepine	B-Drug	['Causes']	[18]
23	.	O	['N']	[23]
#348
0	Antacid	O	['N']	[0]
1	and	O	['N']	[1]
2	sucralfate	B-Drug	['Causes']	[6]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	hypophosphatemic	B	['N']	[5]
6	osteomalacia	I-Adverse_Effect	['N']	[6]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	and	O	['N']	[11]
12	review	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	literature	O	['N']	[15]
16	.	O	['N']	[16]
#349
0	Acute	O	['N']	[0]
1	severe	O	['N']	[1]
2	intoxication	O	['N']	[2]
3	with	O	['N']	[3]
4	carbamazepine	B-Drug	['Causes']	[8]
5	is	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	seizures	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	coma	O	['N']	[10]
11	and	O	['N']	[11]
12	respiratory	O	['N']	[12]
13	depression	O	['N']	[13]
14	.	O	['N']	[14]
#350
0	Exacerbation	O	['N']	[0]
1	of	O	['N']	[1]
2	schizophrenia	B-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	amantadine	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#351
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	second	O	['N']	[2]
3	day	O	['N']	[3]
4	of	O	['N']	[4]
5	hospitalization	O	['N']	[5]
6	,	O	['N']	[6]
7	it	O	['N']	[7]
8	was	O	['N']	[8]
9	noted	O	['N']	[9]
10	that	O	['N']	[10]
11	the	O	['N']	[11]
12	patient	O	['N']	[12]
13	's	O	['N']	[13]
14	dyspnea	B-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	sinus	O	['N']	[16]
17	bradycardia	O	['N']	[17]
18	could	O	['N']	[18]
19	be	O	['N']	[19]
20	related	O	['N']	[20]
21	to	O	['N']	[21]
22	a	O	['N']	[22]
23	recent	O	['N']	[23]
24	increase	O	['N']	[24]
25	in	O	['N']	[25]
26	his	O	['N']	[26]
27	timolol	B-Drug	['Causes']	[14]
28	dosage	O	['N']	[28]
29	.	O	['N']	[29]
#352
0	Fatal	B	['N']	[0]
1	interstitial	I	['N']	[1]
2	pneumonitis	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	docetaxel	B-Drug	['Causes']	[2]
6	administration	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	hormone	O	['N']	[11]
12	-	O	['N']	[12]
13	refractory	O	['N']	[13]
14	prostate	O	['N']	[14]
15	cancer	O	['N']	[15]
16	.	O	['N']	[16]
#353
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Thrombotic	B	['N']	[5]
6	Thrombocytopenic	I	['N']	[6]
7	Purpura	I-Adverse_Effect	['N']	[7]
8	occurring	O	['N']	[8]
9	as	O	['N']	[9]
10	an	O	['N']	[10]
11	allergic	O	['N']	[11]
12	response	O	['N']	[12]
13	to	O	['N']	[13]
14	trimethoprim	O	['N']	[14]
15	-	O	['N']	[15]
16	sulfamethoxazole	B-Drug	['Causes']	[7]
17	therapy	O	['N']	[17]
18	(	O	['N']	[18]
19	Bactrim	O	['N']	[19]
20	,	O	['N']	[20]
21	Septra	O	['N']	[21]
22	)	O	['N']	[22]
23	in	O	['N']	[23]
24	a	O	['N']	[24]
25	Jehovah	O	['N']	[25]
26	's	O	['N']	[26]
27	Witness	O	['N']	[27]
28	patient	O	['N']	[28]
29	.	O	['N']	[29]
#354
0	Liver	O	['N']	[0]
1	transplantation	O	['N']	[1]
2	for	O	['N']	[2]
3	fulminant	B	['N']	[3]
4	hepatitis	I-Adverse_Effect	['N']	[4]
5	related	O	['N']	[5]
6	to	O	['N']	[6]
7	nevirapine	B-Drug	['Causes']	[4]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#355
0	Mesalamine	B-Drug	['Causes']	[4]
1	may	O	['N']	[1]
2	cause	O	['N']	[2]
3	hypersensitivity	B	['N']	[3]
4	pneumonitis	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	Crohn	O	['N']	[8]
9	's	O	['N']	[9]
10	disease	O	['N']	[10]
11	.	O	['N']	[11]
#356
0	Three	O	['N']	[0]
1	of	O	['N']	[1]
2	these	O	['N']	[2]
3	patients	O	['N']	[3]
4	had	O	['N']	[4]
5	convulsions	B-Adverse_Effect	['N']	[5]
6	attributed	O	['N']	[6]
7	to	O	['N']	[7]
8	imipenem	B-Drug	['Causes']	[5]
9	/	O	['N']	[9]
10	cilastatin	O	['N']	[10]
11	;	O	['N']	[11]
12	3.6	O	['N']	[12]
13	%	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	patients	O	['N']	[16]
17	had	O	['N']	[17]
18	seizure	O	['N']	[18]
19	,	O	['N']	[19]
20	or	O	['N']	[20]
21	2	O	['N']	[21]
22	%	O	['N']	[22]
23	of	O	['N']	[23]
24	imipenem	O	['N']	[24]
25	/	O	['N']	[25]
26	cilastatin	O	['N']	[26]
27	administrations	O	['N']	[27]
28	was	O	['N']	[28]
29	followed	O	['N']	[29]
30	by	O	['N']	[30]
31	a	O	['N']	[31]
32	seizure	O	['N']	[32]
33	attack	O	['N']	[33]
34	.	O	['N']	[34]
#357
0	Following	O	['N']	[0]
1	are	O	['N']	[1]
2	two	O	['N']	[2]
3	clinical	O	['N']	[3]
4	case	O	['N']	[4]
5	reports	O	['N']	[5]
6	demonstrating	O	['N']	[6]
7	profound	O	['N']	[7]
8	cerebral	B	['N']	[8]
9	edema	I-Adverse_Effect	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	implantation	O	['N']	[12]
13	of	O	['N']	[13]
14	Gliadel	B-Drug	['Causes']	[9]
15	wafers	O	['N']	[15]
16	.	O	['N']	[16]
#358
0	The	O	['N']	[0]
1	main	O	['N']	[1]
2	clinical	O	['N']	[2]
3	features	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	58-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	patient	O	['N']	[10]
11	were	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	leucopenia	O	['N']	[15]
16	and	O	['N']	[16]
17	cholestasis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	biopsy	O	['N']	[20]
21	features	O	['N']	[21]
22	of	O	['N']	[22]
23	fatty	O	['N']	[23]
24	liver	O	['N']	[24]
25	parenchyma	O	['N']	[25]
26	degeneration	O	['N']	[26]
27	with	O	['N']	[27]
28	granulocytic	O	['N']	[28]
29	portal	O	['N']	[29]
30	infiltration	O	['N']	[30]
31	and	O	['N']	[31]
32	bile	O	['N']	[32]
33	stasis	O	['N']	[33]
34	,	O	['N']	[34]
35	demonstrated	O	['N']	[35]
36	20	O	['N']	[36]
37	days	O	['N']	[37]
38	after	O	['N']	[38]
39	the	O	['N']	[39]
40	initiation	O	['N']	[40]
41	of	O	['N']	[41]
42	antithyroid	O	['N']	[42]
43	therapy	O	['N']	[43]
44	with	O	['N']	[44]
45	20	B	['N']	[45]
46	mg	I-Dose	['N']	[46]
47	methimazole	B-Drug	['Dosage']	[46]
48	daily	O	['N']	[48]
49	.	O	['N']	[49]
#359
0	Of	O	['N']	[0]
1	the	O	['N']	[1]
2	four	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	responded	O	['N']	[5]
6	to	O	['N']	[6]
7	HU	B-Drug	['Causes']	[13]
8	with	O	['N']	[8]
9	an	O	['N']	[9]
10	increase	B	['N']	[10]
11	in	I	['N']	[11]
12	total	I	['N']	[12]
13	Hb	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	all	O	['N']	[15]
16	reported	O	['N']	[16]
17	symptomatic	O	['N']	[17]
18	improvement	O	['N']	[18]
19	and	O	['N']	[19]
20	three	O	['N']	[20]
21	have	O	['N']	[21]
22	not	O	['N']	[22]
23	required	O	['N']	[23]
24	further	O	['N']	[24]
25	transfusions	O	['N']	[25]
26	.	O	['N']	[26]
#360
0	The	O	['N']	[0]
1	possible	O	['N']	[1]
2	development	O	['N']	[2]
3	of	O	['N']	[3]
4	a	O	['N']	[4]
5	drug	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	vasculitis	O	['N']	[8]
9	or	O	['N']	[9]
10	lupus	B	['N']	[10]
11	-	I	['N']	[11]
12	like	I	['N']	[12]
13	syndrome	I-Adverse_Effect	['N']	[13]
14	should	O	['N']	[14]
15	be	O	['N']	[15]
16	added	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	list	O	['N']	[19]
20	of	O	['N']	[20]
21	rare	O	['N']	[21]
22	toxic	O	['N']	[22]
23	effects	O	['N']	[23]
24	of	O	['N']	[24]
25	vancomycin	B-Drug	['Causes']	[13]
26	.	O	['N']	[26]
#361
0	A	O	['N']	[0]
1	woman	O	['N']	[1]
2	with	O	['N']	[2]
3	a	O	['N']	[3]
4	20-year	O	['N']	[4]
5	history	O	['N']	[5]
6	of	O	['N']	[6]
7	acral	O	['N']	[7]
8	pustular	O	['N']	[8]
9	psoriasis	O	['N']	[9]
10	of	O	['N']	[10]
11	Hallopeau	O	['N']	[11]
12	and	O	['N']	[12]
13	recurrent	O	['N']	[13]
14	pustular	O	['N']	[14]
15	lesions	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	forearms	O	['N']	[18]
19	and	O	['N']	[19]
20	lower	O	['N']	[20]
21	legs	O	['N']	[21]
22	,	O	['N']	[22]
23	developed	O	['N']	[23]
24	a	O	['N']	[24]
25	B	B	['N']	[25]
26	-	I	['N']	[26]
27	cell	I	['N']	[27]
28	lymphoma	I-Adverse_Effect	['N']	[28]
29	of	O	['N']	[29]
30	the	O	['N']	[30]
31	lip	O	['N']	[31]
32	following	O	['N']	[32]
33	4	O	['N']	[33]
34	1/2	O	['N']	[34]
35	years	O	['N']	[35]
36	of	O	['N']	[36]
37	treatment	O	['N']	[37]
38	with	O	['N']	[38]
39	razoxane	B-Drug	['Causes']	[28]
40	.	O	['N']	[40]
#362
0	Moreover	O	['N']	[0]
1	,	O	['N']	[1]
2	treatment	O	['N']	[2]
3	with	O	['N']	[3]
4	immunosuppressive	O	['N']	[4]
5	drugs	O	['N']	[5]
6	such	O	['N']	[6]
7	as	O	['N']	[7]
8	cyclosporine	O	['N']	[8]
9	,	O	['N']	[9]
10	cisplatin	O	['N']	[10]
11	,	O	['N']	[11]
12	tacrolimus	B-Drug	['Causes']	[23]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	interferon	O	['N']	[15]
16	-	O	['N']	[16]
17	alpha	O	['N']	[17]
18	can	O	['N']	[18]
19	induce	O	['N']	[19]
20	a	O	['N']	[20]
21	condition	O	['N']	[21]
22	resembling	O	['N']	[22]
23	RPLS	B-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#363
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	peripheral	O	['N']	[2]
3	neuropathy	B-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	bone	O	['N']	[5]
6	marrow	O	['N']	[6]
7	depression	O	['N']	[7]
8	led	O	['N']	[8]
9	to	O	['N']	[9]
10	linezolid	B-Drug	['Causes']	[3]
11	withdrawal	O	['N']	[11]
12	in	O	['N']	[12]
13	seven	O	['N']	[13]
14	patients	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	neuropathy	O	['N']	[17]
18	may	O	['N']	[18]
19	not	O	['N']	[19]
20	be	O	['N']	[20]
21	fully	O	['N']	[21]
22	reversible	O	['N']	[22]
23	in	O	['N']	[23]
24	all	O	['N']	[24]
25	patients	O	['N']	[25]
26	.	O	['N']	[26]
#364
0	We	O	['N']	[0]
1	suspect	O	['N']	[1]
2	that	O	['N']	[2]
3	nefazodone	B-Drug	['Causes']	[7]
4	inhibits	B	['N']	[4]
5	metabolism	I	['N']	[5]
6	of	I	['N']	[6]
7	tacrolimus	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#365
0	When	O	['N']	[0]
1	the	O	['N']	[1]
2	acute	O	['N']	[2]
3	manic	O	['N']	[3]
4	state	O	['N']	[4]
5	is	O	['N']	[5]
6	characterized	O	['N']	[6]
7	by	O	['N']	[7]
8	marked	O	['N']	[8]
9	psychotic	B	['N']	[9]
10	symptoms	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	intense	O	['N']	[12]
13	anxiety	O	['N']	[13]
14	,	O	['N']	[14]
15	it	O	['N']	[15]
16	may	O	['N']	[16]
17	be	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	increased	O	['N']	[20]
21	vulnerability	O	['N']	[21]
22	to	O	['N']	[22]
23	the	O	['N']	[23]
24	development	O	['N']	[24]
25	of	O	['N']	[25]
26	severe	O	['N']	[26]
27	lithium	B-Drug	['Causes']	[10]
28	neurotoxicity	O	['N']	[28]
29	.	O	['N']	[29]
#366
0	A	O	['N']	[0]
1	diagnosis	O	['N']	[1]
2	of	O	['N']	[2]
3	infliximab	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	lupus	B-Adverse_Effect	['N']	[6]
7	was	O	['N']	[7]
8	made	O	['N']	[8]
9	and	O	['N']	[9]
10	the	O	['N']	[10]
11	drug	O	['N']	[11]
12	treatment	O	['N']	[12]
13	was	O	['N']	[13]
14	withdrawn	O	['N']	[14]
15	.	O	['N']	[15]
#367
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	52-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	white	O	['N']	[7]
8	woman	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	a	O	['N']	[11]
12	spontaneous	B	['N']	[12]
13	nasal	I	['N']	[13]
14	septal	I	['N']	[14]
15	perforation	I-Adverse_Effect	['N']	[15]
16	after	O	['N']	[16]
17	given	O	['N']	[17]
18	the	O	['N']	[18]
19	antiangiogenic	O	['N']	[19]
20	drug	O	['N']	[20]
21	,	O	['N']	[21]
22	bevacizumab	B-Drug	['Causes']	[15]
23	,	O	['N']	[23]
24	for	O	['N']	[24]
25	metastatic	O	['N']	[25]
26	ovarian	O	['N']	[26]
27	cancer	O	['N']	[27]
28	treatment	O	['N']	[28]
29	.	O	['N']	[29]
#368
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	subacute	O	['N']	[6]
7	methanol	B-Drug	['Causes']	[8]
8	toxicity	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	associated	O	['N']	[10]
11	diffuse	O	['N']	[11]
12	brain	O	['N']	[12]
13	involvement	O	['N']	[13]
14	,	O	['N']	[14]
15	including	O	['N']	[15]
16	bilateral	O	['N']	[16]
17	putaminal	O	['N']	[17]
18	necrosis	O	['N']	[18]
19	and	O	['N']	[19]
20	cerebral	O	['N']	[20]
21	edema	O	['N']	[21]
22	with	O	['N']	[22]
23	ventricular	O	['N']	[23]
24	compression	O	['N']	[24]
25	.	O	['N']	[25]
#369
0	In	O	['N']	[0]
1	our	O	['N']	[1]
2	patient	O	['N']	[2]
3	,	O	['N']	[3]
4	an	O	['N']	[4]
5	objective	O	['N']	[5]
6	causality	O	['N']	[6]
7	scale	O	['N']	[7]
8	showed	O	['N']	[8]
9	that	O	['N']	[9]
10	therapeutic	O	['N']	[10]
11	doses	O	['N']	[11]
12	of	O	['N']	[12]
13	colchicine	B-Drug	['Causes']	[21]
14	for	O	['N']	[14]
15	FMF	O	['N']	[15]
16	were	O	['N']	[16]
17	the	O	['N']	[17]
18	definite	O	['N']	[18]
19	cause	O	['N']	[19]
20	of	O	['N']	[20]
21	myopathy	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	even	O	['N']	[23]
24	though	O	['N']	[24]
25	his	O	['N']	[25]
26	renal	O	['N']	[26]
27	and	O	['N']	[27]
28	hepatic	O	['N']	[28]
29	function	O	['N']	[29]
30	were	O	['N']	[30]
31	normal	O	['N']	[31]
32	.	O	['N']	[32]
#370
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	report	O	['N']	[4]
5	the	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	31-year	O	['N']	[9]
10	-	O	['N']	[10]
11	old	O	['N']	[11]
12	patient	O	['N']	[12]
13	hospitalized	O	['N']	[13]
14	due	O	['N']	[14]
15	to	O	['N']	[15]
16	behavioral	O	['N']	[16]
17	alterations	O	['N']	[17]
18	and	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	oral	O	['N']	[21]
22	zuclopenthixol	B-Drug	['Causes']	[37]
23	,	O	['N']	[23]
24	an	O	['N']	[24]
25	antipsychotic	O	['N']	[25]
26	from	O	['N']	[26]
27	the	O	['N']	[27]
28	thioxanthene	O	['N']	[28]
29	family	O	['N']	[29]
30	,	O	['N']	[30]
31	who	O	['N']	[31]
32	developed	O	['N']	[32]
33	an	O	['N']	[33]
34	acute	O	['N']	[34]
35	,	O	['N']	[35]
36	painful	B	['N']	[36]
37	erection	I-Adverse_Effect	['N']	[37]
38	.	O	['N']	[38]
#371
0	Near	O	['N']	[0]
1	fatal	O	['N']	[1]
2	acute	O	['N']	[2]
3	colchicine	B-Drug	['Causes']	[4]
4	intoxication	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	child	O	['N']	[7]
8	.	O	['N']	[8]
#372
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	two	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	B	['N']	[6]
7	dystonic	I	['N']	[7]
8	reactions	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	ADRs	O	['N']	[10]
11	)	O	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	side	O	['N']	[14]
15	effect	O	['N']	[15]
16	of	O	['N']	[16]
17	lamivudine	B-Drug	['Causes']	[8]
18	.	O	['N']	[18]
#373
0	High	B	['N']	[0]
1	-	I	['N']	[1]
2	dose	I-Dose	['N']	[2]
3	methylprednisolone	B-Drug	['Dosage']	[2]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	pregnant	O	['N']	[6]
7	woman	O	['N']	[7]
8	with	O	['N']	[8]
9	Crohn	O	['N']	[9]
10	's	O	['N']	[10]
11	disease	O	['N']	[11]
12	and	O	['N']	[12]
13	adrenal	O	['N']	[13]
14	suppression	O	['N']	[14]
15	in	O	['N']	[15]
16	her	O	['N']	[16]
17	newborn	O	['N']	[17]
18	.	O	['N']	[18]
#374
0	Inappropriate	B	['N']	[0]
1	antidiuretic	I	['N']	[1]
2	hormone	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	adenine	B	['N']	[4]
5	arabinoside	I-Drug	['Causes']	[2]
6	administration	O	['N']	[6]
7	.	O	['N']	[7]
#375
0	Intravenous	O	['N']	[0]
1	verapamil	B-Drug	['Causes']	[12]
2	therapy	O	['N']	[2]
3	in	O	['N']	[3]
4	babies	O	['N']	[4]
5	may	O	['N']	[5]
6	cause	O	['N']	[6]
7	apnea	O	['N']	[7]
8	,	O	['N']	[8]
9	hypotension	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	bradycardia	B-Adverse_Effect	['N']	[12]
13	;	O	['N']	[13]
14	continued	O	['N']	[14]
15	episodes	O	['N']	[15]
16	of	O	['N']	[16]
17	atrial	O	['N']	[17]
18	flutter	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	child	O	['N']	[21]
22	may	O	['N']	[22]
23	cause	O	['N']	[23]
24	sudden	O	['N']	[24]
25	death	O	['N']	[25]
26	;	O	['N']	[26]
27	quinidine	O	['N']	[27]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	related	O	['N']	[30]
31	to	O	['N']	[31]
32	the	O	['N']	[32]
33	death	O	['N']	[33]
34	;	O	['N']	[34]
35	children	O	['N']	[35]
36	with	O	['N']	[36]
37	"	O	['N']	[37]
38	familial	O	['N']	[38]
39	seizure	O	['N']	[39]
40	disorders	O	['N']	[40]
41	"	O	['N']	[41]
42	may	O	['N']	[42]
43	in	O	['N']	[43]
44	fact	O	['N']	[44]
45	have	O	['N']	[45]
46	the	O	['N']	[46]
47	long	O	['N']	[47]
48	QT	O	['N']	[48]
49	interval	O	['N']	[49]
50	syndrome	O	['N']	[50]
51	.	O	['N']	[51]
#376
0	Azathioprine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	myelosuppression	B-Adverse_Effect	['N']	[3]
4	due	O	['N']	[4]
5	to	O	['N']	[5]
6	thiopurine	O	['N']	[6]
7	methyltransferase	O	['N']	[7]
8	deficiency	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	with	O	['N']	[12]
13	autoimmune	O	['N']	[13]
14	hepatitis	O	['N']	[14]
15	.	O	['N']	[15]
#377
0	Posterior	O	['N']	[0]
1	reversible	O	['N']	[1]
2	encephalopathy	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	(	O	['N']	[4]
5	PRES	B-Drug	['Causes']	[9]
6	)	O	['N']	[6]
7	induced	O	['N']	[7]
8	by	O	['N']	[8]
9	cyclosporine	B-Adverse_Effect	['N']	[9]
10	use	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	collapsing	O	['N']	[15]
16	focal	O	['N']	[16]
17	glomeruloesclerosis	O	['N']	[17]
18	.	O	['N']	[18]
#378
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	45-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	Chinese	O	['N']	[6]
7	man	O	['N']	[7]
8	with	O	['N']	[8]
9	CML	O	['N']	[9]
10	and	O	['N']	[10]
11	chronic	O	['N']	[11]
12	hepatitis	O	['N']	[12]
13	B	O	['N']	[13]
14	virus	O	['N']	[14]
15	infection	O	['N']	[15]
16	,	O	['N']	[16]
17	on	O	['N']	[17]
18	imatinib	B-Drug	['Causes']	[24]
19	treatment	O	['N']	[19]
20	,	O	['N']	[20]
21	presenting	O	['N']	[21]
22	with	O	['N']	[22]
23	herpetic	B	['N']	[23]
24	rash	I-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	acute	O	['N']	[26]
27	liver	O	['N']	[27]
28	failure	O	['N']	[28]
29	.	O	['N']	[29]
#379
0	Calcipotriol	B-Drug	['Causes']	[21]
1	(	O	['N']	[1]
2	Daivonex	O	['N']	[2]
3	R	O	['N']	[3]
4	;	O	['N']	[4]
5	Leo	O	['N']	[5]
6	Pharmaceuticals	O	['N']	[6]
7	,	O	['N']	[7]
8	Zurich	O	['N']	[8]
9	,	O	['N']	[9]
10	Switzerland	O	['N']	[10]
11	)	O	['N']	[11]
12	may	O	['N']	[12]
13	cause	O	['N']	[13]
14	irritation	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	skin	O	['N']	[17]
18	,	O	['N']	[18]
19	whereas	O	['N']	[19]
20	allergic	B	['N']	[20]
21	reactions	I-Adverse_Effect	['N']	[21]
22	are	O	['N']	[22]
23	less	O	['N']	[23]
24	common	O	['N']	[24]
25	.	O	['N']	[25]
#380
0	After	O	['N']	[0]
1	receiving	O	['N']	[1]
2	3	O	['N']	[2]
3	doses	O	['N']	[3]
4	of	O	['N']	[4]
5	ifosfamide	O	['N']	[5]
6	/	O	['N']	[6]
7	mesna	B-Drug	['Causes']	[14]
8	,	O	['N']	[8]
9	she	O	['N']	[9]
10	was	O	['N']	[10]
11	found	O	['N']	[11]
12	to	O	['N']	[12]
13	be	O	['N']	[13]
14	unresponsive	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#381
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	68-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	woman	O	['N']	[7]
8	developed	O	['N']	[8]
9	a	O	['N']	[9]
10	dry	O	['N']	[10]
11	,	O	['N']	[11]
12	irritating	B	['N']	[12]
13	cough	I-Adverse_Effect	['N']	[13]
14	within	O	['N']	[14]
15	one	O	['N']	[15]
16	month	O	['N']	[16]
17	of	O	['N']	[17]
18	starting	O	['N']	[18]
19	quinapril	B-Drug	['Causes']	[13]
20	therapy	O	['N']	[20]
21	for	O	['N']	[21]
22	the	O	['N']	[22]
23	treatment	O	['N']	[23]
24	of	O	['N']	[24]
25	essential	O	['N']	[25]
26	hypertension	O	['N']	[26]
27	.	O	['N']	[27]
#382
0	Intranasal	O	['N']	[0]
1	desmopressin	B-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	hyponatremia	B-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#383
0	Fatal	O	['N']	[0]
1	radiation	O	['N']	[1]
2	myelopathy	O	['N']	[2]
3	after	O	['N']	[3]
4	high	B	['N']	[4]
5	-	I	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	busulfan	O	['N']	[7]
8	and	O	['N']	[8]
9	melphalan	B-Drug	['Dosage']	[6]
10	chemotherapy	O	['N']	[10]
11	and	O	['N']	[11]
12	radiotherapy	O	['N']	[12]
13	for	O	['N']	[13]
14	Ewing	O	['N']	[14]
15	's	O	['N']	[15]
16	sarcoma	O	['N']	[16]
17	:	O	['N']	[17]
18	a	O	['N']	[18]
19	review	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	literature	O	['N']	[22]
23	and	O	['N']	[23]
24	implications	O	['N']	[24]
25	for	O	['N']	[25]
26	practice	O	['N']	[26]
27	.	O	['N']	[27]
#384
0	In	O	['N']	[0]
1	rare	O	['N']	[1]
2	cases	O	['N']	[2]
3	mitomycin	B	['N']	[3]
4	C	I-Drug	['Causes']	[24]
5	(	O	['N']	[5]
6	MMC	O	['N']	[6]
7	)	O	['N']	[7]
8	may	O	['N']	[8]
9	induce	O	['N']	[9]
10	cancer	O	['N']	[10]
11	-	O	['N']	[11]
12	associated	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	uremic	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	is	O	['N']	[18]
19	characterized	O	['N']	[19]
20	by	O	['N']	[20]
21	hemolytic	O	['N']	[21]
22	anemia	O	['N']	[22]
23	,	O	['N']	[23]
24	thrombocytopenia	B-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	progressive	O	['N']	[26]
27	renal	O	['N']	[27]
28	failure	O	['N']	[28]
29	.	O	['N']	[29]
#385
0	While	O	['N']	[0]
1	most	O	['N']	[1]
2	physicians	O	['N']	[2]
3	are	O	['N']	[3]
4	aware	O	['N']	[4]
5	of	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[19]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	thrombocytopenia	O	['N']	[9]
10	and	O	['N']	[10]
11	skin	O	['N']	[11]
12	necrosis	O	['N']	[12]
13	,	O	['N']	[13]
14	the	O	['N']	[14]
15	association	O	['N']	[15]
16	of	O	['N']	[16]
17	heparin	O	['N']	[17]
18	and	O	['N']	[18]
19	hyperkalemia	B-Adverse_Effect	['N']	[19]
20	is	O	['N']	[20]
21	less	O	['N']	[21]
22	well	O	['N']	[22]
23	recognized	O	['N']	[23]
24	.	O	['N']	[24]
#386
0	Since	O	['N']	[0]
1	the	O	['N']	[1]
2	bronchospasm	B-Adverse_Effect	['N']	[2]
3	was	O	['N']	[3]
4	relieved	O	['N']	[4]
5	with	O	['N']	[5]
6	discontinuation	O	['N']	[6]
7	of	O	['N']	[7]
8	propranolol	B-Drug	['Causes']	[2]
9	and	O	['N']	[9]
10	supportive	O	['N']	[10]
11	bronchodilator	O	['N']	[11]
12	therapy	O	['N']	[12]
13	,	O	['N']	[13]
14	the	O	['N']	[14]
15	bronchospasm	O	['N']	[15]
16	was	O	['N']	[16]
17	believed	O	['N']	[17]
18	to	O	['N']	[18]
19	be	O	['N']	[19]
20	caused	O	['N']	[20]
21	by	O	['N']	[21]
22	propranolol	O	['N']	[22]
23	.	O	['N']	[23]
#387
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	for	O	['N']	[2]
3	the	O	['N']	[3]
4	first	O	['N']	[4]
5	time	O	['N']	[5]
6	the	O	['N']	[6]
7	development	O	['N']	[7]
8	of	O	['N']	[8]
9	symptomatic	B	['N']	[9]
10	methemoglobinemia	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	an	O	['N']	[12]
13	acute	O	['N']	[13]
14	ingestion	O	['N']	[14]
15	of	O	['N']	[15]
16	divalproex	O	['N']	[16]
17	sodium	O	['N']	[17]
18	(	O	['N']	[18]
19	Depakote	B-Drug	['Causes']	[10]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	resulting	O	['N']	[22]
23	in	O	['N']	[23]
24	serum	O	['N']	[24]
25	concentrations	O	['N']	[25]
26	10	O	['N']	[26]
27	times	O	['N']	[27]
28	greater	O	['N']	[28]
29	than	O	['N']	[29]
30	the	O	['N']	[30]
31	therapeutic	O	['N']	[31]
32	range	O	['N']	[32]
33	.	O	['N']	[33]
#388
0	Therapy	O	['N']	[0]
1	with	O	['N']	[1]
2	IFN	B	['N']	[2]
3	-	I	['N']	[3]
4	alpha	I-Drug	['Causes']	[13]
5	may	O	['N']	[5]
6	be	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	number	O	['N']	[10]
11	of	O	['N']	[11]
12	neuropsychiatric	B	['N']	[12]
13	symptoms	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	such	O	['N']	[15]
16	as	O	['N']	[16]
17	Parkinsonism	O	['N']	[17]
18	,	O	['N']	[18]
19	akathisia	O	['N']	[19]
20	,	O	['N']	[20]
21	seizure	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	depressive	O	['N']	[24]
25	disorders	O	['N']	[25]
26	.	O	['N']	[26]
#389
0	Three	O	['N']	[0]
1	months	O	['N']	[1]
2	after	O	['N']	[2]
3	starting	O	['N']	[3]
4	citalopram	B-Drug	['Causes']	[13]
5	,	O	['N']	[5]
6	she	O	['N']	[6]
7	experienced	O	['N']	[7]
8	episodes	O	['N']	[8]
9	of	O	['N']	[9]
10	chest	O	['N']	[10]
11	tightness	O	['N']	[11]
12	and	O	['N']	[12]
13	dizziness	B-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#390
0	Heparin	O	['N']	[0]
1	-	O	['N']	[1]
2	dependent	O	['N']	[2]
3	antibodies	O	['N']	[3]
4	and	O	['N']	[4]
5	thrombosis	O	['N']	[5]
6	without	O	['N']	[6]
7	heparin	B-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	thrombocytopenia	B-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#391
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	with	O	['N']	[2]
3	parenteral	O	['N']	[3]
4	amiodarone	B-Drug	['Causes']	[39]
5	(	O	['N']	[5]
6	2300	O	['N']	[6]
7	mg	O	['N']	[7]
8	in	O	['N']	[8]
9	3	O	['N']	[9]
10	days	O	['N']	[10]
11	)	O	['N']	[11]
12	and	O	['N']	[12]
13	other	O	['N']	[13]
14	measures	O	['N']	[14]
15	,	O	['N']	[15]
16	signs	O	['N']	[16]
17	of	O	['N']	[17]
18	congestive	O	['N']	[18]
19	heart	O	['N']	[19]
20	failure	O	['N']	[20]
21	disappeared	O	['N']	[21]
22	;	O	['N']	[22]
23	subsequently	O	['N']	[23]
24	the	O	['N']	[24]
25	patient	O	['N']	[25]
26	developed	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	marked	O	['N']	[29]
30	increase	O	['N']	[30]
31	in	O	['N']	[31]
32	serum	O	['N']	[32]
33	transaminase	O	['N']	[33]
34	levels	O	['N']	[34]
35	and	O	['N']	[35]
36	fall	B	['N']	[36]
37	in	I	['N']	[37]
38	prothrombin	I	['N']	[38]
39	time	I-Adverse_Effect	['N']	[39]
40	,	O	['N']	[40]
41	and	O	['N']	[41]
42	histologic	O	['N']	[42]
43	changes	O	['N']	[43]
44	of	O	['N']	[44]
45	severe	O	['N']	[45]
46	centrilobular	O	['N']	[46]
47	necrosis	O	['N']	[47]
48	were	O	['N']	[48]
49	observed	O	['N']	[49]
50	in	O	['N']	[50]
51	hepatic	O	['N']	[51]
52	biopsy	O	['N']	[52]
53	.	O	['N']	[53]
#392
0	The	O	['N']	[0]
1	literature	O	['N']	[1]
2	is	O	['N']	[2]
3	also	O	['N']	[3]
4	reviewed	O	['N']	[4]
5	for	O	['N']	[5]
6	ARF	B-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	mannitol	B-Drug	['Causes']	[6]
10	infusion	O	['N']	[10]
11	in	O	['N']	[11]
12	patients	O	['N']	[12]
13	who	O	['N']	[13]
14	received	O	['N']	[14]
15	dialysis	O	['N']	[15]
16	and	O	['N']	[16]
17	those	O	['N']	[17]
18	who	O	['N']	[18]
19	did	O	['N']	[19]
20	not	O	['N']	[20]
21	receive	O	['N']	[21]
22	dialysis	O	['N']	[22]
23	;	O	['N']	[23]
24	and	O	['N']	[24]
25	the	O	['N']	[25]
26	possible	O	['N']	[26]
27	mechanism(s	O	['N']	[27]
28	)	O	['N']	[28]
29	of	O	['N']	[29]
30	mannitol	O	['N']	[30]
31	nephrotoxicity	O	['N']	[31]
32	are	O	['N']	[32]
33	discussed	O	['N']	[33]
34	.	O	['N']	[34]
#393
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	risk	O	['N']	[8]
9	of	O	['N']	[9]
10	serotonin	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	with	O	['N']	[12]
13	serious	O	['N']	[13]
14	extrapyramidal	O	['N']	[14]
15	reactions	O	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	receiving	O	['N']	[18]
19	sertraline	O	['N']	[19]
20	or	O	['N']	[20]
21	venlafaxine	B-Drug	['Dosage']	[31]
22	when	O	['N']	[22]
23	metoclopramide	O	['N']	[23]
24	is	O	['N']	[24]
25	coadministered	O	['N']	[25]
26	even	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	,	O	['N']	[30]
31	conventional	B-Dose	['N']	[31]
32	dose	O	['N']	[32]
33	.	O	['N']	[33]
#394
0	Salicylate	O	['N']	[0]
1	intoxication	B-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	excluded	O	['N']	[3]
4	,	O	['N']	[4]
5	and	O	['N']	[5]
6	theophylline	B-Drug	['Causes']	[1]
7	was	O	['N']	[7]
8	finally	O	['N']	[8]
9	incriminated	O	['N']	[9]
10	.	O	['N']	[10]
#395
0	Neurologic	O	['N']	[0]
1	symptoms	O	['N']	[1]
2	resolved	O	['N']	[2]
3	after	O	['N']	[3]
4	stopping	O	['N']	[4]
5	CAP	B-Drug	['Dosage']	[24]
6	for	O	['N']	[6]
7	4	O	['N']	[7]
8	weeks	O	['N']	[8]
9	in	O	['N']	[9]
10	Patient	O	['N']	[10]
11	A	O	['N']	[11]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	no	O	['N']	[14]
15	recurrence	O	['N']	[15]
16	after	O	['N']	[16]
17	reinitiating	O	['N']	[17]
18	CAP	O	['N']	[18]
19	alone	O	['N']	[19]
20	at	O	['N']	[20]
21	2000	B	['N']	[21]
22	mg	I	['N']	[22]
23	/	I	['N']	[23]
24	m2	I-Dose	['N']	[24]
25	.	O	['N']	[25]
#396
0	An	O	['N']	[0]
1	evaluation	O	['N']	[1]
2	of	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	structure	O	['N']	[4]
5	and	O	['N']	[5]
6	function	O	['N']	[6]
7	should	O	['N']	[7]
8	be	O	['N']	[8]
9	considered	O	['N']	[9]
10	in	O	['N']	[10]
11	women	O	['N']	[11]
12	of	O	['N']	[12]
13	reproductive	O	['N']	[13]
14	age	O	['N']	[14]
15	being	O	['N']	[15]
16	treated	O	['N']	[16]
17	with	O	['N']	[17]
18	valproate	B-Drug	['Causes']	[28]
19	for	O	['N']	[19]
20	epilepsy	O	['N']	[20]
21	,	O	['N']	[21]
22	especially	O	['N']	[22]
23	if	O	['N']	[23]
24	they	O	['N']	[24]
25	develop	O	['N']	[25]
26	menstrual	B	['N']	[26]
27	cycle	I	['N']	[27]
28	disturbances	I-Adverse_Effect	['N']	[28]
29	during	O	['N']	[29]
30	treatment	O	['N']	[30]
31	.	O	['N']	[31]
#397
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	one	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	incomplete	B	['N']	[6]
7	posterior	I	['N']	[7]
8	hyaloid	I	['N']	[8]
9	detachment	I-Adverse_Effect	['N']	[9]
10	(	O	['N']	[10]
11	PHD	O	['N']	[11]
12	)	O	['N']	[12]
13	following	O	['N']	[13]
14	intravitreal	O	['N']	[14]
15	pegaptanib	B-Drug	['Causes']	[9]
16	to	O	['N']	[16]
17	treat	O	['N']	[17]
18	DME	O	['N']	[18]
19	.	O	['N']	[19]
#398
0	Pneumonitis	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	emerging	O	['N']	[2]
3	as	O	['N']	[3]
4	one	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	most	O	['N']	[7]
8	unpredictable	O	['N']	[8]
9	and	O	['N']	[9]
10	potentially	O	['N']	[10]
11	serious	O	['N']	[11]
12	,	O	['N']	[12]
13	adverse	O	['N']	[13]
14	effects	O	['N']	[14]
15	of	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	MTX	B-Drug	['Causes']	[0]
19	.	O	['N']	[19]
#399
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	diabetic	O	['N']	[6]
7	patient	O	['N']	[7]
8	taking	O	['N']	[8]
9	glyburide	B-Drug	['Causes']	[17]
10	who	O	['N']	[10]
11	was	O	['N']	[11]
12	prescribed	O	['N']	[12]
13	ciprofloxacin	O	['N']	[13]
14	and	O	['N']	[14]
15	developed	O	['N']	[15]
16	prolonged	B	['N']	[16]
17	hypoglycemia	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	which	O	['N']	[19]
20	persisted	O	['N']	[20]
21	for	O	['N']	[21]
22	over	O	['N']	[22]
23	24	O	['N']	[23]
24	hours	O	['N']	[24]
25	.	O	['N']	[25]
#400
0	Autoimmune	B	['N']	[0]
1	thyroid	I	['N']	[1]
2	disease	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	common	O	['N']	[5]
6	side	O	['N']	[6]
7	-	O	['N']	[7]
8	effect	O	['N']	[8]
9	of	O	['N']	[9]
10	interferon	B	['N']	[10]
11	-	I	['N']	[11]
12	alpha	I-Drug	['Causes']	[2]
13	(	O	['N']	[13]
14	IFN	O	['N']	[14]
15	-	O	['N']	[15]
16	alpha	O	['N']	[16]
17	)	O	['N']	[17]
18	treatment	O	['N']	[18]
19	of	O	['N']	[19]
20	viral	O	['N']	[20]
21	hepatitis	O	['N']	[21]
22	C.	O	['N']	[22]
#401
0	Further	O	['N']	[0]
1	studies	O	['N']	[1]
2	are	O	['N']	[2]
3	necessary	O	['N']	[3]
4	to	O	['N']	[4]
5	evaluate	O	['N']	[5]
6	whether	O	['N']	[6]
7	the	O	['N']	[7]
8	study	O	['N']	[8]
9	of	O	['N']	[9]
10	HLA	O	['N']	[10]
11	antigens	O	['N']	[11]
12	may	O	['N']	[12]
13	be	O	['N']	[13]
14	a	O	['N']	[14]
15	very	O	['N']	[15]
16	useful	O	['N']	[16]
17	tool	O	['N']	[17]
18	to	O	['N']	[18]
19	detect	O	['N']	[19]
20	the	O	['N']	[20]
21	patients	O	['N']	[21]
22	with	O	['N']	[22]
23	a	O	['N']	[23]
24	predisposition	O	['N']	[24]
25	to	O	['N']	[25]
26	develop	O	['N']	[26]
27	autoimmune	B	['N']	[27]
28	thyroiditis	I-Adverse_Effect	['N']	[28]
29	,	O	['N']	[29]
30	in	O	['N']	[30]
31	order	O	['N']	[31]
32	to	O	['N']	[32]
33	make	O	['N']	[33]
34	a	O	['N']	[34]
35	early	O	['N']	[35]
36	diagnosis	O	['N']	[36]
37	of	O	['N']	[37]
38	thyroid	O	['N']	[38]
39	disorders	O	['N']	[39]
40	during	O	['N']	[40]
41	the	O	['N']	[41]
42	IFN	B	['N']	[42]
43	-	I	['N']	[43]
44	alpha	I-Drug	['Causes']	[28]
45	treatment	O	['N']	[45]
46	.	O	['N']	[46]
#402
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	treated	O	['N']	[2]
3	for	O	['N']	[3]
4	chronic	O	['N']	[4]
5	myeloid	O	['N']	[5]
6	leukemia	O	['N']	[6]
7	with	O	['N']	[7]
8	high	B	['N']	[8]
9	doses	I-Dose	['N']	[9]
10	of	O	['N']	[10]
11	CCNU	B-Drug	['Dosage']	[9]
12	(	O	['N']	[12]
13	1100	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	m2	O	['N']	[16]
17	and	O	['N']	[17]
18	1240	O	['N']	[18]
19	mg	O	['N']	[19]
20	/	O	['N']	[20]
21	m2	O	['N']	[21]
22	,	O	['N']	[22]
23	respectively	O	['N']	[23]
24	)	O	['N']	[24]
25	developed	O	['N']	[25]
26	a	O	['N']	[26]
27	fatal	O	['N']	[27]
28	pulmonary	O	['N']	[28]
29	fibrosis	O	['N']	[29]
30	.	O	['N']	[30]
#403
0	One	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	side	O	['N']	[3]
4	-	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	intravitreal	O	['N']	[7]
8	triamcinolone	B-Drug	['Causes']	[13]
9	is	O	['N']	[9]
10	the	O	['N']	[10]
11	development	O	['N']	[11]
12	of	O	['N']	[12]
13	cataract	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	it	O	['N']	[16]
17	is	O	['N']	[17]
18	known	O	['N']	[18]
19	that	O	['N']	[19]
20	cataract	O	['N']	[20]
21	extraction	O	['N']	[21]
22	can	O	['N']	[22]
23	exacerbate	O	['N']	[23]
24	macular	O	['N']	[24]
25	degeneration	O	['N']	[25]
26	.	O	['N']	[26]
#404
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	is	O	['N']	[2]
3	described	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	a	O	['N']	[6]
7	poorly	O	['N']	[7]
8	differentiated	O	['N']	[8]
9	sarcoma	B-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	cyclophosphamide	B-Drug	['Causes']	[9]
12	was	O	['N']	[12]
13	used	O	['N']	[13]
14	to	O	['N']	[14]
15	treat	O	['N']	[15]
16	his	O	['N']	[16]
17	rheumatoid	O	['N']	[17]
18	arthritis	O	['N']	[18]
19	.	O	['N']	[19]
#405
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	56-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	female	O	['N']	[7]
8	who	O	['N']	[8]
9	exhibited	O	['N']	[9]
10	drug	O	['N']	[10]
11	refractory	O	['N']	[11]
12	paroxysmal	O	['N']	[12]
13	atrial	O	['N']	[13]
14	fibrillation	O	['N']	[14]
15	,	O	['N']	[15]
16	in	O	['N']	[16]
17	which	O	['N']	[17]
18	marked	O	['N']	[18]
19	prolongation	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	QT	O	['N']	[22]
23	interval	O	['N']	[23]
24	and	O	['N']	[24]
25	T	B	['N']	[25]
26	wave	I	['N']	[26]
27	inversion	I-Adverse_Effect	['N']	[27]
28	on	O	['N']	[28]
29	electrocardiogram	O	['N']	[29]
30	was	O	['N']	[30]
31	demonstrated	O	['N']	[31]
32	reproducibly	O	['N']	[32]
33	shortly	O	['N']	[33]
34	after	O	['N']	[34]
35	the	O	['N']	[35]
36	administration	O	['N']	[36]
37	of	O	['N']	[37]
38	oral	O	['N']	[38]
39	pirmenol	B-Drug	['Causes']	[27]
40	therapy	O	['N']	[40]
41	.	O	['N']	[41]
#406
0	Life	O	['N']	[0]
1	-	O	['N']	[1]
2	threatening	O	['N']	[2]
3	acute	O	['N']	[3]
4	hyponatraemia	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	low	B	['N']	[7]
8	dose	I-Dose	['N']	[8]
9	cyclophosphamide	B-Drug	['Dosage']	[8]
10	and	O	['N']	[10]
11	indomethacin	O	['N']	[11]
12	.	O	['N']	[12]
#407
0	Cisplatin	B-Drug	['Causes']	[7]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	syndrome	B	['N']	[3]
4	of	I	['N']	[4]
5	inappropriate	I	['N']	[5]
6	antidiuretic	I	['N']	[6]
7	hormone	I-Adverse_Effect	['N']	[7]
8	(	O	['N']	[8]
9	SIADH	O	['N']	[9]
10	)	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	neuroendocrine	O	['N']	[15]
16	tumor	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	cervix	O	['N']	[19]
20	:	O	['N']	[20]
21	a	O	['N']	[21]
22	case	O	['N']	[22]
23	report	O	['N']	[23]
24	and	O	['N']	[24]
25	review	O	['N']	[25]
26	of	O	['N']	[26]
27	the	O	['N']	[27]
28	literature	O	['N']	[28]
29	.	O	['N']	[29]
#408
0	Thirty	O	['N']	[0]
1	-	O	['N']	[1]
2	six	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	AL	O	['N']	[5]
6	received	O	['N']	[6]
7	,	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	three	O	['N']	[10]
11	-	O	['N']	[11]
12	month	O	['N']	[12]
13	period	O	['N']	[13]
14	,	O	['N']	[14]
15	51	O	['N']	[15]
16	cycles	O	['N']	[16]
17	of	O	['N']	[17]
18	combined	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	which	O	['N']	[20]
21	included	O	['N']	[21]
22	,	O	['N']	[22]
23	in	O	['N']	[23]
24	all	O	['N']	[24]
25	of	O	['N']	[25]
26	them	O	['N']	[26]
27	,	O	['N']	[27]
28	cytosine	B	['N']	[28]
29	arabinoside	I-Drug	['Causes']	[52]
30	(	O	['N']	[30]
31	ARA	O	['N']	[31]
32	-	O	['N']	[32]
33	C	O	['N']	[33]
34	)	O	['N']	[34]
35	;	O	['N']	[35]
36	among	O	['N']	[36]
37	them	O	['N']	[37]
38	,	O	['N']	[38]
39	along	O	['N']	[39]
40	with	O	['N']	[40]
41	myelosuppression	O	['N']	[41]
42	,	O	['N']	[42]
43	five	O	['N']	[43]
44	experienced	O	['N']	[44]
45	fever	O	['N']	[45]
46	,	O	['N']	[46]
47	infectious	O	['N']	[47]
48	complications	O	['N']	[48]
49	,	O	['N']	[49]
50	gastrointestinal	B	['N']	[50]
51	tract	I	['N']	[51]
52	symptoms	I-Adverse_Effect	['N']	[52]
53	and	O	['N']	[53]
54	severe	O	['N']	[54]
55	myalgias	O	['N']	[55]
56	.	O	['N']	[56]
#409
0	The	O	['N']	[0]
1	former	O	['N']	[1]
2	patient	O	['N']	[2]
3	had	O	['N']	[3]
4	complained	O	['N']	[4]
5	once	O	['N']	[5]
6	that	O	['N']	[6]
7	his	O	['N']	[7]
8	visual	B	['N']	[8]
9	acuity	I	['N']	[9]
10	had	I	['N']	[10]
11	decreased	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	termination	O	['N']	[14]
15	of	O	['N']	[15]
16	IFN	B-Drug	['Causes']	[11]
17	therapy	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	the	O	['N']	[20]
21	latter	O	['N']	[21]
22	patient	O	['N']	[22]
23	complained	O	['N']	[23]
24	twice	O	['N']	[24]
25	during	O	['N']	[25]
26	IFN	O	['N']	[26]
27	therapy	O	['N']	[27]
28	that	O	['N']	[28]
29	his	O	['N']	[29]
30	visual	O	['N']	[30]
31	acuity	O	['N']	[31]
32	had	O	['N']	[32]
33	decreased	O	['N']	[33]
34	.	O	['N']	[34]
#410
0	A	O	['N']	[0]
1	77-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	no	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	epilepsy	O	['N']	[9]
10	presented	O	['N']	[10]
11	a	O	['N']	[11]
12	probable	O	['N']	[12]
13	nonconvulsive	B	['N']	[13]
14	status	I	['N']	[14]
15	epilepticus	I-Adverse_Effect	['N']	[15]
16	while	O	['N']	[16]
17	receiving	O	['N']	[17]
18	continuous	O	['N']	[18]
19	intravenous	O	['N']	[19]
20	morphine	B-Drug	['Causes']	[15]
21	for	O	['N']	[21]
22	back	O	['N']	[22]
23	pain	O	['N']	[23]
24	relating	O	['N']	[24]
25	to	O	['N']	[25]
26	vertebral	O	['N']	[26]
27	metastasis	O	['N']	[27]
28	of	O	['N']	[28]
29	a	O	['N']	[29]
30	malignant	O	['N']	[30]
31	lymphoma	O	['N']	[31]
32	.	O	['N']	[32]
#411
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Brimonidine	B-Drug	['Causes']	[8]
3	was	O	['N']	[3]
4	observed	O	['N']	[4]
5	to	O	['N']	[5]
6	cause	O	['N']	[6]
7	IOP	B	['N']	[7]
8	elevation	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	confirmed	O	['N']	[10]
11	on	O	['N']	[11]
12	rechallenge	O	['N']	[12]
13	,	O	['N']	[13]
14	scoring	O	['N']	[14]
15	8	O	['N']	[15]
16	(	O	['N']	[16]
17	strong	O	['N']	[17]
18	probability	O	['N']	[18]
19	)	O	['N']	[19]
20	on	O	['N']	[20]
21	an	O	['N']	[21]
22	adverse	O	['N']	[22]
23	drug	O	['N']	[23]
24	reaction	O	['N']	[24]
25	probability	O	['N']	[25]
26	score	O	['N']	[26]
27	.	O	['N']	[27]
#412
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	27-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	Indian	O	['N']	[9]
10	woman	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	maculopapular	O	['N']	[13]
14	rash	O	['N']	[14]
15	and	O	['N']	[15]
16	angioedema	B-Adverse_Effect	['N']	[16]
17	secondary	O	['N']	[17]
18	to	O	['N']	[18]
19	carbamazepine	B-Drug	['Causes']	[16]
20	administration	O	['N']	[20]
21	.	O	['N']	[21]
#413
0	Stupor	B-Adverse_Effect	['N']	[0]
1	from	O	['N']	[1]
2	lamotrigine	B-Drug	['Causes']	[0]
3	toxicity	O	['N']	[3]
4	.	O	['N']	[4]
#414
0	This	O	['N']	[0]
1	prompted	O	['N']	[1]
2	us	O	['N']	[2]
3	to	O	['N']	[3]
4	suspect	O	['N']	[4]
5	that	O	['N']	[5]
6	ddI	B-Drug	['Causes']	[12]
7	might	O	['N']	[7]
8	be	O	['N']	[8]
9	responsible	O	['N']	[9]
10	for	O	['N']	[10]
11	fulminant	B	['N']	[11]
12	hepatitis	I-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	all	O	['N']	[14]
15	three	O	['N']	[15]
16	AIDS	O	['N']	[16]
17	patients	O	['N']	[17]
18	.	O	['N']	[18]
#415
0	Thus	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	confirm	O	['N']	[3]
4	that	O	['N']	[4]
5	desensitization	O	['N']	[5]
6	may	O	['N']	[6]
7	be	O	['N']	[7]
8	a	O	['N']	[8]
9	safe	O	['N']	[9]
10	procedure	O	['N']	[10]
11	in	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	cancer	O	['N']	[14]
15	who	O	['N']	[15]
16	experience	O	['N']	[16]
17	methotrexate	B-Drug	['Causes']	[20]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	anaphylaxis	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#416
0	Acute	B	['N']	[0]
1	endophthalmitis	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	intravitreal	O	['N']	[3]
4	bevacizumab	B-Drug	['Causes']	[1]
5	(	O	['N']	[5]
6	Avastin	O	['N']	[6]
7	)	O	['N']	[7]
8	injection	O	['N']	[8]
9	.	O	['N']	[9]
#417
0	The	O	['N']	[0]
1	toxic	O	['N']	[1]
2	effects	O	['N']	[2]
3	of	O	['N']	[3]
4	methotrexate	B-Drug	['Causes']	[8]
5	included	O	['N']	[5]
6	elevated	B	['N']	[6]
7	liver	I	['N']	[7]
8	transaminases	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	3/4	O	['N']	[10]
11	)	O	['N']	[11]
12	,	O	['N']	[12]
13	nausea	O	['N']	[13]
14	(	O	['N']	[14]
15	2/4	O	['N']	[15]
16	)	O	['N']	[16]
17	,	O	['N']	[17]
18	abdominal	O	['N']	[18]
19	pain	O	['N']	[19]
20	(	O	['N']	[20]
21	2/4	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	bone	O	['N']	[24]
25	pain	O	['N']	[25]
26	(	O	['N']	[26]
27	2/4	O	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	mild	O	['N']	[30]
31	neutropenia	O	['N']	[31]
32	(	O	['N']	[32]
33	1/4	O	['N']	[33]
34	)	O	['N']	[34]
35	,	O	['N']	[35]
36	and	O	['N']	[36]
37	mild	O	['N']	[37]
38	pruritus	O	['N']	[38]
39	(	O	['N']	[39]
40	1/4	O	['N']	[40]
41	)	O	['N']	[41]
42	.	O	['N']	[42]
#418
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	76-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	an	O	['N']	[9]
10	acute	B	['N']	[10]
11	blistering	I	['N']	[11]
12	eruption	I-Adverse_Effect	['N']	[12]
13	following	O	['N']	[13]
14	high	O	['N']	[14]
15	-	O	['N']	[15]
16	dose	O	['N']	[16]
17	penicillin	B-Drug	['Causes']	[12]
18	treatment	O	['N']	[18]
19	for	O	['N']	[19]
20	pneumococcal	O	['N']	[20]
21	septicaemia	O	['N']	[21]
22	.	O	['N']	[22]
#419
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	histories	O	['N']	[2]
3	are	O	['N']	[3]
4	presented	O	['N']	[4]
5	of	O	['N']	[5]
6	two	O	['N']	[6]
7	patients	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	lung	O	['N']	[10]
11	disease	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	the	O	['N']	[14]
15	use	O	['N']	[15]
16	of	O	['N']	[16]
17	nitrofurantoin	B-Drug	['Causes']	[27]
18	with	O	['N']	[18]
19	histological	O	['N']	[19]
20	features	O	['N']	[20]
21	of	O	['N']	[21]
22	bronchiolitis	O	['N']	[22]
23	obliterans	O	['N']	[23]
24	organising	O	['N']	[24]
25	pneumonia	O	['N']	[25]
26	(	O	['N']	[26]
27	BOOP	B-Adverse_Effect	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	a	O	['N']	[30]
31	rare	O	['N']	[31]
32	but	O	['N']	[32]
33	recognised	O	['N']	[33]
34	form	O	['N']	[34]
35	of	O	['N']	[35]
36	drug	O	['N']	[36]
37	induced	O	['N']	[37]
38	injury	O	['N']	[38]
39	.	O	['N']	[39]
#420
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Significant	O	['N']	[2]
3	ocular	B	['N']	[3]
4	complications	I-Adverse_Effect	['N']	[4]
5	such	O	['N']	[5]
6	as	O	['N']	[6]
7	an	O	['N']	[7]
8	irreversible	O	['N']	[8]
9	decrease	O	['N']	[9]
10	of	O	['N']	[10]
11	visual	O	['N']	[11]
12	acuity	O	['N']	[12]
13	may	O	['N']	[13]
14	develop	O	['N']	[14]
15	in	O	['N']	[15]
16	patients	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	pegylated	B	['N']	[19]
20	interferon	I-Drug	['Causes']	[4]
21	.	O	['N']	[21]
#421
0	Uveitis	B-Adverse_Effect	['N']	[0]
1	during	O	['N']	[1]
2	treatment	O	['N']	[2]
3	of	O	['N']	[3]
4	disseminated	O	['N']	[4]
5	Mycobacterium	O	['N']	[5]
6	avium	O	['N']	[6]
7	-	O	['N']	[7]
8	intracellulare	O	['N']	[8]
9	complex	O	['N']	[9]
10	infection	O	['N']	[10]
11	with	O	['N']	[11]
12	the	O	['N']	[12]
13	combination	O	['N']	[13]
14	of	O	['N']	[14]
15	rifabutin	O	['N']	[15]
16	,	O	['N']	[16]
17	clarithromycin	O	['N']	[17]
18	and	O	['N']	[18]
19	ethambutol	B-Drug	['Causes']	[0]
20	.	O	['N']	[20]
#422
0	A	O	['N']	[0]
1	young	O	['N']	[1]
2	woman	O	['N']	[2]
3	developed	O	['N']	[3]
4	galactorrhea	B-Adverse_Effect	['N']	[4]
5	during	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	a	O	['N']	[8]
9	new	O	['N']	[9]
10	dibenzoxazepine	O	['N']	[10]
11	antidepressant	O	['N']	[11]
12	,	O	['N']	[12]
13	amoxapine	B-Drug	['Causes']	[4]
14	.	O	['N']	[14]
#423
0	Amiodarone	B-Drug	['Causes']	[7]
1	was	O	['N']	[1]
2	the	O	['N']	[2]
3	third	O	['N']	[3]
4	drug	O	['N']	[4]
5	to	O	['N']	[5]
6	induce	O	['N']	[6]
7	AVT	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	this	O	['N']	[9]
10	patient	O	['N']	[10]
11	;	O	['N']	[11]
12	she	O	['N']	[12]
13	received	O	['N']	[13]
14	200	O	['N']	[14]
15	mg	O	['N']	[15]
16	/	O	['N']	[16]
17	day	O	['N']	[17]
18	six	O	['N']	[18]
19	days	O	['N']	[19]
20	per	O	['N']	[20]
21	week	O	['N']	[21]
22	for	O	['N']	[22]
23	six	O	['N']	[23]
24	months	O	['N']	[24]
25	.	O	['N']	[25]
#424
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Cyanamide	B-Drug	['Causes']	[26]
3	,	O	['N']	[3]
4	an	O	['N']	[4]
5	aversive	O	['N']	[5]
6	agent	O	['N']	[6]
7	widely	O	['N']	[7]
8	used	O	['N']	[8]
9	in	O	['N']	[9]
10	Japan	O	['N']	[10]
11	,	O	['N']	[11]
12	is	O	['N']	[12]
13	known	O	['N']	[13]
14	to	O	['N']	[14]
15	induce	O	['N']	[15]
16	various	O	['N']	[16]
17	degrees	O	['N']	[17]
18	of	O	['N']	[18]
19	hepatic	B	['N']	[19]
20	lesion	I	['N']	[20]
21	with	I	['N']	[21]
22	ground	I	['N']	[22]
23	-	I	['N']	[23]
24	glass	I	['N']	[24]
25	inclusion	I	['N']	[25]
26	bodies	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#425
0	Restless	B	['N']	[0]
1	legs	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	may	O	['N']	[3]
4	thus	O	['N']	[4]
5	be	O	['N']	[5]
6	an	O	['N']	[6]
7	adverse	O	['N']	[7]
8	effect	O	['N']	[8]
9	of	O	['N']	[9]
10	IFN	B	['N']	[10]
11	alpha	I-Drug	['Causes']	[2]
12	treatment	O	['N']	[12]
13	.	O	['N']	[13]
#426
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	intraoperative	O	['N']	[5]
6	gelatine	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	anaphylaxis	B-Adverse_Effect	['N']	[9]
10	whose	O	['N']	[10]
11	diagnosis	O	['N']	[11]
12	was	O	['N']	[12]
13	delayed	O	['N']	[13]
14	as	O	['N']	[14]
15	the	O	['N']	[15]
16	use	O	['N']	[16]
17	of	O	['N']	[17]
18	gelatine	O	['N']	[18]
19	during	O	['N']	[19]
20	surgical	O	['N']	[20]
21	procedures	O	['N']	[21]
22	was	O	['N']	[22]
23	omitted	O	['N']	[23]
24	for	O	['N']	[24]
25	two	O	['N']	[25]
26	times	O	['N']	[26]
27	in	O	['N']	[27]
28	patient	O	['N']	[28]
29	's	O	['N']	[29]
30	medical	O	['N']	[30]
31	records	O	['N']	[31]
32	.	O	['N']	[32]
#427
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	ovarian	O	['N']	[6]
7	endometrioid	O	['N']	[7]
8	carcinoma	O	['N']	[8]
9	and	O	['N']	[9]
10	endometriosis	B-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	postmenopausal	O	['N']	[13]
14	patient	O	['N']	[14]
15	who	O	['N']	[15]
16	was	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	tamoxifen	B-Drug	['Causes']	[10]
20	for	O	['N']	[20]
21	breast	O	['N']	[21]
22	cancer	O	['N']	[22]
23	.	O	['N']	[23]
#428
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	sideroblastic	B	['N']	[3]
4	anemia	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	presented	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	a	O	['N']	[11]
12	left	O	['N']	[12]
13	ventricular	O	['N']	[13]
14	assist	O	['N']	[14]
15	device	O	['N']	[15]
16	drive	O	['N']	[16]
17	-	O	['N']	[17]
18	line	O	['N']	[18]
19	infection	O	['N']	[19]
20	who	O	['N']	[20]
21	was	O	['N']	[21]
22	receiving	O	['N']	[22]
23	linezolid	B-Drug	['Causes']	[4]
24	,	O	['N']	[24]
25	an	O	['N']	[25]
26	antibiotic	O	['N']	[26]
27	used	O	['N']	[27]
28	for	O	['N']	[28]
29	serious	O	['N']	[29]
30	infections	O	['N']	[30]
31	with	O	['N']	[31]
32	gram	O	['N']	[32]
33	-	O	['N']	[33]
34	positive	O	['N']	[34]
35	organisms	O	['N']	[35]
36	.	O	['N']	[36]
#429
0	Azathioprine	B-Drug	['Causes']	[4]
1	can	O	['N']	[1]
2	cause	O	['N']	[2]
3	severe	O	['N']	[3]
4	myelosuppression	B-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#430
0	Methotrexate	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pneumonitis	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	and	O	['N']	[9]
10	psoriatic	O	['N']	[10]
11	arthritis	O	['N']	[11]
12	:	O	['N']	[12]
13	report	O	['N']	[13]
14	of	O	['N']	[14]
15	five	O	['N']	[15]
16	cases	O	['N']	[16]
17	and	O	['N']	[17]
18	review	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	literature	O	['N']	[21]
22	.	O	['N']	[22]
#431
0	This	O	['N']	[0]
1	treatment	O	['N']	[1]
2	has	O	['N']	[2]
3	the	O	['N']	[3]
4	potential	O	['N']	[4]
5	to	O	['N']	[5]
6	cause	O	['N']	[6]
7	severe	B	['N']	[7]
8	vision	I	['N']	[8]
9	loss	I-Adverse_Effect	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	result	O	['N']	[12]
13	of	O	['N']	[13]
14	intractable	O	['N']	[14]
15	corticosteroid	B-Drug	['Causes']	[9]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	glaucoma	O	['N']	[18]
19	.	O	['N']	[19]
#432
0	Two	O	['N']	[0]
1	weeks	O	['N']	[1]
2	following	O	['N']	[2]
3	rechallenge	O	['N']	[3]
4	with	O	['N']	[4]
5	alendronate	B	['N']	[5]
6	sodium	I-Drug	['Causes']	[12]
7	resulted	O	['N']	[7]
8	in	O	['N']	[8]
9	recurrence	O	['N']	[9]
10	of	O	['N']	[10]
11	his	O	['N']	[11]
12	scleritis	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#433
0	Although	O	['N']	[0]
1	it	O	['N']	[1]
2	is	O	['N']	[2]
3	difficult	O	['N']	[3]
4	to	O	['N']	[4]
5	solely	O	['N']	[5]
6	attribute	O	['N']	[6]
7	intratumoral	B	['N']	[7]
8	hemorrhage	I-Adverse_Effect	['N']	[8]
9	to	O	['N']	[9]
10	aspirin	B-Drug	['Causes']	[8]
11	,	O	['N']	[11]
12	we	O	['N']	[12]
13	have	O	['N']	[13]
14	to	O	['N']	[14]
15	be	O	['N']	[15]
16	careful	O	['N']	[16]
17	when	O	['N']	[17]
18	prescribing	O	['N']	[18]
19	aspirin	O	['N']	[19]
20	for	O	['N']	[20]
21	patients	O	['N']	[21]
22	who	O	['N']	[22]
23	have	O	['N']	[23]
24	asymptomatic	O	['N']	[24]
25	meningioma	O	['N']	[25]
26	.	O	['N']	[26]
#434
0	Gynecomastia	O	['N']	[0]
1	developed	O	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	epileptic	O	['N']	[4]
5	patients	O	['N']	[5]
6	some	O	['N']	[6]
7	months	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	addition	O	['N']	[10]
11	of	O	['N']	[11]
12	oral	O	['N']	[12]
13	fluoresone	B-Drug	['Dosage']	[15]
14	750	B	['N']	[14]
15	mg	I-Dose	['N']	[15]
16	daily	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	phenobarbital	O	['N']	[19]
20	and	O	['N']	[20]
21	phenytoin	O	['N']	[21]
22	already	O	['N']	[22]
23	being	O	['N']	[23]
24	administered	O	['N']	[24]
25	.	O	['N']	[25]
#435
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	grade	O	['N']	[3]
4	3	O	['N']	[4]
5	capecitabine	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	headache	B-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#436
0	This	O	['N']	[0]
1	severe	B	['N']	[1]
2	illness	I-Adverse_Effect	['N']	[2]
3	was	O	['N']	[3]
4	likely	O	['N']	[4]
5	caused	O	['N']	[5]
6	by	O	['N']	[6]
7	minocycline	B-Drug	['Causes']	[2]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	we	O	['N']	[10]
11	speculate	O	['N']	[11]
12	that	O	['N']	[12]
13	minocycline	O	['N']	[13]
14	may	O	['N']	[14]
15	have	O	['N']	[15]
16	acted	O	['N']	[16]
17	as	O	['N']	[17]
18	a	O	['N']	[18]
19	superantigen	O	['N']	[19]
20	,	O	['N']	[20]
21	causing	O	['N']	[21]
22	lymphocyte	O	['N']	[22]
23	over	O	['N']	[23]
24	-	O	['N']	[24]
25	activation	O	['N']	[25]
26	and	O	['N']	[26]
27	massive	O	['N']	[27]
28	cytokine	O	['N']	[28]
29	release	O	['N']	[29]
30	.	O	['N']	[30]
#437
0	Haemolytic	B	['N']	[0]
1	-	I	['N']	[1]
2	uraemic	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	complicating	O	['N']	[4]
5	long	O	['N']	[5]
6	-	O	['N']	[6]
7	term	O	['N']	[7]
8	mitomycin	O	['N']	[8]
9	C	O	['N']	[9]
10	and	O	['N']	[10]
11	5-fluorouracil	B-Drug	['Causes']	[3]
12	therapy	O	['N']	[12]
13	for	O	['N']	[13]
14	gastric	O	['N']	[14]
15	carcinoma	O	['N']	[15]
16	.	O	['N']	[16]
#438
0	Four	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	adverse	B	['N']	[3]
4	experiences	I-Adverse_Effect	['N']	[4]
5	with	O	['N']	[5]
6	clonidine	B-Drug	['Causes']	[4]
7	are	O	['N']	[7]
8	described	O	['N']	[8]
9	.	O	['N']	[9]
#439
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	present	O	['N']	[2]
3	the	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	woman	O	['N']	[7]
8	who	O	['N']	[8]
9	received	O	['N']	[9]
10	high	O	['N']	[10]
11	doses	O	['N']	[11]
12	of	O	['N']	[12]
13	methylprednisolone	B-Drug	['Causes']	[29]
14	(	O	['N']	[14]
15	1	O	['N']	[15]
16	g	O	['N']	[16]
17	iv	O	['N']	[17]
18	daily	O	['N']	[18]
19	)	O	['N']	[19]
20	for	O	['N']	[20]
21	active	O	['N']	[21]
22	Graves	O	['N']	[22]
23	'	O	['N']	[23]
24	ophthalmopathy	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	developed	O	['N']	[27]
28	severe	B	['N']	[28]
29	hypertension	I-Adverse_Effect	['N']	[29]
30	followed	O	['N']	[30]
31	by	O	['N']	[31]
32	myocardial	O	['N']	[32]
33	infarction	O	['N']	[33]
34	on	O	['N']	[34]
35	the	O	['N']	[35]
36	fifth	O	['N']	[36]
37	day	O	['N']	[37]
38	of	O	['N']	[38]
39	treatment	O	['N']	[39]
40	.	O	['N']	[40]
#440
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	O	['N']	[32]
33	(	O	['N']	[33]
34	CBZ	B-Drug	['Causes']	[15]
35	;	O	['N']	[35]
36	Tegretol	O	['N']	[36]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#441
0	Rapidly	O	['N']	[0]
1	developing	O	['N']	[1]
2	hyperglycemia	B-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	olanzapine	B-Drug	['Causes']	[2]
7	.	O	['N']	[7]
#442
0	Traumatic	O	['N']	[0]
1	late	O	['N']	[1]
2	flap	O	['N']	[2]
3	dehiscence	O	['N']	[3]
4	and	O	['N']	[4]
5	Enterobacter	B	['N']	[5]
6	keratitis	I-Adverse_Effect	['N']	[6]
7	following	O	['N']	[7]
8	LASIK	B-Drug	['Causes']	[6]
9	.	O	['N']	[9]
#443
0	CD4	B	['N']	[0]
1	T	I	['N']	[1]
2	-	I	['N']	[2]
3	lymphocyte	I	['N']	[3]
4	depletion	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	myelosuppression	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	subsequent	O	['N']	[9]
10	severe	O	['N']	[10]
11	infections	O	['N']	[11]
12	are	O	['N']	[12]
13	the	O	['N']	[13]
14	major	O	['N']	[14]
15	side	O	['N']	[15]
16	effects	O	['N']	[16]
17	of	O	['N']	[17]
18	fludarabine	B	['N']	[18]
19	phosphate	I-Drug	['Causes']	[4]
20	therapy	O	['N']	[20]
21	.	O	['N']	[21]
#444
0	Severe	O	['N']	[0]
1	leukopenia	O	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	mild	B	['N']	[4]
5	hepatotoxicity	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	an	O	['N']	[7]
8	HIV	O	['N']	[8]
9	carrier	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	nevirapine	B-Drug	['Causes']	[5]
13	.	O	['N']	[13]
#445
0	A	O	['N']	[0]
1	transient	B	['N']	[1]
2	tonic	I	['N']	[2]
3	pupillary	I	['N']	[3]
4	response	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	denervation	O	['N']	[6]
7	supersensitivity	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	abnormal	O	['N']	[10]
11	visual	O	['N']	[11]
12	-	O	['N']	[12]
13	evoked	O	['N']	[13]
14	potentials	O	['N']	[14]
15	in	O	['N']	[15]
16	quinine	B-Drug	['Causes']	[4]
17	toxicity	O	['N']	[17]
18	,	O	['N']	[18]
19	to	O	['N']	[19]
20	our	O	['N']	[20]
21	knowledge	O	['N']	[21]
22	,	O	['N']	[22]
23	have	O	['N']	[23]
24	not	O	['N']	[24]
25	been	O	['N']	[25]
26	previously	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#446
0	Acute	O	['N']	[0]
1	isoniazid	B-Drug	['Causes']	[2]
2	neurotoxicity	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	an	O	['N']	[4]
5	urban	O	['N']	[5]
6	hospital	O	['N']	[6]
7	.	O	['N']	[7]
#447
0	Intravenous	O	['N']	[0]
1	azithromycin	B-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	ototoxicity	B-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#448
0	Heparin	O	['N']	[0]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	thrombocytopenia	B-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	thrombosis	O	['N']	[5]
6	is	O	['N']	[6]
7	a	O	['N']	[7]
8	severe	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	systemic	O	['N']	[11]
12	heparin	B-Drug	['Causes']	[3]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#449
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	three	O	['N']	[2]
3	cases	O	['N']	[3]
4	from	O	['N']	[4]
5	the	O	['N']	[5]
6	Provincial	O	['N']	[6]
7	Toxicology	O	['N']	[7]
8	Center	O	['N']	[8]
9	of	O	['N']	[9]
10	British	O	['N']	[10]
11	Columbia	O	['N']	[11]
12	,	O	['N']	[12]
13	Canada	O	['N']	[13]
14	in	O	['N']	[14]
15	which	O	['N']	[15]
16	suicidal	O	['N']	[16]
17	overdose	B-Dose	['N']	[17]
18	deaths	O	['N']	[18]
19	were	O	['N']	[19]
20	associated	O	['N']	[20]
21	with	O	['N']	[21]
22	quetiapine	B-Drug	['Dosage']	[17]
23	.	O	['N']	[23]
#450
0	Warfarin	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	thoracic	B	['N']	[3]
4	aortic	I	['N']	[4]
5	dissection	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	an	O	['N']	[7]
8	elderly	O	['N']	[8]
9	woman	O	['N']	[9]
10	.	O	['N']	[10]
#451
0	The	O	['N']	[0]
1	risk	O	['N']	[1]
2	of	O	['N']	[2]
3	new	O	['N']	[3]
4	-	O	['N']	[4]
5	onset	O	['N']	[5]
6	diabetic	B	['N']	[6]
7	ketoacidosis	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	diabetic	O	['N']	[11]
12	risk	O	['N']	[12]
13	factors	O	['N']	[13]
14	who	O	['N']	[14]
15	are	O	['N']	[15]
16	taking	O	['N']	[16]
17	perospirone	B	['N']	[17]
18	hydrochloride	I-Drug	['Causes']	[7]
19	or	O	['N']	[19]
20	other	O	['N']	[20]
21	atypical	O	['N']	[21]
22	antipsychotics	O	['N']	[22]
23	should	O	['N']	[23]
24	be	O	['N']	[24]
25	kept	O	['N']	[25]
26	in	O	['N']	[26]
27	mind	O	['N']	[27]
28	.	O	['N']	[28]
#452
0	Captopril	B-Drug	['Causes']	[16]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	angiotensin	O	['N']	[3]
4	-	O	['N']	[4]
5	converting	O	['N']	[5]
6	enzyme	O	['N']	[6]
7	(	O	['N']	[7]
8	ACE	O	['N']	[8]
9	)	O	['N']	[9]
10	inhibitor	O	['N']	[10]
11	and	O	['N']	[11]
12	their	O	['N']	[12]
13	cutaneous	B	['N']	[13]
14	side	I	['N']	[14]
15	-	I	['N']	[15]
16	effects	I-Adverse_Effect	['N']	[16]
17	are	O	['N']	[17]
18	documented	O	['N']	[18]
19	,	O	['N']	[19]
20	but	O	['N']	[20]
21	little	O	['N']	[21]
22	has	O	['N']	[22]
23	been	O	['N']	[23]
24	published	O	['N']	[24]
25	concerning	O	['N']	[25]
26	the	O	['N']	[26]
27	usefulness	O	['N']	[27]
28	of	O	['N']	[28]
29	patch	O	['N']	[29]
30	test	O	['N']	[30]
31	when	O	['N']	[31]
32	they	O	['N']	[32]
33	occur	O	['N']	[33]
34	.	O	['N']	[34]
#453
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	68-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	developed	O	['N']	[7]
8	intense	B	['N']	[8]
9	conjunctival	I	['N']	[9]
10	hyperemia	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	cystoid	O	['N']	[12]
13	macula	O	['N']	[13]
14	edema	O	['N']	[14]
15	after	O	['N']	[15]
16	switching	O	['N']	[16]
17	from	O	['N']	[17]
18	latanoprost	B-Drug	['Causes']	[10]
19	to	O	['N']	[19]
20	bimatoprost	O	['N']	[20]
21	9	O	['N']	[21]
22	months	O	['N']	[22]
23	after	O	['N']	[23]
24	cataract	O	['N']	[24]
25	surgery	O	['N']	[25]
26	in	O	['N']	[26]
27	an	O	['N']	[27]
28	eye	O	['N']	[28]
29	at	O	['N']	[29]
30	low	O	['N']	[30]
31	-	O	['N']	[31]
32	risk	O	['N']	[32]
33	for	O	['N']	[33]
34	this	O	['N']	[34]
35	cystoid	O	['N']	[35]
36	macular	O	['N']	[36]
37	edema	O	['N']	[37]
38	.	O	['N']	[38]
#454
0	Acute	B	['N']	[0]
1	vision	I	['N']	[1]
2	loss	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	intravitreal	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	bevacizumab	O	['N']	[7]
8	(	O	['N']	[8]
9	avastin	B-Drug	['Causes']	[2]
10	)	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	ocular	O	['N']	[13]
14	ischemic	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	.	O	['N']	[16]
#455
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	2	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	serotonin	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	with	O	['N']	[9]
10	serious	O	['N']	[10]
11	extrapyramidal	B	['N']	[11]
12	movement	I	['N']	[12]
13	disorders	I-Adverse_Effect	['N']	[13]
14	occurring	O	['N']	[14]
15	when	O	['N']	[15]
16	metoclopramide	O	['N']	[16]
17	was	O	['N']	[17]
18	coadministered	O	['N']	[18]
19	with	O	['N']	[19]
20	sertraline	O	['N']	[20]
21	or	O	['N']	[21]
22	venlafaxine	B-Drug	['Causes']	[13]
23	.	O	['N']	[23]
#456
0	Since	O	['N']	[0]
1	1979	O	['N']	[1]
2	,	O	['N']	[2]
3	over	O	['N']	[3]
4	30	O	['N']	[4]
5	published	O	['N']	[5]
6	case	O	['N']	[6]
7	reports	O	['N']	[7]
8	have	O	['N']	[8]
9	documented	O	['N']	[9]
10	the	O	['N']	[10]
11	relationship	O	['N']	[11]
12	between	O	['N']	[12]
13	phenylpropanolamine	B-Drug	['Causes']	[15]
14	and	O	['N']	[14]
15	stroke	B-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#457
0	Nephrotic	O	['N']	[0]
1	syndrome	O	['N']	[1]
2	related	O	['N']	[2]
3	to	O	['N']	[3]
4	systemic	B	['N']	[4]
5	lupus	I	['N']	[5]
6	erythematosus	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	griseofulvin	B-Drug	['Causes']	[6]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#458
0	A	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[9]
2	hypersensitivity	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	,	O	['N']	[4]
5	consisting	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	headache	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	nausea	O	['N']	[11]
12	,	O	['N']	[12]
13	vomiting	O	['N']	[13]
14	,	O	['N']	[14]
15	lymphadenopathy	O	['N']	[15]
16	,	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	,	O	['N']	[18]
19	hemolysis	O	['N']	[19]
20	,	O	['N']	[20]
21	leukopenia	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	mononucleosis	O	['N']	[24]
25	,	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	for	O	['N']	[35]
36	leprosy	O	['N']	[36]
37	.	O	['N']	[37]
#459
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	20-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	Basedow	O	['N']	[8]
9	-	O	['N']	[9]
10	Graves	O	['N']	[10]
11	'	O	['N']	[11]
12	disease	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	PTU	B-Drug	['Causes']	[19]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	fulminant	B	['N']	[18]
19	hepatitis	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	which	O	['N']	[21]
22	progressed	O	['N']	[22]
23	to	O	['N']	[23]
24	acute	O	['N']	[24]
25	hepatic	O	['N']	[25]
26	failure	O	['N']	[26]
27	with	O	['N']	[27]
28	grade	O	['N']	[28]
29	III	O	['N']	[29]
30	hepatic	O	['N']	[30]
31	encephalopathy	O	['N']	[31]
32	.	O	['N']	[32]
#460
0	An	O	['N']	[0]
1	episode	O	['N']	[1]
2	of	O	['N']	[2]
3	leukoencephalopathy	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	reported	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	13-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	girl	O	['N']	[11]
12	who	O	['N']	[12]
13	,	O	['N']	[13]
14	after	O	['N']	[14]
15	standard	O	['N']	[15]
16	radiotherapy	O	['N']	[16]
17	for	O	['N']	[17]
18	a	O	['N']	[18]
19	posterior	O	['N']	[19]
20	fossa	O	['N']	[20]
21	medulloblastoma	O	['N']	[21]
22	,	O	['N']	[22]
23	received	O	['N']	[23]
24	8	O	['N']	[24]
25	treatments	O	['N']	[25]
26	with	O	['N']	[26]
27	a	O	['N']	[27]
28	protocol	O	['N']	[28]
29	containing	O	['N']	[29]
30	a	O	['N']	[30]
31	4-hour	O	['N']	[31]
32	infusion	O	['N']	[32]
33	of	O	['N']	[33]
34	500	O	['N']	[34]
35	mg	O	['N']	[35]
36	/	O	['N']	[36]
37	m2	O	['N']	[37]
38	methotrexate	B-Drug	['Causes']	[3]
39	and	O	['N']	[39]
40	12	O	['N']	[40]
41	mg	O	['N']	[41]
42	intrathecal	O	['N']	[42]
43	methotrexate	O	['N']	[43]
44	.	O	['N']	[44]
#461
0	Case	O	['N']	[0]
1	report	O	['N']	[1]
2	:	O	['N']	[2]
3	lack	O	['N']	[3]
4	of	O	['N']	[4]
5	control	O	['N']	[5]
6	of	O	['N']	[6]
7	diabetes	B-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	weight	O	['N']	[9]
10	gain	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	on	O	['N']	[14]
15	initiation	O	['N']	[15]
16	and	O	['N']	[16]
17	rechallenge	O	['N']	[17]
18	of	O	['N']	[18]
19	therapy	O	['N']	[19]
20	with	O	['N']	[20]
21	olanzapine	B-Drug	['Causes']	[7]
22	.	O	['N']	[22]
#462
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	placed	O	['N']	[2]
3	on	O	['N']	[3]
4	adjuvant	O	['N']	[4]
5	Adriamycin	B-Drug	['Causes']	[18]
6	(	O	['N']	[6]
7	doxorubicin	O	['N']	[7]
8	)	O	['N']	[8]
9	chemotherapy	O	['N']	[9]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	6	O	['N']	[12]
13	months	O	['N']	[13]
14	later	O	['N']	[14]
15	died	O	['N']	[15]
16	of	O	['N']	[16]
17	Adriamycin	B	['N']	[17]
18	toxicity	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#463
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	polyserositis	O	['N']	[9]
10	(	O	['N']	[10]
11	pericardial	O	['N']	[11]
12	effusion	O	['N']	[12]
13	,	O	['N']	[13]
14	pleural	B	['N']	[14]
15	effusion	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	pericarditis	O	['N']	[18]
19	)	O	['N']	[19]
20	after	O	['N']	[20]
21	being	O	['N']	[21]
22	started	O	['N']	[22]
23	on	O	['N']	[23]
24	clozapine	B-Drug	['Causes']	[15]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	whose	O	['N']	[27]
28	symptoms	O	['N']	[28]
29	remitted	O	['N']	[29]
30	upon	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	clozapine	O	['N']	[33]
34	.	O	['N']	[34]
#464
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	58-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	white	O	['N']	[7]
8	woman	O	['N']	[8]
9	developed	O	['N']	[9]
10	fulminant	B	['N']	[10]
11	liver	I	['N']	[11]
12	failure	I-Adverse_Effect	['N']	[12]
13	while	O	['N']	[13]
14	being	O	['N']	[14]
15	treated	O	['N']	[15]
16	with	O	['N']	[16]
17	the	O	['N']	[17]
18	macrolide	O	['N']	[18]
19	antibiotic	O	['N']	[19]
20	clarithromycin	B-Drug	['Causes']	[12]
21	for	O	['N']	[21]
22	pneumonia	O	['N']	[22]
23	.	O	['N']	[23]
#465
0	Aggressive	B	['N']	[0]
1	endometrial	I	['N']	[1]
2	carcinoma	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	breast	O	['N']	[5]
6	cancer	O	['N']	[6]
7	patient	O	['N']	[7]
8	treated	O	['N']	[8]
9	with	O	['N']	[9]
10	tamoxifen	B-Drug	['Causes']	[2]
11	with	O	['N']	[11]
12	normal	O	['N']	[12]
13	transvaginal	O	['N']	[13]
14	ultrasonography	O	['N']	[14]
15	.	O	['N']	[15]
#466
0	These	O	['N']	[0]
1	cases	O	['N']	[1]
2	demonstrate	O	['N']	[2]
3	that	O	['N']	[3]
4	CBZ	B-Drug	['Causes']	[9]
5	can	O	['N']	[5]
6	induce	O	['N']	[6]
7	simple	O	['N']	[7]
8	motor	B	['N']	[8]
9	tics	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	children	O	['N']	[11]
12	.	O	['N']	[12]
#467
0	Treatment	O	['N']	[0]
1	of	O	['N']	[1]
2	lithium	B-Drug	['Causes']	[6]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	diabetes	B	['N']	[5]
6	insipidus	I-Adverse_Effect	['N']	[6]
7	with	O	['N']	[7]
8	amiloride	O	['N']	[8]
9	.	O	['N']	[9]
#468
0	These	O	['N']	[0]
1	data	O	['N']	[1]
2	indicated	O	['N']	[2]
3	that	O	['N']	[3]
4	infliximab	B-Drug	['Causes']	[16]
5	possibly	O	['N']	[5]
6	triggered	O	['N']	[6]
7	production	O	['N']	[7]
8	of	O	['N']	[8]
9	granulocyte	O	['N']	[9]
10	and	O	['N']	[10]
11	neutrophil	O	['N']	[11]
12	autoantibodies	O	['N']	[12]
13	with	O	['N']	[13]
14	resultant	O	['N']	[14]
15	autoimmune	B	['N']	[15]
16	agranulocytosis	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#469
0	The	O	['N']	[0]
1	main	O	['N']	[1]
2	side	O	['N']	[2]
3	-	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	Lp	B	['N']	[6]
7	-	I	['N']	[7]
8	TAE	I-Drug	['Causes']	[19]
9	combined	O	['N']	[9]
10	with	O	['N']	[10]
11	HT	O	['N']	[11]
12	were	O	['N']	[12]
13	low	O	['N']	[13]
14	-	O	['N']	[14]
15	grade	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	localized	B	['N']	[18]
19	pain	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	myelo	O	['N']	[21]
22	-	O	['N']	[22]
23	suppression	O	['N']	[23]
24	and	O	['N']	[24]
25	liver	O	['N']	[25]
26	dysfunction	O	['N']	[26]
27	,	O	['N']	[27]
28	but	O	['N']	[28]
29	these	O	['N']	[29]
30	were	O	['N']	[30]
31	transient	O	['N']	[31]
32	and	O	['N']	[32]
33	eventually	O	['N']	[33]
34	disappeared	O	['N']	[34]
35	.	O	['N']	[35]
#470
0	A	O	['N']	[0]
1	56-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Caucasian	O	['N']	[4]
5	man	O	['N']	[5]
6	who	O	['N']	[6]
7	received	O	['N']	[7]
8	concomitant	O	['N']	[8]
9	chemotherapy	O	['N']	[9]
10	and	O	['N']	[10]
11	radiation	O	['N']	[11]
12	for	O	['N']	[12]
13	head	O	['N']	[13]
14	and	O	['N']	[14]
15	neck	O	['N']	[15]
16	cancer	O	['N']	[16]
17	developed	O	['N']	[17]
18	fever	B-Adverse_Effect	['N']	[18]
19	concurrent	O	['N']	[19]
20	with	O	['N']	[20]
21	the	O	['N']	[21]
22	administration	O	['N']	[22]
23	of	O	['N']	[23]
24	amifostine	B-Drug	['Causes']	[18]
25	.	O	['N']	[25]
#471
0	Other	O	['N']	[0]
1	thiazolidinediones	O	['N']	[1]
2	currently	O	['N']	[2]
3	in	O	['N']	[3]
4	clinical	O	['N']	[4]
5	trials	O	['N']	[5]
6	may	O	['N']	[6]
7	be	O	['N']	[7]
8	able	O	['N']	[8]
9	to	O	['N']	[9]
10	provide	O	['N']	[10]
11	the	O	['N']	[11]
12	therapeutic	O	['N']	[12]
13	benefits	O	['N']	[13]
14	of	O	['N']	[14]
15	troglitazone	B-Drug	['Causes']	[18]
16	without	O	['N']	[16]
17	significant	O	['N']	[17]
18	hepatotoxicity	B-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#472
0	Gold	B	['N']	[0]
1	nephropathy	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	auranofin	O	['N']	[4]
5	obscured	O	['N']	[5]
6	by	O	['N']	[6]
7	tolmetin	B-Drug	['Causes']	[1]
8	pseudoproteinuria	O	['N']	[8]
9	.	O	['N']	[9]
#473
0	Methotrexate	O	['N']	[0]
1	(	O	['N']	[1]
2	MTX	B-Drug	['Causes']	[32]
3	)	O	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	commonly	O	['N']	[6]
7	used	O	['N']	[7]
8	second	O	['N']	[8]
9	line	O	['N']	[9]
10	agent	O	['N']	[10]
11	for	O	['N']	[11]
12	RA	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	there	O	['N']	[15]
16	have	O	['N']	[16]
17	been	O	['N']	[17]
18	several	O	['N']	[18]
19	recent	O	['N']	[19]
20	reports	O	['N']	[20]
21	of	O	['N']	[21]
22	Epstein	B	['N']	[22]
23	-	I	['N']	[23]
24	Barr	I	['N']	[24]
25	virus	I	['N']	[25]
26	(	I	['N']	[26]
27	EBV)-associated	I	['N']	[27]
28	polyclonal	I	['N']	[28]
29	B	I	['N']	[29]
30	cell	I	['N']	[30]
31	lymphoproliferative	I	['N']	[31]
32	disorder	I-Adverse_Effect	['N']	[32]
33	in	O	['N']	[33]
34	MTX	O	['N']	[34]
35	-	O	['N']	[35]
36	treated	O	['N']	[36]
37	RA	O	['N']	[37]
38	patients	O	['N']	[38]
39	.	O	['N']	[39]
#474
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	(	O	['N']	[5]
6	to	O	['N']	[6]
7	our	O	['N']	[7]
8	knowledge	O	['N']	[8]
9	)	O	['N']	[9]
10	of	O	['N']	[10]
11	a	O	['N']	[11]
12	potentially	O	['N']	[12]
13	serious	O	['N']	[13]
14	drug	B	['N']	[14]
15	-	I	['N']	[15]
16	drug	I	['N']	[16]
17	interaction	I-Adverse_Effect	['N']	[17]
18	between	O	['N']	[18]
19	zafirlukast	O	['N']	[19]
20	and	O	['N']	[20]
21	theophylline	B-Drug	['Causes']	[17]
22	.	O	['N']	[22]
#475
0	Four	O	['N']	[0]
1	weeks	O	['N']	[1]
2	earlier	O	['N']	[2]
3	she	O	['N']	[3]
4	had	O	['N']	[4]
5	developed	O	['N']	[5]
6	hepatopathy	B-Adverse_Effect	['N']	[6]
7	during	O	['N']	[7]
8	a	O	['N']	[8]
9	regimen	O	['N']	[9]
10	of	O	['N']	[10]
11	carbamazepine	B-Drug	['Causes']	[6]
12	,	O	['N']	[12]
13	lynestrenol	O	['N']	[13]
14	and	O	['N']	[14]
15	sodium	O	['N']	[15]
16	valproate	O	['N']	[16]
17	.	O	['N']	[17]
#476
0	Overdose	B-Dose	['N']	[0]
1	of	O	['N']	[1]
2	magnesium	B-Drug	['Dosage']	[0]
3	sulfate	O	['N']	[3]
4	in	O	['N']	[4]
5	combination	O	['N']	[5]
6	with	O	['N']	[6]
7	renal	O	['N']	[7]
8	insufficiency	O	['N']	[8]
9	,	O	['N']	[9]
10	hypocalcemia	O	['N']	[10]
11	,	O	['N']	[11]
12	or	O	['N']	[12]
13	compromise	O	['N']	[13]
14	of	O	['N']	[14]
15	intestinal	O	['N']	[15]
16	integrity	O	['N']	[16]
17	may	O	['N']	[17]
18	predispose	O	['N']	[18]
19	horses	O	['N']	[19]
20	to	O	['N']	[20]
21	magnesium	O	['N']	[21]
22	toxicosis	O	['N']	[22]
23	.	O	['N']	[23]
#477
0	ARA	B	['N']	[0]
1	-	I	['N']	[1]
2	C	I-Drug	['Causes']	[20]
3	is	O	['N']	[3]
4	frequently	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	dermatologic	O	['N']	[7]
8	toxicity	O	['N']	[8]
9	,	O	['N']	[9]
10	but	O	['N']	[10]
11	this	O	['N']	[11]
12	is	O	['N']	[12]
13	only	O	['N']	[13]
14	the	O	['N']	[14]
15	second	O	['N']	[15]
16	case	O	['N']	[16]
17	of	O	['N']	[17]
18	toxic	B	['N']	[18]
19	epidermal	I	['N']	[19]
20	necrolysis	I-Adverse_Effect	['N']	[20]
21	described	O	['N']	[21]
22	in	O	['N']	[22]
23	connection	O	['N']	[23]
24	with	O	['N']	[24]
25	this	O	['N']	[25]
26	drug	O	['N']	[26]
27	.	O	['N']	[27]
#478
0	We	O	['N']	[0]
1	discuss	O	['N']	[1]
2	a	O	['N']	[2]
3	variety	O	['N']	[3]
4	of	O	['N']	[4]
5	bronchopulmonary	O	['N']	[5]
6	complications	O	['N']	[6]
7	of	O	['N']	[7]
8	IBD	B-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	their	O	['N']	[10]
11	association	O	['N']	[11]
12	with	O	['N']	[12]
13	sulfasalazine	B-Drug	['Causes']	[8]
14	.	O	['N']	[14]
#479
0	Fatal	B	['N']	[0]
1	outcome	I-Adverse_Effect	['N']	[1]
2	of	O	['N']	[2]
3	intravesical	O	['N']	[3]
4	formalin	B-Drug	['Causes']	[1]
5	instillation	O	['N']	[5]
6	,	O	['N']	[6]
7	with	O	['N']	[7]
8	changes	O	['N']	[8]
9	mimicking	O	['N']	[9]
10	renal	O	['N']	[10]
11	tuberculosis	O	['N']	[11]
12	.	O	['N']	[12]
#480
0	A	O	['N']	[0]
1	paradoxical	B	['N']	[1]
2	ocular	I	['N']	[2]
3	effect	I-Adverse_Effect	['N']	[3]
4	of	O	['N']	[4]
5	brimonidine	B-Drug	['Causes']	[3]
6	.	O	['N']	[6]
#481
0	Polyarthritis	O	['N']	[0]
1	,	O	['N']	[1]
2	hepatitis	B-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	anti	O	['N']	[4]
5	-	O	['N']	[5]
6	native	O	['N']	[6]
7	DNA	O	['N']	[7]
8	antibodies	O	['N']	[8]
9	after	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	ethambutol	B-Drug	['Causes']	[2]
13	and	O	['N']	[13]
14	rifampicin	O	['N']	[14]
15	.	O	['N']	[15]
#482
0	Treatment	O	['N']	[0]
1	of	O	['N']	[1]
2	ELP	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	children	O	['N']	[4]
5	is	O	['N']	[5]
6	generally	O	['N']	[6]
7	supportive	O	['N']	[7]
8	,	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	and	O	['N']	[12]
13	roentgenographic	O	['N']	[13]
14	abnormalities	O	['N']	[14]
15	resolving	O	['N']	[15]
16	within	O	['N']	[16]
17	months	O	['N']	[17]
18	after	O	['N']	[18]
19	stopping	O	['N']	[19]
20	the	O	['N']	[20]
21	use	O	['N']	[21]
22	of	O	['N']	[22]
23	mineral	B	['N']	[23]
24	oil	I-Drug	['Causes']	[2]
25	.	O	['N']	[25]
#483
0	Rifampin	B-Drug	['Causes']	[14]
1	can	O	['N']	[1]
2	be	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	severe	O	['N']	[5]
6	adverse	O	['N']	[6]
7	effects	O	['N']	[7]
8	such	O	['N']	[8]
9	as	O	['N']	[9]
10	hepatitis	O	['N']	[10]
11	,	O	['N']	[11]
12	acute	B	['N']	[12]
13	renal	I	['N']	[13]
14	failure	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	hemolytic	O	['N']	[16]
17	anemia	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	thrombocytopenia	O	['N']	[20]
21	.	O	['N']	[21]
#484
0	There	O	['N']	[0]
1	remains	O	['N']	[1]
2	a	O	['N']	[2]
3	paucity	O	['N']	[3]
4	of	O	['N']	[4]
5	information	O	['N']	[5]
6	pertaining	O	['N']	[6]
7	to	O	['N']	[7]
8	alternative	O	['N']	[8]
9	anticoagulation	O	['N']	[9]
10	strategies	O	['N']	[10]
11	for	O	['N']	[11]
12	use	O	['N']	[12]
13	during	O	['N']	[13]
14	cardiopulmonary	O	['N']	[14]
15	bypass	O	['N']	[15]
16	concomitant	O	['N']	[16]
17	with	O	['N']	[17]
18	heparin	B-Drug	['Causes']	[21]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	thrombocytopenia	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	especially	O	['N']	[23]
24	in	O	['N']	[24]
25	children	O	['N']	[25]
26	.	O	['N']	[26]
#485
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	rapidly	O	['N']	[7]
8	occurring	O	['N']	[8]
9	hyperglycemia	B-Adverse_Effect	['N']	[9]
10	that	O	['N']	[10]
11	occurred	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	geriatric	O	['N']	[14]
15	patient	O	['N']	[15]
16	3	O	['N']	[16]
17	days	O	['N']	[17]
18	after	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	olanzapine	B-Drug	['Causes']	[9]
22	.	O	['N']	[22]
#486
0	Methanol	B-Drug	['Causes']	[17]
1	toxicity	O	['N']	[1]
2	can	O	['N']	[2]
3	cause	O	['N']	[3]
4	severe	O	['N']	[4]
5	central	O	['N']	[5]
6	nervous	O	['N']	[6]
7	system	O	['N']	[7]
8	insult	O	['N']	[8]
9	in	O	['N']	[9]
10	which	O	['N']	[10]
11	a	O	['N']	[11]
12	characteristic	O	['N']	[12]
13	pattern	O	['N']	[13]
14	of	O	['N']	[14]
15	bilateral	B	['N']	[15]
16	putaminal	I	['N']	[16]
17	injury	I-Adverse_Effect	['N']	[17]
18	is	O	['N']	[18]
19	noted	O	['N']	[19]
20	on	O	['N']	[20]
21	brain	O	['N']	[21]
22	imaging	O	['N']	[22]
23	studies	O	['N']	[23]
24	.	O	['N']	[24]
#487
0	Flutamide	O	['N']	[0]
1	withdrawal	O	['N']	[1]
2	syndrome	O	['N']	[2]
3	is	O	['N']	[3]
4	characterized	O	['N']	[4]
5	by	O	['N']	[5]
6	a	O	['N']	[6]
7	decrease	B	['N']	[7]
8	in	I	['N']	[8]
9	prostate	I	['N']	[9]
10	-	I	['N']	[10]
11	specific	I	['N']	[11]
12	antigen	I-Adverse_Effect	['N']	[12]
13	(	O	['N']	[13]
14	PSA	O	['N']	[14]
15	)	O	['N']	[15]
16	after	O	['N']	[16]
17	flutamide	B-Drug	['Causes']	[12]
18	withdrawal	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	subset	O	['N']	[21]
22	of	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	progressing	O	['N']	[25]
26	metastatic	O	['N']	[26]
27	carcinoma	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	prostate	O	['N']	[30]
31	.	O	['N']	[31]
#488
0	A	O	['N']	[0]
1	retrospective	O	['N']	[1]
2	epidemiological	O	['N']	[2]
3	study	O	['N']	[3]
4	of	O	['N']	[4]
5	deaths	O	['N']	[5]
6	from	O	['N']	[6]
7	hepatic	B	['N']	[7]
8	angiosarcoma	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	HAS	O	['N']	[10]
11	)	O	['N']	[11]
12	in	O	['N']	[12]
13	the	O	['N']	[13]
14	U.S.	O	['N']	[14]
15	showed	O	['N']	[15]
16	that	O	['N']	[16]
17	during	O	['N']	[17]
18	1964	O	['N']	[18]
19	-	O	['N']	[19]
20	-74	O	['N']	[20]
21	there	O	['N']	[21]
22	were	O	['N']	[22]
23	168	O	['N']	[23]
24	such	O	['N']	[24]
25	cases	O	['N']	[25]
26	,	O	['N']	[26]
27	of	O	['N']	[27]
28	which	O	['N']	[28]
29	37	O	['N']	[29]
30	(	O	['N']	[30]
31	22	O	['N']	[31]
32	%	O	['N']	[32]
33	)	O	['N']	[33]
34	were	O	['N']	[34]
35	associated	O	['N']	[35]
36	with	O	['N']	[36]
37	previously	O	['N']	[37]
38	known	O	['N']	[38]
39	causes	O	['N']	[39]
40	(	O	['N']	[40]
41	vinyl	O	['N']	[41]
42	chloride	O	['N']	[42]
43	,	O	['N']	[43]
44	'	O	['N']	[44]
45	Thorotrast	B-Drug	['Causes']	[8]
46	'	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	inorganic	O	['N']	[49]
50	arsenic	O	['N']	[50]
51	)	O	['N']	[51]
52	and	O	['N']	[52]
53	4	O	['N']	[53]
54	(	O	['N']	[54]
55	3.1	O	['N']	[55]
56	%	O	['N']	[56]
57	)	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	remaining	O	['N']	[60]
61	131	O	['N']	[61]
62	cases	O	['N']	[62]
63	with	O	['N']	[63]
64	the	O	['N']	[64]
65	use	O	['N']	[65]
66	of	O	['N']	[66]
67	androgenic	O	['N']	[67]
68	-	O	['N']	[68]
69	anabolic	O	['N']	[69]
70	steroids	O	['N']	[70]
71	.	O	['N']	[71]
#489
0	Hyperkalaemia	B-Adverse_Effect	['N']	[0]
1	with	O	['N']	[1]
2	renal	O	['N']	[2]
3	tubular	O	['N']	[3]
4	dysfunction	O	['N']	[4]
5	by	O	['N']	[5]
6	oral	O	['N']	[6]
7	therapy	O	['N']	[7]
8	of	O	['N']	[8]
9	sulfamethoxazole	O	['N']	[9]
10	-	O	['N']	[10]
11	trimethoprim	O	['N']	[11]
12	(	O	['N']	[12]
13	co	B	['N']	[13]
14	-	I	['N']	[14]
15	trimoxazole	I-Drug	['Causes']	[0]
16	)	O	['N']	[16]
17	is	O	['N']	[17]
18	described	O	['N']	[18]
19	in	O	['N']	[19]
20	2	O	['N']	[20]
21	elderly	O	['N']	[21]
22	Japanese	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	lymphoid	O	['N']	[25]
26	malignancy	O	['N']	[26]
27	,	O	['N']	[27]
28	who	O	['N']	[28]
29	developed	O	['N']	[29]
30	Pneumocystis	O	['N']	[30]
31	carinii	O	['N']	[31]
32	pneumonia	O	['N']	[32]
33	and	O	['N']	[33]
34	improved	O	['N']	[34]
35	.	O	['N']	[35]
#490
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	O	['N']	[9]
10	mg	O	['N']	[10]
11	sertraline	B-Drug	['Causes']	[29]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	O	['N']	[17]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	B	['N']	[24]
25	of	I	['N']	[25]
26	the	I	['N']	[26]
27	lamotrigine	I	['N']	[27]
28	blood	I	['N']	[28]
29	level	I-Adverse_Effect	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	toxicity	O	['N']	[33]
34	.	O	['N']	[34]
#491
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	a	O	['N']	[3]
4	lower	B	['N']	[4]
5	average	I	['N']	[5]
6	heart	I	['N']	[6]
7	rate	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	had	O	['N']	[11]
12	lower	O	['N']	[12]
13	average	O	['N']	[13]
14	mean	O	['N']	[14]
15	blood	O	['N']	[15]
16	pressure	O	['N']	[16]
17	values	O	['N']	[17]
18	during	O	['N']	[18]
19	propranolol	B-Drug	['Causes']	[7]
20	treatment	O	['N']	[20]
21	,	O	['N']	[21]
22	none	O	['N']	[22]
23	of	O	['N']	[23]
24	which	O	['N']	[24]
25	was	O	['N']	[25]
26	clinically	O	['N']	[26]
27	significant	O	['N']	[27]
28	.	O	['N']	[28]
#492
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	26-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	with	O	['N']	[7]
8	bipolar	O	['N']	[8]
9	disorder	O	['N']	[9]
10	developed	O	['N']	[10]
11	hyperammonemia	B-Adverse_Effect	['N']	[11]
12	three	O	['N']	[12]
13	weeks	O	['N']	[13]
14	after	O	['N']	[14]
15	initiating	O	['N']	[15]
16	carbamazepine	B-Drug	['Causes']	[11]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#493
0	Allergic	O	['N']	[0]
1	reaction	O	['N']	[1]
2	to	O	['N']	[2]
3	gemfibrozil	B-Drug	['Causes']	[7]
4	manifesting	O	['N']	[4]
5	as	O	['N']	[5]
6	eosinophilic	B	['N']	[6]
7	gastroenteritis	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#494
0	2-CdA	B-Drug	['Causes']	[9]
1	typically	O	['N']	[1]
2	causes	O	['N']	[2]
3	a	O	['N']	[3]
4	long	O	['N']	[4]
5	-	O	['N']	[5]
6	lasting	O	['N']	[6]
7	state	O	['N']	[7]
8	of	O	['N']	[8]
9	immunodeficiency	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	the	O	['N']	[11]
12	profound	O	['N']	[12]
13	influence	O	['N']	[13]
14	of	O	['N']	[14]
15	this	O	['N']	[15]
16	drug	O	['N']	[16]
17	on	O	['N']	[17]
18	the	O	['N']	[18]
19	immune	O	['N']	[19]
20	system	O	['N']	[20]
21	has	O	['N']	[21]
22	raised	O	['N']	[22]
23	questions	O	['N']	[23]
24	concerning	O	['N']	[24]
25	the	O	['N']	[25]
26	emergence	O	['N']	[26]
27	of	O	['N']	[27]
28	secondary	O	['N']	[28]
29	neoplasms	O	['N']	[29]
30	after	O	['N']	[30]
31	its	O	['N']	[31]
32	use	O	['N']	[32]
33	.	O	['N']	[33]
#495
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	SIADH	B-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	desipramine	B-Drug	['Causes']	[3]
7	treatment	O	['N']	[7]
8	in	O	['N']	[8]
9	an	O	['N']	[9]
10	elderly	O	['N']	[10]
11	depressed	O	['N']	[11]
12	woman	O	['N']	[12]
13	is	O	['N']	[13]
14	described	O	['N']	[14]
15	.	O	['N']	[15]
#496
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	Case	O	['N']	[2]
3	analysis	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	poly	O	['N']	[6]
7	-	O	['N']	[7]
8	drug	O	['N']	[8]
9	overdose	O	['N']	[9]
10	(	O	['N']	[10]
11	venlafaxine	O	['N']	[11]
12	,	O	['N']	[12]
13	topiramate	O	['N']	[13]
14	,	O	['N']	[14]
15	divalproex	O	['N']	[15]
16	sodium	O	['N']	[16]
17	,	O	['N']	[17]
18	risperidone	B-Drug	['Causes']	[28]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	carbamazepine	O	['N']	[21]
22	)	O	['N']	[22]
23	presenting	O	['N']	[23]
24	with	O	['N']	[24]
25	mixed	O	['N']	[25]
26	SS	O	['N']	[26]
27	/	O	['N']	[27]
28	NMS	B-Adverse_Effect	['N']	[28]
29	features	O	['N']	[29]
30	and	O	['N']	[30]
31	whose	O	['N']	[31]
32	clinical	O	['N']	[32]
33	management	O	['N']	[33]
34	suggests	O	['N']	[34]
35	a	O	['N']	[35]
36	practical	O	['N']	[36]
37	algorithm	O	['N']	[37]
38	for	O	['N']	[38]
39	treatment	O	['N']	[39]
40	of	O	['N']	[40]
41	undifferentiated	O	['N']	[41]
42	SS	O	['N']	[42]
43	/	O	['N']	[43]
44	NMS	O	['N']	[44]
45	in	O	['N']	[45]
46	critical	O	['N']	[46]
47	care	O	['N']	[47]
48	settings	O	['N']	[48]
49	.	O	['N']	[49]
#497
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	toxic	B	['N']	[3]
4	hepatitis	I-Adverse_Effect	['N']	[4]
5	caused	O	['N']	[5]
6	by	O	['N']	[6]
7	combination	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	methotrexate	B-Drug	['Causes']	[4]
11	and	O	['N']	[11]
12	etretinate	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	treatment	O	['N']	[15]
16	of	O	['N']	[16]
17	severe	O	['N']	[17]
18	psoriasis	O	['N']	[18]
19	is	O	['N']	[19]
20	presented	O	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	47-year	O	['N']	[23]
24	-	O	['N']	[24]
25	old	O	['N']	[25]
26	woman	O	['N']	[26]
27	.	O	['N']	[27]
#498
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	pulmonary	O	['N']	[8]
9	hypertension	O	['N']	[9]
10	and	O	['N']	[10]
11	undifferentiated	O	['N']	[11]
12	connective	O	['N']	[12]
13	tissue	O	['N']	[13]
14	disease	O	['N']	[14]
15	who	O	['N']	[15]
16	,	O	['N']	[16]
17	after	O	['N']	[17]
18	2	O	['N']	[18]
19	months	O	['N']	[19]
20	of	O	['N']	[20]
21	treatment	O	['N']	[21]
22	with	O	['N']	[22]
23	epoprostenol	B-Drug	['Causes']	[29]
24	,	O	['N']	[24]
25	presented	O	['N']	[25]
26	with	O	['N']	[26]
27	rapidly	B	['N']	[27]
28	progressive	I	['N']	[28]
29	erythema	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	scaling	O	['N']	[31]
32	,	O	['N']	[32]
33	nausea	O	['N']	[33]
34	and	O	['N']	[34]
35	vomiting	O	['N']	[35]
36	,	O	['N']	[36]
37	and	O	['N']	[37]
38	fever	O	['N']	[38]
39	.	O	['N']	[39]
#499
0	We	O	['N']	[0]
1	consider	O	['N']	[1]
2	asterixis	O	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	an	O	['N']	[5]
6	easily	O	['N']	[6]
7	overlooked	O	['N']	[7]
8	sign	O	['N']	[8]
9	of	O	['N']	[9]
10	neurotoxicity	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	may	O	['N']	[13]
14	occur	O	['N']	[14]
15	even	O	['N']	[15]
16	at	O	['N']	[16]
17	low	O	['N']	[17]
18	or	O	['N']	[18]
19	moderate	O	['N']	[19]
20	dosage	O	['N']	[20]
21	levels	O	['N']	[21]
22	,	O	['N']	[22]
23	if	O	['N']	[23]
24	certain	O	['N']	[24]
25	drugs	O	['N']	[25]
26	as	O	['N']	[26]
27	lithium	B-Drug	['Causes']	[10]
28	or	O	['N']	[28]
29	clozapine	O	['N']	[29]
30	are	O	['N']	[30]
31	used	O	['N']	[31]
32	in	O	['N']	[32]
33	combination	O	['N']	[33]
34	with	O	['N']	[34]
35	CBZ	O	['N']	[35]
36	.	O	['N']	[36]
#500
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	the	O	['N']	[2]
3	temporal	O	['N']	[3]
4	association	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	abnormal	B	['N']	[7]
8	liver	I	['N']	[8]
9	enzymes	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	this	O	['N']	[11]
12	patient	O	['N']	[12]
13	,	O	['N']	[13]
14	in	O	['N']	[14]
15	the	O	['N']	[15]
16	absence	O	['N']	[16]
17	of	O	['N']	[17]
18	other	O	['N']	[18]
19	offending	O	['N']	[19]
20	agents	O	['N']	[20]
21	,	O	['N']	[21]
22	argues	O	['N']	[22]
23	strongly	O	['N']	[23]
24	in	O	['N']	[24]
25	favor	O	['N']	[25]
26	of	O	['N']	[26]
27	6-TG	B-Drug	['Causes']	[9]
28	as	O	['N']	[28]
29	a	O	['N']	[29]
30	cause	O	['N']	[30]
31	of	O	['N']	[31]
32	liver	O	['N']	[32]
33	enzyme	O	['N']	[33]
34	abnormalities	O	['N']	[34]
35	.	O	['N']	[35]
#501
0	Sodium	B	['N']	[0]
1	valproate	I-Drug	['Causes']	[32]
2	and	O	['N']	[2]
3	carbamazepine	O	['N']	[3]
4	,	O	['N']	[4]
5	antiepileptic	O	['N']	[5]
6	drugs	O	['N']	[6]
7	that	O	['N']	[7]
8	are	O	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	a	O	['N']	[11]
12	relatively	O	['N']	[12]
13	low	O	['N']	[13]
14	rate	O	['N']	[14]
15	of	O	['N']	[15]
16	adverse	O	['N']	[16]
17	cutaneous	O	['N']	[17]
18	reactions	O	['N']	[18]
19	,	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	added	O	['N']	[22]
23	to	O	['N']	[23]
24	the	O	['N']	[24]
25	growing	O	['N']	[25]
26	list	O	['N']	[26]
27	of	O	['N']	[27]
28	drugs	O	['N']	[28]
29	that	O	['N']	[29]
30	produce	O	['N']	[30]
31	psoriasiform	B	['N']	[31]
32	eruptions	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#502
0	Incomplete	B	['N']	[0]
1	posterior	I	['N']	[1]
2	hyaloid	I	['N']	[2]
3	detachment	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	intravitreal	O	['N']	[5]
6	pegaptanib	B-Drug	['Causes']	[3]
7	injection	O	['N']	[7]
8	in	O	['N']	[8]
9	diabetic	O	['N']	[9]
10	macular	O	['N']	[10]
11	edema	O	['N']	[11]
12	.	O	['N']	[12]
#503
0	Acute	B	['N']	[0]
1	intravascular	I	['N']	[1]
2	hemolysis	I-Adverse_Effect	['N']	[2]
3	developed	O	['N']	[3]
4	when	O	['N']	[4]
5	a	O	['N']	[5]
6	diabetic	O	['N']	[6]
7	patient	O	['N']	[7]
8	,	O	['N']	[8]
9	previously	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	glyburide	B-Drug	['Causes']	[2]
13	,	O	['N']	[13]
14	was	O	['N']	[14]
15	started	O	['N']	[15]
16	on	O	['N']	[16]
17	another	O	['N']	[17]
18	oral	O	['N']	[18]
19	sulfonylurea	O	['N']	[19]
20	drug	O	['N']	[20]
21	,	O	['N']	[21]
22	chlorpropamide	O	['N']	[22]
23	.	O	['N']	[23]
#504
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	allogeneic	O	['N']	[3]
4	bone	O	['N']	[4]
5	marrow	O	['N']	[5]
6	transplant	O	['N']	[6]
7	recipient	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	CMV	B	['N']	[10]
11	infection	I-Adverse_Effect	['N']	[11]
12	refractory	O	['N']	[12]
13	to	O	['N']	[13]
14	sequential	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	ganciclovir	B-Drug	['Causes']	[11]
18	,	O	['N']	[18]
19	foscarnet	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	cidofovir	O	['N']	[22]
23	.	O	['N']	[23]
#505
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Acute	B	['N']	[2]
3	severe	I	['N']	[3]
4	hepatitis	I-Adverse_Effect	['N']	[4]
5	though	O	['N']	[5]
6	rare	O	['N']	[6]
7	is	O	['N']	[7]
8	occasionally	O	['N']	[8]
9	observed	O	['N']	[9]
10	with	O	['N']	[10]
11	EGFR	O	['N']	[11]
12	inhibitors	O	['N']	[12]
13	gefitinib	O	['N']	[13]
14	or	O	['N']	[14]
15	erlotinib	B-Drug	['Causes']	[4]
16	.	O	['N']	[16]
#506
0	Intensive	O	['N']	[0]
1	high	O	['N']	[1]
2	-	O	['N']	[2]
3	flux	O	['N']	[3]
4	hemodiafiltration	O	['N']	[4]
5	is	O	['N']	[5]
6	often	O	['N']	[6]
7	used	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	management	O	['N']	[10]
11	of	O	['N']	[11]
12	vancomycin	B-Drug	['Causes']	[13]
13	toxicity	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#507
0	A	O	['N']	[0]
1	33-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	recreational	O	['N']	[9]
10	benztropine	B-Drug	['Dosage']	[11]
11	abuse	B-Dose	['N']	[11]
12	presented	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	emergency	O	['N']	[15]
16	department	O	['N']	[16]
17	with	O	['N']	[17]
18	confusion	O	['N']	[18]
19	,	O	['N']	[19]
20	abdominal	O	['N']	[20]
21	pain	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	distention	O	['N']	[24]
25	.	O	['N']	[25]
#508
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	flucytosine	B-Drug	['Causes']	[22]
7	-	O	['N']	[7]
8	associated	O	['N']	[8]
9	ulcerating	O	['N']	[9]
10	enteritis	O	['N']	[10]
11	in	O	['N']	[11]
12	which	O	['N']	[12]
13	the	O	['N']	[13]
14	small	O	['N']	[14]
15	bowel	O	['N']	[15]
16	x	O	['N']	[16]
17	-	O	['N']	[17]
18	ray	O	['N']	[18]
19	demonstrated	O	['N']	[19]
20	severe	B	['N']	[20]
21	luminal	I	['N']	[21]
22	narrowing	I-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	ulceration	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	marked	O	['N']	[27]
28	separation	O	['N']	[28]
29	of	O	['N']	[29]
30	loops	O	['N']	[30]
31	of	O	['N']	[31]
32	bowel	O	['N']	[32]
33	.	O	['N']	[33]
#509
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	patient	O	['N']	[2]
3	developed	O	['N']	[3]
4	mild	O	['N']	[4]
5	nitritoid	O	['N']	[5]
6	symptoms	O	['N']	[6]
7	and	O	['N']	[7]
8	pain	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	band	O	['N']	[11]
12	-	O	['N']	[12]
13	like	O	['N']	[13]
14	distribution	O	['N']	[14]
15	,	O	['N']	[15]
16	corresponding	O	['N']	[16]
17	to	O	['N']	[17]
18	T10-T12	B	['N']	[18]
19	dermatomes	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	shortly	O	['N']	[21]
22	after	O	['N']	[22]
23	gold	B	['N']	[23]
24	sodium	I	['N']	[24]
25	thiomalate	I-Drug	['Causes']	[19]
26	(	O	['N']	[26]
27	GSTM	O	['N']	[27]
28	)	O	['N']	[28]
29	injection	O	['N']	[29]
30	.	O	['N']	[30]
#510
0	One	O	['N']	[0]
1	should	O	['N']	[1]
2	therefore	O	['N']	[2]
3	be	O	['N']	[3]
4	aware	O	['N']	[4]
5	of	O	['N']	[5]
6	possible	O	['N']	[6]
7	extrapyramidal	B	['N']	[7]
8	side	I	['N']	[8]
9	effects	I-Adverse_Effect	['N']	[9]
10	with	O	['N']	[10]
11	olanzapine	B-Drug	['Causes']	[9]
12	that	O	['N']	[12]
13	are	O	['N']	[13]
14	reduced	O	['N']	[14]
15	compared	O	['N']	[15]
16	to	O	['N']	[16]
17	classical	O	['N']	[17]
18	neuroleptic	O	['N']	[18]
19	drugs	O	['N']	[19]
20	but	O	['N']	[20]
21	not	O	['N']	[21]
22	completely	O	['N']	[22]
23	eliminated	O	['N']	[23]
24	.	O	['N']	[24]
#511
0	Coagulopathy	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	the	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	cephalosporin	O	['N']	[6]
7	or	O	['N']	[7]
8	moxalactam	B-Drug	['Causes']	[0]
9	antibiotics	O	['N']	[9]
10	in	O	['N']	[10]
11	acute	O	['N']	[11]
12	and	O	['N']	[12]
13	chronic	O	['N']	[13]
14	renal	O	['N']	[14]
15	failure	O	['N']	[15]
16	.	O	['N']	[16]
#512
0	According	O	['N']	[0]
1	to	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	et	O	['N']	[4]
5	al	O	['N']	[5]
6	.	O	['N']	[6]
7	adverse	O	['N']	[7]
8	-	O	['N']	[8]
9	reaction	O	['N']	[9]
10	probability	O	['N']	[10]
11	scale	O	['N']	[11]
12	,	O	['N']	[12]
13	enoxaparin	B-Drug	['Causes']	[19]
14	was	O	['N']	[14]
15	the	O	['N']	[15]
16	probable	O	['N']	[16]
17	cause	O	['N']	[17]
18	of	O	['N']	[18]
19	hepatotoxicity	B-Adverse_Effect	['N']	[19]
20	in	O	['N']	[20]
21	this	O	['N']	[21]
22	patient	O	['N']	[22]
23	.	O	['N']	[23]
#513
0	A	O	['N']	[0]
1	third	O	['N']	[1]
2	patient	O	['N']	[2]
3	experienced	O	['N']	[3]
4	disabling	B	['N']	[4]
5	neurotoxicity	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	extremity	O	['N']	[8]
9	of	O	['N']	[9]
10	a	O	['N']	[10]
11	prior	O	['N']	[11]
12	ulnar	O	['N']	[12]
13	nerve	O	['N']	[13]
14	and	O	['N']	[14]
15	tendon	O	['N']	[15]
16	transposition	O	['N']	[16]
17	after	O	['N']	[17]
18	receiving	O	['N']	[18]
19	paclitaxel	B-Drug	['Causes']	[5]
20	.	O	['N']	[20]
#514
0	Para	B	['N']	[0]
1	-	I	['N']	[1]
2	aminosalicylic	I	['N']	[2]
3	acid	I-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	hypoglycaemia	B-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	diabetic	O	['N']	[11]
12	nephropathy	O	['N']	[12]
13	.	O	['N']	[13]
#515
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	are	O	['N']	[2]
3	reported	O	['N']	[3]
4	of	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	a	O	['N']	[8]
9	hematologic	B	['N']	[9]
10	malignancy	I-Adverse_Effect	['N']	[10]
11	several	O	['N']	[11]
12	years	O	['N']	[12]
13	after	O	['N']	[13]
14	intravesical	O	['N']	[14]
15	chemotherapy	O	['N']	[15]
16	of	O	['N']	[16]
17	superficial	O	['N']	[17]
18	bladder	O	['N']	[18]
19	cancer	O	['N']	[19]
20	with	O	['N']	[20]
21	etoglucid	O	['N']	[21]
22	,	O	['N']	[22]
23	doxorubicin	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	mitomycin	-	['N']	[26]
27	C.	-	['N']	[27]
#516
0	A	O	['N']	[0]
1	47	O	['N']	[1]
2	year	O	['N']	[2]
3	-	O	['N']	[3]
4	old	O	['N']	[4]
5	woman	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	a	O	['N']	[8]
9	4-year	O	['N']	[9]
10	history	O	['N']	[10]
11	of	O	['N']	[11]
12	intramuscular	O	['N']	[12]
13	pentazocine	B-Drug	['Causes']	[28]
14	injections	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	lower	O	['N']	[17]
18	extremities	O	['N']	[18]
19	,	O	['N']	[19]
20	developed	O	['N']	[20]
21	gradual	O	['N']	[21]
22	stiffness	O	['N']	[22]
23	and	O	['N']	[23]
24	weakness	B	['N']	[24]
25	of	I	['N']	[25]
26	the	I	['N']	[26]
27	lower	I	['N']	[27]
28	extremities	I-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#517
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	B	['N']	[5]
6	hepatitis	I-Adverse_Effect	['N']	[6]
7	induced	O	['N']	[7]
8	by	O	['N']	[8]
9	gliclazide	B-Drug	['Causes']	[6]
10	,	O	['N']	[10]
11	a	O	['N']	[11]
12	second	O	['N']	[12]
13	generation	O	['N']	[13]
14	sulfonylurea	O	['N']	[14]
15	.	O	['N']	[15]
#518
0	Even	O	['N']	[0]
1	though	O	['N']	[1]
2	only	O	['N']	[2]
3	a	O	['N']	[3]
4	few	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	this	O	['N']	[7]
8	adverse	O	['N']	[8]
9	event	O	['N']	[9]
10	have	O	['N']	[10]
11	been	O	['N']	[11]
12	reported	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	literature	O	['N']	[15]
16	,	O	['N']	[16]
17	severe	O	['N']	[17]
18	docetaxel	B-Drug	['Causes']	[22]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	pulmonary	B	['N']	[21]
22	toxicity	I-Adverse_Effect	['N']	[22]
23	needs	O	['N']	[23]
24	to	O	['N']	[24]
25	be	O	['N']	[25]
26	considered	O	['N']	[26]
27	in	O	['N']	[27]
28	the	O	['N']	[28]
29	differential	O	['N']	[29]
30	diagnosis	O	['N']	[30]
31	when	O	['N']	[31]
32	such	O	['N']	[32]
33	patients	O	['N']	[33]
34	present	O	['N']	[34]
35	with	O	['N']	[35]
36	respiratory	O	['N']	[36]
37	symptoms	O	['N']	[37]
38	.	O	['N']	[38]
#519
0	Hyponatraemia	O	['N']	[0]
1	during	O	['N']	[1]
2	low	B	['N']	[2]
3	-	I	['N']	[3]
4	dose	I-Dose	['N']	[4]
5	carbamazepine	B-Drug	['Dosage']	[4]
6	therapy	O	['N']	[6]
7	.	O	['N']	[7]
#520
0	Increased	O	['N']	[0]
1	awareness	O	['N']	[1]
2	is	O	['N']	[2]
3	needed	O	['N']	[3]
4	on	O	['N']	[4]
5	the	O	['N']	[5]
6	possible	O	['N']	[6]
7	occurrence	O	['N']	[7]
8	of	O	['N']	[8]
9	LPD	B-Adverse_Effect	['N']	[9]
10	resembling	O	['N']	[10]
11	gastric	O	['N']	[11]
12	cancer	O	['N']	[12]
13	in	O	['N']	[13]
14	rheumatoid	O	['N']	[14]
15	arthritis	O	['N']	[15]
16	patients	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	MTX	B-Drug	['Causes']	[9]
20	.	O	['N']	[20]
#521
0	Atrial	B	['N']	[0]
1	fibrillation	I-Adverse_Effect	['N']	[1]
2	occurring	O	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	taking	O	['N']	[6]
7	etanercept	B-Drug	['Causes']	[1]
8	plus	O	['N']	[8]
9	methotrexate	O	['N']	[9]
10	for	O	['N']	[10]
11	rheumatoid	O	['N']	[11]
12	arthritis	O	['N']	[12]
13	.	O	['N']	[13]
#522
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	B	['N']	[5]
6	pancreatitis	I-Adverse_Effect	['N']	[6]
7	that	O	['N']	[7]
8	occurred	O	['N']	[8]
9	after	O	['N']	[9]
10	long	O	['N']	[10]
11	term	O	['N']	[11]
12	mesalamine	B-Drug	['Causes']	[6]
13	therapy	O	['N']	[13]
14	for	O	['N']	[14]
15	ulcerative	O	['N']	[15]
16	colitis	O	['N']	[16]
17	.	O	['N']	[17]
#523
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	43-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	sore	O	['N']	[9]
10	throat	O	['N']	[10]
11	,	O	['N']	[11]
12	swelling	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	lips	O	['N']	[15]
16	and	O	['N']	[16]
17	oral	O	['N']	[17]
18	cavity	O	['N']	[18]
19	and	O	['N']	[19]
20	dysphagia	B-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	2	O	['N']	[22]
23	weeks	O	['N']	[23]
24	after	O	['N']	[24]
25	the	O	['N']	[25]
26	use	O	['N']	[26]
27	of	O	['N']	[27]
28	budesonide	B-Drug	['Causes']	[20]
29	spray	O	['N']	[29]
30	(	O	['N']	[30]
31	Budefat	O	['N']	[31]
32	)	O	['N']	[32]
33	for	O	['N']	[33]
34	treatment	O	['N']	[34]
35	of	O	['N']	[35]
36	bronchial	O	['N']	[36]
37	asthma	O	['N']	[37]
38	.	O	['N']	[38]
#524
0	The	O	['N']	[0]
1	pathophysiological	O	['N']	[1]
2	mechanisms	O	['N']	[2]
3	remain	O	['N']	[3]
4	unknown	O	['N']	[4]
5	,	O	['N']	[5]
6	although	O	['N']	[6]
7	the	O	['N']	[7]
8	drug	O	['N']	[8]
9	could	O	['N']	[9]
10	act	O	['N']	[10]
11	through	O	['N']	[11]
12	massive	O	['N']	[12]
13	cytokines	O	['N']	[13]
14	liberation	O	['N']	[14]
15	after	O	['N']	[15]
16	destruction	B	['N']	[16]
17	of	I	['N']	[17]
18	CD20	I	['N']	[18]
19	positive	I	['N']	[19]
20	cells	I-Adverse_Effect	['N']	[20]
21	by	O	['N']	[21]
22	rituximab	B-Drug	['Causes']	[20]
23	.	O	['N']	[23]
#525
0	Massive	B	['N']	[0]
1	plasmocytosis	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	methimazole	B-Drug	['Causes']	[1]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	bone	O	['N']	[7]
8	marrow	O	['N']	[8]
9	toxicity	O	['N']	[9]
10	.	O	['N']	[10]
#526
0	Retinopathy	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	hepatitis	O	['N']	[2]
3	C	O	['N']	[3]
4	patients	O	['N']	[4]
5	due	O	['N']	[5]
6	to	O	['N']	[6]
7	combination	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	pegylated	O	['N']	[10]
11	interferon	O	['N']	[11]
12	and	O	['N']	[12]
13	ribavirin	B-Drug	['Causes']	[0]
14	.	O	['N']	[14]
#527
0	Phenylpropanolamine	B-Drug	['Causes']	[13]
1	(	O	['N']	[1]
2	PPA	O	['N']	[2]
3	)	O	['N']	[3]
4	recently	O	['N']	[4]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	publicly	O	['N']	[7]
8	implicated	O	['N']	[8]
9	as	O	['N']	[9]
10	a	O	['N']	[10]
11	cause	O	['N']	[11]
12	of	O	['N']	[12]
13	stroke	B-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	other	O	['N']	[15]
16	neurologic	O	['N']	[16]
17	events	O	['N']	[17]
18	.	O	['N']	[18]
#528
0	Risperidone	B-Drug	['Causes']	[44]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	frequently	O	['N']	[3]
4	used	O	['N']	[4]
5	member	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	new	O	['N']	[8]
9	class	O	['N']	[9]
10	of	O	['N']	[10]
11	atypical	O	['N']	[11]
12	antipsychotics	O	['N']	[12]
13	-	O	['N']	[13]
14	the	O	['N']	[14]
15	serotonin	O	['N']	[15]
16	-	O	['N']	[16]
17	dopamine	O	['N']	[17]
18	antagonists	O	['N']	[18]
19	(	O	['N']	[19]
20	SDAs)-due	O	['N']	[20]
21	to	O	['N']	[21]
22	its	O	['N']	[22]
23	comparatively	O	['N']	[23]
24	high	O	['N']	[24]
25	efficacy	O	['N']	[25]
26	and	O	['N']	[26]
27	low	O	['N']	[27]
28	D2/5HT2	O	['N']	[28]
29	binding	O	['N']	[29]
30	ratio	O	['N']	[30]
31	,	O	['N']	[31]
32	which	O	['N']	[32]
33	results	O	['N']	[33]
34	in	O	['N']	[34]
35	a	O	['N']	[35]
36	low	O	['N']	[36]
37	incidence	O	['N']	[37]
38	of	O	['N']	[38]
39	extrapyramidal	O	['N']	[39]
40	side	O	['N']	[40]
41	effects	O	['N']	[41]
42	including	O	['N']	[42]
43	tardive	B	['N']	[43]
44	dyskinesia	I-Adverse_Effect	['N']	[44]
45	(	O	['N']	[45]
46	TD	O	['N']	[46]
47	)	O	['N']	[47]
48	.	O	['N']	[48]
#529
0	Two	O	['N']	[0]
1	case	O	['N']	[1]
2	reports	O	['N']	[2]
3	of	O	['N']	[3]
4	bilateral	O	['N']	[4]
5	granulomatous	O	['N']	[5]
6	anterior	O	['N']	[6]
7	uveitis	O	['N']	[7]
8	are	O	['N']	[8]
9	described	O	['N']	[9]
10	in	O	['N']	[10]
11	patients	O	['N']	[11]
12	with	O	['N']	[12]
13	open	O	['N']	[13]
14	angle	O	['N']	[14]
15	glaucoma	O	['N']	[15]
16	treated	O	['N']	[16]
17	with	O	['N']	[17]
18	metripranolol	B-Drug	['Dosage']	[19]
19	0.6	B-Dose	['N']	[19]
20	%	O	['N']	[20]
21	eye	O	['N']	[21]
22	drops	O	['N']	[22]
23	.	O	['N']	[23]
#530
0	An	O	['N']	[0]
1	encephalopathy	B-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	cardiomyopathy	O	['N']	[3]
4	developed	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	seventeen	O	['N']	[7]
8	-	O	['N']	[8]
9	year	O	['N']	[9]
10	-	O	['N']	[10]
11	old	O	['N']	[11]
12	girl	O	['N']	[12]
13	with	O	['N']	[13]
14	chemotherapy	O	['N']	[14]
15	-	O	['N']	[15]
16	induced	O	['N']	[16]
17	renal	O	['N']	[17]
18	failure	O	['N']	[18]
19	while	O	['N']	[19]
20	receiving	O	['N']	[20]
21	an	O	['N']	[21]
22	intravesical	O	['N']	[22]
23	aluminum	B-Drug	['Causes']	[1]
24	infusion	O	['N']	[24]
25	for	O	['N']	[25]
26	hemorrhagic	O	['N']	[26]
27	cystitis	O	['N']	[27]
28	.	O	['N']	[28]
#531
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	report	O	['N']	[3]
4	indicates	O	['N']	[4]
5	clindamycin	B	['N']	[5]
6	phosphate	I-Drug	['Causes']	[25]
7	vaginal	O	['N']	[7]
8	cream	O	['N']	[8]
9	as	O	['N']	[9]
10	the	O	['N']	[10]
11	most	O	['N']	[11]
12	probable	O	['N']	[12]
13	cause	O	['N']	[13]
14	of	O	['N']	[14]
15	CDIC	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	temporal	O	['N']	[19]
20	relationship	O	['N']	[20]
21	between	O	['N']	[21]
22	the	O	['N']	[22]
23	occurrence	O	['N']	[23]
24	of	O	['N']	[24]
25	diarrhea	B-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	clindamycin	O	['N']	[27]
28	administration	O	['N']	[28]
29	,	O	['N']	[29]
30	lack	O	['N']	[30]
31	of	O	['N']	[31]
32	concomitant	O	['N']	[32]
33	medications	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	documentation	O	['N']	[36]
37	of	O	['N']	[37]
38	C.	O	['N']	[38]
39	difficile	O	['N']	[39]
40	toxin	O	['N']	[40]
41	.	O	['N']	[41]
#532
0	Serotonin	B	['N']	[0]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	transitioning	O	['N']	[4]
5	from	O	['N']	[5]
6	phenelzine	O	['N']	[6]
7	to	O	['N']	[7]
8	venlafaxine	B-Drug	['Causes']	[1]
9	:	O	['N']	[9]
10	four	O	['N']	[10]
11	patient	O	['N']	[11]
12	reports	O	['N']	[12]
13	.	O	['N']	[13]
#533
0	Drug	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	agranulocytosis	B-Adverse_Effect	['N']	[3]
4	during	O	['N']	[4]
5	treatment	O	['N']	[5]
6	with	O	['N']	[6]
7	infliximab	B-Drug	['Causes']	[3]
8	in	O	['N']	[8]
9	enteropathic	O	['N']	[9]
10	spondyloarthropathy	O	['N']	[10]
11	.	O	['N']	[11]
#534
0	Intravenous	O	['N']	[0]
1	diazepam	B-Drug	['Causes']	[4]
2	exacerbated	O	['N']	[2]
3	the	O	['N']	[3]
4	seizures	B-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#535
0	Therefore	O	['N']	[0]
1	,	O	['N']	[1]
2	although	O	['N']	[2]
3	garenoxacin	B-Drug	['Causes']	[11]
4	reportedly	O	['N']	[4]
5	causes	O	['N']	[5]
6	fewer	O	['N']	[6]
7	adverse	O	['N']	[7]
8	reactions	O	['N']	[8]
9	for	O	['N']	[9]
10	cardiac	B	['N']	[10]
11	rhythms	I-Adverse_Effect	['N']	[11]
12	than	O	['N']	[12]
13	third	O	['N']	[13]
14	-	O	['N']	[14]
15	generation	O	['N']	[15]
16	quinolone	O	['N']	[16]
17	antibiotics	O	['N']	[17]
18	,	O	['N']	[18]
19	one	O	['N']	[19]
20	must	O	['N']	[20]
21	be	O	['N']	[21]
22	cautious	O	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	interference	O	['N']	[25]
26	of	O	['N']	[26]
27	other	O	['N']	[27]
28	drugs	O	['N']	[28]
29	during	O	['N']	[29]
30	hypokalemia	O	['N']	[30]
31	in	O	['N']	[31]
32	order	O	['N']	[32]
33	to	O	['N']	[33]
34	prevent	O	['N']	[34]
35	TdP.	O	['N']	[35]
#536
0	Allergy	B-Adverse_Effect	['N']	[0]
1	to	O	['N']	[1]
2	cloxacillin	B-Drug	['Causes']	[0]
3	with	O	['N']	[3]
4	normal	O	['N']	[4]
5	tolerance	O	['N']	[5]
6	to	O	['N']	[6]
7	amoxicillin	O	['N']	[7]
8	and	O	['N']	[8]
9	cefuroxime	O	['N']	[9]
10	.	O	['N']	[10]
#537
0	Severe	B	['N']	[0]
1	osteomalacia	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	present	O	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	epileptic	O	['N']	[6]
7	patients	O	['N']	[7]
8	who	O	['N']	[8]
9	were	O	['N']	[9]
10	under	O	['N']	[10]
11	long	O	['N']	[11]
12	-	O	['N']	[12]
13	term	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	congeners	O	['N']	[16]
17	of	O	['N']	[17]
18	phenytoin	O	['N']	[18]
19	,	O	['N']	[19]
20	phenobarbital	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	acetazolamide	B-Drug	['Causes']	[1]
24	.	O	['N']	[24]
#538
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	an	O	['N']	[2]
3	immediate	O	['N']	[3]
4	hypersensitivity	O	['N']	[4]
5	reaction	O	['N']	[5]
6	during	O	['N']	[6]
7	the	O	['N']	[7]
8	initiation	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	MTX	B-Drug	['Causes']	[15]
12	infusion	O	['N']	[12]
13	with	O	['N']	[13]
14	diffuse	B	['N']	[14]
15	urticaria	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	facial	O	['N']	[17]
18	swelling	O	['N']	[18]
19	,	O	['N']	[19]
20	cough	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	chest	O	['N']	[23]
24	tightness	O	['N']	[24]
25	.	O	['N']	[25]
#539
0	The	O	['N']	[0]
1	toxicity	B-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	plasma	O	['N']	[3]
4	concentrations	O	['N']	[4]
5	of	O	['N']	[5]
6	ifosfamide	B-Drug	['Causes']	[1]
7	,	O	['N']	[7]
8	chloroacetaldehyde	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	4-hydroxyifosfamide	O	['N']	[11]
12	were	O	['N']	[12]
13	then	O	['N']	[13]
14	determined	O	['N']	[14]
15	over	O	['N']	[15]
16	24	O	['N']	[16]
17	h	O	['N']	[17]
18	after	O	['N']	[18]
19	a	O	['N']	[19]
20	single	O	['N']	[20]
21	1.6	O	['N']	[21]
22	g	O	['N']	[22]
23	/	O	['N']	[23]
24	m2	O	['N']	[24]
25	dose	O	['N']	[25]
26	of	O	['N']	[26]
27	ifosfamide	O	['N']	[27]
28	.	O	['N']	[28]
#540
0	Listeria	O	['N']	[0]
1	brain	O	['N']	[1]
2	abscess	O	['N']	[2]
3	,	O	['N']	[3]
4	Pneumocystis	B	['N']	[4]
5	pneumonia	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	Kaposi	O	['N']	[7]
8	's	O	['N']	[8]
9	sarcoma	O	['N']	[9]
10	after	O	['N']	[10]
11	temozolomide	B-Drug	['Causes']	[5]
12	.	O	['N']	[12]
#541
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	intravenous	O	['N']	[2]
3	nitroglycerin	B-Drug	['Causes']	[18]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	idiopathic	O	['N']	[8]
9	pulmonary	O	['N']	[9]
10	hypertension	O	['N']	[10]
11	resulted	O	['N']	[11]
12	in	O	['N']	[12]
13	an	O	['N']	[13]
14	increase	B	['N']	[14]
15	in	I	['N']	[15]
16	pulmonary	I	['N']	[16]
17	artery	I	['N']	[17]
18	pressure	I-Adverse_Effect	['N']	[18]
19	associated	O	['N']	[19]
20	with	O	['N']	[20]
21	a	O	['N']	[21]
22	decrease	O	['N']	[22]
23	in	O	['N']	[23]
24	blood	O	['N']	[24]
25	flow	O	['N']	[25]
26	that	O	['N']	[26]
27	is	O	['N']	[27]
28	best	O	['N']	[28]
29	explained	O	['N']	[29]
30	by	O	['N']	[30]
31	an	O	['N']	[31]
32	increase	O	['N']	[32]
33	in	O	['N']	[33]
34	pulmonary	O	['N']	[34]
35	vascular	O	['N']	[35]
36	resistance	O	['N']	[36]
37	.	O	['N']	[37]
#542
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	late	O	['N']	[5]
6	development	O	['N']	[6]
7	of	O	['N']	[7]
8	immune	B	['N']	[8]
9	-	I	['N']	[9]
10	mediated	I	['N']	[10]
11	diabetes	I	['N']	[11]
12	mellitus	I-Adverse_Effect	['N']	[12]
13	after	O	['N']	[13]
14	completion	O	['N']	[14]
15	of	O	['N']	[15]
16	alfa	B	['N']	[16]
17	-	I	['N']	[17]
18	interferon	I-Drug	['Causes']	[12]
19	therapy	O	['N']	[19]
20	for	O	['N']	[20]
21	hepatitis	O	['N']	[21]
22	C	O	['N']	[22]
23	in	O	['N']	[23]
24	an	O	['N']	[24]
25	Asian	O	['N']	[25]
26	patient	O	['N']	[26]
27	.	O	['N']	[27]
#543
0	Visceral	B	['N']	[0]
1	leishmaniasis	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	macrophagic	O	['N']	[3]
4	activation	O	['N']	[4]
5	syndrome	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	rheumatoid	O	['N']	[10]
11	arthritis	O	['N']	[11]
12	under	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	adalimumab	B-Drug	['Causes']	[1]
16	.	O	['N']	[16]
#544
0	This	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	sequential	O	['N']	[3]
4	symptoms	O	['N']	[4]
5	including	O	['N']	[5]
6	alternative	O	['N']	[6]
7	hemiparesis	O	['N']	[7]
8	,	O	['N']	[8]
9	dysarthria	O	['N']	[9]
10	and	O	['N']	[10]
11	altered	B	['N']	[11]
12	consciousness	I-Adverse_Effect	['N']	[12]
13	5	O	['N']	[13]
14	days	O	['N']	[14]
15	after	O	['N']	[15]
16	the	O	['N']	[16]
17	second	O	['N']	[17]
18	course	O	['N']	[18]
19	of	O	['N']	[19]
20	HD	B	['N']	[20]
21	-	I	['N']	[21]
22	MTX	I-Drug	['Causes']	[12]
23	(	O	['N']	[23]
24	8	O	['N']	[24]
25	gm	O	['N']	[25]
26	/	O	['N']	[26]
27	m2	O	['N']	[27]
28	by	O	['N']	[28]
29	6	O	['N']	[29]
30	h	O	['N']	[30]
31	continuous	O	['N']	[31]
32	infusion	O	['N']	[32]
33	)	O	['N']	[33]
34	with	O	['N']	[34]
35	leucovorin	O	['N']	[35]
36	rescue	O	['N']	[36]
37	.	O	['N']	[37]
#545
0	Two	O	['N']	[0]
1	children	O	['N']	[1]
2	with	O	['N']	[2]
3	rheumatic	O	['N']	[3]
4	fever	O	['N']	[4]
5	developed	O	['N']	[5]
6	anicteric	O	['N']	[6]
7	hepatitis	O	['N']	[7]
8	while	O	['N']	[8]
9	on	O	['N']	[9]
10	high	B	['N']	[10]
11	-	I	['N']	[11]
12	dose	I-Dose	['N']	[12]
13	aspirin	B-Drug	['Dosage']	[12]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#546
0	Pleuropulmonary	B	['N']	[0]
1	fibrosis	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	long	O	['N']	[3]
4	-	O	['N']	[4]
5	term	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	dopamine	O	['N']	[9]
10	agonist	O	['N']	[10]
11	pergolide	B-Drug	['Causes']	[1]
12	for	O	['N']	[12]
13	Parkinson	O	['N']	[13]
14	Disease	O	['N']	[14]
15	.	O	['N']	[15]
#547
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	reported	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	BOOP	B-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	single	O	['N']	[10]
11	-	O	['N']	[11]
12	agent	O	['N']	[12]
13	rituximab	B-Drug	['Causes']	[7]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	along	O	['N']	[16]
17	with	O	['N']	[17]
18	two	O	['N']	[18]
19	other	O	['N']	[19]
20	patients	O	['N']	[20]
21	we	O	['N']	[21]
22	describe	O	['N']	[22]
23	,	O	['N']	[23]
24	as	O	['N']	[24]
25	well	O	['N']	[25]
26	as	O	['N']	[26]
27	two	O	['N']	[27]
28	prior	O	['N']	[28]
29	reports	O	['N']	[29]
30	of	O	['N']	[30]
31	BOOP	O	['N']	[31]
32	in	O	['N']	[32]
33	NHL	O	['N']	[33]
34	patients	O	['N']	[34]
35	receiving	O	['N']	[35]
36	rituximab	O	['N']	[36]
37	-	O	['N']	[37]
38	based	O	['N']	[38]
39	combinations	O	['N']	[39]
40	,	O	['N']	[40]
41	strengthens	O	['N']	[41]
42	the	O	['N']	[42]
43	possibility	O	['N']	[43]
44	of	O	['N']	[44]
45	a	O	['N']	[45]
46	causal	O	['N']	[46]
47	relationship	O	['N']	[47]
48	.	O	['N']	[48]
#548
0	Because	O	['N']	[0]
1	of	O	['N']	[1]
2	a	O	['N']	[2]
3	hypersensitivity	B	['N']	[3]
4	reaction	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	initial	O	['N']	[6]
7	therapy	O	['N']	[7]
8	with	O	['N']	[8]
9	penicillin	O	['N']	[9]
10	G	O	['N']	[10]
11	and	O	['N']	[11]
12	gentamicin	B-Drug	['Causes']	[4]
13	was	O	['N']	[13]
14	stopped	O	['N']	[14]
15	and	O	['N']	[15]
16	substituted	O	['N']	[16]
17	with	O	['N']	[17]
18	cefazolin	O	['N']	[18]
19	.	O	['N']	[19]
#549
0	The	O	['N']	[0]
1	condition	O	['N']	[1]
2	should	O	['N']	[2]
3	be	O	['N']	[3]
4	suspected	O	['N']	[4]
5	in	O	['N']	[5]
6	patients	O	['N']	[6]
7	who	O	['N']	[7]
8	develop	O	['N']	[8]
9	unexplained	O	['N']	[9]
10	abdominal	B	['N']	[10]
11	pain	I-Adverse_Effect	['N']	[11]
12	or	O	['N']	[12]
13	collapse	O	['N']	[13]
14	following	O	['N']	[14]
15	vasopressin	B-Drug	['Causes']	[11]
16	treatment	O	['N']	[16]
17	.	O	['N']	[17]
#550
0	Agranulocytosis	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	adverse	O	['N']	[4]
5	effect	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	prolonged	O	['N']	[8]
9	vancomycin	B-Drug	['Causes']	[0]
10	therapy	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	is	O	['N']	[13]
14	potentially	O	['N']	[14]
15	serious	O	['N']	[15]
16	,	O	['N']	[16]
17	especially	O	['N']	[17]
18	in	O	['N']	[18]
19	end	O	['N']	[19]
20	stage	O	['N']	[20]
21	renal	O	['N']	[21]
22	disease	O	['N']	[22]
23	(	O	['N']	[23]
24	ESRD	O	['N']	[24]
25	)	O	['N']	[25]
26	patients	O	['N']	[26]
27	.	O	['N']	[27]
#551
0	A	O	['N']	[0]
1	51-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	type	B	['N']	[6]
7	1	I	['N']	[7]
8	diabetes	I	['N']	[8]
9	mellitus	I-Adverse_Effect	['N']	[9]
10	following	O	['N']	[10]
11	24	O	['N']	[11]
12	weeks	O	['N']	[12]
13	of	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	recombinant	O	['N']	[16]
17	alpha-2b	O	['N']	[17]
18	peginterferon	O	['N']	[18]
19	plus	O	['N']	[19]
20	ribavirin	B-Drug	['Causes']	[9]
21	for	O	['N']	[21]
22	chronic	O	['N']	[22]
23	hepatitis	O	['N']	[23]
24	C.	O	['N']	[24]
#552
0	Ticlopidine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	aplastic	B	['N']	[3]
4	anemia	I-Adverse_Effect	['N']	[4]
5	(	O	['N']	[5]
6	TIAA	O	['N']	[6]
7	)	O	['N']	[7]
8	is	O	['N']	[8]
9	considered	O	['N']	[9]
10	very	O	['N']	[10]
11	uncommon	O	['N']	[11]
12	.	O	['N']	[12]
#553
0	Leflunomide	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	weight	B	['N']	[3]
4	loss	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	rheumatoid	O	['N']	[6]
7	arthritis	O	['N']	[7]
8	.	O	['N']	[8]
#554
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Hydroxyurea	B-Drug	['Causes']	[22]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	cytostatic	O	['N']	[5]
6	agent	O	['N']	[6]
7	used	O	['N']	[7]
8	to	O	['N']	[8]
9	treat	O	['N']	[9]
10	myeloproliferative	O	['N']	[10]
11	disorders	O	['N']	[11]
12	and	O	['N']	[12]
13	long	O	['N']	[13]
14	-	O	['N']	[14]
15	term	O	['N']	[15]
16	treatment	O	['N']	[16]
17	is	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	mucocutaneous	B	['N']	[20]
21	adverse	I	['N']	[21]
22	events	I-Adverse_Effect	['N']	[22]
23	and	O	['N']	[23]
24	nail	O	['N']	[24]
25	hyperpigmentation	O	['N']	[25]
26	.	O	['N']	[26]
#555
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	infectious	O	['N']	[3]
4	toxicities	O	['N']	[4]
5	experienced	O	['N']	[5]
6	by	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	in	O	['N']	[11]
12	our	O	['N']	[12]
13	institution	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	dexamethasone	B-Drug	['Dosage']	[21]
17	(	O	['N']	[17]
18	10	B	['N']	[18]
19	mg	I	['N']	[19]
20	/	I	['N']	[20]
21	m(2)/day	I-Dose	['N']	[21]
22	for	O	['N']	[22]
23	4	O	['N']	[23]
24	weeks	O	['N']	[24]
25	with	O	['N']	[25]
26	gradual	O	['N']	[26]
27	tapering	O	['N']	[27]
28	)	O	['N']	[28]
29	during	O	['N']	[29]
30	induction	O	['N']	[30]
31	according	O	['N']	[31]
32	to	O	['N']	[32]
33	the	O	['N']	[33]
34	dexamethasone	O	['N']	[34]
35	arm	O	['N']	[35]
36	of	O	['N']	[36]
37	BFM	O	['N']	[37]
38	2000	O	['N']	[38]
39	and	O	['N']	[39]
40	review	O	['N']	[40]
41	the	O	['N']	[41]
42	relevant	O	['N']	[42]
43	literature	O	['N']	[43]
44	that	O	['N']	[44]
45	suggests	O	['N']	[45]
46	an	O	['N']	[46]
47	increased	O	['N']	[47]
48	risk	O	['N']	[48]
49	of	O	['N']	[49]
50	infectious	O	['N']	[50]
51	complications	O	['N']	[51]
52	with	O	['N']	[52]
53	dexamethasone	O	['N']	[53]
54	.	O	['N']	[54]
#556
0	MATERIALS	O	['N']	[0]
1	AND	O	['N']	[1]
2	METHODS	O	['N']	[2]
3	:	O	['N']	[3]
4	We	O	['N']	[4]
5	present	O	['N']	[5]
6	two	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	significant	O	['N']	[9]
10	morbidity	O	['N']	[10]
11	related	O	['N']	[11]
12	to	O	['N']	[12]
13	primary	B	['N']	[13]
14	and	I	['N']	[14]
15	secondary	I	['N']	[15]
16	perforation	I	['N']	[16]
17	of	I	['N']	[17]
18	the	I	['N']	[18]
19	bladder	I-Adverse_Effect	['N']	[19]
20	following	O	['N']	[20]
21	two	O	['N']	[21]
22	instillations	O	['N']	[22]
23	of	O	['N']	[23]
24	epirubicin	B-Drug	['Causes']	[19]
25	.	O	['N']	[25]
#557
0	Fatal	B	['N']	[0]
1	acute	I	['N']	[1]
2	tubular	I	['N']	[2]
3	necrosis	I-Adverse_Effect	['N']	[3]
4	occurred	O	['N']	[4]
5	in	O	['N']	[5]
6	1	O	['N']	[6]
7	patient	O	['N']	[7]
8	in	O	['N']	[8]
9	whom	O	['N']	[9]
10	intravesical	O	['N']	[10]
11	formalin	B-Drug	['Causes']	[3]
12	was	O	['N']	[12]
13	used	O	['N']	[13]
14	to	O	['N']	[14]
15	control	O	['N']	[15]
16	massive	O	['N']	[16]
17	persistent	O	['N']	[17]
18	hemorrhage	O	['N']	[18]
19	from	O	['N']	[19]
20	radiation	O	['N']	[20]
21	cystitis	O	['N']	[21]
22	.	O	['N']	[22]
#558
0	Neurologic	B	['N']	[0]
1	symptoms	I-Adverse_Effect	['N']	[1]
2	resolved	O	['N']	[2]
3	after	O	['N']	[3]
4	stopping	O	['N']	[4]
5	CAP	B-Drug	['Causes']	[1]
6	for	O	['N']	[6]
7	4	O	['N']	[7]
8	weeks	O	['N']	[8]
9	in	O	['N']	[9]
10	Patient	O	['N']	[10]
11	A	O	['N']	[11]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	no	O	['N']	[14]
15	recurrence	O	['N']	[15]
16	after	O	['N']	[16]
17	reinitiating	O	['N']	[17]
18	CAP	O	['N']	[18]
19	alone	O	['N']	[19]
20	at	O	['N']	[20]
21	2000	O	['N']	[21]
22	mg	O	['N']	[22]
23	/	O	['N']	[23]
24	m2	O	['N']	[24]
25	.	O	['N']	[25]
#559
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	After	O	['N']	[2]
3	exclusion	O	['N']	[3]
4	of	O	['N']	[4]
5	other	O	['N']	[5]
6	causes	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	onset	O	['N']	[9]
10	of	O	['N']	[10]
11	thrombocytopenia	B-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	administration	O	['N']	[13]
14	of	O	['N']	[14]
15	lansoprazole	B-Drug	['Causes']	[11]
16	,	O	['N']	[16]
17	the	O	['N']	[17]
18	resolution	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	adverse	O	['N']	[21]
22	reaction	O	['N']	[22]
23	after	O	['N']	[23]
24	discontinuation	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	drug	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	the	O	['N']	[30]
31	fact	O	['N']	[31]
32	that	O	['N']	[32]
33	no	O	['N']	[33]
34	other	O	['N']	[34]
35	medicines	O	['N']	[35]
36	were	O	['N']	[36]
37	introduced	O	['N']	[37]
38	during	O	['N']	[38]
39	this	O	['N']	[39]
40	time	O	['N']	[40]
41	frame	O	['N']	[41]
42	lead	O	['N']	[42]
43	us	O	['N']	[43]
44	to	O	['N']	[44]
45	believe	O	['N']	[45]
46	that	O	['N']	[46]
47	this	O	['N']	[47]
48	was	O	['N']	[48]
49	most	O	['N']	[49]
50	likely	O	['N']	[50]
51	an	O	['N']	[51]
52	idiosyncratic	O	['N']	[52]
53	thrombocytopenic	O	['N']	[53]
54	response	O	['N']	[54]
55	to	O	['N']	[55]
56	lansoprazole	O	['N']	[56]
57	.	O	['N']	[57]
#560
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	who	O	['N']	[2]
3	received	O	['N']	[3]
4	clindamycin	B-Drug	['Causes']	[24]
5	had	O	['N']	[5]
6	liver	O	['N']	[6]
7	biopsy	O	['N']	[7]
8	findings	O	['N']	[8]
9	of	O	['N']	[9]
10	marked	O	['N']	[10]
11	cholestasis	O	['N']	[11]
12	,	O	['N']	[12]
13	portal	O	['N']	[13]
14	inflammation	O	['N']	[14]
15	,	O	['N']	[15]
16	bile	O	['N']	[16]
17	duct	O	['N']	[17]
18	injury	O	['N']	[18]
19	and	O	['N']	[19]
20	bile	O	['N']	[20]
21	duct	O	['N']	[21]
22	paucity	O	['N']	[22]
23	(	O	['N']	[23]
24	ductopenia	B-Adverse_Effect	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#561
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	spectral	O	['N']	[4]
5	-	O	['N']	[5]
6	domain	O	['N']	[6]
7	optical	O	['N']	[7]
8	coherence	O	['N']	[8]
9	tomography	O	['N']	[9]
10	(	O	['N']	[10]
11	SD	O	['N']	[11]
12	-	O	['N']	[12]
13	OCT	O	['N']	[13]
14	)	O	['N']	[14]
15	and	O	['N']	[15]
16	adaptive	O	['N']	[16]
17	optics	O	['N']	[17]
18	(	O	['N']	[18]
19	AO	O	['N']	[19]
20	)	O	['N']	[20]
21	imaging	O	['N']	[21]
22	in	O	['N']	[22]
23	hydroxychloroquine	B-Drug	['Causes']	[25]
24	retinal	B	['N']	[24]
25	toxicity	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#562
0	Autopsy	O	['N']	[0]
1	evidence	O	['N']	[1]
2	of	O	['N']	[2]
3	herpesvirus	B	['N']	[3]
4	infection	I-Adverse_Effect	['N']	[4]
5	was	O	['N']	[5]
6	found	O	['N']	[6]
7	in	O	['N']	[7]
8	visceral	O	['N']	[8]
9	organs	O	['N']	[9]
10	of	O	['N']	[10]
11	four	O	['N']	[11]
12	leukemic	O	['N']	[12]
13	patients	O	['N']	[13]
14	who	O	['N']	[14]
15	had	O	['N']	[15]
16	received	O	['N']	[16]
17	large	O	['N']	[17]
18	doses	O	['N']	[18]
19	of	O	['N']	[19]
20	cytarabine	O	['N']	[20]
21	(	O	['N']	[21]
22	cytosine	B	['N']	[22]
23	arabinoside	I-Drug	['Causes']	[4]
24	;	O	['N']	[24]
25	Ara	O	['N']	[25]
26	-	O	['N']	[26]
27	C	O	['N']	[27]
28	)	O	['N']	[28]
29	shortly	O	['N']	[29]
30	before	O	['N']	[30]
31	their	O	['N']	[31]
32	death	O	['N']	[32]
33	.	O	['N']	[33]
#563
0	Warfarin	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	skin	O	['N']	[3]
4	necrosis	O	['N']	[4]
5	and	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	thrombocytopenia	B-Adverse_Effect	['N']	[9]
10	following	O	['N']	[10]
11	mitral	O	['N']	[11]
12	valve	O	['N']	[12]
13	replacement	O	['N']	[13]
14	for	O	['N']	[14]
15	marantic	O	['N']	[15]
16	endocarditis	O	['N']	[16]
17	.	O	['N']	[17]
#564
0	Gemcitabine	B-Drug	['Causes']	[11]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	known	O	['N']	[3]
4	risk	O	['N']	[4]
5	factor	O	['N']	[5]
6	for	O	['N']	[6]
7	hemolytic	O	['N']	[7]
8	uremic	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	(	O	['N']	[10]
11	HUS	B-Adverse_Effect	['N']	[11]
12	)	O	['N']	[12]
13	,	O	['N']	[13]
14	which	O	['N']	[14]
15	can	O	['N']	[15]
16	often	O	['N']	[16]
17	have	O	['N']	[17]
18	a	O	['N']	[18]
19	rapidly	O	['N']	[19]
20	fatal	O	['N']	[20]
21	clinical	O	['N']	[21]
22	course	O	['N']	[22]
23	despite	O	['N']	[23]
24	intervention	O	['N']	[24]
25	with	O	['N']	[25]
26	steroids	O	['N']	[26]
27	,	O	['N']	[27]
28	plasmapheresis	O	['N']	[28]
29	and	O	['N']	[29]
30	hemodialysis	O	['N']	[30]
31	.	O	['N']	[31]
#565
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	severe	O	['N']	[5]
6	erosive	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	and	O	['N']	[9]
10	rheumatoid	O	['N']	[10]
11	vasculitis	O	['N']	[11]
12	,	O	['N']	[12]
13	respectively	O	['N']	[13]
14	,	O	['N']	[14]
15	in	O	['N']	[15]
16	whom	O	['N']	[16]
17	infliximab	B-Drug	['Causes']	[37]
18	therapy	O	['N']	[18]
19	was	O	['N']	[19]
20	associated	O	['N']	[20]
21	with	O	['N']	[21]
22	peripheral	O	['N']	[22]
23	neuropathy	O	['N']	[23]
24	due	O	['N']	[24]
25	to	O	['N']	[25]
26	necrotizing	O	['N']	[26]
27	vasculitis	O	['N']	[27]
28	in	O	['N']	[28]
29	one	O	['N']	[29]
30	patient	O	['N']	[30]
31	and	O	['N']	[31]
32	to	O	['N']	[32]
33	progression	B	['N']	[33]
34	of	I	['N']	[34]
35	preexisting	I	['N']	[35]
36	mononeuritis	I	['N']	[36]
37	multiplex	I-Adverse_Effect	['N']	[37]
38	in	O	['N']	[38]
39	the	O	['N']	[39]
40	other	O	['N']	[40]
41	.	O	['N']	[41]
#566
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	stroke	B-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	PPA	B-Drug	['Causes']	[5]
8	ingestion	O	['N']	[8]
9	that	O	['N']	[9]
10	occurred	O	['N']	[10]
11	4	O	['N']	[11]
12	months	O	['N']	[12]
13	after	O	['N']	[13]
14	the	O	['N']	[14]
15	recall	O	['N']	[15]
16	in	O	['N']	[16]
17	an	O	['N']	[17]
18	8-year	O	['N']	[18]
19	-	O	['N']	[19]
20	old	O	['N']	[20]
21	boy	O	['N']	[21]
22	on	O	['N']	[22]
23	chronic	O	['N']	[23]
24	peritoneal	O	['N']	[24]
25	dialysis	O	['N']	[25]
26	.	O	['N']	[26]
#567
0	Fatal	B	['N']	[0]
1	lung	I	['N']	[1]
2	fibrosis	I-Adverse_Effect	['N']	[2]
3	caused	O	['N']	[3]
4	by	O	['N']	[4]
5	paclitaxel	B-Drug	['Causes']	[2]
6	toxicity	O	['N']	[6]
7	has	O	['N']	[7]
8	not	O	['N']	[8]
9	been	O	['N']	[9]
10	reported	O	['N']	[10]
11	In	O	['N']	[11]
12	this	O	['N']	[12]
13	report	O	['N']	[13]
14	,	O	['N']	[14]
15	we	O	['N']	[15]
16	describe	O	['N']	[16]
17	the	O	['N']	[17]
18	case	O	['N']	[18]
19	of	O	['N']	[19]
20	a	O	['N']	[20]
21	62-year	O	['N']	[21]
22	-	O	['N']	[22]
23	old	O	['N']	[23]
24	woman	O	['N']	[24]
25	who	O	['N']	[25]
26	received	O	['N']	[26]
27	six	O	['N']	[27]
28	cycles	O	['N']	[28]
29	of	O	['N']	[29]
30	paclitaxel	O	['N']	[30]
31	and	O	['N']	[31]
32	carboplatin	O	['N']	[32]
33	as	O	['N']	[33]
34	combination	O	['N']	[34]
35	chemotherapy	O	['N']	[35]
36	for	O	['N']	[36]
37	advanced	O	['N']	[37]
38	ovarian	O	['N']	[38]
39	cancer	O	['N']	[39]
40	.	O	['N']	[40]
#568
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	restless	B	['N']	[3]
4	legs	I	['N']	[4]
5	symptoms	I-Adverse_Effect	['N']	[5]
6	paralleling	O	['N']	[6]
7	the	O	['N']	[7]
8	course	O	['N']	[8]
9	of	O	['N']	[9]
10	interferon	B	['N']	[10]
11	-	I	['N']	[11]
12	alpha	I-Drug	['Causes']	[5]
13	(	O	['N']	[13]
14	IFN	O	['N']	[14]
15	alpha	O	['N']	[15]
16	)	O	['N']	[16]
17	therapy	O	['N']	[17]
18	for	O	['N']	[18]
19	chronic	O	['N']	[19]
20	hepatitis	O	['N']	[20]
21	C.	O	['N']	[21]
#569
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	74-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	with	O	['N']	[7]
8	rheumatoid	O	['N']	[8]
9	arthritis	O	['N']	[9]
10	(	O	['N']	[10]
11	RA	O	['N']	[11]
12	)	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	of	O	['N']	[16]
17	inappropriate	O	['N']	[17]
18	secretion	O	['N']	[18]
19	of	O	['N']	[19]
20	antidiuretic	O	['N']	[20]
21	hormone	O	['N']	[21]
22	(	O	['N']	[22]
23	SIADH	B-Adverse_Effect	['N']	[23]
24	)	O	['N']	[24]
25	1.5	O	['N']	[25]
26	months	O	['N']	[26]
27	after	O	['N']	[27]
28	commencement	O	['N']	[28]
29	of	O	['N']	[29]
30	mizoribin	B-Drug	['Causes']	[23]
31	prescription	O	['N']	[31]
32	when	O	['N']	[32]
33	his	O	['N']	[33]
34	arthritis	O	['N']	[34]
35	was	O	['N']	[35]
36	improved	O	['N']	[36]
37	.	O	['N']	[37]
#570
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	B-Drug	['Causes']	[27]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	O	['N']	[34]
35	.	O	['N']	[35]
#571
0	Primary	O	['N']	[0]
1	CNS	B	['N']	[1]
2	lymphoma	I-Adverse_Effect	['N']	[2]
3	regressed	O	['N']	[3]
4	on	O	['N']	[4]
5	withdrawal	O	['N']	[5]
6	of	O	['N']	[6]
7	MM	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#572
0	Peripheral	B	['N']	[0]
1	nerve	I	['N']	[1]
2	dysfunction	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	potentially	O	['N']	[5]
6	serious	O	['N']	[6]
7	complication	O	['N']	[7]
8	of	O	['N']	[8]
9	high	O	['N']	[9]
10	-	O	['N']	[10]
11	dose	O	['N']	[11]
12	cytosine	B	['N']	[12]
13	arabinoside	I-Drug	['Causes']	[2]
14	.	O	['N']	[14]
#573
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	keep	O	['N']	[2]
3	in	O	['N']	[3]
4	mind	O	['N']	[4]
5	that	O	['N']	[5]
6	taxanes	O	['N']	[6]
7	such	O	['N']	[7]
8	as	O	['N']	[8]
9	paclitaxel	B-Drug	['Causes']	[18]
10	have	O	['N']	[10]
11	the	O	['N']	[11]
12	potential	O	['N']	[12]
13	to	O	['N']	[13]
14	cause	O	['N']	[14]
15	pneumonitis	O	['N']	[15]
16	and	O	['N']	[16]
17	lung	B	['N']	[17]
18	fibrosis	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#574
0	These	O	['N']	[0]
1	evolutional	O	['N']	[1]
2	changes	O	['N']	[2]
3	in	O	['N']	[3]
4	both	O	['N']	[4]
5	proteinuria	O	['N']	[5]
6	and	O	['N']	[6]
7	glomerular	O	['N']	[7]
8	histology	O	['N']	[8]
9	suggest	O	['N']	[9]
10	a	O	['N']	[10]
11	close	O	['N']	[11]
12	linkage	O	['N']	[12]
13	between	O	['N']	[13]
14	the	O	['N']	[14]
15	M	B	['N']	[15]
16	-	I	['N']	[16]
17	CSF	I-Drug	['Causes']	[24]
18	treatment	O	['N']	[18]
19	and	O	['N']	[19]
20	macrophage	B	['N']	[20]
21	-	I	['N']	[21]
22	related	I	['N']	[22]
23	glomerular	I	['N']	[23]
24	injury	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#575
0	Theophylline	B	['N']	[0]
1	intoxication	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	viloxazine	B-Drug	['Causes']	[1]
4	induced	O	['N']	[4]
5	decrease	O	['N']	[5]
6	in	O	['N']	[6]
7	clearance	O	['N']	[7]
8	.	O	['N']	[8]
#576
0	NCSE	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	an	O	['N']	[2]
3	epileptic	O	['N']	[3]
4	disorder	O	['N']	[4]
5	in	O	['N']	[5]
6	which	O	['N']	[6]
7	typical	O	['N']	[7]
8	convulsive	O	['N']	[8]
9	activity	O	['N']	[9]
10	is	O	['N']	[10]
11	absent	O	['N']	[11]
12	,	O	['N']	[12]
13	has	O	['N']	[13]
14	previously	O	['N']	[14]
15	been	O	['N']	[15]
16	reported	O	['N']	[16]
17	in	O	['N']	[17]
18	only	O	['N']	[18]
19	4	O	['N']	[19]
20	patients	O	['N']	[20]
21	receiving	O	['N']	[21]
22	ifosfamide	B-Drug	['Causes']	[0]
23	.	O	['N']	[23]
#577
0	The	O	['N']	[0]
1	presence	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	lymphocyte	O	['N']	[4]
5	alveolitis	O	['N']	[5]
6	with	O	['N']	[6]
7	a	O	['N']	[7]
8	predominance	O	['N']	[8]
9	of	O	['N']	[9]
10	CD4	O	['N']	[10]
11	+	O	['N']	[11]
12	T	O	['N']	[12]
13	cells	O	['N']	[13]
14	in	O	['N']	[14]
15	3	O	['N']	[15]
16	RA	O	['N']	[16]
17	patients	O	['N']	[17]
18	and	O	['N']	[18]
19	CD8	O	['N']	[19]
20	+	O	['N']	[20]
21	T	O	['N']	[21]
22	cells	O	['N']	[22]
23	with	O	['N']	[23]
24	a	O	['N']	[24]
25	concomitant	O	['N']	[25]
26	increase	O	['N']	[26]
27	in	O	['N']	[27]
28	neutrophils	O	['N']	[28]
29	in	O	['N']	[29]
30	another	O	['N']	[30]
31	case	O	['N']	[31]
32	suggests	O	['N']	[32]
33	that	O	['N']	[33]
34	immunologically	O	['N']	[34]
35	mediated	O	['N']	[35]
36	reactions	O	['N']	[36]
37	may	O	['N']	[37]
38	be	O	['N']	[38]
39	one	O	['N']	[39]
40	damage	O	['N']	[40]
41	mechanism	O	['N']	[41]
42	in	O	['N']	[42]
43	MTX	B-Drug	['Causes']	[46]
44	-	O	['N']	[44]
45	induced	O	['N']	[45]
46	pneumonitis	B-Adverse_Effect	['N']	[46]
47	.	O	['N']	[47]
#578
0	The	O	['N']	[0]
1	aim	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	study	O	['N']	[4]
5	was	O	['N']	[5]
6	to	O	['N']	[6]
7	describe	O	['N']	[7]
8	the	O	['N']	[8]
9	occurrence	O	['N']	[9]
10	of	O	['N']	[10]
11	acute	B	['N']	[11]
12	coronary	I	['N']	[12]
13	syndromes	I-Adverse_Effect	['N']	[13]
14	in	O	['N']	[14]
15	3	O	['N']	[15]
16	cases	O	['N']	[16]
17	of	O	['N']	[17]
18	rituximab	B-Drug	['Causes']	[13]
19	infusions	O	['N']	[19]
20	.	O	['N']	[20]
#579
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	had	O	['N']	[8]
9	undergone	O	['N']	[9]
10	cholecystectomy	O	['N']	[10]
11	previously	O	['N']	[11]
12	,	O	['N']	[12]
13	but	O	['N']	[13]
14	in	O	['N']	[14]
15	whom	O	['N']	[15]
16	morphine	B-Drug	['Causes']	[27]
17	given	O	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	Emergency	O	['N']	[20]
21	Department	O	['N']	[21]
22	precipitated	O	['N']	[22]
23	pain	O	['N']	[23]
24	consistent	O	['N']	[24]
25	with	O	['N']	[25]
26	biliary	B	['N']	[26]
27	colic	I-Adverse_Effect	['N']	[27]
28	;	O	['N']	[28]
29	the	O	['N']	[29]
30	pain	O	['N']	[30]
31	resolved	O	['N']	[31]
32	promptly	O	['N']	[32]
33	after	O	['N']	[33]
34	administration	O	['N']	[34]
35	of	O	['N']	[35]
36	naloxone	O	['N']	[36]
37	.	O	['N']	[37]
#580
0	Because	O	['N']	[0]
1	the	O	['N']	[1]
2	combination	O	['N']	[2]
3	of	O	['N']	[3]
4	bleomycin	B-Drug	['Causes']	[32]
5	and	O	['N']	[5]
6	vinca	O	['N']	[6]
7	alkaloids	O	['N']	[7]
8	is	O	['N']	[8]
9	commonly	O	['N']	[9]
10	used	O	['N']	[10]
11	for	O	['N']	[11]
12	the	O	['N']	[12]
13	treatment	O	['N']	[13]
14	of	O	['N']	[14]
15	AIDS	O	['N']	[15]
16	-	O	['N']	[16]
17	related	O	['N']	[17]
18	Kaposi	O	['N']	[18]
19	's	O	['N']	[19]
20	sarcoma	O	['N']	[20]
21	,	O	['N']	[21]
22	clinicians	O	['N']	[22]
23	should	O	['N']	[23]
24	be	O	['N']	[24]
25	aware	O	['N']	[25]
26	of	O	['N']	[26]
27	the	O	['N']	[27]
28	risk	O	['N']	[28]
29	of	O	['N']	[29]
30	provoking	O	['N']	[30]
31	acral	B	['N']	[31]
32	necrosis	I-Adverse_Effect	['N']	[32]
33	in	O	['N']	[33]
34	patients	O	['N']	[34]
35	who	O	['N']	[35]
36	develop	O	['N']	[36]
37	Raynaud	O	['N']	[37]
38	's	O	['N']	[38]
39	phenomenon	O	['N']	[39]
40	under	O	['N']	[40]
41	chemotherapy	O	['N']	[41]
42	.	O	['N']	[42]
#581
0	Graft	O	['N']	[0]
1	versus	O	['N']	[1]
2	host	O	['N']	[2]
3	-	O	['N']	[3]
4	like	O	['N']	[4]
5	illness	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	child	O	['N']	[8]
9	with	O	['N']	[9]
10	phenobarbital	B-Drug	['Causes']	[11]
11	hypersensitivity	B-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#582
0	Pheripheral	B	['N']	[0]
1	edema	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	in	O	['N']	[4]
5	five	O	['N']	[5]
6	female	O	['N']	[6]
7	patients	O	['N']	[7]
8	after	O	['N']	[8]
9	taking	O	['N']	[9]
10	proton	O	['N']	[10]
11	pump	O	['N']	[11]
12	inhibitors	O	['N']	[12]
13	omeprazole	O	['N']	[13]
14	,	O	['N']	[14]
15	lansoprazole	B-Drug	['Causes']	[1]
16	,	O	['N']	[16]
17	or	O	['N']	[17]
18	pantoprazole	O	['N']	[18]
19	for	O	['N']	[19]
20	7	O	['N']	[20]
21	-	O	['N']	[21]
22	15	O	['N']	[22]
23	days	O	['N']	[23]
24	for	O	['N']	[24]
25	peptic	O	['N']	[25]
26	acid	O	['N']	[26]
27	diseases	O	['N']	[27]
28	in	O	['N']	[28]
29	recommended	O	['N']	[29]
30	standard	O	['N']	[30]
31	doses	O	['N']	[31]
32	.	O	['N']	[32]
#583
0	Simvastatin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	rhabdomyolysis	B-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	cyclosporine	O	['N']	[5]
6	treatment	O	['N']	[6]
7	for	O	['N']	[7]
8	uveitis	O	['N']	[8]
9	.	O	['N']	[9]
#584
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	fatal	B	['N']	[5]
6	stroke	I-Adverse_Effect	['N']	[6]
7	may	O	['N']	[7]
8	have	O	['N']	[8]
9	resulted	O	['N']	[9]
10	from	O	['N']	[10]
11	arterial	O	['N']	[11]
12	spasm	O	['N']	[12]
13	caused	O	['N']	[13]
14	by	O	['N']	[14]
15	ergotamine	B-Drug	['Causes']	[6]
16	overdosage	O	['N']	[16]
17	and	O	['N']	[17]
18	possibly	O	['N']	[18]
19	complicated	O	['N']	[19]
20	by	O	['N']	[20]
21	thrombosis	O	['N']	[21]
22	.	O	['N']	[22]
#585
0	Polymyositis	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	complication	O	['N']	[4]
5	of	O	['N']	[5]
6	interferon	B	['N']	[6]
7	alpha	I-Drug	['Causes']	[0]
8	treatment	O	['N']	[8]
9	as	O	['N']	[9]
10	a	O	['N']	[10]
11	result	O	['N']	[11]
12	of	O	['N']	[12]
13	immune	O	['N']	[13]
14	-	O	['N']	[14]
15	modulating	O	['N']	[15]
16	role	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	drug	O	['N']	[19]
20	itself	O	['N']	[20]
21	.	O	['N']	[21]
#586
0	Our	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	a	O	['N']	[3]
4	72-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	with	O	['N']	[8]
9	advanced	O	['N']	[9]
10	Parkinson	O	['N']	[10]
11	's	O	['N']	[11]
12	disease	O	['N']	[12]
13	(	O	['N']	[13]
14	PD	O	['N']	[14]
15	)	O	['N']	[15]
16	who	O	['N']	[16]
17	received	O	['N']	[17]
18	levodopa	B-Drug	['Causes']	[31]
19	and	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	cholinergic	O	['N']	[22]
23	drugs	O	['N']	[23]
24	and	O	['N']	[24]
25	whose	O	['N']	[25]
26	head	O	['N']	[26]
27	had	O	['N']	[27]
28	become	O	['N']	[28]
29	almost	O	['N']	[29]
30	completely	B	['N']	[30]
31	bald	I-Adverse_Effect	['N']	[31]
32	.	O	['N']	[32]
#587
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	,	O	['N']	[3]
4	interferon	B	['N']	[4]
5	alpha	I-Drug	['Causes']	[7]
6	induced	O	['N']	[6]
7	polymyositis	B-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	cardiomyopathy	O	['N']	[9]
10	is	O	['N']	[10]
11	diagnosed	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	33-yr	O	['N']	[14]
15	-	O	['N']	[15]
16	old	O	['N']	[16]
17	male	O	['N']	[17]
18	patient	O	['N']	[18]
19	with	O	['N']	[19]
20	history	O	['N']	[20]
21	of	O	['N']	[21]
22	chronic	O	['N']	[22]
23	hepatitis	O	['N']	[23]
24	B.	O	['N']	[24]
#588
0	A	O	['N']	[0]
1	62-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	pranlukast	B-Drug	['Causes']	[13]
8	for	O	['N']	[8]
9	2	O	['N']	[9]
10	months	O	['N']	[10]
11	developed	O	['N']	[11]
12	interstitial	B	['N']	[12]
13	pneumonitis	I-Adverse_Effect	['N']	[13]
14	with	O	['N']	[14]
15	a	O	['N']	[15]
16	high	O	['N']	[16]
17	fever	O	['N']	[17]
18	.	O	['N']	[18]
#589
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Fixed	O	['N']	[2]
3	drug	O	['N']	[3]
4	eruption	B-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	many	O	['N']	[8]
9	drugs	O	['N']	[9]
10	but	O	['N']	[10]
11	this	O	['N']	[11]
12	is	O	['N']	[12]
13	the	O	['N']	[13]
14	first	O	['N']	[14]
15	such	O	['N']	[15]
16	report	O	['N']	[16]
17	with	O	['N']	[17]
18	omeprazole	B-Drug	['Causes']	[4]
19	.	O	['N']	[19]
#590
0	Well	O	['N']	[0]
1	-	O	['N']	[1]
2	known	O	['N']	[2]
3	signs	O	['N']	[3]
4	of	O	['N']	[4]
5	methotrexate	B-Drug	['Causes']	[6]
6	toxicity	I-Adverse_Effect	['N']	[6]
7	include	O	['N']	[7]
8	bone	O	['N']	[8]
9	marrow	O	['N']	[9]
10	suppression	O	['N']	[10]
11	and	O	['N']	[11]
12	oral	O	['N']	[12]
13	and	O	['N']	[13]
14	gastrointestinal	O	['N']	[14]
15	ulceration	O	['N']	[15]
16	.	O	['N']	[16]
#591
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Reproductive	B	['N']	[2]
3	endocrine	I	['N']	[3]
4	disorders	I-Adverse_Effect	['N']	[4]
5	characterized	O	['N']	[5]
6	by	O	['N']	[6]
7	menstrual	O	['N']	[7]
8	disorders	O	['N']	[8]
9	,	O	['N']	[9]
10	polycystic	O	['N']	[10]
11	ovaries	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	hyperandrogenism	O	['N']	[14]
15	seem	O	['N']	[15]
16	to	O	['N']	[16]
17	be	O	['N']	[17]
18	common	O	['N']	[18]
19	among	O	['N']	[19]
20	women	O	['N']	[20]
21	treated	O	['N']	[21]
22	with	O	['N']	[22]
23	sodium	B	['N']	[23]
24	valproate	I-Drug	['Causes']	[4]
25	for	O	['N']	[25]
26	epilepsy	O	['N']	[26]
27	.	O	['N']	[27]
#592
0	PURPOSE	O	['N']	[0]
1	/	O	['N']	[1]
2	OBJECTIVES	O	['N']	[2]
3	:	O	['N']	[3]
4	To	O	['N']	[4]
5	describe	O	['N']	[5]
6	the	O	['N']	[6]
7	pharmacogenetic	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	of	O	['N']	[9]
10	dihydropyrimidine	O	['N']	[10]
11	dehydrogenase	O	['N']	[11]
12	(	O	['N']	[12]
13	DPD	O	['N']	[13]
14	)	O	['N']	[14]
15	deficiency	O	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	predisposes	O	['N']	[18]
19	patients	O	['N']	[19]
20	with	O	['N']	[20]
21	cancer	O	['N']	[21]
22	to	O	['N']	[22]
23	potentially	O	['N']	[23]
24	lethal	B	['N']	[24]
25	adverse	I	['N']	[25]
26	reactions	I-Adverse_Effect	['N']	[26]
27	following	O	['N']	[27]
28	5-fluorouracil	O	['N']	[28]
29	(	O	['N']	[29]
30	5-FU)-based	-	['N']	[30]
31	chemotherapy	O	['N']	[31]
32	.	O	['N']	[32]
#593
0	Seizures	B-Adverse_Effect	['N']	[0]
1	occurred	O	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	probable	O	['N']	[6]
7	Alzheimer	O	['N']	[7]
8	's	O	['N']	[8]
9	disease	O	['N']	[9]
10	who	O	['N']	[10]
11	were	O	['N']	[11]
12	receiving	O	['N']	[12]
13	long	O	['N']	[13]
14	-	O	['N']	[14]
15	term	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	metrifonate	B-Drug	['Causes']	[0]
19	,	O	['N']	[19]
20	an	O	['N']	[20]
21	irreversible	O	['N']	[21]
22	acetylcholinesterase	O	['N']	[22]
23	inhibitor	O	['N']	[23]
24	.	O	['N']	[24]
#594
0	Surgeons	O	['N']	[0]
1	and	O	['N']	[1]
2	physicians	O	['N']	[2]
3	should	O	['N']	[3]
4	therefore	O	['N']	[4]
5	be	O	['N']	[5]
6	aware	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	potential	O	['N']	[9]
10	for	O	['N']	[10]
11	RTA	B-Adverse_Effect	['N']	[11]
12	to	O	['N']	[12]
13	occur	O	['N']	[13]
14	with	O	['N']	[14]
15	FK506	B-Drug	['Causes']	[11]
16	after	O	['N']	[16]
17	any	O	['N']	[17]
18	organ	O	['N']	[18]
19	transplantation	O	['N']	[19]
20	.	O	['N']	[20]
#595
0	Acute	B	['N']	[0]
1	respiratory	I	['N']	[1]
2	depression	I-Adverse_Effect	['N']	[2]
3	as	O	['N']	[3]
4	a	O	['N']	[4]
5	complication	O	['N']	[5]
6	of	O	['N']	[6]
7	nebulised	O	['N']	[7]
8	morphine	B-Drug	['Causes']	[2]
9	.	O	['N']	[9]
#596
0	The	O	['N']	[0]
1	more	O	['N']	[1]
2	common	O	['N']	[2]
3	grade	O	['N']	[3]
4	3	O	['N']	[4]
5	or	O	['N']	[5]
6	4	O	['N']	[6]
7	adverse	O	['N']	[7]
8	effects	O	['N']	[8]
9	of	O	['N']	[9]
10	sunitinib	B-Drug	['Causes']	[19]
11	include	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	,	O	['N']	[13]
14	fatigue	O	['N']	[14]
15	,	O	['N']	[15]
16	hand	B	['N']	[16]
17	-	I	['N']	[17]
18	foot	I	['N']	[18]
19	syndrome	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	elevated	O	['N']	[21]
22	lipase	O	['N']	[22]
23	and	O	['N']	[23]
24	lymphopenia	O	['N']	[24]
25	.	O	['N']	[25]
#597
0	The	O	['N']	[0]
1	chemotherapeutics	O	['N']	[1]
2	,	O	['N']	[2]
3	including	O	['N']	[3]
4	vincristine	B-Drug	['Causes']	[27]
5	,	O	['N']	[5]
6	actinomycin	O	['N']	[6]
7	D	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	epirubicin	O	['N']	[10]
11	in	O	['N']	[11]
12	case	O	['N']	[12]
13	1	O	['N']	[13]
14	and	O	['N']	[14]
15	vincristine	O	['N']	[15]
16	and	O	['N']	[16]
17	actinomycin	O	['N']	[17]
18	D	O	['N']	[18]
19	in	O	['N']	[19]
20	case	O	['N']	[20]
21	2	O	['N']	[21]
22	,	O	['N']	[22]
23	were	O	['N']	[23]
24	given	O	['N']	[24]
25	before	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatotoxicity	B-Adverse_Effect	['N']	[27]
28	developed	O	['N']	[28]
29	.	O	['N']	[29]
#598
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	study	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	unusual	B	['N']	[8]
9	weight	I	['N']	[9]
10	fluctuation	I-Adverse_Effect	['N']	[10]
11	under	O	['N']	[11]
12	corticosteroid	O	['N']	[12]
13	and	O	['N']	[13]
14	psychotropic	O	['N']	[14]
15	treatment	O	['N']	[15]
16	such	O	['N']	[16]
17	as	O	['N']	[17]
18	mianserin	B-Drug	['Causes']	[10]
19	and	O	['N']	[19]
20	aripiprazole	O	['N']	[20]
21	.	O	['N']	[21]
#599
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	osteosarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	normal	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	manifested	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	impending	O	['N']	[15]
16	renal	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	and	O	['N']	[18]
19	extreme	O	['N']	[19]
20	elevation	O	['N']	[20]
21	of	O	['N']	[21]
22	aspartate	O	['N']	[22]
23	aminotrasferase	O	['N']	[23]
24	and	O	['N']	[24]
25	alanine	O	['N']	[25]
26	aminotransferase	O	['N']	[26]
27	within	O	['N']	[27]
28	2	O	['N']	[28]
29	hours	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	completion	O	['N']	[32]
33	of	O	['N']	[33]
34	a	O	['N']	[34]
35	4-hour	O	['N']	[35]
36	infusion	O	['N']	[36]
37	of	O	['N']	[37]
38	high	O	['N']	[38]
39	-	O	['N']	[39]
40	dose	O	['N']	[40]
41	methotrexate	O	['N']	[41]
42	(	O	['N']	[42]
43	MTX	B-Drug	['Causes']	[59]
44	)	O	['N']	[44]
45	(	O	['N']	[45]
46	12	O	['N']	[46]
47	g	O	['N']	[47]
48	/	O	['N']	[48]
49	m2	O	['N']	[49]
50	)	O	['N']	[50]
51	,	O	['N']	[51]
52	and	O	['N']	[52]
53	went	O	['N']	[53]
54	on	O	['N']	[54]
55	to	O	['N']	[55]
56	develop	O	['N']	[56]
57	acute	B	['N']	[57]
58	renal	I	['N']	[58]
59	failure	I-Adverse_Effect	['N']	[59]
60	with	O	['N']	[60]
61	life	O	['N']	[61]
62	-	O	['N']	[62]
63	threatening	O	['N']	[63]
64	hyperkalemia	O	['N']	[64]
65	29	O	['N']	[65]
66	hours	O	['N']	[66]
67	later	O	['N']	[67]
68	.	O	['N']	[68]
#600
0	Primary	O	['N']	[0]
1	CNS	B	['N']	[1]
2	lymphoma	I-Adverse_Effect	['N']	[2]
3	complicating	O	['N']	[3]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	myasthenia	O	['N']	[6]
7	gravis	O	['N']	[7]
8	with	O	['N']	[8]
9	mycophenolate	B	['N']	[9]
10	mofetil	I-Drug	['Causes']	[2]
11	.	O	['N']	[11]
#601
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	unusual	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	massive	O	['N']	[6]
7	fluoxetine	B-Drug	['Causes']	[17]
8	ingestion	O	['N']	[8]
9	resulting	O	['N']	[9]
10	in	O	['N']	[10]
11	neurological	O	['N']	[11]
12	and	O	['N']	[12]
13	cardiovascular	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	resulting	O	['N']	[15]
16	in	O	['N']	[16]
17	death	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#602
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	typical	O	['N']	[5]
6	symptoms	O	['N']	[6]
7	of	O	['N']	[7]
8	Charles	O	['N']	[8]
9	-	O	['N']	[9]
10	Bonnet	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	(	O	['N']	[12]
13	CBS	B-Adverse_Effect	['N']	[13]
14	)	O	['N']	[14]
15	in	O	['N']	[15]
16	patients	O	['N']	[16]
17	with	O	['N']	[17]
18	severe	O	['N']	[18]
19	AMD	O	['N']	[19]
20	after	O	['N']	[20]
21	intravitreal	O	['N']	[21]
22	Avastin	B-Drug	['Causes']	[13]
23	-	O	['N']	[23]
24	injections	O	['N']	[24]
25	.	O	['N']	[25]
#603
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	B-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	B-Drug	['Causes']	[29]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#604
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	young	O	['N']	[6]
7	man	O	['N']	[7]
8	,	O	['N']	[8]
9	affected	O	['N']	[9]
10	by	O	['N']	[10]
11	rheumatoid	O	['N']	[11]
12	arthritis	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	a	O	['N']	[15]
16	rapid	O	['N']	[16]
17	-	O	['N']	[17]
18	onset	O	['N']	[18]
19	short	O	['N']	[19]
20	-	O	['N']	[20]
21	of	O	['N']	[21]
22	-	O	['N']	[22]
23	breath	O	['N']	[23]
24	,	O	['N']	[24]
25	hemoptysis	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	severe	B	['N']	[28]
29	weakness	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	about	O	['N']	[31]
32	2	O	['N']	[32]
33	weeks	O	['N']	[33]
34	after	O	['N']	[34]
35	the	O	['N']	[35]
36	administration	O	['N']	[36]
37	of	O	['N']	[37]
38	leflunomide	B-Drug	['Causes']	[29]
39	.	O	['N']	[39]
#605
0	Acute	B	['N']	[0]
1	renal	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	intravenous	O	['N']	[4]
5	immunoglobulin	B-Drug	['Causes']	[2]
6	therapy	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	HIV	O	['N']	[9]
10	-	O	['N']	[10]
11	infected	O	['N']	[11]
12	patient	O	['N']	[12]
13	.	O	['N']	[13]
#606
0	Four	O	['N']	[0]
1	patients	O	['N']	[1]
2	receiving	O	['N']	[2]
3	high	O	['N']	[3]
4	-	O	['N']	[4]
5	dose	O	['N']	[5]
6	tamoxifen	B-Drug	['Causes']	[16]
7	for	O	['N']	[7]
8	greater	O	['N']	[8]
9	than	O	['N']	[9]
10	1	O	['N']	[10]
11	year	O	['N']	[11]
12	have	O	['N']	[12]
13	demonstrated	O	['N']	[13]
14	similar	O	['N']	[14]
15	retinal	B	['N']	[15]
16	changes	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#607
0	Upper	B	['N']	[0]
1	tract	I	['N']	[1]
2	urothelial	I	['N']	[2]
3	malignancy	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	cyclophosphamide	B-Drug	['Causes']	[3]
6	therapy	O	['N']	[6]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	and	O	['N']	[11]
12	literature	O	['N']	[12]
13	review	O	['N']	[13]
14	.	O	['N']	[14]
#608
0	CASE	O	['N']	[0]
1	PRESENTATION	O	['N']	[1]
2	:	O	['N']	[2]
3	Three	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	Leishmania	O	['N']	[6]
7	infantum	O	['N']	[7]
8	leishmaniasis	O	['N']	[8]
9	in	O	['N']	[9]
10	corticosteroid	O	['N']	[10]
11	(	O	['N']	[11]
12	CS)-treated	-	['N']	[12]
13	patients	O	['N']	[13]
14	are	O	['N']	[14]
15	reported	O	['N']	[15]
16	:	O	['N']	[16]
17	an	O	['N']	[17]
18	isolated	O	['N']	[18]
19	lingual	B	['N']	[19]
20	leishmaniasis	I-Adverse_Effect	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	farmer	O	['N']	[23]
24	treated	O	['N']	[24]
25	with	O	['N']	[25]
26	CS	O	['N']	[26]
27	for	O	['N']	[27]
28	asthma	O	['N']	[28]
29	,	O	['N']	[29]
30	a	O	['N']	[30]
31	severe	O	['N']	[31]
32	visceral	O	['N']	[32]
33	leishmaniasis	O	['N']	[33]
34	associated	O	['N']	[34]
35	with	O	['N']	[35]
36	cutaneous	O	['N']	[36]
37	lesions	O	['N']	[37]
38	in	O	['N']	[38]
39	a	O	['N']	[39]
40	woman	O	['N']	[40]
41	with	O	['N']	[41]
42	myasthenia	O	['N']	[42]
43	gravis	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	a	O	['N']	[46]
47	visceral	O	['N']	[47]
48	involvement	O	['N']	[48]
49	after	O	['N']	[49]
50	cutaneous	O	['N']	[50]
51	leishmaniasis	O	['N']	[51]
52	in	O	['N']	[52]
53	a	O	['N']	[53]
54	man	O	['N']	[54]
55	receiving	O	['N']	[55]
56	CS	O	['N']	[56]
57	.	O	['N']	[57]
#609
0	Asthma	O	['N']	[0]
1	and	O	['N']	[1]
2	urticaria	B-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	disodium	B	['N']	[4]
5	cromoglycate	I-Drug	['Causes']	[2]
6	treatment	O	['N']	[6]
7	.	O	['N']	[7]
#610
0	The	O	['N']	[0]
1	autopsy	O	['N']	[1]
2	findings	O	['N']	[2]
3	and	O	['N']	[3]
4	a	O	['N']	[4]
5	detailed	O	['N']	[5]
6	medical	O	['N']	[6]
7	history	O	['N']	[7]
8	supported	O	['N']	[8]
9	the	O	['N']	[9]
10	conclusion	O	['N']	[10]
11	that	O	['N']	[11]
12	clozapine	B-Drug	['Causes']	[16]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	hypersensitivity	B	['N']	[15]
16	myocarditis	I-Adverse_Effect	['N']	[16]
17	was	O	['N']	[17]
18	the	O	['N']	[18]
19	most	O	['N']	[19]
20	likely	O	['N']	[20]
21	cause	O	['N']	[21]
22	of	O	['N']	[22]
23	death	O	['N']	[23]
24	.	O	['N']	[24]
#611
0	Zidovudine	B-Drug	['Causes']	[15]
1	use	O	['N']	[1]
2	in	O	['N']	[2]
3	pregnancy	O	['N']	[3]
4	:	O	['N']	[4]
5	a	O	['N']	[5]
6	report	O	['N']	[6]
7	on	O	['N']	[7]
8	104	O	['N']	[8]
9	cases	O	['N']	[9]
10	and	O	['N']	[10]
11	the	O	['N']	[11]
12	occurrence	O	['N']	[12]
13	of	O	['N']	[13]
14	birth	B	['N']	[14]
15	defects	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#612
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	present	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	28-yr	O	['N']	[9]
10	-	O	['N']	[10]
11	old	O	['N']	[11]
12	male	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	a	O	['N']	[15]
16	severe	O	['N']	[16]
17	case	O	['N']	[17]
18	of	O	['N']	[18]
19	nephrotic	B	['N']	[19]
20	syndrome	I-Adverse_Effect	['N']	[20]
21	while	O	['N']	[21]
22	being	O	['N']	[22]
23	treated	O	['N']	[23]
24	for	O	['N']	[24]
25	relapsing	O	['N']	[25]
26	/	O	['N']	[26]
27	remitting	O	['N']	[27]
28	Multiple	O	['N']	[28]
29	Sclerosis	O	['N']	[29]
30	(	O	['N']	[30]
31	RRMS	O	['N']	[31]
32	)	O	['N']	[32]
33	with	O	['N']	[33]
34	weekly	O	['N']	[34]
35	injections	O	['N']	[35]
36	of	O	['N']	[36]
37	interferon	B	['N']	[37]
38	beta	I	['N']	[38]
39	1a	I-Drug	['Causes']	[20]
40	.	O	['N']	[40]
#613
0	Hemodialysis	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	performed	O	['N']	[3]
4	for	O	['N']	[4]
5	rapid	O	['N']	[5]
6	reversal	O	['N']	[6]
7	of	O	['N']	[7]
8	mannitol	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	ARF	B-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#614
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	lepromatous	O	['N']	[3]
4	leprosy	O	['N']	[4]
5	with	O	['N']	[5]
6	erythema	O	['N']	[6]
7	nodosum	O	['N']	[7]
8	leprosum	O	['N']	[8]
9	who	O	['N']	[9]
10	were	O	['N']	[10]
11	on	O	['N']	[11]
12	high	B	['N']	[12]
13	doses	I-Dose	['N']	[13]
14	of	O	['N']	[14]
15	clofazimine	B-Drug	['Dosage']	[13]
16	,	O	['N']	[16]
17	showed	O	['N']	[17]
18	discoloration	O	['N']	[18]
19	of	O	['N']	[19]
20	nail	O	['N']	[20]
21	plate	O	['N']	[21]
22	,	O	['N']	[22]
23	subungual	O	['N']	[23]
24	hyperkeratosis	O	['N']	[24]
25	and	O	['N']	[25]
26	onycholysis	O	['N']	[26]
27	.	O	['N']	[27]
#615
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	an	O	['N']	[3]
4	allergy	O	['N']	[4]
5	to	O	['N']	[5]
6	a	O	['N']	[6]
7	macrolide	O	['N']	[7]
8	antibiotic	O	['N']	[8]
9	was	O	['N']	[9]
10	given	O	['N']	[10]
11	tacrolimus	B-Drug	['Causes']	[17]
12	and	O	['N']	[12]
13	developed	O	['N']	[13]
14	a	O	['N']	[14]
15	sudden	B	['N']	[15]
16	cutaneous	I	['N']	[16]
17	reaction	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#616
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	that	O	['N']	[2]
3	these	O	['N']	[3]
4	skin	B	['N']	[4]
5	eruptions	I-Adverse_Effect	['N']	[5]
6	belong	O	['N']	[6]
7	to	O	['N']	[7]
8	a	O	['N']	[8]
9	spectrum	O	['N']	[9]
10	of	O	['N']	[10]
11	neutrophilic	O	['N']	[11]
12	dermatoses	O	['N']	[12]
13	that	O	['N']	[13]
14	can	O	['N']	[14]
15	be	O	['N']	[15]
16	induced	O	['N']	[16]
17	or	O	['N']	[17]
18	aggravated	O	['N']	[18]
19	by	O	['N']	[19]
20	G	B	['N']	[20]
21	-	I	['N']	[21]
22	CSF	I-Drug	['Causes']	[5]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#617
0	Propafenone	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	ataxia	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	report	O	['N']	[5]
6	of	O	['N']	[6]
7	three	O	['N']	[7]
8	cases	O	['N']	[8]
9	.	O	['N']	[9]
#618
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	development	O	['N']	[5]
6	of	O	['N']	[6]
7	valproate	B-Drug	['Causes']	[12]
8	-	O	['N']	[8]
9	related	O	['N']	[9]
10	reproductive	B	['N']	[10]
11	endocrine	I	['N']	[11]
12	disorders	I-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	women	O	['N']	[14]
15	with	O	['N']	[15]
16	epilepsy	O	['N']	[16]
17	.	O	['N']	[17]
#619
0	Six	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	no	O	['N']	[3]
4	previous	O	['N']	[4]
5	signs	O	['N']	[5]
6	or	O	['N']	[6]
7	symptoms	O	['N']	[7]
8	suggestive	O	['N']	[8]
9	of	O	['N']	[9]
10	coronary	O	['N']	[10]
11	artery	O	['N']	[11]
12	disease	O	['N']	[12]
13	developed	O	['N']	[13]
14	acute	O	['N']	[14]
15	coronary	O	['N']	[15]
16	ischemia	O	['N']	[16]
17	/	O	['N']	[17]
18	infarction	B-Adverse_Effect	['N']	[18]
19	shortly	O	['N']	[19]
20	after	O	['N']	[20]
21	cis	B	['N']	[21]
22	-	I	['N']	[22]
23	diamine	I	['N']	[23]
24	-	I	['N']	[24]
25	dichloroplatinum	I	['N']	[25]
26	II	I-Drug	['Causes']	[18]
27	(	O	['N']	[27]
28	cisplatin	O	['N']	[28]
29	)	O	['N']	[29]
30	-based	O	['N']	[30]
31	chemotherapy	O	['N']	[31]
32	.	O	['N']	[32]
#620
0	When	O	['N']	[0]
1	vague	O	['N']	[1]
2	symptoms	O	['N']	[2]
3	develop	O	['N']	[3]
4	during	O	['N']	[4]
5	desmopressin	B-Drug	['Causes']	[8]
6	therapy	O	['N']	[6]
7	,	O	['N']	[7]
8	hyponatremia	B-Adverse_Effect	['N']	[8]
9	must	O	['N']	[9]
10	be	O	['N']	[10]
11	considered	O	['N']	[11]
12	as	O	['N']	[12]
13	part	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	differential	O	['N']	[16]
17	diagnosis	O	['N']	[17]
18	.	O	['N']	[18]
#621
0	A	O	['N']	[0]
1	small	O	['N']	[1]
2	initial	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	prazosin	B-Drug	['Dosage']	[11]
6	ranging	O	['N']	[6]
7	from	O	['N']	[7]
8	0.5	B	['N']	[8]
9	to	I	['N']	[9]
10	1	I	['N']	[10]
11	mg	I-Dose	['N']	[11]
12	has	O	['N']	[12]
13	been	O	['N']	[13]
14	recommended	O	['N']	[14]
15	to	O	['N']	[15]
16	avoid	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	-	O	['N']	[19]
20	dose	O	['N']	[20]
21	phenomenon	O	['N']	[21]
22	characterized	O	['N']	[22]
23	by	O	['N']	[23]
24	a	O	['N']	[24]
25	sudden	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	O	['N']	[27]
28	drop	O	['N']	[28]
29	in	O	['N']	[29]
30	blood	O	['N']	[30]
31	pressure	O	['N']	[31]
32	after	O	['N']	[32]
33	the	O	['N']	[33]
34	administration	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	first	O	['N']	[37]
38	dose	O	['N']	[38]
39	of	O	['N']	[39]
40	prazosin	O	['N']	[40]
41	.	O	['N']	[41]
#622
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	marked	O	['N']	[2]
3	QT	O	['N']	[3]
4	prolongation	O	['N']	[4]
5	and	O	['N']	[5]
6	torsades	B	['N']	[6]
7	de	I	['N']	[7]
8	pointes	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	setting	O	['N']	[11]
12	of	O	['N']	[12]
13	flash	O	['N']	[13]
14	pulmonary	O	['N']	[14]
15	edema	O	['N']	[15]
16	resulting	O	['N']	[16]
17	from	O	['N']	[17]
18	acute	O	['N']	[18]
19	myocardial	O	['N']	[19]
20	ischemia	O	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	patient	O	['N']	[23]
24	who	O	['N']	[24]
25	was	O	['N']	[25]
26	being	O	['N']	[26]
27	treated	O	['N']	[27]
28	with	O	['N']	[28]
29	dofetilide	B-Drug	['Causes']	[8]
30	for	O	['N']	[30]
31	atrial	O	['N']	[31]
32	fibrillation	O	['N']	[32]
33	.	O	['N']	[33]
#623
0	Meperidine	B-Drug	['Causes']	[22]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	central	O	['N']	[3]
4	nervous	O	['N']	[4]
5	system	O	['N']	[5]
6	(	O	['N']	[6]
7	CNS	O	['N']	[7]
8	)	O	['N']	[8]
9	excitatory	O	['N']	[9]
10	toxicities	O	['N']	[10]
11	are	O	['N']	[11]
12	believed	O	['N']	[12]
13	to	O	['N']	[13]
14	be	O	['N']	[14]
15	caused	O	['N']	[15]
16	by	O	['N']	[16]
17	accumulation	B	['N']	[17]
18	of	I	['N']	[18]
19	the	I	['N']	[19]
20	active	I	['N']	[20]
21	metabolite	I	['N']	[21]
22	normeperidine	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#624
0	Cholestatic	B	['N']	[0]
1	liver	I	['N']	[1]
2	disease	I-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	ductopenia	O	['N']	[4]
5	(	O	['N']	[5]
6	vanishing	O	['N']	[6]
7	bile	O	['N']	[7]
8	duct	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	)	O	['N']	[10]
11	after	O	['N']	[11]
12	administration	O	['N']	[12]
13	of	O	['N']	[13]
14	clindamycin	B-Drug	['Causes']	[2]
15	and	O	['N']	[15]
16	trimethoprim	O	['N']	[16]
17	-	O	['N']	[17]
18	sulfamethoxazole	O	['N']	[18]
19	.	O	['N']	[19]
#625
0	In	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	a	O	['N']	[3]
4	known	O	['N']	[4]
5	access	O	['N']	[5]
6	to	O	['N']	[6]
7	INH	B-Drug	['Causes']	[9]
8	,	O	['N']	[8]
9	seizures	B-Adverse_Effect	['N']	[9]
10	should	O	['N']	[10]
11	be	O	['N']	[11]
12	considered	O	['N']	[12]
13	to	O	['N']	[13]
14	be	O	['N']	[14]
15	caused	O	['N']	[15]
16	by	O	['N']	[16]
17	INH	O	['N']	[17]
18	toxicity	O	['N']	[18]
19	unless	O	['N']	[19]
20	proved	O	['N']	[20]
21	otherwise	O	['N']	[21]
22	.	O	['N']	[22]
#626
0	We	O	['N']	[0]
1	reported	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	disulfiram	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	hepatitis	B-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	unique	O	['N']	[10]
11	clinical	O	['N']	[11]
12	features	O	['N']	[12]
13	and	O	['N']	[13]
14	compared	O	['N']	[14]
15	our	O	['N']	[15]
16	case	O	['N']	[16]
17	with	O	['N']	[17]
18	others	O	['N']	[18]
19	in	O	['N']	[19]
20	the	O	['N']	[20]
21	literature	O	['N']	[21]
22	.	O	['N']	[22]
#627
0	Pirmenol	B	['N']	[0]
1	hydrochloride	I-Drug	['Causes']	[9]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	QT	O	['N']	[4]
5	prolongation	O	['N']	[5]
6	and	O	['N']	[6]
7	T	B	['N']	[7]
8	wave	I	['N']	[8]
9	inversion	I-Adverse_Effect	['N']	[9]
10	on	O	['N']	[10]
11	electrocardiogram	O	['N']	[11]
12	during	O	['N']	[12]
13	treatment	O	['N']	[13]
14	for	O	['N']	[14]
15	symptomatic	O	['N']	[15]
16	atrial	O	['N']	[16]
17	fibrillation	O	['N']	[17]
18	.	O	['N']	[18]
#628
0	Four	O	['N']	[0]
1	months	O	['N']	[1]
2	after	O	['N']	[2]
3	receiving	O	['N']	[3]
4	an	O	['N']	[4]
5	orthotopic	O	['N']	[5]
6	liver	O	['N']	[6]
7	transplant	O	['N']	[7]
8	,	O	['N']	[8]
9	a	O	['N']	[9]
10	51-year	O	['N']	[10]
11	-	O	['N']	[11]
12	old	O	['N']	[12]
13	man	O	['N']	[13]
14	was	O	['N']	[14]
15	admitted	O	['N']	[15]
16	for	O	['N']	[16]
17	progressive	O	['N']	[17]
18	liver	O	['N']	[18]
19	failure	O	['N']	[19]
20	and	O	['N']	[20]
21	severe	B	['N']	[21]
22	hepatocellular	I	['N']	[22]
23	necrosis	I-Adverse_Effect	['N']	[23]
24	thought	O	['N']	[24]
25	to	O	['N']	[25]
26	be	O	['N']	[26]
27	due	O	['N']	[27]
28	to	O	['N']	[28]
29	tacrolimus	B-Drug	['Causes']	[23]
30	.	O	['N']	[30]
#629
0	A	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	bipolar	O	['N']	[6]
7	disorder	O	['N']	[7]
8	and	O	['N']	[8]
9	complicated	O	['N']	[9]
10	cardiovascular	O	['N']	[10]
11	disease	O	['N']	[11]
12	who	O	['N']	[12]
13	was	O	['N']	[13]
14	on	O	['N']	[14]
15	maintenance	O	['N']	[15]
16	lithium	O	['N']	[16]
17	therapy	O	['N']	[17]
18	developed	O	['N']	[18]
19	a	O	['N']	[19]
20	movement	O	['N']	[20]
21	disorder	O	['N']	[21]
22	following	O	['N']	[22]
23	high	B	['N']	[23]
24	doses	I-Dose	['N']	[24]
25	of	O	['N']	[25]
26	trazodone	B-Drug	['Dosage']	[24]
27	for	O	['N']	[27]
28	treatment	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	acute	O	['N']	[31]
32	depression	O	['N']	[32]
33	.	O	['N']	[33]
#630
0	Severe	O	['N']	[0]
1	rhabdomyolysis	O	['N']	[1]
2	following	O	['N']	[2]
3	massive	O	['N']	[3]
4	ingestion	O	['N']	[4]
5	of	O	['N']	[5]
6	oolong	O	['N']	[6]
7	tea	O	['N']	[7]
8	:	O	['N']	[8]
9	caffeine	B-Drug	['Causes']	[10]
10	intoxication	I-Adverse_Effect	['N']	[10]
11	with	O	['N']	[11]
12	coexisting	O	['N']	[12]
13	hyponatremia	O	['N']	[13]
14	.	O	['N']	[14]
#631
0	Hyponatraemia	B-Adverse_Effect	['N']	[0]
1	during	O	['N']	[1]
2	low	O	['N']	[2]
3	-	O	['N']	[3]
4	dose	O	['N']	[4]
5	carbamazepine	B-Drug	['Causes']	[0]
6	therapy	O	['N']	[6]
7	.	O	['N']	[7]
#632
0	During	O	['N']	[0]
1	clarithromycin	O	['N']	[1]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	B-Drug	['Causes']	[28]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	O	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	B-Adverse_Effect	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#633
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	ST	B	['N']	[5]
6	elevation	I	['N']	[6]
7	in	I	['N']	[7]
8	right	I	['N']	[8]
9	precordial	I	['N']	[9]
10	leads	I-Adverse_Effect	['N']	[10]
11	compatible	O	['N']	[11]
12	with	O	['N']	[12]
13	type	O	['N']	[13]
14	1	O	['N']	[14]
15	Brugada	O	['N']	[15]
16	syndrome	O	['N']	[16]
17	following	O	['N']	[17]
18	administration	O	['N']	[18]
19	of	O	['N']	[19]
20	propafenone	B-Drug	['Causes']	[10]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	patient	O	['N']	[23]
24	with	O	['N']	[24]
25	Wolff	O	['N']	[25]
26	-	O	['N']	[26]
27	Parkinson	O	['N']	[27]
28	-	O	['N']	[28]
29	White	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	who	O	['N']	[31]
32	was	O	['N']	[32]
33	receiving	O	['N']	[33]
34	lithium	O	['N']	[34]
35	at	O	['N']	[35]
36	concentrations	O	['N']	[36]
37	within	O	['N']	[37]
38	therapeutic	O	['N']	[38]
39	levels	O	['N']	[39]
40	.	O	['N']	[40]
#634
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	unusual	O	['N']	[3]
4	pattern	O	['N']	[4]
5	of	O	['N']	[5]
6	supravenous	B	['N']	[6]
7	hyperpigmentation	I-Adverse_Effect	['N']	[7]
8	occurring	O	['N']	[8]
9	after	O	['N']	[9]
10	CHOP	B-Drug	['Causes']	[7]
11	chemotherapy	O	['N']	[11]
12	.	O	['N']	[12]
#635
0	Colonic	B	['N']	[0]
1	mucosal	I	['N']	[1]
2	necrosis	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	administration	O	['N']	[4]
5	of	O	['N']	[5]
6	calcium	O	['N']	[6]
7	polystryrene	O	['N']	[7]
8	sulfonate	O	['N']	[8]
9	(	O	['N']	[9]
10	Kalimate	B-Drug	['Causes']	[2]
11	)	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	uremic	O	['N']	[14]
15	patient	O	['N']	[15]
16	.	O	['N']	[16]
#636
0	Although	O	['N']	[0]
1	the	O	['N']	[1]
2	t	B	['N']	[2]
3	-	I	['N']	[3]
4	AML	I-Adverse_Effect	['N']	[4]
5	developed	O	['N']	[5]
6	following	O	['N']	[6]
7	oral	O	['N']	[7]
8	etoposide	B-Drug	['Causes']	[4]
9	therapy	O	['N']	[9]
10	,	O	['N']	[10]
11	the	O	['N']	[11]
12	child	O	['N']	[12]
13	had	O	['N']	[13]
14	previously	O	['N']	[14]
15	received	O	['N']	[15]
16	high	O	['N']	[16]
17	-	O	['N']	[17]
18	dose	O	['N']	[18]
19	,	O	['N']	[19]
20	multiagent	O	['N']	[20]
21	chemotherapy	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	rearrangement	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	MLL	O	['N']	[27]
28	gene	O	['N']	[28]
29	was	O	['N']	[29]
30	not	O	['N']	[30]
31	demonstrated	O	['N']	[31]
32	.	O	['N']	[32]
#637
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	infectious	B	['N']	[5]
6	mononucleosis	I	['N']	[6]
7	-	I	['N']	[7]
8	like	I	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	induced	O	['N']	[10]
11	by	O	['N']	[11]
12	salazosulfapyridine	B-Drug	['Causes']	[9]
13	(	O	['N']	[13]
14	SASP	O	['N']	[14]
15	)	O	['N']	[15]
16	.	O	['N']	[16]
#638
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	two	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	rhabdomyolysis	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	taking	O	['N']	[10]
11	lovastatin	O	['N']	[11]
12	that	O	['N']	[12]
13	were	O	['N']	[13]
14	precipitated	O	['N']	[14]
15	by	O	['N']	[15]
16	the	O	['N']	[16]
17	use	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	newer	O	['N']	[20]
21	macrolide	O	['N']	[21]
22	antibiotics	O	['N']	[22]
23	clarithromycin	B-Drug	['Causes']	[7]
24	and	O	['N']	[24]
25	azithromycin	O	['N']	[25]
26	.	O	['N']	[26]
#639
0	The	O	['N']	[0]
1	international	O	['N']	[1]
2	literature	O	['N']	[2]
3	regarding	O	['N']	[3]
4	opportunistic	O	['N']	[4]
5	infections	O	['N']	[5]
6	after	O	['N']	[6]
7	immunosuppressive	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	alemtuzumab	B-Drug	['Causes']	[16]
11	with	O	['N']	[11]
12	particular	O	['N']	[12]
13	attention	O	['N']	[13]
14	on	O	['N']	[14]
15	fungal	B	['N']	[15]
16	infections	I-Adverse_Effect	['N']	[16]
17	has	O	['N']	[17]
18	also	O	['N']	[18]
19	been	O	['N']	[19]
20	reviewed	O	['N']	[20]
21	.	O	['N']	[21]
#640
0	Recurrent	O	['N']	[0]
1	septicemia	B-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	lethal	O	['N']	[3]
4	outcome	O	['N']	[4]
5	during	O	['N']	[5]
6	and	O	['N']	[6]
7	after	O	['N']	[7]
8	cyclosporine	B-Drug	['Causes']	[1]
9	therapy	O	['N']	[9]
10	in	O	['N']	[10]
11	severe	O	['N']	[11]
12	ulcerative	O	['N']	[12]
13	colitis	O	['N']	[13]
14	.	O	['N']	[14]
#641
0	Scrotal	B	['N']	[0]
1	ulceration	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	all	O	['N']	[4]
5	-	O	['N']	[5]
6	trans	O	['N']	[6]
7	retinoic	B	['N']	[7]
8	acid	I-Drug	['Causes']	[1]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	with	O	['N']	[12]
13	acute	O	['N']	[13]
14	promyelocytic	O	['N']	[14]
15	leukemia	O	['N']	[15]
16	.	O	['N']	[16]
#642
0	Patients	O	['N']	[0]
1	receiving	O	['N']	[1]
2	amifostine	B-Drug	['Causes']	[6]
3	who	O	['N']	[3]
4	develop	O	['N']	[4]
5	only	O	['N']	[5]
6	fever	B-Adverse_Effect	['N']	[6]
7	should	O	['N']	[7]
8	be	O	['N']	[8]
9	evaluated	O	['N']	[9]
10	for	O	['N']	[10]
11	an	O	['N']	[11]
12	adverse	O	['N']	[12]
13	drug	O	['N']	[13]
14	reaction	O	['N']	[14]
15	,	O	['N']	[15]
16	as	O	['N']	[16]
17	well	O	['N']	[17]
18	as	O	['N']	[18]
19	for	O	['N']	[19]
20	sepsis	O	['N']	[20]
21	and	O	['N']	[21]
22	fevers	O	['N']	[22]
23	of	O	['N']	[23]
24	neutropenia	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	it	O	['N']	[27]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	necessary	O	['N']	[30]
31	to	O	['N']	[31]
32	discontinue	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	.	O	['N']	[35]
#643
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	64-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	man	O	['N']	[9]
10	with	O	['N']	[10]
11	secondary	O	['N']	[11]
12	adrenocortical	B	['N']	[12]
13	insufficiency	I-Adverse_Effect	['N']	[13]
14	who	O	['N']	[14]
15	has	O	['N']	[15]
16	been	O	['N']	[16]
17	on	O	['N']	[17]
18	a	O	['N']	[18]
19	chronic	O	['N']	[19]
20	transdermal	O	['N']	[20]
21	fentanyl	B-Drug	['Causes']	[13]
22	treatment	O	['N']	[22]
23	because	O	['N']	[23]
24	of	O	['N']	[24]
25	sciatic	O	['N']	[25]
26	pain	O	['N']	[26]
27	syndrome	O	['N']	[27]
28	.	O	['N']	[28]
#644
0	Pancreatitis	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	very	O	['N']	[3]
4	rare	O	['N']	[4]
5	adverse	O	['N']	[5]
6	effect	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	use	O	['N']	[10]
11	of	O	['N']	[11]
12	amiodarone	B-Drug	['Causes']	[0]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	only	O	['N']	[15]
16	four	O	['N']	[16]
17	cases	O	['N']	[17]
18	of	O	['N']	[18]
19	amiodarone	O	['N']	[19]
20	-	O	['N']	[20]
21	induced	O	['N']	[21]
22	pancreatitis	O	['N']	[22]
23	have	O	['N']	[23]
24	been	O	['N']	[24]
25	reported	O	['N']	[25]
26	in	O	['N']	[26]
27	literature	O	['N']	[27]
28	.	O	['N']	[28]
#645
0	In	O	['N']	[0]
1	deciding	O	['N']	[1]
2	if	O	['N']	[2]
3	tamoxifen	B-Drug	['Causes']	[27]
4	therapy	O	['N']	[4]
5	is	O	['N']	[5]
6	warranted	O	['N']	[6]
7	,	O	['N']	[7]
8	all	O	['N']	[8]
9	potentially	O	['N']	[9]
10	life	O	['N']	[10]
11	-	O	['N']	[11]
12	threatening	O	['N']	[12]
13	adverse	O	['N']	[13]
14	events	O	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	tamoxifen	O	['N']	[17]
18	should	O	['N']	[18]
19	be	O	['N']	[19]
20	considered	O	['N']	[20]
21	,	O	['N']	[21]
22	including	O	['N']	[22]
23	endometrial	O	['N']	[23]
24	adenocarcinoma	O	['N']	[24]
25	or	O	['N']	[25]
26	uterine	B	['N']	[26]
27	sarcoma	I-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#646
0	Masculinization	O	['N']	[0]
1	of	O	['N']	[1]
2	a	O	['N']	[2]
3	female	O	['N']	[3]
4	fetus	O	['N']	[4]
5	occurred	O	['N']	[5]
6	in	O	['N']	[6]
7	5	O	['N']	[7]
8	of	O	['N']	[8]
9	39	O	['N']	[9]
10	(	O	['N']	[10]
11	12.8	O	['N']	[11]
12	%	O	['N']	[12]
13	)	O	['N']	[13]
14	exposed	O	['N']	[14]
15	to	O	['N']	[15]
16	norethisterone	B-Drug	['Causes']	[23]
17	;	O	['N']	[17]
18	all	O	['N']	[18]
19	were	O	['N']	[19]
20	cases	O	['N']	[20]
21	of	O	['N']	[21]
22	clitoral	B	['N']	[22]
23	hypertrophy	I-Adverse_Effect	['N']	[23]
24	not	O	['N']	[24]
25	requiring	O	['N']	[25]
26	surgical	O	['N']	[26]
27	treatment	O	['N']	[27]
28	.	O	['N']	[28]
#647
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	27-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	Indian	O	['N']	[9]
10	woman	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	maculopapular	B	['N']	[13]
14	rash	I-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	angioedema	O	['N']	[16]
17	secondary	O	['N']	[17]
18	to	O	['N']	[18]
19	carbamazepine	B-Drug	['Causes']	[14]
20	administration	O	['N']	[20]
21	.	O	['N']	[21]
#648
0	Parenteral	O	['N']	[0]
1	pyridoxine	O	['N']	[1]
2	,	O	['N']	[2]
3	the	O	['N']	[3]
4	specific	O	['N']	[4]
5	antidote	O	['N']	[5]
6	for	O	['N']	[6]
7	INH	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	refractory	B	['N']	[10]
11	seizures	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	should	O	['N']	[13]
14	be	O	['N']	[14]
15	readily	O	['N']	[15]
16	available	O	['N']	[16]
17	in	O	['N']	[17]
18	every	O	['N']	[18]
19	emergency	O	['N']	[19]
20	department	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	areas	O	['N']	[23]
24	similarly	O	['N']	[24]
25	experiencing	O	['N']	[25]
26	increasing	O	['N']	[26]
27	trends	O	['N']	[27]
28	of	O	['N']	[28]
29	TB	O	['N']	[29]
30	.	O	['N']	[30]
#649
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	administered	O	['N']	[2]
3	metoclopramide	B-Drug	['Causes']	[23]
4	because	O	['N']	[4]
5	of	O	['N']	[5]
6	nausea	O	['N']	[6]
7	and	O	['N']	[7]
8	,	O	['N']	[8]
9	within	O	['N']	[9]
10	2	O	['N']	[10]
11	hours	O	['N']	[11]
12	,	O	['N']	[12]
13	developed	O	['N']	[13]
14	agitation	O	['N']	[14]
15	,	O	['N']	[15]
16	dysarthria	O	['N']	[16]
17	,	O	['N']	[17]
18	diaphoresis	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	a	O	['N']	[21]
22	movement	B	['N']	[22]
23	disorder	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#650
0	A	O	['N']	[0]
1	sixty	O	['N']	[1]
2	-	O	['N']	[2]
3	year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	advanced	O	['N']	[8]
9	breast	O	['N']	[9]
10	cancer	O	['N']	[10]
11	,	O	['N']	[11]
12	previously	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	cisplatin	O	['N']	[15]
16	,	O	['N']	[16]
17	developed	O	['N']	[17]
18	an	O	['N']	[18]
19	irreversible	O	['N']	[19]
20	lethal	O	['N']	[20]
21	renal	O	['N']	[21]
22	failure	O	['N']	[22]
23	with	O	['N']	[23]
24	anuria	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	the	O	['N']	[26]
27	day	O	['N']	[27]
28	after	O	['N']	[28]
29	5	O	['N']	[29]
30	g	O	['N']	[30]
31	/	O	['N']	[31]
32	m2	O	['N']	[32]
33	bolus	O	['N']	[33]
34	ifosfamide	B-Drug	['Causes']	[24]
35	.	O	['N']	[35]
#651
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	underscores	O	['N']	[2]
3	problems	O	['N']	[3]
4	in	O	['N']	[4]
5	clinical	O	['N']	[5]
6	management	O	['N']	[6]
7	with	O	['N']	[7]
8	sulfadiazine	B-Drug	['Causes']	[9]
9	hypersensitivity	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	potential	O	['N']	[11]
12	immunosuppression	O	['N']	[12]
13	from	O	['N']	[13]
14	corticosteroids	O	['N']	[14]
15	and	O	['N']	[15]
16	selection	O	['N']	[16]
17	of	O	['N']	[17]
18	medications	O	['N']	[18]
19	for	O	['N']	[19]
20	recurrences	O	['N']	[20]
21	of	O	['N']	[21]
22	toxoplasmic	O	['N']	[22]
23	chorioretinitis	O	['N']	[23]
24	.	O	['N']	[24]
#652
0	Spontaneous	O	['N']	[0]
1	bacterial	B	['N']	[1]
2	peritonitis	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	intraarterial	O	['N']	[5]
6	vasopressin	B-Drug	['Causes']	[2]
7	therapy	O	['N']	[7]
8	.	O	['N']	[8]
#653
0	Alternating	B	['N']	[0]
1	sinus	I	['N']	[1]
2	rhythm	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	intermittent	O	['N']	[4]
5	sinoatrial	O	['N']	[5]
6	(	O	['N']	[6]
7	S	O	['N']	[7]
8	-	O	['N']	[8]
9	A	O	['N']	[9]
10	)	O	['N']	[10]
11	block	O	['N']	[11]
12	was	O	['N']	[12]
13	observed	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	57-year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	woman	O	['N']	[19]
20	,	O	['N']	[20]
21	under	O	['N']	[21]
22	treatment	O	['N']	[22]
23	for	O	['N']	[23]
24	angina	O	['N']	[24]
25	with	O	['N']	[25]
26	80	O	['N']	[26]
27	mg	O	['N']	[27]
28	propranolol	B-Drug	['Causes']	[2]
29	daily	O	['N']	[29]
30	.	O	['N']	[30]
#654
0	Since	O	['N']	[0]
1	this	O	['N']	[1]
2	amount	O	['N']	[2]
3	of	O	['N']	[3]
4	FAB	O	['N']	[4]
5	was	O	['N']	[5]
6	insufficient	O	['N']	[6]
7	to	O	['N']	[7]
8	bind	O	['N']	[8]
9	all	O	['N']	[9]
10	DGTX	B-Drug	['Causes']	[18]
11	present	O	['N']	[11]
12	in	O	['N']	[12]
13	the	O	['N']	[13]
14	serum	O	['N']	[14]
15	,	O	['N']	[15]
16	cardiac	B	['N']	[16]
17	DGTX	I	['N']	[17]
18	toxicity	I-Adverse_Effect	['N']	[18]
19	(	O	['N']	[19]
20	total	O	['N']	[20]
21	AV	O	['N']	[21]
22	-	O	['N']	[22]
23	block	O	['N']	[23]
24	)	O	['N']	[24]
25	persisted	O	['N']	[25]
26	.	O	['N']	[26]
#655
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	described	O	['N']	[3]
4	of	O	['N']	[4]
5	severe	B	['N']	[5]
6	splenic	I	['N']	[6]
7	hemorrhage	I	['N']	[7]
8	and	I	['N']	[8]
9	rupture	I-Adverse_Effect	['N']	[9]
10	which	O	['N']	[10]
11	developed	O	['N']	[11]
12	3	O	['N']	[12]
13	h	O	['N']	[13]
14	after	O	['N']	[14]
15	completion	O	['N']	[15]
16	of	O	['N']	[16]
17	tPA	B-Drug	['Causes']	[9]
18	infusion	O	['N']	[18]
19	for	O	['N']	[19]
20	suspected	O	['N']	[20]
21	acute	O	['N']	[21]
22	myocardial	O	['N']	[22]
23	infarction	O	['N']	[23]
24	.	O	['N']	[24]
#656
0	We	O	['N']	[0]
1	presented	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	status	O	['N']	[5]
6	asthmaticus	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	combination	O	['N']	[10]
11	of	O	['N']	[11]
12	theophylline	B-Drug	['Causes']	[20]
13	and	O	['N']	[13]
14	prednisone	O	['N']	[14]
15	who	O	['N']	[15]
16	developed	O	['N']	[16]
17	a	O	['N']	[17]
18	perforated	B	['N']	[18]
19	gastric	I	['N']	[19]
20	ulcer	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#657
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	completed	O	['N']	[2]
3	a	O	['N']	[3]
4	10-month	O	['N']	[4]
5	follow	O	['N']	[5]
6	-	O	['N']	[6]
7	up	O	['N']	[7]
8	,	O	['N']	[8]
9	maintaining	O	['N']	[9]
10	a	O	['N']	[10]
11	complete	O	['N']	[11]
12	resolution	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	treated	O	['N']	[15]
16	skin	O	['N']	[16]
17	lesions	O	['N']	[17]
18	;	O	['N']	[18]
19	however	O	['N']	[19]
20	,	O	['N']	[20]
21	the	O	['N']	[21]
22	development	O	['N']	[22]
23	of	O	['N']	[23]
24	a	O	['N']	[24]
25	painful	O	['N']	[25]
26	hand	O	['N']	[26]
27	ulcer	O	['N']	[27]
28	,	O	['N']	[28]
29	possibly	O	['N']	[29]
30	associated	O	['N']	[30]
31	with	O	['N']	[31]
32	the	O	['N']	[32]
33	hydroxyurea	B-Drug	['Causes']	[38]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	new	O	['N']	[36]
37	skin	B	['N']	[37]
38	cancers	I-Adverse_Effect	['N']	[38]
39	were	O	['N']	[39]
40	observed	O	['N']	[40]
41	at	O	['N']	[41]
42	the	O	['N']	[42]
43	last	O	['N']	[43]
44	follow	O	['N']	[44]
45	-	O	['N']	[45]
46	up	O	['N']	[46]
47	visit	O	['N']	[47]
48	.	O	['N']	[48]
#658
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	bipolar	O	['N']	[3]
4	affective	O	['N']	[4]
5	disorder	O	['N']	[5]
6	and	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchospastic	O	['N']	[10]
11	phenomena	O	['N']	[11]
12	experienced	O	['N']	[12]
13	tremor	B-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	lithium	B	['N']	[15]
16	carbonate	I-Drug	['Causes']	[13]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#659
0	Myoclonic	B	['N']	[0]
1	spasms	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	intrathecal	O	['N']	[3]
4	morphine	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#660
0	Isonicotinic	B	['N']	[0]
1	acid	I	['N']	[1]
2	hydrazide	I-Drug	['Causes']	[9]
3	induced	O	['N']	[3]
4	anagen	O	['N']	[4]
5	effluvium	O	['N']	[5]
6	and	O	['N']	[6]
7	associated	O	['N']	[7]
8	lichenoid	B	['N']	[8]
9	eruption	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#661
0	There	O	['N']	[0]
1	are	O	['N']	[1]
2	major	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	anastrozole	B-Drug	['Causes']	[46]
7	including	O	['N']	[7]
8	decrease	O	['N']	[8]
9	in	O	['N']	[9]
10	both	O	['N']	[10]
11	lumbar	O	['N']	[11]
12	spine	O	['N']	[12]
13	and	O	['N']	[13]
14	total	O	['N']	[14]
15	hip	O	['N']	[15]
16	bone	O	['N']	[16]
17	mineral	O	['N']	[17]
18	density	O	['N']	[18]
19	,	O	['N']	[19]
20	increase	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	incidence	O	['N']	[23]
24	of	O	['N']	[24]
25	all	O	['N']	[25]
26	bone	O	['N']	[26]
27	fractures	O	['N']	[27]
28	(	O	['N']	[28]
29	especially	O	['N']	[29]
30	fractures	O	['N']	[30]
31	of	O	['N']	[31]
32	spine	O	['N']	[32]
33	,	O	['N']	[33]
34	hip	O	['N']	[34]
35	and	O	['N']	[35]
36	wrist	O	['N']	[36]
37	)	O	['N']	[37]
38	,	O	['N']	[38]
39	joint	O	['N']	[39]
40	disorders	O	['N']	[40]
41	and	O	['N']	[41]
42	increase	B	['N']	[42]
43	in	I	['N']	[43]
44	the	I	['N']	[44]
45	cholesterol	I	['N']	[45]
46	level	I-Adverse_Effect	['N']	[46]
47	.	O	['N']	[47]
#662
0	Captopril	B-Drug	['Causes']	[14]
1	is	O	['N']	[1]
2	known	O	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	dermatologic	B	['N']	[7]
8	,	I	['N']	[8]
9	hematologic	I	['N']	[9]
10	,	I	['N']	[10]
11	and	I	['N']	[11]
12	pulmonary	I	['N']	[12]
13	adverse	I	['N']	[13]
14	effects	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#663
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	two	O	['N']	[4]
5	newborns	O	['N']	[5]
6	with	O	['N']	[6]
7	congenital	O	['N']	[7]
8	heart	O	['N']	[8]
9	anomalies	O	['N']	[9]
10	demonstrated	O	['N']	[10]
11	the	O	['N']	[11]
12	harlequin	B	['N']	[12]
13	color	I	['N']	[13]
14	change	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	one	O	['N']	[16]
17	whose	O	['N']	[17]
18	skin	O	['N']	[18]
19	findings	O	['N']	[19]
20	showed	O	['N']	[20]
21	a	O	['N']	[21]
22	course	O	['N']	[22]
23	related	O	['N']	[23]
24	to	O	['N']	[24]
25	the	O	['N']	[25]
26	dose	O	['N']	[26]
27	of	O	['N']	[27]
28	systemic	O	['N']	[28]
29	prostaglandin	B	['N']	[29]
30	E1	I-Drug	['Causes']	[14]
31	,	O	['N']	[31]
32	suggesting	O	['N']	[32]
33	a	O	['N']	[33]
34	possible	O	['N']	[34]
35	association	O	['N']	[35]
36	.	O	['N']	[36]
#664
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	2	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	serotonin	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	serious	O	['N']	[10]
11	extrapyramidal	O	['N']	[11]
12	movement	O	['N']	[12]
13	disorders	O	['N']	[13]
14	occurring	O	['N']	[14]
15	when	O	['N']	[15]
16	metoclopramide	B-Drug	['Causes']	[8]
17	was	O	['N']	[17]
18	coadministered	O	['N']	[18]
19	with	O	['N']	[19]
20	sertraline	O	['N']	[20]
21	or	O	['N']	[21]
22	venlafaxine	O	['N']	[22]
23	.	O	['N']	[23]
#665
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	1	O	['N']	[2]
3	)	O	['N']	[3]
4	To	O	['N']	[4]
5	describe	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	rheumatoid	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	receiving	O	['N']	[11]
12	adalimumab	B-Drug	['Causes']	[19]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	pancytopenia	O	['N']	[17]
18	,	O	['N']	[18]
19	splenomegaly	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	extreme	O	['N']	[22]
23	hyperferritinemia	O	['N']	[23]
24	.	O	['N']	[24]
#666
0	Thus	O	['N']	[0]
1	,	O	['N']	[1]
2	tardive	B	['N']	[2]
3	seizures	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	our	O	['N']	[5]
6	cases	O	['N']	[6]
7	are	O	['N']	[7]
8	thought	O	['N']	[8]
9	to	O	['N']	[9]
10	be	O	['N']	[10]
11	related	O	['N']	[11]
12	to	O	['N']	[12]
13	piperacillin	O	['N']	[13]
14	and	O	['N']	[14]
15	cefotiam	B-Drug	['Causes']	[3]
16	.	O	['N']	[16]
#667
0	In	O	['N']	[0]
1	one	O	['N']	[1]
2	patient	O	['N']	[2]
3	the	O	['N']	[3]
4	vasculitis	O	['N']	[4]
5	resolved	O	['N']	[5]
6	after	O	['N']	[6]
7	termination	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	ciprofloxacin	B-Drug	['Causes']	[34]
11	therapy	O	['N']	[11]
12	;	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	other	O	['N']	[15]
16	patient	O	['N']	[16]
17	the	O	['N']	[17]
18	ciprofloxacin	O	['N']	[18]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	hemorrhagic	O	['N']	[21]
22	vasculitis	O	['N']	[22]
23	was	O	['N']	[23]
24	superimposed	O	['N']	[24]
25	on	O	['N']	[25]
26	a	O	['N']	[26]
27	severe	O	['N']	[27]
28	forefoot	O	['N']	[28]
29	infection	O	['N']	[29]
30	,	O	['N']	[30]
31	leading	O	['N']	[31]
32	to	O	['N']	[32]
33	progressive	B	['N']	[33]
34	gangrene	I-Adverse_Effect	['N']	[34]
35	and	O	['N']	[35]
36	a	O	['N']	[36]
37	below	O	['N']	[37]
38	-	O	['N']	[38]
39	knee	O	['N']	[39]
40	amputation	O	['N']	[40]
41	.	O	['N']	[41]
#668
0	Rhabdomyolysis	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[0]
4	treatment	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	decreased	O	['N']	[9]
10	calcium	O	['N']	[10]
11	-	O	['N']	[11]
12	dependent	O	['N']	[12]
13	potassium	O	['N']	[13]
14	permeability	O	['N']	[14]
15	of	O	['N']	[15]
16	cell	O	['N']	[16]
17	membranes	O	['N']	[17]
18	.	O	['N']	[18]
#669
0	Intrahepatic	O	['N']	[0]
1	cholestasis	O	['N']	[1]
2	and	O	['N']	[2]
3	cutaneous	B	['N']	[3]
4	bullae	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	glibenclamide	B-Drug	['Causes']	[4]
8	therapy	O	['N']	[8]
9	are	O	['N']	[9]
10	described	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	61-year	O	['N']	[13]
14	-	O	['N']	[14]
15	old	O	['N']	[15]
16	diabetic	O	['N']	[16]
17	patient	O	['N']	[17]
18	who	O	['N']	[18]
19	presented	O	['N']	[19]
20	wit	O	['N']	[20]
21	hypoglycaemic	O	['N']	[21]
22	coma	O	['N']	[22]
23	.	O	['N']	[23]
#670
0	Central	O	['N']	[0]
1	nervous	O	['N']	[1]
2	system	O	['N']	[2]
3	effects	O	['N']	[3]
4	secondary	O	['N']	[4]
5	to	O	['N']	[5]
6	ciprofloxacin	B-Drug	['Causes']	[27]
7	treatment	O	['N']	[7]
8	are	O	['N']	[8]
9	uncommon	O	['N']	[9]
10	and	O	['N']	[10]
11	usually	O	['N']	[11]
12	consist	O	['N']	[12]
13	only	O	['N']	[13]
14	of	O	['N']	[14]
15	minor	O	['N']	[15]
16	dizziness	O	['N']	[16]
17	or	O	['N']	[17]
18	mild	O	['N']	[18]
19	headache	O	['N']	[19]
20	,	O	['N']	[20]
21	although	O	['N']	[21]
22	rare	O	['N']	[22]
23	occurrences	O	['N']	[23]
24	of	O	['N']	[24]
25	seizures	O	['N']	[25]
26	and	O	['N']	[26]
27	hallucinations	B-Adverse_Effect	['N']	[27]
28	have	O	['N']	[28]
29	been	O	['N']	[29]
30	reported	O	['N']	[30]
31	.	O	['N']	[31]
#671
0	Multiple	O	['N']	[0]
1	syncopal	O	['N']	[1]
2	episodes	O	['N']	[2]
3	started	O	['N']	[3]
4	to	O	['N']	[4]
5	occur	O	['N']	[5]
6	during	O	['N']	[6]
7	thalidomide	B-Drug	['Causes']	[24]
8	treatment	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	a	O	['N']	[11]
12	Holter	O	['N']	[12]
13	electrocardiogram	O	['N']	[13]
14	showed	O	['N']	[14]
15	multiple	O	['N']	[15]
16	abnormalities	O	['N']	[16]
17	,	O	['N']	[17]
18	with	O	['N']	[18]
19	an	O	['N']	[19]
20	episode	O	['N']	[20]
21	of	O	['N']	[21]
22	sustained	B	['N']	[22]
23	ventricular	I	['N']	[23]
24	tachycardia	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#672
0	Severe	O	['N']	[0]
1	C.	B	['N']	[1]
2	difficile	I	['N']	[2]
3	colitis	I-Adverse_Effect	['N']	[3]
4	occurred	O	['N']	[4]
5	in	O	['N']	[5]
6	2	O	['N']	[6]
7	patients	O	['N']	[7]
8	(	O	['N']	[8]
9	6.1	O	['N']	[9]
10	%	O	['N']	[10]
11	)	O	['N']	[11]
12	after	O	['N']	[12]
13	receiving	O	['N']	[13]
14	cisplatin	B-Drug	['Causes']	[3]
15	-	O	['N']	[15]
16	based	O	['N']	[16]
17	combination	O	['N']	[17]
18	chemotherapy	O	['N']	[18]
19	for	O	['N']	[19]
20	ovarian	O	['N']	[20]
21	malignancies	O	['N']	[21]
22	.	O	['N']	[22]
#673
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	treated	O	['N']	[2]
3	with	O	['N']	[3]
4	5-fluorouracil	O	['N']	[4]
5	(	O	['N']	[5]
6	5-FU	B-Drug	['Causes']	[20]
7	)	O	['N']	[7]
8	for	O	['N']	[8]
9	disseminated	O	['N']	[9]
10	adenocarcinoma	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	colon	O	['N']	[13]
14	developed	O	['N']	[14]
15	cerebellar	O	['N']	[15]
16	dysfunction	O	['N']	[16]
17	typical	O	['N']	[17]
18	of	O	['N']	[18]
19	5-FU	O	['N']	[19]
20	neurotoxicity	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#674
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Interferon	B-Drug	['Causes']	[11]
3	(	O	['N']	[3]
4	IFN)-associated	O	['N']	[4]
5	retinopathy	O	['N']	[5]
6	is	O	['N']	[6]
7	typically	O	['N']	[7]
8	characterized	O	['N']	[8]
9	by	O	['N']	[9]
10	retinal	B	['N']	[10]
11	hemorrhages	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	cotton	O	['N']	[13]
14	wool	O	['N']	[14]
15	spots	O	['N']	[15]
16	at	O	['N']	[16]
17	the	O	['N']	[17]
18	posterior	O	['N']	[18]
19	fundus	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	visual	O	['N']	[22]
23	function	O	['N']	[23]
24	is	O	['N']	[24]
25	usually	O	['N']	[25]
26	maintained	O	['N']	[26]
27	.	O	['N']	[27]
#675
0	Gynecomastia	B-Adverse_Effect	['N']	[0]
1	developed	O	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	epileptic	O	['N']	[4]
5	patients	O	['N']	[5]
6	some	O	['N']	[6]
7	months	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	addition	O	['N']	[10]
11	of	O	['N']	[11]
12	oral	O	['N']	[12]
13	fluoresone	B-Drug	['Causes']	[0]
14	750	O	['N']	[14]
15	mg	O	['N']	[15]
16	daily	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	phenobarbital	O	['N']	[19]
20	and	O	['N']	[20]
21	phenytoin	O	['N']	[21]
22	already	O	['N']	[22]
23	being	O	['N']	[23]
24	administered	O	['N']	[24]
25	.	O	['N']	[25]
#676
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	determine	O	['N']	[3]
4	the	O	['N']	[4]
5	frequency	O	['N']	[5]
6	of	O	['N']	[6]
7	weight	B	['N']	[7]
8	loss	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	leflunomide	B-Drug	['Causes']	[8]
14	for	O	['N']	[14]
15	rheumatoid	O	['N']	[15]
16	arthritis	O	['N']	[16]
17	at	O	['N']	[17]
18	an	O	['N']	[18]
19	arthritis	O	['N']	[19]
20	referral	O	['N']	[20]
21	center	O	['N']	[21]
22	.	O	['N']	[22]
#677
0	Case	O	['N']	[0]
1	2	O	['N']	[1]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	29-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	woman	O	['N']	[7]
8	,	O	['N']	[8]
9	developed	O	['N']	[9]
10	bilateral	O	['N']	[10]
11	optic	O	['N']	[11]
12	neuritis	O	['N']	[12]
13	combined	O	['N']	[13]
14	with	O	['N']	[14]
15	numbness	B	['N']	[15]
16	of	I	['N']	[16]
17	the	I	['N']	[17]
18	lower	I	['N']	[18]
19	extremities	I-Adverse_Effect	['N']	[19]
20	as	O	['N']	[20]
21	well	O	['N']	[21]
22	as	O	['N']	[22]
23	bowel	O	['N']	[23]
24	and	O	['N']	[24]
25	bladder	O	['N']	[25]
26	dysfunction	O	['N']	[26]
27	after	O	['N']	[27]
28	a	O	['N']	[28]
29	22-month	O	['N']	[29]
30	use	O	['N']	[30]
31	of	O	['N']	[31]
32	recombinant	B	['N']	[32]
33	interferon	I	['N']	[33]
34	alpha-2b	I-Drug	['Causes']	[19]
35	for	O	['N']	[35]
36	chronic	O	['N']	[36]
37	myelogenous	O	['N']	[37]
38	leukemia	O	['N']	[38]
39	.	O	['N']	[39]
#678
0	Aggressive	O	['N']	[0]
1	management	O	['N']	[1]
2	of	O	['N']	[2]
3	doxorubicin	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	cardiomyopathy	B-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	'	O	['N']	[9]
10	low	O	['N']	[10]
11	'	O	['N']	[11]
12	doses	O	['N']	[12]
13	of	O	['N']	[13]
14	doxorubicin	O	['N']	[14]
15	.	O	['N']	[15]
#679
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	risk	O	['N']	[8]
9	of	O	['N']	[9]
10	serotonin	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	with	O	['N']	[12]
13	serious	O	['N']	[13]
14	extrapyramidal	B	['N']	[14]
15	reactions	I-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	receiving	O	['N']	[18]
19	sertraline	O	['N']	[19]
20	or	O	['N']	[20]
21	venlafaxine	B-Drug	['Causes']	[15]
22	when	O	['N']	[22]
23	metoclopramide	O	['N']	[23]
24	is	O	['N']	[24]
25	coadministered	O	['N']	[25]
26	even	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	,	O	['N']	[30]
31	conventional	O	['N']	[31]
32	dose	O	['N']	[32]
33	.	O	['N']	[33]
#680
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	two	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	acute	B	['N']	[7]
8	endophthalmitis	I-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	intravitreal	O	['N']	[10]
11	bevacizumab	B-Drug	['Causes']	[8]
12	injection	O	['N']	[12]
13	.	O	['N']	[13]
#681
0	Propranolol	B-Drug	['Causes']	[9]
1	:	O	['N']	[1]
2	an	O	['N']	[2]
3	unrecognized	O	['N']	[3]
4	cause	O	['N']	[4]
5	of	O	['N']	[5]
6	central	B	['N']	[6]
7	nervous	I	['N']	[7]
8	system	I	['N']	[8]
9	dysfunction	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	patients	O	['N']	[11]
12	undergoing	O	['N']	[12]
13	cardiopulmonary	O	['N']	[13]
14	bypass	O	['N']	[14]
15	.	O	['N']	[15]
#682
0	Hashimoto	B	['N']	[0]
1	's	I	['N']	[1]
2	disease	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	interferon	B	['N']	[4]
5	-	I	['N']	[5]
6	alpha	I-Drug	['Causes']	[2]
7	therapy	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	pre	O	['N']	[12]
13	-	O	['N']	[13]
14	treatment	O	['N']	[14]
15	negative	O	['N']	[15]
16	anti	O	['N']	[16]
17	-	O	['N']	[17]
18	thyroid	O	['N']	[18]
19	autoantibodies	O	['N']	[19]
20	and	O	['N']	[20]
21	with	O	['N']	[21]
22	the	O	['N']	[22]
23	specific	O	['N']	[23]
24	genetic	O	['N']	[24]
25	susceptibility	O	['N']	[25]
26	to	O	['N']	[26]
27	the	O	['N']	[27]
28	thyroid	O	['N']	[28]
29	disease	O	['N']	[29]
30	.	O	['N']	[30]
#683
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	toxin	B	['N']	[7]
8	-	I	['N']	[8]
9	positive	I	['N']	[9]
10	Clostridium	I	['N']	[10]
11	difficile	I	['N']	[11]
12	-	I	['N']	[12]
13	induced	I	['N']	[13]
14	colitis	I-Adverse_Effect	['N']	[14]
15	(	O	['N']	[15]
16	CDIC	O	['N']	[16]
17	)	O	['N']	[17]
18	after	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	clindamycin	B	['N']	[21]
22	phosphate	I-Drug	['Causes']	[14]
23	vaginal	O	['N']	[23]
24	cream	O	['N']	[24]
25	.	O	['N']	[25]
#684
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	UFT	B-Drug	['Causes']	[12]
7	-	I	['N']	[7]
8	induced	I	['N']	[8]
9	scleroderma	I	['N']	[9]
10	-	I	['N']	[10]
11	like	I	['N']	[11]
12	reaction	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#685
0	We	O	['N']	[0]
1	conjectured	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	side	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	insulin	B-Drug	['Causes']	[17]
8	,	O	['N']	[8]
9	such	O	['N']	[9]
10	as	O	['N']	[10]
11	anti	O	['N']	[11]
12	-	O	['N']	[12]
13	natriuresis	O	['N']	[13]
14	and	O	['N']	[14]
15	increased	B	['N']	[15]
16	vascular	I	['N']	[16]
17	permeability	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	might	O	['N']	[19]
20	be	O	['N']	[20]
21	pronounced	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	presence	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatic	O	['N']	[27]
28	dysfunction	O	['N']	[28]
29	that	O	['N']	[29]
30	accompanies	O	['N']	[30]
31	insulin	O	['N']	[31]
32	insensitivity	O	['N']	[32]
33	,	O	['N']	[33]
34	hyperinsulinaemia	O	['N']	[34]
35	and	O	['N']	[35]
36	hypoalbuminaemia	O	['N']	[36]
37	.	O	['N']	[37]
#686
0	This	O	['N']	[0]
1	paper	O	['N']	[1]
2	reports	O	['N']	[2]
3	an	O	['N']	[3]
4	autopsy	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	78-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	male	O	['N']	[11]
12	with	O	['N']	[12]
13	multiple	B	['N']	[13]
14	nodules	I	['N']	[14]
15	in	I	['N']	[15]
16	the	I	['N']	[16]
17	liver	I-Adverse_Effect	['N']	[17]
18	developed	O	['N']	[18]
19	after	O	['N']	[19]
20	long	O	['N']	[20]
21	-	O	['N']	[21]
22	termed	O	['N']	[22]
23	administration	O	['N']	[23]
24	of	O	['N']	[24]
25	phosphate	O	['N']	[25]
26	diethylstilbestrol	O	['N']	[26]
27	(	O	['N']	[27]
28	PDES	B-Drug	['Causes']	[17]
29	)	O	['N']	[29]
30	for	O	['N']	[30]
31	prostatic	O	['N']	[31]
32	cancer	O	['N']	[32]
33	.	O	['N']	[33]
#687
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Methotrexate	O	['N']	[2]
3	(	O	['N']	[3]
4	MTX	B-Drug	['Causes']	[20]
5	)	O	['N']	[5]
6	may	O	['N']	[6]
7	induce	O	['N']	[7]
8	liver	O	['N']	[8]
9	damage	O	['N']	[9]
10	,	O	['N']	[10]
11	which	O	['N']	[11]
12	in	O	['N']	[12]
13	some	O	['N']	[13]
14	psoriatics	O	['N']	[14]
15	will	O	['N']	[15]
16	lead	O	['N']	[16]
17	to	O	['N']	[17]
18	fibrosis	O	['N']	[18]
19	or	O	['N']	[19]
20	cirrhosis	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#688
0	Despite	O	['N']	[0]
1	minimal	O	['N']	[1]
2	short	O	['N']	[2]
3	-	O	['N']	[3]
4	term	O	['N']	[4]
5	side	O	['N']	[5]
6	effects	O	['N']	[6]
7	and	O	['N']	[7]
8	apparent	O	['N']	[8]
9	efficacy	O	['N']	[9]
10	,	O	['N']	[10]
11	chronic	O	['N']	[11]
12	treatment	O	['N']	[12]
13	of	O	['N']	[13]
14	MG	O	['N']	[14]
15	with	O	['N']	[15]
16	MM	B-Drug	['Causes']	[25]
17	may	O	['N']	[17]
18	be	O	['N']	[18]
19	associated	O	['N']	[19]
20	with	O	['N']	[20]
21	increased	O	['N']	[21]
22	risk	O	['N']	[22]
23	of	O	['N']	[23]
24	lymphoproliferative	B	['N']	[24]
25	disorders	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#689
0	A	O	['N']	[0]
1	22-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	drug	O	['N']	[4]
5	-	O	['N']	[5]
6	abuser	O	['N']	[6]
7	injected	O	['N']	[7]
8	flunitrazepam	B-Drug	['Causes']	[30]
9	tablets	O	['N']	[9]
10	dissolved	O	['N']	[10]
11	in	O	['N']	[11]
12	tap	O	['N']	[12]
13	water	O	['N']	[13]
14	into	O	['N']	[14]
15	her	O	['N']	[15]
16	left	O	['N']	[16]
17	femoral	O	['N']	[17]
18	artery	O	['N']	[18]
19	and	O	['N']	[19]
20	presented	O	['N']	[20]
21	with	O	['N']	[21]
22	clinical	O	['N']	[22]
23	signs	O	['N']	[23]
24	of	O	['N']	[24]
25	acute	B	['N']	[25]
26	ischaemia	I	['N']	[26]
27	of	I	['N']	[27]
28	the	I	['N']	[28]
29	left	I	['N']	[29]
30	leg	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#690
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Itraconazole	B-Drug	['Causes']	[25]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	liver	O	['N']	[5]
6	injury	O	['N']	[6]
7	presents	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	cholestatic	O	['N']	[10]
11	pattern	O	['N']	[11]
12	of	O	['N']	[12]
13	injury	O	['N']	[13]
14	with	O	['N']	[14]
15	damage	O	['N']	[15]
16	to	O	['N']	[16]
17	the	O	['N']	[17]
18	interlobular	O	['N']	[18]
19	bile	O	['N']	[19]
20	ducts	O	['N']	[20]
21	,	O	['N']	[21]
22	possibly	O	['N']	[22]
23	leading	O	['N']	[23]
24	to	O	['N']	[24]
25	ductopenia	B-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#691
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	described	O	['N']	[2]
3	feeling	B	['N']	[3]
4	cold	I-Adverse_Effect	['N']	[4]
5	with	O	['N']	[5]
6	worsening	O	['N']	[6]
7	headache	O	['N']	[7]
8	and	O	['N']	[8]
9	chills	O	['N']	[9]
10	approximately	O	['N']	[10]
11	one	O	['N']	[11]
12	hour	O	['N']	[12]
13	after	O	['N']	[13]
14	infusion	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	first	O	['N']	[17]
18	dose	O	['N']	[18]
19	of	O	['N']	[19]
20	penicillin	B-Drug	['Causes']	[4]
21	.	O	['N']	[21]
#692
0	Chronic	O	['N']	[0]
1	fentanyl	B-Drug	['Causes']	[5]
2	application	O	['N']	[2]
3	induces	O	['N']	[3]
4	adrenocortical	B	['N']	[4]
5	insufficiency	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#693
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	low	O	['N']	[3]
4	-	O	['N']	[4]
5	dose	O	['N']	[5]
6	HU	B-Drug	['Causes']	[16]
7	therapy	O	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	thalassemia	O	['N']	[11]
12	intermedia	O	['N']	[12]
13	may	O	['N']	[13]
14	increase	B	['N']	[14]
15	total	I	['N']	[15]
16	Hb	I-Adverse_Effect	['N']	[16]
17	levels	O	['N']	[17]
18	sufficiently	O	['N']	[18]
19	to	O	['N']	[19]
20	eliminate	O	['N']	[20]
21	the	O	['N']	[21]
22	need	O	['N']	[22]
23	for	O	['N']	[23]
24	transfusions	O	['N']	[24]
25	.	O	['N']	[25]
#694
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	B-Drug	['Causes']	[46]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	O	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	B	['N']	[42]
43	-	I	['N']	[43]
44	reaction	I	['N']	[44]
45	to	I	['N']	[45]
46	promethazine	I-Adverse_Effect	['N']	[46]
47	,	O	['N']	[47]
48	decreased	O	['N']	[48]
49	MED	O	['N']	[49]
50	to	O	['N']	[50]
51	both	O	['N']	[51]
52	UVA	O	['N']	[52]
53	and	O	['N']	[53]
54	UVB	O	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	photosensitivity	O	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#695
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	37-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	African-	O	['N']	[6]
7	American	O	['N']	[7]
8	man	O	['N']	[8]
9	with	O	['N']	[9]
10	G6PD	O	['N']	[10]
11	deficiency	O	['N']	[11]
12	developed	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	anemia	O	['N']	[14]
15	,	O	['N']	[15]
16	hepatitis	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	orthostatic	O	['N']	[18]
19	hypotension	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	aseptic	O	['N']	[22]
23	meningitis	O	['N']	[23]
24	simultaneously	O	['N']	[24]
25	after	O	['N']	[25]
26	using	O	['N']	[26]
27	trimethoprim	B-Drug	['Causes']	[16]
28	-	O	['N']	[28]
29	sulfamethoxazole	O	['N']	[29]
30	.	O	['N']	[30]
#696
0	Three	O	['N']	[0]
1	of	O	['N']	[1]
2	these	O	['N']	[2]
3	patients	O	['N']	[3]
4	had	O	['N']	[4]
5	convulsions	O	['N']	[5]
6	attributed	O	['N']	[6]
7	to	O	['N']	[7]
8	imipenem	B-Drug	['Causes']	[18]
9	/	O	['N']	[9]
10	cilastatin	O	['N']	[10]
11	;	O	['N']	[11]
12	3.6	O	['N']	[12]
13	%	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	patients	O	['N']	[16]
17	had	O	['N']	[17]
18	seizure	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	or	O	['N']	[20]
21	2	O	['N']	[21]
22	%	O	['N']	[22]
23	of	O	['N']	[23]
24	imipenem	O	['N']	[24]
25	/	O	['N']	[25]
26	cilastatin	O	['N']	[26]
27	administrations	O	['N']	[27]
28	was	O	['N']	[28]
29	followed	O	['N']	[29]
30	by	O	['N']	[30]
31	a	O	['N']	[31]
32	seizure	O	['N']	[32]
33	attack	O	['N']	[33]
34	.	O	['N']	[34]
#697
0	Because	O	['N']	[0]
1	there	O	['N']	[1]
2	were	O	['N']	[2]
3	no	O	['N']	[3]
4	other	O	['N']	[4]
5	obvious	O	['N']	[5]
6	causes	O	['N']	[6]
7	of	O	['N']	[7]
8	renal	O	['N']	[8]
9	failure	O	['N']	[9]
10	in	O	['N']	[10]
11	either	O	['N']	[11]
12	patient	O	['N']	[12]
13	,	O	['N']	[13]
14	we	O	['N']	[14]
15	propose	O	['N']	[15]
16	that	O	['N']	[16]
17	skeletal	B	['N']	[17]
18	muscle	I	['N']	[18]
19	ischemia	I-Adverse_Effect	['N']	[19]
20	developed	O	['N']	[20]
21	during	O	['N']	[21]
22	vasopressin	B-Drug	['Causes']	[19]
23	infusion	O	['N']	[23]
24	,	O	['N']	[24]
25	followed	O	['N']	[25]
26	by	O	['N']	[26]
27	release	O	['N']	[27]
28	of	O	['N']	[28]
29	myoglobin	O	['N']	[29]
30	and	O	['N']	[30]
31	renal	O	['N']	[31]
32	damage	O	['N']	[32]
33	.	O	['N']	[33]
#698
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	extrinsic	O	['N']	[3]
4	asthma	O	['N']	[4]
5	and	O	['N']	[5]
6	coexistent	O	['N']	[6]
7	insulin	O	['N']	[7]
8	-	O	['N']	[8]
9	dependent	O	['N']	[9]
10	diabetes	O	['N']	[10]
11	mellitus	O	['N']	[11]
12	sustained	O	['N']	[12]
13	an	O	['N']	[13]
14	anaphylactoid	B	['N']	[14]
15	reaction	I-Adverse_Effect	['N']	[15]
16	after	O	['N']	[16]
17	the	O	['N']	[17]
18	intravenous	O	['N']	[18]
19	administration	O	['N']	[19]
20	of	O	['N']	[20]
21	50	O	['N']	[21]
22	%	O	['N']	[22]
23	solution	O	['N']	[23]
24	of	O	['N']	[24]
25	dextrose	B-Drug	['Causes']	[15]
26	.	O	['N']	[26]
#699
0	In	O	['N']	[0]
1	one	O	['N']	[1]
2	instance	O	['N']	[2]
3	a	O	['N']	[3]
4	systemic	O	['N']	[4]
5	hypoglycemic	O	['N']	[5]
6	reaction	O	['N']	[6]
7	resulting	O	['N']	[7]
8	in	O	['N']	[8]
9	head	O	['N']	[9]
10	trauma	O	['N']	[10]
11	and	O	['N']	[11]
12	confusion	B-Adverse_Effect	['N']	[12]
13	ended	O	['N']	[13]
14	in	O	['N']	[14]
15	an	O	['N']	[15]
16	emegency	O	['N']	[16]
17	hospital	O	['N']	[17]
18	admission	O	['N']	[18]
19	following	O	['N']	[19]
20	the	O	['N']	[20]
21	substitution	O	['N']	[21]
22	of	O	['N']	[22]
23	acetohexamide	B-Drug	['Causes']	[12]
24	for	O	['N']	[24]
25	acetazolamide	O	['N']	[25]
26	.	O	['N']	[26]
#700
0	Patients	O	['N']	[0]
1	from	O	['N']	[1]
2	endemic	O	['N']	[2]
3	areas	O	['N']	[3]
4	referred	O	['N']	[4]
5	to	O	['N']	[5]
6	transplant	O	['N']	[6]
7	centers	O	['N']	[7]
8	may	O	['N']	[8]
9	be	O	['N']	[9]
10	at	O	['N']	[10]
11	high	O	['N']	[11]
12	risk	O	['N']	[12]
13	for	O	['N']	[13]
14	disseminated	B	['N']	[14]
15	histoplasmosis	I-Adverse_Effect	['N']	[15]
16	when	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	long	O	['N']	[19]
20	-	O	['N']	[20]
21	term	O	['N']	[21]
22	prednisone	B-Drug	['Causes']	[15]
23	for	O	['N']	[23]
24	graft	O	['N']	[24]
25	-	O	['N']	[25]
26	versus	O	['N']	[26]
27	-	O	['N']	[27]
28	host	O	['N']	[28]
29	disease	O	['N']	[29]
30	.	O	['N']	[30]
#701
0	Sideroblastic	B	['N']	[0]
1	anemia	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	linezolid	B-Drug	['Causes']	[1]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	left	O	['N']	[10]
11	ventricular	O	['N']	[11]
12	assist	O	['N']	[12]
13	device	O	['N']	[13]
14	.	O	['N']	[14]
#702
0	CASE	O	['N']	[0]
1	DESCRIPTION	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	59-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	with	O	['N']	[8]
9	known	O	['N']	[9]
10	neurocysticercosis	O	['N']	[10]
11	developed	O	['N']	[11]
12	a	O	['N']	[12]
13	large	B	['N']	[13]
14	cerebral	I	['N']	[14]
15	infarction	I-Adverse_Effect	['N']	[15]
16	during	O	['N']	[16]
17	praziquantel	B-Drug	['Causes']	[15]
18	therapy	O	['N']	[18]
19	.	O	['N']	[19]
#703
0	A	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	bipolar	O	['N']	[6]
7	disorder	O	['N']	[7]
8	and	O	['N']	[8]
9	complicated	O	['N']	[9]
10	cardiovascular	O	['N']	[10]
11	disease	O	['N']	[11]
12	who	O	['N']	[12]
13	was	O	['N']	[13]
14	on	O	['N']	[14]
15	maintenance	O	['N']	[15]
16	lithium	O	['N']	[16]
17	therapy	O	['N']	[17]
18	developed	O	['N']	[18]
19	a	O	['N']	[19]
20	movement	B	['N']	[20]
21	disorder	I-Adverse_Effect	['N']	[21]
22	following	O	['N']	[22]
23	high	O	['N']	[23]
24	doses	O	['N']	[24]
25	of	O	['N']	[25]
26	trazodone	B-Drug	['Causes']	[21]
27	for	O	['N']	[27]
28	treatment	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	acute	O	['N']	[31]
32	depression	O	['N']	[32]
33	.	O	['N']	[33]
#704
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	vitiligo	B-Adverse_Effect	['N']	[5]
6	that	O	['N']	[6]
7	occurred	O	['N']	[7]
8	during	O	['N']	[8]
9	the	O	['N']	[9]
10	second	O	['N']	[10]
11	month	O	['N']	[11]
12	of	O	['N']	[12]
13	interferon	B	['N']	[13]
14	alpha	I	['N']	[14]
15	2a	I-Drug	['Causes']	[5]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	chronic	O	['N']	[18]
19	active	O	['N']	[19]
20	hepatitis	O	['N']	[20]
21	C.	O	['N']	[21]
#705
0	This	O	['N']	[0]
1	paper	O	['N']	[1]
2	reports	O	['N']	[2]
3	on	O	['N']	[3]
4	a	O	['N']	[4]
5	6.9-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	autistic	O	['N']	[8]
9	male	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	repeated	O	['N']	[12]
13	episodes	O	['N']	[13]
14	of	O	['N']	[14]
15	acute	O	['N']	[15]
16	dystonic	O	['N']	[16]
17	reactions	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	pimozide	B-Drug	['Dosage']	[31]
21	administration	O	['N']	[21]
22	at	O	['N']	[22]
23	the	O	['N']	[23]
24	doses	O	['N']	[24]
25	of	O	['N']	[25]
26	0.096	B	['N']	[26]
27	mg	I	['N']	[27]
28	/	I	['N']	[28]
29	kg	I	['N']	[29]
30	/	I	['N']	[30]
31	day	I-Dose	['N']	[31]
32	and	O	['N']	[32]
33	0.032	O	['N']	[33]
34	mg	O	['N']	[34]
35	/	O	['N']	[35]
36	kg	O	['N']	[36]
37	/	O	['N']	[37]
38	day	O	['N']	[38]
39	and	O	['N']	[39]
40	32	O	['N']	[40]
41	hours	O	['N']	[41]
42	following	O	['N']	[42]
43	pimozide	O	['N']	[43]
44	withdrawal	O	['N']	[44]
45	,	O	['N']	[45]
46	as	O	['N']	[46]
47	well	O	['N']	[47]
48	as	O	['N']	[48]
49	during	O	['N']	[49]
50	subsequent	O	['N']	[50]
51	thioridazine	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#706
0	The	O	['N']	[0]
1	photosensitivity	B-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	still	O	['N']	[3]
4	present	O	['N']	[4]
5	3	O	['N']	[5]
6	years	O	['N']	[6]
7	after	O	['N']	[7]
8	the	O	['N']	[8]
9	withdrawal	O	['N']	[9]
10	of	O	['N']	[10]
11	quinine	B-Drug	['Causes']	[1]
12	.	O	['N']	[12]
#707
0	Allopurinol	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	hand	B	['N']	[3]
4	and	I	['N']	[4]
5	foot	I	['N']	[5]
6	deformities	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	chronic	O	['N']	[8]
9	tophaceous	O	['N']	[9]
10	gout	O	['N']	[10]
11	.	O	['N']	[11]
#708
0	High	O	['N']	[0]
1	-	O	['N']	[1]
2	dose	O	['N']	[2]
3	intravenous	O	['N']	[3]
4	mannitol	B-Drug	['Causes']	[17]
5	infusion	O	['N']	[5]
6	in	O	['N']	[6]
7	various	O	['N']	[7]
8	clinical	O	['N']	[8]
9	settings	O	['N']	[9]
10	may	O	['N']	[10]
11	result	O	['N']	[11]
12	in	O	['N']	[12]
13	acute	O	['N']	[13]
14	renal	O	['N']	[14]
15	failure	O	['N']	[15]
16	(	O	['N']	[16]
17	ARF	B-Adverse_Effect	['N']	[17]
18	)	O	['N']	[18]
19	.	O	['N']	[19]
#709
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	B-Drug	['Causes']	[30]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	B	['N']	[29]
30	jerks	I-Adverse_Effect	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#710
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	5-FU	B-Drug	['Causes']	[25]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	colon	O	['N']	[9]
10	cancer	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	suffered	O	['N']	[13]
14	severe	O	['N']	[14]
15	mucositis	O	['N']	[15]
16	,	O	['N']	[16]
17	desquamating	O	['N']	[17]
18	dermatitis	O	['N']	[18]
19	,	O	['N']	[19]
20	prolonged	O	['N']	[20]
21	myelosuppression	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	neurologic	B	['N']	[24]
25	toxicity	I-Adverse_Effect	['N']	[25]
26	that	O	['N']	[26]
27	required	O	['N']	[27]
28	admission	O	['N']	[28]
29	to	O	['N']	[29]
30	the	O	['N']	[30]
31	intensive	O	['N']	[31]
32	care	O	['N']	[32]
33	unit	O	['N']	[33]
34	.	O	['N']	[34]
#711
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	exacerbated	O	['N']	[7]
8	mania	B-Adverse_Effect	['N']	[8]
9	potentially	O	['N']	[9]
10	related	O	['N']	[10]
11	to	O	['N']	[11]
12	an	O	['N']	[12]
13	interaction	O	['N']	[13]
14	between	O	['N']	[14]
15	lopinavir	B-Drug	['Causes']	[8]
16	/	O	['N']	[16]
17	ritonavir	O	['N']	[17]
18	and	O	['N']	[18]
19	valproic	O	['N']	[19]
20	acid	O	['N']	[20]
21	(	O	['N']	[21]
22	VPA	O	['N']	[22]
23	)	O	['N']	[23]
24	and	O	['N']	[24]
25	propose	O	['N']	[25]
26	a	O	['N']	[26]
27	mechanism	O	['N']	[27]
28	of	O	['N']	[28]
29	action	O	['N']	[29]
30	for	O	['N']	[30]
31	this	O	['N']	[31]
32	interaction	O	['N']	[32]
33	.	O	['N']	[33]
#712
0	Transient	O	['N']	[0]
1	left	O	['N']	[1]
2	homonymous	O	['N']	[2]
3	hemianopsia	O	['N']	[3]
4	and	O	['N']	[4]
5	encephalopathy	B-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	testicular	O	['N']	[9]
10	carcinoma	O	['N']	[10]
11	with	O	['N']	[11]
12	cisplatinum	O	['N']	[12]
13	,	O	['N']	[13]
14	vinblastine	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	bleomycin	B-Drug	['Causes']	[5]
18	.	O	['N']	[18]
#713
0	Paradoxical	B	['N']	[0]
1	ventricular	I	['N']	[1]
2	tachycardia	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	fibrillation	O	['N']	[4]
5	after	O	['N']	[5]
6	intravenous	O	['N']	[6]
7	bretylium	B-Drug	['Causes']	[2]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#714
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	Two	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	exudative	O	['N']	[5]
6	age	B	['N']	[6]
7	-	I	['N']	[7]
8	related	I	['N']	[8]
9	macular	I	['N']	[9]
10	degeneration	I-Adverse_Effect	['N']	[10]
11	were	O	['N']	[11]
12	treated	O	['N']	[12]
13	sequentially	O	['N']	[13]
14	with	O	['N']	[14]
15	an	O	['N']	[15]
16	intravitreal	O	['N']	[16]
17	injection	O	['N']	[17]
18	of	O	['N']	[18]
19	bevacizumab	B-Drug	['Causes']	[10]
20	and	O	['N']	[20]
21	developed	O	['N']	[21]
22	signs	O	['N']	[22]
23	of	O	['N']	[23]
24	severe	O	['N']	[24]
25	but	O	['N']	[25]
26	painless	O	['N']	[26]
27	infectious	O	['N']	[27]
28	endophthalmitis	O	['N']	[28]
29	2	O	['N']	[29]
30	days	O	['N']	[30]
31	later	O	['N']	[31]
32	.	O	['N']	[32]
#715
0	A	O	['N']	[0]
1	62-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Indian	O	['N']	[4]
5	with	O	['N']	[5]
6	diabetic	O	['N']	[6]
7	nephropathy	O	['N']	[7]
8	controlled	O	['N']	[8]
9	with	O	['N']	[9]
10	metformin	B-Drug	['Causes']	[14]
11	,	O	['N']	[11]
12	developed	O	['N']	[12]
13	miliary	B	['N']	[13]
14	tuberculosis	I-Adverse_Effect	['N']	[14]
15	for	O	['N']	[15]
16	which	O	['N']	[16]
17	he	O	['N']	[17]
18	was	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	rifampicin	O	['N']	[21]
22	,	O	['N']	[22]
23	isoniazid	O	['N']	[23]
24	and	O	['N']	[24]
25	ethambutol	O	['N']	[25]
26	.	O	['N']	[26]
#716
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	described	O	['N']	[2]
3	feeling	O	['N']	[3]
4	cold	O	['N']	[4]
5	with	O	['N']	[5]
6	worsening	B	['N']	[6]
7	headache	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	chills	O	['N']	[9]
10	approximately	O	['N']	[10]
11	one	O	['N']	[11]
12	hour	O	['N']	[12]
13	after	O	['N']	[13]
14	infusion	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	first	O	['N']	[17]
18	dose	O	['N']	[18]
19	of	O	['N']	[19]
20	penicillin	B-Drug	['Causes']	[7]
21	.	O	['N']	[21]
#717
0	Masculinization	B	['N']	[0]
1	of	I	['N']	[1]
2	a	I	['N']	[2]
3	female	I	['N']	[3]
4	fetus	I-Adverse_Effect	['N']	[4]
5	occurred	O	['N']	[5]
6	in	O	['N']	[6]
7	5	O	['N']	[7]
8	of	O	['N']	[8]
9	39	O	['N']	[9]
10	(	O	['N']	[10]
11	12.8	O	['N']	[11]
12	%	O	['N']	[12]
13	)	O	['N']	[13]
14	exposed	O	['N']	[14]
15	to	O	['N']	[15]
16	norethisterone	B-Drug	['Causes']	[4]
17	;	O	['N']	[17]
18	all	O	['N']	[18]
19	were	O	['N']	[19]
20	cases	O	['N']	[20]
21	of	O	['N']	[21]
22	clitoral	O	['N']	[22]
23	hypertrophy	O	['N']	[23]
24	not	O	['N']	[24]
25	requiring	O	['N']	[25]
26	surgical	O	['N']	[26]
27	treatment	O	['N']	[27]
28	.	O	['N']	[28]
#718
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	depressive	O	['N']	[3]
4	patient	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	mild	O	['N']	[7]
8	parkinsonian	O	['N']	[8]
9	signs	O	['N']	[9]
10	and	O	['N']	[10]
11	camptocormia	B-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	introduction	O	['N']	[14]
15	of	O	['N']	[15]
16	olanzapine	B-Drug	['Causes']	[11]
17	.	O	['N']	[17]
#719
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	pulmonary	O	['N']	[5]
6	adenocarcinoma	O	['N']	[6]
7	complicated	O	['N']	[7]
8	by	O	['N']	[8]
9	the	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	of	O	['N']	[11]
12	inappropriate	O	['N']	[12]
13	secretion	O	['N']	[13]
14	of	O	['N']	[14]
15	antidiuretic	O	['N']	[15]
16	hormone	O	['N']	[16]
17	(	O	['N']	[17]
18	SIADH	B-Adverse_Effect	['N']	[18]
19	)	O	['N']	[19]
20	following	O	['N']	[20]
21	systemic	O	['N']	[21]
22	chemotherapy	O	['N']	[22]
23	with	O	['N']	[23]
24	cisplatin	O	['N']	[24]
25	(	O	['N']	[25]
26	CDDP	O	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	vindesine	B-Drug	['Causes']	[18]
30	(	O	['N']	[30]
31	VDS	O	['N']	[31]
32	)	O	['N']	[32]
33	.	O	['N']	[33]
#720
0	Thiopurine	O	['N']	[0]
1	methyltransferase	O	['N']	[1]
2	deficiency	O	['N']	[2]
3	occurs	O	['N']	[3]
4	at	O	['N']	[4]
5	a	O	['N']	[5]
6	frequency	O	['N']	[6]
7	of	O	['N']	[7]
8	one	O	['N']	[8]
9	in	O	['N']	[9]
10	300	O	['N']	[10]
11	and	O	['N']	[11]
12	is	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	profound	O	['N']	[15]
16	myelosuppression	B-Adverse_Effect	['N']	[16]
17	after	O	['N']	[17]
18	a	O	['N']	[18]
19	short	O	['N']	[19]
20	course	O	['N']	[20]
21	of	O	['N']	[21]
22	azathioprine	B-Drug	['Causes']	[16]
23	.	O	['N']	[23]
#721
0	Fatal	B	['N']	[0]
1	acute	I	['N']	[1]
2	encephalomyelitis	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	a	O	['N']	[4]
5	single	O	['N']	[5]
6	dose	O	['N']	[6]
7	of	O	['N']	[7]
8	intrathecal	O	['N']	[8]
9	methotrexate	B-Drug	['Causes']	[2]
10	.	O	['N']	[10]
#722
0	The	O	['N']	[0]
1	spectrum	O	['N']	[1]
2	of	O	['N']	[2]
3	nitrofurantoin	B-Drug	['Causes']	[5]
4	lung	B	['N']	[4]
5	injury	I-Adverse_Effect	['N']	[5]
6	continues	O	['N']	[6]
7	to	O	['N']	[7]
8	widen	O	['N']	[8]
9	.	O	['N']	[9]
#723
0	He	O	['N']	[0]
1	developed	O	['N']	[1]
2	recurrent	O	['N']	[2]
3	skin	O	['N']	[3]
4	rash	O	['N']	[4]
5	,	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	hypereosinophilia	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	acute	B	['N']	[11]
12	renal	I	['N']	[12]
13	failure	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	rechallenge	O	['N']	[15]
16	with	O	['N']	[16]
17	chlorambucil	B-Drug	['Causes']	[13]
18	.	O	['N']	[18]
#724
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	severe	O	['N']	[7]
8	corticosteroid	O	['N']	[8]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	glaucoma	B-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	intravitreal	O	['N']	[13]
14	injection	O	['N']	[14]
15	of	O	['N']	[15]
16	triamcinolone	B	['N']	[16]
17	acetate	I-Drug	['Causes']	[11]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	34-year	O	['N']	[20]
21	-	O	['N']	[21]
22	old	O	['N']	[22]
23	man	O	['N']	[23]
24	without	O	['N']	[24]
25	a	O	['N']	[25]
26	history	O	['N']	[26]
27	of	O	['N']	[27]
28	glaucoma	O	['N']	[28]
29	.	O	['N']	[29]
#725
0	Reversible	O	['N']	[0]
1	cholestasis	B-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	bile	O	['N']	[3]
4	duct	O	['N']	[4]
5	injury	O	['N']	[5]
6	following	O	['N']	[6]
7	azathioprine	B-Drug	['Causes']	[1]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#726
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	interstitial	O	['N']	[5]
6	pulmonary	O	['N']	[6]
7	disease	O	['N']	[7]
8	that	O	['N']	[8]
9	occurred	O	['N']	[9]
10	together	O	['N']	[10]
11	with	O	['N']	[11]
12	lymphocytic	B	['N']	[12]
13	colitis	I-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	treatment	O	['N']	[15]
16	with	O	['N']	[16]
17	ticlopidine	B-Drug	['Causes']	[13]
18	.	O	['N']	[18]
#727
0	After	O	['N']	[0]
1	5	O	['N']	[1]
2	weeks	O	['N']	[2]
3	of	O	['N']	[3]
4	therapy	O	['N']	[4]
5	,	O	['N']	[5]
6	she	O	['N']	[6]
7	stopped	O	['N']	[7]
8	taking	O	['N']	[8]
9	pantoprazole	B-Drug	['Causes']	[13]
10	due	O	['N']	[10]
11	to	O	['N']	[11]
12	general	B	['N']	[12]
13	malaise	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#728
0	Adverse	O	['N']	[0]
1	effects	O	['N']	[1]
2	of	O	['N']	[2]
3	amiodarone	B-Drug	['Causes']	[16]
4	including	O	['N']	[4]
5	pulmonary	O	['N']	[5]
6	toxicity	O	['N']	[6]
7	,	O	['N']	[7]
8	hepatotoxicity	O	['N']	[8]
9	,	O	['N']	[9]
10	aggravation	O	['N']	[10]
11	of	O	['N']	[11]
12	arrhythmia	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	thyroid	B	['N']	[15]
16	diseases	I-Adverse_Effect	['N']	[16]
17	are	O	['N']	[17]
18	well	O	['N']	[18]
19	understood	O	['N']	[19]
20	.	O	['N']	[20]
#729
0	Acute	O	['N']	[0]
1	asymptomatic	B	['N']	[1]
2	hepatitis	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	healthy	O	['N']	[5]
6	normal	O	['N']	[6]
7	volunteer	O	['N']	[7]
8	exposed	O	['N']	[8]
9	to	O	['N']	[9]
10	2	O	['N']	[10]
11	oral	O	['N']	[11]
12	doses	O	['N']	[12]
13	of	O	['N']	[13]
14	amodiaquine	O	['N']	[14]
15	and	O	['N']	[15]
16	artesunate	B-Drug	['Causes']	[2]
17	.	O	['N']	[17]
#730
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	linear	O	['N']	[7]
8	immunoglobulin	O	['N']	[8]
9	(	O	['N']	[9]
10	Ig	O	['N']	[10]
11	)	O	['N']	[11]
12	A	O	['N']	[12]
13	bullous	O	['N']	[13]
14	dermatosis	O	['N']	[14]
15	(	O	['N']	[15]
16	LABD	B-Adverse_Effect	['N']	[16]
17	)	O	['N']	[17]
18	induced	O	['N']	[18]
19	by	O	['N']	[19]
20	gemcitabine	B-Drug	['Causes']	[16]
21	.	O	['N']	[21]
#731
0	Since	O	['N']	[0]
1	amiodarone	B-Drug	['Causes']	[18]
2	was	O	['N']	[2]
3	first	O	['N']	[3]
4	marketed	O	['N']	[4]
5	in	O	['N']	[5]
6	1992	O	['N']	[6]
7	in	O	['N']	[7]
8	Japan	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	incidence	O	['N']	[11]
12	of	O	['N']	[12]
13	amiodarone	O	['N']	[13]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	thyrotoxicosis	O	['N']	[16]
17	(	O	['N']	[17]
18	AIT	B-Adverse_Effect	['N']	[18]
19	)	O	['N']	[19]
20	has	O	['N']	[20]
21	been	O	['N']	[21]
22	increasing	O	['N']	[22]
23	.	O	['N']	[23]
#732
0	Case	O	['N']	[0]
1	2	O	['N']	[1]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	29-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	woman	O	['N']	[7]
8	,	O	['N']	[8]
9	developed	O	['N']	[9]
10	bilateral	B	['N']	[10]
11	optic	I	['N']	[11]
12	neuritis	I-Adverse_Effect	['N']	[12]
13	combined	O	['N']	[13]
14	with	O	['N']	[14]
15	numbness	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	lower	O	['N']	[18]
19	extremities	O	['N']	[19]
20	as	O	['N']	[20]
21	well	O	['N']	[21]
22	as	O	['N']	[22]
23	bowel	O	['N']	[23]
24	and	O	['N']	[24]
25	bladder	O	['N']	[25]
26	dysfunction	O	['N']	[26]
27	after	O	['N']	[27]
28	a	O	['N']	[28]
29	22-month	O	['N']	[29]
30	use	O	['N']	[30]
31	of	O	['N']	[31]
32	recombinant	B	['N']	[32]
33	interferon	I	['N']	[33]
34	alpha-2b	I-Drug	['Causes']	[12]
35	for	O	['N']	[35]
36	chronic	O	['N']	[36]
37	myelogenous	O	['N']	[37]
38	leukemia	O	['N']	[38]
39	.	O	['N']	[39]
#733
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	Case	O	['N']	[2]
3	analysis	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	poly	O	['N']	[6]
7	-	O	['N']	[7]
8	drug	O	['N']	[8]
9	overdose	O	['N']	[9]
10	(	O	['N']	[10]
11	venlafaxine	O	['N']	[11]
12	,	O	['N']	[12]
13	topiramate	B-Drug	['Causes']	[28]
14	,	O	['N']	[14]
15	divalproex	O	['N']	[15]
16	sodium	O	['N']	[16]
17	,	O	['N']	[17]
18	risperidone	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	carbamazepine	O	['N']	[21]
22	)	O	['N']	[22]
23	presenting	O	['N']	[23]
24	with	O	['N']	[24]
25	mixed	O	['N']	[25]
26	SS	O	['N']	[26]
27	/	O	['N']	[27]
28	NMS	B-Adverse_Effect	['N']	[28]
29	features	O	['N']	[29]
30	and	O	['N']	[30]
31	whose	O	['N']	[31]
32	clinical	O	['N']	[32]
33	management	O	['N']	[33]
34	suggests	O	['N']	[34]
35	a	O	['N']	[35]
36	practical	O	['N']	[36]
37	algorithm	O	['N']	[37]
38	for	O	['N']	[38]
39	treatment	O	['N']	[39]
40	of	O	['N']	[40]
41	undifferentiated	O	['N']	[41]
42	SS	O	['N']	[42]
43	/	O	['N']	[43]
44	NMS	O	['N']	[44]
45	in	O	['N']	[45]
46	critical	O	['N']	[46]
47	care	O	['N']	[47]
48	settings	O	['N']	[48]
49	.	O	['N']	[49]
#734
0	Interferon	B	['N']	[0]
1	-	I	['N']	[1]
2	alpha	I-Drug	['Causes']	[7]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	focal	B	['N']	[5]
6	segmental	I	['N']	[6]
7	glomerulosclerosis	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	chronic	O	['N']	[9]
10	myelogenous	O	['N']	[10]
11	leukemia	O	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	case	O	['N']	[14]
15	report	O	['N']	[15]
16	and	O	['N']	[16]
17	review	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	literature	O	['N']	[20]
21	.	O	['N']	[21]
#735
0	Avascular	B	['N']	[0]
1	necrosis	I	['N']	[1]
2	of	I	['N']	[2]
3	the	I	['N']	[3]
4	femoral	I	['N']	[4]
5	head	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	prostate	O	['N']	[9]
10	cancer	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	cyproterone	B	['N']	[13]
14	acetate	I-Drug	['Causes']	[5]
15	and	O	['N']	[15]
16	radiotherapy	O	['N']	[16]
17	.	O	['N']	[17]
#736
0	Adult	B	['N']	[0]
1	respiratory	I	['N']	[1]
2	distress	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	treatment	O	['N']	[5]
6	with	O	['N']	[6]
7	pegylated	B	['N']	[7]
8	interferon	I	['N']	[8]
9	alpha-2a	I-Drug	['Causes']	[3]
10	and	O	['N']	[10]
11	ribavirin	O	['N']	[11]
12	.	O	['N']	[12]
#737
0	The	O	['N']	[0]
1	cases	O	['N']	[1]
2	are	O	['N']	[2]
3	important	O	['N']	[3]
4	in	O	['N']	[4]
5	documenting	O	['N']	[5]
6	that	O	['N']	[6]
7	drug	O	['N']	[7]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	dystonias	-	['N']	[10]
11	do	O	['N']	[11]
12	occur	O	['N']	[12]
13	in	O	['N']	[13]
14	patients	O	['N']	[14]
15	with	O	['N']	[15]
16	dementia	O	['N']	[16]
17	,	O	['N']	[17]
18	that	O	['N']	[18]
19	risperidone	B-Drug	['N']	[19]
20	appears	O	['N']	[20]
21	to	O	['N']	[21]
22	have	O	['N']	[22]
23	contributed	O	['N']	[23]
24	to	O	['N']	[24]
25	dystonia	O	['N']	[25]
26	among	O	['N']	[26]
27	elderly	O	['N']	[27]
28	patients	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	that	O	['N']	[31]
32	the	O	['N']	[32]
33	categorization	O	['N']	[33]
34	of	O	['N']	[34]
35	dystonic	O	['N']	[35]
36	reactions	O	['N']	[36]
37	needs	O	['N']	[37]
38	further	O	['N']	[38]
39	clarification	O	['N']	[39]
40	.	O	['N']	[40]
#738
0	The	O	['N']	[0]
1	fever	B-Adverse_Effect	['N']	[1]
2	abated	O	['N']	[2]
3	promptly	O	['N']	[3]
4	following	O	['N']	[4]
5	discontinuation	O	['N']	[5]
6	of	O	['N']	[6]
7	acyclovir	B-Drug	['Causes']	[1]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	radiographic	O	['N']	[10]
11	abnormalities	O	['N']	[11]
12	resolved	O	['N']	[12]
13	over	O	['N']	[13]
14	ten	O	['N']	[14]
15	days	O	['N']	[15]
16	.	O	['N']	[16]
#739
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	48-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	seizure	O	['N']	[10]
11	disorder	O	['N']	[11]
12	on	O	['N']	[12]
13	divalproex	B	['N']	[13]
14	sodium	I-Drug	['Causes']	[21]
15	(	O	['N']	[15]
16	Depakote	O	['N']	[16]
17	)	O	['N']	[17]
18	who	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	dyspnea	B-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#740
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	traumatic	O	['N']	[7]
8	flap	O	['N']	[8]
9	dehiscence	O	['N']	[9]
10	and	O	['N']	[10]
11	Enterobacter	B	['N']	[11]
12	keratitis	I-Adverse_Effect	['N']	[12]
13	34	O	['N']	[13]
14	months	O	['N']	[14]
15	after	O	['N']	[15]
16	LASIK	B-Drug	['Causes']	[12]
17	.	O	['N']	[17]
#741
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	case	O	['N']	[3]
4	shows	O	['N']	[4]
5	that	O	['N']	[5]
6	switching	O	['N']	[6]
7	to	O	['N']	[7]
8	zidovudine	B-Drug	['Causes']	[15]
9	potentially	O	['N']	[9]
10	can	O	['N']	[10]
11	lead	O	['N']	[11]
12	to	O	['N']	[12]
13	a	O	['N']	[13]
14	hyperlactatemia	B	['N']	[14]
15	relapse	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#742
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	In	O	['N']	[2]
3	these	O	['N']	[3]
4	3	O	['N']	[4]
5	cases	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	unique	O	['N']	[8]
9	positive	O	['N']	[9]
10	ocular	O	['N']	[10]
11	finding	O	['N']	[11]
12	was	O	['N']	[12]
13	corneal	B	['N']	[13]
14	endothelial	I	['N']	[14]
15	deposits	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	may	O	['N']	[18]
19	be	O	['N']	[19]
20	related	O	['N']	[20]
21	to	O	['N']	[21]
22	the	O	['N']	[22]
23	use	O	['N']	[23]
24	of	O	['N']	[24]
25	rifabutin	B-Drug	['Causes']	[15]
26	.	O	['N']	[26]
#743
0	By	O	['N']	[0]
1	means	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	in	O	['N']	[4]
5	vitro	O	['N']	[5]
6	heparin	O	['N']	[6]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	platelet	B	['N']	[9]
10	activation	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	HIPA	O	['N']	[12]
13	)	O	['N']	[13]
14	assay	O	['N']	[14]
15	it	O	['N']	[15]
16	was	O	['N']	[16]
17	shown	O	['N']	[17]
18	that	O	['N']	[18]
19	standard	O	['N']	[19]
20	heparin	O	['N']	[20]
21	and	O	['N']	[21]
22	the	O	['N']	[22]
23	LMW	O	['N']	[23]
24	heparins	O	['N']	[24]
25	Fragmin	B-Drug	['Causes']	[10]
26	and	O	['N']	[26]
27	Fraxiparin	O	['N']	[27]
28	(	O	['N']	[28]
29	Sanofi	O	['N']	[29]
30	Labaz	O	['N']	[30]
31	,	O	['N']	[31]
32	Munich	O	['N']	[32]
33	,	O	['N']	[33]
34	FRG	O	['N']	[34]
35	)	O	['N']	[35]
36	,	O	['N']	[36]
37	as	O	['N']	[37]
38	well	O	['N']	[38]
39	as	O	['N']	[39]
40	the	O	['N']	[40]
41	enoxaparine	O	['N']	[41]
42	Clexane	O	['N']	[42]
43	(	O	['N']	[43]
44	Nattermann	O	['N']	[44]
45	,	O	['N']	[45]
46	Cologne	O	['N']	[46]
47	,	O	['N']	[47]
48	FRG	O	['N']	[48]
49	)	O	['N']	[49]
50	,	O	['N']	[50]
51	all	O	['N']	[51]
52	induced	O	['N']	[52]
53	platelet	O	['N']	[53]
54	activation	O	['N']	[54]
55	with	O	['N']	[55]
56	the	O	['N']	[56]
57	patient	O	['N']	[57]
58	's	O	['N']	[58]
59	serum	O	['N']	[59]
60	.	O	['N']	[60]
#744
0	Leflunomide	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	toxic	B	['N']	[3]
4	epidermal	I	['N']	[4]
5	necrolysis	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	rheumatoid	O	['N']	[10]
11	arthritis	O	['N']	[11]
12	.	O	['N']	[12]
#745
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	fundus	O	['N']	[3]
4	picture	O	['N']	[4]
5	shown	O	['N']	[5]
6	in	O	['N']	[6]
7	these	O	['N']	[7]
8	cases	O	['N']	[8]
9	may	O	['N']	[9]
10	be	O	['N']	[10]
11	typical	O	['N']	[11]
12	of	O	['N']	[12]
13	ASPPC	B-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	IVTA	B-Drug	['Causes']	[13]
16	injection	O	['N']	[16]
17	.	O	['N']	[17]
#746
0	On	O	['N']	[0]
1	day	O	['N']	[1]
2	7	O	['N']	[2]
3	of	O	['N']	[3]
4	linezolid	B-Drug	['Causes']	[14]
5	treatment	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	developed	O	['N']	[9]
10	severe	O	['N']	[10]
11	pruritus	O	['N']	[11]
12	,	O	['N']	[12]
13	macular	B	['N']	[13]
14	rash	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	facial	O	['N']	[16]
17	edema	O	['N']	[17]
18	,	O	['N']	[18]
19	eosinophilia	O	['N']	[19]
20	,	O	['N']	[20]
21	marked	O	['N']	[21]
22	increase	O	['N']	[22]
23	in	O	['N']	[23]
24	serum	O	['N']	[24]
25	creatinine	O	['N']	[25]
26	level	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	mild	O	['N']	[29]
30	hepatitis	O	['N']	[30]
31	.	O	['N']	[31]
#747
0	Other	O	['N']	[0]
1	potential	O	['N']	[1]
2	causes	O	['N']	[2]
3	of	O	['N']	[3]
4	renal	B	['N']	[4]
5	failure	I-Adverse_Effect	['N']	[5]
6	were	O	['N']	[6]
7	not	O	['N']	[7]
8	present	O	['N']	[8]
9	in	O	['N']	[9]
10	our	O	['N']	[10]
11	patient	O	['N']	[11]
12	and	O	['N']	[12]
13	his	O	['N']	[13]
14	renal	O	['N']	[14]
15	function	O	['N']	[15]
16	gradually	O	['N']	[16]
17	recovered	O	['N']	[17]
18	with	O	['N']	[18]
19	the	O	['N']	[19]
20	cessation	O	['N']	[20]
21	of	O	['N']	[21]
22	suramin	B-Drug	['Causes']	[5]
23	treatment	O	['N']	[23]
24	.	O	['N']	[24]
#748
0	Paradoxical	O	['N']	[0]
1	ventricular	O	['N']	[1]
2	tachycardia	O	['N']	[2]
3	and	O	['N']	[3]
4	fibrillation	B-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	intravenous	O	['N']	[6]
7	bretylium	B-Drug	['Causes']	[4]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#749
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	combined	O	['N']	[6]
7	lithium	O	['N']	[7]
8	and	O	['N']	[8]
9	haloperidol	B-Drug	['Causes']	[25]
10	toxicity	O	['N']	[10]
11	characterized	O	['N']	[11]
12	by	O	['N']	[12]
13	hyperpyrexia	O	['N']	[13]
14	,	O	['N']	[14]
15	severe	O	['N']	[15]
16	rigidity	O	['N']	[16]
17	,	O	['N']	[17]
18	mutism	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	development	O	['N']	[21]
22	of	O	['N']	[22]
23	irreversible	B	['N']	[23]
24	tardive	I	['N']	[24]
25	dyskinesia	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#750
0	Stevens	B	['N']	[0]
1	-	I	['N']	[1]
2	Johnson	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	caused	O	['N']	[4]
5	by	O	['N']	[5]
6	the	O	['N']	[6]
7	antiretroviral	O	['N']	[7]
8	drug	O	['N']	[8]
9	nevirapine	B-Drug	['Causes']	[3]
10	.	O	['N']	[10]
#751
0	Fixed	B	['N']	[0]
1	drug	I	['N']	[1]
2	eruption	I-Adverse_Effect	['N']	[2]
3	to	O	['N']	[3]
4	rofecoxib	B-Drug	['Causes']	[2]
5	.	O	['N']	[5]
#752
0	Toxic	B	['N']	[0]
1	hepatitis	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	disulfiram	B-Drug	['Causes']	[1]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	non	O	['N']	[7]
8	-	O	['N']	[8]
9	alcoholic	O	['N']	[9]
10	.	O	['N']	[10]
#753
0	The	O	['N']	[0]
1	most	O	['N']	[1]
2	common	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	amifostine	B-Drug	['Causes']	[18]
8	are	O	['N']	[8]
9	nausea	O	['N']	[9]
10	,	O	['N']	[10]
11	vomiting	O	['N']	[11]
12	,	O	['N']	[12]
13	hypotension	O	['N']	[13]
14	,	O	['N']	[14]
15	hypocalcemia	O	['N']	[15]
16	and	O	['N']	[16]
17	allergic	B	['N']	[17]
18	reactions	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#754
0	Concurrent	B	['N']	[0]
1	acute	I	['N']	[1]
2	megaloblastic	I	['N']	[2]
3	anaemia	I-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	pneumonitis	O	['N']	[5]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	severe	O	['N']	[8]
9	side	O	['N']	[9]
10	-	O	['N']	[10]
11	effect	O	['N']	[11]
12	of	O	['N']	[12]
13	low	O	['N']	[13]
14	-	O	['N']	[14]
15	dose	O	['N']	[15]
16	methotrexate	B-Drug	['Causes']	[3]
17	therapy	O	['N']	[17]
18	during	O	['N']	[18]
19	rheumatoid	O	['N']	[19]
20	arthritis	O	['N']	[20]
21	.	O	['N']	[21]
#755
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	O	['N']	[3]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	B-Drug	['Causes']	[27]
13	150	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	d	O	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	O	['N']	[20]
21	oddly	O	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	O	['N']	[24]
25	profusely	O	['N']	[25]
26	,	O	['N']	[26]
27	shivering	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	O	['N']	[31]
32	,	O	['N']	[32]
33	agitated	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	O	['N']	[36]
37	.	O	['N']	[37]
#756
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	recurrent	O	['N']	[6]
7	(	O	['N']	[7]
8	stuttering	B-Adverse_Effect	['N']	[8]
9	)	O	['N']	[9]
10	priapism	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	protein	O	['N']	[15]
16	C	O	['N']	[16]
17	deficiency	O	['N']	[17]
18	while	O	['N']	[18]
19	maintained	O	['N']	[19]
20	on	O	['N']	[20]
21	Warfarin	B-Drug	['Causes']	[8]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#757
0	The	O	['N']	[0]
1	principle	O	['N']	[1]
2	treatment	O	['N']	[2]
3	for	O	['N']	[3]
4	DPD	O	['N']	[4]
5	-	O	['N']	[5]
6	deficient	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	severe	O	['N']	[9]
10	acute	O	['N']	[10]
11	5-FU	B-Drug	['Causes']	[34]
12	reactions	O	['N']	[12]
13	is	O	['N']	[13]
14	supportive	O	['N']	[14]
15	care	O	['N']	[15]
16	;	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	thymidine	O	['N']	[22]
23	potentially	O	['N']	[23]
24	may	O	['N']	[24]
25	reverse	O	['N']	[25]
26	severe	O	['N']	[26]
27	5-FU	O	['N']	[27]
28	-	O	['N']	[28]
29	induced	O	['N']	[29]
30	neurologic	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	such	O	['N']	[32]
33	as	O	['N']	[33]
34	encephalopathy	B-Adverse_Effect	['N']	[34]
35	and	O	['N']	[35]
36	coma	O	['N']	[36]
37	.	O	['N']	[37]
#758
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	25-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	postpartum	O	['N']	[7]
8	white	O	['N']	[8]
9	woman	O	['N']	[9]
10	developed	O	['N']	[10]
11	multiple	B	['N']	[11]
12	watery	I	['N']	[12]
13	stools	I-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	abdominal	O	['N']	[15]
16	cramping	O	['N']	[16]
17	on	O	['N']	[17]
18	day	O	['N']	[18]
19	6	O	['N']	[19]
20	of	O	['N']	[20]
21	therapy	O	['N']	[21]
22	with	O	['N']	[22]
23	clindamycin	B-Drug	['Causes']	[13]
24	vaginal	O	['N']	[24]
25	cream	O	['N']	[25]
26	for	O	['N']	[26]
27	bacterial	O	['N']	[27]
28	vaginosis	O	['N']	[28]
29	.	O	['N']	[29]
#759
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	receiving	O	['N']	[2]
3	vancomycin	B-Drug	['Causes']	[29]
4	for	O	['N']	[4]
5	a	O	['N']	[5]
6	serious	O	['N']	[6]
7	staphylococcal	O	['N']	[7]
8	infection	O	['N']	[8]
9	had	O	['N']	[9]
10	a	O	['N']	[10]
11	lupus	O	['N']	[11]
12	-	O	['N']	[12]
13	like	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	characterized	O	['N']	[15]
16	by	O	['N']	[16]
17	a	O	['N']	[17]
18	malar	O	['N']	[18]
19	rash	O	['N']	[19]
20	,	O	['N']	[20]
21	pain	O	['N']	[21]
22	and	O	['N']	[22]
23	erythema	B	['N']	[23]
24	of	I	['N']	[24]
25	the	I	['N']	[25]
26	cartilage	I	['N']	[26]
27	of	I	['N']	[27]
28	both	I	['N']	[28]
29	ears	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	tender	O	['N']	[32]
33	erythematous	O	['N']	[33]
34	and	O	['N']	[34]
35	hemorrhagic	O	['N']	[35]
36	lesions	O	['N']	[36]
37	of	O	['N']	[37]
38	the	O	['N']	[38]
39	finger	O	['N']	[39]
40	tips	O	['N']	[40]
41	.	O	['N']	[41]
#760
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	had	O	['N']	[2]
3	acute	O	['N']	[3]
4	cystitis	O	['N']	[4]
5	and	O	['N']	[5]
6	was	O	['N']	[6]
7	treated	O	['N']	[7]
8	by	O	['N']	[8]
9	sulphonamide	B-Drug	['Causes']	[14]
10	and	O	['N']	[10]
11	the	O	['N']	[11]
12	third	O	['N']	[12]
13	developed	O	['N']	[13]
14	myopia	B-Adverse_Effect	['N']	[14]
15	coincident	O	['N']	[15]
16	with	O	['N']	[16]
17	metronidazole	O	['N']	[17]
18	treatment	O	['N']	[18]
19	for	O	['N']	[19]
20	trichomonas	O	['N']	[20]
21	vaginalis	O	['N']	[21]
22	.	O	['N']	[22]
#761
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	main	O	['N']	[3]
4	adverse	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	leflunomide	B-Drug	['Causes']	[20]
8	consist	O	['N']	[8]
9	of	O	['N']	[9]
10	diarrhea	O	['N']	[10]
11	,	O	['N']	[11]
12	nausea	O	['N']	[12]
13	,	O	['N']	[13]
14	liver	O	['N']	[14]
15	enzyme	O	['N']	[15]
16	elevation	O	['N']	[16]
17	,	O	['N']	[17]
18	hypertension	O	['N']	[18]
19	,	O	['N']	[19]
20	alopecia	B-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	allergic	O	['N']	[23]
24	skin	O	['N']	[24]
25	reactions	O	['N']	[25]
26	.	O	['N']	[26]
#762
0	Heparin	B-Drug	['Causes']	[12]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	thrombocytopenia	O	['N']	[3]
4	complicated	O	['N']	[4]
5	with	O	['N']	[5]
6	massive	B	['N']	[6]
7	thrombosis	I	['N']	[7]
8	of	I	['N']	[8]
9	the	I	['N']	[9]
10	inferior	I	['N']	[10]
11	vena	I	['N']	[11]
12	cava	I-Adverse_Effect	['N']	[12]
13	after	O	['N']	[13]
14	filter	O	['N']	[14]
15	placement	O	['N']	[15]
16	.	O	['N']	[16]
#763
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	aforementioned	O	['N']	[5]
6	pathological	O	['N']	[6]
7	manifestations	O	['N']	[7]
8	were	O	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	chemotherapy	O	['N']	[11]
12	and	O	['N']	[12]
13	included	O	['N']	[13]
14	a	O	['N']	[14]
15	pulmonary	B	['N']	[15]
16	adverse	I	['N']	[16]
17	reaction	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	a	O	['N']	[19]
20	feature	O	['N']	[20]
21	never	O	['N']	[21]
22	previously	O	['N']	[22]
23	associated	O	['N']	[23]
24	with	O	['N']	[24]
25	oxaliplatinum	B-Drug	['Causes']	[17]
26	and	O	['N']	[26]
27	5-fluorouracil	O	['N']	[27]
28	regimens	O	['N']	[28]
29	.	O	['N']	[29]
#764
0	The	O	['N']	[0]
1	known	O	['N']	[1]
2	side	O	['N']	[2]
3	effects	O	['N']	[3]
4	of	O	['N']	[4]
5	sibutramine	B-Drug	['Causes']	[11]
6	,	O	['N']	[6]
7	ie	O	['N']	[7]
8	,	O	['N']	[8]
9	hypertension	O	['N']	[9]
10	and	O	['N']	[10]
11	tachycardia	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	depend	O	['N']	[13]
14	on	O	['N']	[14]
15	its	O	['N']	[15]
16	adrenergic	O	['N']	[16]
17	and	O	['N']	[17]
18	serotoninergic	O	['N']	[18]
19	effects	O	['N']	[19]
20	.	O	['N']	[20]
#765
0	Vancomycin	B-Drug	['Causes']	[24]
1	is	O	['N']	[1]
2	widely	O	['N']	[2]
3	used	O	['N']	[3]
4	against	O	['N']	[4]
5	methicillin	O	['N']	[5]
6	-	O	['N']	[6]
7	resistant	O	['N']	[7]
8	Staphylococcus	O	['N']	[8]
9	aureus	O	['N']	[9]
10	infections	O	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	it	O	['N']	[13]
14	is	O	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	many	O	['N']	[17]
18	adverse	O	['N']	[18]
19	effects	O	['N']	[19]
20	such	O	['N']	[20]
21	as	O	['N']	[21]
22	nephrotoxicity	O	['N']	[22]
23	,	O	['N']	[23]
24	ototoxicity	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	gastrointestinal	O	['N']	[26]
27	disturbances	O	['N']	[27]
28	,	O	['N']	[28]
29	blood	O	['N']	[29]
30	disorders	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	two	O	['N']	[33]
34	types	O	['N']	[34]
35	of	O	['N']	[35]
36	hypersensitivity	O	['N']	[36]
37	reactions	O	['N']	[37]
38	-	O	['N']	[38]
39	an	O	['N']	[39]
40	anaphylactoid	O	['N']	[40]
41	reaction	O	['N']	[41]
42	known	O	['N']	[42]
43	as	O	['N']	[43]
44	"	O	['N']	[44]
45	red	O	['N']	[45]
46	man	O	['N']	[46]
47	syndrome	O	['N']	[47]
48	"	O	['N']	[48]
49	and	O	['N']	[49]
50	anaphylaxis	O	['N']	[50]
51	.	O	['N']	[51]
#766
0	Disulfiram	B-Drug	['Causes']	[8]
1	encephalopathy	O	['N']	[1]
2	as	O	['N']	[2]
3	a	O	['N']	[3]
4	cause	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	catatonia	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#767
0	Although	O	['N']	[0]
1	transient	O	['N']	[1]
2	increases	O	['N']	[2]
3	in	O	['N']	[3]
4	ectopy	O	['N']	[4]
5	after	O	['N']	[5]
6	bretylium	B-Drug	['Causes']	[29]
7	therapy	O	['N']	[7]
8	have	O	['N']	[8]
9	been	O	['N']	[9]
10	described	O	['N']	[10]
11	,	O	['N']	[11]
12	presumably	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	catecholamine	O	['N']	[15]
16	release	O	['N']	[16]
17	,	O	['N']	[17]
18	the	O	['N']	[18]
19	occurrence	O	['N']	[19]
20	of	O	['N']	[20]
21	life	O	['N']	[21]
22	-	O	['N']	[22]
23	threatening	O	['N']	[23]
24	ventricular	O	['N']	[24]
25	arrhythmia	O	['N']	[25]
26	leading	O	['N']	[26]
27	to	O	['N']	[27]
28	cardiac	B	['N']	[28]
29	arrest	I-Adverse_Effect	['N']	[29]
30	has	O	['N']	[30]
31	not	O	['N']	[31]
32	previously	O	['N']	[32]
33	been	O	['N']	[33]
34	emphasized	O	['N']	[34]
35	.	O	['N']	[35]
#768
0	A	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	angina	O	['N']	[6]
7	pectoris	O	['N']	[7]
8	presented	O	['N']	[8]
9	with	O	['N']	[9]
10	syncope	O	['N']	[10]
11	after	O	['N']	[11]
12	sublingual	O	['N']	[12]
13	ingestion	O	['N']	[13]
14	of	O	['N']	[14]
15	isosorbide	B	['N']	[15]
16	dinitrate	I-Drug	['Dosage']	[19]
17	(	O	['N']	[17]
18	5	B	['N']	[18]
19	mg	I-Dose	['N']	[19]
20	)	O	['N']	[20]
21	.	O	['N']	[21]
#769
0	This	O	['N']	[0]
1	unusual	O	['N']	[1]
2	pattern	O	['N']	[2]
3	of	O	['N']	[3]
4	low	O	['N']	[4]
5	-	O	['N']	[5]
6	grade	O	['N']	[6]
7	endometrial	O	['N']	[7]
8	carcinoma	O	['N']	[8]
9	adds	O	['N']	[9]
10	to	O	['N']	[10]
11	the	O	['N']	[11]
12	spectrum	O	['N']	[12]
13	of	O	['N']	[13]
14	uterine	B	['N']	[14]
15	neoplasia	I-Adverse_Effect	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	tamoxifen	B-Drug	['Causes']	[15]
19	therapy	O	['N']	[19]
20	.	O	['N']	[20]
#770
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	subacute	O	['N']	[6]
7	methanol	B-Drug	['Causes']	[18]
8	toxicity	O	['N']	[8]
9	with	O	['N']	[9]
10	associated	O	['N']	[10]
11	diffuse	O	['N']	[11]
12	brain	O	['N']	[12]
13	involvement	O	['N']	[13]
14	,	O	['N']	[14]
15	including	O	['N']	[15]
16	bilateral	B	['N']	[16]
17	putaminal	I	['N']	[17]
18	necrosis	I-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	cerebral	O	['N']	[20]
21	edema	O	['N']	[21]
22	with	O	['N']	[22]
23	ventricular	O	['N']	[23]
24	compression	O	['N']	[24]
25	.	O	['N']	[25]
#771
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	possible	O	['N']	[7]
8	foscarnet	B-Drug	['Causes']	[16]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	severe	O	['N']	[11]
12	hypomagnesemia	O	['N']	[12]
13	and	O	['N']	[13]
14	other	O	['N']	[14]
15	electrolyte	B	['N']	[15]
16	disorders	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#772
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	B-Drug	['Causes']	[41]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	B-Adverse_Effect	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#773
0	Careful	O	['N']	[0]
1	follow	O	['N']	[1]
2	-	O	['N']	[2]
3	up	O	['N']	[3]
4	of	O	['N']	[4]
5	so	O	['N']	[5]
6	-	O	['N']	[6]
7	called	O	['N']	[7]
8	"	O	['N']	[8]
9	self	O	['N']	[9]
10	-	O	['N']	[10]
11	limited	O	['N']	[11]
12	"	O	['N']	[12]
13	insulin	B-Drug	['Causes']	[14]
14	edema	B-Adverse_Effect	['N']	[14]
15	is	O	['N']	[15]
16	encouraged	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	the	O	['N']	[19]
20	early	O	['N']	[20]
21	institution	O	['N']	[21]
22	of	O	['N']	[22]
23	diuretic	O	['N']	[23]
24	therapy	O	['N']	[24]
25	is	O	['N']	[25]
26	advocated	O	['N']	[26]
27	in	O	['N']	[27]
28	elderly	O	['N']	[28]
29	patients	O	['N']	[29]
30	to	O	['N']	[30]
31	prevent	O	['N']	[31]
32	the	O	['N']	[32]
33	development	O	['N']	[33]
34	of	O	['N']	[34]
35	overt	O	['N']	[35]
36	cardiac	O	['N']	[36]
37	failure	O	['N']	[37]
38	.	O	['N']	[38]
#774
0	The	O	['N']	[0]
1	observation	O	['N']	[1]
2	of	O	['N']	[2]
3	cutaneous	B	['N']	[3]
4	vasculitis	I-Adverse_Effect	['N']	[4]
5	during	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	propylthiouracil	B-Drug	['Causes']	[4]
9	suggested	O	['N']	[9]
10	that	O	['N']	[10]
11	clinical	O	['N']	[11]
12	awareness	O	['N']	[12]
13	of	O	['N']	[13]
14	this	O	['N']	[14]
15	complication	O	['N']	[15]
16	should	O	['N']	[16]
17	be	O	['N']	[17]
18	of	O	['N']	[18]
19	considerable	O	['N']	[19]
20	importance	O	['N']	[20]
21	.	O	['N']	[21]
#775
0	A	O	['N']	[0]
1	17-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	refractory	O	['N']	[6]
7	psoriatic	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	and	O	['N']	[9]
10	alpha-1	O	['N']	[10]
11	antitrypsin	O	['N']	[11]
12	deficiency	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	a	O	['N']	[15]
16	syringotropic	B	['N']	[16]
17	hypersensitivity	I	['N']	[17]
18	reaction	I-Adverse_Effect	['N']	[18]
19	after	O	['N']	[19]
20	9	O	['N']	[20]
21	months	O	['N']	[21]
22	of	O	['N']	[22]
23	therapy	O	['N']	[23]
24	with	O	['N']	[24]
25	infliximab	B-Drug	['Causes']	[18]
26	and	O	['N']	[26]
27	leflunomide	O	['N']	[27]
28	is	O	['N']	[28]
29	described	O	['N']	[29]
30	.	O	['N']	[30]
#776
0	A	O	['N']	[0]
1	well	O	['N']	[1]
2	-	O	['N']	[2]
3	recognized	O	['N']	[3]
4	complication	O	['N']	[4]
5	of	O	['N']	[5]
6	ethambutol	O	['N']	[6]
7	use	O	['N']	[7]
8	is	O	['N']	[8]
9	optic	O	['N']	[9]
10	neuropathy	O	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	the	O	['N']	[13]
14	potential	O	['N']	[14]
15	ocular	B	['N']	[15]
16	toxicity	I-Adverse_Effect	['N']	[16]
17	of	O	['N']	[17]
18	isoniazid	B-Drug	['Causes']	[16]
19	is	O	['N']	[19]
20	often	O	['N']	[20]
21	overlooked	O	['N']	[21]
22	.	O	['N']	[22]
#777
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	patient	O	['N']	[3]
4	's	O	['N']	[4]
5	rhabdomyolysis	B-Adverse_Effect	['N']	[5]
6	was	O	['N']	[6]
7	probably	O	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	sertraline	B-Drug	['Causes']	[5]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#778
0	In	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	swallowing	B	['N']	[3]
4	dysfunction	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	pneumonia	O	['N']	[6]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	mineral	B	['N']	[11]
12	oil	I-Drug	['Causes']	[4]
13	use	O	['N']	[13]
14	should	O	['N']	[14]
15	be	O	['N']	[15]
16	obtained	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	diagnosis	O	['N']	[19]
20	of	O	['N']	[20]
21	ELP	O	['N']	[21]
22	should	O	['N']	[22]
23	be	O	['N']	[23]
24	considered	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	differential	O	['N']	[27]
28	diagnoses	O	['N']	[28]
29	if	O	['N']	[29]
30	mineral	O	['N']	[30]
31	oil	O	['N']	[31]
32	use	O	['N']	[32]
33	has	O	['N']	[33]
34	occurred	O	['N']	[34]
35	.	O	['N']	[35]
#779
0	Although	O	['N']	[0]
1	a	O	['N']	[1]
2	lot	O	['N']	[2]
3	of	O	['N']	[3]
4	amiodarone	B-Drug	['Causes']	[9]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	torsades	B	['N']	[7]
8	de	I	['N']	[8]
9	pointe	I-Adverse_Effect	['N']	[9]
10	have	O	['N']	[10]
11	been	O	['N']	[11]
12	published	O	['N']	[12]
13	,	O	['N']	[13]
14	a	O	['N']	[14]
15	review	O	['N']	[15]
16	of	O	['N']	[16]
17	all	O	['N']	[17]
18	these	O	['N']	[18]
19	cases	O	['N']	[19]
20	and	O	['N']	[20]
21	the	O	['N']	[21]
22	underlying	O	['N']	[22]
23	risk	O	['N']	[23]
24	-	O	['N']	[24]
25	factors	O	['N']	[25]
26	has	O	['N']	[26]
27	never	O	['N']	[27]
28	been	O	['N']	[28]
29	made	O	['N']	[29]
30	.	O	['N']	[30]
#780
0	Itraconazole	O	['N']	[0]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	increased	O	['N']	[3]
4	vincristine	B-Drug	['Causes']	[5]
5	neurotoxicity	I-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	case	O	['N']	[7]
8	report	O	['N']	[8]
9	and	O	['N']	[9]
10	review	O	['N']	[10]
11	of	O	['N']	[11]
12	literature	O	['N']	[12]
13	.	O	['N']	[13]
#781
0	Diarrhea	B	['N']	[0]
1	-	I	['N']	[1]
2	associated	I	['N']	[2]
3	over	I	['N']	[3]
4	-	I	['N']	[4]
5	anticoagulation	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	taking	O	['N']	[9]
10	warfarin	B-Drug	['Causes']	[5]
11	:	O	['N']	[11]
12	therapeutic	O	['N']	[12]
13	role	O	['N']	[13]
14	of	O	['N']	[14]
15	cholestyramine	O	['N']	[15]
16	.	O	['N']	[16]
#782
0	The	O	['N']	[0]
1	main	O	['N']	[1]
2	side	O	['N']	[2]
3	-	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	Lp	B	['N']	[6]
7	-	I	['N']	[7]
8	TAE	I-Drug	['Causes']	[26]
9	combined	O	['N']	[9]
10	with	O	['N']	[10]
11	HT	O	['N']	[11]
12	were	O	['N']	[12]
13	low	O	['N']	[13]
14	-	O	['N']	[14]
15	grade	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	localized	O	['N']	[18]
19	pain	O	['N']	[19]
20	,	O	['N']	[20]
21	myelo	O	['N']	[21]
22	-	O	['N']	[22]
23	suppression	O	['N']	[23]
24	and	O	['N']	[24]
25	liver	B	['N']	[25]
26	dysfunction	I-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	but	O	['N']	[28]
29	these	O	['N']	[29]
30	were	O	['N']	[30]
31	transient	O	['N']	[31]
32	and	O	['N']	[32]
33	eventually	O	['N']	[33]
34	disappeared	O	['N']	[34]
35	.	O	['N']	[35]
#783
0	Here	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	RFP	B-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	hypothyroidism	B-Adverse_Effect	['N']	[10]
11	without	O	['N']	[11]
12	underlying	O	['N']	[12]
13	thyroid	O	['N']	[13]
14	disease	O	['N']	[14]
15	.	O	['N']	[15]
#784
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	two	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	rhabdomyolysis	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	taking	O	['N']	[10]
11	lovastatin	O	['N']	[11]
12	that	O	['N']	[12]
13	were	O	['N']	[13]
14	precipitated	O	['N']	[14]
15	by	O	['N']	[15]
16	the	O	['N']	[16]
17	use	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	newer	O	['N']	[20]
21	macrolide	O	['N']	[21]
22	antibiotics	O	['N']	[22]
23	clarithromycin	O	['N']	[23]
24	and	O	['N']	[24]
25	azithromycin	B-Drug	['Causes']	[7]
26	.	O	['N']	[26]
#785
0	Ceftriaxone	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	fixed	B	['N']	[3]
4	drug	I	['N']	[4]
5	eruption	I-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	first	O	['N']	[7]
8	report	O	['N']	[8]
9	.	O	['N']	[9]
#786
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	pancytopenia	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	23-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	man	O	['N']	[11]
12	with	O	['N']	[12]
13	Crohn	O	['N']	[13]
14	's	O	['N']	[14]
15	disease	O	['N']	[15]
16	who	O	['N']	[16]
17	was	O	['N']	[17]
18	treated	O	['N']	[18]
19	with	O	['N']	[19]
20	5-aminosalicylic	O	['N']	[20]
21	acid	O	['N']	[21]
22	(	O	['N']	[22]
23	Pentasa	B-Drug	['Causes']	[5]
24	;	O	['N']	[24]
25	Nisshin	O	['N']	[25]
26	,	O	['N']	[26]
27	Tokyo	O	['N']	[27]
28	,	O	['N']	[28]
29	Japan	O	['N']	[29]
30	)	O	['N']	[30]
31	3.0	O	['N']	[31]
32	g	O	['N']	[32]
33	/	O	['N']	[33]
34	day	O	['N']	[34]
35	.	O	['N']	[35]
#787
0	Behavioral	O	['N']	[0]
1	side	O	['N']	[1]
2	effects	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	clonazepam	B-Drug	['Causes']	[12]
6	may	O	['N']	[6]
7	include	O	['N']	[7]
8	agitation	O	['N']	[8]
9	,	O	['N']	[9]
10	aggression	O	['N']	[10]
11	,	O	['N']	[11]
12	hyperactivity	B-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	irritability	O	['N']	[14]
15	,	O	['N']	[15]
16	property	O	['N']	[16]
17	destruction	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	temper	O	['N']	[20]
21	tantrums	O	['N']	[21]
22	.	O	['N']	[22]
#788
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	57-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	female	O	['N']	[7]
8	with	O	['N']	[8]
9	cardiomyopathy	O	['N']	[9]
10	and	O	['N']	[10]
11	"	O	['N']	[11]
12	sulfa	O	['N']	[12]
13	"	O	['N']	[13]
14	(	O	['N']	[14]
15	trimethoprim	O	['N']	[15]
16	/	O	['N']	[16]
17	sulfamethoxazole	O	['N']	[17]
18	)	O	['N']	[18]
19	allergy	O	['N']	[19]
20	documented	O	['N']	[20]
21	as	O	['N']	[21]
22	pancreatitis	B-Adverse_Effect	['N']	[22]
23	presented	O	['N']	[23]
24	with	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	consistent	O	['N']	[26]
27	with	O	['N']	[27]
28	pancreatitis	O	['N']	[28]
29	after	O	['N']	[29]
30	use	O	['N']	[30]
31	of	O	['N']	[31]
32	furosemide	B-Drug	['Causes']	[22]
33	.	O	['N']	[33]
#789
0	Ciprofloxacin	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	toxic	B	['N']	[3]
4	epidermal	I	['N']	[4]
5	necrolysis	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	systemic	O	['N']	[10]
11	lupus	O	['N']	[11]
12	erythematosus	O	['N']	[12]
13	.	O	['N']	[13]
#790
0	NMS	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	drug	O	['N']	[3]
4	-	O	['N']	[4]
5	related	O	['N']	[5]
6	response	O	['N']	[6]
7	to	O	['N']	[7]
8	various	O	['N']	[8]
9	medications	O	['N']	[9]
10	,	O	['N']	[10]
11	such	O	['N']	[11]
12	as	O	['N']	[12]
13	Haloperidol	B-Drug	['Causes']	[0]
14	,	O	['N']	[14]
15	which	O	['N']	[15]
16	the	O	['N']	[16]
17	patient	O	['N']	[17]
18	was	O	['N']	[18]
19	receiving	O	['N']	[19]
20	.	O	['N']	[20]
#791
0	Our	O	['N']	[0]
1	report	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	CBDCA	B-Drug	['Causes']	[5]
5	hypersensitivity	B-Adverse_Effect	['N']	[5]
6	was	O	['N']	[6]
7	correlated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	total	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	previously	O	['N']	[13]
14	administered	O	['N']	[14]
15	platinum	O	['N']	[15]
16	agents	O	['N']	[16]
17	and	O	['N']	[17]
18	that	O	['N']	[18]
19	CBDCA	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	excluded	O	['N']	[22]
23	in	O	['N']	[23]
24	patients	O	['N']	[24]
25	who	O	['N']	[25]
26	have	O	['N']	[26]
27	received	O	['N']	[27]
28	multiple	O	['N']	[28]
29	platinum	O	['N']	[29]
30	-	O	['N']	[30]
31	based	O	['N']	[31]
32	chemotherapy	O	['N']	[32]
33	,	O	['N']	[33]
34	even	O	['N']	[34]
35	in	O	['N']	[35]
36	platinum	O	['N']	[36]
37	-	O	['N']	[37]
38	sensitive	O	['N']	[38]
39	cases	O	['N']	[39]
40	,	O	['N']	[40]
41	because	O	['N']	[41]
42	CBDCA	O	['N']	[42]
43	hypersensitivity	O	['N']	[43]
44	can	O	['N']	[44]
45	occur	O	['N']	[45]
46	even	O	['N']	[46]
47	with	O	['N']	[47]
48	low	O	['N']	[48]
49	-	O	['N']	[49]
50	dose	O	['N']	[50]
51	CBDCA	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#792
0	Esophageal	B	['N']	[0]
1	spasm	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	propranolol	B-Drug	['Causes']	[1]
4	overdose	O	['N']	[4]
5	relieved	O	['N']	[5]
6	by	O	['N']	[6]
7	glucagon	O	['N']	[7]
8	.	O	['N']	[8]
#793
0	Renal	B	['N']	[0]
1	injury	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	anastrozole	B-Drug	['Causes']	[1]
5	has	O	['N']	[5]
6	not	O	['N']	[6]
7	been	O	['N']	[7]
8	published	O	['N']	[8]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	English	O	['N']	[11]
12	literature	O	['N']	[12]
13	.	O	['N']	[13]
#794
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	O	['N']	[3]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	B-Drug	['Causes']	[31]
13	150	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	d	O	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	O	['N']	[20]
21	oddly	O	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	O	['N']	[24]
25	profusely	O	['N']	[25]
26	,	O	['N']	[26]
27	shivering	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	B-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	agitated	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	O	['N']	[36]
37	.	O	['N']	[37]
#795
0	Milk	B	['N']	[0]
1	-	I	['N']	[1]
2	alkali	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	1,25(OH)2D	B-Drug	['Causes']	[3]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	hypoparathyroidism	O	['N']	[11]
12	.	O	['N']	[12]
#796
0	After	O	['N']	[0]
1	initiation	O	['N']	[1]
2	of	O	['N']	[2]
3	topical	O	['N']	[3]
4	vitamin	B	['N']	[4]
5	D3	I-Drug	['Dosage']	[12]
6	ointment	O	['N']	[6]
7	(	O	['N']	[7]
8	20	B	['N']	[8]
9	micro	I	['N']	[9]
10	g	I	['N']	[10]
11	/	I	['N']	[11]
12	g	I-Dose	['N']	[12]
13	of	O	['N']	[13]
14	tacalcitol	O	['N']	[14]
15	)	O	['N']	[15]
16	10	O	['N']	[16]
17	g	O	['N']	[17]
18	/	O	['N']	[18]
19	day	O	['N']	[19]
20	for	O	['N']	[20]
21	the	O	['N']	[21]
22	skin	O	['N']	[22]
23	lesions	O	['N']	[23]
24	,	O	['N']	[24]
25	both	O	['N']	[25]
26	the	O	['N']	[26]
27	serum	O	['N']	[27]
28	level	O	['N']	[28]
29	of	O	['N']	[29]
30	calcium	O	['N']	[30]
31	and	O	['N']	[31]
32	urinary	O	['N']	[32]
33	excretion	O	['N']	[33]
34	of	O	['N']	[34]
35	calcium	O	['N']	[35]
36	increased	O	['N']	[36]
37	gradually	O	['N']	[37]
38	.	O	['N']	[38]
#797
0	Nitrofurantoin	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	acute	B	['N']	[3]
4	liver	I	['N']	[4]
5	damage	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	pregnancy	O	['N']	[7]
8	.	O	['N']	[8]
#798
0	Ifosfamide	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	nonconvulsive	B	['N']	[3]
4	status	I	['N']	[4]
5	epilepticus	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#799
0	Idiosyncratic	O	['N']	[0]
1	factors	O	['N']	[1]
2	involving	O	['N']	[2]
3	vasopressin	B-Drug	['Causes']	[12]
4	receptor	O	['N']	[4]
5	affinity	O	['N']	[5]
6	and	O	['N']	[6]
7	distribution	O	['N']	[7]
8	,	O	['N']	[8]
9	vasopressin	O	['N']	[9]
10	-	O	['N']	[10]
11	associated	O	['N']	[11]
12	vasodilation	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	some	O	['N']	[14]
15	vascular	O	['N']	[15]
16	beds	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	the	O	['N']	[19]
20	effect	O	['N']	[20]
21	of	O	['N']	[21]
22	vasopressin	O	['N']	[22]
23	on	O	['N']	[23]
24	the	O	['N']	[24]
25	renin	O	['N']	[25]
26	-	O	['N']	[26]
27	angiotensin	O	['N']	[27]
28	system	O	['N']	[28]
29	may	O	['N']	[29]
30	further	O	['N']	[30]
31	contribute	O	['N']	[31]
32	to	O	['N']	[32]
33	impaired	O	['N']	[33]
34	tissue	O	['N']	[34]
35	perfusion	O	['N']	[35]
36	.	O	['N']	[36]
#800
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	dramatic	O	['N']	[6]
7	,	O	['N']	[7]
8	permanent	O	['N']	[8]
9	vision	B	['N']	[9]
10	loss	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	a	O	['N']	[12]
13	9-month	O	['N']	[13]
14	course	O	['N']	[14]
15	of	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	ethambutol	O	['N']	[18]
19	and	O	['N']	[19]
20	isoniazid	B-Drug	['Causes']	[10]
21	for	O	['N']	[21]
22	pulmonary	O	['N']	[22]
23	tuberculosis	O	['N']	[23]
24	is	O	['N']	[24]
25	presented	O	['N']	[25]
26	.	O	['N']	[26]
#801
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	report	O	['N']	[3]
4	,	O	['N']	[4]
5	we	O	['N']	[5]
6	have	O	['N']	[6]
7	described	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	Crohn	O	['N']	[11]
12	's	O	['N']	[12]
13	disease	O	['N']	[13]
14	who	O	['N']	[14]
15	developed	O	['N']	[15]
16	subfulminant	B	['N']	[16]
17	hepatitis	I	['N']	[17]
18	B	I-Adverse_Effect	['N']	[18]
19	after	O	['N']	[19]
20	the	O	['N']	[20]
21	fourth	O	['N']	[21]
22	infusion	O	['N']	[22]
23	of	O	['N']	[23]
24	infliximab	B-Drug	['Causes']	[18]
25	due	O	['N']	[25]
26	to	O	['N']	[26]
27	an	O	['N']	[27]
28	unrecognized	O	['N']	[28]
29	HBs	O	['N']	[29]
30	-	O	['N']	[30]
31	antigen	O	['N']	[31]
32	carrier	O	['N']	[32]
33	state	O	['N']	[33]
34	.	O	['N']	[34]
#802
0	Concomitant	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	lithium	B-Drug	['Causes']	[12]
4	with	O	['N']	[4]
5	olanzapine	O	['N']	[5]
6	may	O	['N']	[6]
7	place	O	['N']	[7]
8	patients	O	['N']	[8]
9	at	O	['N']	[9]
10	risk	O	['N']	[10]
11	for	O	['N']	[11]
12	NMS	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#803
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	cerebrospinal	B	['N']	[5]
6	fluid	I	['N']	[6]
7	eosinophilia	I-Adverse_Effect	['N']	[7]
8	(	O	['N']	[8]
9	CSFE	O	['N']	[9]
10	)	O	['N']	[10]
11	secondary	O	['N']	[11]
12	to	O	['N']	[12]
13	the	O	['N']	[13]
14	intraventricular	O	['N']	[14]
15	administration	O	['N']	[15]
16	of	O	['N']	[16]
17	vancomycin	B-Drug	['Causes']	[7]
18	.	O	['N']	[18]
#804
0	An	O	['N']	[0]
1	8-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	child	O	['N']	[4]
5	with	O	['N']	[5]
6	familial	O	['N']	[6]
7	Mediterranean	O	['N']	[7]
8	fever	O	['N']	[8]
9	exhibited	O	['N']	[9]
10	signs	O	['N']	[10]
11	of	O	['N']	[11]
12	colchicine	B-Drug	['Causes']	[13]
13	intoxication	I-Adverse_Effect	['N']	[13]
14	while	O	['N']	[14]
15	receiving	O	['N']	[15]
16	prophylactic	O	['N']	[16]
17	doses	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	drug	O	['N']	[20]
21	.	O	['N']	[21]
#805
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	neuroleptic	B	['N']	[6]
7	malignant	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	occurred	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	on	O	['N']	[14]
15	amitriptyline	O	['N']	[15]
16	and	O	['N']	[16]
17	lithium	B	['N']	[17]
18	carbonate	I-Drug	['Causes']	[8]
19	.	O	['N']	[19]
#806
0	The	O	['N']	[0]
1	current	O	['N']	[1]
2	study	O	['N']	[2]
3	investigated	O	['N']	[3]
4	the	O	['N']	[4]
5	visual	O	['N']	[5]
6	fields	O	['N']	[6]
7	and	O	['N']	[7]
8	visual	O	['N']	[8]
9	electrophysiology	O	['N']	[9]
10	of	O	['N']	[10]
11	eight	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	known	O	['N']	[14]
15	vigabatrin	B-Drug	['Causes']	[20]
16	-	O	['N']	[16]
17	attributed	O	['N']	[17]
18	visual	B	['N']	[18]
19	field	I	['N']	[19]
20	loss	I-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	three	O	['N']	[22]
23	of	O	['N']	[23]
24	whom	O	['N']	[24]
25	were	O	['N']	[25]
26	reported	O	['N']	[26]
27	previously	O	['N']	[27]
28	.	O	['N']	[28]
#807
0	Following	O	['N']	[0]
1	7	O	['N']	[1]
2	days	O	['N']	[2]
3	of	O	['N']	[3]
4	tigecycline	B-Drug	['Causes']	[9]
5	she	O	['N']	[5]
6	developed	O	['N']	[6]
7	severe	B	['N']	[7]
8	abdominal	I	['N']	[8]
9	pain	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	elevated	O	['N']	[11]
12	pancreatic	O	['N']	[12]
13	enzymes	O	['N']	[13]
14	suggesting	O	['N']	[14]
15	acute	O	['N']	[15]
16	pancreatitis	O	['N']	[16]
17	.	O	['N']	[17]
#808
0	Evaluation	O	['N']	[0]
1	revealed	O	['N']	[1]
2	elevated	B	['N']	[2]
3	serum	I	['N']	[3]
4	LTG	B-Drug	['Causes']	[5]
5	levels	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	no	O	['N']	[7]
8	other	O	['N']	[8]
9	etiology	O	['N']	[9]
10	for	O	['N']	[10]
11	encephalopathy	O	['N']	[11]
12	.	O	['N']	[12]
#809
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	an	O	['N']	[2]
3	immediate	O	['N']	[3]
4	hypersensitivity	B	['N']	[4]
5	reaction	I-Adverse_Effect	['N']	[5]
6	during	O	['N']	[6]
7	the	O	['N']	[7]
8	initiation	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	MTX	B-Drug	['Causes']	[5]
12	infusion	O	['N']	[12]
13	with	O	['N']	[13]
14	diffuse	O	['N']	[14]
15	urticaria	O	['N']	[15]
16	,	O	['N']	[16]
17	facial	O	['N']	[17]
18	swelling	O	['N']	[18]
19	,	O	['N']	[19]
20	cough	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	chest	O	['N']	[23]
24	tightness	O	['N']	[24]
25	.	O	['N']	[25]
#810
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	presented	O	['N']	[2]
3	with	O	['N']	[3]
4	fulminant	B	['N']	[4]
5	microangiopathic	I	['N']	[5]
6	hemolytic	I	['N']	[6]
7	anemia	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	thrombocytopenia	O	['N']	[9]
10	within	O	['N']	[10]
11	48	O	['N']	[11]
12	hr	O	['N']	[12]
13	of	O	['N']	[13]
14	initiating	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	trimethoprim	B-Drug	['Causes']	[7]
18	-	O	['N']	[18]
19	sulfamethoxazole	O	['N']	[19]
20	.	O	['N']	[20]
#811
0	Protease	O	['N']	[0]
1	inhibitors	O	['N']	[1]
2	(	O	['N']	[2]
3	ritonavir	B-Drug	['Causes']	[21]
4	and	O	['N']	[4]
5	saquinavir	O	['N']	[5]
6	)	O	['N']	[6]
7	were	O	['N']	[7]
8	added	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	treatment	O	['N']	[11]
12	and	O	['N']	[12]
13	the	O	['N']	[13]
14	patient	O	['N']	[14]
15	developed	O	['N']	[15]
16	progressive	O	['N']	[16]
17	ataxia	O	['N']	[17]
18	related	O	['N']	[18]
19	to	O	['N']	[19]
20	carbamazepine	B	['N']	[20]
21	toxicity	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#812
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Amphotericin	B	['N']	[2]
3	B	I	['N']	[3]
4	deoxycholate	I-Drug	['Causes']	[16]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	reported	O	['N']	[7]
8	to	O	['N']	[8]
9	produce	O	['N']	[9]
10	significant	O	['N']	[10]
11	cardiac	O	['N']	[11]
12	toxicity	O	['N']	[12]
13	,	O	['N']	[13]
14	with	O	['N']	[14]
15	ventricular	B	['N']	[15]
16	arrhythmias	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	bradycardia	O	['N']	[18]
19	reported	O	['N']	[19]
20	in	O	['N']	[20]
21	overdoses	O	['N']	[21]
22	in	O	['N']	[22]
23	children	O	['N']	[23]
24	and	O	['N']	[24]
25	in	O	['N']	[25]
26	adults	O	['N']	[26]
27	with	O	['N']	[27]
28	preexisting	O	['N']	[28]
29	cardiac	O	['N']	[29]
30	disease	O	['N']	[30]
31	,	O	['N']	[31]
32	even	O	['N']	[32]
33	when	O	['N']	[33]
34	administered	O	['N']	[34]
35	in	O	['N']	[35]
36	conventional	O	['N']	[36]
37	dosages	O	['N']	[37]
38	and	O	['N']	[38]
39	infusion	O	['N']	[39]
40	rates	O	['N']	[40]
41	.	O	['N']	[41]
#813
0	She	O	['N']	[0]
1	developed	O	['N']	[1]
2	a	O	['N']	[2]
3	generalized	O	['N']	[3]
4	rash	O	['N']	[4]
5	and	O	['N']	[5]
6	itching	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	sore	O	['N']	[8]
9	throat	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	dizziness	O	['N']	[12]
13	approximately	O	['N']	[13]
14	4	O	['N']	[14]
15	hours	O	['N']	[15]
16	after	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	dose	O	['N']	[19]
20	of	O	['N']	[20]
21	capecitabine	B-Drug	['Causes']	[6]
22	.	O	['N']	[22]
#814
0	In	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	cirrhosis	O	['N']	[3]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	metabolism	O	['N']	[6]
7	of	O	['N']	[7]
8	meperidine	B-Drug	['Causes']	[23]
9	is	O	['N']	[9]
10	decreased	O	['N']	[10]
11	,	O	['N']	[11]
12	leading	O	['N']	[12]
13	to	O	['N']	[13]
14	accumulation	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	parent	O	['N']	[17]
18	drug	O	['N']	[18]
19	and	O	['N']	[19]
20	possible	O	['N']	[20]
21	CNS	B	['N']	[21]
22	depressive	I	['N']	[22]
23	effects	I-Adverse_Effect	['N']	[23]
24	similar	O	['N']	[24]
25	to	O	['N']	[25]
26	hepatic	O	['N']	[26]
27	encephalopathy	O	['N']	[27]
28	.	O	['N']	[28]
#815
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[16]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	B	['N']	[15]
16	reactions	I-Adverse_Effect	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	O	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#816
0	Cardiomyopathy	B-Adverse_Effect	['N']	[0]
1	after	O	['N']	[1]
2	widely	O	['N']	[2]
3	separated	O	['N']	[3]
4	courses	O	['N']	[4]
5	of	O	['N']	[5]
6	adriamycin	B-Drug	['Causes']	[0]
7	exacerbated	O	['N']	[7]
8	by	O	['N']	[8]
9	actinomycin	O	['N']	[9]
10	-	O	['N']	[10]
11	D	O	['N']	[11]
12	and	O	['N']	[12]
13	mithramycin	O	['N']	[13]
14	.	O	['N']	[14]
#817
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	acute	B	['N']	[8]
9	pancreatitis	I-Adverse_Effect	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	danazol	B-Drug	['Causes']	[9]
13	treatment	O	['N']	[13]
14	of	O	['N']	[14]
15	endometriosis	O	['N']	[15]
16	.	O	['N']	[16]
#818
0	Falling	B	['N']	[0]
1	backward	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	elderly	O	['N']	[4]
5	patients	O	['N']	[5]
6	taking	O	['N']	[6]
7	bupropion	B-Drug	['Causes']	[1]
8	.	O	['N']	[8]
#819
0	It	O	['N']	[0]
1	was	O	['N']	[1]
2	highly	O	['N']	[2]
3	suspected	O	['N']	[3]
4	that	O	['N']	[4]
5	finasteride	B-Drug	['Causes']	[15]
6	was	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	anterior	B	['N']	[10]
11	subcapsular	I	['N']	[11]
12	opacity	I	['N']	[12]
13	on	I	['N']	[13]
14	the	I	['N']	[14]
15	lens	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	the	O	['N']	[18]
19	patient	O	['N']	[19]
20	therefore	O	['N']	[20]
21	discontinued	O	['N']	[21]
22	use	O	['N']	[22]
23	of	O	['N']	[23]
24	finasteride	O	['N']	[24]
25	.	O	['N']	[25]
#820
0	Voriconazole	O	['N']	[0]
1	(	O	['N']	[1]
2	VRC	B-Drug	['Causes']	[13]
3	)	O	['N']	[3]
4	has	O	['N']	[4]
5	not	O	['N']	[5]
6	previously	O	['N']	[6]
7	been	O	['N']	[7]
8	reported	O	['N']	[8]
9	to	O	['N']	[9]
10	cause	O	['N']	[10]
11	angio	B	['N']	[11]
12	-	I	['N']	[12]
13	oedema	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#821
0	Indinavir	B-Drug	['Causes']	[7]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	nephrolithiasis	O	['N']	[3]
4	and	O	['N']	[4]
5	chronic	O	['N']	[5]
6	interstitial	B	['N']	[6]
7	nephritis	I-Adverse_Effect	['N']	[7]
8	were	O	['N']	[8]
9	the	O	['N']	[9]
10	only	O	['N']	[10]
11	possible	O	['N']	[11]
12	causes	O	['N']	[12]
13	identified	O	['N']	[13]
14	in	O	['N']	[14]
15	this	O	['N']	[15]
16	patient	O	['N']	[16]
17	.	O	['N']	[17]
#822
0	An	O	['N']	[0]
1	unusual	O	['N']	[1]
2	presentation	O	['N']	[2]
3	of	O	['N']	[3]
4	spontaneous	O	['N']	[4]
5	sub	B	['N']	[5]
6	-	I	['N']	[6]
7	conjunctival	I	['N']	[7]
8	haematoma	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	receiving	O	['N']	[12]
13	warfarin	B-Drug	['Causes']	[8]
14	.	O	['N']	[14]
#823
0	Sixteen	O	['N']	[0]
1	of	O	['N']	[1]
2	33	O	['N']	[2]
3	patients	O	['N']	[3]
4	developed	O	['N']	[4]
5	significant	O	['N']	[5]
6	hyponatremia	O	['N']	[6]
7	and	O	['N']	[7]
8	hypoosmolality	B-Adverse_Effect	['N']	[8]
9	during	O	['N']	[9]
10	oral	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	lorcainide	B-Drug	['Causes']	[8]
14	.	O	['N']	[14]
#824
0	Acute	B	['N']	[0]
1	myocardial	I	['N']	[1]
2	necrosis	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	administration	O	['N']	[4]
5	of	O	['N']	[5]
6	amsacrine	B-Drug	['Causes']	[2]
7	.	O	['N']	[7]
#825
0	Neurological	O	['N']	[0]
1	improvement	O	['N']	[1]
2	and	O	['N']	[2]
3	rehabilitation	O	['N']	[3]
4	potential	O	['N']	[4]
5	following	O	['N']	[5]
6	toxic	B	['N']	[6]
7	myelopathy	I-Adverse_Effect	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	intrathecal	O	['N']	[10]
11	injection	O	['N']	[11]
12	of	O	['N']	[12]
13	doxorubicin	B-Drug	['Causes']	[7]
14	.	O	['N']	[14]
#826
0	These	O	['N']	[0]
1	nail	B	['N']	[1]
2	changes	I-Adverse_Effect	['N']	[2]
3	gradually	O	['N']	[3]
4	disappeared	O	['N']	[4]
5	when	O	['N']	[5]
6	the	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	clofazimine	B-Drug	['Causes']	[2]
10	was	O	['N']	[10]
11	reduced	O	['N']	[11]
12	.	O	['N']	[12]
#827
0	Acute	O	['N']	[0]
1	severe	O	['N']	[1]
2	intoxication	O	['N']	[2]
3	with	O	['N']	[3]
4	carbamazepine	B-Drug	['Causes']	[13]
5	is	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	seizures	O	['N']	[8]
9	,	O	['N']	[9]
10	coma	O	['N']	[10]
11	and	O	['N']	[11]
12	respiratory	B	['N']	[12]
13	depression	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#828
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	diffuse	B	['N']	[8]
9	papular	I	['N']	[9]
10	eruption	I-Adverse_Effect	['N']	[10]
11	following	O	['N']	[11]
12	treatment	O	['N']	[12]
13	of	O	['N']	[13]
14	psoriasis	O	['N']	[14]
15	with	O	['N']	[15]
16	methotrexate	B-Drug	['Causes']	[10]
17	injections	O	['N']	[17]
18	.	O	['N']	[18]
#829
0	All	B	['N']	[0]
1	-	I	['N']	[1]
2	trans	I	['N']	[2]
3	retinoic	I	['N']	[3]
4	acid	I-Drug	['Causes']	[13]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	focal	O	['N']	[7]
8	myositis	O	['N']	[8]
9	,	O	['N']	[9]
10	synovitis	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	mononeuritis	B-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#830
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	other	O	['N']	[2]
3	hand	O	['N']	[3]
4	,	O	['N']	[4]
5	aspirin	B-Drug	['Causes']	[13]
6	may	O	['N']	[6]
7	have	O	['N']	[7]
8	promoted	O	['N']	[8]
9	the	O	['N']	[9]
10	enlargement	B	['N']	[10]
11	of	I	['N']	[11]
12	spontaneous	I	['N']	[12]
13	hemorrhage	I-Adverse_Effect	['N']	[13]
14	from	O	['N']	[14]
15	meningioma	O	['N']	[15]
16	.	O	['N']	[16]
#831
0	Possible	O	['N']	[0]
1	recurrence	O	['N']	[1]
2	of	O	['N']	[2]
3	amiodarone	B-Drug	['Causes']	[5]
4	pulmonary	B	['N']	[4]
5	toxicity	I-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	corticosteroid	O	['N']	[7]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#832
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	report	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	intracerebral	B	['N']	[8]
9	hemorrhage	I-Adverse_Effect	['N']	[9]
10	occurring	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	middle	O	['N']	[13]
14	-	O	['N']	[14]
15	aged	O	['N']	[15]
16	man	O	['N']	[16]
17	who	O	['N']	[17]
18	suffered	O	['N']	[18]
19	from	O	['N']	[19]
20	chronic	O	['N']	[20]
21	sinusitis	O	['N']	[21]
22	and	O	['N']	[22]
23	had	O	['N']	[23]
24	been	O	['N']	[24]
25	ingesting	O	['N']	[25]
26	pseudoephedrine	B-Drug	['Causes']	[9]
27	daily	O	['N']	[27]
28	for	O	['N']	[28]
29	one	O	['N']	[29]
30	year	O	['N']	[30]
31	.	O	['N']	[31]
#833
0	Despite	O	['N']	[0]
1	a	O	['N']	[1]
2	response	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	meningeal	O	['N']	[5]
6	tumor	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	developed	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	third	O	['N']	[12]
13	week	O	['N']	[13]
14	of	O	['N']	[14]
15	MTX	O	['N']	[15]
16	treatment	O	['N']	[16]
17	a	O	['N']	[17]
18	progressive	O	['N']	[18]
19	visual	O	['N']	[19]
20	loss	O	['N']	[20]
21	and	O	['N']	[21]
22	loss	B	['N']	[22]
23	of	I	['N']	[23]
24	consciousness	I-Adverse_Effect	['N']	[24]
25	which	O	['N']	[25]
26	worsened	O	['N']	[26]
27	during	O	['N']	[27]
28	subsequent	O	['N']	[28]
29	Ara	B	['N']	[29]
30	-	I	['N']	[30]
31	C	I-Drug	['Causes']	[24]
32	treatment	O	['N']	[32]
33	and	O	['N']	[33]
34	led	O	['N']	[34]
35	to	O	['N']	[35]
36	death	O	['N']	[36]
37	within	O	['N']	[37]
38	3	O	['N']	[38]
39	weeks	O	['N']	[39]
40	.	O	['N']	[40]
#834
0	The	O	['N']	[0]
1	latter	O	['N']	[1]
2	form	O	['N']	[2]
3	(	O	['N']	[3]
4	Macrodantin	B-Drug	['Causes']	[33]
5	)	O	['N']	[5]
6	is	O	['N']	[6]
7	reported	O	['N']	[7]
8	to	O	['N']	[8]
9	engender	O	['N']	[9]
10	less	O	['N']	[10]
11	gastrointestinal	O	['N']	[11]
12	intolerance	O	['N']	[12]
13	but	O	['N']	[13]
14	it	O	['N']	[14]
15	can	O	['N']	[15]
16	produce	O	['N']	[16]
17	the	O	['N']	[17]
18	same	O	['N']	[18]
19	adverse	O	['N']	[19]
20	effects	O	['N']	[20]
21	as	O	['N']	[21]
22	the	O	['N']	[22]
23	conventional	O	['N']	[23]
24	form	O	['N']	[24]
25	--	O	['N']	[25]
26	liver	O	['N']	[26]
27	damage	O	['N']	[27]
28	,	O	['N']	[28]
29	acute	B	['N']	[29]
30	and	I	['N']	[30]
31	chronic	I	['N']	[31]
32	pulmonary	I	['N']	[32]
33	reactions	I-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	peripheral	O	['N']	[35]
36	neuropathy	O	['N']	[36]
37	,	O	['N']	[37]
38	blood	O	['N']	[38]
39	dyscrasias	O	['N']	[39]
40	and	O	['N']	[40]
41	allergic	O	['N']	[41]
42	reactions	O	['N']	[42]
43	--	O	['N']	[43]
44	and	O	['N']	[44]
45	does	O	['N']	[45]
46	so	O	['N']	[46]
47	just	O	['N']	[47]
48	as	O	['N']	[48]
49	rapidly	O	['N']	[49]
50	and	O	['N']	[50]
51	floridly	O	['N']	[51]
52	;	O	['N']	[52]
53	one	O	['N']	[53]
54	such	O	['N']	[54]
55	case	O	['N']	[55]
56	is	O	['N']	[56]
57	reported	O	['N']	[57]
58	here	O	['N']	[58]
59	.	O	['N']	[59]
#835
0	This	O	['N']	[0]
1	patient	O	['N']	[1]
2	rapidly	O	['N']	[2]
3	progressed	O	['N']	[3]
4	from	O	['N']	[4]
5	mild	O	['N']	[5]
6	neurotoxicity	O	['N']	[6]
7	to	O	['N']	[7]
8	fatal	B	['N']	[8]
9	encephalopathy	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	one	O	['N']	[11]
12	dose	O	['N']	[12]
13	of	O	['N']	[13]
14	intrathecal	O	['N']	[14]
15	methotrexate	B-Drug	['Causes']	[9]
16	during	O	['N']	[16]
17	his	O	['N']	[17]
18	third	O	['N']	[18]
19	cycle	O	['N']	[19]
20	of	O	['N']	[20]
21	chemotherapy	O	['N']	[21]
22	.	O	['N']	[22]
#836
0	When	O	['N']	[0]
1	measured	O	['N']	[1]
2	,	O	['N']	[2]
3	the	O	['N']	[3]
4	serum	B	['N']	[4]
5	lithium	I	['N']	[5]
6	level	I	['N']	[6]
7	had	I	['N']	[7]
8	increased	I-Adverse_Effect	['N']	[8]
9	4-fold	O	['N']	[9]
10	during	O	['N']	[10]
11	acyclovir	B-Drug	['Causes']	[8]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#837
0	The	O	['N']	[0]
1	results	O	['N']	[1]
2	clearly	O	['N']	[2]
3	demonstrate	O	['N']	[3]
4	that	O	['N']	[4]
5	CPH82	B-Drug	['Causes']	[17]
6	was	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	suppression	B	['N']	[9]
10	of	I	['N']	[10]
11	the	I	['N']	[11]
12	endogeneous	I	['N']	[12]
13	production	I	['N']	[13]
14	of	I	['N']	[14]
15	ACTH	I	['N']	[15]
16	and	I	['N']	[16]
17	cortisol	I-Adverse_Effect	['N']	[17]
18	with	O	['N']	[18]
19	a	O	['N']	[19]
20	concomitant	O	['N']	[20]
21	paradoxical	O	['N']	[21]
22	picture	O	['N']	[22]
23	of	O	['N']	[23]
24	clinical	O	['N']	[24]
25	hypercortisolism	O	['N']	[25]
26	.	O	['N']	[26]
#838
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	(	O	['N']	[3]
4	a	O	['N']	[4]
5	)	O	['N']	[5]
6	cyclophosphamide	B-Drug	['Causes']	[10]
7	is	O	['N']	[7]
8	a	O	['N']	[8]
9	human	B	['N']	[9]
10	teratogen	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	(	O	['N']	[12]
13	b	O	['N']	[13]
14	)	O	['N']	[14]
15	a	O	['N']	[15]
16	distinct	O	['N']	[16]
17	phenotype	O	['N']	[17]
18	exists	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	(	O	['N']	[21]
22	c	O	['N']	[22]
23	)	O	['N']	[23]
24	the	O	['N']	[24]
25	safety	O	['N']	[25]
26	of	O	['N']	[26]
27	CP	O	['N']	[27]
28	in	O	['N']	[28]
29	pregnancy	O	['N']	[29]
30	is	O	['N']	[30]
31	in	O	['N']	[31]
32	serious	O	['N']	[32]
33	question	O	['N']	[33]
34	.	O	['N']	[34]
#839
0	Acute	O	['N']	[0]
1	interstitial	B	['N']	[1]
2	pneumonia	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	ONO-1078	B-Drug	['Causes']	[2]
6	(	O	['N']	[6]
7	pranlukast	O	['N']	[7]
8	)	O	['N']	[8]
9	,	O	['N']	[9]
10	a	O	['N']	[10]
11	leukotriene	O	['N']	[11]
12	receptor	O	['N']	[12]
13	antagonist	O	['N']	[13]
14	.	O	['N']	[14]
#840
0	Videopolysomnographic	O	['N']	[0]
1	and	O	['N']	[1]
2	pharmacokinetic	O	['N']	[2]
3	studies	O	['N']	[3]
4	with	O	['N']	[4]
5	monitoring	O	['N']	[5]
6	of	O	['N']	[6]
7	plasma	O	['N']	[7]
8	levodopa	B-Drug	['Causes']	[13]
9	levels	O	['N']	[9]
10	demonstrated	O	['N']	[10]
11	marked	B	['N']	[11]
12	motor	I	['N']	[12]
13	hyperactivity	I-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	augmentation	O	['N']	[15]
16	,	O	['N']	[16]
17	with	O	['N']	[17]
18	anarchic	O	['N']	[18]
19	discharges	O	['N']	[19]
20	of	O	['N']	[20]
21	motor	O	['N']	[21]
22	unit	O	['N']	[22]
23	potentials	O	['N']	[23]
24	,	O	['N']	[24]
25	tonic	O	['N']	[25]
26	grouped	O	['N']	[26]
27	discharges	O	['N']	[27]
28	and	O	['N']	[28]
29	flexor	O	['N']	[29]
30	spasms	O	['N']	[30]
31	,	O	['N']	[31]
32	associated	O	['N']	[32]
33	with	O	['N']	[33]
34	painful	O	['N']	[34]
35	dysesthesia	O	['N']	[35]
36	.	O	['N']	[36]
#841
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	report	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	clarithromycin	B-Drug	['Causes']	[18]
6	coadministration	O	['N']	[6]
7	induces	O	['N']	[7]
8	increased	O	['N']	[8]
9	plasma	O	['N']	[9]
10	carbamazepine	O	['N']	[10]
11	concentrations	O	['N']	[11]
12	,	O	['N']	[12]
13	which	O	['N']	[13]
14	may	O	['N']	[14]
15	result	O	['N']	[15]
16	in	O	['N']	[16]
17	carbamazepine	B	['N']	[17]
18	toxicity	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#842
0	Type	O	['N']	[0]
1	II	O	['N']	[1]
2	heparin	B-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	thrombocytopenia	B-Adverse_Effect	['N']	[5]
6	(	O	['N']	[6]
7	HIT	O	['N']	[7]
8	)	O	['N']	[8]
9	is	O	['N']	[9]
10	an	O	['N']	[10]
11	immunological	O	['N']	[11]
12	disorder	O	['N']	[12]
13	characterized	O	['N']	[13]
14	by	O	['N']	[14]
15	antibodies	O	['N']	[15]
16	to	O	['N']	[16]
17	heparin	O	['N']	[17]
18	-	O	['N']	[18]
19	platelet	O	['N']	[19]
20	factor	O	['N']	[20]
21	4	O	['N']	[21]
22	complexes	O	['N']	[22]
23	and	O	['N']	[23]
24	a	O	['N']	[24]
25	high	O	['N']	[25]
26	risk	O	['N']	[26]
27	of	O	['N']	[27]
28	thrombotic	O	['N']	[28]
29	complications	O	['N']	[29]
30	.	O	['N']	[30]
#843
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	three	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	acute	O	['N']	[7]
8	liver	B	['N']	[8]
9	damage	I-Adverse_Effect	['N']	[9]
10	during	O	['N']	[10]
11	therapy	O	['N']	[11]
12	with	O	['N']	[12]
13	itraconazole	B-Drug	['Causes']	[9]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	in	O	['N']	[16]
17	whom	O	['N']	[17]
18	liver	O	['N']	[18]
19	biopsy	O	['N']	[19]
20	specimens	O	['N']	[20]
21	were	O	['N']	[21]
22	obtained	O	['N']	[22]
23	.	O	['N']	[23]
#844
0	She	O	['N']	[0]
1	continued	O	['N']	[1]
2	taking	O	['N']	[2]
3	verapamil	B-Drug	['Causes']	[26]
4	for	O	['N']	[4]
5	6	O	['N']	[5]
6	months	O	['N']	[6]
7	,	O	['N']	[7]
8	then	O	['N']	[8]
9	,	O	['N']	[9]
10	on	O	['N']	[10]
11	her	O	['N']	[11]
12	own	O	['N']	[12]
13	,	O	['N']	[13]
14	stopped	O	['N']	[14]
15	all	O	['N']	[15]
16	medications	O	['N']	[16]
17	including	O	['N']	[17]
18	the	O	['N']	[18]
19	sustained	O	['N']	[19]
20	-	O	['N']	[20]
21	release	O	['N']	[21]
22	verapamil	O	['N']	[22]
23	,	O	['N']	[23]
24	and	O	['N']	[24]
25	her	O	['N']	[25]
26	asthma	B-Adverse_Effect	['N']	[26]
27	symptoms	O	['N']	[27]
28	disappeared	O	['N']	[28]
29	.	O	['N']	[29]
#845
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[27]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	eruptions	O	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	B	['N']	[26]
27	jaundice	I-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	O	['N']	[41]
42	infectious	O	['N']	[42]
43	mononucleosis	O	['N']	[43]
44	-	O	['N']	[44]
45	like	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	O	['N']	[49]
50	neurological	O	['N']	[50]
51	and	O	['N']	[51]
52	gastrointestinal	O	['N']	[52]
53	complaints	O	['N']	[53]
54	.	O	['N']	[54]
#846
0	Myoclonus	B-Adverse_Effect	['N']	[0]
1	was	O	['N']	[1]
2	induced	O	['N']	[2]
3	and	O	['N']	[3]
4	enhanced	O	['N']	[4]
5	by	O	['N']	[5]
6	L	B	['N']	[6]
7	-	I	['N']	[7]
8	dopa	I-Drug	['Causes']	[0]
9	,	O	['N']	[9]
10	developing	O	['N']	[10]
11	into	O	['N']	[11]
12	generalized	O	['N']	[12]
13	seizures	O	['N']	[13]
14	.	O	['N']	[14]
#847
0	Polyarthritis	O	['N']	[0]
1	,	O	['N']	[1]
2	hepatitis	B-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	anti	O	['N']	[4]
5	-	O	['N']	[5]
6	native	O	['N']	[6]
7	DNA	O	['N']	[7]
8	antibodies	O	['N']	[8]
9	after	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	ethambutol	O	['N']	[12]
13	and	O	['N']	[13]
14	rifampicin	B-Drug	['Causes']	[2]
15	.	O	['N']	[15]
#848
0	Based	O	['N']	[0]
1	on	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	probability	O	['N']	[4]
5	scale	O	['N']	[5]
6	,	O	['N']	[6]
7	serotonin	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	was	O	['N']	[9]
10	a	O	['N']	[10]
11	probable	O	['N']	[11]
12	adverse	O	['N']	[12]
13	reaction	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	co	O	['N']	[16]
17	-	O	['N']	[17]
18	administration	O	['N']	[18]
19	of	O	['N']	[19]
20	citalopram	O	['N']	[20]
21	and	O	['N']	[21]
22	fentanyl	B-Drug	['Causes']	[8]
23	.	O	['N']	[23]
#849
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	During	O	['N']	[2]
3	and	O	['N']	[3]
4	after	O	['N']	[4]
5	IFN	B-Drug	['Causes']	[17]
6	therapy	O	['N']	[6]
7	,	O	['N']	[7]
8	OCT	O	['N']	[8]
9	is	O	['N']	[9]
10	a	O	['N']	[10]
11	useful	O	['N']	[11]
12	examination	O	['N']	[12]
13	technique	O	['N']	[13]
14	for	O	['N']	[14]
15	revealing	O	['N']	[15]
16	macular	B	['N']	[16]
17	edema	I-Adverse_Effect	['N']	[17]
18	in	O	['N']	[18]
19	patients	O	['N']	[19]
20	who	O	['N']	[20]
21	have	O	['N']	[21]
22	decreased	O	['N']	[22]
23	vision	O	['N']	[23]
24	.	O	['N']	[24]
#850
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	60-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	affected	O	['N']	[10]
11	by	O	['N']	[11]
12	squamous	O	['N']	[12]
13	lung	O	['N']	[13]
14	carcinoma	O	['N']	[14]
15	,	O	['N']	[15]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	paroxysmal	B	['N']	[18]
19	supraventricular	I	['N']	[19]
20	tachycardia	I-Adverse_Effect	['N']	[20]
21	during	O	['N']	[21]
22	cisplatin	O	['N']	[22]
23	and	O	['N']	[23]
24	etoposide	B-Drug	['Causes']	[20]
25	combination	O	['N']	[25]
26	chemotherapy	O	['N']	[26]
27	.	O	['N']	[27]
#851
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	thought	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	clinico	O	['N']	[5]
6	-	O	['N']	[6]
7	pathological	O	['N']	[7]
8	features	O	['N']	[8]
9	and	O	['N']	[9]
10	chronology	O	['N']	[10]
11	of	O	['N']	[11]
12	this	O	['N']	[12]
13	case	O	['N']	[13]
14	bore	O	['N']	[14]
15	the	O	['N']	[15]
16	hallmarks	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	so	O	['N']	[19]
20	-	O	['N']	[20]
21	called	O	['N']	[21]
22	"	O	['N']	[22]
23	3-week	O	['N']	[23]
24	sulphasalazine	B-Drug	['Causes']	[33]
25	syndrome	O	['N']	[25]
26	"	O	['N']	[26]
27	,	O	['N']	[27]
28	a	O	['N']	[28]
29	rare	O	['N']	[29]
30	,	O	['N']	[30]
31	but	O	['N']	[31]
32	often	O	['N']	[32]
33	fatal	B-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	immunoallergic	O	['N']	[35]
36	reaction	O	['N']	[36]
37	to	O	['N']	[37]
38	sulphasalazine	O	['N']	[38]
39	.	O	['N']	[39]
#852
0	Severe	B	['N']	[0]
1	hepatocellular	I	['N']	[1]
2	dysfunction	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	cyproterone	B	['N']	[4]
5	acetate	I-Drug	['Causes']	[2]
6	therapy	O	['N']	[6]
7	.	O	['N']	[7]
#853
0	A	O	['N']	[0]
1	unique	O	['N']	[1]
2	case	O	['N']	[2]
3	of	O	['N']	[3]
4	a	O	['N']	[4]
5	transient	O	['N']	[5]
6	,	O	['N']	[6]
7	nonpigmenting	O	['N']	[7]
8	fixed	B	['N']	[8]
9	drug	I	['N']	[9]
10	eruption	I-Adverse_Effect	['N']	[10]
11	caused	O	['N']	[11]
12	by	O	['N']	[12]
13	the	O	['N']	[13]
14	radiopaque	O	['N']	[14]
15	contrast	O	['N']	[15]
16	medium	O	['N']	[16]
17	iothalamate	B-Drug	['Causes']	[10]
18	is	O	['N']	[18]
19	reported	O	['N']	[19]
20	.	O	['N']	[20]
#854
0	Flecainide	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	pneumonitis	B-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	acute	O	['N']	[5]
6	respiratory	O	['N']	[6]
7	failure	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	the	O	['N']	[12]
13	LEOPARD	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	.	O	['N']	[15]
#855
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	report	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	renal	O	['N']	[6]
7	transplant	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	Pneumocystis	O	['N']	[10]
11	pneumonia	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	chemical	O	['N']	[14]
15	cellulitis	O	['N']	[15]
16	and	O	['N']	[16]
17	ulceration	B-Adverse_Effect	['N']	[17]
18	following	O	['N']	[18]
19	the	O	['N']	[19]
20	extravasation	O	['N']	[20]
21	of	O	['N']	[21]
22	intravenous	O	['N']	[22]
23	pentamidine	B-Drug	['Causes']	[17]
24	into	O	['N']	[24]
25	the	O	['N']	[25]
26	soft	O	['N']	[26]
27	tissues	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	left	O	['N']	[30]
31	hand	O	['N']	[31]
32	and	O	['N']	[32]
33	forearm	O	['N']	[33]
34	.	O	['N']	[34]
#856
0	Acute	O	['N']	[0]
1	vision	O	['N']	[1]
2	loss	O	['N']	[2]
3	after	O	['N']	[3]
4	intravitreal	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	bevacizumab	O	['N']	[7]
8	(	O	['N']	[8]
9	avastin	B-Drug	['Causes']	[15]
10	)	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	ocular	B	['N']	[13]
14	ischemic	I	['N']	[14]
15	syndrome	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#857
0	Amphotericin	B	['N']	[0]
1	B	I-Drug	['Causes']	[21]
2	(	O	['N']	[2]
3	AmB	O	['N']	[3]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	effective	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	its	O	['N']	[9]
10	use	O	['N']	[10]
11	is	O	['N']	[11]
12	limited	O	['N']	[12]
13	by	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	:	O	['N']	[15]
16	renal	O	['N']	[16]
17	impairment	O	['N']	[17]
18	,	O	['N']	[18]
19	anaemia	O	['N']	[19]
20	,	O	['N']	[20]
21	fever	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	malaise	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hypokalaemia	O	['N']	[26]
27	are	O	['N']	[27]
28	common	O	['N']	[28]
29	.	O	['N']	[29]
#858
0	Disulfiram	B-Drug	['Causes']	[1]
1	encephalopathy	B-Adverse_Effect	['N']	[1]
2	as	O	['N']	[2]
3	a	O	['N']	[3]
4	cause	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	catatonia	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	.	O	['N']	[9]
#859
0	Localized	B	['N']	[0]
1	panniculitis	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	subsequent	O	['N']	[3]
4	lipoatrophy	O	['N']	[4]
5	with	O	['N']	[5]
6	subcutaneous	O	['N']	[6]
7	glatiramer	B	['N']	[7]
8	acetate	I-Drug	['Causes']	[1]
9	(	O	['N']	[9]
10	Copaxone	O	['N']	[10]
11	)	O	['N']	[11]
12	injection	O	['N']	[12]
13	for	O	['N']	[13]
14	the	O	['N']	[14]
15	treatment	O	['N']	[15]
16	of	O	['N']	[16]
17	multiple	O	['N']	[17]
18	sclerosis	O	['N']	[18]
19	.	O	['N']	[19]
#860
0	These	O	['N']	[0]
1	findings	O	['N']	[1]
2	are	O	['N']	[2]
3	consistent	O	['N']	[3]
4	with	O	['N']	[4]
5	an	O	['N']	[5]
6	immune	O	['N']	[6]
7	-	O	['N']	[7]
8	complex	O	['N']	[8]
9	form	O	['N']	[9]
10	of	O	['N']	[10]
11	glomerulopathy	O	['N']	[11]
12	in	O	['N']	[12]
13	which	O	['N']	[13]
14	gold	B-Drug	['Causes']	[50]
15	is	O	['N']	[15]
16	neither	O	['N']	[16]
17	the	O	['N']	[17]
18	antigen	O	['N']	[18]
19	nor	O	['N']	[19]
20	a	O	['N']	[20]
21	hapten	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	glomerular	O	['N']	[24]
25	deposits	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	they	O	['N']	[28]
29	suggest	O	['N']	[29]
30	the	O	['N']	[30]
31	hypothesis	O	['N']	[31]
32	that	O	['N']	[32]
33	antibodies	O	['N']	[33]
34	to	O	['N']	[34]
35	tubular	O	['N']	[35]
36	epithelial	O	['N']	[36]
37	antigens	O	['N']	[37]
38	induced	O	['N']	[38]
39	by	O	['N']	[39]
40	gold	O	['N']	[40]
41	therapy	O	['N']	[41]
42	may	O	['N']	[42]
43	be	O	['N']	[43]
44	a	O	['N']	[44]
45	causative	O	['N']	[45]
46	factor	O	['N']	[46]
47	in	O	['N']	[47]
48	the	O	['N']	[48]
49	renal	B	['N']	[49]
50	disease	I-Adverse_Effect	['N']	[50]
51	associated	O	['N']	[51]
52	with	O	['N']	[52]
53	gold	O	['N']	[53]
54	therapy	O	['N']	[54]
55	in	O	['N']	[55]
56	rheumatoid	O	['N']	[56]
57	arthritis	O	['N']	[57]
58	.	O	['N']	[58]
#861
0	Our	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	headache	O	['N']	[3]
4	,	O	['N']	[4]
5	mild	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	nausea	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	vomiting	O	['N']	[10]
11	,	O	['N']	[11]
12	rash	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	eosinophilia	O	['N']	[15]
16	after	O	['N']	[16]
17	3	O	['N']	[17]
18	weeks	O	['N']	[18]
19	of	O	['N']	[19]
20	disulfiram	B-Drug	['Causes']	[8]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#862
0	The	O	['N']	[0]
1	purpose	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	article	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	present	O	['N']	[7]
8	the	O	['N']	[8]
9	first	O	['N']	[9]
10	case	O	['N']	[10]
11	-	O	['N']	[11]
12	series	O	['N']	[12]
13	of	O	['N']	[13]
14	posterior	O	['N']	[14]
15	reversible	O	['N']	[15]
16	encephalopathy	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	(	O	['N']	[18]
19	PRES	B-Adverse_Effect	['N']	[19]
20	)	O	['N']	[20]
21	associated	O	['N']	[21]
22	with	O	['N']	[22]
23	L	B	['N']	[23]
24	-	I	['N']	[24]
25	asparaginase	I-Drug	['Causes']	[19]
26	treatment	O	['N']	[26]
27	.	O	['N']	[27]
#863
0	A	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[17]
2	hypersensitivity	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	,	O	['N']	[4]
5	consisting	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	nausea	O	['N']	[11]
12	,	O	['N']	[12]
13	vomiting	O	['N']	[13]
14	,	O	['N']	[14]
15	lymphadenopathy	O	['N']	[15]
16	,	O	['N']	[16]
17	hepatitis	B-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	hemolysis	O	['N']	[19]
20	,	O	['N']	[20]
21	leukopenia	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	mononucleosis	O	['N']	[24]
25	,	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	for	O	['N']	[35]
36	leprosy	O	['N']	[36]
37	.	O	['N']	[37]
#864
0	Without	O	['N']	[0]
1	other	O	['N']	[1]
2	causes	O	['N']	[2]
3	for	O	['N']	[3]
4	the	O	['N']	[4]
5	hyponatremia	O	['N']	[5]
6	,	O	['N']	[6]
7	she	O	['N']	[7]
8	was	O	['N']	[8]
9	diagnosed	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	syndrome	B	['N']	[12]
13	of	I	['N']	[13]
14	inappropriate	I	['N']	[14]
15	antidiuretic	I	['N']	[15]
16	hormone	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	presumably	O	['N']	[18]
19	caused	O	['N']	[19]
20	by	O	['N']	[20]
21	desmopressin	B-Drug	['Causes']	[16]
22	.	O	['N']	[22]
#865
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	O	['N']	[32]
33	(	O	['N']	[33]
34	CBZ	O	['N']	[34]
35	;	O	['N']	[35]
36	Tegretol	B-Drug	['Causes']	[15]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#866
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	B-Drug	['Causes']	[43]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	B-Adverse_Effect	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#867
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	pancytopenia	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	23-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	man	O	['N']	[11]
12	with	O	['N']	[12]
13	Crohn	O	['N']	[13]
14	's	O	['N']	[14]
15	disease	O	['N']	[15]
16	who	O	['N']	[16]
17	was	O	['N']	[17]
18	treated	O	['N']	[18]
19	with	O	['N']	[19]
20	5-aminosalicylic	B	['N']	[20]
21	acid	I-Drug	['Causes']	[5]
22	(	O	['N']	[22]
23	Pentasa	O	['N']	[23]
24	;	O	['N']	[24]
25	Nisshin	O	['N']	[25]
26	,	O	['N']	[26]
27	Tokyo	O	['N']	[27]
28	,	O	['N']	[28]
29	Japan	O	['N']	[29]
30	)	O	['N']	[30]
31	3.0	O	['N']	[31]
32	g	O	['N']	[32]
33	/	O	['N']	[33]
34	day	O	['N']	[34]
35	.	O	['N']	[35]
#868
0	Due	O	['N']	[0]
1	to	O	['N']	[1]
2	the	O	['N']	[2]
3	increasing	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	TMP	B	['N']	[6]
7	-	I	['N']	[7]
8	SMX	I-Drug	['Causes']	[25]
9	in	O	['N']	[9]
10	children	O	['N']	[10]
11	,	O	['N']	[11]
12	clinicians	O	['N']	[12]
13	should	O	['N']	[13]
14	be	O	['N']	[14]
15	aware	O	['N']	[15]
16	of	O	['N']	[16]
17	this	O	['N']	[17]
18	potentially	O	['N']	[18]
19	life	O	['N']	[19]
20	-	O	['N']	[20]
21	threatening	O	['N']	[21]
22	,	O	['N']	[22]
23	immunemediated	B	['N']	[23]
24	hypersensitivity	I	['N']	[24]
25	reaction	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#869
0	We	O	['N']	[0]
1	introduce	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	sixty	O	['N']	[6]
7	years	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	several	O	['N']	[11]
12	previous	O	['N']	[12]
13	episodes	O	['N']	[13]
14	of	O	['N']	[14]
15	rhinitis	O	['N']	[15]
16	,	O	['N']	[16]
17	conjunctivitis	B-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	perspiration	O	['N']	[19]
20	immediately	O	['N']	[20]
21	after	O	['N']	[21]
22	the	O	['N']	[22]
23	administration	O	['N']	[23]
24	of	O	['N']	[24]
25	salmon	O	['N']	[25]
26	calcitonin	O	['N']	[26]
27	with	O	['N']	[27]
28	nasal	O	['N']	[28]
29	spray	O	['N']	[29]
30	or	O	['N']	[30]
31	intramuscular	O	['N']	[31]
32	administration	O	['N']	[32]
33	(	O	['N']	[33]
34	Calsynar	B-Drug	['Causes']	[17]
35	)	O	['N']	[35]
36	.	O	['N']	[36]
#870
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	described	O	['N']	[2]
3	feeling	O	['N']	[3]
4	cold	O	['N']	[4]
5	with	O	['N']	[5]
6	worsening	O	['N']	[6]
7	headache	O	['N']	[7]
8	and	O	['N']	[8]
9	chills	B-Adverse_Effect	['N']	[9]
10	approximately	O	['N']	[10]
11	one	O	['N']	[11]
12	hour	O	['N']	[12]
13	after	O	['N']	[13]
14	infusion	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	first	O	['N']	[17]
18	dose	O	['N']	[18]
19	of	O	['N']	[19]
20	penicillin	B-Drug	['Causes']	[9]
21	.	O	['N']	[21]
#871
0	Intravenous	O	['N']	[0]
1	verapamil	O	['N']	[1]
2	therapy	O	['N']	[2]
3	in	O	['N']	[3]
4	babies	O	['N']	[4]
5	may	O	['N']	[5]
6	cause	O	['N']	[6]
7	apnea	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	hypotension	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	bradycardia	O	['N']	[12]
13	;	O	['N']	[13]
14	continued	O	['N']	[14]
15	episodes	O	['N']	[15]
16	of	O	['N']	[16]
17	atrial	O	['N']	[17]
18	flutter	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	child	O	['N']	[21]
22	may	O	['N']	[22]
23	cause	O	['N']	[23]
24	sudden	O	['N']	[24]
25	death	O	['N']	[25]
26	;	O	['N']	[26]
27	quinidine	B-Drug	['Causes']	[7]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	related	O	['N']	[30]
31	to	O	['N']	[31]
32	the	O	['N']	[32]
33	death	O	['N']	[33]
34	;	O	['N']	[34]
35	children	O	['N']	[35]
36	with	O	['N']	[36]
37	"	O	['N']	[37]
38	familial	O	['N']	[38]
39	seizure	O	['N']	[39]
40	disorders	O	['N']	[40]
41	"	O	['N']	[41]
42	may	O	['N']	[42]
43	in	O	['N']	[43]
44	fact	O	['N']	[44]
45	have	O	['N']	[45]
46	the	O	['N']	[46]
47	long	O	['N']	[47]
48	QT	O	['N']	[48]
49	interval	O	['N']	[49]
50	syndrome	O	['N']	[50]
51	.	O	['N']	[51]
#872
0	High	O	['N']	[0]
1	-	O	['N']	[1]
2	resolution	O	['N']	[2]
3	computed	O	['N']	[3]
4	tomography	O	['N']	[4]
5	scan	O	['N']	[5]
6	findings	O	['N']	[6]
7	were	O	['N']	[7]
8	consistent	O	['N']	[8]
9	with	O	['N']	[9]
10	ILD	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	was	O	['N']	[13]
14	sufficient	O	['N']	[14]
15	to	O	['N']	[15]
16	diagnose	O	['N']	[16]
17	as	O	['N']	[17]
18	erlotinib	B-Drug	['Causes']	[10]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	ILD	O	['N']	[21]
22	.	O	['N']	[22]
#873
0	Lethal	O	['N']	[0]
1	anuria	O	['N']	[1]
2	complicating	O	['N']	[2]
3	high	B	['N']	[3]
4	dose	I-Dose	['N']	[4]
5	ifosfamide	B-Drug	['Dosage']	[4]
6	chemotherapy	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	breast	O	['N']	[9]
10	cancer	O	['N']	[10]
11	patient	O	['N']	[11]
12	with	O	['N']	[12]
13	an	O	['N']	[13]
14	impaired	O	['N']	[14]
15	renal	O	['N']	[15]
16	function	O	['N']	[16]
17	.	O	['N']	[17]
#874
0	This	O	['N']	[0]
1	fourth	O	['N']	[1]
2	type	O	['N']	[2]
3	of	O	['N']	[3]
4	cutaneous	O	['N']	[4]
5	minocycline	B-Drug	['Causes']	[6]
6	hyperpigmentation	B-Adverse_Effect	['N']	[6]
7	may	O	['N']	[7]
8	be	O	['N']	[8]
9	a	O	['N']	[9]
10	variant	O	['N']	[10]
11	of	O	['N']	[11]
12	Type	O	['N']	[12]
13	I	O	['N']	[13]
14	,	O	['N']	[14]
15	but	O	['N']	[15]
16	based	O	['N']	[16]
17	on	O	['N']	[17]
18	clinical	O	['N']	[18]
19	,	O	['N']	[19]
20	pathological	O	['N']	[20]
21	and	O	['N']	[21]
22	microanalytical	O	['N']	[22]
23	differences	O	['N']	[23]
24	,	O	['N']	[24]
25	appears	O	['N']	[25]
26	to	O	['N']	[26]
27	be	O	['N']	[27]
28	a	O	['N']	[28]
29	new	O	['N']	[29]
30	entity	O	['N']	[30]
31	.	O	['N']	[31]
#875
0	Erythropoietin	O	['N']	[0]
1	is	O	['N']	[1]
2	beneficial	O	['N']	[2]
3	in	O	['N']	[3]
4	mitomycin	B-Drug	['Causes']	[10]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	hemolytic	B	['N']	[7]
8	-	I	['N']	[8]
9	uremic	I	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#876
0	In	O	['N']	[0]
1	all	O	['N']	[1]
2	cases	O	['N']	[2]
3	,	O	['N']	[3]
4	seizures	B-Adverse_Effect	['N']	[4]
5	were	O	['N']	[5]
6	controlled	O	['N']	[6]
7	by	O	['N']	[7]
8	withdrawal	O	['N']	[8]
9	of	O	['N']	[9]
10	phenytoin	B-Drug	['Causes']	[4]
11	and	O	['N']	[11]
12	reduction	O	['N']	[12]
13	of	O	['N']	[13]
14	drug	O	['N']	[14]
15	levels	O	['N']	[15]
16	.	O	['N']	[16]
#877
0	A	O	['N']	[0]
1	60-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	white	O	['N']	[4]
5	man	O	['N']	[5]
6	with	O	['N']	[6]
7	chronic	O	['N']	[7]
8	bronchitis	O	['N']	[8]
9	was	O	['N']	[9]
10	noted	O	['N']	[10]
11	to	O	['N']	[11]
12	develop	O	['N']	[12]
13	acute	O	['N']	[13]
14	respiratory	O	['N']	[14]
15	failure	O	['N']	[15]
16	and	O	['N']	[16]
17	metabolic	B	['N']	[17]
18	acidosis	I-Adverse_Effect	['N']	[18]
19	four	O	['N']	[19]
20	days	O	['N']	[20]
21	after	O	['N']	[21]
22	being	O	['N']	[22]
23	started	O	['N']	[23]
24	on	O	['N']	[24]
25	methazolamide	O	['N']	[25]
26	(	O	['N']	[26]
27	Neptazane	B-Drug	['Causes']	[18]
28	)	O	['N']	[28]
29	for	O	['N']	[29]
30	an	O	['N']	[30]
31	ophthalmologic	O	['N']	[31]
32	problem	O	['N']	[32]
33	.	O	['N']	[33]
#878
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	follow	O	['N']	[2]
3	-	O	['N']	[3]
4	up	O	['N']	[4]
5	revealed	O	['N']	[5]
6	that	O	['N']	[6]
7	gestational	O	['N']	[7]
8	diabetes	O	['N']	[8]
9	when	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	norethisterone	B-Drug	['Causes']	[24]
13	had	O	['N']	[13]
14	a	O	['N']	[14]
15	lesser	O	['N']	[15]
16	risk	O	['N']	[16]
17	of	O	['N']	[17]
18	emerging	O	['N']	[18]
19	diabetes	O	['N']	[19]
20	mellitus	O	['N']	[20]
21	and	O	['N']	[21]
22	impaired	B	['N']	[22]
23	glucose	I	['N']	[23]
24	tolerance	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#879
0	Typical	O	['N']	[0]
1	symptoms	O	['N']	[1]
2	of	O	['N']	[2]
3	active	O	['N']	[3]
4	CD	B-Adverse_Effect	['N']	[4]
5	occurred	O	['N']	[5]
6	11	O	['N']	[6]
7	,	O	['N']	[7]
8	12	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	26	O	['N']	[11]
12	months	O	['N']	[12]
13	after	O	['N']	[13]
14	start	O	['N']	[14]
15	of	O	['N']	[15]
16	etanercept	B-Drug	['Causes']	[4]
17	therapy	O	['N']	[17]
18	,	O	['N']	[18]
19	respectively	O	['N']	[19]
20	.	O	['N']	[20]
#880
0	Oncologists	O	['N']	[0]
1	supervising	O	['N']	[1]
2	future	O	['N']	[2]
3	clinical	O	['N']	[3]
4	trials	O	['N']	[4]
5	for	O	['N']	[5]
6	lung	O	['N']	[6]
7	cancer	O	['N']	[7]
8	should	O	['N']	[8]
9	be	O	['N']	[9]
10	alert	O	['N']	[10]
11	to	O	['N']	[11]
12	the	O	['N']	[12]
13	fact	O	['N']	[13]
14	that	O	['N']	[14]
15	sorafenib	B-Drug	['Causes']	[22]
16	can	O	['N']	[16]
17	potentially	O	['N']	[17]
18	induce	O	['N']	[18]
19	serious	O	['N']	[19]
20	interstitial	B	['N']	[20]
21	lung	I	['N']	[21]
22	disease	I-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	although	O	['N']	[24]
25	this	O	['N']	[25]
26	might	O	['N']	[26]
27	depend	O	['N']	[27]
28	on	O	['N']	[28]
29	racial	O	['N']	[29]
30	differences	O	['N']	[30]
31	.	O	['N']	[31]
#881
0	The	O	['N']	[0]
1	polycystic	O	['N']	[1]
2	changes	O	['N']	[2]
3	disappeared	O	['N']	[3]
4	from	O	['N']	[4]
5	the	O	['N']	[5]
6	ovaries	O	['N']	[6]
7	in	O	['N']	[7]
8	2	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	women	O	['N']	[11]
12	after	O	['N']	[12]
13	valproate	B-Drug	['Causes']	[25]
14	therapy	O	['N']	[14]
15	was	O	['N']	[15]
16	discontinued	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	the	O	['N']	[19]
20	2	O	['N']	[20]
21	women	O	['N']	[21]
22	who	O	['N']	[22]
23	had	O	['N']	[23]
24	gained	B	['N']	[24]
25	weight	I-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	developed	O	['N']	[27]
28	amenorrhea	O	['N']	[28]
29	while	O	['N']	[29]
30	being	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	valproate	O	['N']	[33]
34	lost	O	['N']	[34]
35	weight	O	['N']	[35]
36	and	O	['N']	[36]
37	resumed	O	['N']	[37]
38	menstruating	O	['N']	[38]
39	after	O	['N']	[39]
40	the	O	['N']	[40]
41	change	O	['N']	[41]
42	in	O	['N']	[42]
43	medication	O	['N']	[43]
44	.	O	['N']	[44]
#882
0	In	O	['N']	[0]
1	contrast	O	['N']	[1]
2	to	O	['N']	[2]
3	chronic	O	['N']	[3]
4	or	O	['N']	[4]
5	subacute	O	['N']	[5]
6	thyroiditis	O	['N']	[6]
7	,	O	['N']	[7]
8	Graves	B	['N']	[8]
9	'	I	['N']	[9]
10	disease	I-Adverse_Effect	['N']	[10]
11	rarely	O	['N']	[11]
12	complicates	O	['N']	[12]
13	IFN	B	['N']	[13]
14	-	I	['N']	[14]
15	alpha	I-Drug	['Causes']	[10]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	chronic	O	['N']	[18]
19	viral	O	['N']	[19]
20	C	O	['N']	[20]
21	hepatitis	O	['N']	[21]
22	.	O	['N']	[22]
#883
0	Prazosin	B-Drug	['Causes']	[11]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	first	O	['N']	[3]
4	-	O	['N']	[4]
5	dose	O	['N']	[5]
6	phenomenon	O	['N']	[6]
7	possibly	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	hemorrhagic	B	['N']	[10]
11	stroke	I-Adverse_Effect	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	report	O	['N']	[14]
15	of	O	['N']	[15]
16	three	O	['N']	[16]
17	cases	O	['N']	[17]
18	.	O	['N']	[18]
#884
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	potential	O	['N']	[6]
7	for	O	['N']	[7]
8	developing	O	['N']	[8]
9	a	O	['N']	[9]
10	gemcitabine	B-Drug	['Causes']	[15]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	radiation	B	['N']	[13]
14	recall	I	['N']	[14]
15	reaction	I-Adverse_Effect	['N']	[15]
16	resulting	O	['N']	[16]
17	in	O	['N']	[17]
18	hemodynamically	O	['N']	[18]
19	significant	O	['N']	[19]
20	pericardial	O	['N']	[20]
21	effusion	O	['N']	[21]
22	.	O	['N']	[22]
#885
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	successful	O	['N']	[5]
6	surgical	O	['N']	[6]
7	management	O	['N']	[7]
8	of	O	['N']	[8]
9	arterial	B	['N']	[9]
10	thrombosis	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	percutaneous	O	['N']	[12]
13	thrombin	B-Drug	['Causes']	[10]
14	injection	O	['N']	[14]
15	of	O	['N']	[15]
16	a	O	['N']	[16]
17	femoral	O	['N']	[17]
18	artery	O	['N']	[18]
19	pseudoaneurysm	O	['N']	[19]
20	in	O	['N']	[20]
21	a	O	['N']	[21]
22	69-year	O	['N']	[22]
23	-	O	['N']	[23]
24	old	O	['N']	[24]
25	woman	O	['N']	[25]
26	.	O	['N']	[26]
#886
0	Early	O	['N']	[0]
1	recognition	O	['N']	[1]
2	of	O	['N']	[2]
3	renal	B	['N']	[3]
4	toxicity	I-Adverse_Effect	['N']	[4]
5	of	O	['N']	[5]
6	high	O	['N']	[6]
7	-	O	['N']	[7]
8	dose	O	['N']	[8]
9	methotrexate	B-Drug	['Causes']	[4]
10	therapy	O	['N']	[10]
11	:	O	['N']	[11]
12	a	O	['N']	[12]
13	case	O	['N']	[13]
14	report	O	['N']	[14]
15	.	O	['N']	[15]
#887
0	High	B	['N']	[0]
1	-	I	['N']	[1]
2	grade	I	['N']	[2]
3	endometrial	I	['N']	[3]
4	stromal	I	['N']	[4]
5	sarcoma	I-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	tamoxifen	B-Drug	['Causes']	[5]
8	therapy	O	['N']	[8]
9	for	O	['N']	[9]
10	breast	O	['N']	[10]
11	cancer	O	['N']	[11]
12	.	O	['N']	[12]
#888
0	Human	B	['N']	[0]
1	insulin	I-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	lipoatrophy	B-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#889
0	Pharmacokinetic	O	['N']	[0]
1	determinants	O	['N']	[1]
2	of	O	['N']	[2]
3	6-mercaptopurine	B-Drug	['Causes']	[4]
4	myelotoxicity	B-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	therapeutic	O	['N']	[6]
7	failure	O	['N']	[7]
8	in	O	['N']	[8]
9	children	O	['N']	[9]
10	with	O	['N']	[10]
11	acute	O	['N']	[11]
12	lymphoblastic	O	['N']	[12]
13	leukemia	O	['N']	[13]
14	.	O	['N']	[14]
#890
0	We	O	['N']	[0]
1	reported	O	['N']	[1]
2	3	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	acute	B	['N']	[6]
7	generalized	I	['N']	[7]
8	dystonia	I-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	akinetic	O	['N']	[10]
11	rigid	O	['N']	[11]
12	syndrome	O	['N']	[12]
13	following	O	['N']	[13]
14	an	O	['N']	[14]
15	initial	O	['N']	[15]
16	therapy	O	['N']	[16]
17	with	O	['N']	[17]
18	d	B	['N']	[18]
19	-	I	['N']	[19]
20	penicillamine	I-Drug	['Causes']	[8]
21	125	O	['N']	[21]
22	-	O	['N']	[22]
23	500	O	['N']	[23]
24	mg	O	['N']	[24]
25	daily	O	['N']	[25]
26	.	O	['N']	[26]
#891
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	this	O	['N']	[4]
5	case	O	['N']	[5]
6	is	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	published	O	['N']	[9]
10	report	O	['N']	[10]
11	of	O	['N']	[11]
12	levofloxacin	B-Drug	['Causes']	[15]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	TEN	B-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#892
0	Native	O	['N']	[0]
1	arterial	B	['N']	[1]
2	thrombosis	I-Adverse_Effect	['N']	[2]
3	,	O	['N']	[3]
4	though	O	['N']	[4]
5	recognized	O	['N']	[5]
6	as	O	['N']	[6]
7	a	O	['N']	[7]
8	severe	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	thrombin	B-Drug	['Causes']	[2]
12	injection	O	['N']	[12]
13	,	O	['N']	[13]
14	has	O	['N']	[14]
15	not	O	['N']	[15]
16	been	O	['N']	[16]
17	well	O	['N']	[17]
18	described	O	['N']	[18]
19	in	O	['N']	[19]
20	the	O	['N']	[20]
21	literature	O	['N']	[21]
22	.	O	['N']	[22]
#893
0	A	O	['N']	[0]
1	51-yr	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	nonsmoking	O	['N']	[4]
5	male	O	['N']	[5]
6	patient	O	['N']	[6]
7	without	O	['N']	[7]
8	any	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	previous	O	['N']	[11]
12	allergies	O	['N']	[12]
13	,	O	['N']	[13]
14	asthma	O	['N']	[14]
15	,	O	['N']	[15]
16	hay	O	['N']	[16]
17	fever	O	['N']	[17]
18	,	O	['N']	[18]
19	or	O	['N']	[19]
20	urticaria	O	['N']	[20]
21	developed	O	['N']	[21]
22	attacks	B	['N']	[22]
23	of	I	['N']	[23]
24	asthma	I-Adverse_Effect	['N']	[24]
25	when	O	['N']	[25]
26	captopril	O	['N']	[26]
27	was	O	['N']	[27]
28	added	O	['N']	[28]
29	to	O	['N']	[29]
30	the	O	['N']	[30]
31	nadolol	O	['N']	[31]
32	and	O	['N']	[32]
33	dyazide	B-Drug	['Causes']	[24]
34	treatment	O	['N']	[34]
35	for	O	['N']	[35]
36	his	O	['N']	[36]
37	high	O	['N']	[37]
38	blood	O	['N']	[38]
39	pressure	O	['N']	[39]
40	.	O	['N']	[40]
#894
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	third	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	reversible	O	['N']	[6]
7	hepatic	B	['N']	[7]
8	decompensation	I-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	prolonged	O	['N']	[11]
12	MTX	B-Drug	['Causes']	[8]
13	therapy	O	['N']	[13]
14	in	O	['N']	[14]
15	patients	O	['N']	[15]
16	with	O	['N']	[16]
17	rheumatoid	O	['N']	[17]
18	arthritis	O	['N']	[18]
19	.	O	['N']	[19]
#895
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Quetiapine	B-Drug	['Causes']	[6]
3	was	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	leucopenia	B-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	two	O	['N']	[8]
9	patients	O	['N']	[9]
10	and	O	['N']	[10]
11	clinically	O	['N']	[11]
12	apparent	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	in	O	['N']	[14]
15	one	O	['N']	[15]
16	patient	O	['N']	[16]
17	.	O	['N']	[17]
#896
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	B-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	B-Drug	['Causes']	[17]
33	(	O	['N']	[33]
34	CBZ	O	['N']	[34]
35	;	O	['N']	[35]
36	Tegretol	O	['N']	[36]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#897
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	also	O	['N']	[2]
3	developed	O	['N']	[3]
4	elevated	B	['N']	[4]
5	serum	I	['N']	[5]
6	ammonia	I	['N']	[6]
7	levels	I-Adverse_Effect	['N']	[7]
8	while	O	['N']	[8]
9	on	O	['N']	[9]
10	valproic	B	['N']	[10]
11	acid	I-Drug	['Causes']	[7]
12	.	O	['N']	[12]
#898
0	This	O	['N']	[0]
1	eruption	B-Adverse_Effect	['N']	[1]
2	emerged	O	['N']	[2]
3	after	O	['N']	[3]
4	1	O	['N']	[4]
5	month	O	['N']	[5]
6	of	O	['N']	[6]
7	therapy	O	['N']	[7]
8	with	O	['N']	[8]
9	salsalate	B-Drug	['Causes']	[1]
10	,	O	['N']	[10]
11	persisted	O	['N']	[11]
12	for	O	['N']	[12]
13	as	O	['N']	[13]
14	long	O	['N']	[14]
15	as	O	['N']	[15]
16	salsalate	O	['N']	[16]
17	was	O	['N']	[17]
18	administered	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	cleared	O	['N']	[21]
22	within	O	['N']	[22]
23	3	O	['N']	[23]
24	weeks	O	['N']	[24]
25	of	O	['N']	[25]
26	discontinuing	O	['N']	[26]
27	the	O	['N']	[27]
28	medication	O	['N']	[28]
29	.	O	['N']	[29]
#899
0	The	O	['N']	[0]
1	toxic	O	['N']	[1]
2	effects	O	['N']	[2]
3	of	O	['N']	[3]
4	methotrexate	B-Drug	['Causes']	[38]
5	included	O	['N']	[5]
6	elevated	O	['N']	[6]
7	liver	O	['N']	[7]
8	transaminases	O	['N']	[8]
9	(	O	['N']	[9]
10	3/4	O	['N']	[10]
11	)	O	['N']	[11]
12	,	O	['N']	[12]
13	nausea	O	['N']	[13]
14	(	O	['N']	[14]
15	2/4	O	['N']	[15]
16	)	O	['N']	[16]
17	,	O	['N']	[17]
18	abdominal	O	['N']	[18]
19	pain	O	['N']	[19]
20	(	O	['N']	[20]
21	2/4	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	bone	O	['N']	[24]
25	pain	O	['N']	[25]
26	(	O	['N']	[26]
27	2/4	O	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	mild	O	['N']	[30]
31	neutropenia	O	['N']	[31]
32	(	O	['N']	[32]
33	1/4	O	['N']	[33]
34	)	O	['N']	[34]
35	,	O	['N']	[35]
36	and	O	['N']	[36]
37	mild	B	['N']	[37]
38	pruritus	I-Adverse_Effect	['N']	[38]
39	(	O	['N']	[39]
40	1/4	O	['N']	[40]
41	)	O	['N']	[41]
42	.	O	['N']	[42]
#900
0	Seizures	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	ofloxacin	B-Drug	['Causes']	[0]
4	therapy	O	['N']	[4]
5	.	O	['N']	[5]
#901
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	prolonged	O	['N']	[5]
6	terbinafine	B-Drug	['Causes']	[11]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	cholestatic	B	['N']	[9]
10	liver	I	['N']	[10]
11	disease	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#902
0	Dyspnea	O	['N']	[0]
1	,	O	['N']	[1]
2	hypoxemia	B-Adverse_Effect	['N']	[2]
3	,	O	['N']	[3]
4	and	O	['N']	[4]
5	pleuritic	O	['N']	[5]
6	chest	O	['N']	[6]
7	pain	O	['N']	[7]
8	occurred	O	['N']	[8]
9	within	O	['N']	[9]
10	24	O	['N']	[10]
11	hours	O	['N']	[11]
12	of	O	['N']	[12]
13	rituximab	B-Drug	['Causes']	[2]
14	administration	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	there	O	['N']	[17]
18	was	O	['N']	[18]
19	no	O	['N']	[19]
20	other	O	['N']	[20]
21	apparent	O	['N']	[21]
22	explanation	O	['N']	[22]
23	.	O	['N']	[23]
#903
0	Metastatic	B	['N']	[0]
1	osteomyelitis	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	BCG	B-Drug	['Causes']	[1]
4	vaccination	O	['N']	[4]
5	.	O	['N']	[5]
#904
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	positive	O	['N']	[3]
4	for	O	['N']	[4]
5	antibody	O	['N']	[5]
6	against	O	['N']	[6]
7	complexes	O	['N']	[7]
8	of	O	['N']	[8]
9	heparin	B-Drug	['Causes']	[22]
10	and	O	['N']	[10]
11	platelet	O	['N']	[11]
12	factor	O	['N']	[12]
13	4	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	was	O	['N']	[16]
17	diagnosed	O	['N']	[17]
18	as	O	['N']	[18]
19	heparin	O	['N']	[19]
20	-	O	['N']	[20]
21	induced	O	['N']	[21]
22	thrombocytopenia	B-Adverse_Effect	['N']	[22]
23	with	O	['N']	[23]
24	thrombosis	O	['N']	[24]
25	syndrome	O	['N']	[25]
26	(	O	['N']	[26]
27	HITTS	O	['N']	[27]
28	)	O	['N']	[28]
29	.	O	['N']	[29]
#905
0	Life	O	['N']	[0]
1	-	O	['N']	[1]
2	threatening	O	['N']	[2]
3	cranial	B	['N']	[3]
4	dystonia	I-Adverse_Effect	['N']	[4]
5	following	O	['N']	[5]
6	trihexyphenidyl	B-Drug	['Causes']	[4]
7	withdrawal	O	['N']	[7]
8	.	O	['N']	[8]
#906
0	Arthritis	O	['N']	[0]
1	and	O	['N']	[1]
2	bursitis	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	multiple	O	['N']	[4]
5	sclerosis	O	['N']	[5]
6	patients	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	interferon	B	['N']	[9]
10	-	I	['N']	[10]
11	beta	I-Drug	['Causes']	[2]
12	.	O	['N']	[12]
#907
0	Even	O	['N']	[0]
1	after	O	['N']	[1]
2	a	O	['N']	[2]
3	strict	O	['N']	[3]
4	warning	O	['N']	[4]
5	,	O	['N']	[5]
6	he	O	['N']	[6]
7	took	O	['N']	[7]
8	another	O	['N']	[8]
9	quinine	B-Drug	['Causes']	[21]
10	tablet	O	['N']	[10]
11	that	O	['N']	[11]
12	evening	O	['N']	[12]
13	,	O	['N']	[13]
14	which	O	['N']	[14]
15	triggered	O	['N']	[15]
16	his	O	['N']	[16]
17	fifth	O	['N']	[17]
18	episode	O	['N']	[18]
19	of	O	['N']	[19]
20	severe	O	['N']	[20]
21	thrombocytopenia	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	confirmed	O	['N']	[24]
25	the	O	['N']	[25]
26	etiology	O	['N']	[26]
27	of	O	['N']	[27]
28	quinine	O	['N']	[28]
29	-	O	['N']	[29]
30	induced	O	['N']	[30]
31	thrombocytopenia	O	['N']	[31]
32	.	O	['N']	[32]
#908
0	We	O	['N']	[0]
1	herein	O	['N']	[1]
2	report	O	['N']	[2]
3	this	O	['N']	[3]
4	rare	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	acute	O	['N']	[7]
8	onset	O	['N']	[8]
9	of	O	['N']	[9]
10	nephrotic	B	['N']	[10]
11	syndrome	I-Adverse_Effect	['N']	[11]
12	during	O	['N']	[12]
13	interferon	B	['N']	[13]
14	-	I	['N']	[14]
15	alpha	I-Drug	['Causes']	[11]
16	retreatment	O	['N']	[16]
17	.	O	['N']	[17]
#909
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	a	O	['N']	[5]
6	liver	O	['N']	[6]
7	abscess	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	Entamoeba	O	['N']	[10]
11	histolytica	O	['N']	[11]
12	,	O	['N']	[12]
13	in	O	['N']	[13]
14	whom	O	['N']	[14]
15	metronidazole	B-Drug	['Dosage']	[25]
16	therapy	O	['N']	[16]
17	(	O	['N']	[17]
18	total	O	['N']	[18]
19	dose	O	['N']	[19]
20	,	O	['N']	[20]
21	21	B	['N']	[21]
22	g	I	['N']	[22]
23	over	I	['N']	[23]
24	14	I	['N']	[24]
25	days	I-Dose	['N']	[25]
26	)	O	['N']	[26]
27	was	O	['N']	[27]
28	complicated	O	['N']	[28]
29	by	O	['N']	[29]
30	reversible	O	['N']	[30]
31	deafness	O	['N']	[31]
32	,	O	['N']	[32]
33	tinnitus	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	ataxia	O	['N']	[36]
37	and	O	['N']	[37]
38	who	O	['N']	[38]
39	relapsed	O	['N']	[39]
40	5	O	['N']	[40]
41	months	O	['N']	[41]
42	later	O	['N']	[42]
43	with	O	['N']	[43]
44	a	O	['N']	[44]
45	splenic	O	['N']	[45]
46	abscess	O	['N']	[46]
47	.	O	['N']	[47]
#910
0	After	O	['N']	[0]
1	a	O	['N']	[1]
2	second	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	metoclopramide	B-Drug	['Causes']	[24]
6	,	O	['N']	[6]
7	these	O	['N']	[7]
8	symptoms	O	['N']	[8]
9	recurred	O	['N']	[9]
10	and	O	['N']	[10]
11	were	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	confusion	O	['N']	[14]
15	,	O	['N']	[15]
16	agitation	O	['N']	[16]
17	,	O	['N']	[17]
18	fever	O	['N']	[18]
19	,	O	['N']	[19]
20	diaphoresis	O	['N']	[20]
21	,	O	['N']	[21]
22	tachypnea	O	['N']	[22]
23	,	O	['N']	[23]
24	tachycardia	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	hypertension	O	['N']	[27]
28	.	O	['N']	[28]
#911
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	B	['N']	[37]
38	syndrome	I-Adverse_Effect	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[38]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#912
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	occurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	renal	O	['N']	[5]
6	failure	O	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	cholesterol	B	['N']	[9]
10	crystal	I	['N']	[10]
11	embolization	I-Adverse_Effect	['N']	[11]
12	following	O	['N']	[12]
13	thrombolytic	O	['N']	[13]
14	therapy	O	['N']	[14]
15	with	O	['N']	[15]
16	intravenous	O	['N']	[16]
17	recombinant	B	['N']	[17]
18	tissue	I	['N']	[18]
19	-	I	['N']	[19]
20	type	I	['N']	[20]
21	plasminogen	I	['N']	[21]
22	activator	I-Drug	['Causes']	[11]
23	(	O	['N']	[23]
24	t	O	['N']	[24]
25	-	O	['N']	[25]
26	PA	O	['N']	[26]
27	)	O	['N']	[27]
28	.	O	['N']	[28]
#913
0	Infections	B-Adverse_Effect	['N']	[0]
1	are	O	['N']	[1]
2	a	O	['N']	[2]
3	major	O	['N']	[3]
4	adverse	O	['N']	[4]
5	effect	O	['N']	[5]
6	during	O	['N']	[6]
7	the	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	anti	B	['N']	[10]
11	-	I	['N']	[11]
12	TNF	I	['N']	[12]
13	-	I	['N']	[13]
14	alpha	I-Drug	['Causes']	[0]
15	.	O	['N']	[15]
#914
0	Adverse	O	['N']	[0]
1	reaction	O	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	aspirin	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	asthma	B-Adverse_Effect	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	zafirlukast	O	['N']	[12]
13	.	O	['N']	[13]
#915
0	Imidazoline	B-Drug	['Causes']	[1]
1	intoxication	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	overdose	O	['N']	[4]
5	or	O	['N']	[5]
6	accidental	O	['N']	[6]
7	ingestion	O	['N']	[7]
8	but	O	['N']	[8]
9	also	O	['N']	[9]
10	after	O	['N']	[10]
11	normal	O	['N']	[11]
12	therapeutic	O	['N']	[12]
13	usage	O	['N']	[13]
14	is	O	['N']	[14]
15	frequent	O	['N']	[15]
16	in	O	['N']	[16]
17	children	O	['N']	[17]
18	.	O	['N']	[18]
#916
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	O	['N']	[14]
15	with	O	['N']	[15]
16	folinic	B	['N']	[16]
17	acid	I-Drug	['Causes']	[43]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	B	['N']	[42]
43	acidosis	I-Adverse_Effect	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#917
0	Two	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	administration	O	['N']	[3]
4	of	O	['N']	[4]
5	Kalimate	B-Drug	['Causes']	[11]
6	enema	O	['N']	[6]
7	,	O	['N']	[7]
8	he	O	['N']	[8]
9	had	O	['N']	[9]
10	profuse	B	['N']	[10]
11	hematochezia	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	a	O	['N']	[14]
15	sigmoidoscopy	O	['N']	[15]
16	showed	O	['N']	[16]
17	diffuse	O	['N']	[17]
18	colonic	O	['N']	[18]
19	mucosal	O	['N']	[19]
20	necrosis	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	rectum	O	['N']	[23]
24	and	O	['N']	[24]
25	sigmoid	O	['N']	[25]
26	colon	O	['N']	[26]
27	.	O	['N']	[27]
#918
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	study	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	second	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	localized	B	['N']	[8]
9	purpura	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	prolonged	O	['N']	[11]
12	lamotrigine	B-Drug	['Causes']	[9]
13	treatment	O	['N']	[13]
14	suggesting	O	['N']	[14]
15	this	O	['N']	[15]
16	may	O	['N']	[16]
17	be	O	['N']	[17]
18	an	O	['N']	[18]
19	atypical	O	['N']	[19]
20	lamotrigine	O	['N']	[20]
21	-	O	['N']	[21]
22	induced	O	['N']	[22]
23	drug	O	['N']	[23]
24	reaction	O	['N']	[24]
25	.	O	['N']	[25]
#919
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	Carbamazepine	B	['N']	[7]
8	toxicity	I-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	the	O	['N']	[10]
11	administration	O	['N']	[11]
12	of	O	['N']	[12]
13	Oxybutynin	B-Drug	['Causes']	[8]
14	and	O	['N']	[14]
15	Dantrolene	O	['N']	[15]
16	.	O	['N']	[16]
#920
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[33]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	O	['N']	[12]
13	150	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	d	O	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	O	['N']	[20]
21	oddly	O	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	O	['N']	[24]
25	profusely	O	['N']	[25]
26	,	O	['N']	[26]
27	shivering	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	O	['N']	[31]
32	,	O	['N']	[32]
33	agitated	B-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	O	['N']	[36]
37	.	O	['N']	[37]
#921
0	Six	O	['N']	[0]
1	of	O	['N']	[1]
2	13	O	['N']	[2]
3	outpatients	O	['N']	[3]
4	with	O	['N']	[4]
5	schizophrenia	O	['N']	[5]
6	who	O	['N']	[6]
7	participated	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	ten	O	['N']	[10]
11	-	O	['N']	[11]
12	week	O	['N']	[12]
13	open	O	['N']	[13]
14	trial	O	['N']	[14]
15	of	O	['N']	[15]
16	risperidone	B-Drug	['Causes']	[43]
17	had	O	['N']	[17]
18	an	O	['N']	[18]
19	initial	O	['N']	[19]
20	good	O	['N']	[20]
21	response	O	['N']	[21]
22	to	O	['N']	[22]
23	the	O	['N']	[23]
24	medication	O	['N']	[24]
25	followed	O	['N']	[25]
26	by	O	['N']	[26]
27	development	O	['N']	[27]
28	of	O	['N']	[28]
29	intolerable	O	['N']	[29]
30	affect	O	['N']	[30]
31	,	O	['N']	[31]
32	including	O	['N']	[32]
33	feelings	O	['N']	[33]
34	of	O	['N']	[34]
35	agitation	O	['N']	[35]
36	and	O	['N']	[36]
37	depression	O	['N']	[37]
38	and	O	['N']	[38]
39	periods	O	['N']	[39]
40	of	O	['N']	[40]
41	crying	O	['N']	[41]
42	and	O	['N']	[42]
43	insomnia	B-Adverse_Effect	['N']	[43]
44	.	O	['N']	[44]
#922
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	development	O	['N']	[3]
4	of	O	['N']	[4]
5	ischemic	B	['N']	[5]
6	colitis	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	was	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	tegaserod	B-Drug	['Causes']	[6]
15	and	O	['N']	[15]
16	review	O	['N']	[16]
17	the	O	['N']	[17]
18	relationship	O	['N']	[18]
19	among	O	['N']	[19]
20	ischemic	O	['N']	[20]
21	colitis	O	['N']	[21]
22	,	O	['N']	[22]
23	tegaserod	O	['N']	[23]
24	use	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	irritable	O	['N']	[27]
28	bowel	O	['N']	[28]
29	syndrome	O	['N']	[29]
30	.	O	['N']	[30]
#923
0	Methemoglobinemia	B-Adverse_Effect	['N']	[0]
1	:	O	['N']	[1]
2	an	O	['N']	[2]
3	occupational	O	['N']	[3]
4	hazard	O	['N']	[4]
5	of	O	['N']	[5]
6	phenylpropanolamine	B-Drug	['Causes']	[0]
7	production	O	['N']	[7]
8	.	O	['N']	[8]
#924
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	B-Drug	['Causes']	[27]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#925
0	The	O	['N']	[0]
1	pharmaceutical	O	['N']	[1]
2	company	O	['N']	[2]
3	producing	O	['N']	[3]
4	Halfan	B-Drug	['Causes']	[14]
5	has	O	['N']	[5]
6	reported	O	['N']	[6]
7	8	O	['N']	[7]
8	cardiac	O	['N']	[8]
9	arrests	O	['N']	[9]
10	,	O	['N']	[10]
11	leading	O	['N']	[11]
12	to	O	['N']	[12]
13	6	O	['N']	[13]
14	deaths	B-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	when	O	['N']	[16]
17	a	O	['N']	[17]
18	higher	O	['N']	[18]
19	dose	O	['N']	[19]
20	than	O	['N']	[20]
21	recommended	O	['N']	[21]
22	was	O	['N']	[22]
23	used	O	['N']	[23]
24	,	O	['N']	[24]
25	there	O	['N']	[25]
26	was	O	['N']	[26]
27	recent	O	['N']	[27]
28	or	O	['N']	[28]
29	concomitant	O	['N']	[29]
30	treatment	O	['N']	[30]
31	with	O	['N']	[31]
32	mefloquine	O	['N']	[32]
33	,	O	['N']	[33]
34	there	O	['N']	[34]
35	was	O	['N']	[35]
36	pre	O	['N']	[36]
37	-	O	['N']	[37]
38	existing	O	['N']	[38]
39	prolongation	O	['N']	[39]
40	of	O	['N']	[40]
41	the	O	['N']	[41]
42	QT	O	['N']	[42]
43	interval	O	['N']	[43]
44	or	O	['N']	[44]
45	the	O	['N']	[45]
46	patient	O	['N']	[46]
47	had	O	['N']	[47]
48	a	O	['N']	[48]
49	thiamine	O	['N']	[49]
50	deficiency	O	['N']	[50]
51	.	O	['N']	[51]
#926
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	human	O	['N']	[7]
8	immunodeficiency	O	['N']	[8]
9	virus	O	['N']	[9]
10	type	O	['N']	[10]
11	1	O	['N']	[11]
12	(	O	['N']	[12]
13	HIV-1)-infected	O	['N']	[13]
14	individual	O	['N']	[14]
15	receiving	O	['N']	[15]
16	combination	O	['N']	[16]
17	antiretroviral	O	['N']	[17]
18	therapy	O	['N']	[18]
19	,	O	['N']	[19]
20	which	O	['N']	[20]
21	included	O	['N']	[21]
22	ritonavir	O	['N']	[22]
23	,	O	['N']	[23]
24	who	O	['N']	[24]
25	developed	O	['N']	[25]
26	Cushing	B	['N']	[26]
27	syndrome	I-Adverse_Effect	['N']	[27]
28	with	O	['N']	[28]
29	profound	O	['N']	[29]
30	complications	O	['N']	[30]
31	after	O	['N']	[31]
32	epidural	O	['N']	[32]
33	triamcinolone	B-Drug	['Causes']	[27]
34	injections	O	['N']	[34]
35	.	O	['N']	[35]
#927
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	,	O	['N']	[5]
6	to	O	['N']	[6]
7	our	O	['N']	[7]
8	knowledge	O	['N']	[8]
9	,	O	['N']	[9]
10	of	O	['N']	[10]
11	onset	O	['N']	[11]
12	of	O	['N']	[12]
13	prolonged	O	['N']	[13]
14	infliximab	B-Drug	['Causes']	[17]
15	-	O	['N']	[15]
16	induced	O	['N']	[16]
17	lupus	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#928
0	Three	O	['N']	[0]
1	nephrotic	O	['N']	[1]
2	patients	O	['N']	[2]
3	who	O	['N']	[3]
4	had	O	['N']	[4]
5	reduced	O	['N']	[5]
6	renal	O	['N']	[6]
7	function	O	['N']	[7]
8	and	O	['N']	[8]
9	active	O	['N']	[9]
10	renal	O	['N']	[10]
11	disease	O	['N']	[11]
12	with	O	['N']	[12]
13	progressive	O	['N']	[13]
14	deterioration	O	['N']	[14]
15	of	O	['N']	[15]
16	renal	O	['N']	[16]
17	function	O	['N']	[17]
18	prior	O	['N']	[18]
19	to	O	['N']	[19]
20	the	O	['N']	[20]
21	use	O	['N']	[21]
22	of	O	['N']	[22]
23	MP	B-Drug	['Causes']	[27]
24	developed	O	['N']	[24]
25	transient	B	['N']	[25]
26	renal	I	['N']	[26]
27	failure	I-Adverse_Effect	['N']	[27]
28	following	O	['N']	[28]
29	an	O	['N']	[29]
30	MP	O	['N']	[30]
31	pulse	O	['N']	[31]
32	therapy	O	['N']	[32]
33	.	O	['N']	[33]
#929
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Reproductive	O	['N']	[2]
3	endocrine	O	['N']	[3]
4	disorders	O	['N']	[4]
5	characterized	O	['N']	[5]
6	by	O	['N']	[6]
7	menstrual	O	['N']	[7]
8	disorders	O	['N']	[8]
9	,	O	['N']	[9]
10	polycystic	B	['N']	[10]
11	ovaries	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	hyperandrogenism	O	['N']	[14]
15	seem	O	['N']	[15]
16	to	O	['N']	[16]
17	be	O	['N']	[17]
18	common	O	['N']	[18]
19	among	O	['N']	[19]
20	women	O	['N']	[20]
21	treated	O	['N']	[21]
22	with	O	['N']	[22]
23	sodium	B	['N']	[23]
24	valproate	I-Drug	['Causes']	[11]
25	for	O	['N']	[25]
26	epilepsy	O	['N']	[26]
27	.	O	['N']	[27]
#930
0	Morphine	B-Drug	['Causes']	[12]
1	,	O	['N']	[1]
2	an	O	['N']	[2]
3	opium	O	['N']	[3]
4	alkaloid	O	['N']	[4]
5	,	O	['N']	[5]
6	frequently	O	['N']	[6]
7	causes	O	['N']	[7]
8	side	O	['N']	[8]
9	effects	O	['N']	[9]
10	such	O	['N']	[10]
11	as	O	['N']	[11]
12	hyperhidrosis	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	facial	O	['N']	[14]
15	flushing	O	['N']	[15]
16	,	O	['N']	[16]
17	but	O	['N']	[17]
18	serious	O	['N']	[18]
19	cutaneous	O	['N']	[19]
20	adverse	O	['N']	[20]
21	drug	O	['N']	[21]
22	reactions	O	['N']	[22]
23	are	O	['N']	[23]
24	seldom	O	['N']	[24]
25	observed	O	['N']	[25]
26	.	O	['N']	[26]
#931
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	B	['N']	[23]
24	eruptions	I-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	-	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#932
0	Osteomyelitis	B-Adverse_Effect	['N']	[0]
1	occurring	O	['N']	[1]
2	during	O	['N']	[2]
3	infliximab	B-Drug	['Causes']	[0]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	severe	O	['N']	[6]
7	psoriasis	O	['N']	[7]
8	.	O	['N']	[8]
#933
0	A	O	['N']	[0]
1	second	O	['N']	[1]
2	episode	O	['N']	[2]
3	of	O	['N']	[3]
4	jaundice	B-Adverse_Effect	['N']	[4]
5	followed	O	['N']	[5]
6	the	O	['N']	[6]
7	intravaginal	O	['N']	[7]
8	administration	O	['N']	[8]
9	of	O	['N']	[9]
10	a	O	['N']	[10]
11	mixture	O	['N']	[11]
12	of	O	['N']	[12]
13	furazolidone	O	['N']	[13]
14	and	O	['N']	[14]
15	nifuroxime	B-Drug	['Causes']	[4]
16	.	O	['N']	[16]
#934
0	An	O	['N']	[0]
1	8-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	girl	O	['N']	[4]
5	,	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	been	O	['N']	[8]
9	vaccinated	O	['N']	[9]
10	with	O	['N']	[10]
11	BCG	B-Drug	['Causes']	[22]
12	without	O	['N']	[12]
13	subsequent	O	['N']	[13]
14	regional	O	['N']	[14]
15	reactions	O	['N']	[15]
16	,	O	['N']	[16]
17	developed	O	['N']	[17]
18	osteomyelitis	B	['N']	[18]
19	in	I	['N']	[19]
20	the	I	['N']	[20]
21	left	I	['N']	[21]
22	calcaneus	I-Adverse_Effect	['N']	[22]
23	7	O	['N']	[23]
24	months	O	['N']	[24]
25	later	O	['N']	[25]
26	.	O	['N']	[26]
#935
0	Type	B	['N']	[0]
1	I	I	['N']	[1]
2	second	I	['N']	[2]
3	-	I	['N']	[3]
4	degree	I	['N']	[4]
5	AV	I	['N']	[5]
6	block	I-Adverse_Effect	['N']	[6]
7	(	O	['N']	[7]
8	Mobitz	O	['N']	[8]
9	type	O	['N']	[9]
10	I	O	['N']	[10]
11	,	O	['N']	[11]
12	Wenckebach	O	['N']	[12]
13	AV	O	['N']	[13]
14	block	O	['N']	[14]
15	)	O	['N']	[15]
16	during	O	['N']	[16]
17	ritodrine	B-Drug	['Causes']	[6]
18	therapy	O	['N']	[18]
19	for	O	['N']	[19]
20	preterm	O	['N']	[20]
21	labor	O	['N']	[21]
22	.	O	['N']	[22]
#936
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	Parkinson	O	['N']	[3]
4	's	O	['N']	[4]
5	disease	O	['N']	[5]
6	,	O	['N']	[6]
7	initially	O	['N']	[7]
8	treated	O	['N']	[8]
9	with	O	['N']	[9]
10	bromocriptine	O	['N']	[10]
11	and	O	['N']	[11]
12	subsequently	O	['N']	[12]
13	with	O	['N']	[13]
14	cabergoline	B-Drug	['Causes']	[19]
15	,	O	['N']	[15]
16	developed	O	['N']	[16]
17	progressive	O	['N']	[17]
18	pleuropulmonary	B	['N']	[18]
19	abnormalities	I-Adverse_Effect	['N']	[19]
20	during	O	['N']	[20]
21	the	O	['N']	[21]
22	latter	O	['N']	[22]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#937
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	undergone	O	['N']	[8]
9	a	O	['N']	[9]
10	renal	O	['N']	[10]
11	transplantation	O	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	result	O	['N']	[14]
15	of	O	['N']	[15]
16	malignant	O	['N']	[16]
17	hypertension	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	who	O	['N']	[20]
21	was	O	['N']	[21]
22	on	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	therapy	O	['N']	[24]
25	consisting	O	['N']	[25]
26	of	O	['N']	[26]
27	cyclosporin	B-Drug	['Causes']	[34]
28	,	O	['N']	[28]
29	prednisone	O	['N']	[29]
30	and	O	['N']	[30]
31	azathioprine	O	['N']	[31]
32	,	O	['N']	[32]
33	developed	O	['N']	[33]
34	thrombosis	B-Adverse_Effect	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	central	O	['N']	[37]
38	retinal	O	['N']	[38]
39	vein	O	['N']	[39]
40	5	O	['N']	[40]
41	years	O	['N']	[41]
42	following	O	['N']	[42]
43	the	O	['N']	[43]
44	transplantation	O	['N']	[44]
45	.	O	['N']	[45]
#938
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	are	O	['N']	[2]
3	described	O	['N']	[3]
4	in	O	['N']	[4]
5	whom	O	['N']	[5]
6	subtle	O	['N']	[6]
7	cognitive	B	['N']	[7]
8	impairments	I-Adverse_Effect	['N']	[8]
9	are	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	therapeutic	O	['N']	[12]
13	doses	O	['N']	[13]
14	of	O	['N']	[14]
15	amoxapine	B-Drug	['Causes']	[8]
16	.	O	['N']	[16]
#939
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	LTG	B-Drug	['Causes']	[11]
3	overdose	O	['N']	[3]
4	may	O	['N']	[4]
5	result	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	severe	O	['N']	[8]
9	but	O	['N']	[9]
10	reversible	O	['N']	[10]
11	encephalopathy	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	previously	O	['N']	[14]
15	undescribed	O	['N']	[15]
16	phenomenon	O	['N']	[16]
17	.	O	['N']	[17]
#940
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	,	O	['N']	[5]
6	after	O	['N']	[6]
7	receiving	O	['N']	[7]
8	his	O	['N']	[8]
9	first	O	['N']	[9]
10	dose	O	['N']	[10]
11	of	O	['N']	[11]
12	pregabalin	B-Drug	['Causes']	[22]
13	to	O	['N']	[13]
14	relieve	O	['N']	[14]
15	neuropathic	O	['N']	[15]
16	pain	O	['N']	[16]
17	,	O	['N']	[17]
18	presented	O	['N']	[18]
19	with	O	['N']	[19]
20	a	O	['N']	[20]
21	negative	B	['N']	[21]
22	myoclonus	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#941
0	The	O	['N']	[0]
1	pharmaceutical	O	['N']	[1]
2	company	O	['N']	[2]
3	producing	O	['N']	[3]
4	Halfan	O	['N']	[4]
5	has	O	['N']	[5]
6	reported	O	['N']	[6]
7	8	O	['N']	[7]
8	cardiac	O	['N']	[8]
9	arrests	O	['N']	[9]
10	,	O	['N']	[10]
11	leading	O	['N']	[11]
12	to	O	['N']	[12]
13	6	O	['N']	[13]
14	deaths	B-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	when	O	['N']	[16]
17	a	O	['N']	[17]
18	higher	O	['N']	[18]
19	dose	O	['N']	[19]
20	than	O	['N']	[20]
21	recommended	O	['N']	[21]
22	was	O	['N']	[22]
23	used	O	['N']	[23]
24	,	O	['N']	[24]
25	there	O	['N']	[25]
26	was	O	['N']	[26]
27	recent	O	['N']	[27]
28	or	O	['N']	[28]
29	concomitant	O	['N']	[29]
30	treatment	O	['N']	[30]
31	with	O	['N']	[31]
32	mefloquine	B-Drug	['Causes']	[14]
33	,	O	['N']	[33]
34	there	O	['N']	[34]
35	was	O	['N']	[35]
36	pre	O	['N']	[36]
37	-	O	['N']	[37]
38	existing	O	['N']	[38]
39	prolongation	O	['N']	[39]
40	of	O	['N']	[40]
41	the	O	['N']	[41]
42	QT	O	['N']	[42]
43	interval	O	['N']	[43]
44	or	O	['N']	[44]
45	the	O	['N']	[45]
46	patient	O	['N']	[46]
47	had	O	['N']	[47]
48	a	O	['N']	[48]
49	thiamine	O	['N']	[49]
50	deficiency	O	['N']	[50]
51	.	O	['N']	[51]
#942
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Intrathecal	O	['N']	[2]
3	baclofen	B-Drug	['Causes']	[7]
4	can	O	['N']	[4]
5	impair	B	['N']	[5]
6	sexual	I	['N']	[6]
7	function	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	ejaculation	O	['N']	[9]
10	in	O	['N']	[10]
11	some	O	['N']	[11]
12	patients	O	['N']	[12]
13	.	O	['N']	[13]
#943
0	On	O	['N']	[0]
1	day	O	['N']	[1]
2	7	O	['N']	[2]
3	of	O	['N']	[3]
4	linezolid	B-Drug	['Causes']	[11]
5	treatment	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	developed	O	['N']	[9]
10	severe	B	['N']	[10]
11	pruritus	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	macular	O	['N']	[13]
14	rash	O	['N']	[14]
15	,	O	['N']	[15]
16	facial	O	['N']	[16]
17	edema	O	['N']	[17]
18	,	O	['N']	[18]
19	eosinophilia	O	['N']	[19]
20	,	O	['N']	[20]
21	marked	O	['N']	[21]
22	increase	O	['N']	[22]
23	in	O	['N']	[23]
24	serum	O	['N']	[24]
25	creatinine	O	['N']	[25]
26	level	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	mild	O	['N']	[29]
30	hepatitis	O	['N']	[30]
31	.	O	['N']	[31]
#944
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	neonate	O	['N']	[3]
4	with	O	['N']	[4]
5	a	O	['N']	[5]
6	seizure	O	['N']	[6]
7	disorder	O	['N']	[7]
8	who	O	['N']	[8]
9	acutely	O	['N']	[9]
10	developed	O	['N']	[10]
11	pupillary	B	['N']	[11]
12	mydriasis	I-Adverse_Effect	['N']	[12]
13	secondary	O	['N']	[13]
14	to	O	['N']	[14]
15	lidocaine	B-Drug	['Causes']	[12]
16	overdose	O	['N']	[16]
17	.	O	['N']	[17]
#945
0	Hepatotoxicity	B-Adverse_Effect	['N']	[0]
1	resolved	O	['N']	[1]
2	once	O	['N']	[2]
3	erlotinib	B-Drug	['Causes']	[0]
4	was	O	['N']	[4]
5	discontinued	O	['N']	[5]
6	and	O	['N']	[6]
7	serum	O	['N']	[7]
8	transaminases	O	['N']	[8]
9	returned	O	['N']	[9]
10	to	O	['N']	[10]
11	baseline	O	['N']	[11]
12	normal	O	['N']	[12]
13	values	O	['N']	[13]
14	.	O	['N']	[14]
#946
0	Caution	O	['N']	[0]
1	with	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	cimetidine	B-Drug	['Causes']	[10]
5	in	O	['N']	[5]
6	tolazoline	O	['N']	[6]
7	induced	O	['N']	[7]
8	upper	B	['N']	[8]
9	gastrointestinal	I	['N']	[9]
10	bleeding	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#947
0	Toxic	B	['N']	[0]
1	epidermal	I	['N']	[1]
2	necrolysis	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	the	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	high	O	['N']	[7]
8	-	O	['N']	[8]
9	dose	O	['N']	[9]
10	cytosine	B	['N']	[10]
11	arabinoside	I-Drug	['Causes']	[2]
12	.	O	['N']	[12]
#948
0	Pulmonary	O	['N']	[0]
1	infiltrates	O	['N']	[1]
2	and	O	['N']	[2]
3	skin	B	['N']	[3]
4	pigmentation	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	sulfasalazine	B-Drug	['Causes']	[4]
8	.	O	['N']	[8]
#949
0	Acute	O	['N']	[0]
1	esmolol	B-Drug	['Causes']	[2]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	self	O	['N']	[5]
6	-	O	['N']	[6]
7	limiting	O	['N']	[7]
8	because	O	['N']	[8]
9	of	O	['N']	[9]
10	its	O	['N']	[10]
11	extremely	O	['N']	[11]
12	short	O	['N']	[12]
13	half	O	['N']	[13]
14	-	O	['N']	[14]
15	life	O	['N']	[15]
16	.	O	['N']	[16]
#950
0	Contrary	O	['N']	[0]
1	to	O	['N']	[1]
2	previous	O	['N']	[2]
3	recommendations	O	['N']	[3]
4	,	O	['N']	[4]
5	our	O	['N']	[5]
6	experience	O	['N']	[6]
7	cautions	O	['N']	[7]
8	against	O	['N']	[8]
9	the	O	['N']	[9]
10	further	O	['N']	[10]
11	use	O	['N']	[11]
12	of	O	['N']	[12]
13	high	O	['N']	[13]
14	-	O	['N']	[14]
15	dose	O	['N']	[15]
16	cytarabine	B-Drug	['Causes']	[21]
17	in	O	['N']	[17]
18	patients	O	['N']	[18]
19	who	O	['N']	[19]
20	develop	O	['N']	[20]
21	PPE	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	is	O	['N']	[24]
25	a	O	['N']	[25]
26	timely	O	['N']	[26]
27	reminder	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	potential	O	['N']	[30]
31	toxicity	O	['N']	[31]
32	of	O	['N']	[32]
33	this	O	['N']	[33]
34	agent	O	['N']	[34]
35	,	O	['N']	[35]
36	which	O	['N']	[36]
37	is	O	['N']	[37]
38	now	O	['N']	[38]
39	increasingly	O	['N']	[39]
40	being	O	['N']	[40]
41	used	O	['N']	[41]
42	as	O	['N']	[42]
43	first	O	['N']	[43]
44	-	O	['N']	[44]
45	line	O	['N']	[45]
46	treatment	O	['N']	[46]
47	in	O	['N']	[47]
48	the	O	['N']	[48]
49	management	O	['N']	[49]
50	of	O	['N']	[50]
51	haematologic	O	['N']	[51]
52	malignancies	O	['N']	[52]
53	.	O	['N']	[53]
#951
0	Severe	B	['N']	[0]
1	apnea	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	an	O	['N']	[3]
4	infant	O	['N']	[4]
5	exposed	O	['N']	[5]
6	to	O	['N']	[6]
7	lamotrigine	B-Drug	['Causes']	[1]
8	in	O	['N']	[8]
9	breast	O	['N']	[9]
10	milk	O	['N']	[10]
11	.	O	['N']	[11]
#952
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	severe	B	['N']	[5]
6	anemia	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	which	O	['N']	[8]
9	responded	O	['N']	[9]
10	well	O	['N']	[10]
11	to	O	['N']	[11]
12	steroid	O	['N']	[12]
13	therapy	O	['N']	[13]
14	,	O	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	receiving	O	['N']	[18]
19	IL-2	B-Drug	['Causes']	[6]
20	plus	O	['N']	[20]
21	IFN	O	['N']	[21]
22	-	O	['N']	[22]
23	alpha	O	['N']	[23]
24	for	O	['N']	[24]
25	metastatic	O	['N']	[25]
26	renal	O	['N']	[26]
27	cell	O	['N']	[27]
28	carcinoma	O	['N']	[28]
29	.	O	['N']	[29]
#953
0	Of	O	['N']	[0]
1	371	O	['N']	[1]
2	patients	O	['N']	[2]
3	treated	O	['N']	[3]
4	with	O	['N']	[4]
5	8MOP	B-Drug	['Causes']	[15]
6	,	O	['N']	[6]
7	three	O	['N']	[7]
8	(	O	['N']	[8]
9	0.8	O	['N']	[9]
10	%	O	['N']	[10]
11	)	O	['N']	[11]
12	developed	O	['N']	[12]
13	an	O	['N']	[13]
14	acute	B	['N']	[14]
15	dermatitis	I-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	PUVA	O	['N']	[18]
19	-	O	['N']	[19]
20	treated	O	['N']	[20]
21	areas	O	['N']	[21]
22	.	O	['N']	[22]
#954
0	A	O	['N']	[0]
1	16-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	fever	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	generalized	O	['N']	[8]
9	rigidity	O	['N']	[9]
10	,	O	['N']	[10]
11	leukocytosis	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	increased	O	['N']	[14]
15	serum	O	['N']	[15]
16	transaminase	O	['N']	[16]
17	and	O	['N']	[17]
18	creatine	O	['N']	[18]
19	kinase	O	['N']	[19]
20	levels	O	['N']	[20]
21	while	O	['N']	[21]
22	receiving	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	O	['N']	[25]
26	and	O	['N']	[26]
27	lithium	B-Drug	['Causes']	[6]
28	.	O	['N']	[28]
#955
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	,	O	['N']	[2]
3	while	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	loop	O	['N']	[6]
7	diuretic	O	['N']	[7]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	pancreatitis	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	including	O	['N']	[12]
13	furosemide	B-Drug	['Causes']	[10]
14	,	O	['N']	[14]
15	have	O	['N']	[15]
16	been	O	['N']	[16]
17	published	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	allergic	O	['N']	[20]
21	manifestations	O	['N']	[21]
22	with	O	['N']	[22]
23	both	O	['N']	[23]
24	sulfonamide	O	['N']	[24]
25	antibiotics	O	['N']	[25]
26	and	O	['N']	[26]
27	non	O	['N']	[27]
28	-	O	['N']	[28]
29	antibiotics	O	['N']	[29]
30	in	O	['N']	[30]
31	our	O	['N']	[31]
32	patient	O	['N']	[32]
33	suggest	O	['N']	[33]
34	possible	O	['N']	[34]
35	cross	O	['N']	[35]
36	-	O	['N']	[36]
37	reactivity	O	['N']	[37]
38	between	O	['N']	[38]
39	these	O	['N']	[39]
40	2	O	['N']	[40]
41	drug	O	['N']	[41]
42	classes	O	['N']	[42]
43	.	O	['N']	[43]
#956
0	A	O	['N']	[0]
1	64-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	presented	O	['N']	[5]
6	with	O	['N']	[6]
7	proteinuria	B-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	postoperative	O	['N']	[9]
10	interferon	B	['N']	[10]
11	(	I	['N']	[11]
12	IFN)-beta	I-Drug	['Causes']	[7]
13	therapy	O	['N']	[13]
14	against	O	['N']	[14]
15	malignant	O	['N']	[15]
16	melanoma	O	['N']	[16]
17	.	O	['N']	[17]
#957
0	Acute	O	['N']	[0]
1	renal	B	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	recognized	O	['N']	[5]
6	as	O	['N']	[6]
7	a	O	['N']	[7]
8	potential	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	suramin	B-Drug	['Causes']	[2]
12	treatment	O	['N']	[12]
13	.	O	['N']	[13]
#958
0	The	O	['N']	[0]
1	addition	O	['N']	[1]
2	of	O	['N']	[2]
3	intrathecal	O	['N']	[3]
4	methotrexate	B-Drug	['Causes']	[26]
5	to	O	['N']	[5]
6	treatment	O	['N']	[6]
7	protocols	O	['N']	[7]
8	has	O	['N']	[8]
9	increased	O	['N']	[9]
10	survival	O	['N']	[10]
11	rates	O	['N']	[11]
12	in	O	['N']	[12]
13	children	O	['N']	[13]
14	with	O	['N']	[14]
15	acute	O	['N']	[15]
16	lymphoblastic	O	['N']	[16]
17	leukemia	O	['N']	[17]
18	but	O	['N']	[18]
19	is	O	['N']	[19]
20	also	O	['N']	[20]
21	associated	O	['N']	[21]
22	with	O	['N']	[22]
23	varying	O	['N']	[23]
24	degrees	O	['N']	[24]
25	of	O	['N']	[25]
26	neurotoxicity	B-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#959
0	Olanzapine	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	neuroleptic	B	['N']	[3]
4	malignant	I	['N']	[4]
5	syndrome	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#960
0	It	O	['N']	[0]
1	occasionally	O	['N']	[1]
2	accompanies	O	['N']	[2]
3	the	O	['N']	[3]
4	heparin	B-Drug	['Causes']	[10]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	thrombocytopenia	O	['N']	[7]
8	and	O	['N']	[8]
9	thrombosis	B	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#961
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	in	O	['N']	[2]
3	1993	O	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	clinical	O	['N']	[6]
7	study	O	['N']	[7]
8	involving	O	['N']	[8]
9	400	O	['N']	[9]
10	patients	O	['N']	[10]
11	on	O	['N']	[11]
12	the	O	['N']	[12]
13	Thai	O	['N']	[13]
14	-	O	['N']	[14]
15	Burmese	O	['N']	[15]
16	border	O	['N']	[16]
17	revealed	O	['N']	[17]
18	cardiac	O	['N']	[18]
19	effects	O	['N']	[19]
20	of	O	['N']	[20]
21	antimalarial	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	halofantrine	B-Drug	['Causes']	[29]
25	,	O	['N']	[25]
26	including	O	['N']	[26]
27	one	O	['N']	[27]
28	sudden	B	['N']	[28]
29	death	I-Adverse_Effect	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	treatment	O	['N']	[32]
33	.	O	['N']	[33]
#962
0	An	O	['N']	[0]
1	11-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	a	O	['N']	[6]
7	severe	B	['N']	[7]
8	enteropathy	I-Adverse_Effect	['N']	[8]
9	2	O	['N']	[9]
10	years	O	['N']	[10]
11	after	O	['N']	[11]
12	initiation	O	['N']	[12]
13	of	O	['N']	[13]
14	clofazimine	B-Drug	['Causes']	[8]
15	treatment	O	['N']	[15]
16	for	O	['N']	[16]
17	graft	O	['N']	[17]
18	-	O	['N']	[18]
19	versus	O	['N']	[19]
20	-	O	['N']	[20]
21	host	O	['N']	[21]
22	disease	O	['N']	[22]
23	.	O	['N']	[23]
#963
0	Additionally	O	['N']	[0]
1	,	O	['N']	[1]
2	danazol	B-Drug	['Causes']	[5]
3	produces	O	['N']	[3]
4	hepatocellular	B	['N']	[4]
5	damage	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	approximately	O	['N']	[7]
8	10	O	['N']	[8]
9	%	O	['N']	[9]
10	of	O	['N']	[10]
11	women	O	['N']	[11]
12	.	O	['N']	[12]
#964
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	chronic	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	HCQ	B-Drug	['Causes']	[30]
7	for	O	['N']	[7]
8	rheumatic	O	['N']	[8]
9	diseases	O	['N']	[9]
10	,	O	['N']	[10]
11	or	O	['N']	[11]
12	as	O	['N']	[12]
13	an	O	['N']	[13]
14	anti	O	['N']	[14]
15	-	O	['N']	[15]
16	malarial	O	['N']	[16]
17	drug	O	['N']	[17]
18	,	O	['N']	[18]
19	should	O	['N']	[19]
20	be	O	['N']	[20]
21	balanced	O	['N']	[21]
22	against	O	['N']	[22]
23	the	O	['N']	[23]
24	risk	O	['N']	[24]
25	of	O	['N']	[25]
26	developing	O	['N']	[26]
27	potentially	O	['N']	[27]
28	lethal	O	['N']	[28]
29	cardiac	B	['N']	[29]
30	arrhythmias	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#965
0	Central	O	['N']	[0]
1	nervous	O	['N']	[1]
2	system	O	['N']	[2]
3	effects	O	['N']	[3]
4	secondary	O	['N']	[4]
5	to	O	['N']	[5]
6	ciprofloxacin	B-Drug	['Causes']	[25]
7	treatment	O	['N']	[7]
8	are	O	['N']	[8]
9	uncommon	O	['N']	[9]
10	and	O	['N']	[10]
11	usually	O	['N']	[11]
12	consist	O	['N']	[12]
13	only	O	['N']	[13]
14	of	O	['N']	[14]
15	minor	O	['N']	[15]
16	dizziness	O	['N']	[16]
17	or	O	['N']	[17]
18	mild	O	['N']	[18]
19	headache	O	['N']	[19]
20	,	O	['N']	[20]
21	although	O	['N']	[21]
22	rare	O	['N']	[22]
23	occurrences	O	['N']	[23]
24	of	O	['N']	[24]
25	seizures	B-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	hallucinations	O	['N']	[27]
28	have	O	['N']	[28]
29	been	O	['N']	[29]
30	reported	O	['N']	[30]
31	.	O	['N']	[31]
#966
0	A	O	['N']	[0]
1	49-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	prednisone	O	['N']	[11]
12	and	O	['N']	[12]
13	mesalamine	B-Drug	['Causes']	[20]
14	(	O	['N']	[14]
15	5-ASA	O	['N']	[15]
16	)	O	['N']	[16]
17	developed	O	['N']	[17]
18	worsening	B	['N']	[18]
19	respiratory	I	['N']	[19]
20	distress	I-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	fever	O	['N']	[22]
23	.	O	['N']	[23]
#967
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	respiratory	B	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	occurring	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	woman	O	['N']	[10]
11	at	O	['N']	[11]
12	16	O	['N']	[12]
13	weeks	O	['N']	[13]
14	'	O	['N']	[14]
15	gestation	O	['N']	[15]
16	who	O	['N']	[16]
17	was	O	['N']	[17]
18	being	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	nitrofurantoin	B-Drug	['Causes']	[6]
22	for	O	['N']	[22]
23	a	O	['N']	[23]
24	urinary	O	['N']	[24]
25	tract	O	['N']	[25]
26	infection	O	['N']	[26]
27	.	O	['N']	[27]
#968
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	observation	O	['N']	[2]
3	suggests	O	['N']	[3]
4	,	O	['N']	[4]
5	that	O	['N']	[5]
6	a	O	['N']	[6]
7	batch	O	['N']	[7]
8	of	O	['N']	[8]
9	different	O	['N']	[9]
10	testing	O	['N']	[10]
11	doses	O	['N']	[11]
12	,	O	['N']	[12]
13	including	O	['N']	[13]
14	lower	O	['N']	[14]
15	testing	O	['N']	[15]
16	doses	O	['N']	[16]
17	may	O	['N']	[17]
18	help	O	['N']	[18]
19	to	O	['N']	[19]
20	differentiate	O	['N']	[20]
21	between	O	['N']	[21]
22	an	O	['N']	[22]
23	allergic	O	['N']	[23]
24	type	O	['N']	[24]
25	of	O	['N']	[25]
26	contact	O	['N']	[26]
27	dermatitis	O	['N']	[27]
28	and	O	['N']	[28]
29	an	O	['N']	[29]
30	irritant	B	['N']	[30]
31	type	I	['N']	[31]
32	of	I	['N']	[32]
33	reaction	I-Adverse_Effect	['N']	[33]
34	after	O	['N']	[34]
35	treatment	O	['N']	[35]
36	with	O	['N']	[36]
37	calcipotriol	B-Drug	['Causes']	[33]
38	.	O	['N']	[38]
#969
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	vincristine	O	['N']	[3]
4	and	O	['N']	[4]
5	actinomycin	B	['N']	[5]
6	D	I-Drug	['Causes']	[15]
7	were	O	['N']	[7]
8	the	O	['N']	[8]
9	cause	O	['N']	[9]
10	of	O	['N']	[10]
11	this	O	['N']	[11]
12	rare	O	['N']	[12]
13	from	O	['N']	[13]
14	of	O	['N']	[14]
15	hepatotoxicity	B-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	that	O	['N']	[17]
18	chemotherapy	O	['N']	[18]
19	for	O	['N']	[19]
20	the	O	['N']	[20]
21	underlying	O	['N']	[21]
22	malignant	O	['N']	[22]
23	disease	O	['N']	[23]
24	could	O	['N']	[24]
25	be	O	['N']	[25]
26	given	O	['N']	[26]
27	safely	O	['N']	[27]
28	after	O	['N']	[28]
29	clinical	O	['N']	[29]
30	recovery	O	['N']	[30]
31	.	O	['N']	[31]
#970
0	Septic	B	['N']	[0]
1	knee	I	['N']	[1]
2	arthritis	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	intra	O	['N']	[4]
5	-	O	['N']	[5]
6	articular	O	['N']	[6]
7	hyaluronate	B-Drug	['Causes']	[2]
8	injection	O	['N']	[8]
9	.	O	['N']	[9]
#971
0	It	O	['N']	[0]
1	also	O	['N']	[1]
2	highlights	O	['N']	[2]
3	a	O	['N']	[3]
4	current	O	['N']	[4]
5	major	O	['N']	[5]
6	etiologic	O	['N']	[6]
7	question	O	['N']	[7]
8	,	O	['N']	[8]
9	that	O	['N']	[9]
10	is	O	['N']	[10]
11	,	O	['N']	[11]
12	whether	O	['N']	[12]
13	and	O	['N']	[13]
14	to	O	['N']	[14]
15	what	O	['N']	[15]
16	degree	O	['N']	[16]
17	lead	B-Drug	['Causes']	[24]
18	exposure	O	['N']	[18]
19	contributes	O	['N']	[19]
20	to	O	['N']	[20]
21	the	O	['N']	[21]
22	development	O	['N']	[22]
23	of	O	['N']	[23]
24	hypertension	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	raises	O	['N']	[27]
28	the	O	['N']	[28]
29	issue	O	['N']	[29]
30	of	O	['N']	[30]
31	whether	O	['N']	[31]
32	lead	O	['N']	[32]
33	-	O	['N']	[33]
34	induced	O	['N']	[34]
35	hypertension	O	['N']	[35]
36	constitutes	O	['N']	[36]
37	a	O	['N']	[37]
38	subset	O	['N']	[38]
39	of	O	['N']	[39]
40	hypertension	O	['N']	[40]
41	that	O	['N']	[41]
42	is	O	['N']	[42]
43	especially	O	['N']	[43]
44	amenable	O	['N']	[44]
45	to	O	['N']	[45]
46	therapy	O	['N']	[46]
47	with	O	['N']	[47]
48	dietary	O	['N']	[48]
49	calcium	O	['N']	[49]
50	.	O	['N']	[50]
#972
0	The	O	['N']	[0]
1	cough	B-Adverse_Effect	['N']	[1]
2	continued	O	['N']	[2]
3	for	O	['N']	[3]
4	the	O	['N']	[4]
5	duration	O	['N']	[5]
6	of	O	['N']	[6]
7	therapy	O	['N']	[7]
8	with	O	['N']	[8]
9	quinapril	B-Drug	['Causes']	[1]
10	.	O	['N']	[10]
#973
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acne	B	['N']	[5]
6	fulminans	I-Adverse_Effect	['N']	[6]
7	occurring	O	['N']	[7]
8	during	O	['N']	[8]
9	treatment	O	['N']	[9]
10	with	O	['N']	[10]
11	13-cis	B	['N']	[11]
12	-	I	['N']	[12]
13	retinoic	I	['N']	[13]
14	acid	I-Drug	['Causes']	[6]
15	for	O	['N']	[15]
16	cystic	O	['N']	[16]
17	acne	O	['N']	[17]
18	.	O	['N']	[18]
#974
0	Lipoid	B	['N']	[0]
1	pneumonia	I-Adverse_Effect	['N']	[1]
2	:	O	['N']	[2]
3	a	O	['N']	[3]
4	silent	O	['N']	[4]
5	complication	O	['N']	[5]
6	of	O	['N']	[6]
7	mineral	B	['N']	[7]
8	oil	I-Drug	['Causes']	[1]
9	aspiration	O	['N']	[9]
10	.	O	['N']	[10]
#975
0	Three	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	gold	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	related	O	['N']	[5]
6	neuropathy	B-Adverse_Effect	['N']	[6]
7	are	O	['N']	[7]
8	reported	O	['N']	[8]
9	.	O	['N']	[9]
#976
0	Alternating	O	['N']	[0]
1	sinus	O	['N']	[1]
2	rhythm	O	['N']	[2]
3	and	O	['N']	[3]
4	intermittent	B	['N']	[4]
5	sinoatrial	I	['N']	[5]
6	block	I-Adverse_Effect	['N']	[6]
7	induced	O	['N']	[7]
8	by	O	['N']	[8]
9	propranolol	B-Drug	['Causes']	[6]
10	.	O	['N']	[10]
#977
0	A	O	['N']	[0]
1	fatal	B	['N']	[1]
2	pancytopenia	I-Adverse_Effect	['N']	[2]
3	occurred	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	an	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	depression	O	['N']	[11]
12	with	O	['N']	[12]
13	hypomanic	O	['N']	[13]
14	rebounds	O	['N']	[14]
15	,	O	['N']	[15]
16	admitted	O	['N']	[16]
17	for	O	['N']	[17]
18	a	O	['N']	[18]
19	manic	O	['N']	[19]
20	episode	O	['N']	[20]
21	and	O	['N']	[21]
22	treated	O	['N']	[22]
23	with	O	['N']	[23]
24	levomepromazine	O	['N']	[24]
25	,	O	['N']	[25]
26	diazepam	B-Drug	['Causes']	[2]
27	and	O	['N']	[27]
28	lithium	O	['N']	[28]
29	carbonate	O	['N']	[29]
30	.	O	['N']	[30]
#978
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	acyclovir	B-Drug	['Dosage']	[14]
5	when	O	['N']	[5]
6	given	O	['N']	[6]
7	intravenously	O	['N']	[7]
8	in	O	['N']	[8]
9	doses	O	['N']	[9]
10	of	O	['N']	[10]
11	10	B	['N']	[11]
12	mg	I	['N']	[12]
13	/	I	['N']	[13]
14	kg	I-Dose	['N']	[14]
15	may	O	['N']	[15]
16	result	O	['N']	[16]
17	in	O	['N']	[17]
18	increased	O	['N']	[18]
19	serum	O	['N']	[19]
20	lithium	O	['N']	[20]
21	concentrations	O	['N']	[21]
22	.	O	['N']	[22]
#979
0	Radiologic	O	['N']	[0]
1	recognition	O	['N']	[1]
2	of	O	['N']	[2]
3	adriamycin	B-Drug	['Causes']	[4]
4	cardiotoxicity	B-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#980
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	with	O	['N']	[2]
3	parenteral	O	['N']	[3]
4	amiodarone	B-Drug	['Causes']	[47]
5	(	O	['N']	[5]
6	2300	O	['N']	[6]
7	mg	O	['N']	[7]
8	in	O	['N']	[8]
9	3	O	['N']	[9]
10	days	O	['N']	[10]
11	)	O	['N']	[11]
12	and	O	['N']	[12]
13	other	O	['N']	[13]
14	measures	O	['N']	[14]
15	,	O	['N']	[15]
16	signs	O	['N']	[16]
17	of	O	['N']	[17]
18	congestive	O	['N']	[18]
19	heart	O	['N']	[19]
20	failure	O	['N']	[20]
21	disappeared	O	['N']	[21]
22	;	O	['N']	[22]
23	subsequently	O	['N']	[23]
24	the	O	['N']	[24]
25	patient	O	['N']	[25]
26	developed	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	marked	O	['N']	[29]
30	increase	O	['N']	[30]
31	in	O	['N']	[31]
32	serum	O	['N']	[32]
33	transaminase	O	['N']	[33]
34	levels	O	['N']	[34]
35	and	O	['N']	[35]
36	fall	O	['N']	[36]
37	in	O	['N']	[37]
38	prothrombin	O	['N']	[38]
39	time	O	['N']	[39]
40	,	O	['N']	[40]
41	and	O	['N']	[41]
42	histologic	O	['N']	[42]
43	changes	O	['N']	[43]
44	of	O	['N']	[44]
45	severe	B	['N']	[45]
46	centrilobular	I	['N']	[46]
47	necrosis	I-Adverse_Effect	['N']	[47]
48	were	O	['N']	[48]
49	observed	O	['N']	[49]
50	in	O	['N']	[50]
51	hepatic	O	['N']	[51]
52	biopsy	O	['N']	[52]
53	.	O	['N']	[53]
#981
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	here	O	['N']	[2]
3	on	O	['N']	[3]
4	a	O	['N']	[4]
5	heretofore	O	['N']	[5]
6	undescribed	O	['N']	[6]
7	respiratory	B	['N']	[7]
8	syncytial	I	['N']	[8]
9	virus	I	['N']	[9]
10	(	I	['N']	[10]
11	RSV	I	['N']	[11]
12	)	I	['N']	[12]
13	infection	I-Adverse_Effect	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	with	O	['N']	[17]
18	a	O	['N']	[18]
19	long	O	['N']	[19]
20	-	O	['N']	[20]
21	standing	O	['N']	[21]
22	history	O	['N']	[22]
23	of	O	['N']	[23]
24	refractory	O	['N']	[24]
25	CLL	O	['N']	[25]
26	that	O	['N']	[26]
27	was	O	['N']	[27]
28	treated	O	['N']	[28]
29	with	O	['N']	[29]
30	fludarabine	B	['N']	[30]
31	phosphate	I-Drug	['Causes']	[13]
32	.	O	['N']	[32]
#982
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	that	O	['N']	[2]
3	this	O	['N']	[3]
4	represents	O	['N']	[4]
5	an	O	['N']	[5]
6	unusual	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	moderate	O	['N']	[9]
10	-	O	['N']	[10]
11	dose	O	['N']	[11]
12	MTX	B-Drug	['Causes']	[15]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	neurotoxicity	B-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	patient	O	['N']	[18]
19	with	O	['N']	[19]
20	gastric	O	['N']	[20]
21	cancer	O	['N']	[21]
22	,	O	['N']	[22]
23	which	O	['N']	[23]
24	has	O	['N']	[24]
25	not	O	['N']	[25]
26	previously	O	['N']	[26]
27	been	O	['N']	[27]
28	reported	O	['N']	[28]
29	.	O	['N']	[29]
#983
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	B	['N']	[9]
10	mg	I-Dose	['N']	[10]
11	sertraline	B-Drug	['Dosage']	[10]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	O	['N']	[17]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	lamotrigine	O	['N']	[27]
28	blood	O	['N']	[28]
29	level	O	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	toxicity	O	['N']	[33]
34	.	O	['N']	[34]
#984
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	B-Drug	['Causes']	[41]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	B-Adverse_Effect	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#985
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	penile	B	['N']	[5]
6	fibrosis	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	intracavernous	O	['N']	[8]
9	self	O	['N']	[9]
10	-	O	['N']	[10]
11	injection	O	['N']	[11]
12	of	O	['N']	[12]
13	a	O	['N']	[13]
14	combination	O	['N']	[14]
15	of	O	['N']	[15]
16	phentolamine	O	['N']	[16]
17	and	O	['N']	[17]
18	papaverine	B-Drug	['Causes']	[6]
19	.	O	['N']	[19]
#986
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	was	O	['N']	[2]
3	an	O	['N']	[3]
4	82-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	receiving	O	['N']	[8]
9	ticlopidine	B-Drug	['Causes']	[23]
10	for	O	['N']	[10]
11	2	O	['N']	[11]
12	years	O	['N']	[12]
13	when	O	['N']	[13]
14	,	O	['N']	[14]
15	during	O	['N']	[15]
16	a	O	['N']	[16]
17	febrile	O	['N']	[17]
18	episode	O	['N']	[18]
19	,	O	['N']	[19]
20	he	O	['N']	[20]
21	was	O	['N']	[21]
22	found	O	['N']	[22]
23	neutropenic	B-Adverse_Effect	['N']	[23]
24	with	O	['N']	[24]
25	marrow	O	['N']	[25]
26	aplasia	O	['N']	[26]
27	.	O	['N']	[27]
#987
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	44-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	taking	O	['N']	[7]
8	naproxen	B-Drug	['Causes']	[28]
9	for	O	['N']	[9]
10	chronic	O	['N']	[10]
11	low	O	['N']	[11]
12	back	O	['N']	[12]
13	pain	O	['N']	[13]
14	and	O	['N']	[14]
15	a	O	['N']	[15]
16	20-year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	woman	O	['N']	[19]
20	on	O	['N']	[20]
21	oxaprozin	O	['N']	[21]
22	for	O	['N']	[22]
23	rheumatoid	O	['N']	[23]
24	arthritis	O	['N']	[24]
25	presented	O	['N']	[25]
26	with	O	['N']	[26]
27	tense	B	['N']	[27]
28	bullae	I-Adverse_Effect	['N']	[28]
29	and	O	['N']	[29]
30	cutaneous	O	['N']	[30]
31	fragility	O	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	face	O	['N']	[34]
35	and	O	['N']	[35]
36	the	O	['N']	[36]
37	back	O	['N']	[37]
38	of	O	['N']	[38]
39	the	O	['N']	[39]
40	hands	O	['N']	[40]
41	.	O	['N']	[41]
#988
0	Transient	B	['N']	[0]
1	left	I	['N']	[1]
2	homonymous	I	['N']	[2]
3	hemianopsia	I-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	encephalopathy	O	['N']	[5]
6	following	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	testicular	O	['N']	[9]
10	carcinoma	O	['N']	[10]
11	with	O	['N']	[11]
12	cisplatinum	B-Drug	['Causes']	[3]
13	,	O	['N']	[13]
14	vinblastine	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	bleomycin	O	['N']	[17]
18	.	O	['N']	[18]
#989
0	That	O	['N']	[0]
1	review	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	patients	O	['N']	[4]
5	receiving	O	['N']	[5]
6	anti	B	['N']	[6]
7	-	I	['N']	[7]
8	D	I	['N']	[8]
9	IGIV	I-Drug	['Causes']	[26]
10	be	O	['N']	[10]
11	monitored	O	['N']	[11]
12	for	O	['N']	[12]
13	those	O	['N']	[13]
14	and	O	['N']	[14]
15	other	O	['N']	[15]
16	potential	O	['N']	[16]
17	complications	O	['N']	[17]
18	of	O	['N']	[18]
19	hemoglobinemia	O	['N']	[19]
20	,	O	['N']	[20]
21	particularly	O	['N']	[21]
22	disseminated	O	['N']	[22]
23	intravascular	O	['N']	[23]
24	coagulation	O	['N']	[24]
25	(	O	['N']	[25]
26	DIC	B-Adverse_Effect	['N']	[26]
27	)	O	['N']	[27]
28	.	O	['N']	[28]
#990
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	prior	O	['N']	[5]
6	amputation	O	['N']	[6]
7	who	O	['N']	[7]
8	experienced	O	['N']	[8]
9	phantom	O	['N']	[9]
10	limb	O	['N']	[10]
11	pain	O	['N']	[11]
12	(	O	['N']	[12]
13	PLP	B-Adverse_Effect	['N']	[13]
14	)	O	['N']	[14]
15	after	O	['N']	[15]
16	receiving	O	['N']	[16]
17	paclitaxel	B-Drug	['Causes']	[13]
18	therapy	O	['N']	[18]
19	.	O	['N']	[19]
#991
0	A	O	['N']	[0]
1	49-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	prednisone	O	['N']	[11]
12	and	O	['N']	[12]
13	mesalamine	B-Drug	['Causes']	[22]
14	(	O	['N']	[14]
15	5-ASA	O	['N']	[15]
16	)	O	['N']	[16]
17	developed	O	['N']	[17]
18	worsening	O	['N']	[18]
19	respiratory	O	['N']	[19]
20	distress	O	['N']	[20]
21	and	O	['N']	[21]
22	fever	B-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#992
0	Ophthalmologists	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	ocular	B	['N']	[6]
7	side	I	['N']	[7]
8	effects	I-Adverse_Effect	['N']	[8]
9	of	O	['N']	[9]
10	IFN	B-Drug	['Causes']	[8]
11	therapy	O	['N']	[11]
12	and	O	['N']	[12]
13	carefully	O	['N']	[13]
14	monitor	O	['N']	[14]
15	patients	O	['N']	[15]
16	for	O	['N']	[16]
17	the	O	['N']	[17]
18	possible	O	['N']	[18]
19	occurrence	O	['N']	[19]
20	of	O	['N']	[20]
21	hypoalbuminemia	O	['N']	[21]
22	and	O	['N']	[22]
23	thrombocytopenia	O	['N']	[23]
24	.	O	['N']	[24]
#993
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	osteosarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	normal	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	manifested	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	impending	O	['N']	[15]
16	renal	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	and	O	['N']	[18]
19	extreme	O	['N']	[19]
20	elevation	O	['N']	[20]
21	of	O	['N']	[21]
22	aspartate	O	['N']	[22]
23	aminotrasferase	O	['N']	[23]
24	and	O	['N']	[24]
25	alanine	O	['N']	[25]
26	aminotransferase	O	['N']	[26]
27	within	O	['N']	[27]
28	2	O	['N']	[28]
29	hours	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	completion	O	['N']	[32]
33	of	O	['N']	[33]
34	a	O	['N']	[34]
35	4-hour	O	['N']	[35]
36	infusion	O	['N']	[36]
37	of	O	['N']	[37]
38	high	B	['N']	[38]
39	-	I	['N']	[39]
40	dose	I-Dose	['N']	[40]
41	methotrexate	B-Drug	['Dosage']	[40]
42	(	O	['N']	[42]
43	MTX	O	['N']	[43]
44	)	O	['N']	[44]
45	(	O	['N']	[45]
46	12	O	['N']	[46]
47	g	O	['N']	[47]
48	/	O	['N']	[48]
49	m2	O	['N']	[49]
50	)	O	['N']	[50]
51	,	O	['N']	[51]
52	and	O	['N']	[52]
53	went	O	['N']	[53]
54	on	O	['N']	[54]
55	to	O	['N']	[55]
56	develop	O	['N']	[56]
57	acute	O	['N']	[57]
58	renal	O	['N']	[58]
59	failure	O	['N']	[59]
60	with	O	['N']	[60]
61	life	O	['N']	[61]
62	-	O	['N']	[62]
63	threatening	O	['N']	[63]
64	hyperkalemia	O	['N']	[64]
65	29	O	['N']	[65]
66	hours	O	['N']	[66]
67	later	O	['N']	[67]
68	.	O	['N']	[68]
#994
0	We	O	['N']	[0]
1	cared	O	['N']	[1]
2	for	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	progressive	O	['N']	[6]
7	renal	O	['N']	[7]
8	impairment	O	['N']	[8]
9	who	O	['N']	[9]
10	presented	O	['N']	[10]
11	with	O	['N']	[11]
12	blurred	B	['N']	[12]
13	vision	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	QRS	O	['N']	[15]
16	broadening	O	['N']	[16]
17	and	O	['N']	[17]
18	cardiac	O	['N']	[18]
19	failure	O	['N']	[19]
20	due	O	['N']	[20]
21	to	O	['N']	[21]
22	chronic	O	['N']	[22]
23	cibenzoline	B-Drug	['Causes']	[13]
24	intoxication	O	['N']	[24]
25	.	O	['N']	[25]
#995
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	16-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	male	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	nephrotic	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	related	O	['N']	[11]
12	to	O	['N']	[12]
13	membranous	O	['N']	[13]
14	glomerulopathy	O	['N']	[14]
15	with	O	['N']	[15]
16	clinical	O	['N']	[16]
17	and	O	['N']	[17]
18	serological	O	['N']	[18]
19	evidence	O	['N']	[19]
20	of	O	['N']	[20]
21	systemic	B	['N']	[21]
22	lupus	I	['N']	[22]
23	erythematosus	I-Adverse_Effect	['N']	[23]
24	after	O	['N']	[24]
25	treatment	O	['N']	[25]
26	with	O	['N']	[26]
27	griseofulvin	B-Drug	['Causes']	[23]
28	.	O	['N']	[28]
#996
0	Colitis	O	['N']	[0]
1	as	O	['N']	[1]
2	a	O	['N']	[2]
3	manifestation	O	['N']	[3]
4	of	O	['N']	[4]
5	infliximab	B-Drug	['Causes']	[9]
6	-	O	['N']	[6]
7	associated	O	['N']	[7]
8	disseminated	B	['N']	[8]
9	cryptococcosis	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#997
0	Seizure	O	['N']	[0]
1	with	O	['N']	[1]
2	hyponatremia	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	child	O	['N']	[5]
6	prescribed	O	['N']	[6]
7	desmopressin	B-Drug	['Causes']	[2]
8	for	O	['N']	[8]
9	nocturnal	O	['N']	[9]
10	enuresis	O	['N']	[10]
11	.	O	['N']	[11]
#998
0	The	O	['N']	[0]
1	typical	O	['N']	[1]
2	fluoxetine	B-Drug	['Causes']	[18]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	symptoms	O	['N']	[5]
6	of	O	['N']	[6]
7	restlessness	O	['N']	[7]
8	,	O	['N']	[8]
9	constant	O	['N']	[9]
10	pacing	O	['N']	[10]
11	,	O	['N']	[11]
12	purposeless	B	['N']	[12]
13	movements	I	['N']	[13]
14	of	I	['N']	[14]
15	the	I	['N']	[15]
16	feet	I	['N']	[16]
17	and	I	['N']	[17]
18	legs	I-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	marked	O	['N']	[21]
22	anxiety	O	['N']	[22]
23	were	O	['N']	[23]
24	indistinguishable	O	['N']	[24]
25	from	O	['N']	[25]
26	those	O	['N']	[26]
27	of	O	['N']	[27]
28	neuroleptic	O	['N']	[28]
29	-	O	['N']	[29]
30	induced	O	['N']	[30]
31	akathisia	O	['N']	[31]
32	.	O	['N']	[32]
#999
0	Seizures	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	fluoxetine	B-Drug	['Causes']	[0]
4	therapy	O	['N']	[4]
5	.	O	['N']	[5]
#1000
0	Interstitial	O	['N']	[0]
1	pneumonitis	O	['N']	[1]
2	and	O	['N']	[2]
3	alveolar	B	['N']	[3]
4	hemorrhage	I-Adverse_Effect	['N']	[4]
5	complicating	O	['N']	[5]
6	use	O	['N']	[6]
7	of	O	['N']	[7]
8	rituximab	B-Drug	['Causes']	[4]
9	:	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	and	O	['N']	[12]
13	review	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	literature	O	['N']	[16]
17	.	O	['N']	[17]
#1001
0	Metformin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	lactic	B	['N']	[3]
4	acidosis	I-Adverse_Effect	['N']	[4]
5	(	O	['N']	[5]
6	MALA	O	['N']	[6]
7	)	O	['N']	[7]
8	is	O	['N']	[8]
9	a	O	['N']	[9]
10	serious	O	['N']	[10]
11	metabolic	O	['N']	[11]
12	complication	O	['N']	[12]
13	that	O	['N']	[13]
14	occurs	O	['N']	[14]
15	because	O	['N']	[15]
16	of	O	['N']	[16]
17	metformin	O	['N']	[17]
18	accumulation	O	['N']	[18]
19	in	O	['N']	[19]
20	patients	O	['N']	[20]
21	who	O	['N']	[21]
22	become	O	['N']	[22]
23	dehydrated	O	['N']	[23]
24	or	O	['N']	[24]
25	developed	O	['N']	[25]
26	acute	O	['N']	[26]
27	renal	O	['N']	[27]
28	failure	O	['N']	[28]
29	.	O	['N']	[29]
#1002
0	We	O	['N']	[0]
1	evaluated	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	a	O	['N']	[6]
7	psychotic	B	['N']	[7]
8	disorder	I-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	4	O	['N']	[10]
11	months	O	['N']	[11]
12	of	O	['N']	[12]
13	isoniazid	B-Drug	['Causes']	[8]
14	prophylaxis	O	['N']	[14]
15	for	O	['N']	[15]
16	a	O	['N']	[16]
17	positive	O	['N']	[17]
18	tuberculosis	O	['N']	[18]
19	tine	O	['N']	[19]
20	test	O	['N']	[20]
21	.	O	['N']	[21]
#1003
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	developing	O	['N']	[6]
7	fulminant	B	['N']	[7]
8	liver	I	['N']	[8]
9	failure	I-Adverse_Effect	['N']	[9]
10	while	O	['N']	[10]
11	being	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	clarithromycin	B-Drug	['Causes']	[9]
15	for	O	['N']	[15]
16	pneumonia	O	['N']	[16]
17	.	O	['N']	[17]
#1004
0	A	O	['N']	[0]
1	64-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	schizophrenia	O	['N']	[6]
7	developed	O	['N']	[7]
8	myoclonic	O	['N']	[8]
9	jerks	O	['N']	[9]
10	when	O	['N']	[10]
11	given	O	['N']	[11]
12	higher	B	['N']	[12]
13	doses	I-Dose	['N']	[13]
14	of	O	['N']	[14]
15	quetiapine	B-Drug	['Dosage']	[13]
16	.	O	['N']	[16]
#1005
0	Venlafaxine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	urinary	B	['N']	[3]
4	incontinence	I-Adverse_Effect	['N']	[4]
5	resolved	O	['N']	[5]
6	after	O	['N']	[6]
7	switching	O	['N']	[7]
8	to	O	['N']	[8]
9	sertraline	O	['N']	[9]
10	.	O	['N']	[10]
#1006
0	After	O	['N']	[0]
1	seven	O	['N']	[1]
2	months	O	['N']	[2]
3	'	O	['N']	[3]
4	continuous	O	['N']	[4]
5	treatment	O	['N']	[5]
6	for	O	['N']	[6]
7	suspected	O	['N']	[7]
8	tuberculosis	O	['N']	[8]
9	with	O	['N']	[9]
10	rifampicin	O	['N']	[10]
11	and	O	['N']	[11]
12	ethambutol	B-Drug	['Causes']	[23]
13	a	O	['N']	[13]
14	nine	O	['N']	[14]
15	-	O	['N']	[15]
16	year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	boy	O	['N']	[19]
20	developed	O	['N']	[20]
21	polyarthritis	O	['N']	[21]
22	,	O	['N']	[22]
23	rash	B-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	hepatitis	O	['N']	[25]
26	in	O	['N']	[26]
27	association	O	['N']	[27]
28	with	O	['N']	[28]
29	anti	O	['N']	[29]
30	-	O	['N']	[30]
31	native	O	['N']	[31]
32	DNA	O	['N']	[32]
33	antibodies	O	['N']	[33]
34	and	O	['N']	[34]
35	positive	O	['N']	[35]
36	antinuclear	O	['N']	[36]
37	factor	O	['N']	[37]
38	.	O	['N']	[38]
#1007
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	fifth	O	['N']	[2]
3	day	O	['N']	[3]
4	after	O	['N']	[4]
5	administration	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	high	O	['N']	[8]
9	dose	O	['N']	[9]
10	of	O	['N']	[10]
11	ARA	B	['N']	[11]
12	-	I	['N']	[12]
13	C	I-Drug	['Causes']	[44]
14	(	O	['N']	[14]
15	2	O	['N']	[15]
16	g	O	['N']	[16]
17	/	O	['N']	[17]
18	m2	O	['N']	[18]
19	intravenously	O	['N']	[19]
20	every	O	['N']	[20]
21	12	O	['N']	[21]
22	hours	O	['N']	[22]
23	)	O	['N']	[23]
24	,	O	['N']	[24]
25	she	O	['N']	[25]
26	developed	O	['N']	[26]
27	bullous	O	['N']	[27]
28	lesions	O	['N']	[28]
29	on	O	['N']	[29]
30	the	O	['N']	[30]
31	hands	O	['N']	[31]
32	and	O	['N']	[32]
33	soles	O	['N']	[33]
34	that	O	['N']	[34]
35	disseminated	O	['N']	[35]
36	,	O	['N']	[36]
37	evolving	O	['N']	[37]
38	to	O	['N']	[38]
39	necrosis	O	['N']	[39]
40	,	O	['N']	[40]
41	sepsis	O	['N']	[41]
42	,	O	['N']	[42]
43	and	O	['N']	[43]
44	death	B-Adverse_Effect	['N']	[44]
45	on	O	['N']	[45]
46	the	O	['N']	[46]
47	22nd	O	['N']	[47]
48	day	O	['N']	[48]
49	.	O	['N']	[49]
#1008
0	Transient	B	['N']	[0]
1	left	I	['N']	[1]
2	homonymous	I	['N']	[2]
3	hemianopsia	I-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	encephalopathy	O	['N']	[5]
6	following	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	testicular	O	['N']	[9]
10	carcinoma	O	['N']	[10]
11	with	O	['N']	[11]
12	cisplatinum	O	['N']	[12]
13	,	O	['N']	[13]
14	vinblastine	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	bleomycin	B-Drug	['Causes']	[3]
18	.	O	['N']	[18]
#1009
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	report	O	['N']	[3]
4	indicates	O	['N']	[4]
5	clindamycin	B-Drug	['Causes']	[15]
6	phosphate	O	['N']	[6]
7	vaginal	O	['N']	[7]
8	cream	O	['N']	[8]
9	as	O	['N']	[9]
10	the	O	['N']	[10]
11	most	O	['N']	[11]
12	probable	O	['N']	[12]
13	cause	O	['N']	[13]
14	of	O	['N']	[14]
15	CDIC	B-Adverse_Effect	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	temporal	O	['N']	[19]
20	relationship	O	['N']	[20]
21	between	O	['N']	[21]
22	the	O	['N']	[22]
23	occurrence	O	['N']	[23]
24	of	O	['N']	[24]
25	diarrhea	O	['N']	[25]
26	and	O	['N']	[26]
27	clindamycin	O	['N']	[27]
28	administration	O	['N']	[28]
29	,	O	['N']	[29]
30	lack	O	['N']	[30]
31	of	O	['N']	[31]
32	concomitant	O	['N']	[32]
33	medications	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	documentation	O	['N']	[36]
37	of	O	['N']	[37]
38	C.	O	['N']	[38]
39	difficile	O	['N']	[39]
40	toxin	O	['N']	[40]
41	.	O	['N']	[41]
#1010
0	Alprazolam	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	mania	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	two	O	['N']	[5]
6	clinical	O	['N']	[6]
7	cases	O	['N']	[7]
8	.	O	['N']	[8]
#1011
0	Due	O	['N']	[0]
1	to	O	['N']	[1]
2	discomfort	O	['N']	[2]
3	,	O	['N']	[3]
4	diplopia	O	['N']	[4]
5	and	O	['N']	[5]
6	lagophthalmos	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	haematoma	B-Adverse_Effect	['N']	[9]
10	necessitated	O	['N']	[10]
11	suspension	O	['N']	[11]
12	of	O	['N']	[12]
13	warfarin	B-Drug	['Causes']	[9]
14	therapy	O	['N']	[14]
15	and	O	['N']	[15]
16	a	O	['N']	[16]
17	surgical	O	['N']	[17]
18	evacuation	O	['N']	[18]
19	.	O	['N']	[19]
#1012
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Because	O	['N']	[2]
3	of	O	['N']	[3]
4	its	O	['N']	[4]
5	structural	O	['N']	[5]
6	similarity	O	['N']	[6]
7	to	O	['N']	[7]
8	the	O	['N']	[8]
9	other	O	['N']	[9]
10	vinca	O	['N']	[10]
11	alkaloids	O	['N']	[11]
12	,	O	['N']	[12]
13	vinorelbine	B-Drug	['Causes']	[20]
14	is	O	['N']	[14]
15	believed	O	['N']	[15]
16	to	O	['N']	[16]
17	be	O	['N']	[17]
18	responsible	O	['N']	[18]
19	for	O	['N']	[19]
20	SIADH	B-Adverse_Effect	['N']	[20]
21	in	O	['N']	[21]
22	our	O	['N']	[22]
23	patient	O	['N']	[23]
24	.	O	['N']	[24]
#1013
0	Although	O	['N']	[0]
1	isradipine	B-Drug	['Causes']	[7]
2	has	O	['N']	[2]
3	been	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	hepatocellular	B	['N']	[6]
7	injury	I-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	there	O	['N']	[9]
10	are	O	['N']	[10]
11	no	O	['N']	[11]
12	reports	O	['N']	[12]
13	of	O	['N']	[13]
14	fulminant	O	['N']	[14]
15	liver	O	['N']	[15]
16	failure	O	['N']	[16]
17	with	O	['N']	[17]
18	this	O	['N']	[18]
19	agent	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	our	O	['N']	[22]
23	patient	O	['N']	[23]
24	had	O	['N']	[24]
25	been	O	['N']	[25]
26	treated	O	['N']	[26]
27	for	O	['N']	[27]
28	>	O	['N']	[28]
29	2	O	['N']	[29]
30	years	O	['N']	[30]
31	without	O	['N']	[31]
32	signs	O	['N']	[32]
33	of	O	['N']	[33]
34	toxicity	O	['N']	[34]
35	.	O	['N']	[35]
#1014
0	The	O	['N']	[0]
1	introduction	O	['N']	[1]
2	of	O	['N']	[2]
3	para	B	['N']	[3]
4	-	I	['N']	[4]
5	aminosalicylic	I	['N']	[5]
6	acid	I-Drug	['Causes']	[13]
7	(	O	['N']	[7]
8	PAS	O	['N']	[8]
9	)	O	['N']	[9]
10	led	O	['N']	[10]
11	to	O	['N']	[11]
12	hypoglycaemic	B	['N']	[12]
13	coma	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#1015
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	79-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	being	O	['N']	[7]
8	treated	O	['N']	[8]
9	with	O	['N']	[9]
10	imiquimod	B-Drug	['Causes']	[23]
11	5	O	['N']	[11]
12	days	O	['N']	[12]
13	per	O	['N']	[13]
14	week	O	['N']	[14]
15	for	O	['N']	[15]
16	a	O	['N']	[16]
17	nodular	O	['N']	[17]
18	basal	O	['N']	[18]
19	cell	O	['N']	[19]
20	developed	O	['N']	[20]
21	a	O	['N']	[21]
22	verrucous	B	['N']	[22]
23	plaque	I-Adverse_Effect	['N']	[23]
24	over	O	['N']	[24]
25	the	O	['N']	[25]
26	treatment	O	['N']	[26]
27	area	O	['N']	[27]
28	after	O	['N']	[28]
29	7	O	['N']	[29]
30	weeks	O	['N']	[30]
31	of	O	['N']	[31]
32	therapy	O	['N']	[32]
33	.	O	['N']	[33]
#1016
0	The	O	['N']	[0]
1	spectrum	O	['N']	[1]
2	of	O	['N']	[2]
3	renal	B	['N']	[3]
4	lesions	I-Adverse_Effect	['N']	[4]
5	occurring	O	['N']	[5]
6	during	O	['N']	[6]
7	antituberculous	O	['N']	[7]
8	therapy	O	['N']	[8]
9	,	O	['N']	[9]
10	particularly	O	['N']	[10]
11	in	O	['N']	[11]
12	association	O	['N']	[12]
13	with	O	['N']	[13]
14	rifampin	B-Drug	['Causes']	[4]
15	,	O	['N']	[15]
16	may	O	['N']	[16]
17	be	O	['N']	[17]
18	wider	O	['N']	[18]
19	than	O	['N']	[19]
20	previously	O	['N']	[20]
21	suspected	O	['N']	[21]
22	.	O	['N']	[22]
#1017
0	When	O	['N']	[0]
1	the	O	['N']	[1]
2	trazodone	B-Drug	['Causes']	[8]
3	was	O	['N']	[3]
4	reduced	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	involuntary	B	['N']	[7]
8	movements	I-Adverse_Effect	['N']	[8]
9	promptly	O	['N']	[9]
10	ceased	O	['N']	[10]
11	.	O	['N']	[11]
#1018
0	Myasthenia	O	['N']	[0]
1	gravis	O	['N']	[1]
2	during	O	['N']	[2]
3	low	B-Dose	['N']	[3]
4	-	O	['N']	[4]
5	dose	O	['N']	[5]
6	IFN	B	['N']	[6]
7	-	I	['N']	[7]
8	alpha	I-Drug	['Dosage']	[3]
9	therapy	O	['N']	[9]
10	for	O	['N']	[10]
11	chronic	O	['N']	[11]
12	hepatitis	O	['N']	[12]
13	C.	O	['N']	[13]
#1019
0	L	B	['N']	[0]
1	-	I	['N']	[1]
2	asparaginase	I-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	pancreatitis	B-Adverse_Effect	['N']	[5]
6	is	O	['N']	[6]
7	an	O	['N']	[7]
8	uncommon	O	['N']	[8]
9	but	O	['N']	[9]
10	potential	O	['N']	[10]
11	lethal	O	['N']	[11]
12	complication	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	treatment	O	['N']	[15]
16	of	O	['N']	[16]
17	leukemia	O	['N']	[17]
18	.	O	['N']	[18]
#1020
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	B-Adverse_Effect	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	-	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#1021
0	Severe	O	['N']	[0]
1	adenovirus	O	['N']	[1]
2	pneumonia	O	['N']	[2]
3	(	O	['N']	[3]
4	AVP	B-Adverse_Effect	['N']	[4]
5	)	O	['N']	[5]
6	following	O	['N']	[6]
7	infliximab	B-Drug	['Causes']	[4]
8	infusion	O	['N']	[8]
9	for	O	['N']	[9]
10	the	O	['N']	[10]
11	treatment	O	['N']	[11]
12	of	O	['N']	[12]
13	Crohn	O	['N']	[13]
14	's	O	['N']	[14]
15	disease	O	['N']	[15]
16	.	O	['N']	[16]
#1022
0	Amphotericin	O	['N']	[0]
1	B	O	['N']	[1]
2	(	O	['N']	[2]
3	AmB	B-Drug	['Causes']	[17]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	effective	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	its	O	['N']	[9]
10	use	O	['N']	[10]
11	is	O	['N']	[11]
12	limited	O	['N']	[12]
13	by	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	:	O	['N']	[15]
16	renal	B	['N']	[16]
17	impairment	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	anaemia	O	['N']	[19]
20	,	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	malaise	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hypokalaemia	O	['N']	[26]
27	are	O	['N']	[27]
28	common	O	['N']	[28]
29	.	O	['N']	[29]
#1023
0	Three	O	['N']	[0]
1	of	O	['N']	[1]
2	these	O	['N']	[2]
3	patients	O	['N']	[3]
4	had	O	['N']	[4]
5	convulsions	B-Adverse_Effect	['N']	[5]
6	attributed	O	['N']	[6]
7	to	O	['N']	[7]
8	imipenem	O	['N']	[8]
9	/	O	['N']	[9]
10	cilastatin	B-Drug	['Causes']	[5]
11	;	O	['N']	[11]
12	3.6	O	['N']	[12]
13	%	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	patients	O	['N']	[16]
17	had	O	['N']	[17]
18	seizure	O	['N']	[18]
19	,	O	['N']	[19]
20	or	O	['N']	[20]
21	2	O	['N']	[21]
22	%	O	['N']	[22]
23	of	O	['N']	[23]
24	imipenem	O	['N']	[24]
25	/	O	['N']	[25]
26	cilastatin	O	['N']	[26]
27	administrations	O	['N']	[27]
28	was	O	['N']	[28]
29	followed	O	['N']	[29]
30	by	O	['N']	[30]
31	a	O	['N']	[31]
32	seizure	O	['N']	[32]
33	attack	O	['N']	[33]
34	.	O	['N']	[34]
#1024
0	She	O	['N']	[0]
1	received	O	['N']	[1]
2	an	O	['N']	[2]
3	accidental	O	['N']	[3]
4	450-mg	O	['N']	[4]
5	bolus	O	['N']	[5]
6	injection	O	['N']	[6]
7	of	O	['N']	[7]
8	morphine	B-Drug	['Causes']	[22]
9	intrathecally	O	['N']	[9]
10	and	O	['N']	[10]
11	developed	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	,	O	['N']	[13]
14	status	O	['N']	[14]
15	epilepticus	O	['N']	[15]
16	,	O	['N']	[16]
17	intracerebral	O	['N']	[17]
18	hemorrhage	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	respiratory	B	['N']	[21]
22	failure	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#1025
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	four	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	hemodynamically	O	['N']	[5]
6	significant	O	['N']	[6]
7	pericardial	B	['N']	[7]
8	effusion	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	refractory	O	['N']	[12]
13	lymphoma	O	['N']	[13]
14	who	O	['N']	[14]
15	were	O	['N']	[15]
16	receiving	O	['N']	[16]
17	gemcitabine	B-Drug	['Causes']	[8]
18	,	O	['N']	[18]
19	all	O	['N']	[19]
20	of	O	['N']	[20]
21	whom	O	['N']	[21]
22	had	O	['N']	[22]
23	a	O	['N']	[23]
24	history	O	['N']	[24]
25	of	O	['N']	[25]
26	mediastinal	O	['N']	[26]
27	radiation	O	['N']	[27]
28	without	O	['N']	[28]
29	subcarinal	O	['N']	[29]
30	blocking	O	['N']	[30]
31	.	O	['N']	[31]
#1026
0	Four	O	['N']	[0]
1	months	O	['N']	[1]
2	after	O	['N']	[2]
3	receiving	O	['N']	[3]
4	an	O	['N']	[4]
5	orthotopic	O	['N']	[5]
6	liver	O	['N']	[6]
7	transplant	O	['N']	[7]
8	,	O	['N']	[8]
9	a	O	['N']	[9]
10	51-year	O	['N']	[10]
11	-	O	['N']	[11]
12	old	O	['N']	[12]
13	man	O	['N']	[13]
14	was	O	['N']	[14]
15	admitted	O	['N']	[15]
16	for	O	['N']	[16]
17	progressive	B	['N']	[17]
18	liver	I	['N']	[18]
19	failure	I-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	severe	O	['N']	[21]
22	hepatocellular	O	['N']	[22]
23	necrosis	O	['N']	[23]
24	thought	O	['N']	[24]
25	to	O	['N']	[25]
26	be	O	['N']	[26]
27	due	O	['N']	[27]
28	to	O	['N']	[28]
29	tacrolimus	B-Drug	['Causes']	[19]
30	.	O	['N']	[30]
#1027
0	The	O	['N']	[0]
1	cause	O	['N']	[1]
2	of	O	['N']	[2]
3	death	O	['N']	[3]
4	was	O	['N']	[4]
5	determined	O	['N']	[5]
6	to	O	['N']	[6]
7	be	O	['N']	[7]
8	acute	B	['N']	[8]
9	intoxication	I-Adverse_Effect	['N']	[9]
10	by	O	['N']	[10]
11	olanzapine	B-Drug	['Causes']	[9]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	the	O	['N']	[14]
15	manner	O	['N']	[15]
16	of	O	['N']	[16]
17	death	O	['N']	[17]
18	was	O	['N']	[18]
19	accidental	O	['N']	[19]
20	.	O	['N']	[20]
#1028
0	Although	O	['N']	[0]
1	a	O	['N']	[1]
2	few	O	['N']	[2]
3	case	O	['N']	[3]
4	reports	O	['N']	[4]
5	link	O	['N']	[5]
6	metronidazole	B-Drug	['Causes']	[12]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	development	O	['N']	[9]
10	of	O	['N']	[10]
11	pseudomembranous	B	['N']	[11]
12	colitis	I-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	albendazole	O	['N']	[14]
15	has	O	['N']	[15]
16	not	O	['N']	[16]
17	been	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	the	O	['N']	[20]
21	development	O	['N']	[21]
22	of	O	['N']	[22]
23	this	O	['N']	[23]
24	condition	O	['N']	[24]
25	.	O	['N']	[25]
#1029
0	Well	O	['N']	[0]
1	-	O	['N']	[1]
2	known	O	['N']	[2]
3	signs	O	['N']	[3]
4	of	O	['N']	[4]
5	methotrexate	B-Drug	['Causes']	[10]
6	toxicity	O	['N']	[6]
7	include	O	['N']	[7]
8	bone	B	['N']	[8]
9	marrow	I	['N']	[9]
10	suppression	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	oral	O	['N']	[12]
13	and	O	['N']	[13]
14	gastrointestinal	O	['N']	[14]
15	ulceration	O	['N']	[15]
16	.	O	['N']	[16]
#1030
0	A	O	['N']	[0]
1	32-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	family	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	type	O	['N']	[10]
11	2	O	['N']	[11]
12	diabetes	O	['N']	[12]
13	mellitus	O	['N']	[13]
14	presented	O	['N']	[14]
15	with	O	['N']	[15]
16	circulatory	O	['N']	[16]
17	collapse	O	['N']	[17]
18	and	O	['N']	[18]
19	deep	B	['N']	[19]
20	coma	I-Adverse_Effect	['N']	[20]
21	after	O	['N']	[21]
22	9	O	['N']	[22]
23	days	O	['N']	[23]
24	of	O	['N']	[24]
25	treatment	O	['N']	[25]
26	with	O	['N']	[26]
27	perospirone	B	['N']	[27]
28	hydrochloride	I-Drug	['Causes']	[20]
29	,	O	['N']	[29]
30	a	O	['N']	[30]
31	recently	O	['N']	[31]
32	developed	O	['N']	[32]
33	atypical	O	['N']	[33]
34	antipsychotic	O	['N']	[34]
35	agent	O	['N']	[35]
36	available	O	['N']	[36]
37	only	O	['N']	[37]
38	in	O	['N']	[38]
39	Japan	O	['N']	[39]
40	.	O	['N']	[40]
#1031
0	A	O	['N']	[0]
1	51-year	O	['N']	[1]
2	old	O	['N']	[2]
3	physically	O	['N']	[3]
4	fit	O	['N']	[4]
5	woman	O	['N']	[5]
6	experienced	O	['N']	[6]
7	angio	B	['N']	[7]
8	-	I	['N']	[8]
9	oedema	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	hypotensive	O	['N']	[11]
12	shock	O	['N']	[12]
13	after	O	['N']	[13]
14	irbesartan	B-Drug	['Causes']	[9]
15	ingestion	O	['N']	[15]
16	requiring	O	['N']	[16]
17	noradrenaline	O	['N']	[17]
18	infusion	O	['N']	[18]
19	.	O	['N']	[19]
#1032
0	Valproate	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hyperammonemia	B-Adverse_Effect	['N']	[3]
4	as	O	['N']	[4]
5	a	O	['N']	[5]
6	cause	O	['N']	[6]
7	of	O	['N']	[7]
8	altered	O	['N']	[8]
9	mental	O	['N']	[9]
10	status	O	['N']	[10]
11	.	O	['N']	[11]
#1033
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	transient	O	['N']	[3]
4	,	O	['N']	[4]
5	acute	B	['N']	[5]
6	myopia	I-Adverse_Effect	['N']	[6]
7	while	O	['N']	[7]
8	on	O	['N']	[8]
9	isotretinoin	B-Drug	['Causes']	[6]
10	(	O	['N']	[10]
11	Accutane	O	['N']	[11]
12	)	O	['N']	[12]
13	therapy	O	['N']	[13]
14	for	O	['N']	[14]
15	acne	O	['N']	[15]
16	.	O	['N']	[16]
#1034
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	girl	O	['N']	[4]
5	developed	O	['N']	[5]
6	diabetes	B	['N']	[6]
7	mellitus	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	exocrine	O	['N']	[9]
10	pancreatic	O	['N']	[10]
11	insufficiency	O	['N']	[11]
12	after	O	['N']	[12]
13	3.5	O	['N']	[13]
14	years	O	['N']	[14]
15	of	O	['N']	[15]
16	almost	O	['N']	[16]
17	continuous	O	['N']	[17]
18	treatment	O	['N']	[18]
19	with	O	['N']	[19]
20	azathioprine	B-Drug	['Causes']	[7]
21	and/or	O	['N']	[21]
22	prednisone	O	['N']	[22]
23	for	O	['N']	[23]
24	idiopathic	O	['N']	[24]
25	auto	O	['N']	[25]
26	-	O	['N']	[26]
27	immune	O	['N']	[27]
28	haemolytic	O	['N']	[28]
29	anaemia	O	['N']	[29]
30	.	O	['N']	[30]
#1035
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	carbamazepine	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	hyperammonemia	B-Adverse_Effect	['N']	[8]
9	is	O	['N']	[9]
10	presented	O	['N']	[10]
11	.	O	['N']	[11]
#1036
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	describe	O	['N']	[2]
3	another	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	VOD	B-Adverse_Effect	['N']	[6]
7	occurring	O	['N']	[7]
8	after	O	['N']	[8]
9	LT	O	['N']	[9]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	in	O	['N']	[12]
13	which	O	['N']	[13]
14	the	O	['N']	[14]
15	causative	O	['N']	[15]
16	role	O	['N']	[16]
17	was	O	['N']	[17]
18	played	O	['N']	[18]
19	by	O	['N']	[19]
20	azathioprine	B-Drug	['Causes']	[6]
21	.	O	['N']	[21]
#1037
0	Hyperkalaemia	O	['N']	[0]
1	with	O	['N']	[1]
2	renal	B	['N']	[2]
3	tubular	I	['N']	[3]
4	dysfunction	I-Adverse_Effect	['N']	[4]
5	by	O	['N']	[5]
6	oral	O	['N']	[6]
7	therapy	O	['N']	[7]
8	of	O	['N']	[8]
9	sulfamethoxazole	O	['N']	[9]
10	-	O	['N']	[10]
11	trimethoprim	O	['N']	[11]
12	(	O	['N']	[12]
13	co	B	['N']	[13]
14	-	I	['N']	[14]
15	trimoxazole	I-Drug	['Causes']	[4]
16	)	O	['N']	[16]
17	is	O	['N']	[17]
18	described	O	['N']	[18]
19	in	O	['N']	[19]
20	2	O	['N']	[20]
21	elderly	O	['N']	[21]
22	Japanese	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	lymphoid	O	['N']	[25]
26	malignancy	O	['N']	[26]
27	,	O	['N']	[27]
28	who	O	['N']	[28]
29	developed	O	['N']	[29]
30	Pneumocystis	O	['N']	[30]
31	carinii	O	['N']	[31]
32	pneumonia	O	['N']	[32]
33	and	O	['N']	[33]
34	improved	O	['N']	[34]
35	.	O	['N']	[35]
#1038
0	As	O	['N']	[0]
1	these	O	['N']	[1]
2	cases	O	['N']	[2]
3	revealed	O	['N']	[3]
4	,	O	['N']	[4]
5	close	O	['N']	[5]
6	monitoring	O	['N']	[6]
7	of	O	['N']	[7]
8	blood	O	['N']	[8]
9	chemistry	O	['N']	[9]
10	is	O	['N']	[10]
11	mandatory	O	['N']	[11]
12	after	O	['N']	[12]
13	starting	O	['N']	[13]
14	spironolactone	B-Drug	['Causes']	[26]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	patients	O	['N']	[17]
18	should	O	['N']	[18]
19	be	O	['N']	[19]
20	advised	O	['N']	[20]
21	to	O	['N']	[21]
22	stop	O	['N']	[22]
23	spironolactone	O	['N']	[23]
24	immediately	O	['N']	[24]
25	if	O	['N']	[25]
26	diarrhoea	B-Adverse_Effect	['N']	[26]
27	develops	O	['N']	[27]
28	.	O	['N']	[28]
#1039
0	Here	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	present	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	sirolimus	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	associated	O	['N']	[9]
10	interstitial	B	['N']	[10]
11	pneumonitis	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	cardiac	O	['N']	[14]
15	transplant	O	['N']	[15]
16	recipient	O	['N']	[16]
17	that	O	['N']	[17]
18	resolved	O	['N']	[18]
19	completely	O	['N']	[19]
20	with	O	['N']	[20]
21	withdrawal	O	['N']	[21]
22	of	O	['N']	[22]
23	the	O	['N']	[23]
24	drug	O	['N']	[24]
25	and	O	['N']	[25]
26	treatment	O	['N']	[26]
27	with	O	['N']	[27]
28	corticosteroids	O	['N']	[28]
29	.	O	['N']	[29]
#1040
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	disseminated	O	['N']	[3]
4	herpes	O	['N']	[4]
5	zoster	O	['N']	[5]
6	developed	O	['N']	[6]
7	a	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	of	O	['N']	[9]
10	inappropriate	O	['N']	[10]
11	antidiuretic	O	['N']	[11]
12	hormone	O	['N']	[12]
13	and	O	['N']	[13]
14	profound	O	['N']	[14]
15	hyponatremia	B-Adverse_Effect	['N']	[15]
16	secondary	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	administration	O	['N']	[19]
20	of	O	['N']	[20]
21	adenine	B	['N']	[21]
22	arabinoside	I-Drug	['Causes']	[15]
23	.	O	['N']	[23]
#1041
0	Pulmonary	B	['N']	[0]
1	fibrosis	I-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	severe	O	['N']	[4]
5	complication	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	bis	O	['N']	[8]
9	-	O	['N']	[9]
10	chloronitrosourea	O	['N']	[10]
11	(	O	['N']	[11]
12	BCNU	B-Drug	['Causes']	[1]
13	)	O	['N']	[13]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#1042
0	The	O	['N']	[0]
1	pathophysiological	O	['N']	[1]
2	mechanisms	O	['N']	[2]
3	remain	O	['N']	[3]
4	unknown	O	['N']	[4]
5	,	O	['N']	[5]
6	although	O	['N']	[6]
7	the	O	['N']	[7]
8	drug	O	['N']	[8]
9	could	O	['N']	[9]
10	act	O	['N']	[10]
11	through	O	['N']	[11]
12	massive	B	['N']	[12]
13	cytokines	I	['N']	[13]
14	liberation	I-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	destruction	O	['N']	[16]
17	of	O	['N']	[17]
18	CD20	O	['N']	[18]
19	positive	O	['N']	[19]
20	cells	O	['N']	[20]
21	by	O	['N']	[21]
22	rituximab	B-Drug	['Causes']	[14]
23	.	O	['N']	[23]
#1043
0	Skin	B	['N']	[0]
1	necrosis	I-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	rare	O	['N']	[4]
5	complication	O	['N']	[5]
6	of	O	['N']	[6]
7	subcutaneous	O	['N']	[7]
8	heparin	B-Drug	['Causes']	[1]
9	therapy	O	['N']	[9]
10	that	O	['N']	[10]
11	usually	O	['N']	[11]
12	occurs	O	['N']	[12]
13	at	O	['N']	[13]
14	injection	O	['N']	[14]
15	sites	O	['N']	[15]
16	.	O	['N']	[16]
#1044
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	5-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	girl	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	bilateral	B	['N']	[12]
13	vocal	I	['N']	[13]
14	cord	I	['N']	[14]
15	paralysis	I-Adverse_Effect	['N']	[15]
16	following	O	['N']	[16]
17	preoperative	O	['N']	[17]
18	peritonsillar	O	['N']	[18]
19	bupivacaine	B-Drug	['Causes']	[15]
20	infiltration	O	['N']	[20]
21	.	O	['N']	[21]
#1045
0	Clinicians	O	['N']	[0]
1	have	O	['N']	[1]
2	been	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[20]
6	toxicity	O	['N']	[6]
7	for	O	['N']	[7]
8	many	O	['N']	[8]
9	years	O	['N']	[9]
10	and	O	['N']	[10]
11	traditionally	O	['N']	[11]
12	have	O	['N']	[12]
13	administered	O	['N']	[13]
14	thiazide	O	['N']	[14]
15	diuretics	O	['N']	[15]
16	for	O	['N']	[16]
17	lithium	O	['N']	[17]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	polyuria	B-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	nephrogenic	O	['N']	[22]
23	diabetes	O	['N']	[23]
24	insipidus	O	['N']	[24]
25	.	O	['N']	[25]
#1046
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	potential	O	['N']	[6]
7	for	O	['N']	[7]
8	the	O	['N']	[8]
9	development	O	['N']	[9]
10	of	O	['N']	[10]
11	RS	B-Adverse_Effect	['N']	[11]
12	among	O	['N']	[12]
13	children	O	['N']	[13]
14	who	O	['N']	[14]
15	are	O	['N']	[15]
16	receiving	O	['N']	[16]
17	long	O	['N']	[17]
18	-	O	['N']	[18]
19	term	O	['N']	[19]
20	aspirin	B-Drug	['Causes']	[11]
21	therapy	O	['N']	[21]
22	for	O	['N']	[22]
23	the	O	['N']	[23]
24	treatment	O	['N']	[24]
25	of	O	['N']	[25]
26	systemic	O	['N']	[26]
27	inflammatory	O	['N']	[27]
28	illnesses	O	['N']	[28]
29	.	O	['N']	[29]
#1047
0	Paradoxical	O	['N']	[0]
1	cerebral	O	['N']	[1]
2	cortical	O	['N']	[2]
3	hyperexcitability	O	['N']	[3]
4	following	O	['N']	[4]
5	flupirtine	B-Drug	['Dosage']	[6]
6	overdose	B-Dose	['N']	[6]
7	.	O	['N']	[7]
#1048
0	Case	O	['N']	[0]
1	1	O	['N']	[1]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	62-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	woman	O	['N']	[7]
8	,	O	['N']	[8]
9	developed	O	['N']	[9]
10	bilateral	O	['N']	[10]
11	optic	O	['N']	[11]
12	neuritis	O	['N']	[12]
13	with	O	['N']	[13]
14	decreased	B	['N']	[14]
15	sensation	I	['N']	[15]
16	of	I	['N']	[16]
17	vibration	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	increased	O	['N']	[19]
20	deep	O	['N']	[20]
21	tendon	O	['N']	[21]
22	reflex	O	['N']	[22]
23	in	O	['N']	[23]
24	the	O	['N']	[24]
25	lower	O	['N']	[25]
26	extremities	O	['N']	[26]
27	after	O	['N']	[27]
28	a	O	['N']	[28]
29	seven	O	['N']	[29]
30	-	O	['N']	[30]
31	month	O	['N']	[31]
32	use	O	['N']	[32]
33	of	O	['N']	[33]
34	recombinant	B	['N']	[34]
35	interferon	I	['N']	[35]
36	alpha-2a	I-Drug	['Causes']	[17]
37	for	O	['N']	[37]
38	chronic	O	['N']	[38]
39	active	O	['N']	[39]
40	hepatitis	O	['N']	[40]
41	C.	O	['N']	[41]
#1049
0	Pulmonary	B	['N']	[0]
1	edema	I-Adverse_Effect	['N']	[1]
2	as	O	['N']	[2]
3	a	O	['N']	[3]
4	delayed	O	['N']	[4]
5	complication	O	['N']	[5]
6	of	O	['N']	[6]
7	ritodrine	B-Drug	['Causes']	[1]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#1050
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	specifics	O	['N']	[3]
4	of	O	['N']	[4]
5	12	O	['N']	[5]
6	cases	O	['N']	[6]
7	of	O	['N']	[7]
8	severe	B	['N']	[8]
9	hypertension	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	the	O	['N']	[11]
12	intraoperative	O	['N']	[12]
13	use	O	['N']	[13]
14	of	O	['N']	[14]
15	topical	O	['N']	[15]
16	phenylephrine	O	['N']	[16]
17	,	O	['N']	[17]
18	submucosal	O	['N']	[18]
19	epinephrine	B-Drug	['Causes']	[9]
20	,	O	['N']	[20]
21	or	O	['N']	[21]
22	both	O	['N']	[22]
23	.	O	['N']	[23]
#1051
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	43-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	sore	B	['N']	[9]
10	throat	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	swelling	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	lips	O	['N']	[15]
16	and	O	['N']	[16]
17	oral	O	['N']	[17]
18	cavity	O	['N']	[18]
19	and	O	['N']	[19]
20	dysphagia	O	['N']	[20]
21	,	O	['N']	[21]
22	2	O	['N']	[22]
23	weeks	O	['N']	[23]
24	after	O	['N']	[24]
25	the	O	['N']	[25]
26	use	O	['N']	[26]
27	of	O	['N']	[27]
28	budesonide	O	['N']	[28]
29	spray	O	['N']	[29]
30	(	O	['N']	[30]
31	Budefat	B-Drug	['Causes']	[10]
32	)	O	['N']	[32]
33	for	O	['N']	[33]
34	treatment	O	['N']	[34]
35	of	O	['N']	[35]
36	bronchial	O	['N']	[36]
37	asthma	O	['N']	[37]
38	.	O	['N']	[38]
#1052
0	Pregabalin	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	cortical	B	['N']	[3]
4	negative	I	['N']	[4]
5	myoclonus	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	neuropathic	O	['N']	[10]
11	pain	O	['N']	[11]
12	.	O	['N']	[12]
#1053
0	Peripheral	B	['N']	[0]
1	nervous	I	['N']	[1]
2	system	I	['N']	[2]
3	disturbances	I-Adverse_Effect	['N']	[3]
4	caused	O	['N']	[4]
5	by	O	['N']	[5]
6	cytosine	B	['N']	[6]
7	arabinoside	I-Drug	['Causes']	[3]
8	have	O	['N']	[8]
9	rarely	O	['N']	[9]
10	been	O	['N']	[10]
11	reported	O	['N']	[11]
12	.	O	['N']	[12]
#1054
0	The	O	['N']	[0]
1	electrocardiogram	O	['N']	[1]
2	(	O	['N']	[2]
3	ECG	O	['N']	[3]
4	)	O	['N']	[4]
5	,	O	['N']	[5]
6	which	O	['N']	[6]
7	was	O	['N']	[7]
8	read	O	['N']	[8]
9	as	O	['N']	[9]
10	normal	O	['N']	[10]
11	prior	O	['N']	[11]
12	to	O	['N']	[12]
13	ritodrine	B-Drug	['Causes']	[24]
14	infusion	O	['N']	[14]
15	,	O	['N']	[15]
16	demonstrated	O	['N']	[16]
17	a	O	['N']	[17]
18	type	B	['N']	[18]
19	I	I	['N']	[19]
20	second	I	['N']	[20]
21	-	I	['N']	[21]
22	degree	I	['N']	[22]
23	AV	I	['N']	[23]
24	block	I-Adverse_Effect	['N']	[24]
25	which	O	['N']	[25]
26	disappeared	O	['N']	[26]
27	upon	O	['N']	[27]
28	discontinuation	O	['N']	[28]
29	of	O	['N']	[29]
30	ritodrine	O	['N']	[30]
31	therapy	O	['N']	[31]
32	.	O	['N']	[32]
#1055
0	A	O	['N']	[0]
1	second	O	['N']	[1]
2	possibility	O	['N']	[2]
3	is	O	['N']	[3]
4	an	O	['N']	[4]
5	interaction	O	['N']	[5]
6	between	O	['N']	[6]
7	clarithromycin	B-Drug	['Causes']	[15]
8	and	O	['N']	[8]
9	isradipine	O	['N']	[9]
10	,	O	['N']	[10]
11	potentially	O	['N']	[11]
12	increasing	B	['N']	[12]
13	the	I	['N']	[13]
14	hepatic	I	['N']	[14]
15	toxicity	I-Adverse_Effect	['N']	[15]
16	of	O	['N']	[16]
17	isradipine	O	['N']	[17]
18	.	O	['N']	[18]
#1056
0	How	O	['N']	[0]
1	low	B-Dose	['N']	[1]
2	can	O	['N']	[2]
3	you	O	['N']	[3]
4	go	O	['N']	[4]
5	?	O	['N']	[5]
6	Use	O	['N']	[6]
7	of	O	['N']	[7]
8	very	O	['N']	[8]
9	low	O	['N']	[9]
10	dosage	O	['N']	[10]
11	of	O	['N']	[11]
12	gold	B-Drug	['Dosage']	[1]
13	in	O	['N']	[13]
14	patients	O	['N']	[14]
15	with	O	['N']	[15]
16	mucocutaneous	O	['N']	[16]
17	reactions	O	['N']	[17]
18	.	O	['N']	[18]
#1057
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	HLH	O	['N']	[3]
4	developed	O	['N']	[4]
5	etoposide	B-Drug	['Causes']	[13]
6	-	O	['N']	[6]
7	related	O	['N']	[7]
8	secondary	O	['N']	[8]
9	acute	O	['N']	[9]
10	myeloid	O	['N']	[10]
11	leukemia	O	['N']	[11]
12	(	O	['N']	[12]
13	sAML	B-Adverse_Effect	['N']	[13]
14	)	O	['N']	[14]
15	following	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	HLH	O	['N']	[18]
19	.	O	['N']	[19]
#1058
0	The	O	['N']	[0]
1	occurrence	O	['N']	[1]
2	of	O	['N']	[2]
3	neuromuscular	O	['N']	[3]
4	blockade	O	['N']	[4]
5	and	O	['N']	[5]
6	the	O	['N']	[6]
7	resulting	O	['N']	[7]
8	potentiation	B	['N']	[8]
9	of	I	['N']	[9]
10	muscle	I	['N']	[10]
11	relaxants	I-Adverse_Effect	['N']	[11]
12	during	O	['N']	[12]
13	magnesium	B	['N']	[13]
14	sulfate	I-Drug	['Causes']	[11]
15	(	O	['N']	[15]
16	MgSO4	O	['N']	[16]
17	)	O	['N']	[17]
18	administration	O	['N']	[18]
19	is	O	['N']	[19]
20	well	O	['N']	[20]
21	known	O	['N']	[21]
22	.	O	['N']	[22]
#1059
0	She	O	['N']	[0]
1	developed	O	['N']	[1]
2	neurotoxicity	B-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	an	O	['N']	[4]
5	adjustment	O	['N']	[5]
6	dosage	O	['N']	[6]
7	of	O	['N']	[7]
8	valacyclovir	B-Drug	['Causes']	[2]
9	for	O	['N']	[9]
10	a	O	['N']	[10]
11	cutaneous	O	['N']	[11]
12	zoster	O	['N']	[12]
13	infection	O	['N']	[13]
14	.	O	['N']	[14]
#1060
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	safe	O	['N']	[5]
6	use	O	['N']	[6]
7	of	O	['N']	[7]
8	fluorouracil	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	with	O	['N']	[12]
13	breast	O	['N']	[13]
14	cancer	O	['N']	[14]
15	who	O	['N']	[15]
16	had	O	['N']	[16]
17	allergic	B	['N']	[17]
18	reactions	I-Adverse_Effect	['N']	[18]
19	to	O	['N']	[19]
20	capecitabine	B-Drug	['Causes']	[18]
21	.	O	['N']	[21]
#1061
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	postulate	O	['N']	[2]
3	that	O	['N']	[3]
4	two	O	['N']	[4]
5	types	O	['N']	[5]
6	of	O	['N']	[6]
7	combined	O	['N']	[7]
8	lithium	O	['N']	[8]
9	-	O	['N']	[9]
10	neuroleptic	O	['N']	[10]
11	toxicity	O	['N']	[11]
12	occur	O	['N']	[12]
13	:	O	['N']	[13]
14	a	O	['N']	[14]
15	neuroleptic	O	['N']	[15]
16	malignant	O	['N']	[16]
17	extrapyramidal	O	['N']	[17]
18	syndrome	O	['N']	[18]
19	and	O	['N']	[19]
20	a	O	['N']	[20]
21	lithium	B	['N']	[21]
22	toxicity	I-Adverse_Effect	['N']	[22]
23	that	O	['N']	[23]
24	occurs	O	['N']	[24]
25	in	O	['N']	[25]
26	combination	O	['N']	[26]
27	with	O	['N']	[27]
28	phenothiazines	O	['N']	[28]
29	,	O	['N']	[29]
30	primarily	O	['N']	[30]
31	thioridazine	B-Drug	['Causes']	[22]
32	.	O	['N']	[32]
#1062
0	Interaction	B-Adverse_Effect	['N']	[0]
1	between	O	['N']	[1]
2	tacrolimus	B-Drug	['Causes']	[0]
3	and	O	['N']	[3]
4	nefazodone	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	stable	O	['N']	[7]
8	renal	O	['N']	[8]
9	transplant	O	['N']	[9]
10	recipient	O	['N']	[10]
11	.	O	['N']	[11]
#1063
0	Heparin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	thrombocytopenia	B-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	thrombosis	O	['N']	[5]
6	is	O	['N']	[6]
7	a	O	['N']	[7]
8	severe	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	systemic	O	['N']	[11]
12	heparin	O	['N']	[12]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#1064
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Zidovudine	B-Drug	['Causes']	[7]
6	induced	O	['N']	[6]
7	anaemia	B-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	bone	O	['N']	[9]
10	marrow	O	['N']	[10]
11	aplasia	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	patient	O	['N']	[14]
15	infected	O	['N']	[15]
16	with	O	['N']	[16]
17	HIV	O	['N']	[17]
18	.	O	['N']	[18]
#1065
0	The	O	['N']	[0]
1	use	O	['N']	[1]
2	of	O	['N']	[2]
3	rituximab	B-Drug	['Causes']	[11]
4	has	O	['N']	[4]
5	been	O	['N']	[5]
6	uncommonly	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	delayed	B	['N']	[9]
10	pulmonary	I	['N']	[10]
11	toxicity	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#1066
0	This	O	['N']	[0]
1	article	O	['N']	[1]
2	describes	O	['N']	[2]
3	the	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	25-year	O	['N']	[7]
8	-	O	['N']	[8]
9	old	O	['N']	[9]
10	man	O	['N']	[10]
11	found	O	['N']	[11]
12	dead	B-Adverse_Effect	['N']	[12]
13	at	O	['N']	[13]
14	home	O	['N']	[14]
15	who	O	['N']	[15]
16	had	O	['N']	[16]
17	been	O	['N']	[17]
18	prescribed	O	['N']	[18]
19	olanzapine	B-Drug	['Causes']	[12]
20	for	O	['N']	[20]
21	schizophrenia	O	['N']	[21]
22	.	O	['N']	[22]
#1067
0	We	O	['N']	[0]
1	thus	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	an	O	['N']	[4]
5	excessive	B-Dose	['N']	[5]
6	dose	O	['N']	[6]
7	of	O	['N']	[7]
8	AZ	B-Drug	['Dosage']	[5]
9	had	O	['N']	[9]
10	probably	O	['N']	[10]
11	destroyed	O	['N']	[11]
12	the	O	['N']	[12]
13	gastric	O	['N']	[13]
14	mucosal	O	['N']	[14]
15	barrier	O	['N']	[15]
16	or	O	['N']	[16]
17	thrombocytopenia	O	['N']	[17]
18	due	O	['N']	[18]
19	to	O	['N']	[19]
20	bone	O	['N']	[20]
21	marrow	O	['N']	[21]
22	disorder	O	['N']	[22]
23	and	O	['N']	[23]
24	thus	O	['N']	[24]
25	eventually	O	['N']	[25]
26	led	O	['N']	[26]
27	to	O	['N']	[27]
28	the	O	['N']	[28]
29	development	O	['N']	[29]
30	of	O	['N']	[30]
31	hemorrhagic	O	['N']	[31]
32	gastritis	O	['N']	[32]
33	.	O	['N']	[33]
#1068
0	The	O	['N']	[0]
1	association	O	['N']	[1]
2	with	O	['N']	[2]
3	prolonged	O	['N']	[3]
4	unopposed	O	['N']	[4]
5	estrogen	O	['N']	[5]
6	-	O	['N']	[6]
7	like	O	['N']	[7]
8	stimulation	O	['N']	[8]
9	with	O	['N']	[9]
10	tamoxifen	B-Drug	['Causes']	[21]
11	as	O	['N']	[11]
12	a	O	['N']	[12]
13	possible	O	['N']	[13]
14	factor	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	development	O	['N']	[17]
18	of	O	['N']	[18]
19	ovarian	B	['N']	[19]
20	endometrioid	I	['N']	[20]
21	carcinoma	I-Adverse_Effect	['N']	[21]
22	is	O	['N']	[22]
23	discussed	O	['N']	[23]
24	.	O	['N']	[24]
#1069
0	Gynecomastia	B-Adverse_Effect	['N']	[0]
1	developed	O	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	epileptic	O	['N']	[4]
5	patients	O	['N']	[5]
6	some	O	['N']	[6]
7	months	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	addition	O	['N']	[10]
11	of	O	['N']	[11]
12	oral	O	['N']	[12]
13	fluoresone	O	['N']	[13]
14	750	O	['N']	[14]
15	mg	O	['N']	[15]
16	daily	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	phenobarbital	B-Drug	['Causes']	[0]
20	and	O	['N']	[20]
21	phenytoin	O	['N']	[21]
22	already	O	['N']	[22]
23	being	O	['N']	[23]
24	administered	O	['N']	[24]
25	.	O	['N']	[25]
#1070
0	Disulfiram	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hepatitis	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#1071
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	syndrome	B	['N']	[6]
7	of	I	['N']	[7]
8	inappropriate	I	['N']	[8]
9	antidiuretic	I	['N']	[9]
10	hormone	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	SIADH	O	['N']	[12]
13	)	O	['N']	[13]
14	secondary	O	['N']	[14]
15	to	O	['N']	[15]
16	cisplatin	B-Drug	['Causes']	[10]
17	therapy	O	['N']	[17]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	patient	O	['N']	[20]
21	with	O	['N']	[21]
22	advanced	O	['N']	[22]
23	-	O	['N']	[23]
24	stage	O	['N']	[24]
25	large	O	['N']	[25]
26	cell	O	['N']	[26]
27	neuroendocrine	O	['N']	[27]
28	carcinoma	O	['N']	[28]
29	of	O	['N']	[29]
30	the	O	['N']	[30]
31	cervix	O	['N']	[31]
32	.	O	['N']	[32]
#1072
0	Ceftriaxone	O	['N']	[0]
1	was	O	['N']	[1]
2	approved	O	['N']	[2]
3	in	O	['N']	[3]
4	1997	O	['N']	[4]
5	for	O	['N']	[5]
6	the	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	otitis	O	['N']	[9]
10	media	O	['N']	[10]
11	despite	O	['N']	[11]
12	previous	O	['N']	[12]
13	studies	O	['N']	[13]
14	that	O	['N']	[14]
15	documented	O	['N']	[15]
16	an	O	['N']	[16]
17	association	O	['N']	[17]
18	of	O	['N']	[18]
19	ceftriaxone	B-Drug	['Causes']	[29]
20	with	O	['N']	[20]
21	elevated	O	['N']	[21]
22	hepato	O	['N']	[22]
23	-	O	['N']	[23]
24	biliary	O	['N']	[24]
25	enzymes	O	['N']	[25]
26	and	O	['N']	[26]
27	transient	B	['N']	[27]
28	biliary	I	['N']	[28]
29	stasis	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#1073
0	Clinicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	possibility	O	['N']	[6]
7	that	O	['N']	[7]
8	vinorelbine	B-Drug	['Causes']	[11]
9	may	O	['N']	[9]
10	cause	O	['N']	[10]
11	SIADH	B-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	possibly	O	['N']	[13]
14	hypokalemia	O	['N']	[14]
15	.	O	['N']	[15]
#1074
0	Polymyoclonus	B	['N']	[0]
1	seizure	I-Adverse_Effect	['N']	[1]
2	resulting	O	['N']	[2]
3	from	O	['N']	[3]
4	accidental	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	tranexamic	B	['N']	[7]
8	acid	I-Drug	['Causes']	[1]
9	in	O	['N']	[9]
10	spinal	O	['N']	[10]
11	anesthesia	O	['N']	[11]
12	.	O	['N']	[12]
#1075
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	suggests	O	['N']	[2]
3	the	O	['N']	[3]
4	importance	O	['N']	[4]
5	of	O	['N']	[5]
6	careful	O	['N']	[6]
7	observation	O	['N']	[7]
8	for	O	['N']	[8]
9	extramedullary	B	['N']	[9]
10	relapse	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	patients	O	['N']	[12]
13	who	O	['N']	[13]
14	are	O	['N']	[14]
15	treated	O	['N']	[15]
16	with	O	['N']	[16]
17	ATRA	B-Drug	['Causes']	[10]
18	.	O	['N']	[18]
#1076
0	A	O	['N']	[0]
1	31-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	multiple	O	['N']	[6]
7	episodes	O	['N']	[7]
8	of	O	['N']	[8]
9	grand	B	['N']	[9]
10	mal	I	['N']	[10]
11	seizures	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	combination	O	['N']	[13]
14	chemotherapy	O	['N']	[14]
15	with	O	['N']	[15]
16	cisplatin	O	['N']	[16]
17	,	O	['N']	[17]
18	vinblastine	B-Drug	['Causes']	[11]
19	and	O	['N']	[19]
20	bleomycin	O	['N']	[20]
21	for	O	['N']	[21]
22	germ	O	['N']	[22]
23	cell	O	['N']	[23]
24	ovarian	O	['N']	[24]
25	cancer	O	['N']	[25]
26	stage	O	['N']	[26]
27	Ic	O	['N']	[27]
28	.	O	['N']	[28]
#1077
0	Adrenaline	B-Drug	['Causes']	[1]
1	dacryolith	B-Adverse_Effect	['N']	[1]
2	:	O	['N']	[2]
3	detection	O	['N']	[3]
4	by	O	['N']	[4]
5	ultrasound	O	['N']	[5]
6	examination	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	nasolacrimal	O	['N']	[9]
10	duct	O	['N']	[10]
11	.	O	['N']	[11]
#1078
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	one	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	gangrene	B-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	bleomycin	O	['N']	[10]
11	and	O	['N']	[11]
12	vincristine	B-Drug	['Causes']	[8]
13	/	O	['N']	[13]
14	vinblastine	O	['N']	[14]
15	chemotherapy	O	['N']	[15]
16	for	O	['N']	[16]
17	AIDS	O	['N']	[17]
18	-	O	['N']	[18]
19	related	O	['N']	[19]
20	Kaposi	O	['N']	[20]
21	's	O	['N']	[21]
22	sarcoma	O	['N']	[22]
23	and	O	['N']	[23]
24	another	O	['N']	[24]
25	HIV	O	['N']	[25]
26	-	O	['N']	[26]
27	infected	O	['N']	[27]
28	patient	O	['N']	[28]
29	who	O	['N']	[29]
30	exhibited	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	severe	O	['N']	[33]
34	Raynaud	O	['N']	[34]
35	's	O	['N']	[35]
36	phenomenon	O	['N']	[36]
37	related	O	['N']	[37]
38	to	O	['N']	[38]
39	the	O	['N']	[39]
40	same	O	['N']	[40]
41	regimen	O	['N']	[41]
42	are	O	['N']	[42]
43	presented	O	['N']	[43]
44	.	O	['N']	[44]
#1079
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	possible	O	['N']	[9]
10	interaction	O	['N']	[10]
11	between	O	['N']	[11]
12	propafenone	O	['N']	[12]
13	and	O	['N']	[13]
14	citalopram	B-Drug	['Causes']	[24]
15	,	O	['N']	[15]
16	which	O	['N']	[16]
17	caused	O	['N']	[17]
18	propafenone	O	['N']	[18]
19	adverse	O	['N']	[19]
20	effects	O	['N']	[20]
21	(	O	['N']	[21]
22	eg	O	['N']	[22]
23	,	O	['N']	[23]
24	dizziness	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	falls	O	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	mimicked	O	['N']	[29]
30	coronary	O	['N']	[30]
31	artery	O	['N']	[31]
32	disease	O	['N']	[32]
33	.	O	['N']	[33]
#1080
0	Adverse	O	['N']	[0]
1	effects	O	['N']	[1]
2	of	O	['N']	[2]
3	amiodarone	B-Drug	['Causes']	[12]
4	including	O	['N']	[4]
5	pulmonary	O	['N']	[5]
6	toxicity	O	['N']	[6]
7	,	O	['N']	[7]
8	hepatotoxicity	O	['N']	[8]
9	,	O	['N']	[9]
10	aggravation	B	['N']	[10]
11	of	I	['N']	[11]
12	arrhythmia	I-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	thyroid	O	['N']	[15]
16	diseases	O	['N']	[16]
17	are	O	['N']	[17]
18	well	O	['N']	[18]
19	understood	O	['N']	[19]
20	.	O	['N']	[20]
#1081
0	Polyarthritis	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	hepatitis	O	['N']	[2]
3	and	O	['N']	[3]
4	anti	O	['N']	[4]
5	-	O	['N']	[5]
6	native	O	['N']	[6]
7	DNA	O	['N']	[7]
8	antibodies	O	['N']	[8]
9	after	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	ethambutol	O	['N']	[12]
13	and	O	['N']	[13]
14	rifampicin	B-Drug	['Causes']	[0]
15	.	O	['N']	[15]
#1082
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	three	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	acute	O	['N']	[6]
7	schizophrenia	O	['N']	[7]
8	,	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	severe	O	['N']	[11]
12	akathisia	O	['N']	[12]
13	during	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	olanzapine	B-Drug	['Dosage']	[23]
17	(	O	['N']	[17]
18	20	B	['N']	[18]
19	-	I	['N']	[19]
20	25	I	['N']	[20]
21	mg	I	['N']	[21]
22	/	I	['N']	[22]
23	d	I-Dose	['N']	[23]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#1083
0	The	O	['N']	[0]
1	wide	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	phenytoin	B-Drug	['Causes']	[29]
5	during	O	['N']	[5]
6	the	O	['N']	[6]
7	recent	O	['N']	[7]
8	tuberculosis	O	['N']	[8]
9	epidemic	O	['N']	[9]
10	makes	O	['N']	[10]
11	it	O	['N']	[11]
12	imperative	O	['N']	[12]
13	to	O	['N']	[13]
14	suspect	O	['N']	[14]
15	this	O	['N']	[15]
16	drug	O	['N']	[16]
17	interaction	O	['N']	[17]
18	in	O	['N']	[18]
19	patients	O	['N']	[19]
20	exhibiting	O	['N']	[20]
21	clinical	O	['N']	[21]
22	features	O	['N']	[22]
23	that	O	['N']	[23]
24	might	O	['N']	[24]
25	be	O	['N']	[25]
26	related	O	['N']	[26]
27	to	O	['N']	[27]
28	phenytoin	B	['N']	[28]
29	toxicity	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#1084
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	paper	O	['N']	[2]
3	we	O	['N']	[3]
4	report	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	nimodipine	B-Drug	['Dosage']	[9]
9	overdosage	B-Dose	['N']	[9]
10	resulting	O	['N']	[10]
11	in	O	['N']	[11]
12	prolonged	O	['N']	[12]
13	hypotension	O	['N']	[13]
14	and	O	['N']	[14]
15	hypoxemia	O	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	was	O	['N']	[18]
19	successfully	O	['N']	[19]
20	treated	O	['N']	[20]
21	with	O	['N']	[21]
22	calcium	O	['N']	[22]
23	gluconate	O	['N']	[23]
24	.	O	['N']	[24]
#1085
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	fulminant	O	['N']	[6]
7	adult	O	['N']	[7]
8	respiratory	O	['N']	[8]
9	distress	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	(	O	['N']	[11]
12	ARDS	B-Adverse_Effect	['N']	[12]
13	)	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	pegylated	O	['N']	[16]
17	interferon	O	['N']	[17]
18	alpha-2a	O	['N']	[18]
19	(	O	['N']	[19]
20	pegIFNalpha-2a	B-Drug	['Causes']	[12]
21	)	O	['N']	[21]
22	and	O	['N']	[22]
23	ribavirin	O	['N']	[23]
24	use	O	['N']	[24]
25	for	O	['N']	[25]
26	hepatitis	O	['N']	[26]
27	C	O	['N']	[27]
28	,	O	['N']	[28]
29	complicated	O	['N']	[29]
30	by	O	['N']	[30]
31	subsequent	O	['N']	[31]
32	and	O	['N']	[32]
33	ultimately	O	['N']	[33]
34	fatal	O	['N']	[34]
35	sepsis	O	['N']	[35]
36	and	O	['N']	[36]
37	multiorgan	O	['N']	[37]
38	failure	O	['N']	[38]
39	.	O	['N']	[39]
#1086
0	In	O	['N']	[0]
1	conclusion	O	['N']	[1]
2	,	O	['N']	[2]
3	RSDS	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	relevant	O	['N']	[6]
7	osteoarticular	O	['N']	[7]
8	complication	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	receiving	O	['N']	[11]
12	either	O	['N']	[12]
13	anticalcineurinic	O	['N']	[13]
14	drug	O	['N']	[14]
15	(	O	['N']	[15]
16	CyA	O	['N']	[16]
17	or	O	['N']	[17]
18	tacrolimus	B-Drug	['Causes']	[3]
19	)	O	['N']	[19]
20	,	O	['N']	[20]
21	even	O	['N']	[21]
22	under	O	['N']	[22]
23	monotherapy	O	['N']	[23]
24	or	O	['N']	[24]
25	with	O	['N']	[25]
26	a	O	['N']	[26]
27	low	O	['N']	[27]
28	steroid	O	['N']	[28]
29	dose	O	['N']	[29]
30	.	O	['N']	[30]
#1087
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	man	O	['N']	[6]
7	,	O	['N']	[7]
8	treated	O	['N']	[8]
9	with	O	['N']	[9]
10	mesalazine	B-Drug	['Causes']	[20]
11	for	O	['N']	[11]
12	Crohn	O	['N']	[12]
13	's	O	['N']	[13]
14	disease	O	['N']	[14]
15	who	O	['N']	[15]
16	developed	O	['N']	[16]
17	drug	O	['N']	[17]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	pericarditis	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#1088
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	article	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	describe	O	['N']	[5]
6	another	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	subcutaneous	B	['N']	[9]
10	changes	I-Adverse_Effect	['N']	[10]
11	following	O	['N']	[11]
12	repeated	O	['N']	[12]
13	glatiramer	B	['N']	[13]
14	acetate	I-Drug	['Causes']	[10]
15	injection	O	['N']	[15]
16	,	O	['N']	[16]
17	presented	O	['N']	[17]
18	as	O	['N']	[18]
19	localized	O	['N']	[19]
20	panniculitis	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	area	O	['N']	[23]
24	around	O	['N']	[24]
25	the	O	['N']	[25]
26	injection	O	['N']	[26]
27	sites	O	['N']	[27]
28	,	O	['N']	[28]
29	in	O	['N']	[29]
30	a	O	['N']	[30]
31	46-year	O	['N']	[31]
32	-	O	['N']	[32]
33	old	O	['N']	[33]
34	female	O	['N']	[34]
35	patient	O	['N']	[35]
36	who	O	['N']	[36]
37	was	O	['N']	[37]
38	treated	O	['N']	[38]
39	with	O	['N']	[39]
40	glatiramer	O	['N']	[40]
41	acetate	O	['N']	[41]
42	for	O	['N']	[42]
43	18	O	['N']	[43]
44	months	O	['N']	[44]
45	.	O	['N']	[45]
#1089
0	Although	O	['N']	[0]
1	major	O	['N']	[1]
2	hazards	O	['N']	[2]
3	of	O	['N']	[3]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	hypophosphatemic	-	['N']	[6]
7	osteomalacia	O	['N']	[7]
8	with	O	['N']	[8]
9	phosphate	O	['N']	[9]
10	and	O	['N']	[10]
11	calcitriol	O	['N']	[11]
12	are	O	['N']	[12]
13	secondary	O	['N']	[13]
14	hyperparathyroidism	O	['N']	[14]
15	and	O	['N']	[15]
16	vitamin	O	['N']	[16]
17	D	O	['N']	[17]
18	intoxication	O	['N']	[18]
19	,	O	['N']	[19]
20	potassium	B	['N']	[20]
21	loss	I-Adverse_Effect	['N']	[21]
22	also	O	['N']	[22]
23	should	O	['N']	[23]
24	be	O	['N']	[24]
25	kept	O	['N']	[25]
26	in	O	['N']	[26]
27	mind	O	['N']	[27]
28	.	O	['N']	[28]
#1090
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	study	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	unusual	B	['N']	[8]
9	weight	I	['N']	[9]
10	fluctuation	I-Adverse_Effect	['N']	[10]
11	under	O	['N']	[11]
12	corticosteroid	O	['N']	[12]
13	and	O	['N']	[13]
14	psychotropic	O	['N']	[14]
15	treatment	O	['N']	[15]
16	such	O	['N']	[16]
17	as	O	['N']	[17]
18	mianserin	O	['N']	[18]
19	and	O	['N']	[19]
20	aripiprazole	B-Drug	['Causes']	[10]
21	.	O	['N']	[21]
#1091
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	transient	O	['N']	[3]
4	,	O	['N']	[4]
5	acute	B	['N']	[5]
6	myopia	I-Adverse_Effect	['N']	[6]
7	while	O	['N']	[7]
8	on	O	['N']	[8]
9	isotretinoin	O	['N']	[9]
10	(	O	['N']	[10]
11	Accutane	B-Drug	['Causes']	[6]
12	)	O	['N']	[12]
13	therapy	O	['N']	[13]
14	for	O	['N']	[14]
15	acne	O	['N']	[15]
16	.	O	['N']	[16]
#1092
0	First	O	['N']	[0]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	review	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	literature	O	['N']	[6]
7	produced	O	['N']	[7]
8	41	O	['N']	[8]
9	anecdotic	O	['N']	[9]
10	cases	O	['N']	[10]
11	of	O	['N']	[11]
12	neutropenia	O	['N']	[12]
13	or	O	['N']	[13]
14	agranulocytosis	B-Adverse_Effect	['N']	[14]
15	during	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	olanzapine	B-Drug	['Causes']	[14]
19	(	O	['N']	[19]
20	Zyprexa	O	['N']	[20]
21	)	O	['N']	[21]
22	reported	O	['N']	[22]
23	in	O	['N']	[23]
24	a	O	['N']	[24]
25	total	O	['N']	[25]
26	of	O	['N']	[26]
27	24	O	['N']	[27]
28	publications	O	['N']	[28]
29	.	O	['N']	[29]
#1093
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	B-Drug	['Causes']	[23]
4	hypersensitivity	O	['N']	[4]
5	reactions	O	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	considered	O	['N']	[8]
9	when	O	['N']	[9]
10	patients	O	['N']	[10]
11	receiving	O	['N']	[11]
12	phenytoin	O	['N']	[12]
13	have	O	['N']	[13]
14	unusual	O	['N']	[14]
15	symptoms	O	['N']	[15]
16	,	O	['N']	[16]
17	particularly	O	['N']	[17]
18	fever	O	['N']	[18]
19	,	O	['N']	[19]
20	rash	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	lymphadenopathy	B-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#1094
0	Lichen	B	['N']	[0]
1	planus	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	hepatitis	B	['N']	[4]
5	B	I	['N']	[5]
6	vaccination	I-Drug	['Causes']	[1]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	new	O	['N']	[9]
10	case	O	['N']	[10]
11	and	O	['N']	[11]
12	review	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	literature	O	['N']	[15]
16	.	O	['N']	[16]
#1095
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	that	O	['N']	[2]
3	nicotinic	B	['N']	[3]
4	acid	I-Drug	['Causes']	[71]
5	was	O	['N']	[5]
6	the	O	['N']	[6]
7	cause	O	['N']	[7]
8	of	O	['N']	[8]
9	his	O	['N']	[9]
10	liver	O	['N']	[10]
11	disease	O	['N']	[11]
12	,	O	['N']	[12]
13	that	O	['N']	[13]
14	this	O	['N']	[14]
15	case	O	['N']	[15]
16	is	O	['N']	[16]
17	of	O	['N']	[17]
18	particular	O	['N']	[18]
19	note	O	['N']	[19]
20	because	O	['N']	[20]
21	of	O	['N']	[21]
22	the	O	['N']	[22]
23	rather	O	['N']	[23]
24	short	O	['N']	[24]
25	period	O	['N']	[25]
26	of	O	['N']	[26]
27	therapy	O	['N']	[27]
28	before	O	['N']	[28]
29	the	O	['N']	[29]
30	onset	O	['N']	[30]
31	of	O	['N']	[31]
32	liver	O	['N']	[32]
33	injury	O	['N']	[33]
34	and	O	['N']	[34]
35	the	O	['N']	[35]
36	severity	O	['N']	[36]
37	of	O	['N']	[37]
38	the	O	['N']	[38]
39	hepatic	O	['N']	[39]
40	failure	O	['N']	[40]
41	,	O	['N']	[41]
42	and	O	['N']	[42]
43	that	O	['N']	[43]
44	the	O	['N']	[44]
45	probable	O	['N']	[45]
46	increased	O	['N']	[46]
47	use	O	['N']	[47]
48	of	O	['N']	[48]
49	nicotinic	O	['N']	[49]
50	acid	O	['N']	[50]
51	for	O	['N']	[51]
52	serum	O	['N']	[52]
53	cholesterol	O	['N']	[53]
54	control	O	['N']	[54]
55	makes	O	['N']	[55]
56	it	O	['N']	[56]
57	especially	O	['N']	[57]
58	important	O	['N']	[58]
59	for	O	['N']	[59]
60	physicians	O	['N']	[60]
61	and	O	['N']	[61]
62	their	O	['N']	[62]
63	patients	O	['N']	[63]
64	to	O	['N']	[64]
65	be	O	['N']	[65]
66	alert	O	['N']	[66]
67	to	O	['N']	[67]
68	the	O	['N']	[68]
69	signs	O	['N']	[69]
70	of	O	['N']	[70]
71	hepatotoxicity	B-Adverse_Effect	['N']	[71]
72	.	O	['N']	[72]
#1096
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	O	['N']	[5]
6	epinephrine	B-Drug	['Causes']	[26]
7	toxicity	O	['N']	[7]
8	resulting	O	['N']	[8]
9	in	O	['N']	[9]
10	acute	O	['N']	[10]
11	myocardial	O	['N']	[11]
12	ischemia	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	young	O	['N']	[15]
16	boy	O	['N']	[16]
17	with	O	['N']	[17]
18	combined	O	['N']	[18]
19	variable	O	['N']	[19]
20	immunodeficiency	O	['N']	[20]
21	syndrome	O	['N']	[21]
22	who	O	['N']	[22]
23	developed	O	['N']	[23]
24	severe	B	['N']	[24]
25	allergic	I	['N']	[25]
26	reaction	I-Adverse_Effect	['N']	[26]
27	to	O	['N']	[27]
28	intravenous	O	['N']	[28]
29	immunoglobulin	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	was	O	['N']	[32]
33	subsequently	O	['N']	[33]
34	given	O	['N']	[34]
35	epinephrine	O	['N']	[35]
36	by	O	['N']	[36]
37	mistake	O	['N']	[37]
38	intravenously	O	['N']	[38]
39	rather	O	['N']	[39]
40	than	O	['N']	[40]
41	subcutaneously	O	['N']	[41]
42	.	O	['N']	[42]
#1097
0	The	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	central	B	['N']	[3]
4	diabetes	I	['N']	[4]
5	insipidus	I-Adverse_Effect	['N']	[5]
6	(	O	['N']	[6]
7	CDI	O	['N']	[7]
8	)	O	['N']	[8]
9	with	O	['N']	[9]
10	lithium	B-Drug	['Causes']	[5]
11	use	O	['N']	[11]
12	is	O	['N']	[12]
13	rare	O	['N']	[13]
14	.	O	['N']	[14]
#1098
0	Four	O	['N']	[0]
1	patients	O	['N']	[1]
2	in	O	['N']	[2]
3	whom	O	['N']	[3]
4	pulmonary	B	['N']	[4]
5	oedema	I-Adverse_Effect	['N']	[5]
6	developed	O	['N']	[6]
7	during	O	['N']	[7]
8	tocolysis	O	['N']	[8]
9	with	O	['N']	[9]
10	hexoprenaline	B-Drug	['Causes']	[5]
11	are	O	['N']	[11]
12	described	O	['N']	[12]
13	and	O	['N']	[13]
14	the	O	['N']	[14]
15	aetiological	O	['N']	[15]
16	factors	O	['N']	[16]
17	and	O	['N']	[17]
18	pathogenesis	O	['N']	[18]
19	of	O	['N']	[19]
20	this	O	['N']	[20]
21	potentially	O	['N']	[21]
22	lethal	O	['N']	[22]
23	complication	O	['N']	[23]
24	discussed	O	['N']	[24]
25	.	O	['N']	[25]
#1099
0	Granulocytopenia	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	agranulocytosis	O	['N']	[2]
3	are	O	['N']	[3]
4	considered	O	['N']	[4]
5	among	O	['N']	[5]
6	the	O	['N']	[6]
7	most	O	['N']	[7]
8	dangerous	O	['N']	[8]
9	adverse	O	['N']	[9]
10	effects	O	['N']	[10]
11	of	O	['N']	[11]
12	clozapine	B-Drug	['Causes']	[0]
13	.	O	['N']	[13]
#1100
0	Toxic	B	['N']	[0]
1	epidermal	I	['N']	[1]
2	necrolysis	I-Adverse_Effect	['N']	[2]
3	resulted	O	['N']	[3]
4	after	O	['N']	[4]
5	19	O	['N']	[5]
6	days	O	['N']	[6]
7	of	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	5-fluorocytosine	B-Drug	['Causes']	[2]
11	and	O	['N']	[11]
12	amphotericin	O	['N']	[12]
13	B.	O	['N']	[13]
#1101
0	Multiple	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	nodules	I-Adverse_Effect	['N']	[2]
3	:	O	['N']	[3]
4	an	O	['N']	[4]
5	unusual	O	['N']	[5]
6	presentation	O	['N']	[6]
7	of	O	['N']	[7]
8	fludarabine	B-Drug	['Causes']	[2]
9	pulmonary	O	['N']	[9]
10	toxicity	O	['N']	[10]
11	:	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	and	O	['N']	[14]
15	review	O	['N']	[15]
16	of	O	['N']	[16]
17	literature	O	['N']	[17]
18	.	O	['N']	[18]
#1102
0	Behavioral	O	['N']	[0]
1	side	O	['N']	[1]
2	effects	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	clonazepam	B-Drug	['Causes']	[17]
6	may	O	['N']	[6]
7	include	O	['N']	[7]
8	agitation	O	['N']	[8]
9	,	O	['N']	[9]
10	aggression	O	['N']	[10]
11	,	O	['N']	[11]
12	hyperactivity	O	['N']	[12]
13	,	O	['N']	[13]
14	irritability	O	['N']	[14]
15	,	O	['N']	[15]
16	property	B	['N']	[16]
17	destruction	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	temper	O	['N']	[20]
21	tantrums	O	['N']	[21]
22	.	O	['N']	[22]
#1103
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	recurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	urticaria	B-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	angioedema	O	['N']	[7]
8	a	O	['N']	[8]
9	year	O	['N']	[9]
10	and	O	['N']	[10]
11	a	O	['N']	[11]
12	half	O	['N']	[12]
13	later	O	['N']	[13]
14	,	O	['N']	[14]
15	at	O	['N']	[15]
16	which	O	['N']	[16]
17	point	O	['N']	[17]
18	the	O	['N']	[18]
19	NPH	O	['N']	[19]
20	was	O	['N']	[20]
21	stopped	O	['N']	[21]
22	and	O	['N']	[22]
23	she	O	['N']	[23]
24	was	O	['N']	[24]
25	desensitized	O	['N']	[25]
26	to	O	['N']	[26]
27	regular	O	['N']	[27]
28	insulin	B-Drug	['Causes']	[5]
29	.	O	['N']	[29]
#1104
0	Disseminated	O	['N']	[0]
1	intravascular	O	['N']	[1]
2	coagulation	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	acute	B	['N']	[5]
6	hemoglobinemia	I-Adverse_Effect	['N']	[6]
7	or	O	['N']	[7]
8	hemoglobinuria	O	['N']	[8]
9	following	O	['N']	[9]
10	Rh(0)(D	B	['N']	[10]
11	)	I	['N']	[11]
12	immune	I	['N']	[12]
13	globulin	I-Drug	['Causes']	[6]
14	intravenous	O	['N']	[14]
15	administration	O	['N']	[15]
16	for	O	['N']	[16]
17	immune	O	['N']	[17]
18	thrombocytopenic	O	['N']	[18]
19	purpura	O	['N']	[19]
20	.	O	['N']	[20]
#1105
0	Such	O	['N']	[0]
1	anagen	B	['N']	[1]
2	effluvium	I-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	lichenoid	O	['N']	[4]
5	eruption	O	['N']	[5]
6	following	O	['N']	[6]
7	INH	B-Drug	['Causes']	[2]
8	therapy	O	['N']	[8]
9	has	O	['N']	[9]
10	not	O	['N']	[10]
11	been	O	['N']	[11]
12	observed	O	['N']	[12]
13	previously	O	['N']	[13]
14	.	O	['N']	[14]
#1106
0	Scleroderma	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	association	O	['N']	[2]
3	with	O	['N']	[3]
4	the	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	bleomycin	B-Drug	['Causes']	[0]
8	:	O	['N']	[8]
9	a	O	['N']	[9]
10	report	O	['N']	[10]
11	of	O	['N']	[11]
12	3	O	['N']	[12]
13	cases	O	['N']	[13]
14	.	O	['N']	[14]
#1107
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	M4	O	['N']	[5]
6	AML	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	standard	O	['N']	[9]
10	chemotherapy	O	['N']	[10]
11	followed	O	['N']	[11]
12	by	O	['N']	[12]
13	G	B	['N']	[13]
14	-	I	['N']	[14]
15	CSF	I-Drug	['Causes']	[19]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	marked	O	['N']	[18]
19	monocytosis	B-Adverse_Effect	['N']	[19]
20	on	O	['N']	[20]
21	day	O	['N']	[21]
22	8	O	['N']	[22]
23	of	O	['N']	[23]
24	G	O	['N']	[24]
25	-	O	['N']	[25]
26	CSF	O	['N']	[26]
27	therapy	O	['N']	[27]
28	.	O	['N']	[28]
#1108
0	CONTEXT	O	['N']	[0]
1	:	O	['N']	[1]
2	Previous	O	['N']	[2]
3	investigators	O	['N']	[3]
4	have	O	['N']	[4]
5	reported	O	['N']	[5]
6	discrepancies	B	['N']	[6]
7	between	I	['N']	[7]
8	hematologic	I	['N']	[8]
9	,	I	['N']	[9]
10	marrow	I	['N']	[10]
11	morphologic	I	['N']	[11]
12	,	I	['N']	[12]
13	and	I	['N']	[13]
14	cytogenetic	I	['N']	[14]
15	responses	I-Adverse_Effect	['N']	[15]
16	to	O	['N']	[16]
17	imatinib	B	['N']	[17]
18	mesylate	I-Drug	['Causes']	[15]
19	among	O	['N']	[19]
20	patients	O	['N']	[20]
21	with	O	['N']	[21]
22	chronic	O	['N']	[22]
23	myeloid	O	['N']	[23]
24	leukemia	O	['N']	[24]
25	(	O	['N']	[25]
26	CML	O	['N']	[26]
27	)	O	['N']	[27]
28	.	O	['N']	[28]
#1109
0	A	O	['N']	[0]
1	62-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	who	O	['N']	[5]
6	was	O	['N']	[6]
7	being	O	['N']	[7]
8	treated	O	['N']	[8]
9	for	O	['N']	[9]
10	squamous	O	['N']	[10]
11	cell	O	['N']	[11]
12	carcinoma	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	head	O	['N']	[15]
16	and	O	['N']	[16]
17	neck	O	['N']	[17]
18	developed	O	['N']	[18]
19	a	O	['N']	[19]
20	chemotherapy	O	['N']	[20]
21	-	O	['N']	[21]
22	related	O	['N']	[22]
23	hemolytic	B	['N']	[23]
24	-	I	['N']	[24]
25	uremic	I	['N']	[25]
26	syndrome	I-Adverse_Effect	['N']	[26]
27	during	O	['N']	[27]
28	the	O	['N']	[28]
29	second	O	['N']	[29]
30	cycle	O	['N']	[30]
31	of	O	['N']	[31]
32	neoadjuvant	O	['N']	[32]
33	chemotherapy	O	['N']	[33]
34	consisting	O	['N']	[34]
35	of	O	['N']	[35]
36	cisplatin	O	['N']	[36]
37	,	O	['N']	[37]
38	bleomycin	B-Drug	['Causes']	[26]
39	,	O	['N']	[39]
40	and	O	['N']	[40]
41	methotrexate	O	['N']	[41]
42	.	O	['N']	[42]
#1110
0	Diphenhydramine	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	wide	O	['N']	[3]
4	complex	O	['N']	[4]
5	dysrhythmia	B-Adverse_Effect	['N']	[5]
6	responds	O	['N']	[6]
7	to	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	sodium	O	['N']	[10]
11	bicarbonate	O	['N']	[11]
12	.	O	['N']	[12]
#1111
0	Cutaneous	B	['N']	[0]
1	sarcoidosis	I-Adverse_Effect	['N']	[1]
2	during	O	['N']	[2]
3	interferon	B	['N']	[3]
4	alfa	I-Drug	['Causes']	[1]
5	and	O	['N']	[5]
6	ribavirin	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	hepatitis	O	['N']	[9]
10	C	O	['N']	[10]
11	virus	O	['N']	[11]
12	infection	O	['N']	[12]
13	:	O	['N']	[13]
14	two	O	['N']	[14]
15	cases	O	['N']	[15]
16	.	O	['N']	[16]
#1112
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	reported	O	['N']	[3]
4	of	O	['N']	[4]
5	theophylline	O	['N']	[5]
6	intoxication	O	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	a	O	['N']	[9]
10	dramatic	O	['N']	[10]
11	decrease	B	['N']	[11]
12	in	I	['N']	[12]
13	theophylline	I	['N']	[13]
14	clearance	I-Adverse_Effect	['N']	[14]
15	following	O	['N']	[15]
16	concomitant	O	['N']	[16]
17	administration	O	['N']	[17]
18	of	O	['N']	[18]
19	viloxazine	B-Drug	['Causes']	[14]
20	.	O	['N']	[20]
#1113
0	Atrial	B	['N']	[0]
1	fibrillation	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	methylprednisolone	B-Drug	['Causes']	[1]
4	pulse	O	['N']	[4]
5	therapy	O	['N']	[5]
6	.	O	['N']	[6]
#1114
0	Assessment	O	['N']	[0]
1	of	O	['N']	[1]
2	cortisol	O	['N']	[2]
3	response	O	['N']	[3]
4	was	O	['N']	[4]
5	by	O	['N']	[5]
6	insulin	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	hypoglycaemia	B-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	three	O	['N']	[11]
12	cases	O	['N']	[12]
13	,	O	['N']	[13]
14	by	O	['N']	[14]
15	short	O	['N']	[15]
16	tetracosactrin	O	['N']	[16]
17	test	O	['N']	[17]
18	in	O	['N']	[18]
19	two	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	by	O	['N']	[22]
23	low	O	['N']	[23]
24	-	O	['N']	[24]
25	dose	O	['N']	[25]
26	tetracosactrin	O	['N']	[26]
27	and	O	['N']	[27]
28	24-hour	O	['N']	[28]
29	urinary	O	['N']	[29]
30	cortisol	O	['N']	[30]
31	/	O	['N']	[31]
32	creatinine	O	['N']	[32]
33	ratio	O	['N']	[33]
34	in	O	['N']	[34]
35	one	O	['N']	[35]
36	.	O	['N']	[36]
#1115
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	this	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	concomitant	O	['N']	[8]
9	appearance	O	['N']	[9]
10	of	O	['N']	[10]
11	multiple	O	['N']	[11]
12	skin	O	['N']	[12]
13	cancers	O	['N']	[13]
14	and	O	['N']	[14]
15	nail	B	['N']	[15]
16	changes	I-Adverse_Effect	['N']	[16]
17	associated	O	['N']	[17]
18	with	O	['N']	[18]
19	hydroxyurea	B-Drug	['Causes']	[16]
20	use	O	['N']	[20]
21	.	O	['N']	[21]
#1116
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	niacin	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	visual	B	['N']	[6]
7	symptoms	I-Adverse_Effect	['N']	[7]
8	had	O	['N']	[8]
9	cystoid	O	['N']	[9]
10	maculopathy	O	['N']	[10]
11	without	O	['N']	[11]
12	leakage	O	['N']	[12]
13	on	O	['N']	[13]
14	fluorescein	O	['N']	[14]
15	angiography	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	fourth	O	['N']	[19]
20	patient	O	['N']	[20]
21	with	O	['N']	[21]
22	no	O	['N']	[22]
23	fundus	O	['N']	[23]
24	abnormality	O	['N']	[24]
25	experienced	O	['N']	[25]
26	cessation	O	['N']	[26]
27	of	O	['N']	[27]
28	visual	O	['N']	[28]
29	symptoms	O	['N']	[29]
30	upon	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	niacin	O	['N']	[33]
34	.	O	['N']	[34]
#1117
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	combined	O	['N']	[6]
7	lithium	B-Drug	['Causes']	[16]
8	and	O	['N']	[8]
9	haloperidol	O	['N']	[9]
10	toxicity	O	['N']	[10]
11	characterized	O	['N']	[11]
12	by	O	['N']	[12]
13	hyperpyrexia	O	['N']	[13]
14	,	O	['N']	[14]
15	severe	B	['N']	[15]
16	rigidity	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	mutism	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	development	O	['N']	[21]
22	of	O	['N']	[22]
23	irreversible	O	['N']	[23]
24	tardive	O	['N']	[24]
25	dyskinesia	O	['N']	[25]
26	.	O	['N']	[26]
#1118
0	Iatrogenic	O	['N']	[0]
1	hypercalcemia	B-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	vitamin	O	['N']	[4]
5	D3	O	['N']	[5]
6	ointment	O	['N']	[6]
7	(	O	['N']	[7]
8	1,24(OH)2D3	O	['N']	[8]
9	)	O	['N']	[9]
10	combined	O	['N']	[10]
11	with	O	['N']	[11]
12	thiazide	B-Drug	['Causes']	[1]
13	diuretics	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	case	O	['N']	[16]
17	of	O	['N']	[17]
18	psoriasis	O	['N']	[18]
19	.	O	['N']	[19]
#1119
0	PATIENTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Three	O	['N']	[2]
3	patients	O	['N']	[3]
4	developed	O	['N']	[4]
5	a	O	['N']	[5]
6	reproductive	B	['N']	[6]
7	endocrine	I	['N']	[7]
8	disorder	I-Adverse_Effect	['N']	[8]
9	during	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	valproate	B-Drug	['Causes']	[8]
13	.	O	['N']	[13]
#1120
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	drug	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	Kaposi	O	['N']	[8]
9	's	O	['N']	[9]
10	sarcoma	O	['N']	[10]
11	(	O	['N']	[11]
12	KS	O	['N']	[12]
13	)	O	['N']	[13]
14	on	O	['N']	[14]
15	the	O	['N']	[15]
16	sole	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	right	O	['N']	[19]
20	foot	O	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	71-year	O	['N']	[23]
24	-	O	['N']	[24]
25	old	O	['N']	[25]
26	man	O	['N']	[26]
27	,	O	['N']	[27]
28	treated	O	['N']	[28]
29	for	O	['N']	[29]
30	6	O	['N']	[30]
31	months	O	['N']	[31]
32	with	O	['N']	[32]
33	corticosteroid	O	['N']	[33]
34	therapy	O	['N']	[34]
35	(	O	['N']	[35]
36	prednisolone	B-Drug	['Dosage']	[40]
37	25	B	['N']	[37]
38	mg	I	['N']	[38]
39	/	I	['N']	[39]
40	day	I-Dose	['N']	[40]
41	)	O	['N']	[41]
42	for	O	['N']	[42]
43	pericardial	O	['N']	[43]
44	effusion	O	['N']	[44]
45	.	O	['N']	[45]
#1121
0	Development	O	['N']	[0]
1	of	O	['N']	[1]
2	sarcoidosis	B-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	interferon	O	['N']	[4]
5	alpha	O	['N']	[5]
6	2b	O	['N']	[6]
7	and	O	['N']	[7]
8	ribavirin	B-Drug	['Causes']	[2]
9	combination	O	['N']	[9]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	chronic	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	C	O	['N']	[14]
15	--	O	['N']	[15]
16	a	O	['N']	[16]
17	case	O	['N']	[17]
18	report	O	['N']	[18]
19	and	O	['N']	[19]
20	review	O	['N']	[20]
21	of	O	['N']	[21]
22	the	O	['N']	[22]
23	literature	O	['N']	[23]
24	.	O	['N']	[24]
#1122
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	description	O	['N']	[4]
5	,	O	['N']	[5]
6	to	O	['N']	[6]
7	our	O	['N']	[7]
8	knowledge	O	['N']	[8]
9	,	O	['N']	[9]
10	of	O	['N']	[10]
11	ductopenia	B-Adverse_Effect	['N']	[11]
12	apparently	O	['N']	[12]
13	caused	O	['N']	[13]
14	by	O	['N']	[14]
15	clindamycin	B-Drug	['Causes']	[11]
16	.	O	['N']	[16]
#1123
0	Anaphylactic	B	['N']	[0]
1	reaction	I-Adverse_Effect	['N']	[1]
2	to	O	['N']	[2]
3	bacitracin	B-Drug	['Causes']	[1]
4	ointment	O	['N']	[4]
5	.	O	['N']	[5]
#1124
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	fatal	B	['N']	[5]
6	fulminant	I	['N']	[6]
7	hepatitis	I-Adverse_Effect	['N']	[7]
8	caused	O	['N']	[8]
9	by	O	['N']	[9]
10	the	O	['N']	[10]
11	use	O	['N']	[11]
12	of	O	['N']	[12]
13	disulfiram	B-Drug	['Causes']	[7]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	man	O	['N']	[16]
17	with	O	['N']	[17]
18	previously	O	['N']	[18]
19	normal	O	['N']	[19]
20	hepatocellular	O	['N']	[20]
21	function	O	['N']	[21]
22	.	O	['N']	[22]
#1125
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	patient	O	['N']	[3]
4	required	O	['N']	[4]
5	insulin	B-Drug	['Causes']	[9]
6	desensitization	O	['N']	[6]
7	for	O	['N']	[7]
8	severe	B	['N']	[8]
9	urticaria	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	angioedema	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	occasional	O	['N']	[14]
15	wheezing	O	['N']	[15]
16	resulting	O	['N']	[16]
17	from	O	['N']	[17]
18	her	O	['N']	[18]
19	insulin	O	['N']	[19]
20	dose	O	['N']	[20]
21	.	O	['N']	[21]
#1126
0	Cardiorespiratory	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	miconazole	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#1127
0	Flutamide	B-Drug	['Causes']	[12]
1	withdrawal	O	['N']	[1]
2	syndrome	O	['N']	[2]
3	is	O	['N']	[3]
4	characterized	O	['N']	[4]
5	by	O	['N']	[5]
6	a	O	['N']	[6]
7	decrease	B	['N']	[7]
8	in	I	['N']	[8]
9	prostate	I	['N']	[9]
10	-	I	['N']	[10]
11	specific	I	['N']	[11]
12	antigen	I-Adverse_Effect	['N']	[12]
13	(	O	['N']	[13]
14	PSA	O	['N']	[14]
15	)	O	['N']	[15]
16	after	O	['N']	[16]
17	flutamide	O	['N']	[17]
18	withdrawal	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	subset	O	['N']	[21]
22	of	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	progressing	O	['N']	[25]
26	metastatic	O	['N']	[26]
27	carcinoma	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	prostate	O	['N']	[30]
31	.	O	['N']	[31]
#1128
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	recently	O	['N']	[3]
4	saw	O	['N']	[4]
5	two	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	renal	O	['N']	[8]
9	tuberculosis	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	ethambutol	B-Drug	['Causes']	[20]
13	in	O	['N']	[13]
14	whom	O	['N']	[14]
15	visual	O	['N']	[15]
16	loss	O	['N']	[16]
17	from	O	['N']	[17]
18	toxic	B	['N']	[18]
19	optic	I	['N']	[19]
20	neuropathies	I-Adverse_Effect	['N']	[20]
21	was	O	['N']	[21]
22	severe	O	['N']	[22]
23	and	O	['N']	[23]
24	irreversible	O	['N']	[24]
25	despite	O	['N']	[25]
26	careful	O	['N']	[26]
27	ophthalmological	O	['N']	[27]
28	monitoring	O	['N']	[28]
29	and	O	['N']	[29]
30	prompt	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	the	O	['N']	[33]
34	agent	O	['N']	[34]
35	at	O	['N']	[35]
36	the	O	['N']	[36]
37	first	O	['N']	[37]
38	sign	O	['N']	[38]
39	of	O	['N']	[39]
40	impaired	O	['N']	[40]
41	visual	O	['N']	[41]
42	function	O	['N']	[42]
43	.	O	['N']	[43]
#1129
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	development	O	['N']	[3]
4	of	O	['N']	[4]
5	ischemic	O	['N']	[5]
6	colitis	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	was	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	tegaserod	B-Drug	['Causes']	[29]
15	and	O	['N']	[15]
16	review	O	['N']	[16]
17	the	O	['N']	[17]
18	relationship	O	['N']	[18]
19	among	O	['N']	[19]
20	ischemic	O	['N']	[20]
21	colitis	O	['N']	[21]
22	,	O	['N']	[22]
23	tegaserod	O	['N']	[23]
24	use	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	irritable	B	['N']	[27]
28	bowel	I	['N']	[28]
29	syndrome	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#1130
0	Our	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	both	O	['N']	[3]
4	nephrogenic	O	['N']	[4]
5	diabetes	O	['N']	[5]
6	insipidus	O	['N']	[6]
7	and	O	['N']	[7]
8	renal	B	['N']	[8]
9	tubular	I	['N']	[9]
10	acidosis	I-Adverse_Effect	['N']	[10]
11	with	O	['N']	[11]
12	a	O	['N']	[12]
13	temporal	O	['N']	[13]
14	pattern	O	['N']	[14]
15	that	O	['N']	[15]
16	demonstrated	O	['N']	[16]
17	a	O	['N']	[17]
18	link	O	['N']	[18]
19	between	O	['N']	[19]
20	foscarnet	B-Drug	['Causes']	[10]
21	therapy	O	['N']	[21]
22	and	O	['N']	[22]
23	these	O	['N']	[23]
24	abnormalities	O	['N']	[24]
25	.	O	['N']	[25]
#1131
0	A	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	patient	O	['N']	[5]
6	presented	O	['N']	[6]
7	with	O	['N']	[7]
8	jaundice	B-Adverse_Effect	['N']	[8]
9	followed	O	['N']	[9]
10	2	O	['N']	[10]
11	days	O	['N']	[11]
12	later	O	['N']	[12]
13	by	O	['N']	[13]
14	severe	O	['N']	[14]
15	dyspnea	O	['N']	[15]
16	and	O	['N']	[16]
17	tachypnea	O	['N']	[17]
18	which	O	['N']	[18]
19	worsened	O	['N']	[19]
20	when	O	['N']	[20]
21	patient	O	['N']	[21]
22	was	O	['N']	[22]
23	lying	O	['N']	[23]
24	flat	O	['N']	[24]
25	,	O	['N']	[25]
26	1	O	['N']	[26]
27	week	O	['N']	[27]
28	after	O	['N']	[28]
29	the	O	['N']	[29]
30	fourth	O	['N']	[30]
31	dose	O	['N']	[31]
32	of	O	['N']	[32]
33	adalimumab	B-Drug	['Causes']	[8]
34	.	O	['N']	[34]
#1132
0	Optic	B	['N']	[0]
1	neuropathy	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	ethambutol	B-Drug	['Causes']	[1]
4	-	O	['N']	[4]
5	treated	O	['N']	[5]
6	renal	O	['N']	[6]
7	tuberculosis	O	['N']	[7]
8	.	O	['N']	[8]
#1133
0	One	O	['N']	[0]
1	explanation	O	['N']	[1]
2	for	O	['N']	[2]
3	the	O	['N']	[3]
4	noted	O	['N']	[4]
5	increase	B	['N']	[5]
6	in	I	['N']	[6]
7	the	I	['N']	[7]
8	theophylline	I	['N']	[8]
9	level	I-Adverse_Effect	['N']	[9]
10	is	O	['N']	[10]
11	that	O	['N']	[11]
12	metabolism	O	['N']	[12]
13	occurs	O	['N']	[13]
14	mainly	O	['N']	[14]
15	by	O	['N']	[15]
16	cytochrome	O	['N']	[16]
17	P450	O	['N']	[17]
18	(	O	['N']	[18]
19	CYP	O	['N']	[19]
20	1A2	O	['N']	[20]
21	)	O	['N']	[21]
22	,	O	['N']	[22]
23	an	O	['N']	[23]
24	enzyme	O	['N']	[24]
25	that	O	['N']	[25]
26	is	O	['N']	[26]
27	known	O	['N']	[27]
28	to	O	['N']	[28]
29	be	O	['N']	[29]
30	inhibited	O	['N']	[30]
31	with	O	['N']	[31]
32	high	O	['N']	[32]
33	concentrations	O	['N']	[33]
34	of	O	['N']	[34]
35	zafirlukast	B-Drug	['Causes']	[9]
36	.	O	['N']	[36]
#1134
0	The	O	['N']	[0]
1	majority	O	['N']	[1]
2	of	O	['N']	[2]
3	radiation	B	['N']	[3]
4	recall	I	['N']	[4]
5	reactions	I-Adverse_Effect	['N']	[5]
6	attributed	O	['N']	[6]
7	to	O	['N']	[7]
8	gemcitabine	B-Drug	['Causes']	[5]
9	are	O	['N']	[9]
10	reported	O	['N']	[10]
11	to	O	['N']	[11]
12	affect	O	['N']	[12]
13	internal	O	['N']	[13]
14	tissue	O	['N']	[14]
15	or	O	['N']	[15]
16	organs	O	['N']	[16]
17	.	O	['N']	[17]
#1135
0	A	O	['N']	[0]
1	55-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	developed	O	['N']	[5]
6	symptoms	O	['N']	[6]
7	suggestive	O	['N']	[7]
8	of	O	['N']	[8]
9	hepatitis	B-Adverse_Effect	['N']	[9]
10	12	O	['N']	[10]
11	weeks	O	['N']	[11]
12	after	O	['N']	[12]
13	first	O	['N']	[13]
14	receiving	O	['N']	[14]
15	methyldopa	B-Drug	['Causes']	[9]
16	for	O	['N']	[16]
17	hypertension	O	['N']	[17]
18	.	O	['N']	[18]
#1136
0	Large	O	['N']	[0]
1	dose	O	['N']	[1]
2	of	O	['N']	[2]
3	methylphenidate	B-Drug	['Causes']	[8]
4	may	O	['N']	[4]
5	cause	O	['N']	[5]
6	cataract	O	['N']	[6]
7	and	O	['N']	[7]
8	glaucoma	B-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#1137
0	During	O	['N']	[0]
1	and	O	['N']	[1]
2	after	O	['N']	[2]
3	IFN	B-Drug	['Causes']	[13]
4	therapy	O	['N']	[4]
5	we	O	['N']	[5]
6	should	O	['N']	[6]
7	consider	O	['N']	[7]
8	the	O	['N']	[8]
9	possibility	O	['N']	[9]
10	of	O	['N']	[10]
11	occurrence	O	['N']	[11]
12	of	O	['N']	[12]
13	IDDM	B-Adverse_Effect	['N']	[13]
14	as	O	['N']	[14]
15	well	O	['N']	[15]
16	as	O	['N']	[16]
17	other	O	['N']	[17]
18	autoimmune	O	['N']	[18]
19	diseases	O	['N']	[19]
20	and	O	['N']	[20]
21	observe	O	['N']	[21]
22	the	O	['N']	[22]
23	clinical	O	['N']	[23]
24	course	O	['N']	[24]
25	carefully	O	['N']	[25]
26	.	O	['N']	[26]
#1138
0	Focal	B	['N']	[0]
1	glomerulonephritis	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	interstitial	O	['N']	[3]
4	nephritis	O	['N']	[4]
5	in	O	['N']	[5]
6	methicillin	B-Drug	['Causes']	[1]
7	-	O	['N']	[7]
8	treated	O	['N']	[8]
9	,	O	['N']	[9]
10	heroin	O	['N']	[10]
11	-	O	['N']	[11]
12	related	O	['N']	[12]
13	infective	O	['N']	[13]
14	endocarditis	O	['N']	[14]
15	.	O	['N']	[15]
#1139
0	The	O	['N']	[0]
1	current	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	man	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	prescribed	O	['N']	[8]
9	zonisamide	B-Drug	['Causes']	[31]
10	for	O	['N']	[10]
11	epilepsy	O	['N']	[11]
12	and	O	['N']	[12]
13	subsequently	O	['N']	[13]
14	developed	O	['N']	[14]
15	widespread	O	['N']	[15]
16	skin	O	['N']	[16]
17	rash	O	['N']	[17]
18	,	O	['N']	[18]
19	acute	O	['N']	[19]
20	kidney	O	['N']	[20]
21	injury	O	['N']	[21]
22	,	O	['N']	[22]
23	high	O	['N']	[23]
24	-	O	['N']	[24]
25	grade	O	['N']	[25]
26	fever	O	['N']	[26]
27	,	O	['N']	[27]
28	eosinophilia	O	['N']	[28]
29	,	O	['N']	[29]
30	liver	B	['N']	[30]
31	dysfunction	I-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	lymphadenopathy	O	['N']	[33]
34	and	O	['N']	[34]
35	an	O	['N']	[35]
36	increase	O	['N']	[36]
37	in	O	['N']	[37]
38	antihuman	O	['N']	[38]
39	herpesvirus-6	O	['N']	[39]
40	immunoglobulin	O	['N']	[40]
41	G	O	['N']	[41]
42	titer	O	['N']	[42]
43	.	O	['N']	[43]
#1140
0	Renal	B	['N']	[0]
1	hypophosphatemia	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	this	O	['N']	[3]
4	patient	O	['N']	[4]
5	was	O	['N']	[5]
6	caused	O	['N']	[6]
7	by	O	['N']	[7]
8	the	O	['N']	[8]
9	erroneous	O	['N']	[9]
10	intake	O	['N']	[10]
11	of	O	['N']	[11]
12	1	O	['N']	[12]
13	g	O	['N']	[13]
14	doxycycline	B-Drug	['Causes']	[1]
15	.	O	['N']	[15]
#1141
0	Juvenile	B	['N']	[0]
1	absence	I	['N']	[1]
2	epilepsy	I-Adverse_Effect	['N']	[2]
3	exacerbated	O	['N']	[3]
4	by	O	['N']	[4]
5	valproic	B	['N']	[5]
6	acid	I-Drug	['Causes']	[2]
7	.	O	['N']	[7]
#1142
0	Cutaneous	B	['N']	[0]
1	sarcoidosis	I-Adverse_Effect	['N']	[1]
2	during	O	['N']	[2]
3	interferon	O	['N']	[3]
4	alfa	O	['N']	[4]
5	and	O	['N']	[5]
6	ribavirin	B-Drug	['Causes']	[1]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	hepatitis	O	['N']	[9]
10	C	O	['N']	[10]
11	virus	O	['N']	[11]
12	infection	O	['N']	[12]
13	:	O	['N']	[13]
14	two	O	['N']	[14]
15	cases	O	['N']	[15]
16	.	O	['N']	[16]
#1143
0	Paradoxical	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	vasoconstriction	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	nitroglycerin	B-Drug	['Causes']	[2]
6	in	O	['N']	[6]
7	idiopathic	O	['N']	[7]
8	pulmonary	O	['N']	[8]
9	hypertension	O	['N']	[9]
10	.	O	['N']	[10]
#1144
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	PRES	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	collapsing	O	['N']	[10]
11	focal	O	['N']	[11]
12	glomeruloesclerosis	O	['N']	[12]
13	(	O	['N']	[13]
14	collapsing	O	['N']	[14]
15	FGS	O	['N']	[15]
16	)	O	['N']	[16]
17	with	O	['N']	[17]
18	complete	O	['N']	[18]
19	recovery	O	['N']	[19]
20	after	O	['N']	[20]
21	withdrawal	O	['N']	[21]
22	of	O	['N']	[22]
23	cyclosporine	B-Drug	['Causes']	[5]
24	(	O	['N']	[24]
25	CSA	O	['N']	[25]
26	)	O	['N']	[26]
27	.	O	['N']	[27]
#1145
0	Aplastic	O	['N']	[0]
1	anemia	O	['N']	[1]
2	and	O	['N']	[2]
3	agranulocytosis	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	using	O	['N']	[6]
7	methazolamide	B-Drug	['Causes']	[3]
8	for	O	['N']	[8]
9	glaucoma	O	['N']	[9]
10	.	O	['N']	[10]
#1146
0	We	O	['N']	[0]
1	explored	O	['N']	[1]
2	ophthalmic	B	['N']	[2]
3	and	I	['N']	[3]
4	neurologic	I	['N']	[4]
5	findings	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	two	O	['N']	[7]
8	children	O	['N']	[8]
9	who	O	['N']	[9]
10	have	O	['N']	[10]
11	been	O	['N']	[11]
12	exposed	O	['N']	[12]
13	prenatally	O	['N']	[13]
14	to	O	['N']	[14]
15	VGB	B-Drug	['Causes']	[5]
16	.	O	['N']	[16]
#1147
0	CASE	O	['N']	[0]
1	PRESENTATION	O	['N']	[1]
2	:	O	['N']	[2]
3	Three	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	Leishmania	B	['N']	[6]
7	infantum	I	['N']	[7]
8	leishmaniasis	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	corticosteroid	B-Drug	['Causes']	[8]
11	(	O	['N']	[11]
12	CS)-treated	O	['N']	[12]
13	patients	O	['N']	[13]
14	are	O	['N']	[14]
15	reported	O	['N']	[15]
16	:	O	['N']	[16]
17	an	O	['N']	[17]
18	isolated	O	['N']	[18]
19	lingual	O	['N']	[19]
20	leishmaniasis	O	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	farmer	O	['N']	[23]
24	treated	O	['N']	[24]
25	with	O	['N']	[25]
26	CS	O	['N']	[26]
27	for	O	['N']	[27]
28	asthma	O	['N']	[28]
29	,	O	['N']	[29]
30	a	O	['N']	[30]
31	severe	O	['N']	[31]
32	visceral	O	['N']	[32]
33	leishmaniasis	O	['N']	[33]
34	associated	O	['N']	[34]
35	with	O	['N']	[35]
36	cutaneous	O	['N']	[36]
37	lesions	O	['N']	[37]
38	in	O	['N']	[38]
39	a	O	['N']	[39]
40	woman	O	['N']	[40]
41	with	O	['N']	[41]
42	myasthenia	O	['N']	[42]
43	gravis	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	a	O	['N']	[46]
47	visceral	O	['N']	[47]
48	involvement	O	['N']	[48]
49	after	O	['N']	[49]
50	cutaneous	O	['N']	[50]
51	leishmaniasis	O	['N']	[51]
52	in	O	['N']	[52]
53	a	O	['N']	[53]
54	man	O	['N']	[54]
55	receiving	O	['N']	[55]
56	CS	O	['N']	[56]
57	.	O	['N']	[57]
#1148
0	There	O	['N']	[0]
1	was	O	['N']	[1]
2	a	O	['N']	[2]
3	clear	O	['N']	[3]
4	relationship	O	['N']	[4]
5	between	O	['N']	[5]
6	restarting	O	['N']	[6]
7	the	O	['N']	[7]
8	Accutane	B-Drug	['Causes']	[14]
9	and	O	['N']	[9]
10	recurrence	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	transient	B	['N']	[13]
14	myopia	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#1149
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	typhoid	O	['N']	[9]
10	fever	O	['N']	[10]
11	who	O	['N']	[11]
12	experienced	O	['N']	[12]
13	a	O	['N']	[13]
14	hypersensitivity	B	['N']	[14]
15	reaction	I-Adverse_Effect	['N']	[15]
16	subsequent	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	infusion	O	['N']	[19]
20	of	O	['N']	[20]
21	chloramphenicol	B	['N']	[21]
22	sodium	I	['N']	[22]
23	succinate	I-Drug	['Causes']	[15]
24	.	O	['N']	[24]
#1150
0	Arrhythmias	O	['N']	[0]
1	and	O	['N']	[1]
2	cardiac	B	['N']	[2]
3	arrest	I-Adverse_Effect	['N']	[3]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	reported	O	['N']	[6]
7	during	O	['N']	[7]
8	amphotericin	B	['N']	[8]
9	B	I-Drug	['Causes']	[3]
10	administration	O	['N']	[10]
11	but	O	['N']	[11]
12	no	O	['N']	[12]
13	effective	O	['N']	[13]
14	technique	O	['N']	[14]
15	has	O	['N']	[15]
16	been	O	['N']	[16]
17	described	O	['N']	[17]
18	to	O	['N']	[18]
19	prevent	O	['N']	[19]
20	them	O	['N']	[20]
21	.	O	['N']	[21]
#1151
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	diabetic	B	['N']	[3]
4	coma	I-Adverse_Effect	['N']	[4]
5	when	O	['N']	[5]
6	taking	O	['N']	[6]
7	a	O	['N']	[7]
8	combination	O	['N']	[8]
9	of	O	['N']	[9]
10	a	O	['N']	[10]
11	thiazide	B-Drug	['Causes']	[4]
12	diuretic	O	['N']	[12]
13	and	O	['N']	[13]
14	propranolol	O	['N']	[14]
15	.	O	['N']	[15]
#1152
0	Progressive	B	['N']	[0]
1	interstitial	I	['N']	[1]
2	fibrosis	I-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	roentgenographic	O	['N']	[4]
5	honeycombing	O	['N']	[5]
6	developed	O	['N']	[6]
7	in	O	['N']	[7]
8	the	O	['N']	[8]
9	case	O	['N']	[9]
10	of	O	['N']	[10]
11	a	O	['N']	[11]
12	psoriatic	O	['N']	[12]
13	patient	O	['N']	[13]
14	who	O	['N']	[14]
15	had	O	['N']	[15]
16	been	O	['N']	[16]
17	on	O	['N']	[17]
18	a	O	['N']	[18]
19	regimen	O	['N']	[19]
20	of	O	['N']	[20]
21	methotrexate	B-Drug	['Causes']	[2]
22	for	O	['N']	[22]
23	18	O	['N']	[23]
24	years	O	['N']	[24]
25	.	O	['N']	[25]
#1153
0	Inhaled	O	['N']	[0]
1	tobramycin	B-Drug	['Causes']	[6]
2	solution	O	['N']	[2]
3	-	O	['N']	[3]
4	associated	O	['N']	[4]
5	recurrent	B	['N']	[5]
6	eosinophilia	I-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	severe	O	['N']	[8]
9	persistent	O	['N']	[9]
10	bronchospasm	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	cystic	O	['N']	[15]
16	fibrosis	O	['N']	[16]
17	:	O	['N']	[17]
18	a	O	['N']	[18]
19	case	O	['N']	[19]
20	report	O	['N']	[20]
21	.	O	['N']	[21]
#1154
0	The	O	['N']	[0]
1	temporal	O	['N']	[1]
2	sequence	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	respiratory	O	['N']	[5]
6	insufficiency	O	['N']	[6]
7	and	O	['N']	[7]
8	the	O	['N']	[8]
9	histopathology	O	['N']	[9]
10	,	O	['N']	[10]
11	when	O	['N']	[11]
12	compared	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	previous	O	['N']	[15]
16	examples	O	['N']	[16]
17	in	O	['N']	[17]
18	the	O	['N']	[18]
19	literature	O	['N']	[19]
20	,	O	['N']	[20]
21	suggest	O	['N']	[21]
22	that	O	['N']	[22]
23	cyclophosphamide	B-Drug	['Causes']	[30]
24	was	O	['N']	[24]
25	aetiologically	O	['N']	[25]
26	responsible	O	['N']	[26]
27	for	O	['N']	[27]
28	the	O	['N']	[28]
29	lung	B	['N']	[29]
30	disease	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#1155
0	Diagnosis	O	['N']	[0]
1	of	O	['N']	[1]
2	sclerosing	B	['N']	[2]
3	glomerulonephritis	I-Adverse_Effect	['N']	[3]
4	occurred	O	['N']	[4]
5	in	O	['N']	[5]
6	this	O	['N']	[6]
7	patient	O	['N']	[7]
8	during	O	['N']	[8]
9	anastrozole	B-Drug	['Causes']	[3]
10	use	O	['N']	[10]
11	,	O	['N']	[11]
12	suggesting	O	['N']	[12]
13	a	O	['N']	[13]
14	newly	O	['N']	[14]
15	defined	O	['N']	[15]
16	side	O	['N']	[16]
17	effect	O	['N']	[17]
18	of	O	['N']	[18]
19	anastrozole	O	['N']	[19]
20	.	O	['N']	[20]
#1156
0	Although	O	['N']	[0]
1	adverse	O	['N']	[1]
2	reactions	O	['N']	[2]
3	to	O	['N']	[3]
4	protamine	B-Drug	['Causes']	[23]
5	are	O	['N']	[5]
6	reported	O	['N']	[6]
7	infrequently	O	['N']	[7]
8	and	O	['N']	[8]
9	are	O	['N']	[9]
10	usually	O	['N']	[10]
11	mild	O	['N']	[11]
12	,	O	['N']	[12]
13	we	O	['N']	[13]
14	recently	O	['N']	[14]
15	observed	O	['N']	[15]
16	the	O	['N']	[16]
17	first	O	['N']	[17]
18	fatal	O	['N']	[18]
19	case	O	['N']	[19]
20	of	O	['N']	[20]
21	type	B	['N']	[21]
22	I	I	['N']	[22]
23	anaphylaxis	I-Adverse_Effect	['N']	[23]
24	resulting	O	['N']	[24]
25	from	O	['N']	[25]
26	protamine	O	['N']	[26]
27	.	O	['N']	[27]
#1157
0	Mequitazine	O	['N']	[0]
1	seemed	O	['N']	[1]
2	to	O	['N']	[2]
3	play	O	['N']	[3]
4	a	O	['N']	[4]
5	part	O	['N']	[5]
6	similar	O	['N']	[6]
7	to	O	['N']	[7]
8	chlorpromazine	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	absence	O	['N']	[11]
12	of	O	['N']	[12]
13	mequitazine	B-Drug	['Causes']	[16]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	photosensitivity	B-Adverse_Effect	['N']	[16]
17	may	O	['N']	[17]
18	be	O	['N']	[18]
19	due	O	['N']	[19]
20	to	O	['N']	[20]
21	a	O	['N']	[21]
22	relatively	O	['N']	[22]
23	low	O	['N']	[23]
24	dosage	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	drug	O	['N']	[27]
28	.	O	['N']	[28]
#1158
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	recurrent	O	['N']	[5]
6	,	O	['N']	[6]
7	increasingly	O	['N']	[7]
8	severe	O	['N']	[8]
9	episodes	O	['N']	[9]
10	of	O	['N']	[10]
11	PPE	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	ultimately	O	['N']	[13]
14	complicated	O	['N']	[14]
15	by	O	['N']	[15]
16	a	O	['N']	[16]
17	severe	O	['N']	[17]
18	bullous	O	['N']	[18]
19	eruption	O	['N']	[19]
20	,	O	['N']	[20]
21	following	O	['N']	[21]
22	successive	O	['N']	[22]
23	cycles	O	['N']	[23]
24	of	O	['N']	[24]
25	high	O	['N']	[25]
26	-	O	['N']	[26]
27	dose	O	['N']	[27]
28	cytarabine	B-Drug	['Causes']	[11]
29	for	O	['N']	[29]
30	the	O	['N']	[30]
31	treatment	O	['N']	[31]
32	of	O	['N']	[32]
33	acute	O	['N']	[33]
34	lymphoblastic	O	['N']	[34]
35	leukaemia	O	['N']	[35]
36	.	O	['N']	[36]
#1159
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	B-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	pneumonitis	B-Adverse_Effect	['N']	[5]
6	has	O	['N']	[6]
7	been	O	['N']	[7]
8	described	O	['N']	[8]
9	previously	O	['N']	[9]
10	in	O	['N']	[10]
11	renal	O	['N']	[11]
12	transplant	O	['N']	[12]
13	recipients	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	this	O	['N']	[16]
17	report	O	['N']	[17]
18	describes	O	['N']	[18]
19	a	O	['N']	[19]
20	stable	O	['N']	[20]
21	heart	O	['N']	[21]
22	-	O	['N']	[22]
23	lung	O	['N']	[23]
24	transplant	O	['N']	[24]
25	recipient	O	['N']	[25]
26	who	O	['N']	[26]
27	developed	O	['N']	[27]
28	a	O	['N']	[28]
29	pulmonary	O	['N']	[29]
30	infiltrate	O	['N']	[30]
31	that	O	['N']	[31]
32	reversed	O	['N']	[32]
33	after	O	['N']	[33]
34	ceasing	O	['N']	[34]
35	SR	O	['N']	[35]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#1160
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	exacerbated	O	['N']	[7]
8	mania	B-Adverse_Effect	['N']	[8]
9	potentially	O	['N']	[9]
10	related	O	['N']	[10]
11	to	O	['N']	[11]
12	an	O	['N']	[12]
13	interaction	O	['N']	[13]
14	between	O	['N']	[14]
15	lopinavir	O	['N']	[15]
16	/	O	['N']	[16]
17	ritonavir	B-Drug	['Causes']	[8]
18	and	O	['N']	[18]
19	valproic	O	['N']	[19]
20	acid	O	['N']	[20]
21	(	O	['N']	[21]
22	VPA	O	['N']	[22]
23	)	O	['N']	[23]
24	and	O	['N']	[24]
25	propose	O	['N']	[25]
26	a	O	['N']	[26]
27	mechanism	O	['N']	[27]
28	of	O	['N']	[28]
29	action	O	['N']	[29]
30	for	O	['N']	[30]
31	this	O	['N']	[31]
32	interaction	O	['N']	[32]
33	.	O	['N']	[33]
#1161
0	Leishmania	B	['N']	[0]
1	infantum	I	['N']	[1]
2	leishmaniasis	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	corticosteroid	B-Drug	['Causes']	[2]
5	--	O	['N']	[5]
6	treated	O	['N']	[6]
7	patients	O	['N']	[7]
8	.	O	['N']	[8]
#1162
0	Fulminant	B	['N']	[0]
1	hepatitis	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	lymphocyte	O	['N']	[3]
4	sensitization	O	['N']	[4]
5	due	O	['N']	[5]
6	to	O	['N']	[6]
7	propylthiouracil	B-Drug	['Causes']	[1]
8	.	O	['N']	[8]
#1163
0	Only	O	['N']	[0]
1	a	O	['N']	[1]
2	few	O	['N']	[2]
3	reports	O	['N']	[3]
4	of	O	['N']	[4]
5	overt	O	['N']	[5]
6	jaundice	B-Adverse_Effect	['N']	[6]
7	are	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	streptokinase	B-Drug	['Causes']	[6]
11	.	O	['N']	[11]
#1164
0	An	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	granulocytopenia	O	['N']	[3]
4	,	O	['N']	[4]
5	eosinophilia	O	['N']	[5]
6	,	O	['N']	[6]
7	skin	O	['N']	[7]
8	reaction	O	['N']	[8]
9	and	O	['N']	[9]
10	hepatitis	B-Adverse_Effect	['N']	[10]
11	during	O	['N']	[11]
12	propylthiouracil	O	['N']	[12]
13	(	O	['N']	[13]
14	PTU	B-Drug	['Causes']	[10]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	thyrotoxicosis	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	47	O	['N']	[21]
22	year	O	['N']	[22]
23	old	O	['N']	[23]
24	black	O	['N']	[24]
25	female	O	['N']	[25]
26	is	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#1165
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	fulminant	B	['N']	[5]
6	hepatic	I	['N']	[6]
7	failure	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	HIV-1-infected	O	['N']	[9]
10	patients	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	didanosine	B-Drug	['Causes']	[7]
14	(	O	['N']	[14]
15	ddI	O	['N']	[15]
16	)	O	['N']	[16]
17	.	O	['N']	[17]
#1166
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	phenolphthalein	B-Drug	['Causes']	[14]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	toxic	O	['N']	[10]
11	epidermal	O	['N']	[11]
12	necrolysis	O	['N']	[12]
13	(	O	['N']	[13]
14	TEN	B-Adverse_Effect	['N']	[14]
15	)	O	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	patient	O	['N']	[18]
19	maintained	O	['N']	[19]
20	on	O	['N']	[20]
21	several	O	['N']	[21]
22	other	O	['N']	[22]
23	medications	O	['N']	[23]
24	more	O	['N']	[24]
25	commonly	O	['N']	[25]
26	known	O	['N']	[26]
27	to	O	['N']	[27]
28	be	O	['N']	[28]
29	associated	O	['N']	[29]
30	with	O	['N']	[30]
31	TEN	O	['N']	[31]
32	.	O	['N']	[32]
#1167
0	Marked	B	['N']	[0]
1	hyperkalemia	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	during	O	['N']	[4]
5	and	O	['N']	[5]
6	immediately	O	['N']	[6]
7	after	O	['N']	[7]
8	an	O	['N']	[8]
9	infusion	O	['N']	[9]
10	of	O	['N']	[10]
11	arginine	B	['N']	[11]
12	monohydrochloride	I-Drug	['Causes']	[1]
13	in	O	['N']	[13]
14	two	O	['N']	[14]
15	patients	O	['N']	[15]
16	with	O	['N']	[16]
17	severe	O	['N']	[17]
18	hepatic	O	['N']	[18]
19	disease	O	['N']	[19]
20	and	O	['N']	[20]
21	moderate	O	['N']	[21]
22	renal	O	['N']	[22]
23	insufficiency	O	['N']	[23]
24	.	O	['N']	[24]
#1168
0	A	O	['N']	[0]
1	78-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	transvenous	O	['N']	[7]
8	cardioverter	O	['N']	[8]
9	defibrillator	O	['N']	[9]
10	system	O	['N']	[10]
11	developed	O	['N']	[11]
12	frequent	O	['N']	[12]
13	shocks	B-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	oral	O	['N']	[15]
16	procainamide	B-Drug	['Causes']	[13]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#1169
0	A	O	['N']	[0]
1	62-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Caucasian	O	['N']	[4]
5	man	O	['N']	[5]
6	with	O	['N']	[6]
7	atrial	O	['N']	[7]
8	fibrillation	O	['N']	[8]
9	who	O	['N']	[9]
10	was	O	['N']	[10]
11	taking	O	['N']	[11]
12	warfarin	B-Drug	['Causes']	[17]
13	reported	O	['N']	[13]
14	an	O	['N']	[14]
15	episode	O	['N']	[15]
16	of	O	['N']	[16]
17	hematochezia	B-Adverse_Effect	['N']	[17]
18	;	O	['N']	[18]
19	his	O	['N']	[19]
20	international	O	['N']	[20]
21	normalized	O	['N']	[21]
22	ratio	O	['N']	[22]
23	(	O	['N']	[23]
24	INR	O	['N']	[24]
25	)	O	['N']	[25]
26	was	O	['N']	[26]
27	1.74	O	['N']	[27]
28	.	O	['N']	[28]
#1170
0	METHODS	O	['N']	[0]
1	/	O	['N']	[1]
2	RESULTS	O	['N']	[2]
3	:	O	['N']	[3]
4	This	O	['N']	[4]
5	paper	O	['N']	[5]
6	presents	O	['N']	[6]
7	a	O	['N']	[7]
8	new	O	['N']	[8]
9	case	O	['N']	[9]
10	of	O	['N']	[10]
11	rifabutin	B-Drug	['Causes']	[12]
12	uveitis	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	a	O	['N']	[14]
15	review	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	various	O	['N']	[18]
19	published	O	['N']	[19]
20	reports	O	['N']	[20]
21	to	O	['N']	[21]
22	date	O	['N']	[22]
23	.	O	['N']	[23]
#1171
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Anaphylactoid	B	['N']	[2]
3	reactions	I-Adverse_Effect	['N']	[3]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	described	O	['N']	[6]
7	previously	O	['N']	[7]
8	with	O	['N']	[8]
9	cisplatin	B-Drug	['Causes']	[3]
10	administration	O	['N']	[10]
11	.	O	['N']	[11]
#1172
0	Thrombotic	O	['N']	[0]
1	microangiopathy	O	['N']	[1]
2	with	O	['N']	[2]
3	renal	B	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	two	O	['N']	[6]
7	patients	O	['N']	[7]
8	undergoing	O	['N']	[8]
9	gemcitabine	B-Drug	['Causes']	[4]
10	chemotherapy	O	['N']	[10]
11	.	O	['N']	[11]
#1173
0	In	O	['N']	[0]
1	two	O	['N']	[1]
2	patients	O	['N']	[2]
3	,	O	['N']	[3]
4	apomorphine	B-Drug	['Causes']	[17]
5	remained	O	['N']	[5]
6	effective	O	['N']	[6]
7	in	O	['N']	[7]
8	the	O	['N']	[8]
9	morning	O	['N']	[9]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	increased	O	['N']	[12]
13	the	O	['N']	[13]
14	intensity	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	dyskinesias	B-Adverse_Effect	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	afternoon	O	['N']	[20]
21	.	O	['N']	[21]
#1174
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	severe	O	['N']	[3]
4	visual	O	['N']	[4]
5	loss	O	['N']	[5]
6	following	O	['N']	[6]
7	a	O	['N']	[7]
8	single	B	['N']	[8]
9	dose	I-Dose	['N']	[9]
10	of	O	['N']	[10]
11	vincristine	B-Drug	['Dosage']	[9]
12	is	O	['N']	[12]
13	described	O	['N']	[13]
14	.	O	['N']	[14]
#1175
0	Like	O	['N']	[0]
1	other	O	['N']	[1]
2	atypical	O	['N']	[2]
3	neuroleptics	O	['N']	[3]
4	olanzapine	B-Drug	['Causes']	[15]
5	is	O	['N']	[5]
6	considered	O	['N']	[6]
7	to	O	['N']	[7]
8	show	O	['N']	[8]
9	a	O	['N']	[9]
10	reduced	O	['N']	[10]
11	prevalence	O	['N']	[11]
12	of	O	['N']	[12]
13	extrapyramidal	B	['N']	[13]
14	side	I	['N']	[14]
15	effects	I-Adverse_Effect	['N']	[15]
16	when	O	['N']	[16]
17	compared	O	['N']	[17]
18	to	O	['N']	[18]
19	classical	O	['N']	[19]
20	neuroleptic	O	['N']	[20]
21	drugs	O	['N']	[21]
22	.	O	['N']	[22]
#1176
0	Allergic	B	['N']	[0]
1	contact	I	['N']	[1]
2	angioedema	I-Adverse_Effect	['N']	[2]
3	to	O	['N']	[3]
4	benzoyl	B	['N']	[4]
5	peroxide	I-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#1177
0	Case	O	['N']	[0]
1	4	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	61-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	male	O	['N']	[7]
8	alcoholic	O	['N']	[8]
9	who	O	['N']	[9]
10	remained	O	['N']	[10]
11	completely	O	['N']	[11]
12	abstinent	O	['N']	[12]
13	while	O	['N']	[13]
14	taking	O	['N']	[14]
15	cyanamide	B-Drug	['Causes']	[24]
16	for	O	['N']	[16]
17	3	O	['N']	[17]
18	years	O	['N']	[18]
19	showed	O	['N']	[19]
20	slight	O	['N']	[20]
21	elevation	B	['N']	[21]
22	of	I	['N']	[22]
23	serum	I	['N']	[23]
24	transaminases	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#1178
0	The	O	['N']	[0]
1	hypercalcemia	B-Adverse_Effect	['N']	[1]
2	responded	O	['N']	[2]
3	to	O	['N']	[3]
4	discontinuation	O	['N']	[4]
5	of	O	['N']	[5]
6	rhGH	B-Drug	['Causes']	[1]
7	and	O	['N']	[7]
8	a	O	['N']	[8]
9	single	O	['N']	[9]
10	dose	O	['N']	[10]
11	of	O	['N']	[11]
12	intravenous	O	['N']	[12]
13	pamidronate	O	['N']	[13]
14	disodium	O	['N']	[14]
15	and	O	['N']	[15]
16	has	O	['N']	[16]
17	not	O	['N']	[17]
18	recurred	O	['N']	[18]
19	in	O	['N']	[19]
20	8	O	['N']	[20]
21	months	O	['N']	[21]
22	of	O	['N']	[22]
23	follow	O	['N']	[23]
24	-	O	['N']	[24]
25	up	O	['N']	[25]
26	.	O	['N']	[26]
#1179
0	Central	O	['N']	[0]
1	nervous	O	['N']	[1]
2	system	O	['N']	[2]
3	effects	O	['N']	[3]
4	secondary	O	['N']	[4]
5	to	O	['N']	[5]
6	ciprofloxacin	B-Drug	['Causes']	[16]
7	treatment	O	['N']	[7]
8	are	O	['N']	[8]
9	uncommon	O	['N']	[9]
10	and	O	['N']	[10]
11	usually	O	['N']	[11]
12	consist	O	['N']	[12]
13	only	O	['N']	[13]
14	of	O	['N']	[14]
15	minor	B	['N']	[15]
16	dizziness	I-Adverse_Effect	['N']	[16]
17	or	O	['N']	[17]
18	mild	O	['N']	[18]
19	headache	O	['N']	[19]
20	,	O	['N']	[20]
21	although	O	['N']	[21]
22	rare	O	['N']	[22]
23	occurrences	O	['N']	[23]
24	of	O	['N']	[24]
25	seizures	O	['N']	[25]
26	and	O	['N']	[26]
27	hallucinations	O	['N']	[27]
28	have	O	['N']	[28]
29	been	O	['N']	[29]
30	reported	O	['N']	[30]
31	.	O	['N']	[31]
#1180
0	These	O	['N']	[0]
1	findings	O	['N']	[1]
2	are	O	['N']	[2]
3	consistent	O	['N']	[3]
4	with	O	['N']	[4]
5	an	O	['N']	[5]
6	immune	O	['N']	[6]
7	-	O	['N']	[7]
8	complex	O	['N']	[8]
9	form	O	['N']	[9]
10	of	O	['N']	[10]
11	glomerulopathy	O	['N']	[11]
12	in	O	['N']	[12]
13	which	O	['N']	[13]
14	gold	B-Drug	['Causes']	[50]
15	is	O	['N']	[15]
16	neither	O	['N']	[16]
17	the	O	['N']	[17]
18	antigen	O	['N']	[18]
19	nor	O	['N']	[19]
20	a	O	['N']	[20]
21	hapten	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	glomerular	O	['N']	[24]
25	deposits	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	they	O	['N']	[28]
29	suggest	O	['N']	[29]
30	the	O	['N']	[30]
31	hypothesis	O	['N']	[31]
32	that	O	['N']	[32]
33	antibodies	O	['N']	[33]
34	to	O	['N']	[34]
35	tubular	O	['N']	[35]
36	epithelial	O	['N']	[36]
37	antigens	O	['N']	[37]
38	induced	O	['N']	[38]
39	by	O	['N']	[39]
40	gold	O	['N']	[40]
41	therapy	O	['N']	[41]
42	may	O	['N']	[42]
43	be	O	['N']	[43]
44	a	O	['N']	[44]
45	causative	O	['N']	[45]
46	factor	O	['N']	[46]
47	in	O	['N']	[47]
48	the	O	['N']	[48]
49	renal	B	['N']	[49]
50	disease	I-Adverse_Effect	['N']	[50]
51	associated	O	['N']	[51]
52	with	O	['N']	[52]
53	gold	O	['N']	[53]
54	therapy	O	['N']	[54]
55	in	O	['N']	[55]
56	rheumatoid	O	['N']	[56]
57	arthritis	O	['N']	[57]
58	.	O	['N']	[58]
#1181
0	She	O	['N']	[0]
1	developed	O	['N']	[1]
2	a	O	['N']	[2]
3	generalized	O	['N']	[3]
4	rash	O	['N']	[4]
5	and	O	['N']	[5]
6	itching	O	['N']	[6]
7	,	O	['N']	[7]
8	sore	O	['N']	[8]
9	throat	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	dizziness	B-Adverse_Effect	['N']	[12]
13	approximately	O	['N']	[13]
14	4	O	['N']	[14]
15	hours	O	['N']	[15]
16	after	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	dose	O	['N']	[19]
20	of	O	['N']	[20]
21	capecitabine	B-Drug	['Causes']	[12]
22	.	O	['N']	[22]
#1182
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	one	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	gangrene	O	['N']	[8]
9	after	O	['N']	[9]
10	bleomycin	O	['N']	[10]
11	and	O	['N']	[11]
12	vincristine	O	['N']	[12]
13	/	O	['N']	[13]
14	vinblastine	B-Drug	['Causes']	[36]
15	chemotherapy	O	['N']	[15]
16	for	O	['N']	[16]
17	AIDS	O	['N']	[17]
18	-	O	['N']	[18]
19	related	O	['N']	[19]
20	Kaposi	O	['N']	[20]
21	's	O	['N']	[21]
22	sarcoma	O	['N']	[22]
23	and	O	['N']	[23]
24	another	O	['N']	[24]
25	HIV	O	['N']	[25]
26	-	O	['N']	[26]
27	infected	O	['N']	[27]
28	patient	O	['N']	[28]
29	who	O	['N']	[29]
30	exhibited	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	severe	B	['N']	[33]
34	Raynaud	I	['N']	[34]
35	's	I	['N']	[35]
36	phenomenon	I-Adverse_Effect	['N']	[36]
37	related	O	['N']	[37]
38	to	O	['N']	[38]
39	the	O	['N']	[39]
40	same	O	['N']	[40]
41	regimen	O	['N']	[41]
42	are	O	['N']	[42]
43	presented	O	['N']	[43]
44	.	O	['N']	[44]
#1183
0	The	O	['N']	[0]
1	ocular	O	['N']	[1]
2	motor	O	['N']	[2]
3	disturbances	O	['N']	[3]
4	are	O	['N']	[4]
5	probably	O	['N']	[5]
6	an	O	['N']	[6]
7	expression	O	['N']	[7]
8	of	O	['N']	[8]
9	regional	O	['N']	[9]
10	5-FU	B-Drug	['Causes']	[11]
11	neurotoxicity	B-Adverse_Effect	['N']	[11]
12	primarily	O	['N']	[12]
13	affecting	O	['N']	[13]
14	the	O	['N']	[14]
15	brain	O	['N']	[15]
16	stem	O	['N']	[16]
17	.	O	['N']	[17]
#1184
0	A	O	['N']	[0]
1	21-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	suffering	O	['N']	[5]
6	from	O	['N']	[6]
7	bipolar	O	['N']	[7]
8	affective	O	['N']	[8]
9	disorder	O	['N']	[9]
10	developed	O	['N']	[10]
11	systemic	O	['N']	[11]
12	lupus	O	['N']	[12]
13	erythematosus	O	['N']	[13]
14	(	O	['N']	[14]
15	SLE	B-Adverse_Effect	['N']	[15]
16	)	O	['N']	[16]
17	with	O	['N']	[17]
18	characteristic	O	['N']	[18]
19	laboratory	O	['N']	[19]
20	findings	O	['N']	[20]
21	,	O	['N']	[21]
22	18	O	['N']	[22]
23	months	O	['N']	[23]
24	after	O	['N']	[24]
25	starting	O	['N']	[25]
26	carbamazepine	B-Drug	['Causes']	[15]
27	maintenance	O	['N']	[27]
28	treatment	O	['N']	[28]
29	.	O	['N']	[29]
#1185
0	Chloroquine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	bilateral	B	['N']	[3]
4	ptosis	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1186
0	Eleven	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	infection	O	['N']	[3]
4	requiring	O	['N']	[4]
5	hospitalization	O	['N']	[5]
6	while	O	['N']	[6]
7	taking	O	['N']	[7]
8	leflunomide	B-Drug	['Causes']	[50]
9	including	O	['N']	[9]
10	:	O	['N']	[10]
11	lower	O	['N']	[11]
12	respiratory	O	['N']	[12]
13	tract	O	['N']	[13]
14	infections	O	['N']	[14]
15	(	O	['N']	[15]
16	3	O	['N']	[16]
17	)	O	['N']	[17]
18	,	O	['N']	[18]
19	cellulitis	O	['N']	[19]
20	(	O	['N']	[20]
21	2	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	disseminated	O	['N']	[24]
25	herpes	O	['N']	[25]
26	zoster	O	['N']	[26]
27	(	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	,	O	['N']	[30]
31	probable	O	['N']	[31]
32	TB	O	['N']	[32]
33	liver	O	['N']	[33]
34	(	O	['N']	[34]
35	1	O	['N']	[35]
36	)	O	['N']	[36]
37	,	O	['N']	[37]
38	abdominal	O	['N']	[38]
39	sepsis	O	['N']	[39]
40	(	O	['N']	[40]
41	1	O	['N']	[41]
42	)	O	['N']	[42]
43	,	O	['N']	[43]
44	mycotic	O	['N']	[44]
45	aneurysm	O	['N']	[45]
46	(	O	['N']	[46]
47	1	O	['N']	[47]
48	)	O	['N']	[48]
49	and	O	['N']	[49]
50	gastroenteritis	B-Adverse_Effect	['N']	[50]
51	(	O	['N']	[51]
52	1	O	['N']	[52]
53	)	O	['N']	[53]
54	.	O	['N']	[54]
#1187
0	Posterior	B	['N']	[0]
1	leukoencephalopathy	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	cisplatin	O	['N']	[3]
4	,	O	['N']	[4]
5	bleomycin	B-Drug	['Causes']	[1]
6	and	O	['N']	[6]
7	vinblastine	O	['N']	[7]
8	therapy	O	['N']	[8]
9	for	O	['N']	[9]
10	germ	O	['N']	[10]
11	cell	O	['N']	[11]
12	tumor	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	ovary	O	['N']	[15]
16	.	O	['N']	[16]
#1188
0	Linear	B	['N']	[0]
1	IgA	I	['N']	[1]
2	bullous	I	['N']	[2]
3	dermatosis	I-Adverse_Effect	['N']	[3]
4	occurring	O	['N']	[4]
5	after	O	['N']	[5]
6	carbamazepine	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#1189
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	myoclonus	B-Adverse_Effect	['N']	[5]
6	induced	O	['N']	[6]
7	by	O	['N']	[7]
8	quetiapine	B-Drug	['Causes']	[5]
9	.	O	['N']	[9]
#1190
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	large	B	['N']	[3]
4	intramural	I	['N']	[4]
5	esophageal	I	['N']	[5]
6	hematoma	I-Adverse_Effect	['N']	[6]
7	as	O	['N']	[7]
8	a	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	heparin	B-Drug	['Causes']	[6]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#1191
0	Gabapentin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	mood	B	['N']	[3]
4	changes	I-Adverse_Effect	['N']	[4]
5	with	O	['N']	[5]
6	hypomanic	O	['N']	[6]
7	features	O	['N']	[7]
8	in	O	['N']	[8]
9	adults	O	['N']	[9]
10	.	O	['N']	[10]
#1192
0	We	O	['N']	[0]
1	further	O	['N']	[1]
2	used	O	['N']	[2]
3	immunohistochemistry	O	['N']	[3]
4	(	O	['N']	[4]
5	IHC	O	['N']	[5]
6	)	O	['N']	[6]
7	to	O	['N']	[7]
8	examine	O	['N']	[8]
9	the	O	['N']	[9]
10	relative	O	['N']	[10]
11	role	O	['N']	[11]
12	of	O	['N']	[12]
13	platelet	O	['N']	[13]
14	-	O	['N']	[14]
15	derived	O	['N']	[15]
16	growth	O	['N']	[16]
17	factor	O	['N']	[17]
18	-	O	['N']	[18]
19	B	O	['N']	[19]
20	(	O	['N']	[20]
21	PDGF	O	['N']	[21]
22	-	O	['N']	[22]
23	B	O	['N']	[23]
24	)	O	['N']	[24]
25	,	O	['N']	[25]
26	insulin	O	['N']	[26]
27	-	O	['N']	[27]
28	like	O	['N']	[28]
29	growth	O	['N']	[29]
30	factor	O	['N']	[30]
31	I	O	['N']	[31]
32	(	O	['N']	[32]
33	IGF	O	['N']	[33]
34	-	O	['N']	[34]
35	I	O	['N']	[35]
36	)	O	['N']	[36]
37	,	O	['N']	[37]
38	transforming	O	['N']	[38]
39	growth	O	['N']	[39]
40	factor	O	['N']	[40]
41	-	O	['N']	[41]
42	beta1	O	['N']	[42]
43	(	O	['N']	[43]
44	TGF	O	['N']	[44]
45	-	O	['N']	[45]
46	beta1	O	['N']	[46]
47	)	O	['N']	[47]
48	and	O	['N']	[48]
49	cyclooxygenase-2	O	['N']	[49]
50	(	O	['N']	[50]
51	COX-2	O	['N']	[51]
52	)	O	['N']	[52]
53	in	O	['N']	[53]
54	the	O	['N']	[54]
55	pathogenesis	O	['N']	[55]
56	of	O	['N']	[56]
57	BCNU	B-Drug	['Causes']	[61]
58	-	O	['N']	[58]
59	related	O	['N']	[59]
60	pulmonary	B	['N']	[60]
61	fibrosis	I-Adverse_Effect	['N']	[61]
62	.	O	['N']	[62]
#1193
0	With	O	['N']	[0]
1	the	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	optical	O	['N']	[4]
5	coherence	O	['N']	[5]
6	tomography	O	['N']	[6]
7	(	O	['N']	[7]
8	OCT	O	['N']	[8]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	two	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	IFN	B-Drug	['Causes']	[17]
15	-	O	['N']	[15]
16	associated	O	['N']	[16]
17	retinopathy	B-Adverse_Effect	['N']	[17]
18	who	O	['N']	[18]
19	had	O	['N']	[19]
20	developed	O	['N']	[20]
21	macular	O	['N']	[21]
22	edema	O	['N']	[22]
23	and	O	['N']	[23]
24	reduced	O	['N']	[24]
25	visual	O	['N']	[25]
26	acuity	O	['N']	[26]
27	during	O	['N']	[27]
28	the	O	['N']	[28]
29	clinical	O	['N']	[29]
30	course	O	['N']	[30]
31	of	O	['N']	[31]
32	IFN	O	['N']	[32]
33	therapy	O	['N']	[33]
34	were	O	['N']	[34]
35	observed	O	['N']	[35]
36	.	O	['N']	[36]
#1194
0	Soon	O	['N']	[0]
1	after	O	['N']	[1]
2	introduction	O	['N']	[2]
3	of	O	['N']	[3]
4	insulin	B-Drug	['Causes']	[17]
5	therapy	O	['N']	[5]
6	,	O	['N']	[6]
7	she	O	['N']	[7]
8	developed	O	['N']	[8]
9	severe	O	['N']	[9]
10	anasarca	O	['N']	[10]
11	,	O	['N']	[11]
12	including	O	['N']	[12]
13	marked	O	['N']	[13]
14	peripheral	O	['N']	[14]
15	oedema	O	['N']	[15]
16	,	O	['N']	[16]
17	ascites	B-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	pleural	O	['N']	[19]
20	effusion	O	['N']	[20]
21	.	O	['N']	[21]
#1195
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	adding	O	['N']	[2]
3	this	O	['N']	[3]
4	side	O	['N']	[4]
5	effect	O	['N']	[5]
6	to	O	['N']	[6]
7	the	O	['N']	[7]
8	list	O	['N']	[8]
9	of	O	['N']	[9]
10	untoward	O	['N']	[10]
11	effects	O	['N']	[11]
12	of	O	['N']	[12]
13	lidocaine	B-Drug	['Causes']	[22]
14	and	O	['N']	[14]
15	to	O	['N']	[15]
16	the	O	['N']	[16]
17	differential	O	['N']	[17]
18	diagnosis	O	['N']	[18]
19	of	O	['N']	[19]
20	fixed	O	['N']	[20]
21	dilated	B	['N']	[21]
22	pupils	I-Adverse_Effect	['N']	[22]
23	in	O	['N']	[23]
24	neonates	O	['N']	[24]
25	treated	O	['N']	[25]
26	with	O	['N']	[26]
27	lidocaine	O	['N']	[27]
28	.	O	['N']	[28]
#1196
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[26]
15	with	O	['N']	[15]
16	folinic	O	['N']	[16]
17	acid	O	['N']	[17]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	B	['N']	[24]
25	shower	I	['N']	[25]
26	syndrome	I-Adverse_Effect	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#1197
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	These	O	['N']	[2]
3	results	O	['N']	[3]
4	suggest	O	['N']	[4]
5	that	O	['N']	[5]
6	clozapine	B-Drug	['Causes']	[31]
7	may	O	['N']	[7]
8	cause	O	['N']	[8]
9	TD	O	['N']	[9]
10	;	O	['N']	[10]
11	however	O	['N']	[11]
12	,	O	['N']	[12]
13	the	O	['N']	[13]
14	prevalence	O	['N']	[14]
15	is	O	['N']	[15]
16	low	O	['N']	[16]
17	and	O	['N']	[17]
18	the	O	['N']	[18]
19	severity	O	['N']	[19]
20	is	O	['N']	[20]
21	relatively	O	['N']	[21]
22	mild	O	['N']	[22]
23	,	O	['N']	[23]
24	with	O	['N']	[24]
25	no	O	['N']	[25]
26	or	O	['N']	[26]
27	mild	O	['N']	[27]
28	self	O	['N']	[28]
29	-	O	['N']	[29]
30	reported	O	['N']	[30]
31	discomfort	B-Adverse_Effect	['N']	[31]
32	.	O	['N']	[32]
#1198
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	5	O	['N']	[2]
3	patients	O	['N']	[3]
4	(	O	['N']	[4]
5	3	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	chronic	O	['N']	[8]
9	hepatitis	O	['N']	[9]
10	C	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	pegylated	O	['N']	[13]
14	interferon	O	['N']	[14]
15	alfa-2b	O	['N']	[15]
16	in	O	['N']	[16]
17	association	O	['N']	[17]
18	with	O	['N']	[18]
19	oral	O	['N']	[19]
20	ribavirin	B-Drug	['Causes']	[33]
21	and	O	['N']	[21]
22	two	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	chronic	O	['N']	[25]
26	myelocytic	O	['N']	[26]
27	leukemia	O	['N']	[27]
28	)	O	['N']	[28]
29	who	O	['N']	[29]
30	developed	O	['N']	[30]
31	local	B	['N']	[31]
32	cutaneous	I	['N']	[32]
33	reactions	I-Adverse_Effect	['N']	[33]
34	at	O	['N']	[34]
35	sites	O	['N']	[35]
36	of	O	['N']	[36]
37	injection	O	['N']	[37]
38	after	O	['N']	[38]
39	the	O	['N']	[39]
40	administration	O	['N']	[40]
41	of	O	['N']	[41]
42	weekly	O	['N']	[42]
43	subcutaneous	O	['N']	[43]
44	injections	O	['N']	[44]
45	of	O	['N']	[45]
46	pegylated	O	['N']	[46]
47	interferon	O	['N']	[47]
48	alfa-2b	O	['N']	[48]
49	at	O	['N']	[49]
50	different	O	['N']	[50]
51	doses	O	['N']	[51]
52	.	O	['N']	[52]
#1199
0	Temozolomide	B-Drug	['Causes']	[12]
1	was	O	['N']	[1]
2	restarted	O	['N']	[2]
3	2	O	['N']	[3]
4	months	O	['N']	[4]
5	later	O	['N']	[5]
6	;	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	again	O	['N']	[9]
10	developed	O	['N']	[10]
11	a	O	['N']	[11]
12	fever	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#1200
0	Sulfasalazine	B-Drug	['Causes']	[7]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hypersensitivity	O	['N']	[3]
4	syndrome	O	['N']	[4]
5	and	O	['N']	[5]
6	hemophagocytic	B	['N']	[6]
7	syndrome	I-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	reactivation	O	['N']	[10]
11	of	O	['N']	[11]
12	Epstein	O	['N']	[12]
13	-	O	['N']	[13]
14	Barr	O	['N']	[14]
15	virus	O	['N']	[15]
16	.	O	['N']	[16]
#1201
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[9]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	tonic	B	['N']	[6]
7	-	I	['N']	[7]
8	clonic	I	['N']	[8]
9	seizures	I-Adverse_Effect	['N']	[9]
10	managed	O	['N']	[10]
11	with	O	['N']	[11]
12	valproate	O	['N']	[12]
13	:	O	['N']	[13]
14	implications	O	['N']	[14]
15	for	O	['N']	[15]
16	clinical	O	['N']	[16]
17	care	O	['N']	[17]
18	.	O	['N']	[18]
#1202
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	B	['N']	[5]
6	generalized	I	['N']	[6]
7	exanthematous	I	['N']	[7]
8	pustulosis	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	AGEP	O	['N']	[10]
11	)	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	50-year	O	['N']	[14]
15	-	O	['N']	[15]
16	old	O	['N']	[16]
17	woman	O	['N']	[17]
18	that	O	['N']	[18]
19	was	O	['N']	[19]
20	attributed	O	['N']	[20]
21	to	O	['N']	[21]
22	the	O	['N']	[22]
23	ingestion	O	['N']	[23]
24	of	O	['N']	[24]
25	nimesulide	B-Drug	['Causes']	[8]
26	.	O	['N']	[26]
#1203
0	Intravenous	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	levodopa	O	['N']	[3]
4	ameliorated	O	['N']	[4]
5	a	O	['N']	[5]
6	refractory	O	['N']	[6]
7	akathisia	B-Adverse_Effect	['N']	[7]
8	case	O	['N']	[8]
9	induced	O	['N']	[9]
10	by	O	['N']	[10]
11	interferon	B	['N']	[11]
12	-	I	['N']	[12]
13	alpha	I-Drug	['Causes']	[7]
14	.	O	['N']	[14]
#1204
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	AILD	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	an	O	['N']	[7]
8	80-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	male	O	['N']	[11]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	a	O	['N']	[15]
16	generalized	O	['N']	[16]
17	pruritic	O	['N']	[17]
18	maculopapular	O	['N']	[18]
19	eruption	O	['N']	[19]
20	and	O	['N']	[20]
21	fever	O	['N']	[21]
22	following	O	['N']	[22]
23	doxycycline	B-Drug	['Causes']	[5]
24	administration	O	['N']	[24]
25	.	O	['N']	[25]
#1205
0	Massive	O	['N']	[0]
1	CBZ	B-Drug	['Causes']	[19]
2	OD	O	['N']	[2]
3	may	O	['N']	[3]
4	produce	O	['N']	[4]
5	a	O	['N']	[5]
6	reversible	O	['N']	[6]
7	encephalopathy	O	['N']	[7]
8	that	O	['N']	[8]
9	includes	O	['N']	[9]
10	cortical	O	['N']	[10]
11	hyperexcitability	O	['N']	[11]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	profound	B	['N']	[14]
15	burst	I	['N']	[15]
16	-	I	['N']	[16]
17	suppression	I	['N']	[17]
18	EEG	I	['N']	[18]
19	pattern	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	cranial	O	['N']	[22]
23	nerve	O	['N']	[23]
24	areflexia	O	['N']	[24]
25	.	O	['N']	[25]
#1206
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	postural	O	['N']	[2]
3	challenge	O	['N']	[3]
4	test	O	['N']	[4]
5	after	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	isosorbide	B	['N']	[8]
9	dinitrate	I-Drug	['Dosage']	[12]
10	(	O	['N']	[10]
11	5	B	['N']	[11]
12	mg	I-Dose	['N']	[12]
13	)	O	['N']	[13]
14	,	O	['N']	[14]
15	blood	O	['N']	[15]
16	pressure	O	['N']	[16]
17	decreased	O	['N']	[17]
18	from	O	['N']	[18]
19	120/67	O	['N']	[19]
20	to	O	['N']	[20]
21	65/35	O	['N']	[21]
22	mmHg	O	['N']	[22]
23	,	O	['N']	[23]
24	followed	O	['N']	[24]
25	by	O	['N']	[25]
26	syncope	O	['N']	[26]
27	with	O	['N']	[27]
28	a	O	['N']	[28]
29	sudden	O	['N']	[29]
30	decrease	O	['N']	[30]
31	in	O	['N']	[31]
32	pulse	O	['N']	[32]
33	rate	O	['N']	[33]
34	from	O	['N']	[34]
35	85	O	['N']	[35]
36	to	O	['N']	[36]
37	60	O	['N']	[37]
38	beats	O	['N']	[38]
39	/	O	['N']	[39]
40	min	O	['N']	[40]
41	.	O	['N']	[41]
#1207
0	Pancreatitis	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	very	O	['N']	[3]
4	rare	O	['N']	[4]
5	adverse	O	['N']	[5]
6	effect	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	use	O	['N']	[10]
11	of	O	['N']	[11]
12	amiodarone	B-Drug	['Causes']	[22]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	only	O	['N']	[15]
16	four	O	['N']	[16]
17	cases	O	['N']	[17]
18	of	O	['N']	[18]
19	amiodarone	O	['N']	[19]
20	-	O	['N']	[20]
21	induced	O	['N']	[21]
22	pancreatitis	B-Adverse_Effect	['N']	[22]
23	have	O	['N']	[23]
24	been	O	['N']	[24]
25	reported	O	['N']	[25]
26	in	O	['N']	[26]
27	literature	O	['N']	[27]
28	.	O	['N']	[28]
#1208
0	Following	O	['N']	[0]
1	7	O	['N']	[1]
2	days	O	['N']	[2]
3	of	O	['N']	[3]
4	tigecycline	B-Drug	['Causes']	[16]
5	she	O	['N']	[5]
6	developed	O	['N']	[6]
7	severe	O	['N']	[7]
8	abdominal	O	['N']	[8]
9	pain	O	['N']	[9]
10	and	O	['N']	[10]
11	elevated	O	['N']	[11]
12	pancreatic	O	['N']	[12]
13	enzymes	O	['N']	[13]
14	suggesting	O	['N']	[14]
15	acute	B	['N']	[15]
16	pancreatitis	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#1209
0	A	O	['N']	[0]
1	61-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	clinical	O	['N']	[6]
7	lupus	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	with	O	['N']	[9]
10	positive	O	['N']	[10]
11	antinuclear	O	['N']	[11]
12	antibody	O	['N']	[12]
13	,	O	['N']	[13]
14	positive	O	['N']	[14]
15	lupus	O	['N']	[15]
16	erythematosus	O	['N']	[16]
17	(	O	['N']	[17]
18	LE	O	['N']	[18]
19	)	O	['N']	[19]
20	cell	O	['N']	[20]
21	preparation	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	diffuse	B	['N']	[24]
25	proliferative	I	['N']	[25]
26	glomerulonephritis	I-Adverse_Effect	['N']	[26]
27	following	O	['N']	[27]
28	26	O	['N']	[28]
29	months	O	['N']	[29]
30	of	O	['N']	[30]
31	procainamide	B-Drug	['Causes']	[26]
32	therapy	O	['N']	[32]
33	.	O	['N']	[33]
#1210
0	Thrombotic	B	['N']	[0]
1	microangiopathy	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	renal	O	['N']	[3]
4	failure	O	['N']	[4]
5	in	O	['N']	[5]
6	two	O	['N']	[6]
7	patients	O	['N']	[7]
8	undergoing	O	['N']	[8]
9	gemcitabine	B-Drug	['Causes']	[1]
10	chemotherapy	O	['N']	[10]
11	.	O	['N']	[11]
#1211
0	Drug	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	fever	B-Adverse_Effect	['N']	[3]
4	should	O	['N']	[4]
5	be	O	['N']	[5]
6	considered	O	['N']	[6]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	who	O	['N']	[9]
10	have	O	['N']	[10]
11	unexplained	O	['N']	[11]
12	high	O	['N']	[12]
13	temperatures	O	['N']	[13]
14	during	O	['N']	[14]
15	diltiazem	B-Drug	['Causes']	[3]
16	therapy	O	['N']	[16]
17	.	O	['N']	[17]
#1212
0	Multiple	O	['N']	[0]
1	myeloma	O	['N']	[1]
2	complicated	O	['N']	[2]
3	by	O	['N']	[3]
4	congestive	B	['N']	[4]
5	heart	I	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	following	O	['N']	[7]
8	first	O	['N']	[8]
9	administration	O	['N']	[9]
10	of	O	['N']	[10]
11	recombinant	B	['N']	[11]
12	alpha	I	['N']	[12]
13	-	I	['N']	[13]
14	interferon	I-Drug	['Causes']	[6]
15	.	O	['N']	[15]
#1213
0	Ovarian	B	['N']	[0]
1	endometrioid	I	['N']	[1]
2	carcinoma	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	endometriosis	O	['N']	[4]
5	developing	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	postmenopausal	O	['N']	[8]
9	breast	O	['N']	[9]
10	cancer	O	['N']	[10]
11	patient	O	['N']	[11]
12	during	O	['N']	[12]
13	tamoxifen	B-Drug	['Causes']	[2]
14	therapy	O	['N']	[14]
15	:	O	['N']	[15]
16	a	O	['N']	[16]
17	case	O	['N']	[17]
18	report	O	['N']	[18]
19	and	O	['N']	[19]
20	review	O	['N']	[20]
21	of	O	['N']	[21]
22	the	O	['N']	[22]
23	literature	O	['N']	[23]
24	.	O	['N']	[24]
#1214
0	When	O	['N']	[0]
1	SASP	O	['N']	[1]
2	was	O	['N']	[2]
3	changed	O	['N']	[3]
4	to	O	['N']	[4]
5	5-aminosalicylic	O	['N']	[5]
6	acid	O	['N']	[6]
7	(	O	['N']	[7]
8	5-ASA	B-Drug	['Causes']	[21]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	his	O	['N']	[11]
12	skin	O	['N']	[12]
13	eruptions	O	['N']	[13]
14	were	O	['N']	[14]
15	resolved	O	['N']	[15]
16	,	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	he	O	['N']	[19]
20	developed	O	['N']	[20]
21	weakness	B-Adverse_Effect	['N']	[21]
22	and	O	['N']	[22]
23	atrophy	O	['N']	[23]
24	in	O	['N']	[24]
25	his	O	['N']	[25]
26	right	O	['N']	[26]
27	arm	O	['N']	[27]
28	as	O	['N']	[28]
29	well	O	['N']	[29]
30	as	O	['N']	[30]
31	progressive	O	['N']	[31]
32	worsening	O	['N']	[32]
33	of	O	['N']	[33]
34	the	O	['N']	[34]
35	dysesthesia	O	['N']	[35]
36	in	O	['N']	[36]
37	his	O	['N']	[37]
38	legs	O	['N']	[38]
39	and	O	['N']	[39]
40	gait	O	['N']	[40]
41	disturbance	O	['N']	[41]
42	.	O	['N']	[42]
#1215
0	Cutaneous	B	['N']	[0]
1	reactions	I-Adverse_Effect	['N']	[1]
2	to	O	['N']	[2]
3	propylthiouracil	B-Drug	['Causes']	[1]
4	and	O	['N']	[4]
5	methimazole	O	['N']	[5]
6	occur	O	['N']	[6]
7	in	O	['N']	[7]
8	3%-5	O	['N']	[8]
9	%	O	['N']	[9]
10	of	O	['N']	[10]
11	adults	O	['N']	[11]
12	.	O	['N']	[12]
#1216
0	Neuroleptic	B	['N']	[0]
1	malignant	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	an	O	['N']	[4]
5	adolescent	O	['N']	[5]
6	receiving	O	['N']	[6]
7	olanzapine	B-Drug	['Causes']	[2]
8	-	O	['N']	[8]
9	lithium	O	['N']	[9]
10	combination	O	['N']	[10]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#1217
0	Diarrhoea	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	T	O	['N']	[2]
3	-	O	['N']	[3]
4	CD4	O	['N']	[4]
5	+	O	['N']	[5]
6	lymphopenia	O	['N']	[6]
7	and	O	['N']	[7]
8	bilateral	O	['N']	[8]
9	patchy	O	['N']	[9]
10	pulmonary	O	['N']	[10]
11	infiltrates	O	['N']	[11]
12	developed	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	male	O	['N']	[15]
16	60	O	['N']	[16]
17	yrs	O	['N']	[17]
18	of	O	['N']	[18]
19	age	O	['N']	[19]
20	,	O	['N']	[20]
21	who	O	['N']	[21]
22	was	O	['N']	[22]
23	treated	O	['N']	[23]
24	with	O	['N']	[24]
25	oxaliplatinum	O	['N']	[25]
26	and	O	['N']	[26]
27	5-fluorouracil	B-Drug	['Causes']	[0]
28	for	O	['N']	[28]
29	unresectable	O	['N']	[29]
30	rectum	O	['N']	[30]
31	carcinoma	O	['N']	[31]
32	.	O	['N']	[32]
#1218
0	Clostridium	B	['N']	[0]
1	difficile	I	['N']	[1]
2	toxin	I	['N']	[2]
3	-	I	['N']	[3]
4	induced	I	['N']	[4]
5	colitis	I-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	clindamycin	B	['N']	[9]
10	phosphate	I-Drug	['Causes']	[5]
11	vaginal	O	['N']	[11]
12	cream	O	['N']	[12]
13	.	O	['N']	[13]
#1219
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	Case	O	['N']	[2]
3	analysis	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	poly	O	['N']	[6]
7	-	O	['N']	[7]
8	drug	O	['N']	[8]
9	overdose	O	['N']	[9]
10	(	O	['N']	[10]
11	venlafaxine	O	['N']	[11]
12	,	O	['N']	[12]
13	topiramate	O	['N']	[13]
14	,	O	['N']	[14]
15	divalproex	O	['N']	[15]
16	sodium	O	['N']	[16]
17	,	O	['N']	[17]
18	risperidone	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	carbamazepine	B-Drug	['Causes']	[26]
22	)	O	['N']	[22]
23	presenting	O	['N']	[23]
24	with	O	['N']	[24]
25	mixed	O	['N']	[25]
26	SS	B-Adverse_Effect	['N']	[26]
27	/	O	['N']	[27]
28	NMS	O	['N']	[28]
29	features	O	['N']	[29]
30	and	O	['N']	[30]
31	whose	O	['N']	[31]
32	clinical	O	['N']	[32]
33	management	O	['N']	[33]
34	suggests	O	['N']	[34]
35	a	O	['N']	[35]
36	practical	O	['N']	[36]
37	algorithm	O	['N']	[37]
38	for	O	['N']	[38]
39	treatment	O	['N']	[39]
40	of	O	['N']	[40]
41	undifferentiated	O	['N']	[41]
42	SS	O	['N']	[42]
43	/	O	['N']	[43]
44	NMS	O	['N']	[44]
45	in	O	['N']	[45]
46	critical	O	['N']	[46]
47	care	O	['N']	[47]
48	settings	O	['N']	[48]
49	.	O	['N']	[49]
#1220
0	Nineteen	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	allergic	B	['N']	[3]
4	contact	I	['N']	[4]
5	dermatitis	I-Adverse_Effect	['N']	[5]
6	to	O	['N']	[6]
7	compound	O	['N']	[7]
8	tincture	O	['N']	[8]
9	of	O	['N']	[9]
10	benzoin	B-Drug	['Causes']	[5]
11	are	O	['N']	[11]
12	described	O	['N']	[12]
13	.	O	['N']	[13]
#1221
0	Increased	B	['N']	[0]
1	libido	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	woman	O	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	fluvoxamine	B-Drug	['Causes']	[1]
8	:	O	['N']	[8]
9	a	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	.	O	['N']	[12]
#1222
0	Protease	O	['N']	[0]
1	inhibitors	O	['N']	[1]
2	(	O	['N']	[2]
3	ritonavir	O	['N']	[3]
4	and	O	['N']	[4]
5	saquinavir	O	['N']	[5]
6	)	O	['N']	[6]
7	were	O	['N']	[7]
8	added	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	treatment	O	['N']	[11]
12	and	O	['N']	[12]
13	the	O	['N']	[13]
14	patient	O	['N']	[14]
15	developed	O	['N']	[15]
16	progressive	B	['N']	[16]
17	ataxia	I-Adverse_Effect	['N']	[17]
18	related	O	['N']	[18]
19	to	O	['N']	[19]
20	carbamazepine	B-Drug	['Causes']	[17]
21	toxicity	O	['N']	[21]
22	.	O	['N']	[22]
#1223
0	A	O	['N']	[0]
1	58-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	rheumatoid	O	['N']	[6]
7	arthritis	O	['N']	[7]
8	(	O	['N']	[8]
9	RA	O	['N']	[9]
10	)	O	['N']	[10]
11	developed	O	['N']	[11]
12	fever	B-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	skin	O	['N']	[14]
15	eruptions	O	['N']	[15]
16	,	O	['N']	[16]
17	leukocytopenia	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	thrombocytopenia	O	['N']	[20]
21	,	O	['N']	[21]
22	3	O	['N']	[22]
23	weeks	O	['N']	[23]
24	after	O	['N']	[24]
25	treatment	O	['N']	[25]
26	with	O	['N']	[26]
27	sulfasalazine	B-Drug	['Causes']	[12]
28	.	O	['N']	[28]
#1224
0	Recurrent	B	['N']	[0]
1	hypotension	I-Adverse_Effect	['N']	[1]
2	immediately	O	['N']	[2]
3	after	O	['N']	[3]
4	seizures	O	['N']	[4]
5	in	O	['N']	[5]
6	nortriptyline	B-Drug	['Causes']	[1]
7	overdose	O	['N']	[7]
8	.	O	['N']	[8]
#1225
0	Livedo	B	['N']	[0]
1	reticularis	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	interferon	B	['N']	[4]
5	alpha	I-Drug	['Causes']	[1]
6	therapy	O	['N']	[6]
7	in	O	['N']	[7]
8	two	O	['N']	[8]
9	melanoma	O	['N']	[9]
10	patients	O	['N']	[10]
11	.	O	['N']	[11]
#1226
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	longitudinal	O	['N']	[4]
5	case	O	['N']	[5]
6	study	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	a	O	['N']	[11]
12	history	O	['N']	[12]
13	of	O	['N']	[13]
14	bipolar	O	['N']	[14]
15	affective	O	['N']	[15]
16	disorder	O	['N']	[16]
17	in	O	['N']	[17]
18	which	O	['N']	[18]
19	L	B	['N']	[19]
20	-	I	['N']	[20]
21	dopa	I-Drug	['Causes']	[27]
22	shortened	B	['N']	[22]
23	the	I	['N']	[23]
24	manic	I	['N']	[24]
25	-	I	['N']	[25]
26	depressive	I	['N']	[26]
27	cycle	I-Adverse_Effect	['N']	[27]
28	length	O	['N']	[28]
29	when	O	['N']	[29]
30	administered	O	['N']	[30]
31	in	O	['N']	[31]
32	a	O	['N']	[32]
33	double	O	['N']	[33]
34	-	O	['N']	[34]
35	blind	O	['N']	[35]
36	trial	O	['N']	[36]
37	.	O	['N']	[37]
#1227
0	While	O	['N']	[0]
1	undergoing	O	['N']	[1]
2	treatment	O	['N']	[2]
3	with	O	['N']	[3]
4	albendazole	B-Drug	['Causes']	[9]
5	,	O	['N']	[5]
6	he	O	['N']	[6]
7	developed	O	['N']	[7]
8	worsening	B	['N']	[8]
9	diarrhea	I-Adverse_Effect	['N']	[9]
10	with	O	['N']	[10]
11	abdominal	O	['N']	[11]
12	pain	O	['N']	[12]
13	and	O	['N']	[13]
14	fever	O	['N']	[14]
15	.	O	['N']	[15]
#1228
0	A	O	['N']	[0]
1	small	O	['N']	[1]
2	initial	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	prazosin	B-Drug	['Dosage']	[11]
6	ranging	O	['N']	[6]
7	from	O	['N']	[7]
8	0.5	B	['N']	[8]
9	to	I	['N']	[9]
10	1	I	['N']	[10]
11	mg	I-Dose	['N']	[11]
12	has	O	['N']	[12]
13	been	O	['N']	[13]
14	recommended	O	['N']	[14]
15	to	O	['N']	[15]
16	avoid	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	-	O	['N']	[19]
20	dose	O	['N']	[20]
21	phenomenon	O	['N']	[21]
22	characterized	O	['N']	[22]
23	by	O	['N']	[23]
24	a	O	['N']	[24]
25	sudden	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	O	['N']	[27]
28	drop	O	['N']	[28]
29	in	O	['N']	[29]
30	blood	O	['N']	[30]
31	pressure	O	['N']	[31]
32	after	O	['N']	[32]
33	the	O	['N']	[33]
34	administration	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	first	O	['N']	[37]
38	dose	O	['N']	[38]
39	of	O	['N']	[39]
40	prazosin	O	['N']	[40]
41	.	O	['N']	[41]
#1229
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Amphotericin	B	['N']	[2]
3	B	I-Drug	['Causes']	[12]
4	seems	O	['N']	[4]
5	to	O	['N']	[5]
6	be	O	['N']	[6]
7	the	O	['N']	[7]
8	probable	O	['N']	[8]
9	cause	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	seizures	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#1230
0	Except	O	['N']	[0]
1	hypothyroidism	B-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	radioiodine	B-Drug	['Causes']	[1]
4	treatment	O	['N']	[4]
5	(	O	['N']	[5]
6	euthyroid	O	['N']	[6]
7	under	O	['N']	[7]
8	substitutional	O	['N']	[8]
9	therapy	O	['N']	[9]
10	)	O	['N']	[10]
11	,	O	['N']	[11]
12	she	O	['N']	[12]
13	suffered	O	['N']	[13]
14	from	O	['N']	[14]
15	no	O	['N']	[15]
16	other	O	['N']	[16]
17	diseases	O	['N']	[17]
18	.	O	['N']	[18]
#1231
0	Thirty	O	['N']	[0]
1	-	O	['N']	[1]
2	six	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	AL	O	['N']	[5]
6	received	O	['N']	[6]
7	,	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	three	O	['N']	[10]
11	-	O	['N']	[11]
12	month	O	['N']	[12]
13	period	O	['N']	[13]
14	,	O	['N']	[14]
15	51	O	['N']	[15]
16	cycles	O	['N']	[16]
17	of	O	['N']	[17]
18	combined	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	which	O	['N']	[20]
21	included	O	['N']	[21]
22	,	O	['N']	[22]
23	in	O	['N']	[23]
24	all	O	['N']	[24]
25	of	O	['N']	[25]
26	them	O	['N']	[26]
27	,	O	['N']	[27]
28	cytosine	B	['N']	[28]
29	arabinoside	I-Drug	['Causes']	[48]
30	(	O	['N']	[30]
31	ARA	O	['N']	[31]
32	-	O	['N']	[32]
33	C	O	['N']	[33]
34	)	O	['N']	[34]
35	;	O	['N']	[35]
36	among	O	['N']	[36]
37	them	O	['N']	[37]
38	,	O	['N']	[38]
39	along	O	['N']	[39]
40	with	O	['N']	[40]
41	myelosuppression	O	['N']	[41]
42	,	O	['N']	[42]
43	five	O	['N']	[43]
44	experienced	O	['N']	[44]
45	fever	O	['N']	[45]
46	,	O	['N']	[46]
47	infectious	B	['N']	[47]
48	complications	I-Adverse_Effect	['N']	[48]
49	,	O	['N']	[49]
50	gastrointestinal	O	['N']	[50]
51	tract	O	['N']	[51]
52	symptoms	O	['N']	[52]
53	and	O	['N']	[53]
54	severe	O	['N']	[54]
55	myalgias	O	['N']	[55]
56	.	O	['N']	[56]
#1232
0	Protamine	B	['N']	[0]
1	allergy	I-Adverse_Effect	['N']	[1]
2	as	O	['N']	[2]
3	a	O	['N']	[3]
4	complication	O	['N']	[4]
5	of	O	['N']	[5]
6	insulin	B-Drug	['Causes']	[1]
7	hypersensitivity	O	['N']	[7]
8	:	O	['N']	[8]
9	A	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	.	O	['N']	[12]
#1233
0	Acute	B	['N']	[0]
1	renal	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	most	O	['N']	[3]
4	likely	O	['N']	[4]
5	was	O	['N']	[5]
6	secondary	O	['N']	[6]
7	to	O	['N']	[7]
8	the	O	['N']	[8]
9	nephrotoxic	O	['N']	[9]
10	effect	O	['N']	[10]
11	of	O	['N']	[11]
12	captopril	B-Drug	['Causes']	[2]
13	on	O	['N']	[13]
14	chronically	O	['N']	[14]
15	hypoperfused	O	['N']	[15]
16	kidneys	O	['N']	[16]
17	.	O	['N']	[17]
#1234
0	Enalapril	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	anemia	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	kidney	O	['N']	[6]
7	transplant	O	['N']	[7]
8	recipients	O	['N']	[8]
9	.	O	['N']	[9]
#1235
0	Pulmonary	B	['N']	[0]
1	fibrosis	I-Adverse_Effect	['N']	[1]
2	subsequent	O	['N']	[2]
3	to	O	['N']	[3]
4	high	O	['N']	[4]
5	doses	O	['N']	[5]
6	of	O	['N']	[6]
7	CCNU	B-Drug	['Causes']	[1]
8	for	O	['N']	[8]
9	chronic	O	['N']	[9]
10	myeloid	O	['N']	[10]
11	leukemia	O	['N']	[11]
12	.	O	['N']	[12]
#1236
0	Though	O	['N']	[0]
1	physicians	O	['N']	[1]
2	treating	O	['N']	[2]
3	large	O	['N']	[3]
4	populations	O	['N']	[4]
5	of	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	HIV	O	['N']	[8]
9	are	O	['N']	[9]
10	well	O	['N']	[10]
11	aware	O	['N']	[11]
12	of	O	['N']	[12]
13	this	O	['N']	[13]
14	complication	O	['N']	[14]
15	,	O	['N']	[15]
16	only	O	['N']	[16]
17	one	O	['N']	[17]
18	other	O	['N']	[18]
19	report	O	['N']	[19]
20	of	O	['N']	[20]
21	nevirapine	B-Drug	['Causes']	[24]
22	-	O	['N']	[22]
23	associated	O	['N']	[23]
24	SJS	B-Adverse_Effect	['N']	[24]
25	has	O	['N']	[25]
26	been	O	['N']	[26]
27	documented	O	['N']	[27]
28	in	O	['N']	[28]
29	the	O	['N']	[29]
30	dermatology	O	['N']	[30]
31	literature	O	['N']	[31]
32	.	O	['N']	[32]
#1237
0	After	O	['N']	[0]
1	an	O	['N']	[1]
2	extensive	O	['N']	[2]
3	review	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	literature	O	['N']	[6]
7	,	O	['N']	[7]
8	we	O	['N']	[8]
9	believe	O	['N']	[9]
10	that	O	['N']	[10]
11	this	O	['N']	[11]
12	is	O	['N']	[12]
13	the	O	['N']	[13]
14	first	O	['N']	[14]
15	communication	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	successful	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	amiodarone	O	['N']	[21]
22	to	O	['N']	[22]
23	control	O	['N']	[23]
24	hyperthyroidism	O	['N']	[24]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	patient	O	['N']	[27]
28	with	O	['N']	[28]
29	PTU	B-Drug	['Causes']	[33]
30	-	O	['N']	[30]
31	induced	O	['N']	[31]
32	fulminant	B	['N']	[32]
33	hepatitis	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#1238
0	Acute	B	['N']	[0]
1	asthma	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	sustained	O	['N']	[4]
5	-	O	['N']	[5]
6	release	O	['N']	[6]
7	verapamil	B-Drug	['Causes']	[1]
8	.	O	['N']	[8]
#1239
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Graves	B	['N']	[5]
6	'	I	['N']	[6]
7	hyperthyroidism	I-Adverse_Effect	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	long	O	['N']	[10]
11	-	O	['N']	[11]
12	term	O	['N']	[12]
13	interferon	O	['N']	[13]
14	(	O	['N']	[14]
15	IFN	B-Drug	['Causes']	[7]
16	)	O	['N']	[16]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#1240
0	Cholelithiasis	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	thrombosis	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	central	O	['N']	[5]
6	retinal	O	['N']	[6]
7	vein	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	renal	O	['N']	[10]
11	transplant	O	['N']	[11]
12	recipient	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	cyclosporin	B-Drug	['Causes']	[0]
16	.	O	['N']	[16]
#1241
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	study	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	report	O	['N']	[5]
6	on	O	['N']	[6]
7	three	O	['N']	[7]
8	individual	O	['N']	[8]
9	patients	O	['N']	[9]
10	who	O	['N']	[10]
11	received	O	['N']	[11]
12	BTX	B	['N']	[12]
13	-	I	['N']	[13]
14	B	I-Drug	['Causes']	[24]
15	and	O	['N']	[15]
16	who	O	['N']	[16]
17	subsequently	O	['N']	[17]
18	developed	O	['N']	[18]
19	parasympathetic	B	['N']	[19]
20	dysfunction	I	['N']	[20]
21	of	I	['N']	[21]
22	the	I	['N']	[22]
23	visual	I	['N']	[23]
24	system	I-Adverse_Effect	['N']	[24]
25	after	O	['N']	[25]
26	injections	O	['N']	[26]
27	of	O	['N']	[27]
28	BTX	O	['N']	[28]
29	-	O	['N']	[29]
30	B	O	['N']	[30]
31	at	O	['N']	[31]
32	remote	O	['N']	[32]
33	sites	O	['N']	[33]
34	.	O	['N']	[34]
#1242
0	Ballistic	O	['N']	[0]
1	movements	O	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	ischemic	B	['N']	[4]
5	infarcts	I-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	intravenous	O	['N']	[7]
8	heroin	B-Drug	['Causes']	[5]
9	overdose	O	['N']	[9]
10	:	O	['N']	[10]
11	report	O	['N']	[11]
12	of	O	['N']	[12]
13	two	O	['N']	[13]
14	cases	O	['N']	[14]
15	.	O	['N']	[15]
#1243
0	An	O	['N']	[0]
1	83-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	receiving	O	['N']	[5]
6	glipizide	B-Drug	['Causes']	[12]
7	10	O	['N']	[7]
8	mg	O	['N']	[8]
9	bid	O	['N']	[9]
10	developed	O	['N']	[10]
11	symptomatic	B	['N']	[11]
12	hypoglycemia	I-Adverse_Effect	['N']	[12]
13	within	O	['N']	[13]
14	three	O	['N']	[14]
15	days	O	['N']	[15]
16	of	O	['N']	[16]
17	adding	O	['N']	[17]
18	trimethoprim	O	['N']	[18]
19	/	O	['N']	[19]
20	sulfamethoxazole	O	['N']	[20]
21	(	O	['N']	[21]
22	TMP	O	['N']	[22]
23	/	O	['N']	[23]
24	SMX	O	['N']	[24]
25	)	O	['N']	[25]
26	to	O	['N']	[26]
27	his	O	['N']	[27]
28	regimen	O	['N']	[28]
29	.	O	['N']	[29]
#1244
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	received	O	['N']	[2]
3	respectively	O	['N']	[3]
4	190	O	['N']	[4]
5	mg	O	['N']	[5]
6	,	O	['N']	[6]
7	175	O	['N']	[7]
8	mg	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	196	O	['N']	[11]
12	mg	O	['N']	[12]
13	of	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[19]
15	and	O	['N']	[15]
16	developed	O	['N']	[16]
17	bilateral	B	['N']	[17]
18	pulmonary	I	['N']	[18]
19	infiltrates	I-Adverse_Effect	['N']	[19]
20	without	O	['N']	[20]
21	evidence	O	['N']	[21]
22	of	O	['N']	[22]
23	peripheral	O	['N']	[23]
24	blood	O	['N']	[24]
25	eosinophilia	O	['N']	[25]
26	.	O	['N']	[26]
#1245
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	experienced	O	['N']	[2]
3	hallucinations	O	['N']	[3]
4	,	O	['N']	[4]
5	agitation	O	['N']	[5]
6	,	O	['N']	[6]
7	vomiting	O	['N']	[7]
8	,	O	['N']	[8]
9	tachycardia	O	['N']	[9]
10	and	O	['N']	[10]
11	seizures	O	['N']	[11]
12	after	O	['N']	[12]
13	ingestion	O	['N']	[13]
14	of	O	['N']	[14]
15	1050	O	['N']	[15]
16	(	O	['N']	[16]
17	48	B	['N']	[17]
18	mg	I	['N']	[18]
19	/	I	['N']	[19]
20	kg	I-Dose	['N']	[20]
21	)	O	['N']	[21]
22	of	O	['N']	[22]
23	extended	O	['N']	[23]
24	-	O	['N']	[24]
25	release	O	['N']	[25]
26	bupropion	B-Drug	['Dosage']	[20]
27	.	O	['N']	[27]
#1246
0	DIAGNOSIS	O	['N']	[0]
1	:	O	['N']	[1]
2	Severe	O	['N']	[2]
3	temozolomide	B-Drug	['Causes']	[25]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	immunosuppression	O	['N']	[6]
7	,	O	['N']	[7]
8	exacerbated	O	['N']	[8]
9	by	O	['N']	[9]
10	corticosteroids	O	['N']	[10]
11	,	O	['N']	[11]
12	with	O	['N']	[12]
13	profound	O	['N']	[13]
14	T	O	['N']	[14]
15	-	O	['N']	[15]
16	cell	O	['N']	[16]
17	lymphocytopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	simultaneous	O	['N']	[19]
20	opportunistic	O	['N']	[20]
21	infections	B	['N']	[21]
22	with	I	['N']	[22]
23	Pneumocystis	I	['N']	[23]
24	jiroveci	I	['N']	[24]
25	pneumonia	I-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	brain	O	['N']	[27]
28	abscess	O	['N']	[28]
29	with	O	['N']	[29]
30	Listeria	O	['N']	[30]
31	monocytogenes	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	cutaneous	O	['N']	[34]
35	Kaposi	O	['N']	[35]
36	's	O	['N']	[36]
37	sarcoma	O	['N']	[37]
38	.	O	['N']	[38]
#1247
0	Severe	B	['N']	[0]
1	hemolytic	I	['N']	[1]
2	uremic	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	an	O	['N']	[5]
6	advanced	O	['N']	[6]
7	ovarian	O	['N']	[7]
8	cancer	O	['N']	[8]
9	patient	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	carboplatin	O	['N']	[12]
13	and	O	['N']	[13]
14	gemcitabine	B-Drug	['Causes']	[3]
15	.	O	['N']	[15]
#1248
0	Alveolar	B	['N']	[0]
1	-	I	['N']	[1]
2	interstitial	I	['N']	[2]
3	pneumopathy	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	gold	B-Drug	['Causes']	[3]
6	-	O	['N']	[6]
7	salts	O	['N']	[7]
8	compounds	O	['N']	[8]
9	administration	O	['N']	[9]
10	,	O	['N']	[10]
11	requiring	O	['N']	[11]
12	mechanical	O	['N']	[12]
13	ventilation	O	['N']	[13]
14	.	O	['N']	[14]
#1249
0	The	O	['N']	[0]
1	ocular	B	['N']	[1]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	of	O	['N']	[3]
4	DCF	B-Drug	['Causes']	[2]
5	,	O	['N']	[5]
6	previously	O	['N']	[6]
7	described	O	['N']	[7]
8	as	O	['N']	[8]
9	conjunctivitis	O	['N']	[9]
10	,	O	['N']	[10]
11	appears	O	['N']	[11]
12	to	O	['N']	[12]
13	be	O	['N']	[13]
14	a	O	['N']	[14]
15	keratitis	O	['N']	[15]
16	of	O	['N']	[16]
17	moderate	O	['N']	[17]
18	severity	O	['N']	[18]
19	which	O	['N']	[19]
20	requires	O	['N']	[20]
21	further	O	['N']	[21]
22	study	O	['N']	[22]
23	.	O	['N']	[23]
#1250
0	The	O	['N']	[0]
1	results	O	['N']	[1]
2	clearly	O	['N']	[2]
3	demonstrate	O	['N']	[3]
4	that	O	['N']	[4]
5	CPH82	B-Drug	['Causes']	[25]
6	was	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	suppression	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	endogeneous	O	['N']	[12]
13	production	O	['N']	[13]
14	of	O	['N']	[14]
15	ACTH	O	['N']	[15]
16	and	O	['N']	[16]
17	cortisol	O	['N']	[17]
18	with	O	['N']	[18]
19	a	O	['N']	[19]
20	concomitant	O	['N']	[20]
21	paradoxical	O	['N']	[21]
22	picture	O	['N']	[22]
23	of	O	['N']	[23]
24	clinical	O	['N']	[24]
25	hypercortisolism	B-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#1251
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	polymorphic	B	['N']	[3]
4	ventricular	I	['N']	[4]
5	tachycardia	I-Adverse_Effect	['N']	[5]
6	induced	O	['N']	[6]
7	by	O	['N']	[7]
8	the	O	['N']	[8]
9	administration	O	['N']	[9]
10	of	O	['N']	[10]
11	verapamil	B-Drug	['Causes']	[5]
12	against	O	['N']	[12]
13	paroxysmal	O	['N']	[13]
14	supraventricular	O	['N']	[14]
15	tachycardia	O	['N']	[15]
16	.	O	['N']	[16]
#1252
0	Rapid	O	['N']	[0]
1	resolution	O	['N']	[1]
2	of	O	['N']	[2]
3	topiramate	O	['N']	[3]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	angle	B	['N']	[6]
7	-	I	['N']	[7]
8	closure	I	['N']	[8]
9	glaucoma	I-Adverse_Effect	['N']	[9]
10	with	O	['N']	[10]
11	methylprednisolone	B-Drug	['Causes']	[9]
12	and	O	['N']	[12]
13	mannitol	O	['N']	[13]
14	.	O	['N']	[14]
#1253
0	Biomicroscopy	O	['N']	[0]
1	revealed	O	['N']	[1]
2	amiodarone	B-Drug	['Causes']	[4]
3	corneal	B	['N']	[3]
4	deposits	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1254
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	present	O	['N']	[2]
3	the	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	woman	O	['N']	[7]
8	who	O	['N']	[8]
9	received	O	['N']	[9]
10	high	O	['N']	[10]
11	doses	O	['N']	[11]
12	of	O	['N']	[12]
13	methylprednisolone	B-Drug	['Causes']	[33]
14	(	O	['N']	[14]
15	1	O	['N']	[15]
16	g	O	['N']	[16]
17	iv	O	['N']	[17]
18	daily	O	['N']	[18]
19	)	O	['N']	[19]
20	for	O	['N']	[20]
21	active	O	['N']	[21]
22	Graves	O	['N']	[22]
23	'	O	['N']	[23]
24	ophthalmopathy	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	developed	O	['N']	[27]
28	severe	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	followed	O	['N']	[30]
31	by	O	['N']	[31]
32	myocardial	B	['N']	[32]
33	infarction	I-Adverse_Effect	['N']	[33]
34	on	O	['N']	[34]
35	the	O	['N']	[35]
36	fifth	O	['N']	[36]
37	day	O	['N']	[37]
38	of	O	['N']	[38]
39	treatment	O	['N']	[39]
40	.	O	['N']	[40]
#1255
0	Due	O	['N']	[0]
1	to	O	['N']	[1]
2	discomfort	O	['N']	[2]
3	,	O	['N']	[3]
4	diplopia	O	['N']	[4]
5	and	O	['N']	[5]
6	lagophthalmos	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	haematoma	O	['N']	[9]
10	necessitated	O	['N']	[10]
11	suspension	O	['N']	[11]
12	of	O	['N']	[12]
13	warfarin	B-Drug	['Causes']	[6]
14	therapy	O	['N']	[14]
15	and	O	['N']	[15]
16	a	O	['N']	[16]
17	surgical	O	['N']	[17]
18	evacuation	O	['N']	[18]
19	.	O	['N']	[19]
#1256
0	This	O	['N']	[0]
1	was	O	['N']	[1]
2	accepted	O	['N']	[2]
3	as	O	['N']	[3]
4	evidence	O	['N']	[4]
5	for	O	['N']	[5]
6	propranolol	B-Drug	['Causes']	[13]
7	being	O	['N']	[7]
8	the	O	['N']	[8]
9	cause	O	['N']	[9]
10	of	O	['N']	[10]
11	this	O	['N']	[11]
12	conduction	B	['N']	[12]
13	disorder	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#1257
0	Gangrene	B-Adverse_Effect	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	fingertips	O	['N']	[3]
4	after	O	['N']	[4]
5	bleomycin	O	['N']	[5]
6	and	O	['N']	[6]
7	methotrexate	B-Drug	['Causes']	[0]
8	.	O	['N']	[8]
#1258
0	Renal	B	['N']	[0]
1	failure	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	acetazolamide	B-Drug	['Causes']	[1]
5	therapy	O	['N']	[5]
6	for	O	['N']	[6]
7	glaucoma	O	['N']	[7]
8	.	O	['N']	[8]
#1259
0	The	O	['N']	[0]
1	main	O	['N']	[1]
2	clinical	O	['N']	[2]
3	features	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	58-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	patient	O	['N']	[10]
11	were	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	leucopenia	B-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	cholestasis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	biopsy	O	['N']	[20]
21	features	O	['N']	[21]
22	of	O	['N']	[22]
23	fatty	O	['N']	[23]
24	liver	O	['N']	[24]
25	parenchyma	O	['N']	[25]
26	degeneration	O	['N']	[26]
27	with	O	['N']	[27]
28	granulocytic	O	['N']	[28]
29	portal	O	['N']	[29]
30	infiltration	O	['N']	[30]
31	and	O	['N']	[31]
32	bile	O	['N']	[32]
33	stasis	O	['N']	[33]
34	,	O	['N']	[34]
35	demonstrated	O	['N']	[35]
36	20	O	['N']	[36]
37	days	O	['N']	[37]
38	after	O	['N']	[38]
39	the	O	['N']	[39]
40	initiation	O	['N']	[40]
41	of	O	['N']	[41]
42	antithyroid	O	['N']	[42]
43	therapy	O	['N']	[43]
44	with	O	['N']	[44]
45	20	O	['N']	[45]
46	mg	O	['N']	[46]
47	methimazole	B-Drug	['Causes']	[15]
48	daily	O	['N']	[48]
49	.	O	['N']	[49]
#1260
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	phase	O	['N']	[2]
3	II	O	['N']	[3]
4	study	O	['N']	[4]
5	of	O	['N']	[5]
6	hycanthone	B-Drug	['Causes']	[17]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	with	O	['N']	[9]
10	breast	O	['N']	[10]
11	cancer	O	['N']	[11]
12	we	O	['N']	[12]
13	have	O	['N']	[13]
14	recently	O	['N']	[14]
15	observed	O	['N']	[15]
16	severe	B	['N']	[16]
17	hepatotoxicity	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	even	O	['N']	[19]
20	at	O	['N']	[20]
21	lower	O	['N']	[21]
22	doses	O	['N']	[22]
23	,	O	['N']	[23]
24	which	O	['N']	[24]
25	resulted	O	['N']	[25]
26	in	O	['N']	[26]
27	two	O	['N']	[27]
28	drug	O	['N']	[28]
29	-	O	['N']	[29]
30	related	O	['N']	[30]
31	deaths	O	['N']	[31]
32	.	O	['N']	[32]
#1261
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	possible	O	['N']	[6]
7	association	O	['N']	[7]
8	of	O	['N']	[8]
9	methylphenidate	B-Drug	['Causes']	[11]
10	and	O	['N']	[10]
11	enuresis	B-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	an	O	['N']	[13]
14	11-year	O	['N']	[14]
15	-	O	['N']	[15]
16	old	O	['N']	[16]
17	boy	O	['N']	[17]
18	with	O	['N']	[18]
19	attention	O	['N']	[19]
20	deficit	O	['N']	[20]
21	hyperactivity	O	['N']	[21]
22	disorder	O	['N']	[22]
23	.	O	['N']	[23]
#1262
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	suffered	O	['N']	[2]
3	coronary	B	['N']	[3]
4	artery	I	['N']	[4]
5	vasospasm	I-Adverse_Effect	['N']	[5]
6	,	O	['N']	[6]
7	attributed	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	use	O	['N']	[10]
11	of	O	['N']	[11]
12	topical	O	['N']	[12]
13	1:1000	O	['N']	[13]
14	epinephrine	B-Drug	['Causes']	[5]
15	during	O	['N']	[15]
16	surgery	O	['N']	[16]
17	.	O	['N']	[17]
#1263
0	Although	O	['N']	[0]
1	both	O	['N']	[1]
2	the	O	['N']	[2]
3	spontaneous	O	['N']	[3]
4	occurrence	O	['N']	[4]
5	of	O	['N']	[5]
6	SLE	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	the	O	['N']	[8]
9	psychosis	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	sign	O	['N']	[12]
13	of	O	['N']	[13]
14	CNS	O	['N']	[14]
15	involvement	O	['N']	[15]
16	of	O	['N']	[16]
17	SLE	O	['N']	[17]
18	can	O	['N']	[18]
19	not	O	['N']	[19]
20	be	O	['N']	[20]
21	excluded	O	['N']	[21]
22	,	O	['N']	[22]
23	SLE	O	['N']	[23]
24	could	O	['N']	[24]
25	be	O	['N']	[25]
26	considered	O	['N']	[26]
27	as	O	['N']	[27]
28	an	O	['N']	[28]
29	adverse	O	['N']	[29]
30	effect	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	B-Drug	['Causes']	[6]
33	.	O	['N']	[33]
#1264
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	probable	O	['N']	[5]
6	enoxaparin	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	hepatotoxicity	B-Adverse_Effect	['N']	[9]
10	is	O	['N']	[10]
11	described	O	['N']	[11]
12	.	O	['N']	[12]
#1265
0	Aseptic	O	['N']	[0]
1	meningitis	O	['N']	[1]
2	,	O	['N']	[2]
3	hemolytic	O	['N']	[3]
4	anemia	O	['N']	[4]
5	,	O	['N']	[5]
6	hepatitis	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	orthostatic	O	['N']	[9]
10	hypotension	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	trimethoprim	O	['N']	[16]
17	-	O	['N']	[17]
18	sulfamethoxazole	B-Drug	['Causes']	[6]
19	.	O	['N']	[19]
#1266
0	The	O	['N']	[0]
1	following	O	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	report	O	['N']	[5]
6	analysis	O	['N']	[6]
7	intended	O	['N']	[7]
8	to	O	['N']	[8]
9	draw	O	['N']	[9]
10	attention	O	['N']	[10]
11	to	O	['N']	[11]
12	the	O	['N']	[12]
13	need	O	['N']	[13]
14	for	O	['N']	[14]
15	better	O	['N']	[15]
16	care	O	['N']	[16]
17	coordination	O	['N']	[17]
18	by	O	['N']	[18]
19	describing	O	['N']	[19]
20	the	O	['N']	[20]
21	observed	O	['N']	[21]
22	relationship	O	['N']	[22]
23	of	O	['N']	[23]
24	olanzapine	B-Drug	['Causes']	[35]
25	to	O	['N']	[25]
26	metabolic	O	['N']	[26]
27	changes	O	['N']	[27]
28	manifested	O	['N']	[28]
29	as	O	['N']	[29]
30	uncontrolled	O	['N']	[30]
31	diabetes	O	['N']	[31]
32	mellitus	O	['N']	[32]
33	and	O	['N']	[33]
34	weight	B	['N']	[34]
35	gain	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#1267
0	Hemodynamic	B	['N']	[0]
1	collapse	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	labetalol	B-Drug	['Causes']	[1]
4	administration	O	['N']	[4]
5	in	O	['N']	[5]
6	preeclampsia	O	['N']	[6]
7	.	O	['N']	[7]
#1268
0	A	O	['N']	[0]
1	complex	O	['N']	[1]
2	pattern	O	['N']	[2]
3	of	O	['N']	[3]
4	melanonychia	O	['N']	[4]
5	and	O	['N']	[5]
6	onycholysis	B-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	pemetrexed	B-Drug	['Causes']	[6]
11	for	O	['N']	[11]
12	lung	O	['N']	[12]
13	cancer	O	['N']	[13]
14	.	O	['N']	[14]
#1269
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	presented	O	['N']	[7]
8	with	O	['N']	[8]
9	diabetic	B	['N']	[9]
10	ketoacidosis	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	treatment	O	['N']	[12]
13	with	O	['N']	[13]
14	quetiapine	O	['N']	[14]
15	and	O	['N']	[15]
16	risperidone	B-Drug	['Causes']	[10]
17	,	O	['N']	[17]
18	respectively	O	['N']	[18]
19	.	O	['N']	[19]
#1270
0	Six	O	['N']	[0]
1	of	O	['N']	[1]
2	13	O	['N']	[2]
3	outpatients	O	['N']	[3]
4	with	O	['N']	[4]
5	schizophrenia	O	['N']	[5]
6	who	O	['N']	[6]
7	participated	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	ten	O	['N']	[10]
11	-	O	['N']	[11]
12	week	O	['N']	[12]
13	open	O	['N']	[13]
14	trial	O	['N']	[14]
15	of	O	['N']	[15]
16	risperidone	B-Drug	['Causes']	[30]
17	had	O	['N']	[17]
18	an	O	['N']	[18]
19	initial	O	['N']	[19]
20	good	O	['N']	[20]
21	response	O	['N']	[21]
22	to	O	['N']	[22]
23	the	O	['N']	[23]
24	medication	O	['N']	[24]
25	followed	O	['N']	[25]
26	by	O	['N']	[26]
27	development	O	['N']	[27]
28	of	O	['N']	[28]
29	intolerable	B	['N']	[29]
30	affect	I-Adverse_Effect	['N']	[30]
31	,	O	['N']	[31]
32	including	O	['N']	[32]
33	feelings	O	['N']	[33]
34	of	O	['N']	[34]
35	agitation	O	['N']	[35]
36	and	O	['N']	[36]
37	depression	O	['N']	[37]
38	and	O	['N']	[38]
39	periods	O	['N']	[39]
40	of	O	['N']	[40]
41	crying	O	['N']	[41]
42	and	O	['N']	[42]
43	insomnia	O	['N']	[43]
44	.	O	['N']	[44]
#1271
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	carboplatin	O	['N']	[5]
6	(	O	['N']	[6]
7	CBDCA	O	['N']	[7]
8	)	O	['N']	[8]
9	hypersensitivity	O	['N']	[9]
10	after	O	['N']	[10]
11	weekly	O	['N']	[11]
12	low	B	['N']	[12]
13	-	I	['N']	[13]
14	dose	I-Dose	['N']	[14]
15	paclitaxel	B-Drug	['Dosage']	[14]
16	(	O	['N']	[16]
17	60	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	m2)/CBDCA	O	['N']	[20]
21	(	O	['N']	[21]
22	area	O	['N']	[22]
23	under	O	['N']	[23]
24	the	O	['N']	[24]
25	concentration	O	['N']	[25]
26	curve	O	['N']	[26]
27	=	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	therapy	O	['N']	[30]
31	in	O	['N']	[31]
32	patients	O	['N']	[32]
33	with	O	['N']	[33]
34	recurrent	O	['N']	[34]
35	ovarian	O	['N']	[35]
36	cancer	O	['N']	[36]
37	receiving	O	['N']	[37]
38	multiple	O	['N']	[38]
39	platinum	O	['N']	[39]
40	-	O	['N']	[40]
41	based	O	['N']	[41]
42	chemotherapy	O	['N']	[42]
43	.	O	['N']	[43]
#1272
0	Thrombotic	B	['N']	[0]
1	thrombocytopenic	I	['N']	[1]
2	purpura	I-Adverse_Effect	['N']	[2]
3	(	O	['N']	[3]
4	TTP	O	['N']	[4]
5	)	O	['N']	[5]
6	developed	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	seropositive	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	(	O	['N']	[14]
15	RA	O	['N']	[15]
16	)	O	['N']	[16]
17	after	O	['N']	[17]
18	2	O	['N']	[18]
19	1/2	O	['N']	[19]
20	months	O	['N']	[20]
21	of	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	penicillamine	B-Drug	['Causes']	[2]
25	.	O	['N']	[25]
#1273
0	Unusual	O	['N']	[0]
1	pigmentary	B	['N']	[1]
2	changes	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	5-fluorouracil	B-Drug	['Causes']	[2]
6	therapy	O	['N']	[6]
7	.	O	['N']	[7]
#1274
0	Life	O	['N']	[0]
1	-	O	['N']	[1]
2	threatening	O	['N']	[2]
3	acute	O	['N']	[3]
4	hyponatraemia	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	low	B	['N']	[7]
8	dose	I-Dose	['N']	[8]
9	cyclophosphamide	O	['N']	[9]
10	and	O	['N']	[10]
11	indomethacin	B-Drug	['Dosage']	[8]
12	.	O	['N']	[12]
#1275
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	initially	O	['N']	[3]
4	treated	O	['N']	[4]
5	with	O	['N']	[5]
6	hydration	O	['N']	[6]
7	and	O	['N']	[7]
8	furosemide	B-Drug	['Causes']	[13]
9	but	O	['N']	[9]
10	developed	O	['N']	[10]
11	congestive	B	['N']	[11]
12	heart	I	['N']	[12]
13	failure	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#1276
0	Further	O	['N']	[0]
1	studies	O	['N']	[1]
2	are	O	['N']	[2]
3	necessary	O	['N']	[3]
4	to	O	['N']	[4]
5	evaluate	O	['N']	[5]
6	whether	O	['N']	[6]
7	the	O	['N']	[7]
8	study	O	['N']	[8]
9	of	O	['N']	[9]
10	HLA	O	['N']	[10]
11	antigens	O	['N']	[11]
12	may	O	['N']	[12]
13	be	O	['N']	[13]
14	a	O	['N']	[14]
15	very	O	['N']	[15]
16	useful	O	['N']	[16]
17	tool	O	['N']	[17]
18	to	O	['N']	[18]
19	detect	O	['N']	[19]
20	the	O	['N']	[20]
21	patients	O	['N']	[21]
22	with	O	['N']	[22]
23	a	O	['N']	[23]
24	predisposition	O	['N']	[24]
25	to	O	['N']	[25]
26	develop	O	['N']	[26]
27	autoimmune	O	['N']	[27]
28	thyroiditis	O	['N']	[28]
29	,	O	['N']	[29]
30	in	O	['N']	[30]
31	order	O	['N']	[31]
32	to	O	['N']	[32]
33	make	O	['N']	[33]
34	a	O	['N']	[34]
35	early	O	['N']	[35]
36	diagnosis	O	['N']	[36]
37	of	O	['N']	[37]
38	thyroid	B	['N']	[38]
39	disorders	I-Adverse_Effect	['N']	[39]
40	during	O	['N']	[40]
41	the	O	['N']	[41]
42	IFN	B	['N']	[42]
43	-	I	['N']	[43]
44	alpha	I-Drug	['Causes']	[39]
45	treatment	O	['N']	[45]
46	.	O	['N']	[46]
#1277
0	Dyspnea	O	['N']	[0]
1	,	O	['N']	[1]
2	hypoxemia	O	['N']	[2]
3	,	O	['N']	[3]
4	and	O	['N']	[4]
5	pleuritic	B	['N']	[5]
6	chest	I	['N']	[6]
7	pain	I-Adverse_Effect	['N']	[7]
8	occurred	O	['N']	[8]
9	within	O	['N']	[9]
10	24	O	['N']	[10]
11	hours	O	['N']	[11]
12	of	O	['N']	[12]
13	rituximab	B-Drug	['Causes']	[7]
14	administration	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	there	O	['N']	[17]
18	was	O	['N']	[18]
19	no	O	['N']	[19]
20	other	O	['N']	[20]
21	apparent	O	['N']	[21]
22	explanation	O	['N']	[22]
23	.	O	['N']	[23]
#1278
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	an	O	['N']	[6]
7	embryonal	O	['N']	[7]
8	teratocarcinoma	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	testicle	O	['N']	[11]
12	who	O	['N']	[12]
13	had	O	['N']	[13]
14	the	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	of	O	['N']	[16]
17	inappropriate	O	['N']	[17]
18	secretion	O	['N']	[18]
19	of	O	['N']	[19]
20	antidiuretic	O	['N']	[20]
21	hormone	O	['N']	[21]
22	after	O	['N']	[22]
23	receiving	O	['N']	[23]
24	a	O	['N']	[24]
25	high	B	['N']	[25]
26	dose	I-Dose	['N']	[26]
27	of	O	['N']	[27]
28	vinblastine	B-Drug	['Dosage']	[26]
29	.	O	['N']	[29]
#1279
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	new	O	['N']	[3]
4	episode	O	['N']	[4]
5	of	O	['N']	[5]
6	neutropenia	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	WBC	O	['N']	[10]
11	count	O	['N']	[11]
12	of	O	['N']	[12]
13	2.8	O	['N']	[13]
14	x	O	['N']	[14]
15	10(3)/mm3	O	['N']	[15]
16	and	O	['N']	[16]
17	ANC	O	['N']	[17]
18	of	O	['N']	[18]
19	0.448	O	['N']	[19]
20	x	O	['N']	[20]
21	10(3)/mm3	O	['N']	[21]
22	,	O	['N']	[22]
23	occurred	O	['N']	[23]
24	11	O	['N']	[24]
25	days	O	['N']	[25]
26	after	O	['N']	[26]
27	teicoplanin	B-Drug	['Causes']	[6]
28	initiation	O	['N']	[28]
29	.	O	['N']	[29]
#1280
0	The	O	['N']	[0]
1	probable	O	['N']	[1]
2	proarrhythmic	B-Adverse_Effect	['N']	[2]
3	action	O	['N']	[3]
4	of	O	['N']	[4]
5	amiodarone	B-Drug	['Causes']	[2]
6	,	O	['N']	[6]
7	although	O	['N']	[7]
8	rare	O	['N']	[8]
9	,	O	['N']	[9]
10	is	O	['N']	[10]
11	reviewed	O	['N']	[11]
12	along	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	discussion	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	novel	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	intravenous	O	['N']	[21]
22	magnesium	O	['N']	[22]
23	sulfate	O	['N']	[23]
24	therapy	O	['N']	[24]
25	.	O	['N']	[25]
#1281
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	marked	O	['N']	[7]
8	elevation	B	['N']	[8]
9	of	I	['N']	[9]
10	serum	I	['N']	[10]
11	creatine	I	['N']	[11]
12	kinase	I-Adverse_Effect	['N']	[12]
13	(	O	['N']	[13]
14	CK	O	['N']	[14]
15	)	O	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	olanzapine	B-Drug	['Causes']	[12]
19	therapy	O	['N']	[19]
20	.	O	['N']	[20]
#1282
0	Anisocoria	B-Adverse_Effect	['N']	[0]
1	from	O	['N']	[1]
2	transdermal	O	['N']	[2]
3	scopolamine	B-Drug	['Causes']	[0]
4	.	O	['N']	[4]
#1283
0	Ectropion	B-Adverse_Effect	['N']	[0]
1	secondary	O	['N']	[1]
2	to	O	['N']	[2]
3	bolus	O	['N']	[3]
4	injection	O	['N']	[4]
5	of	O	['N']	[5]
6	5-fluorouracil	B-Drug	['Causes']	[0]
7	.	O	['N']	[7]
#1284
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	receiving	O	['N']	[2]
3	phenytoin	O	['N']	[3]
4	sodium	O	['N']	[4]
5	300	O	['N']	[5]
6	mg	O	['N']	[6]
7	/	O	['N']	[7]
8	day	O	['N']	[8]
9	;	O	['N']	[9]
10	carbamazepine	B-Drug	['Causes']	[25]
11	200	O	['N']	[11]
12	mg	O	['N']	[12]
13	four	O	['N']	[13]
14	times	O	['N']	[14]
15	daily	O	['N']	[15]
16	had	O	['N']	[16]
17	been	O	['N']	[17]
18	discontinued	O	['N']	[18]
19	four	O	['N']	[19]
20	days	O	['N']	[20]
21	before	O	['N']	[21]
22	admission	O	['N']	[22]
23	because	O	['N']	[23]
24	of	O	['N']	[24]
25	leukopenia	B-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#1285
0	Focal	O	['N']	[0]
1	glomerulonephritis	O	['N']	[1]
2	and	O	['N']	[2]
3	interstitial	B	['N']	[3]
4	nephritis	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	methicillin	B-Drug	['Causes']	[4]
7	-	O	['N']	[7]
8	treated	O	['N']	[8]
9	,	O	['N']	[9]
10	heroin	O	['N']	[10]
11	-	O	['N']	[11]
12	related	O	['N']	[12]
13	infective	O	['N']	[13]
14	endocarditis	O	['N']	[14]
15	.	O	['N']	[15]
#1286
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	tenofovir	O	['N']	[5]
6	(	O	['N']	[6]
7	TDF)-associated	-	['N']	[7]
8	nephrotoxicity	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	perinatally	O	['N']	[10]
11	HIV	O	['N']	[11]
12	-	O	['N']	[12]
13	infected	O	['N']	[13]
14	adolescents	O	['N']	[14]
15	.	O	['N']	[15]
#1287
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	neuroleptic	B	['N']	[7]
8	malignant	I	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	(	O	['N']	[10]
11	NMS	O	['N']	[11]
12	)	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	fluphenazine	B-Drug	['Causes']	[9]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	schizophrenic	O	['N']	[18]
19	patient	O	['N']	[19]
20	and	O	['N']	[20]
21	review	O	['N']	[21]
22	the	O	['N']	[22]
23	literature	O	['N']	[23]
24	related	O	['N']	[24]
25	to	O	['N']	[25]
26	this	O	['N']	[26]
27	condition	O	['N']	[27]
28	.	O	['N']	[28]
#1288
0	Reversible	B	['N']	[0]
1	heart	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	receiving	O	['N']	[6]
7	etanercept	B-Drug	['Causes']	[2]
8	for	O	['N']	[8]
9	ankylosing	O	['N']	[9]
10	spondylitis	O	['N']	[10]
11	.	O	['N']	[11]
#1289
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	acute	O	['N']	[3]
4	changes	O	['N']	[4]
5	suggesting	O	['N']	[5]
6	acute	B	['N']	[6]
7	hepatitis	I-Adverse_Effect	['N']	[7]
8	after	O	['N']	[8]
9	parenteral	O	['N']	[9]
10	amiodarone	B-Drug	['Causes']	[7]
11	administration	O	['N']	[11]
12	is	O	['N']	[12]
13	described	O	['N']	[13]
14	.	O	['N']	[14]
#1290
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	second	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	lactic	B	['N']	[6]
7	acidosis	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	on	O	['N']	[11]
12	stavudine	O	['N']	[12]
13	and	O	['N']	[13]
14	lamivudine	B-Drug	['Causes']	[7]
15	.	O	['N']	[15]
#1291
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	unique	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	GTBM	B-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	myeloma	O	['N']	[11]
12	following	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	Melphalan	B-Drug	['Causes']	[6]
16	.	O	['N']	[16]
#1292
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	four	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	severe	B	['N']	[5]
6	corneal	I	['N']	[6]
7	ulceration	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	methamphetamine	B-Drug	['Causes']	[7]
10	abusers	O	['N']	[10]
11	.	O	['N']	[11]
#1293
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	of	O	['N']	[4]
5	inappropriate	O	['N']	[5]
6	antidiuresis	B-Adverse_Effect	['N']	[6]
7	as	O	['N']	[7]
8	a	O	['N']	[8]
9	much	O	['N']	[9]
10	earlier	O	['N']	[10]
11	side	O	['N']	[11]
12	-	O	['N']	[12]
13	effect	O	['N']	[13]
14	of	O	['N']	[14]
15	carbamazepine	B-Drug	['Causes']	[6]
16	administration	O	['N']	[16]
17	in	O	['N']	[17]
18	a	O	['N']	[18]
19	29-year	O	['N']	[19]
20	Nigerian	O	['N']	[20]
21	female	O	['N']	[21]
22	patient	O	['N']	[22]
23	with	O	['N']	[23]
24	generalized	O	['N']	[24]
25	tonic	O	['N']	[25]
26	-	O	['N']	[26]
27	elonic	O	['N']	[27]
28	seizures	O	['N']	[28]
29	.	O	['N']	[29]
#1294
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	no	O	['N']	[3]
4	history	O	['N']	[4]
5	of	O	['N']	[5]
6	asthma	O	['N']	[6]
7	or	O	['N']	[7]
8	allergy	O	['N']	[8]
9	developed	O	['N']	[9]
10	bronchospasm	B-Adverse_Effect	['N']	[10]
11	while	O	['N']	[11]
12	taking	O	['N']	[12]
13	propranolol	B-Drug	['Causes']	[10]
14	for	O	['N']	[14]
15	hypertension	O	['N']	[15]
16	.	O	['N']	[16]
#1295
0	Because	O	['N']	[0]
1	of	O	['N']	[1]
2	a	O	['N']	[2]
3	hypersensitivity	B	['N']	[3]
4	reaction	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	initial	O	['N']	[6]
7	therapy	O	['N']	[7]
8	with	O	['N']	[8]
9	penicillin	B	['N']	[9]
10	G	I-Drug	['Causes']	[4]
11	and	O	['N']	[11]
12	gentamicin	O	['N']	[12]
13	was	O	['N']	[13]
14	stopped	O	['N']	[14]
15	and	O	['N']	[15]
16	substituted	O	['N']	[16]
17	with	O	['N']	[17]
18	cefazolin	O	['N']	[18]
19	.	O	['N']	[19]
#1296
0	Gynecomastia	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	epileptics	O	['N']	[2]
3	treated	O	['N']	[3]
4	with	O	['N']	[4]
5	phenobarbital	B-Drug	['Causes']	[0]
6	,	O	['N']	[6]
7	phenytoin	O	['N']	[7]
8	and	O	['N']	[8]
9	fluoresone	O	['N']	[9]
10	:	O	['N']	[10]
11	two	O	['N']	[11]
12	case	O	['N']	[12]
13	reports	O	['N']	[13]
14	.	O	['N']	[14]
#1297
0	Toxicity	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	pharmacokinetics	O	['N']	[2]
3	,	O	['N']	[3]
4	and	O	['N']	[4]
5	in	O	['N']	[5]
6	vitro	O	['N']	[6]
7	hemodialysis	O	['N']	[7]
8	clearance	O	['N']	[8]
9	of	O	['N']	[9]
10	ifosfamide	B-Drug	['Causes']	[0]
11	and	O	['N']	[11]
12	metabolites	O	['N']	[12]
13	in	O	['N']	[13]
14	an	O	['N']	[14]
15	anephric	O	['N']	[15]
16	pediatric	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	Wilms	O	['N']	[19]
20	'	O	['N']	[20]
21	tumor	O	['N']	[21]
22	.	O	['N']	[22]
#1298
0	Disopyramide	B-Drug	['Causes']	[3]
1	(	O	['N']	[1]
2	Norpace)-induced	O	['N']	[2]
3	hypoglycemia	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#1299
0	Six	O	['N']	[0]
1	of	O	['N']	[1]
2	13	O	['N']	[2]
3	outpatients	O	['N']	[3]
4	with	O	['N']	[4]
5	schizophrenia	O	['N']	[5]
6	who	O	['N']	[6]
7	participated	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	ten	O	['N']	[10]
11	-	O	['N']	[11]
12	week	O	['N']	[12]
13	open	O	['N']	[13]
14	trial	O	['N']	[14]
15	of	O	['N']	[15]
16	risperidone	B-Drug	['Causes']	[37]
17	had	O	['N']	[17]
18	an	O	['N']	[18]
19	initial	O	['N']	[19]
20	good	O	['N']	[20]
21	response	O	['N']	[21]
22	to	O	['N']	[22]
23	the	O	['N']	[23]
24	medication	O	['N']	[24]
25	followed	O	['N']	[25]
26	by	O	['N']	[26]
27	development	O	['N']	[27]
28	of	O	['N']	[28]
29	intolerable	O	['N']	[29]
30	affect	O	['N']	[30]
31	,	O	['N']	[31]
32	including	O	['N']	[32]
33	feelings	O	['N']	[33]
34	of	O	['N']	[34]
35	agitation	O	['N']	[35]
36	and	O	['N']	[36]
37	depression	B-Adverse_Effect	['N']	[37]
38	and	O	['N']	[38]
39	periods	O	['N']	[39]
40	of	O	['N']	[40]
41	crying	O	['N']	[41]
42	and	O	['N']	[42]
43	insomnia	O	['N']	[43]
44	.	O	['N']	[44]
#1300
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	treating	O	['N']	[3]
4	elderly	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	olanzapine	B-Drug	['Causes']	[17]
8	should	O	['N']	[8]
9	be	O	['N']	[9]
10	aware	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	potential	O	['N']	[13]
14	for	O	['N']	[14]
15	rapidly	O	['N']	[15]
16	developing	O	['N']	[16]
17	hyperglycemia	B-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	monitor	O	['N']	[19]
20	such	O	['N']	[20]
21	patients	O	['N']	[21]
22	accordingly	O	['N']	[22]
23	.	O	['N']	[23]
#1301
0	One	O	['N']	[0]
1	type	O	['N']	[1]
2	of	O	['N']	[2]
3	SMON	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	acrodermatitis	O	['N']	[7]
8	enteropathica	O	['N']	[8]
9	which	O	['N']	[9]
10	has	O	['N']	[10]
11	a	O	['N']	[11]
12	very	O	['N']	[12]
13	high	O	['N']	[13]
14	frequency	O	['N']	[14]
15	of	O	['N']	[15]
16	occurrence	O	['N']	[16]
17	in	O	['N']	[17]
18	association	O	['N']	[18]
19	with	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	clioquinol	B-Drug	['Causes']	[3]
23	.	O	['N']	[23]
#1302
0	OBJECTIVES	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	presentation	O	['N']	[5]
6	and	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	acute	O	['N']	[9]
10	isoniazid	B-Drug	['Causes']	[14]
11	(	O	['N']	[11]
12	INH	O	['N']	[12]
13	)	O	['N']	[13]
14	neurotoxicity	B-Adverse_Effect	['N']	[14]
15	appearing	O	['N']	[15]
16	at	O	['N']	[16]
17	an	O	['N']	[17]
18	inner	O	['N']	[18]
19	-	O	['N']	[19]
20	city	O	['N']	[20]
21	municipal	O	['N']	[21]
22	hospital	O	['N']	[22]
23	.	O	['N']	[23]
#1303
0	The	O	['N']	[0]
1	other	O	['N']	[1]
2	woman	O	['N']	[2]
3	had	O	['N']	[3]
4	rheumatoid	O	['N']	[4]
5	arthritis	O	['N']	[5]
6	and	O	['N']	[6]
7	developed	O	['N']	[7]
8	acute	B	['N']	[8]
9	tubular	I	['N']	[9]
10	necrosis	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	treatment	O	['N']	[12]
13	with	O	['N']	[13]
14	gentamicin	B-Drug	['Causes']	[10]
15	and	O	['N']	[15]
16	cefoxitin	O	['N']	[16]
17	.	O	['N']	[17]
#1304
0	STUDY	O	['N']	[0]
1	DESIGN	O	['N']	[1]
2	:	O	['N']	[2]
3	Case	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	31-year	O	['N']	[7]
8	-	O	['N']	[8]
9	old	O	['N']	[9]
10	woman	O	['N']	[10]
11	who	O	['N']	[11]
12	presented	O	['N']	[12]
13	with	O	['N']	[13]
14	toxic	B	['N']	[14]
15	myelopathy	I-Adverse_Effect	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	intrathecal	O	['N']	[18]
19	administration	O	['N']	[19]
20	of	O	['N']	[20]
21	doxorubicin	B-Drug	['Causes']	[15]
22	.	O	['N']	[22]
#1305
0	Though	O	['N']	[0]
1	they	O	['N']	[1]
2	are	O	['N']	[2]
3	generally	O	['N']	[3]
4	considered	O	['N']	[4]
5	safe	O	['N']	[5]
6	,	O	['N']	[6]
7	there	O	['N']	[7]
8	have	O	['N']	[8]
9	been	O	['N']	[9]
10	a	O	['N']	[10]
11	few	O	['N']	[11]
12	reports	O	['N']	[12]
13	of	O	['N']	[13]
14	myocardial	B	['N']	[14]
15	infarction	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	stroke	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	triptan	B-Drug	['Causes']	[15]
21	use	O	['N']	[21]
22	.	O	['N']	[22]
#1306
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	tenofovir	B-Drug	['Causes']	[8]
6	(	O	['N']	[6]
7	TDF)-associated	O	['N']	[7]
8	nephrotoxicity	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	perinatally	O	['N']	[10]
11	HIV	O	['N']	[11]
12	-	O	['N']	[12]
13	infected	O	['N']	[13]
14	adolescents	O	['N']	[14]
15	.	O	['N']	[15]
#1307
0	Persisent	B	['N']	[0]
1	ocular	I	['N']	[1]
2	hypertension	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	intravitreal	O	['N']	[4]
5	ranibizumab	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#1308
0	Overdose	B-Dose	['N']	[0]
1	of	O	['N']	[1]
2	magnesium	B	['N']	[2]
3	sulfate	I-Drug	['Dosage']	[0]
4	in	O	['N']	[4]
5	combination	O	['N']	[5]
6	with	O	['N']	[6]
7	renal	O	['N']	[7]
8	insufficiency	O	['N']	[8]
9	,	O	['N']	[9]
10	hypocalcemia	O	['N']	[10]
11	,	O	['N']	[11]
12	or	O	['N']	[12]
13	compromise	O	['N']	[13]
14	of	O	['N']	[14]
15	intestinal	O	['N']	[15]
16	integrity	O	['N']	[16]
17	may	O	['N']	[17]
18	predispose	O	['N']	[18]
19	horses	O	['N']	[19]
20	to	O	['N']	[20]
21	magnesium	O	['N']	[21]
22	toxicosis	O	['N']	[22]
23	.	O	['N']	[23]
#1309
0	This	O	['N']	[0]
1	severe	O	['N']	[1]
2	illness	O	['N']	[2]
3	was	O	['N']	[3]
4	likely	O	['N']	[4]
5	caused	O	['N']	[5]
6	by	O	['N']	[6]
7	minocycline	B-Drug	['Causes']	[25]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	we	O	['N']	[10]
11	speculate	O	['N']	[11]
12	that	O	['N']	[12]
13	minocycline	O	['N']	[13]
14	may	O	['N']	[14]
15	have	O	['N']	[15]
16	acted	O	['N']	[16]
17	as	O	['N']	[17]
18	a	O	['N']	[18]
19	superantigen	O	['N']	[19]
20	,	O	['N']	[20]
21	causing	O	['N']	[21]
22	lymphocyte	B	['N']	[22]
23	over	I	['N']	[23]
24	-	I	['N']	[24]
25	activation	I-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	massive	O	['N']	[27]
28	cytokine	O	['N']	[28]
29	release	O	['N']	[29]
30	.	O	['N']	[30]
#1310
0	Carbamazepine	B-Drug	['Causes']	[2]
1	hypersensitivity	B	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	rare	O	['N']	[5]
6	,	O	['N']	[6]
7	life	O	['N']	[7]
8	-	O	['N']	[8]
9	threatening	O	['N']	[9]
10	condition	O	['N']	[10]
11	.	O	['N']	[11]
#1311
0	Case	O	['N']	[0]
1	1	O	['N']	[1]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	62-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	woman	O	['N']	[7]
8	,	O	['N']	[8]
9	developed	O	['N']	[9]
10	bilateral	B	['N']	[10]
11	optic	I	['N']	[11]
12	neuritis	I-Adverse_Effect	['N']	[12]
13	with	O	['N']	[13]
14	decreased	O	['N']	[14]
15	sensation	O	['N']	[15]
16	of	O	['N']	[16]
17	vibration	O	['N']	[17]
18	and	O	['N']	[18]
19	increased	O	['N']	[19]
20	deep	O	['N']	[20]
21	tendon	O	['N']	[21]
22	reflex	O	['N']	[22]
23	in	O	['N']	[23]
24	the	O	['N']	[24]
25	lower	O	['N']	[25]
26	extremities	O	['N']	[26]
27	after	O	['N']	[27]
28	a	O	['N']	[28]
29	seven	O	['N']	[29]
30	-	O	['N']	[30]
31	month	O	['N']	[31]
32	use	O	['N']	[32]
33	of	O	['N']	[33]
34	recombinant	B	['N']	[34]
35	interferon	I	['N']	[35]
36	alpha-2a	I-Drug	['Causes']	[12]
37	for	O	['N']	[37]
38	chronic	O	['N']	[38]
39	active	O	['N']	[39]
40	hepatitis	O	['N']	[40]
41	C.	O	['N']	[41]
#1312
0	Acne	B-Adverse_Effect	['N']	[0]
1	provoked	O	['N']	[1]
2	by	O	['N']	[2]
3	gold	B-Drug	['Causes']	[0]
4	seems	O	['N']	[4]
5	not	O	['N']	[5]
6	to	O	['N']	[6]
7	have	O	['N']	[7]
8	been	O	['N']	[8]
9	described	O	['N']	[9]
10	elsewhere	O	['N']	[10]
11	.	O	['N']	[11]
#1313
0	Drug	O	['N']	[0]
1	induced	O	['N']	[1]
2	liver	B	['N']	[2]
3	injury	I-Adverse_Effect	['N']	[3]
4	secondary	O	['N']	[4]
5	to	O	['N']	[5]
6	interferon	O	['N']	[6]
7	-	O	['N']	[7]
8	beta	O	['N']	[8]
9	(	O	['N']	[9]
10	IFN	B	['N']	[10]
11	-	I	['N']	[11]
12	beta	I-Drug	['Causes']	[3]
13	)	O	['N']	[13]
14	in	O	['N']	[14]
15	multiple	O	['N']	[15]
16	sclerosis	O	['N']	[16]
17	.	O	['N']	[17]
#1314
0	Hypoxemia	O	['N']	[0]
1	improved	O	['N']	[1]
2	during	O	['N']	[2]
3	continuous	O	['N']	[3]
4	tolazoline	B-Drug	['Causes']	[9]
5	infusion	O	['N']	[5]
6	,	O	['N']	[6]
7	but	O	['N']	[7]
8	gastrointestinal	B	['N']	[8]
9	bleeding	I-Adverse_Effect	['N']	[9]
10	occurred	O	['N']	[10]
11	.	O	['N']	[11]
#1315
0	Asthenozoospermia	B-Adverse_Effect	['N']	[0]
1	:	O	['N']	[1]
2	possible	O	['N']	[2]
3	association	O	['N']	[3]
4	with	O	['N']	[4]
5	long	O	['N']	[5]
6	-	O	['N']	[6]
7	term	O	['N']	[7]
8	exposure	O	['N']	[8]
9	to	O	['N']	[9]
10	an	O	['N']	[10]
11	anti	O	['N']	[11]
12	-	O	['N']	[12]
13	epileptic	O	['N']	[13]
14	drug	O	['N']	[14]
15	of	O	['N']	[15]
16	carbamazepine	B-Drug	['Causes']	[0]
17	.	O	['N']	[17]
#1316
0	Erosion	O	['N']	[0]
1	of	O	['N']	[1]
2	psoriatic	O	['N']	[2]
3	plaques	O	['N']	[3]
4	:	O	['N']	[4]
5	an	O	['N']	[5]
6	early	O	['N']	[6]
7	sign	O	['N']	[7]
8	of	O	['N']	[8]
9	methotrexate	B-Drug	['Causes']	[10]
10	toxicity	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#1317
0	Retrospectively	O	['N']	[0]
1	,	O	['N']	[1]
2	bucillamine	O	['N']	[2]
3	was	O	['N']	[3]
4	believed	O	['N']	[4]
5	to	O	['N']	[5]
6	be	O	['N']	[6]
7	the	O	['N']	[7]
8	cause	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	giant	O	['N']	[11]
12	hypertrophy	O	['N']	[12]
13	because	O	['N']	[13]
14	of	O	['N']	[14]
15	its	O	['N']	[15]
16	structural	O	['N']	[16]
17	similarity	O	['N']	[17]
18	to	O	['N']	[18]
19	D	B	['N']	[19]
20	-	I	['N']	[20]
21	penicillamine	I-Drug	['Causes']	[34]
22	,	O	['N']	[22]
23	which	O	['N']	[23]
24	was	O	['N']	[24]
25	the	O	['N']	[25]
26	subject	O	['N']	[26]
27	of	O	['N']	[27]
28	an	O	['N']	[28]
29	abundance	O	['N']	[29]
30	of	O	['N']	[30]
31	reports	O	['N']	[31]
32	of	O	['N']	[32]
33	mammary	B	['N']	[33]
34	hyperplasia	I-Adverse_Effect	['N']	[34]
35	.	O	['N']	[35]
#1318
0	We	O	['N']	[0]
1	conjectured	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	side	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	insulin	B-Drug	['Causes']	[32]
8	,	O	['N']	[8]
9	such	O	['N']	[9]
10	as	O	['N']	[10]
11	anti	O	['N']	[11]
12	-	O	['N']	[12]
13	natriuresis	O	['N']	[13]
14	and	O	['N']	[14]
15	increased	O	['N']	[15]
16	vascular	O	['N']	[16]
17	permeability	O	['N']	[17]
18	,	O	['N']	[18]
19	might	O	['N']	[19]
20	be	O	['N']	[20]
21	pronounced	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	presence	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatic	O	['N']	[27]
28	dysfunction	O	['N']	[28]
29	that	O	['N']	[29]
30	accompanies	O	['N']	[30]
31	insulin	B	['N']	[31]
32	insensitivity	I-Adverse_Effect	['N']	[32]
33	,	O	['N']	[33]
34	hyperinsulinaemia	O	['N']	[34]
35	and	O	['N']	[35]
36	hypoalbuminaemia	O	['N']	[36]
37	.	O	['N']	[37]
#1319
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	findings	O	['N']	[2]
3	from	O	['N']	[3]
4	three	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	experienced	O	['N']	[7]
8	a	O	['N']	[8]
9	psoriasiform	B	['N']	[9]
10	eruption	I-Adverse_Effect	['N']	[10]
11	apparently	O	['N']	[11]
12	due	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	antiepileptic	O	['N']	[15]
16	agents	O	['N']	[16]
17	sodium	O	['N']	[17]
18	valproate	O	['N']	[18]
19	and	O	['N']	[19]
20	carbamazepine	B-Drug	['Causes']	[10]
21	.	O	['N']	[21]
#1320
0	Piloerection	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	replacing	O	['N']	[3]
4	fluvoxamine	O	['N']	[4]
5	with	O	['N']	[5]
6	milnacipran	B-Drug	['Causes']	[0]
7	.	O	['N']	[7]
#1321
0	Phenytoin	O	['N']	[0]
1	was	O	['N']	[1]
2	discontinued	O	['N']	[2]
3	after	O	['N']	[3]
4	admission	O	['N']	[4]
5	;	O	['N']	[5]
6	however	O	['N']	[6]
7	,	O	['N']	[7]
8	phenytoin	B-Drug	['Dosage']	[10]
9	1	B	['N']	[9]
10	g	I-Dose	['N']	[10]
11	i.v	O	['N']	[11]
12	.	O	['N']	[12]
13	was	O	['N']	[13]
14	given	O	['N']	[14]
15	for	O	['N']	[15]
16	a	O	['N']	[16]
17	tonic	O	['N']	[17]
18	-	O	['N']	[18]
19	clonic	O	['N']	[19]
20	seizure	O	['N']	[20]
21	two	O	['N']	[21]
22	days	O	['N']	[22]
23	after	O	['N']	[23]
24	admission	O	['N']	[24]
25	,	O	['N']	[25]
26	after	O	['N']	[26]
27	which	O	['N']	[27]
28	swelling	O	['N']	[28]
29	of	O	['N']	[29]
30	the	O	['N']	[30]
31	face	O	['N']	[31]
32	and	O	['N']	[32]
33	legs	O	['N']	[33]
34	and	O	['N']	[34]
35	pruritus	O	['N']	[35]
36	developed	O	['N']	[36]
37	.	O	['N']	[37]
#1322
0	In	O	['N']	[0]
1	2	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	3	O	['N']	[4]
5	cases	O	['N']	[5]
6	the	O	['N']	[6]
7	patients	O	['N']	[7]
8	were	O	['N']	[8]
9	also	O	['N']	[9]
10	taking	O	['N']	[10]
11	lithium	B	['N']	[11]
12	carbonate	I-Drug	['Causes']	[26]
13	and	O	['N']	[13]
14	beta	O	['N']	[14]
15	-	O	['N']	[15]
16	blockers	O	['N']	[16]
17	,	O	['N']	[17]
18	both	O	['N']	[18]
19	of	O	['N']	[19]
20	which	O	['N']	[20]
21	could	O	['N']	[21]
22	have	O	['N']	[22]
23	contributed	O	['N']	[23]
24	to	O	['N']	[24]
25	the	O	['N']	[25]
26	incontinence	B-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#1323
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	cutaneous	O	['N']	[5]
6	lupus	O	['N']	[6]
7	erythematosus	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	severe	O	['N']	[10]
11	dapsone	B-Drug	['Causes']	[12]
12	reaction	I-Adverse_Effect	['N']	[12]
13	after	O	['N']	[13]
14	low	O	['N']	[14]
15	dose	O	['N']	[15]
16	therapy	O	['N']	[16]
17	,	O	['N']	[17]
18	with	O	['N']	[18]
19	a	O	['N']	[19]
20	fatal	O	['N']	[20]
21	outcome	O	['N']	[21]
22	in	O	['N']	[22]
23	one	O	['N']	[23]
24	.	O	['N']	[24]
#1324
0	Monitoring	O	['N']	[0]
1	of	O	['N']	[1]
2	liver	O	['N']	[2]
3	function	O	['N']	[3]
4	tests	O	['N']	[4]
5	should	O	['N']	[5]
6	be	O	['N']	[6]
7	mandatory	O	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	receiving	O	['N']	[10]
11	high	O	['N']	[11]
12	doses	O	['N']	[12]
13	of	O	['N']	[13]
14	cyproterone	B	['N']	[14]
15	acetate	I-Drug	['Causes']	[27]
16	;	O	['N']	[16]
17	the	O	['N']	[17]
18	drug	O	['N']	[18]
19	should	O	['N']	[19]
20	be	O	['N']	[20]
21	withdrawn	O	['N']	[21]
22	immediately	O	['N']	[22]
23	if	O	['N']	[23]
24	abnormal	B	['N']	[24]
25	liver	I	['N']	[25]
26	function	I	['N']	[26]
27	tests	I-Adverse_Effect	['N']	[27]
28	are	O	['N']	[28]
29	found	O	['N']	[29]
30	.	O	['N']	[30]
#1325
0	Eye	B	['N']	[0]
1	movement	I	['N']	[1]
2	disorders	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	bone	O	['N']	[4]
5	marrow	O	['N']	[5]
6	transplant	O	['N']	[6]
7	patients	O	['N']	[7]
8	on	O	['N']	[8]
9	cyclosporin	B-Drug	['Causes']	[2]
10	and	O	['N']	[10]
11	ganciclovir	O	['N']	[11]
12	.	O	['N']	[12]
#1326
0	The	O	['N']	[0]
1	cause	O	['N']	[1]
2	of	O	['N']	[2]
3	these	O	['N']	[3]
4	previously	O	['N']	[4]
5	unreported	O	['N']	[5]
6	side	O	['N']	[6]
7	effects	O	['N']	[7]
8	of	O	['N']	[8]
9	niacin	B-Drug	['Causes']	[27]
10	therapy	O	['N']	[10]
11	is	O	['N']	[11]
12	uncertain	O	['N']	[12]
13	but	O	['N']	[13]
14	may	O	['N']	[14]
15	be	O	['N']	[15]
16	related	O	['N']	[16]
17	to	O	['N']	[17]
18	prostaglandin	O	['N']	[18]
19	-	O	['N']	[19]
20	mediated	O	['N']	[20]
21	vasodilatation	O	['N']	[21]
22	,	O	['N']	[22]
23	hyperalgesia	B	['N']	[23]
24	of	I	['N']	[24]
25	sensory	I	['N']	[25]
26	nerve	I	['N']	[26]
27	receptors	I-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	potentiation	O	['N']	[30]
31	of	O	['N']	[31]
32	inflammation	O	['N']	[32]
33	in	O	['N']	[33]
34	the	O	['N']	[34]
35	gingiva	O	['N']	[35]
36	with	O	['N']	[36]
37	referral	O	['N']	[37]
38	of	O	['N']	[38]
39	pain	O	['N']	[39]
40	to	O	['N']	[40]
41	the	O	['N']	[41]
42	teeth	O	['N']	[42]
43	.	O	['N']	[43]
#1327
0	Linezolid	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	dyserythropoiesis	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	chloramphenicol	O	['N']	[5]
6	toxicity	O	['N']	[6]
7	revisited	O	['N']	[7]
8	.	O	['N']	[8]
#1328
0	Hepatitis	O	['N']	[0]
1	with	O	['N']	[1]
2	bridging	O	['N']	[2]
3	fibrosis	O	['N']	[3]
4	and	O	['N']	[4]
5	reversible	B	['N']	[5]
6	hepatic	I	['N']	[6]
7	insufficiency	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	woman	O	['N']	[10]
11	with	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	taking	O	['N']	[14]
15	methotrexate	B-Drug	['Causes']	[7]
16	.	O	['N']	[16]
#1329
0	A	O	['N']	[0]
1	22-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	black	O	['N']	[4]
5	man	O	['N']	[5]
6	developed	O	['N']	[6]
7	fever	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	chills	O	['N']	[9]
10	,	O	['N']	[10]
11	fatigue	O	['N']	[11]
12	,	O	['N']	[12]
13	night	O	['N']	[13]
14	sweats	O	['N']	[14]
15	,	O	['N']	[15]
16	tender	O	['N']	[16]
17	lymphadenopathy	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	a	O	['N']	[20]
21	generalized	O	['N']	[21]
22	,	O	['N']	[22]
23	pruritic	O	['N']	[23]
24	,	O	['N']	[24]
25	macular	O	['N']	[25]
26	eruption	O	['N']	[26]
27	3	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	starting	O	['N']	[30]
31	minocycline	B-Drug	['Causes']	[7]
32	therapy	O	['N']	[32]
33	for	O	['N']	[33]
34	acne	O	['N']	[34]
35	.	O	['N']	[35]
#1330
0	The	O	['N']	[0]
1	occurrence	O	['N']	[1]
2	of	O	['N']	[2]
3	neuromuscular	B	['N']	[3]
4	blockade	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	the	O	['N']	[6]
7	resulting	O	['N']	[7]
8	potentiation	O	['N']	[8]
9	of	O	['N']	[9]
10	muscle	O	['N']	[10]
11	relaxants	O	['N']	[11]
12	during	O	['N']	[12]
13	magnesium	O	['N']	[13]
14	sulfate	O	['N']	[14]
15	(	O	['N']	[15]
16	MgSO4	B-Drug	['Causes']	[4]
17	)	O	['N']	[17]
18	administration	O	['N']	[18]
19	is	O	['N']	[19]
20	well	O	['N']	[20]
21	known	O	['N']	[21]
22	.	O	['N']	[22]
#1331
0	A	O	['N']	[0]
1	64-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	schizophrenia	O	['N']	[6]
7	developed	O	['N']	[7]
8	myoclonic	B	['N']	[8]
9	jerks	I-Adverse_Effect	['N']	[9]
10	when	O	['N']	[10]
11	given	O	['N']	[11]
12	higher	O	['N']	[12]
13	doses	O	['N']	[13]
14	of	O	['N']	[14]
15	quetiapine	B-Drug	['Causes']	[9]
16	.	O	['N']	[16]
#1332
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	43-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	man	O	['N']	[9]
10	with	O	['N']	[10]
11	ITP	O	['N']	[11]
12	refractory	O	['N']	[12]
13	to	O	['N']	[13]
14	steroids	O	['N']	[14]
15	and	O	['N']	[15]
16	intravenous	O	['N']	[16]
17	immunoglobulin	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	acute	B	['N']	[20]
21	respiratory	I	['N']	[21]
22	distress	I	['N']	[22]
23	syndrome	I-Adverse_Effect	['N']	[23]
24	(	O	['N']	[24]
25	ARDS	O	['N']	[25]
26	)	O	['N']	[26]
27	after	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	infusion	O	['N']	[30]
31	of	O	['N']	[31]
32	rituximab	B-Drug	['Causes']	[23]
33	.	O	['N']	[33]
#1333
0	Fatal	B	['N']	[0]
1	lung	I	['N']	[1]
2	fibrosis	I-Adverse_Effect	['N']	[2]
3	caused	O	['N']	[3]
4	by	O	['N']	[4]
5	paclitaxel	O	['N']	[5]
6	toxicity	O	['N']	[6]
7	has	O	['N']	[7]
8	not	O	['N']	[8]
9	been	O	['N']	[9]
10	reported	O	['N']	[10]
11	In	O	['N']	[11]
12	this	O	['N']	[12]
13	report	O	['N']	[13]
14	,	O	['N']	[14]
15	we	O	['N']	[15]
16	describe	O	['N']	[16]
17	the	O	['N']	[17]
18	case	O	['N']	[18]
19	of	O	['N']	[19]
20	a	O	['N']	[20]
21	62-year	O	['N']	[21]
22	-	O	['N']	[22]
23	old	O	['N']	[23]
24	woman	O	['N']	[24]
25	who	O	['N']	[25]
26	received	O	['N']	[26]
27	six	O	['N']	[27]
28	cycles	O	['N']	[28]
29	of	O	['N']	[29]
30	paclitaxel	O	['N']	[30]
31	and	O	['N']	[31]
32	carboplatin	B-Drug	['Causes']	[2]
33	as	O	['N']	[33]
34	combination	O	['N']	[34]
35	chemotherapy	O	['N']	[35]
36	for	O	['N']	[36]
37	advanced	O	['N']	[37]
38	ovarian	O	['N']	[38]
39	cancer	O	['N']	[39]
40	.	O	['N']	[40]
#1334
0	Development	O	['N']	[0]
1	of	O	['N']	[1]
2	porphyria	B	['N']	[2]
3	cutanea	I	['N']	[3]
4	tarda	I-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	cyclophosphamide	B-Drug	['Causes']	[4]
9	.	O	['N']	[9]
#1335
0	Ataxia	B-Adverse_Effect	['N']	[0]
1	caused	O	['N']	[1]
2	by	O	['N']	[2]
3	propafenone	B-Drug	['Causes']	[0]
4	has	O	['N']	[4]
5	been	O	['N']	[5]
6	reported	O	['N']	[6]
7	to	O	['N']	[7]
8	the	O	['N']	[8]
9	pharmaceutical	O	['N']	[9]
10	companies	O	['N']	[10]
11	and	O	['N']	[11]
12	drug	O	['N']	[12]
13	monitoring	O	['N']	[13]
14	agencies	O	['N']	[14]
15	,	O	['N']	[15]
16	but	O	['N']	[16]
17	has	O	['N']	[17]
18	not	O	['N']	[18]
19	been	O	['N']	[19]
20	well	O	['N']	[20]
21	described	O	['N']	[21]
22	or	O	['N']	[22]
23	emphasized	O	['N']	[23]
24	in	O	['N']	[24]
25	the	O	['N']	[25]
26	medical	O	['N']	[26]
27	literature	O	['N']	[27]
28	.	O	['N']	[28]
#1336
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	carboplatin	O	['N']	[5]
6	(	O	['N']	[6]
7	CBDCA	O	['N']	[7]
8	)	O	['N']	[8]
9	hypersensitivity	B-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	weekly	O	['N']	[11]
12	low	O	['N']	[12]
13	-	O	['N']	[13]
14	dose	O	['N']	[14]
15	paclitaxel	B-Drug	['Causes']	[9]
16	(	O	['N']	[16]
17	60	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	m2)/CBDCA	O	['N']	[20]
21	(	O	['N']	[21]
22	area	O	['N']	[22]
23	under	O	['N']	[23]
24	the	O	['N']	[24]
25	concentration	O	['N']	[25]
26	curve	O	['N']	[26]
27	=	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	therapy	O	['N']	[30]
31	in	O	['N']	[31]
32	patients	O	['N']	[32]
33	with	O	['N']	[33]
34	recurrent	O	['N']	[34]
35	ovarian	O	['N']	[35]
36	cancer	O	['N']	[36]
37	receiving	O	['N']	[37]
38	multiple	O	['N']	[38]
39	platinum	O	['N']	[39]
40	-	O	['N']	[40]
41	based	O	['N']	[41]
42	chemotherapy	O	['N']	[42]
43	.	O	['N']	[43]
#1337
0	Rhabdomyolysis	B-Adverse_Effect	['N']	[0]
1	following	O	['N']	[1]
2	clarithromycin	B-Drug	['Causes']	[0]
3	monotherapy	O	['N']	[3]
4	.	O	['N']	[4]
#1338
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	article	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	describe	O	['N']	[5]
6	another	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	subcutaneous	O	['N']	[9]
10	changes	O	['N']	[10]
11	following	O	['N']	[11]
12	repeated	O	['N']	[12]
13	glatiramer	B	['N']	[13]
14	acetate	I-Drug	['Causes']	[20]
15	injection	O	['N']	[15]
16	,	O	['N']	[16]
17	presented	O	['N']	[17]
18	as	O	['N']	[18]
19	localized	B	['N']	[19]
20	panniculitis	I-Adverse_Effect	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	area	O	['N']	[23]
24	around	O	['N']	[24]
25	the	O	['N']	[25]
26	injection	O	['N']	[26]
27	sites	O	['N']	[27]
28	,	O	['N']	[28]
29	in	O	['N']	[29]
30	a	O	['N']	[30]
31	46-year	O	['N']	[31]
32	-	O	['N']	[32]
33	old	O	['N']	[33]
34	female	O	['N']	[34]
35	patient	O	['N']	[35]
36	who	O	['N']	[36]
37	was	O	['N']	[37]
38	treated	O	['N']	[38]
39	with	O	['N']	[39]
40	glatiramer	O	['N']	[40]
41	acetate	O	['N']	[41]
42	for	O	['N']	[42]
43	18	O	['N']	[43]
44	months	O	['N']	[44]
45	.	O	['N']	[45]
#1339
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	with	O	['N']	[2]
3	parenteral	O	['N']	[3]
4	amiodarone	B-Drug	['Dosage']	[10]
5	(	O	['N']	[5]
6	2300	B	['N']	[6]
7	mg	I	['N']	[7]
8	in	I	['N']	[8]
9	3	I	['N']	[9]
10	days	I-Dose	['N']	[10]
11	)	O	['N']	[11]
12	and	O	['N']	[12]
13	other	O	['N']	[13]
14	measures	O	['N']	[14]
15	,	O	['N']	[15]
16	signs	O	['N']	[16]
17	of	O	['N']	[17]
18	congestive	O	['N']	[18]
19	heart	O	['N']	[19]
20	failure	O	['N']	[20]
21	disappeared	O	['N']	[21]
22	;	O	['N']	[22]
23	subsequently	O	['N']	[23]
24	the	O	['N']	[24]
25	patient	O	['N']	[25]
26	developed	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	marked	O	['N']	[29]
30	increase	O	['N']	[30]
31	in	O	['N']	[31]
32	serum	O	['N']	[32]
33	transaminase	O	['N']	[33]
34	levels	O	['N']	[34]
35	and	O	['N']	[35]
36	fall	O	['N']	[36]
37	in	O	['N']	[37]
38	prothrombin	O	['N']	[38]
39	time	O	['N']	[39]
40	,	O	['N']	[40]
41	and	O	['N']	[41]
42	histologic	O	['N']	[42]
43	changes	O	['N']	[43]
44	of	O	['N']	[44]
45	severe	O	['N']	[45]
46	centrilobular	O	['N']	[46]
47	necrosis	O	['N']	[47]
48	were	O	['N']	[48]
49	observed	O	['N']	[49]
50	in	O	['N']	[50]
51	hepatic	O	['N']	[51]
52	biopsy	O	['N']	[52]
53	.	O	['N']	[53]
#1340
0	To	O	['N']	[0]
1	the	O	['N']	[1]
2	best	O	['N']	[2]
3	of	O	['N']	[3]
4	our	O	['N']	[4]
5	knowledge	O	['N']	[5]
6	,	O	['N']	[6]
7	this	O	['N']	[7]
8	is	O	['N']	[8]
9	the	O	['N']	[9]
10	first	O	['N']	[10]
11	reported	O	['N']	[11]
12	patient	O	['N']	[12]
13	with	O	['N']	[13]
14	captopril	B-Drug	['Causes']	[17]
15	-	O	['N']	[15]
16	induced	O	['N']	[16]
17	pemphigus	B-Adverse_Effect	['N']	[17]
18	in	O	['N']	[18]
19	whom	O	['N']	[19]
20	no	O	['N']	[20]
21	new	O	['N']	[21]
22	lesions	O	['N']	[22]
23	developed	O	['N']	[23]
24	after	O	['N']	[24]
25	subsequent	O	['N']	[25]
26	treatment	O	['N']	[26]
27	with	O	['N']	[27]
28	enalapril	O	['N']	[28]
29	.	O	['N']	[29]
#1341
0	Fluorouracil	O	['N']	[0]
1	for	O	['N']	[1]
2	allergic	B	['N']	[2]
3	reactions	I-Adverse_Effect	['N']	[3]
4	to	O	['N']	[4]
5	capecitabine	B-Drug	['Causes']	[3]
6	.	O	['N']	[6]
#1342
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	two	O	['N']	[2]
3	children	O	['N']	[3]
4	with	O	['N']	[4]
5	acute	O	['N']	[5]
6	lymphocytic	O	['N']	[6]
7	leukemia	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	leukoencephalopathy	B-Adverse_Effect	['N']	[10]
11	following	O	['N']	[11]
12	administration	O	['N']	[12]
13	of	O	['N']	[13]
14	a	O	['N']	[14]
15	combination	O	['N']	[15]
16	of	O	['N']	[16]
17	intravenous	O	['N']	[17]
18	ara	B	['N']	[18]
19	=	I	['N']	[19]
20	C	I-Drug	['Causes']	[10]
21	and	O	['N']	[21]
22	methotrexate	O	['N']	[22]
23	during	O	['N']	[23]
24	the	O	['N']	[24]
25	consolidation	O	['N']	[25]
26	phase	O	['N']	[26]
27	of	O	['N']	[27]
28	chemotherapy	O	['N']	[28]
29	.	O	['N']	[29]
#1343
0	Thus	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	patient	O	['N']	[3]
4	's	O	['N']	[4]
5	clinical	O	['N']	[5]
6	course	O	['N']	[6]
7	and	O	['N']	[7]
8	workup	O	['N']	[8]
9	strongly	O	['N']	[9]
10	support	O	['N']	[10]
11	a	O	['N']	[11]
12	diagnosis	O	['N']	[12]
13	of	O	['N']	[13]
14	lenalidomide	B-Drug	['Causes']	[21]
15	-	O	['N']	[15]
16	induced	O	['N']	[16]
17	hypersensitivity	B	['N']	[17]
18	pneumonitis	I	['N']	[18]
19	-	I	['N']	[19]
20	like	I	['N']	[20]
21	syndrome	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1344
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	development	O	['N']	[3]
4	of	O	['N']	[4]
5	ischemic	B	['N']	[5]
6	colitis	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	was	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	tegaserod	B-Drug	['Causes']	[6]
15	and	O	['N']	[15]
16	review	O	['N']	[16]
17	the	O	['N']	[17]
18	relationship	O	['N']	[18]
19	among	O	['N']	[19]
20	ischemic	O	['N']	[20]
21	colitis	O	['N']	[21]
22	,	O	['N']	[22]
23	tegaserod	O	['N']	[23]
24	use	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	irritable	O	['N']	[27]
28	bowel	O	['N']	[28]
29	syndrome	O	['N']	[29]
30	.	O	['N']	[30]
#1345
0	Clinicians	O	['N']	[0]
1	have	O	['N']	[1]
2	been	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[6]
6	toxicity	I-Adverse_Effect	['N']	[6]
7	for	O	['N']	[7]
8	many	O	['N']	[8]
9	years	O	['N']	[9]
10	and	O	['N']	[10]
11	traditionally	O	['N']	[11]
12	have	O	['N']	[12]
13	administered	O	['N']	[13]
14	thiazide	O	['N']	[14]
15	diuretics	O	['N']	[15]
16	for	O	['N']	[16]
17	lithium	O	['N']	[17]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	polyuria	O	['N']	[20]
21	and	O	['N']	[21]
22	nephrogenic	O	['N']	[22]
23	diabetes	O	['N']	[23]
24	insipidus	O	['N']	[24]
25	.	O	['N']	[25]
#1346
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	chronic	O	['N']	[8]
9	lymphocytic	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	(	O	['N']	[11]
12	CLL	O	['N']	[12]
13	)	O	['N']	[13]
14	who	O	['N']	[14]
15	developed	O	['N']	[15]
16	fatal	O	['N']	[16]
17	intravascular	O	['N']	[17]
18	autoimmune	O	['N']	[18]
19	hemolytic	O	['N']	[19]
20	anemia	O	['N']	[20]
21	(	O	['N']	[21]
22	AIHA	B-Adverse_Effect	['N']	[22]
23	)	O	['N']	[23]
24	after	O	['N']	[24]
25	fludarabine	B-Drug	['Causes']	[22]
26	treatment	O	['N']	[26]
27	.	O	['N']	[27]
#1347
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	purpose	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	study	O	['N']	[6]
7	was	O	['N']	[7]
8	to	O	['N']	[8]
9	report	O	['N']	[9]
10	the	O	['N']	[10]
11	concomitant	O	['N']	[11]
12	occurrence	O	['N']	[12]
13	of	O	['N']	[13]
14	multiple	B	['N']	[14]
15	squamous	I	['N']	[15]
16	cell	I	['N']	[16]
17	carcinomas	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	diffuse	O	['N']	[19]
20	nail	O	['N']	[20]
21	hyperpigmentation	O	['N']	[21]
22	associated	O	['N']	[22]
23	with	O	['N']	[23]
24	hydroxyurea	B-Drug	['Causes']	[17]
25	treatment	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	to	O	['N']	[28]
29	describe	O	['N']	[29]
30	a	O	['N']	[30]
31	successful	O	['N']	[31]
32	therapeutic	O	['N']	[32]
33	approach	O	['N']	[33]
34	using	O	['N']	[34]
35	imiquimod	O	['N']	[35]
36	5	O	['N']	[36]
37	%	O	['N']	[37]
38	.	O	['N']	[38]
#1348
0	The	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	an	O	['N']	[3]
4	IgG	O	['N']	[4]
5	lambda	O	['N']	[5]
6	-	O	['N']	[6]
7	type	O	['N']	[7]
8	monoclonal	O	['N']	[8]
9	gammopathy	O	['N']	[9]
10	and	O	['N']	[10]
11	subsequent	O	['N']	[11]
12	multiple	B	['N']	[12]
13	myeloma	I-Adverse_Effect	['N']	[13]
14	in	O	['N']	[14]
15	an	O	['N']	[15]
16	epilepsy	O	['N']	[16]
17	patient	O	['N']	[17]
18	on	O	['N']	[18]
19	diphenylhydantoin	O	['N']	[19]
20	(	O	['N']	[20]
21	DILANTIN	B-Drug	['Causes']	[13]
22	)	O	['N']	[22]
23	therapy	O	['N']	[23]
24	for	O	['N']	[24]
25	20	O	['N']	[25]
26	years	O	['N']	[26]
27	is	O	['N']	[27]
28	reported	O	['N']	[28]
29	.	O	['N']	[29]
#1349
0	Both	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	hypoadrenalism	B-Adverse_Effect	['N']	[3]
4	while	O	['N']	[4]
5	on	O	['N']	[5]
6	o	B	['N']	[6]
7	,	I	['N']	[7]
8	p'-DDD	I-Drug	['Causes']	[3]
9	and	O	['N']	[9]
10	apparently	O	['N']	[10]
11	adequate	O	['N']	[11]
12	dexamethasone	O	['N']	[12]
13	replacement	O	['N']	[13]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#1350
0	Although	O	['N']	[0]
1	various	O	['N']	[1]
2	manifestations	O	['N']	[2]
3	of	O	['N']	[3]
4	pentamidine	B-Drug	['Causes']	[20]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	cardiotoxicity	O	['N']	[7]
8	have	O	['N']	[8]
9	been	O	['N']	[9]
10	reported	O	['N']	[10]
11	,	O	['N']	[11]
12	to	O	['N']	[12]
13	our	O	['N']	[13]
14	knowledge	O	['N']	[14]
15	,	O	['N']	[15]
16	second	B	['N']	[16]
17	-	I	['N']	[17]
18	degree	I	['N']	[18]
19	heart	I	['N']	[19]
20	block	I-Adverse_Effect	['N']	[20]
21	associated	O	['N']	[21]
22	with	O	['N']	[22]
23	this	O	['N']	[23]
24	agent	O	['N']	[24]
25	has	O	['N']	[25]
26	not	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	.	O	['N']	[29]
#1351
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	presented	O	['N']	[5]
6	with	O	['N']	[6]
7	bloody	B	['N']	[7]
8	diarrhoea	I-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	15	O	['N']	[10]
11	mg	O	['N']	[11]
12	meloxicam	B-Drug	['Causes']	[8]
13	daily	O	['N']	[13]
14	for	O	['N']	[14]
15	10	O	['N']	[15]
16	days	O	['N']	[16]
17	for	O	['N']	[17]
18	osteoarthritis	O	['N']	[18]
19	.	O	['N']	[19]
#1352
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	absence	O	['N']	[2]
3	of	O	['N']	[3]
4	mucositis	O	['N']	[4]
5	or	O	['N']	[5]
6	diarrhea	O	['N']	[6]
7	,	O	['N']	[7]
8	severe	O	['N']	[8]
9	dermatologic	O	['N']	[9]
10	toxicity	O	['N']	[10]
11	following	O	['N']	[11]
12	a	O	['N']	[12]
13	single	O	['N']	[13]
14	low	O	['N']	[14]
15	dose	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	drug	O	['N']	[18]
19	suggests	O	['N']	[19]
20	an	O	['N']	[20]
21	'	O	['N']	[21]
22	allergic	O	['N']	[22]
23	'	O	['N']	[23]
24	or	O	['N']	[24]
25	acute	B	['N']	[25]
26	hypersensitivity	I	['N']	[26]
27	reaction	I-Adverse_Effect	['N']	[27]
28	to	O	['N']	[28]
29	MTX	B-Drug	['Causes']	[27]
30	in	O	['N']	[30]
31	this	O	['N']	[31]
32	patient	O	['N']	[32]
33	.	O	['N']	[33]
#1353
0	Niflumic	B	['N']	[0]
1	acid	I-Drug	['Causes']	[5]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	skeletal	B	['N']	[4]
5	fluorosis	I-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	iatrogenic	O	['N']	[7]
8	disease	O	['N']	[8]
9	or	O	['N']	[9]
10	therapeutic	O	['N']	[10]
11	perspective	O	['N']	[11]
12	for	O	['N']	[12]
13	osteoporosis	O	['N']	[13]
14	?	O	['N']	[14]
#1354
0	A	O	['N']	[0]
1	66-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Japanese	O	['N']	[4]
5	woman	O	['N']	[5]
6	with	O	['N']	[6]
7	severe	O	['N']	[7]
8	scleroderma	O	['N']	[8]
9	developed	O	['N']	[9]
10	anemia	O	['N']	[10]
11	and	O	['N']	[11]
12	thrombocytopenia	B-Adverse_Effect	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	D	B	['N']	[15]
16	-	I	['N']	[16]
17	penicillamine	I-Drug	['Causes']	[12]
18	(	O	['N']	[18]
19	D	O	['N']	[19]
20	-	O	['N']	[20]
21	Pen	O	['N']	[21]
22	)	O	['N']	[22]
23	treatment	O	['N']	[23]
24	,	O	['N']	[24]
25	although	O	['N']	[25]
26	the	O	['N']	[26]
27	leukopenia	O	['N']	[27]
28	was	O	['N']	[28]
29	not	O	['N']	[29]
30	markedly	O	['N']	[30]
31	severe	O	['N']	[31]
32	.	O	['N']	[32]
#1355
0	Neuroleptic	B	['N']	[0]
1	malignant	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	risperidone	B-Drug	['Causes']	[2]
6	treatment	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	child	O	['N']	[9]
10	with	O	['N']	[10]
11	Joubert	O	['N']	[11]
12	syndrome	O	['N']	[12]
13	.	O	['N']	[13]
#1356
0	When	O	['N']	[0]
1	DSCG	B-Drug	['Causes']	[5]
2	was	O	['N']	[2]
3	withdrawn	O	['N']	[3]
4	,	O	['N']	[4]
5	urticaria	B-Adverse_Effect	['N']	[5]
6	vanished	O	['N']	[6]
7	and	O	['N']	[7]
8	the	O	['N']	[8]
9	child	O	['N']	[9]
10	remained	O	['N']	[10]
11	symptom	O	['N']	[11]
12	-	O	['N']	[12]
13	free	O	['N']	[13]
14	.	O	['N']	[14]
#1357
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	excessive	O	['N']	[2]
3	insulin	B-Drug	['Causes']	[15]
4	induced	O	['N']	[4]
5	hypoglycemia	O	['N']	[5]
6	within	O	['N']	[6]
7	4	O	['N']	[7]
8	to	O	['N']	[8]
9	8	O	['N']	[9]
10	hours	O	['N']	[10]
11	,	O	['N']	[11]
12	followed	O	['N']	[12]
13	by	O	['N']	[13]
14	rebound	B	['N']	[14]
15	hyperglycemia	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#1358
0	Other	O	['N']	[0]
1	upper	B	['N']	[1]
2	tract	I	['N']	[2]
3	neoplasms	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	cyclophosphamide	B-Drug	['Causes']	[3]
6	are	O	['N']	[6]
7	reviewed	O	['N']	[7]
8	.	O	['N']	[8]
#1359
0	The	O	['N']	[0]
1	exophthalmos	B-Adverse_Effect	['N']	[1]
2	improved	O	['N']	[2]
3	dramatically	O	['N']	[3]
4	within	O	['N']	[4]
5	72	O	['N']	[5]
6	hours	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	withdrawal	O	['N']	[9]
10	of	O	['N']	[10]
11	lithium	B-Drug	['Causes']	[1]
12	.	O	['N']	[12]
#1360
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	one	O	['N']	[2]
3	patient	O	['N']	[3]
4	exhibited	O	['N']	[4]
5	severe	O	['N']	[5]
6	hypersensitivity	O	['N']	[6]
7	reactions	O	['N']	[7]
8	including	O	['N']	[8]
9	cardiac	O	['N']	[9]
10	arrest	O	['N']	[10]
11	and	O	['N']	[11]
12	apnea	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	another	O	['N']	[15]
16	four	O	['N']	[16]
17	patients	O	['N']	[17]
18	developed	O	['N']	[18]
19	eruptions	O	['N']	[19]
20	,	O	['N']	[20]
21	hypotension	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	soon	O	['N']	[25]
26	after	O	['N']	[26]
27	administration	O	['N']	[27]
28	of	O	['N']	[28]
29	CBDCA	B-Drug	['Causes']	[21]
30	.	O	['N']	[30]
#1361
0	Even	O	['N']	[0]
1	after	O	['N']	[1]
2	a	O	['N']	[2]
3	strict	O	['N']	[3]
4	warning	O	['N']	[4]
5	,	O	['N']	[5]
6	he	O	['N']	[6]
7	took	O	['N']	[7]
8	another	O	['N']	[8]
9	quinine	B-Drug	['Causes']	[21]
10	tablet	O	['N']	[10]
11	that	O	['N']	[11]
12	evening	O	['N']	[12]
13	,	O	['N']	[13]
14	which	O	['N']	[14]
15	triggered	O	['N']	[15]
16	his	O	['N']	[16]
17	fifth	O	['N']	[17]
18	episode	O	['N']	[18]
19	of	O	['N']	[19]
20	severe	O	['N']	[20]
21	thrombocytopenia	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	confirmed	O	['N']	[24]
25	the	O	['N']	[25]
26	etiology	O	['N']	[26]
27	of	O	['N']	[27]
28	quinine	O	['N']	[28]
29	-	O	['N']	[29]
30	induced	O	['N']	[30]
31	thrombocytopenia	O	['N']	[31]
32	.	O	['N']	[32]
#1362
0	A	O	['N']	[0]
1	toxic	O	['N']	[1]
2	encephalopathy	O	['N']	[2]
3	characterized	O	['N']	[3]
4	by	O	['N']	[4]
5	depressed	O	['N']	[5]
6	level	O	['N']	[6]
7	of	O	['N']	[7]
8	consciousness	O	['N']	[8]
9	,	O	['N']	[9]
10	marked	B	['N']	[10]
11	irritability	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	ataxia	O	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	seven	O	['N']	[17]
18	children	O	['N']	[18]
19	,	O	['N']	[19]
20	5	O	['N']	[20]
21	years	O	['N']	[21]
22	of	O	['N']	[22]
23	age	O	['N']	[23]
24	and	O	['N']	[24]
25	younger	O	['N']	[25]
26	,	O	['N']	[26]
27	following	O	['N']	[27]
28	administration	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	antiemetic	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	pentobarbital	B-Drug	['Causes']	[11]
35	and	O	['N']	[35]
36	pyrilamine	O	['N']	[36]
37	maleate	O	['N']	[37]
38	.	O	['N']	[38]
#1363
0	Complications	O	['N']	[0]
1	of	O	['N']	[1]
2	chemotherapy	O	['N']	[2]
3	for	O	['N']	[3]
4	a	O	['N']	[4]
5	synovial	O	['N']	[5]
6	sarcoma	O	['N']	[6]
7	in	O	['N']	[7]
8	an	O	['N']	[8]
9	eight	O	['N']	[9]
10	-	O	['N']	[10]
11	year	O	['N']	[11]
12	old	O	['N']	[12]
13	boy	O	['N']	[13]
14	included	O	['N']	[14]
15	cisplatinum	B-Drug	['Causes']	[16]
16	nephrotoxicity	B-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	adriamycin	O	['N']	[18]
19	cardiotoxicity	O	['N']	[19]
20	.	O	['N']	[20]
#1364
0	A	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[7]
2	hypersensitivity	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	,	O	['N']	[4]
5	consisting	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	nausea	O	['N']	[11]
12	,	O	['N']	[12]
13	vomiting	O	['N']	[13]
14	,	O	['N']	[14]
15	lymphadenopathy	O	['N']	[15]
16	,	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	,	O	['N']	[18]
19	hemolysis	O	['N']	[19]
20	,	O	['N']	[20]
21	leukopenia	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	mononucleosis	O	['N']	[24]
25	,	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	for	O	['N']	[35]
36	leprosy	O	['N']	[36]
37	.	O	['N']	[37]
#1365
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	undergone	O	['N']	[8]
9	a	O	['N']	[9]
10	renal	O	['N']	[10]
11	transplantation	O	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	result	O	['N']	[14]
15	of	O	['N']	[15]
16	malignant	O	['N']	[16]
17	hypertension	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	who	O	['N']	[20]
21	was	O	['N']	[21]
22	on	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	therapy	O	['N']	[24]
25	consisting	O	['N']	[25]
26	of	O	['N']	[26]
27	cyclosporin	O	['N']	[27]
28	,	O	['N']	[28]
29	prednisone	B-Drug	['Causes']	[34]
30	and	O	['N']	[30]
31	azathioprine	O	['N']	[31]
32	,	O	['N']	[32]
33	developed	O	['N']	[33]
34	thrombosis	B-Adverse_Effect	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	central	O	['N']	[37]
38	retinal	O	['N']	[38]
39	vein	O	['N']	[39]
40	5	O	['N']	[40]
41	years	O	['N']	[41]
42	following	O	['N']	[42]
43	the	O	['N']	[43]
44	transplantation	O	['N']	[44]
45	.	O	['N']	[45]
#1366
0	Choanal	O	['N']	[0]
1	atresia	O	['N']	[1]
2	and	O	['N']	[2]
3	athelia	O	['N']	[3]
4	:	O	['N']	[4]
5	methimazole	B-Drug	['Causes']	[6]
6	teratogenicity	B-Adverse_Effect	['N']	[6]
7	or	O	['N']	[7]
8	a	O	['N']	[8]
9	new	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	?	O	['N']	[11]
#1367
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	describe	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	receiving	O	['N']	[8]
9	lenalidomide	B-Drug	['Causes']	[12]
10	in	O	['N']	[10]
11	whom	O	['N']	[11]
12	dyspnea	B-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	fever	O	['N']	[14]
15	,	O	['N']	[15]
16	hypoxia	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	diffuse	O	['N']	[19]
20	pulmonary	O	['N']	[20]
21	infiltrates	O	['N']	[21]
22	developed	O	['N']	[22]
23	.	O	['N']	[23]
#1368
0	Eleven	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	infection	O	['N']	[3]
4	requiring	O	['N']	[4]
5	hospitalization	O	['N']	[5]
6	while	O	['N']	[6]
7	taking	O	['N']	[7]
8	leflunomide	B-Drug	['Causes']	[14]
9	including	O	['N']	[9]
10	:	O	['N']	[10]
11	lower	B	['N']	[11]
12	respiratory	I	['N']	[12]
13	tract	I	['N']	[13]
14	infections	I-Adverse_Effect	['N']	[14]
15	(	O	['N']	[15]
16	3	O	['N']	[16]
17	)	O	['N']	[17]
18	,	O	['N']	[18]
19	cellulitis	O	['N']	[19]
20	(	O	['N']	[20]
21	2	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	disseminated	O	['N']	[24]
25	herpes	O	['N']	[25]
26	zoster	O	['N']	[26]
27	(	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	,	O	['N']	[30]
31	probable	O	['N']	[31]
32	TB	O	['N']	[32]
33	liver	O	['N']	[33]
34	(	O	['N']	[34]
35	1	O	['N']	[35]
36	)	O	['N']	[36]
37	,	O	['N']	[37]
38	abdominal	O	['N']	[38]
39	sepsis	O	['N']	[39]
40	(	O	['N']	[40]
41	1	O	['N']	[41]
42	)	O	['N']	[42]
43	,	O	['N']	[43]
44	mycotic	O	['N']	[44]
45	aneurysm	O	['N']	[45]
46	(	O	['N']	[46]
47	1	O	['N']	[47]
48	)	O	['N']	[48]
49	and	O	['N']	[49]
50	gastroenteritis	O	['N']	[50]
51	(	O	['N']	[51]
52	1	O	['N']	[52]
53	)	O	['N']	[53]
54	.	O	['N']	[54]
#1369
0	Sulfasalazine	B-Drug	['Causes']	[12]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	bronchopulmonary	O	['N']	[5]
6	complications	O	['N']	[6]
7	of	O	['N']	[7]
8	inflammatory	O	['N']	[8]
9	bowel	O	['N']	[9]
10	disease	O	['N']	[10]
11	(	O	['N']	[11]
12	IBD	B-Adverse_Effect	['N']	[12]
13	)	O	['N']	[13]
14	in	O	['N']	[14]
15	adults	O	['N']	[15]
16	.	O	['N']	[16]
#1370
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	allogeneic	O	['N']	[3]
4	bone	O	['N']	[4]
5	marrow	O	['N']	[5]
6	transplant	O	['N']	[6]
7	recipient	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	CMV	B	['N']	[10]
11	infection	I-Adverse_Effect	['N']	[11]
12	refractory	O	['N']	[12]
13	to	O	['N']	[13]
14	sequential	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	ganciclovir	O	['N']	[17]
18	,	O	['N']	[18]
19	foscarnet	B-Drug	['Causes']	[11]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	cidofovir	O	['N']	[22]
23	.	O	['N']	[23]
#1371
0	Tenofovir	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	nephrotoxicity	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	HIV	O	['N']	[6]
7	-	O	['N']	[7]
8	infected	O	['N']	[8]
9	adolescent	O	['N']	[9]
10	males	O	['N']	[10]
11	.	O	['N']	[11]
#1372
0	Pediatric	O	['N']	[0]
1	heparin	B-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	thrombocytopenia	B-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	management	O	['N']	[6]
7	with	O	['N']	[7]
8	Danaparoid	O	['N']	[8]
9	(	O	['N']	[9]
10	orgaran	O	['N']	[10]
11	)	O	['N']	[11]
12	.	O	['N']	[12]
#1373
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	child	O	['N']	[3]
4	with	O	['N']	[4]
5	yolk	O	['N']	[5]
6	sac	O	['N']	[6]
7	tumor	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	localized	B	['N']	[10]
11	pigmentation	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	first	O	['N']	[14]
15	course	O	['N']	[15]
16	of	O	['N']	[16]
17	chemotherapy	O	['N']	[17]
18	regimen	O	['N']	[18]
19	that	O	['N']	[19]
20	included	O	['N']	[20]
21	cisplatin	O	['N']	[21]
22	,	O	['N']	[22]
23	etoposide	O	['N']	[23]
24	and	O	['N']	[24]
25	bleomycin	B-Drug	['Causes']	[11]
26	.	O	['N']	[26]
#1374
0	Exfoliative	B	['N']	[0]
1	dermatitis	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	tobramycin	B	['N']	[4]
5	sulfate	I-Drug	['Causes']	[1]
6	.	O	['N']	[6]
#1375
0	Bleomycin	B-Drug	['Causes']	[1]
1	pneumonitis	B-Adverse_Effect	['N']	[1]
2	potentiated	O	['N']	[2]
3	by	O	['N']	[3]
4	oxygen	O	['N']	[4]
5	administration	O	['N']	[5]
6	.	O	['N']	[6]
#1376
0	We	O	['N']	[0]
1	consider	O	['N']	[1]
2	asterixis	O	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	an	O	['N']	[5]
6	easily	O	['N']	[6]
7	overlooked	O	['N']	[7]
8	sign	O	['N']	[8]
9	of	O	['N']	[9]
10	neurotoxicity	O	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	may	O	['N']	[13]
14	occur	O	['N']	[14]
15	even	O	['N']	[15]
16	at	O	['N']	[16]
17	low	B	['N']	[17]
18	or	I	['N']	[18]
19	moderate	I	['N']	[19]
20	dosage	I-Dose	['N']	[20]
21	levels	O	['N']	[21]
22	,	O	['N']	[22]
23	if	O	['N']	[23]
24	certain	O	['N']	[24]
25	drugs	O	['N']	[25]
26	as	O	['N']	[26]
27	lithium	B-Drug	['Dosage']	[20]
28	or	O	['N']	[28]
29	clozapine	O	['N']	[29]
30	are	O	['N']	[30]
31	used	O	['N']	[31]
32	in	O	['N']	[32]
33	combination	O	['N']	[33]
34	with	O	['N']	[34]
35	CBZ	O	['N']	[35]
36	.	O	['N']	[36]
#1377
0	Progressive	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	fibrosis	I-Adverse_Effect	['N']	[2]
3	complicating	O	['N']	[3]
4	cyclophosphamide	B-Drug	['Causes']	[2]
5	therapy	O	['N']	[5]
6	.	O	['N']	[6]
#1378
0	A	O	['N']	[0]
1	56-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	white	O	['N']	[4]
5	woman	O	['N']	[5]
6	with	O	['N']	[6]
7	a	O	['N']	[7]
8	diagnosis	O	['N']	[8]
9	of	O	['N']	[9]
10	reactive	O	['N']	[10]
11	depression	O	['N']	[11]
12	developed	O	['N']	[12]
13	severe	O	['N']	[13]
14	UI	O	['N']	[14]
15	after	O	['N']	[15]
16	a	O	['N']	[16]
17	30	O	['N']	[17]
18	days	O	['N']	[18]
19	'	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	venlafaxine	B-Drug	['Dosage']	[26]
23	75	B	['N']	[23]
24	mg	I	['N']	[24]
25	/	I	['N']	[25]
26	day	I-Dose	['N']	[26]
27	.	O	['N']	[27]
#1379
0	Isotretinoin	B-Drug	['Causes']	[1]
1	teratogenicity	B-Adverse_Effect	['N']	[1]
2	.	O	['N']	[2]
#1380
0	Subfulminant	B	['N']	[0]
1	hepatitis	I	['N']	[1]
2	B	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	infliximab	B-Drug	['Causes']	[2]
5	in	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	:	O	['N']	[9]
10	need	O	['N']	[10]
11	for	O	['N']	[11]
12	HBV	O	['N']	[12]
13	-	O	['N']	[13]
14	screening	O	['N']	[14]
15	?	O	['N']	[15]
#1381
0	The	O	['N']	[0]
1	multiple	B	['N']	[1]
2	comedones	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	ruptured	O	['N']	[4]
5	epidermoid	O	['N']	[5]
6	cysts	O	['N']	[6]
7	are	O	['N']	[7]
8	newly	O	['N']	[8]
9	reported	O	['N']	[9]
10	adverse	O	['N']	[10]
11	effects	O	['N']	[11]
12	of	O	['N']	[12]
13	imiquimod	B-Drug	['Causes']	[2]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#1382
0	Initiation	O	['N']	[0]
1	of	O	['N']	[1]
2	posaconazole	B-Drug	['Causes']	[18]
3	led	O	['N']	[3]
4	to	O	['N']	[4]
5	clinical	O	['N']	[5]
6	improvement	O	['N']	[6]
7	until	O	['N']	[7]
8	the	O	['N']	[8]
9	patient	O	['N']	[9]
10	's	O	['N']	[10]
11	demise	O	['N']	[11]
12	from	O	['N']	[12]
13	bacteremic	O	['N']	[13]
14	vancomycin	O	['N']	[14]
15	-	O	['N']	[15]
16	resistant	O	['N']	[16]
17	enterococcal	B	['N']	[17]
18	peritonitis	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#1383
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	presumed	O	['N']	[2]
3	that	O	['N']	[3]
4	her	O	['N']	[4]
5	hyperchloremic	B	['N']	[5]
6	metabolic	I	['N']	[6]
7	acidosis	I-Adverse_Effect	['N']	[7]
8	was	O	['N']	[8]
9	secondary	O	['N']	[9]
10	to	O	['N']	[10]
11	cholestyramine	B-Drug	['Causes']	[7]
12	because	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	similarity	O	['N']	[15]
16	to	O	['N']	[16]
17	pediatric	O	['N']	[17]
18	reports	O	['N']	[18]
19	;	O	['N']	[19]
20	the	O	['N']	[20]
21	rapid	O	['N']	[21]
22	and	O	['N']	[22]
23	lasting	O	['N']	[23]
24	response	O	['N']	[24]
25	to	O	['N']	[25]
26	intravenous	O	['N']	[26]
27	sodium	O	['N']	[27]
28	bicarbonate	O	['N']	[28]
29	;	O	['N']	[29]
30	the	O	['N']	[30]
31	absence	O	['N']	[31]
32	of	O	['N']	[32]
33	another	O	['N']	[33]
34	etiology	O	['N']	[34]
35	;	O	['N']	[35]
36	normal	O	['N']	[36]
37	serum	O	['N']	[37]
38	potassium	O	['N']	[38]
39	,	O	['N']	[39]
40	chloride	O	['N']	[40]
41	and	O	['N']	[41]
42	bicarbonate	O	['N']	[42]
43	despite	O	['N']	[43]
44	continued	O	['N']	[44]
45	spironolactone	O	['N']	[45]
46	therapy	O	['N']	[46]
47	after	O	['N']	[47]
48	recovery	O	['N']	[48]
49	.	O	['N']	[49]
#1384
0	Both	O	['N']	[0]
1	PAN	B-Drug	['Causes']	[12]
2	and	O	['N']	[2]
3	methotrexate	O	['N']	[3]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	independently	O	['N']	[6]
7	demonstrated	O	['N']	[7]
8	to	O	['N']	[8]
9	cause	O	['N']	[9]
10	sensorineural	B	['N']	[10]
11	hearing	I	['N']	[11]
12	loss	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#1385
0	Thrombotic	B	['N']	[0]
1	thrombocytopenic	I	['N']	[1]
2	purpura	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	trimethoprim	B-Drug	['Causes']	[2]
6	-	O	['N']	[6]
7	sulfamethoxazole	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	Jehovah	O	['N']	[10]
11	's	O	['N']	[11]
12	Witness	O	['N']	[12]
13	.	O	['N']	[13]
#1386
0	AIM	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	three	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	extensive	O	['N']	[7]
8	skin	B	['N']	[8]
9	necrosis	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	cirrhotic	O	['N']	[11]
12	patients	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	vasoconstrictor	O	['N']	[16]
17	agent	O	['N']	[17]
18	terlipressin	O	['N']	[18]
19	(	O	['N']	[19]
20	Glypressin	B-Drug	['Causes']	[9]
21	)	O	['N']	[21]
22	.	O	['N']	[22]
#1387
0	A	O	['N']	[0]
1	60	O	['N']	[1]
2	year	O	['N']	[2]
3	-	O	['N']	[3]
4	old	O	['N']	[4]
5	woman	O	['N']	[5]
6	with	O	['N']	[6]
7	chronic	O	['N']	[7]
8	renal	O	['N']	[8]
9	failure	O	['N']	[9]
10	developed	O	['N']	[10]
11	acute	O	['N']	[11]
12	proximal	O	['N']	[12]
13	muscle	O	['N']	[13]
14	weakness	O	['N']	[14]
15	after	O	['N']	[15]
16	receiving	O	['N']	[16]
17	a	O	['N']	[17]
18	regular	B-Dose	['N']	[18]
19	dosage	O	['N']	[19]
20	of	O	['N']	[20]
21	colchicine	B-Drug	['Dosage']	[18]
22	.	O	['N']	[22]
#1388
0	A	O	['N']	[0]
1	high	B-Dose	['N']	[1]
2	dose	O	['N']	[2]
3	of	O	['N']	[3]
4	cotrimoxazole	B-Drug	['Dosage']	[1]
5	induced	O	['N']	[5]
6	hyperkalaemia	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	elevation	O	['N']	[9]
10	of	O	['N']	[10]
11	serum	O	['N']	[11]
12	creatinine	O	['N']	[12]
13	and	O	['N']	[13]
14	blood	O	['N']	[14]
15	urea	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	increased	O	['N']	[18]
19	urinary	O	['N']	[19]
20	N	O	['N']	[20]
21	-	O	['N']	[21]
22	acetyl	O	['N']	[22]
23	glucosaminase	O	['N']	[23]
24	after	O	['N']	[24]
25	several	O	['N']	[25]
26	days	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	drug	O	['N']	[29]
30	administration	O	['N']	[30]
31	in	O	['N']	[31]
32	these	O	['N']	[32]
33	patients	O	['N']	[33]
34	;	O	['N']	[34]
35	one	O	['N']	[35]
36	patient	O	['N']	[36]
37	became	O	['N']	[37]
38	unconscious	O	['N']	[38]
39	.	O	['N']	[39]
#1389
0	Cholestyramine	B-Drug	['Causes']	[4]
1	induced	O	['N']	[1]
2	hyperchloremic	B	['N']	[2]
3	metabolic	I	['N']	[3]
4	acidosis	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1390
0	Trimethoprim	B	['N']	[0]
1	-	I	['N']	[1]
2	sulfamethoxazole	I-Drug	['Causes']	[6]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	hypersensitivity	B	['N']	[5]
6	syndrome	I-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	reactivation	O	['N']	[9]
10	of	O	['N']	[10]
11	human	O	['N']	[11]
12	herpesvirus-6	O	['N']	[12]
13	.	O	['N']	[13]
#1391
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	urinary	O	['N']	[6]
7	incontinence	O	['N']	[7]
8	(	O	['N']	[8]
9	UI	B-Adverse_Effect	['N']	[9]
10	)	O	['N']	[10]
11	that	O	['N']	[11]
12	occurred	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	woman	O	['N']	[15]
16	after	O	['N']	[16]
17	administration	O	['N']	[17]
18	of	O	['N']	[18]
19	venlafaxine	B-Drug	['Causes']	[9]
20	.	O	['N']	[20]
#1392
0	In	O	['N']	[0]
1	deciding	O	['N']	[1]
2	if	O	['N']	[2]
3	tamoxifen	B-Drug	['Causes']	[24]
4	therapy	O	['N']	[4]
5	is	O	['N']	[5]
6	warranted	O	['N']	[6]
7	,	O	['N']	[7]
8	all	O	['N']	[8]
9	potentially	O	['N']	[9]
10	life	O	['N']	[10]
11	-	O	['N']	[11]
12	threatening	O	['N']	[12]
13	adverse	O	['N']	[13]
14	events	O	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	tamoxifen	O	['N']	[17]
18	should	O	['N']	[18]
19	be	O	['N']	[19]
20	considered	O	['N']	[20]
21	,	O	['N']	[21]
22	including	O	['N']	[22]
23	endometrial	B	['N']	[23]
24	adenocarcinoma	I-Adverse_Effect	['N']	[24]
25	or	O	['N']	[25]
26	uterine	O	['N']	[26]
27	sarcoma	O	['N']	[27]
28	.	O	['N']	[28]
#1393
0	After	O	['N']	[0]
1	nine	O	['N']	[1]
2	previous	O	['N']	[2]
3	uncomplicated	O	['N']	[3]
4	cycles	O	['N']	[4]
5	she	O	['N']	[5]
6	developed	O	['N']	[6]
7	severe	O	['N']	[7]
8	anaphylaxis	B-Adverse_Effect	['N']	[8]
9	to	O	['N']	[9]
10	cisplatin	B-Drug	['Causes']	[8]
11	.	O	['N']	[11]
#1394
0	We	O	['N']	[0]
1	reported	O	['N']	[1]
2	3	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	acute	O	['N']	[6]
7	generalized	O	['N']	[7]
8	dystonia	O	['N']	[8]
9	and	O	['N']	[9]
10	akinetic	B	['N']	[10]
11	rigid	I	['N']	[11]
12	syndrome	I-Adverse_Effect	['N']	[12]
13	following	O	['N']	[13]
14	an	O	['N']	[14]
15	initial	O	['N']	[15]
16	therapy	O	['N']	[16]
17	with	O	['N']	[17]
18	d	B	['N']	[18]
19	-	I	['N']	[19]
20	penicillamine	I-Drug	['Causes']	[12]
21	125	O	['N']	[21]
22	-	O	['N']	[22]
23	500	O	['N']	[23]
24	mg	O	['N']	[24]
25	daily	O	['N']	[25]
26	.	O	['N']	[26]
#1395
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	demonstrates	O	['N']	[2]
3	that	O	['N']	[3]
4	hypersensitivity	B	['N']	[4]
5	reaction	I-Adverse_Effect	['N']	[5]
6	to	O	['N']	[6]
7	pranlukast	B-Drug	['Causes']	[5]
8	and	O	['N']	[8]
9	resultant	O	['N']	[9]
10	ATIN	O	['N']	[10]
11	is	O	['N']	[11]
12	possible	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	that	O	['N']	[15]
16	periodic	O	['N']	[16]
17	urine	O	['N']	[17]
18	testing	O	['N']	[18]
19	in	O	['N']	[19]
20	patients	O	['N']	[20]
21	receiving	O	['N']	[21]
22	pranlukast	O	['N']	[22]
23	should	O	['N']	[23]
24	be	O	['N']	[24]
25	considered	O	['N']	[25]
26	.	O	['N']	[26]
#1396
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	combined	O	['N']	[6]
7	lithium	B-Drug	['Causes']	[25]
8	and	O	['N']	[8]
9	haloperidol	O	['N']	[9]
10	toxicity	O	['N']	[10]
11	characterized	O	['N']	[11]
12	by	O	['N']	[12]
13	hyperpyrexia	O	['N']	[13]
14	,	O	['N']	[14]
15	severe	O	['N']	[15]
16	rigidity	O	['N']	[16]
17	,	O	['N']	[17]
18	mutism	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	development	O	['N']	[21]
22	of	O	['N']	[22]
23	irreversible	B	['N']	[23]
24	tardive	I	['N']	[24]
25	dyskinesia	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#1397
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	hypersensitivity	B	['N']	[5]
6	syndrome	I-Adverse_Effect	['N']	[6]
7	occurring	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	being	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	dapsone	B-Drug	['Causes']	[6]
15	for	O	['N']	[15]
16	a	O	['N']	[16]
17	brown	O	['N']	[17]
18	recluse	O	['N']	[18]
19	spider	O	['N']	[19]
20	bite	O	['N']	[20]
21	is	O	['N']	[21]
22	presented	O	['N']	[22]
23	.	O	['N']	[23]
#1398
0	Rifampin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	thrombocytopenia	B-Adverse_Effect	['N']	[3]
4	secondary	O	['N']	[4]
5	to	O	['N']	[5]
6	poor	O	['N']	[6]
7	compliance	O	['N']	[7]
8	.	O	['N']	[8]
#1399
0	On	O	['N']	[0]
1	day	O	['N']	[1]
2	4	O	['N']	[2]
3	,	O	['N']	[3]
4	following	O	['N']	[4]
5	3	O	['N']	[5]
6	doses	O	['N']	[6]
7	of	O	['N']	[7]
8	dalteparin	B-Drug	['Causes']	[15]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	patient	O	['N']	[11]
12	developed	O	['N']	[12]
13	acute	B	['N']	[13]
14	respiratory	I	['N']	[14]
15	distress	I-Adverse_Effect	['N']	[15]
16	attributable	O	['N']	[16]
17	to	O	['N']	[17]
18	a	O	['N']	[18]
19	massive	O	['N']	[19]
20	right	O	['N']	[20]
21	hemothorax	O	['N']	[21]
22	confirmed	O	['N']	[22]
23	by	O	['N']	[23]
24	computed	O	['N']	[24]
25	tomography	O	['N']	[25]
26	pulmonary	O	['N']	[26]
27	angiography	O	['N']	[27]
28	(	O	['N']	[28]
29	CTPA	O	['N']	[29]
30	)	O	['N']	[30]
31	and	O	['N']	[31]
32	intercostal	O	['N']	[32]
33	drainage	O	['N']	[33]
34	of	O	['N']	[34]
35	1500	O	['N']	[35]
36	mL	O	['N']	[36]
37	of	O	['N']	[37]
38	frank	O	['N']	[38]
39	blood	O	['N']	[39]
40	.	O	['N']	[40]
#1400
0	Tardive	B	['N']	[0]
1	dyskinesia	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	2	O	['N']	[3]
4	patients	O	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	ziprasidone	B-Drug	['Causes']	[1]
8	.	O	['N']	[8]
#1401
0	Hypotension	O	['N']	[0]
1	and	O	['N']	[1]
2	sinus	B	['N']	[2]
3	arrest	I-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	nifedipine	B-Drug	['Causes']	[3]
6	in	O	['N']	[6]
7	pulmonary	O	['N']	[7]
8	hypertension	O	['N']	[8]
9	.	O	['N']	[9]
#1402
0	Nine	O	['N']	[0]
1	azotemic	O	['N']	[1]
2	patients	O	['N']	[2]
3	who	O	['N']	[3]
4	developed	O	['N']	[4]
5	a	O	['N']	[5]
6	coagulopathy	B-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	use	O	['N']	[10]
11	of	O	['N']	[11]
12	either	O	['N']	[12]
13	cephalosporin	B-Drug	['Causes']	[6]
14	or	O	['N']	[14]
15	moxalactam	O	['N']	[15]
16	antibiotics	O	['N']	[16]
17	are	O	['N']	[17]
18	reported	O	['N']	[18]
19	.	O	['N']	[19]
#1403
0	Hypersensitivity	B	['N']	[0]
1	reactions	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	chloramphenicol	B-Drug	['Causes']	[1]
5	are	O	['N']	[5]
6	rarely	O	['N']	[6]
7	reported	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	literature	O	['N']	[10]
11	.	O	['N']	[11]
#1404
0	Syndrome	B	['N']	[0]
1	of	I	['N']	[1]
2	inappropriate	I	['N']	[2]
3	secretion	I	['N']	[3]
4	of	I	['N']	[4]
5	ADH	I-Adverse_Effect	['N']	[5]
6	(	O	['N']	[6]
7	SIADH	O	['N']	[7]
8	)	O	['N']	[8]
9	following	O	['N']	[9]
10	cisplatin	B-Drug	['Causes']	[5]
11	administration	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	pulmonary	O	['N']	[14]
15	adenocarcinoma	O	['N']	[15]
16	patient	O	['N']	[16]
17	with	O	['N']	[17]
18	a	O	['N']	[18]
19	malignant	O	['N']	[19]
20	pleural	O	['N']	[20]
21	effusion	O	['N']	[21]
22	.	O	['N']	[22]
#1405
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	60-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	erythema	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	erosions	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	axilla	O	['N']	[17]
18	and	O	['N']	[18]
19	groin	O	['N']	[19]
20	while	O	['N']	[20]
21	on	O	['N']	[21]
22	PLD	B-Drug	['Causes']	[12]
23	for	O	['N']	[23]
24	breast	O	['N']	[24]
25	cancer	O	['N']	[25]
26	.	O	['N']	[26]
#1406
0	EEG	B	['N']	[0]
1	abnormalities	I-Adverse_Effect	['N']	[1]
2	were	O	['N']	[2]
3	observed	O	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	nine	O	['N']	[8]
9	children	O	['N']	[9]
10	during	O	['N']	[10]
11	chlorambucil	B-Drug	['Causes']	[1]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#1407
0	Goiter	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	hypothyroidism	O	['N']	[2]
3	during	O	['N']	[3]
4	re	O	['N']	[4]
5	-	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	amiodarone	B-Drug	['Causes']	[0]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	previously	O	['N']	[13]
14	experienced	O	['N']	[14]
15	amiodarone	O	['N']	[15]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	thyrotoxicosis	O	['N']	[18]
19	.	O	['N']	[19]
#1408
0	Sensorimotor	B	['N']	[0]
1	polyneuropathy	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	5-aminosalicylic	B	['N']	[3]
4	acid	I-Drug	['Causes']	[1]
5	:	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	report	O	['N']	[8]
9	.	O	['N']	[9]
#1409
0	Lithium	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	transient	B	['N']	[3]
4	thyrotoxicosis	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	4	O	['N']	[6]
7	Chinese	O	['N']	[7]
8	women	O	['N']	[8]
9	with	O	['N']	[9]
10	autoimmune	O	['N']	[10]
11	thyroiditis	O	['N']	[11]
12	.	O	['N']	[12]
#1410
0	A	O	['N']	[0]
1	toxic	O	['N']	[1]
2	encephalopathy	O	['N']	[2]
3	characterized	O	['N']	[3]
4	by	O	['N']	[4]
5	depressed	O	['N']	[5]
6	level	O	['N']	[6]
7	of	O	['N']	[7]
8	consciousness	O	['N']	[8]
9	,	O	['N']	[9]
10	marked	B	['N']	[10]
11	irritability	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	ataxia	O	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	seven	O	['N']	[17]
18	children	O	['N']	[18]
19	,	O	['N']	[19]
20	5	O	['N']	[20]
21	years	O	['N']	[21]
22	of	O	['N']	[22]
23	age	O	['N']	[23]
24	and	O	['N']	[24]
25	younger	O	['N']	[25]
26	,	O	['N']	[26]
27	following	O	['N']	[27]
28	administration	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	antiemetic	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	pentobarbital	O	['N']	[34]
35	and	O	['N']	[35]
36	pyrilamine	B	['N']	[36]
37	maleate	I-Drug	['Causes']	[11]
38	.	O	['N']	[38]
#1411
0	Gemcitabine	B-Drug	['Causes']	[13]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	added	O	['N']	[3]
4	to	O	['N']	[4]
5	the	O	['N']	[5]
6	list	O	['N']	[6]
7	of	O	['N']	[7]
8	drugs	O	['N']	[8]
9	known	O	['N']	[9]
10	to	O	['N']	[10]
11	cause	O	['N']	[11]
12	radiation	B	['N']	[12]
13	recall	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#1412
0	After	O	['N']	[0]
1	seven	O	['N']	[1]
2	months	O	['N']	[2]
3	'	O	['N']	[3]
4	continuous	O	['N']	[4]
5	treatment	O	['N']	[5]
6	for	O	['N']	[6]
7	suspected	O	['N']	[7]
8	tuberculosis	O	['N']	[8]
9	with	O	['N']	[9]
10	rifampicin	O	['N']	[10]
11	and	O	['N']	[11]
12	ethambutol	B-Drug	['Causes']	[25]
13	a	O	['N']	[13]
14	nine	O	['N']	[14]
15	-	O	['N']	[15]
16	year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	boy	O	['N']	[19]
20	developed	O	['N']	[20]
21	polyarthritis	O	['N']	[21]
22	,	O	['N']	[22]
23	rash	O	['N']	[23]
24	and	O	['N']	[24]
25	hepatitis	B-Adverse_Effect	['N']	[25]
26	in	O	['N']	[26]
27	association	O	['N']	[27]
28	with	O	['N']	[28]
29	anti	O	['N']	[29]
30	-	O	['N']	[30]
31	native	O	['N']	[31]
32	DNA	O	['N']	[32]
33	antibodies	O	['N']	[33]
34	and	O	['N']	[34]
35	positive	O	['N']	[35]
36	antinuclear	O	['N']	[36]
37	factor	O	['N']	[37]
38	.	O	['N']	[38]
#1413
0	Torsade	B	['N']	[0]
1	de	I	['N']	[1]
2	pointes	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	loading	O	['N']	[4]
5	with	O	['N']	[5]
6	amiodarone	B-Drug	['Causes']	[2]
7	.	O	['N']	[7]
#1414
0	Infant	O	['N']	[0]
1	twins	O	['N']	[1]
2	sustained	O	['N']	[2]
3	severe	O	['N']	[3]
4	circumoral	B	['N']	[4]
5	and	I	['N']	[5]
6	pharyngeal	I	['N']	[6]
7	burns	I-Adverse_Effect	['N']	[7]
8	from	O	['N']	[8]
9	a	O	['N']	[9]
10	concentrated	O	['N']	[10]
11	solution	O	['N']	[11]
12	of	O	['N']	[12]
13	benzalkonium	B-Drug	['Causes']	[7]
14	(	O	['N']	[14]
15	Zephiran	O	['N']	[15]
16	)	O	['N']	[16]
17	chloride	O	['N']	[17]
18	prescribed	O	['N']	[18]
19	for	O	['N']	[19]
20	treatment	O	['N']	[20]
21	of	O	['N']	[21]
22	candidiasis	O	['N']	[22]
23	.	O	['N']	[23]
#1415
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	risk	O	['N']	[6]
7	of	O	['N']	[7]
8	severe	O	['N']	[8]
9	AIHA	B-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	CLL	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	history	O	['N']	[15]
16	of	O	['N']	[16]
17	AIHA	O	['N']	[17]
18	or	O	['N']	[18]
19	positivation	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	DAT	O	['N']	[22]
23	during	O	['N']	[23]
24	previous	O	['N']	[24]
25	fludarabine	B-Drug	['Causes']	[9]
26	administration	O	['N']	[26]
27	,	O	['N']	[27]
28	or	O	['N']	[28]
29	in	O	['N']	[29]
30	case	O	['N']	[30]
31	of	O	['N']	[31]
32	secondary	O	['N']	[32]
33	fixation	O	['N']	[33]
34	of	O	['N']	[34]
35	complement	O	['N']	[35]
36	to	O	['N']	[36]
37	the	O	['N']	[37]
38	red	O	['N']	[38]
39	cell	O	['N']	[39]
40	membrane	O	['N']	[40]
41	occurring	O	['N']	[41]
42	during	O	['N']	[42]
43	fludarabine	O	['N']	[43]
44	treatment	O	['N']	[44]
45	.	O	['N']	[45]
#1416
0	When	O	['N']	[0]
1	SASP	O	['N']	[1]
2	was	O	['N']	[2]
3	changed	O	['N']	[3]
4	to	O	['N']	[4]
5	5-aminosalicylic	O	['N']	[5]
6	acid	O	['N']	[6]
7	(	O	['N']	[7]
8	5-ASA	B-Drug	['Causes']	[23]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	his	O	['N']	[11]
12	skin	O	['N']	[12]
13	eruptions	O	['N']	[13]
14	were	O	['N']	[14]
15	resolved	O	['N']	[15]
16	,	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	he	O	['N']	[19]
20	developed	O	['N']	[20]
21	weakness	O	['N']	[21]
22	and	O	['N']	[22]
23	atrophy	B-Adverse_Effect	['N']	[23]
24	in	O	['N']	[24]
25	his	O	['N']	[25]
26	right	O	['N']	[26]
27	arm	O	['N']	[27]
28	as	O	['N']	[28]
29	well	O	['N']	[29]
30	as	O	['N']	[30]
31	progressive	O	['N']	[31]
32	worsening	O	['N']	[32]
33	of	O	['N']	[33]
34	the	O	['N']	[34]
35	dysesthesia	O	['N']	[35]
36	in	O	['N']	[36]
37	his	O	['N']	[37]
38	legs	O	['N']	[38]
39	and	O	['N']	[39]
40	gait	O	['N']	[40]
41	disturbance	O	['N']	[41]
42	.	O	['N']	[42]
#1417
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	mild	O	['N']	[8]
9	chronic	O	['N']	[9]
10	renal	O	['N']	[10]
11	insufficiency	O	['N']	[11]
12	who	O	['N']	[12]
13	had	O	['N']	[13]
14	been	O	['N']	[14]
15	taking	O	['N']	[15]
16	simvastatin	B-Drug	['Causes']	[24]
17	for	O	['N']	[17]
18	over	O	['N']	[18]
19	a	O	['N']	[19]
20	year	O	['N']	[20]
21	and	O	['N']	[21]
22	developed	O	['N']	[22]
23	acute	B	['N']	[23]
24	weakness	I-Adverse_Effect	['N']	[24]
25	within	O	['N']	[25]
26	3	O	['N']	[26]
27	weeks	O	['N']	[27]
28	after	O	['N']	[28]
29	the	O	['N']	[29]
30	start	O	['N']	[30]
31	of	O	['N']	[31]
32	treatment	O	['N']	[32]
33	with	O	['N']	[33]
34	colchicine	O	['N']	[34]
35	for	O	['N']	[35]
36	acute	O	['N']	[36]
37	gouty	O	['N']	[37]
38	bursitis	O	['N']	[38]
39	.	O	['N']	[39]
#1418
0	Ampicillin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	interstitial	B	['N']	[3]
4	nephritis	I-Adverse_Effect	['N']	[4]
5	with	O	['N']	[5]
6	generalised	O	['N']	[6]
7	exfoliative	O	['N']	[7]
8	dermatitis	O	['N']	[8]
9	.	O	['N']	[9]
#1419
0	A	O	['N']	[0]
1	53-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	lower	B	['N']	[6]
7	leg	I	['N']	[7]
8	edema	I-Adverse_Effect	['N']	[8]
9	4	O	['N']	[9]
10	weeks	O	['N']	[10]
11	after	O	['N']	[11]
12	rosiglitazone	B-Drug	['Causes']	[8]
13	was	O	['N']	[13]
14	increased	O	['N']	[14]
15	from	O	['N']	[15]
16	4	O	['N']	[16]
17	mg	O	['N']	[17]
18	once	O	['N']	[18]
19	/	O	['N']	[19]
20	day	O	['N']	[20]
21	to	O	['N']	[21]
22	4	O	['N']	[22]
23	mg	O	['N']	[23]
24	twice	O	['N']	[24]
25	/	O	['N']	[25]
26	day	O	['N']	[26]
27	.	O	['N']	[27]
#1420
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	fluoxetine	B-Drug	['Causes']	[5]
4	induced	O	['N']	[4]
5	seizures	B-Adverse_Effect	['N']	[5]
6	,	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	person	O	['N']	[9]
10	with	O	['N']	[10]
11	Down	O	['N']	[11]
12	syndrome	O	['N']	[12]
13	,	O	['N']	[13]
14	is	O	['N']	[14]
15	described	O	['N']	[15]
16	.	O	['N']	[16]
#1421
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	28-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	suffering	O	['N']	[8]
9	from	O	['N']	[9]
10	panic	O	['N']	[10]
11	disorder	O	['N']	[11]
12	,	O	['N']	[12]
13	developed	O	['N']	[13]
14	several	O	['N']	[14]
15	first	B	['N']	[15]
16	-	I	['N']	[16]
17	rank	I	['N']	[17]
18	symptoms	I-Adverse_Effect	['N']	[18]
19	during	O	['N']	[19]
20	fluvoxamine	B-Drug	['Causes']	[18]
21	administration	O	['N']	[21]
22	.	O	['N']	[22]
#1422
0	Previous	O	['N']	[0]
1	studies	O	['N']	[1]
2	have	O	['N']	[2]
3	demonstrated	O	['N']	[3]
4	the	O	['N']	[4]
5	interaction	O	['N']	[5]
6	of	O	['N']	[6]
7	MTX	B-Drug	['Causes']	[40]
8	and	O	['N']	[8]
9	a	O	['N']	[9]
10	variety	O	['N']	[10]
11	of	O	['N']	[11]
12	non	O	['N']	[12]
13	-	O	['N']	[13]
14	steroidal	O	['N']	[14]
15	,	O	['N']	[15]
16	anti	O	['N']	[16]
17	-	O	['N']	[17]
18	inflammatory	O	['N']	[18]
19	drugs	O	['N']	[19]
20	(	O	['N']	[20]
21	NSAIDs	O	['N']	[21]
22	)	O	['N']	[22]
23	with	O	['N']	[23]
24	various	O	['N']	[24]
25	clinical	O	['N']	[25]
26	manifestations	O	['N']	[26]
27	including	O	['N']	[27]
28	acute	O	['N']	[28]
29	renal	O	['N']	[29]
30	failure	O	['N']	[30]
31	,	O	['N']	[31]
32	pancytopenia	O	['N']	[32]
33	,	O	['N']	[33]
34	vomiting	O	['N']	[34]
35	,	O	['N']	[35]
36	diarrhea	O	['N']	[36]
37	,	O	['N']	[37]
38	elevated	B	['N']	[38]
39	liver	I	['N']	[39]
40	transaminases	I-Adverse_Effect	['N']	[40]
41	,	O	['N']	[41]
42	jaundice	O	['N']	[42]
43	,	O	['N']	[43]
44	mucosal	O	['N']	[44]
45	ulcerations	O	['N']	[45]
46	,	O	['N']	[46]
47	and	O	['N']	[47]
48	pyrexia	O	['N']	[48]
49	.	O	['N']	[49]
#1423
0	Spontaneous	B	['N']	[0]
1	hemothorax	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	anticoagulation	O	['N']	[3]
4	with	O	['N']	[4]
5	low	O	['N']	[5]
6	-	O	['N']	[6]
7	molecular	O	['N']	[7]
8	-	O	['N']	[8]
9	weight	O	['N']	[9]
10	heparin	B-Drug	['Causes']	[1]
11	.	O	['N']	[11]
#1424
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	human	O	['N']	[5]
6	immunodeficiency	O	['N']	[6]
7	virus	O	['N']	[7]
8	infection	O	['N']	[8]
9	under	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	foscarnet	B-Drug	['Causes']	[21]
13	for	O	['N']	[13]
14	CMV	O	['N']	[14]
15	retinitis	O	['N']	[15]
16	who	O	['N']	[16]
17	complained	O	['N']	[17]
18	of	O	['N']	[18]
19	thirst	O	['N']	[19]
20	and	O	['N']	[20]
21	polyuria	B-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1425
0	ARDS	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	rarely	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	rituximab	B-Drug	['Causes']	[0]
6	infusion	O	['N']	[6]
7	for	O	['N']	[7]
8	lympho	O	['N']	[8]
9	-	O	['N']	[9]
10	proliferative	O	['N']	[10]
11	disorders	O	['N']	[11]
12	,	O	['N']	[12]
13	but	O	['N']	[13]
14	it	O	['N']	[14]
15	should	O	['N']	[15]
16	be	O	['N']	[16]
17	considered	O	['N']	[17]
18	by	O	['N']	[18]
19	those	O	['N']	[19]
20	administering	O	['N']	[20]
21	rituximab	O	['N']	[21]
22	,	O	['N']	[22]
23	especially	O	['N']	[23]
24	when	O	['N']	[24]
25	a	O	['N']	[25]
26	patient	O	['N']	[26]
27	develops	O	['N']	[27]
28	severe	O	['N']	[28]
29	pulmonary	O	['N']	[29]
30	symptoms	O	['N']	[30]
31	soon	O	['N']	[31]
32	after	O	['N']	[32]
33	infusion	O	['N']	[33]
34	.	O	['N']	[34]
#1426
0	The	O	['N']	[0]
1	principle	O	['N']	[1]
2	treatment	O	['N']	[2]
3	for	O	['N']	[3]
4	DPD	O	['N']	[4]
5	-	O	['N']	[5]
6	deficient	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	severe	O	['N']	[9]
10	acute	O	['N']	[10]
11	5-FU	B-Drug	['Causes']	[31]
12	reactions	O	['N']	[12]
13	is	O	['N']	[13]
14	supportive	O	['N']	[14]
15	care	O	['N']	[15]
16	;	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	thymidine	O	['N']	[22]
23	potentially	O	['N']	[23]
24	may	O	['N']	[24]
25	reverse	O	['N']	[25]
26	severe	O	['N']	[26]
27	5-FU	O	['N']	[27]
28	-	O	['N']	[28]
29	induced	O	['N']	[29]
30	neurologic	B	['N']	[30]
31	symptoms	I-Adverse_Effect	['N']	[31]
32	such	O	['N']	[32]
33	as	O	['N']	[33]
34	encephalopathy	O	['N']	[34]
35	and	O	['N']	[35]
36	coma	O	['N']	[36]
37	.	O	['N']	[37]
#1427
0	A	O	['N']	[0]
1	49-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	prednisone	O	['N']	[11]
12	and	O	['N']	[12]
13	mesalamine	O	['N']	[13]
14	(	O	['N']	[14]
15	5-ASA	B-Drug	['Causes']	[22]
16	)	O	['N']	[16]
17	developed	O	['N']	[17]
18	worsening	O	['N']	[18]
19	respiratory	O	['N']	[19]
20	distress	O	['N']	[20]
21	and	O	['N']	[21]
22	fever	B-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#1428
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	osteosarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	normal	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	manifested	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	impending	O	['N']	[15]
16	renal	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	and	O	['N']	[18]
19	extreme	O	['N']	[19]
20	elevation	O	['N']	[20]
21	of	O	['N']	[21]
22	aspartate	O	['N']	[22]
23	aminotrasferase	O	['N']	[23]
24	and	O	['N']	[24]
25	alanine	O	['N']	[25]
26	aminotransferase	O	['N']	[26]
27	within	O	['N']	[27]
28	2	O	['N']	[28]
29	hours	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	completion	O	['N']	[32]
33	of	O	['N']	[33]
34	a	O	['N']	[34]
35	4-hour	O	['N']	[35]
36	infusion	O	['N']	[36]
37	of	O	['N']	[37]
38	high	O	['N']	[38]
39	-	O	['N']	[39]
40	dose	O	['N']	[40]
41	methotrexate	O	['N']	[41]
42	(	O	['N']	[42]
43	MTX	B-Drug	['Dosage']	[49]
44	)	O	['N']	[44]
45	(	O	['N']	[45]
46	12	B	['N']	[46]
47	g	I	['N']	[47]
48	/	I	['N']	[48]
49	m2	I-Dose	['N']	[49]
50	)	O	['N']	[50]
51	,	O	['N']	[51]
52	and	O	['N']	[52]
53	went	O	['N']	[53]
54	on	O	['N']	[54]
55	to	O	['N']	[55]
56	develop	O	['N']	[56]
57	acute	O	['N']	[57]
58	renal	O	['N']	[58]
59	failure	O	['N']	[59]
60	with	O	['N']	[60]
61	life	O	['N']	[61]
62	-	O	['N']	[62]
63	threatening	O	['N']	[63]
64	hyperkalemia	O	['N']	[64]
65	29	O	['N']	[65]
66	hours	O	['N']	[66]
67	later	O	['N']	[67]
68	.	O	['N']	[68]
#1429
0	Severe	B	['N']	[0]
1	visual	I	['N']	[1]
2	loss	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	a	O	['N']	[4]
5	single	O	['N']	[5]
6	dose	O	['N']	[6]
7	of	O	['N']	[7]
8	vincristine	B-Drug	['Causes']	[2]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	with	O	['N']	[12]
13	spinal	O	['N']	[13]
14	cord	O	['N']	[14]
15	astrocytoma	O	['N']	[15]
16	.	O	['N']	[16]
#1430
0	Mammary	B	['N']	[0]
1	gigantism	I-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	rare	O	['N']	[4]
5	complication	O	['N']	[5]
6	of	O	['N']	[6]
7	D	B	['N']	[7]
8	-	I	['N']	[8]
9	penicillamine	I-Drug	['Causes']	[1]
10	treatment	O	['N']	[10]
11	.	O	['N']	[11]
#1431
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Hypersensitivity	O	['N']	[2]
3	reaction	O	['N']	[3]
4	should	O	['N']	[4]
5	be	O	['N']	[5]
6	considered	O	['N']	[6]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	who	O	['N']	[9]
10	develop	O	['N']	[10]
11	recurrent	O	['N']	[11]
12	eosinophilia	O	['N']	[12]
13	and	O	['N']	[13]
14	deterioration	B	['N']	[14]
15	of	I	['N']	[15]
16	pulmonary	I	['N']	[16]
17	function	I-Adverse_Effect	['N']	[17]
18	following	O	['N']	[18]
19	the	O	['N']	[19]
20	use	O	['N']	[20]
21	of	O	['N']	[21]
22	tobramycin	B-Drug	['Causes']	[17]
23	by	O	['N']	[23]
24	inhalation	O	['N']	[24]
25	or	O	['N']	[25]
26	by	O	['N']	[26]
27	intravenous	O	['N']	[27]
28	administration	O	['N']	[28]
29	.	O	['N']	[29]
#1432
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	37-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	African-	O	['N']	[6]
7	American	O	['N']	[7]
8	man	O	['N']	[8]
9	with	O	['N']	[9]
10	G6PD	O	['N']	[10]
11	deficiency	O	['N']	[11]
12	developed	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	anemia	O	['N']	[14]
15	,	O	['N']	[15]
16	hepatitis	O	['N']	[16]
17	,	O	['N']	[17]
18	orthostatic	B	['N']	[18]
19	hypotension	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	aseptic	O	['N']	[22]
23	meningitis	O	['N']	[23]
24	simultaneously	O	['N']	[24]
25	after	O	['N']	[25]
26	using	O	['N']	[26]
27	trimethoprim	B-Drug	['Causes']	[19]
28	-	O	['N']	[28]
29	sulfamethoxazole	O	['N']	[29]
30	.	O	['N']	[30]
#1433
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	tuberculosis	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	on	O	['N']	[7]
8	Efalizumab	O	['N']	[8]
9	and	O	['N']	[9]
10	Etanercept	B-Drug	['Causes']	[3]
11	for	O	['N']	[11]
12	treatment	O	['N']	[12]
13	of	O	['N']	[13]
14	refractory	O	['N']	[14]
15	palmopustular	O	['N']	[15]
16	psoriasis	O	['N']	[16]
17	and	O	['N']	[17]
18	psoriatic	O	['N']	[18]
19	arthritis	O	['N']	[19]
20	.	O	['N']	[20]
#1434
0	A	O	['N']	[0]
1	17-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	been	O	['N']	[8]
9	taking	O	['N']	[9]
10	oral	O	['N']	[10]
11	minocycline	B-Drug	['Causes']	[31]
12	(	O	['N']	[12]
13	50	O	['N']	[13]
14	mg	O	['N']	[14]
15	twice	O	['N']	[15]
16	daily	O	['N']	[16]
17	)	O	['N']	[17]
18	for	O	['N']	[18]
19	3	O	['N']	[19]
20	weeks	O	['N']	[20]
21	for	O	['N']	[21]
22	acne	O	['N']	[22]
23	developed	O	['N']	[23]
24	an	O	['N']	[24]
25	eruption	O	['N']	[25]
26	that	O	['N']	[26]
27	progressed	O	['N']	[27]
28	to	O	['N']	[28]
29	an	O	['N']	[29]
30	exfoliative	B	['N']	[30]
31	dermatitis	I-Adverse_Effect	['N']	[31]
32	.	O	['N']	[32]
#1435
0	Paraplegia	B-Adverse_Effect	['N']	[0]
1	following	O	['N']	[1]
2	prophylactic	O	['N']	[2]
3	intrathecal	O	['N']	[3]
4	cytosine	O	['N']	[4]
5	arabinoside	O	['N']	[5]
6	(	O	['N']	[6]
7	Ara	B	['N']	[7]
8	-	I	['N']	[8]
9	C	I-Drug	['Causes']	[0]
10	)	O	['N']	[10]
11	is	O	['N']	[11]
12	described	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	patient	O	['N']	[15]
16	with	O	['N']	[16]
17	acute	O	['N']	[17]
18	myelogenous	O	['N']	[18]
19	leukemia	O	['N']	[19]
20	in	O	['N']	[20]
21	remission	O	['N']	[21]
22	who	O	['N']	[22]
23	received	O	['N']	[23]
24	doses	O	['N']	[24]
25	of	O	['N']	[25]
26	100	O	['N']	[26]
27	mg	O	['N']	[27]
28	/	O	['N']	[28]
29	m2/d	O	['N']	[29]
30	for	O	['N']	[30]
31	5	O	['N']	[31]
32	consecutive	O	['N']	[32]
33	days	O	['N']	[33]
34	.	O	['N']	[34]
#1436
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	interstitial	B	['N']	[5]
6	pneumonitis	I-Adverse_Effect	['N']	[6]
7	induced	O	['N']	[7]
8	by	O	['N']	[8]
9	bicalutamide	O	['N']	[9]
10	and/or	O	['N']	[10]
11	leuprorelin	B	['N']	[11]
12	acetate	I-Drug	['Causes']	[6]
13	given	O	['N']	[13]
14	as	O	['N']	[14]
15	therapy	O	['N']	[15]
16	for	O	['N']	[16]
17	prostate	O	['N']	[17]
18	cancer	O	['N']	[18]
19	,	O	['N']	[19]
20	in	O	['N']	[20]
21	which	O	['N']	[21]
22	the	O	['N']	[22]
23	pneumonitis	O	['N']	[23]
24	was	O	['N']	[24]
25	successfully	O	['N']	[25]
26	managed	O	['N']	[26]
27	by	O	['N']	[27]
28	steroid	O	['N']	[28]
29	treatment	O	['N']	[29]
30	.	O	['N']	[30]
#1437
0	He	O	['N']	[0]
1	was	O	['N']	[1]
2	diagnosed	O	['N']	[2]
3	with	O	['N']	[3]
4	possible	O	['N']	[4]
5	serotonin	B	['N']	[5]
6	syndrome	I-Adverse_Effect	['N']	[6]
7	;	O	['N']	[7]
8	his	O	['N']	[8]
9	symptoms	O	['N']	[9]
10	resolved	O	['N']	[10]
11	after	O	['N']	[11]
12	clomipramine	B-Drug	['Causes']	[6]
13	was	O	['N']	[13]
14	stopped	O	['N']	[14]
15	but	O	['N']	[15]
16	before	O	['N']	[16]
17	clozapine	O	['N']	[17]
18	was	O	['N']	[18]
19	restarted	O	['N']	[19]
20	eight	O	['N']	[20]
21	days	O	['N']	[21]
22	later	O	['N']	[22]
23	.	O	['N']	[23]
#1438
0	Thrombocytosis	B-Adverse_Effect	['N']	[0]
1	under	O	['N']	[1]
2	ciprofloxacin	O	['N']	[2]
3	and	O	['N']	[3]
4	tazobactam	O	['N']	[4]
5	/	O	['N']	[5]
6	piperacillin	B-Drug	['Causes']	[0]
7	.	O	['N']	[7]
#1439
0	A	O	['N']	[0]
1	further	O	['N']	[1]
2	case	O	['N']	[2]
3	of	O	['N']	[3]
4	anaphylactoid	B	['N']	[4]
5	reaction	I-Adverse_Effect	['N']	[5]
6	to	O	['N']	[6]
7	methylprednisolone	B-Drug	['Causes']	[5]
8	is	O	['N']	[8]
9	reported	O	['N']	[9]
10	.	O	['N']	[10]
#1440
0	Renal	O	['N']	[0]
1	hypophosphatemia	O	['N']	[1]
2	in	O	['N']	[2]
3	this	O	['N']	[3]
4	patient	O	['N']	[4]
5	was	O	['N']	[5]
6	caused	O	['N']	[6]
7	by	O	['N']	[7]
8	the	O	['N']	[8]
9	erroneous	O	['N']	[9]
10	intake	O	['N']	[10]
11	of	O	['N']	[11]
12	1	B	['N']	[12]
13	g	I-Dose	['N']	[13]
14	doxycycline	B-Drug	['Dosage']	[13]
15	.	O	['N']	[15]
#1441
0	The	O	['N']	[0]
1	most	O	['N']	[1]
2	likely	O	['N']	[2]
3	cause	O	['N']	[3]
4	of	O	['N']	[4]
5	such	O	['N']	[5]
6	hyponatremic	B	['N']	[6]
7	episode	I-Adverse_Effect	['N']	[7]
8	is	O	['N']	[8]
9	vinblastine	B-Drug	['Causes']	[7]
10	.	O	['N']	[10]
#1442
0	Lansoprazole	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	collagenous	B	['N']	[3]
4	colitis	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	report	O	['N']	[8]
9	.	O	['N']	[9]
#1443
0	Herein	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	AIDS	O	['N']	[7]
8	who	O	['N']	[8]
9	presented	O	['N']	[9]
10	to	O	['N']	[10]
11	medical	O	['N']	[11]
12	attention	O	['N']	[12]
13	with	O	['N']	[13]
14	pancytopenia	B-Adverse_Effect	['N']	[14]
15	48	O	['N']	[15]
16	months	O	['N']	[16]
17	postchemotherapy	O	['N']	[17]
18	with	O	['N']	[18]
19	etoposide	O	['N']	[19]
20	,	O	['N']	[20]
21	prednisone	B-Drug	['Causes']	[14]
22	,	O	['N']	[22]
23	vincristine	O	['N']	[23]
24	,	O	['N']	[24]
25	cyclophosphamide	O	['N']	[25]
26	,	O	['N']	[26]
27	doxorubicin	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	rituximab	O	['N']	[30]
31	(	O	['N']	[31]
32	R	O	['N']	[32]
33	-	O	['N']	[33]
34	EPOCH	O	['N']	[34]
35	)	O	['N']	[35]
36	for	O	['N']	[36]
37	diffuse	O	['N']	[37]
38	large	O	['N']	[38]
39	B	O	['N']	[39]
40	-	O	['N']	[40]
41	cell	O	['N']	[41]
42	lymphoma	O	['N']	[42]
43	.	O	['N']	[43]
#1444
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	4-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	girl	O	['N']	[6]
7	who	O	['N']	[7]
8	presented	O	['N']	[8]
9	with	O	['N']	[9]
10	acute	O	['N']	[10]
11	bilateral	O	['N']	[11]
12	blindness	O	['N']	[12]
13	,	O	['N']	[13]
14	a	O	['N']	[14]
15	focal	O	['N']	[15]
16	seizure	O	['N']	[16]
17	and	O	['N']	[17]
18	hypertension	B-Adverse_Effect	['N']	[18]
19	10	O	['N']	[19]
20	days	O	['N']	[20]
21	after	O	['N']	[21]
22	commencing	O	['N']	[22]
23	oxybutynin	B-Drug	['Causes']	[18]
24	to	O	['N']	[24]
25	treat	O	['N']	[25]
26	enuresis	O	['N']	[26]
27	.	O	['N']	[27]
#1445
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	three	O	['N']	[3]
4	cases	O	['N']	[4]
5	wherein	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	dexmedetomidine	O	['N']	[8]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	bradycardia	O	['N']	[11]
12	with	O	['N']	[12]
13	i.v	O	['N']	[13]
14	.	O	['N']	[14]
15	glycopyrrolate	B-Drug	['Dosage']	[20]
16	(	O	['N']	[16]
17	5.0	B	['N']	[17]
18	microg	I	['N']	[18]
19	/	I	['N']	[19]
20	kg	I-Dose	['N']	[20]
21	)	O	['N']	[21]
22	not	O	['N']	[22]
23	only	O	['N']	[23]
24	resulting	O	['N']	[24]
25	in	O	['N']	[25]
26	resolution	O	['N']	[26]
27	of	O	['N']	[27]
28	bradycardia	O	['N']	[28]
29	but	O	['N']	[29]
30	also	O	['N']	[30]
31	resulting	O	['N']	[31]
32	in	O	['N']	[32]
33	an	O	['N']	[33]
34	exaggerated	O	['N']	[34]
35	increase	O	['N']	[35]
36	of	O	['N']	[36]
37	arterial	O	['N']	[37]
38	blood	O	['N']	[38]
39	pressure	O	['N']	[39]
40	.	O	['N']	[40]
#1446
0	Hypersensitivity	O	['N']	[0]
1	to	O	['N']	[1]
2	aspirin	B-Drug	['Causes']	[18]
3	can	O	['N']	[3]
4	be	O	['N']	[4]
5	manifested	O	['N']	[5]
6	as	O	['N']	[6]
7	acute	O	['N']	[7]
8	asthma	O	['N']	[8]
9	,	O	['N']	[9]
10	urticaria	O	['N']	[10]
11	and/or	O	['N']	[11]
12	angioedema	O	['N']	[12]
13	,	O	['N']	[13]
14	or	O	['N']	[14]
15	a	O	['N']	[15]
16	systemic	B	['N']	[16]
17	anaphylactoid	I	['N']	[17]
18	reaction	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#1447
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	How	O	['N']	[2]
3	to	O	['N']	[3]
4	best	O	['N']	[4]
5	treat	O	['N']	[5]
6	psychotic	O	['N']	[6]
7	patients	O	['N']	[7]
8	who	O	['N']	[8]
9	have	O	['N']	[9]
10	had	O	['N']	[10]
11	past	O	['N']	[11]
12	clozapine	B-Drug	['Causes']	[17]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	agranulocytosis	O	['N']	[15]
16	or	O	['N']	[16]
17	granulocytopenia	B-Adverse_Effect	['N']	[17]
18	remains	O	['N']	[18]
19	a	O	['N']	[19]
20	problem	O	['N']	[20]
21	.	O	['N']	[21]
#1448
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	5-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	girl	O	['N']	[6]
7	showed	O	['N']	[7]
8	recovery	O	['N']	[8]
9	of	O	['N']	[9]
10	vincristine	B-Drug	['Causes']	[13]
11	induced	O	['N']	[11]
12	cranial	B	['N']	[12]
13	polyneuropathy	I-Adverse_Effect	['N']	[13]
14	with	O	['N']	[14]
15	pyridoxine	O	['N']	[15]
16	and	O	['N']	[16]
17	pyridostigmine	O	['N']	[17]
18	treatment	O	['N']	[18]
19	.	O	['N']	[19]
#1449
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	document	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	serotonin	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	SS	O	['N']	[10]
11	)	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	mirtazapine	B-Drug	['Causes']	[8]
15	monotherapy	O	['N']	[15]
16	,	O	['N']	[16]
17	review	O	['N']	[17]
18	the	O	['N']	[18]
19	previously	O	['N']	[19]
20	reported	O	['N']	[20]
21	cases	O	['N']	[21]
22	of	O	['N']	[22]
23	SS	O	['N']	[23]
24	associated	O	['N']	[24]
25	with	O	['N']	[25]
26	this	O	['N']	[26]
27	tetracyclic	O	['N']	[27]
28	antidepressant	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	discuss	O	['N']	[31]
32	the	O	['N']	[32]
33	possible	O	['N']	[33]
34	pathogenic	O	['N']	[34]
35	mechanisms	O	['N']	[35]
36	leading	O	['N']	[36]
37	to	O	['N']	[37]
38	this	O	['N']	[38]
39	serious	O	['N']	[39]
40	adverse	O	['N']	[40]
41	drug	O	['N']	[41]
42	reaction	O	['N']	[42]
43	.	O	['N']	[43]
#1450
0	Gynecomastia	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	epileptics	O	['N']	[2]
3	treated	O	['N']	[3]
4	with	O	['N']	[4]
5	phenobarbital	O	['N']	[5]
6	,	O	['N']	[6]
7	phenytoin	B-Drug	['Causes']	[0]
8	and	O	['N']	[8]
9	fluoresone	O	['N']	[9]
10	:	O	['N']	[10]
11	two	O	['N']	[11]
12	case	O	['N']	[12]
13	reports	O	['N']	[13]
14	.	O	['N']	[14]
#1451
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	psoriasis	O	['N']	[3]
4	is	O	['N']	[4]
5	described	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	an	O	['N']	[8]
9	abnormal	O	['N']	[9]
10	response	O	['N']	[10]
11	to	O	['N']	[11]
12	the	O	['N']	[12]
13	glucose	O	['N']	[13]
14	tolerance	O	['N']	[14]
15	test	O	['N']	[15]
16	without	O	['N']	[16]
17	other	O	['N']	[17]
18	evidence	O	['N']	[18]
19	of	O	['N']	[19]
20	diabetes	O	['N']	[20]
21	and	O	['N']	[21]
22	then	O	['N']	[22]
23	developed	O	['N']	[23]
24	postprandial	B	['N']	[24]
25	hyperglycemia	I-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	glycosuria	O	['N']	[27]
28	during	O	['N']	[28]
29	a	O	['N']	[29]
30	period	O	['N']	[30]
31	of	O	['N']	[31]
32	topical	O	['N']	[32]
33	administration	O	['N']	[33]
34	of	O	['N']	[34]
35	a	O	['N']	[35]
36	corticosteroid	O	['N']	[36]
37	cream	O	['N']	[37]
38	,	O	['N']	[38]
39	halcinonide	B-Drug	['Causes']	[25]
40	cream	O	['N']	[40]
41	0.1	O	['N']	[41]
42	%	O	['N']	[42]
43	,	O	['N']	[43]
44	under	O	['N']	[44]
45	occlusion	O	['N']	[45]
46	.	O	['N']	[46]
#1452
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	's	O	['N']	[2]
3	other	O	['N']	[3]
4	comorbidities	O	['N']	[4]
5	and	O	['N']	[5]
6	medications	O	['N']	[6]
7	have	O	['N']	[7]
8	not	O	['N']	[8]
9	been	O	['N']	[9]
10	suggested	O	['N']	[10]
11	as	O	['N']	[11]
12	possible	O	['N']	[12]
13	interactions	O	['N']	[13]
14	with	O	['N']	[14]
15	sertraline	B-Drug	['Causes']	[19]
16	that	O	['N']	[16]
17	can	O	['N']	[17]
18	cause	O	['N']	[18]
19	rhabdomyolysis	B-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#1453
0	Imidazoline	B-Drug	['Causes']	[1]
1	intoxication	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	children	O	['N']	[3]
4	.	O	['N']	[4]
#1454
0	A	O	['N']	[0]
1	68-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	advanced	O	['N']	[7]
8	ovarian	O	['N']	[8]
9	carcinoma	O	['N']	[9]
10	collapsed	B-Adverse_Effect	['N']	[10]
11	whilst	O	['N']	[11]
12	receiving	O	['N']	[12]
13	a	O	['N']	[13]
14	carboplatin	B-Drug	['Causes']	[10]
15	and	O	['N']	[15]
16	cyclophosphamide	O	['N']	[16]
17	infusion	O	['N']	[17]
18	.	O	['N']	[18]
#1455
0	Pneumonitis	O	['N']	[0]
1	,	O	['N']	[1]
2	bilateral	B	['N']	[2]
3	pleural	I	['N']	[3]
4	effusions	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	echocardiographic	O	['N']	[6]
7	evidence	O	['N']	[7]
8	of	O	['N']	[8]
9	cardiac	O	['N']	[9]
10	tamponade	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	positive	O	['N']	[13]
14	autoantibodies	O	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	43-year	O	['N']	[18]
19	-	O	['N']	[19]
20	old	O	['N']	[20]
21	man	O	['N']	[21]
22	,	O	['N']	[22]
23	who	O	['N']	[23]
24	was	O	['N']	[24]
25	receiving	O	['N']	[25]
26	long	O	['N']	[26]
27	-	O	['N']	[27]
28	term	O	['N']	[28]
29	sulfasalazine	B-Drug	['Causes']	[4]
30	therapy	O	['N']	[30]
31	for	O	['N']	[31]
32	chronic	O	['N']	[32]
33	ulcerative	O	['N']	[33]
34	colitis	O	['N']	[34]
35	.	O	['N']	[35]
#1456
0	Atenolol	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pseudolymphoma	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#1457
0	Although	O	['N']	[0]
1	retinoic	B	['N']	[1]
2	acid	I-Drug	['Causes']	[32]
3	is	O	['N']	[3]
4	well	O	['N']	[4]
5	tolerated	O	['N']	[5]
6	by	O	['N']	[6]
7	the	O	['N']	[7]
8	majority	O	['N']	[8]
9	of	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	this	O	['N']	[12]
13	disease	O	['N']	[13]
14	,	O	['N']	[14]
15	a	O	['N']	[15]
16	potentially	O	['N']	[16]
17	fatal	O	['N']	[17]
18	complication	O	['N']	[18]
19	of	O	['N']	[19]
20	this	O	['N']	[20]
21	kind	O	['N']	[21]
22	of	O	['N']	[22]
23	treatment	O	['N']	[23]
24	has	O	['N']	[24]
25	been	O	['N']	[25]
26	reported	O	['N']	[26]
27	:	O	['N']	[27]
28	"	O	['N']	[28]
29	the	O	['N']	[29]
30	retinoic	B	['N']	[30]
31	acid	I	['N']	[31]
32	syndrome	I-Adverse_Effect	['N']	[32]
33	"	O	['N']	[33]
34	.	O	['N']	[34]
#1458
0	Multiple	O	['N']	[0]
1	complications	O	['N']	[1]
2	of	O	['N']	[2]
3	propylthiouracil	B-Drug	['Causes']	[8]
4	treatment	O	['N']	[4]
5	:	O	['N']	[5]
6	granulocytopenia	O	['N']	[6]
7	,	O	['N']	[7]
8	eosinophilia	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	skin	O	['N']	[10]
11	reaction	O	['N']	[11]
12	and	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	with	O	['N']	[14]
15	lymphocyte	O	['N']	[15]
16	sensitization	O	['N']	[16]
17	.	O	['N']	[17]
#1459
0	Although	O	['N']	[0]
1	this	O	['N']	[1]
2	combination	O	['N']	[2]
3	agent	O	['N']	[3]
4	has	O	['N']	[4]
5	been	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	a	O	['N']	[8]
9	hypersensitivity	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	involving	O	['N']	[11]
12	cutaneous	B	['N']	[12]
13	skin	I	['N']	[13]
14	eruptions	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	pediatric	O	['N']	[16]
17	cases	O	['N']	[17]
18	of	O	['N']	[18]
19	TMP	B	['N']	[19]
20	-	I	['N']	[20]
21	SMX	I-Drug	['Causes']	[14]
22	-	O	['N']	[22]
23	induced	O	['N']	[23]
24	hepatotoxicity	O	['N']	[24]
25	are	O	['N']	[25]
26	rare	O	['N']	[26]
27	.	O	['N']	[27]
#1460
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	ARDS	B-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	lithium	B-Drug	['Causes']	[6]
10	intoxication	O	['N']	[10]
11	.	O	['N']	[11]
#1461
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	O	['N']	[5]
6	epinephrine	B-Drug	['Causes']	[12]
7	toxicity	O	['N']	[7]
8	resulting	O	['N']	[8]
9	in	O	['N']	[9]
10	acute	B	['N']	[10]
11	myocardial	I	['N']	[11]
12	ischemia	I-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	young	O	['N']	[15]
16	boy	O	['N']	[16]
17	with	O	['N']	[17]
18	combined	O	['N']	[18]
19	variable	O	['N']	[19]
20	immunodeficiency	O	['N']	[20]
21	syndrome	O	['N']	[21]
22	who	O	['N']	[22]
23	developed	O	['N']	[23]
24	severe	O	['N']	[24]
25	allergic	O	['N']	[25]
26	reaction	O	['N']	[26]
27	to	O	['N']	[27]
28	intravenous	O	['N']	[28]
29	immunoglobulin	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	was	O	['N']	[32]
33	subsequently	O	['N']	[33]
34	given	O	['N']	[34]
35	epinephrine	O	['N']	[35]
36	by	O	['N']	[36]
37	mistake	O	['N']	[37]
38	intravenously	O	['N']	[38]
39	rather	O	['N']	[39]
40	than	O	['N']	[40]
41	subcutaneously	O	['N']	[41]
42	.	O	['N']	[42]
#1462
0	At	O	['N']	[0]
1	the	O	['N']	[1]
2	end	O	['N']	[2]
3	of	O	['N']	[3]
4	his	O	['N']	[4]
5	fifth	O	['N']	[5]
6	cycle	O	['N']	[6]
7	of	O	['N']	[7]
8	sunitinib	B-Drug	['Causes']	[21]
9	therapy	O	['N']	[9]
10	,	O	['N']	[10]
11	the	O	['N']	[11]
12	patient	O	['N']	[12]
13	complained	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	development	B	['N']	[16]
17	of	I	['N']	[17]
18	abnormally	I	['N']	[18]
19	large	I	['N']	[19]
20	mammary	I	['N']	[20]
21	glands	I-Adverse_Effect	['N']	[21]
22	associated	O	['N']	[22]
23	with	O	['N']	[23]
24	pain	O	['N']	[24]
25	and	O	['N']	[25]
26	peri	O	['N']	[26]
27	-	O	['N']	[27]
28	areolar	O	['N']	[28]
29	erythema	O	['N']	[29]
30	.	O	['N']	[30]
#1463
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	described	O	['N']	[2]
3	three	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	C	O	['N']	[7]
8	for	O	['N']	[8]
9	whom	O	['N']	[9]
10	IFN	O	['N']	[10]
11	-	O	['N']	[11]
12	alpha	O	['N']	[12]
13	and	O	['N']	[13]
14	ribavirin	B-Drug	['Causes']	[25]
15	were	O	['N']	[15]
16	prescribed	O	['N']	[16]
17	and	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	two	O	['N']	[20]
21	successive	O	['N']	[21]
22	phases	O	['N']	[22]
23	of	O	['N']	[23]
24	silent	O	['N']	[24]
25	thyroiditis	B-Adverse_Effect	['N']	[25]
26	followed	O	['N']	[26]
27	by	O	['N']	[27]
28	hyperthryroidism	O	['N']	[28]
29	relapse	O	['N']	[29]
30	due	O	['N']	[30]
31	to	O	['N']	[31]
32	Graves	O	['N']	[32]
33	'	O	['N']	[33]
34	disease	O	['N']	[34]
35	.	O	['N']	[35]
#1464
0	A	O	['N']	[0]
1	15-year	O	['N']	[1]
2	follow	O	['N']	[2]
3	-	O	['N']	[3]
4	up	O	['N']	[4]
5	of	O	['N']	[5]
6	phenytoin	B-Drug	['Causes']	[11]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	unilateral	B	['N']	[9]
10	gingival	I	['N']	[10]
11	hyperplasia	I-Adverse_Effect	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	case	O	['N']	[14]
15	report	O	['N']	[15]
16	.	O	['N']	[16]
#1465
0	Following	O	['N']	[0]
1	the	O	['N']	[1]
2	institution	O	['N']	[2]
3	of	O	['N']	[3]
4	intravenous	O	['N']	[4]
5	therapy	O	['N']	[5]
6	with	O	['N']	[6]
7	acyclovir	B-Drug	['Causes']	[20]
8	,	O	['N']	[8]
9	the	O	['N']	[9]
10	patient	O	['N']	[10]
11	developed	O	['N']	[11]
12	fever	O	['N']	[12]
13	,	O	['N']	[13]
14	hemoptysis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	a	O	['N']	[17]
18	pleural	B	['N']	[18]
19	friction	I	['N']	[19]
20	rub	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#1466
0	The	O	['N']	[0]
1	occurrence	O	['N']	[1]
2	of	O	['N']	[2]
3	severe	O	['N']	[3]
4	AIHA	B-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	CLL	O	['N']	[6]
7	patients	O	['N']	[7]
8	treated	O	['N']	[8]
9	with	O	['N']	[9]
10	fludarabine	B-Drug	['Causes']	[4]
11	has	O	['N']	[11]
12	been	O	['N']	[12]
13	reported	O	['N']	[13]
14	by	O	['N']	[14]
15	several	O	['N']	[15]
16	authors	O	['N']	[16]
17	.	O	['N']	[17]
#1467
0	Norethisterone	B-Drug	['Causes']	[17]
1	in	O	['N']	[1]
2	these	O	['N']	[2]
3	69	O	['N']	[3]
4	pregnancies	O	['N']	[4]
5	accounted	O	['N']	[5]
6	for	O	['N']	[6]
7	33.3	O	['N']	[7]
8	%	O	['N']	[8]
9	(	O	['N']	[9]
10	5	O	['N']	[10]
11	of	O	['N']	[11]
12	15	O	['N']	[12]
13	)	O	['N']	[13]
14	cases	O	['N']	[14]
15	of	O	['N']	[15]
16	clitoral	B	['N']	[16]
17	hypertrophy	I-Adverse_Effect	['N']	[17]
18	diagnosed	O	['N']	[18]
19	in	O	['N']	[19]
20	100,756	O	['N']	[20]
21	consecutive	O	['N']	[21]
22	births	O	['N']	[22]
23	.	O	['N']	[23]
#1468
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	O	['N']	[9]
10	mg	O	['N']	[10]
11	sertraline	B-Drug	['Causes']	[29]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	O	['N']	[17]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	B	['N']	[24]
25	of	I	['N']	[25]
26	the	I	['N']	[26]
27	lamotrigine	I	['N']	[27]
28	blood	I	['N']	[28]
29	level	I-Adverse_Effect	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	toxicity	O	['N']	[33]
34	.	O	['N']	[34]
#1469
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	50-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	advanced	O	['N']	[11]
12	non	O	['N']	[12]
13	-	O	['N']	[13]
14	small	O	['N']	[14]
15	cell	O	['N']	[15]
16	lung	O	['N']	[16]
17	cancer	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	status	B	['N']	[20]
21	epilepticus	I-Adverse_Effect	['N']	[21]
22	shortly	O	['N']	[22]
23	after	O	['N']	[23]
24	receiving	O	['N']	[24]
25	cisplatin	O	['N']	[25]
26	and	O	['N']	[26]
27	gemcitabine	B-Drug	['Causes']	[21]
28	chemotherapy	O	['N']	[28]
29	.	O	['N']	[29]
#1470
0	The	O	['N']	[0]
1	possible	O	['N']	[1]
2	development	O	['N']	[2]
3	of	O	['N']	[3]
4	a	O	['N']	[4]
5	drug	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	vasculitis	B-Adverse_Effect	['N']	[8]
9	or	O	['N']	[9]
10	lupus	O	['N']	[10]
11	-	O	['N']	[11]
12	like	O	['N']	[12]
13	syndrome	O	['N']	[13]
14	should	O	['N']	[14]
15	be	O	['N']	[15]
16	added	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	list	O	['N']	[19]
20	of	O	['N']	[20]
21	rare	O	['N']	[21]
22	toxic	O	['N']	[22]
23	effects	O	['N']	[23]
24	of	O	['N']	[24]
25	vancomycin	B-Drug	['Causes']	[8]
26	.	O	['N']	[26]
#1471
0	Investigation	O	['N']	[0]
1	confirmed	O	['N']	[1]
2	the	O	['N']	[2]
3	diagnosis	O	['N']	[3]
4	of	O	['N']	[4]
5	rhabdomyolysis	O	['N']	[5]
6	,	O	['N']	[6]
7	and	O	['N']	[7]
8	discontinuation	O	['N']	[8]
9	of	O	['N']	[9]
10	colchicine	B-Drug	['Causes']	[20]
11	resulted	O	['N']	[11]
12	in	O	['N']	[12]
13	resolution	O	['N']	[13]
14	of	O	['N']	[14]
15	clinical	O	['N']	[15]
16	and	O	['N']	[16]
17	biochemical	O	['N']	[17]
18	features	O	['N']	[18]
19	of	O	['N']	[19]
20	rhabdomylysis	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#1472
0	OBJECTIVES	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	clinical	O	['N']	[4]
5	and	O	['N']	[5]
6	pathologic	O	['N']	[6]
7	findings	O	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	noted	O	['N']	[10]
11	to	O	['N']	[11]
12	develop	O	['N']	[12]
13	lower	B	['N']	[13]
14	gastrointestinal	I	['N']	[14]
15	symptoms	I-Adverse_Effect	['N']	[15]
16	when	O	['N']	[16]
17	exposed	O	['N']	[17]
18	to	O	['N']	[18]
19	rofecoxib	B-Drug	['Causes']	[15]
20	.	O	['N']	[20]
#1473
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	patient	O	['N']	[3]
4	required	O	['N']	[4]
5	insulin	B-Drug	['Causes']	[11]
6	desensitization	O	['N']	[6]
7	for	O	['N']	[7]
8	severe	O	['N']	[8]
9	urticaria	O	['N']	[9]
10	,	O	['N']	[10]
11	angioedema	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	occasional	O	['N']	[14]
15	wheezing	O	['N']	[15]
16	resulting	O	['N']	[16]
17	from	O	['N']	[17]
18	her	O	['N']	[18]
19	insulin	O	['N']	[19]
20	dose	O	['N']	[20]
21	.	O	['N']	[21]
#1474
0	Myotonia	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	sarcoidosis	O	['N']	[3]
4	:	O	['N']	[4]
5	marked	O	['N']	[5]
6	exacerbation	O	['N']	[6]
7	with	O	['N']	[7]
8	pravastatin	B-Drug	['Causes']	[0]
9	.	O	['N']	[9]
#1475
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	hypoglycaemia	O	['N']	[5]
6	after	O	['N']	[6]
7	mefloquine	B-Drug	['Dosage']	[14]
8	therapy	O	['N']	[8]
9	(	O	['N']	[9]
10	1,500	B	['N']	[10]
11	mg	I	['N']	[11]
12	over	I	['N']	[12]
13	two	I	['N']	[13]
14	days	I-Dose	['N']	[14]
15	)	O	['N']	[15]
16	for	O	['N']	[16]
17	severe	O	['N']	[17]
18	gastrointestinal	O	['N']	[18]
19	cryptosporidiasis	O	['N']	[19]
20	in	O	['N']	[20]
21	a	O	['N']	[21]
22	cachectic	O	['N']	[22]
23	AIDS	O	['N']	[23]
24	patient	O	['N']	[24]
25	with	O	['N']	[25]
26	protracted	O	['N']	[26]
27	diarrhoea	O	['N']	[27]
28	.	O	['N']	[28]
#1476
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	development	O	['N']	[3]
4	of	O	['N']	[4]
5	cutaneous	B	['N']	[5]
6	scleroderma	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	3	O	['N']	[8]
9	patients	O	['N']	[9]
10	coincident	O	['N']	[10]
11	with	O	['N']	[11]
12	the	O	['N']	[12]
13	use	O	['N']	[13]
14	of	O	['N']	[14]
15	bleomycin	B-Drug	['Causes']	[6]
16	in	O	['N']	[16]
17	low	O	['N']	[17]
18	cumulative	O	['N']	[18]
19	doses	O	['N']	[19]
20	of	O	['N']	[20]
21	less	O	['N']	[21]
22	than	O	['N']	[22]
23	100	O	['N']	[23]
24	U.	O	['N']	[24]
#1477
0	Both	O	['N']	[0]
1	had	O	['N']	[1]
2	impaired	O	['N']	[2]
3	lung	O	['N']	[3]
4	function	O	['N']	[4]
5	and	O	['N']	[5]
6	abnormal	B	['N']	[6]
7	computed	I	['N']	[7]
8	tomographic	I	['N']	[8]
9	scans	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	their	O	['N']	[12]
13	condition	O	['N']	[13]
14	improved	O	['N']	[14]
15	when	O	['N']	[15]
16	nitrofurantoin	B-Drug	['Causes']	[9]
17	was	O	['N']	[17]
18	withdrawn	O	['N']	[18]
19	and	O	['N']	[19]
20	corticosteroid	O	['N']	[20]
21	treatment	O	['N']	[21]
22	commenced	O	['N']	[22]
23	.	O	['N']	[23]
#1478
0	Mesalamine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hypersensitivity	B	['N']	[3]
4	pneumonitis	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1479
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	B-Drug	['Causes']	[38]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	B	['N']	[37]
38	syndrome	I-Adverse_Effect	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#1480
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	woman	O	['N']	[4]
5	of	O	['N']	[5]
6	80	O	['N']	[6]
7	years	O	['N']	[7]
8	,	O	['N']	[8]
9	on	O	['N']	[9]
10	long	O	['N']	[10]
11	-	O	['N']	[11]
12	term	O	['N']	[12]
13	warfarin	B-Drug	['Causes']	[22]
14	therapy	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	an	O	['N']	[17]
18	acute	B	['N']	[18]
19	dissecting	I	['N']	[19]
20	thoracic	I	['N']	[20]
21	aortic	I	['N']	[21]
22	aneurysm	I-Adverse_Effect	['N']	[22]
23	;	O	['N']	[23]
24	on	O	['N']	[24]
25	investigation	O	['N']	[25]
26	the	O	['N']	[26]
27	only	O	['N']	[27]
28	precipitating	O	['N']	[28]
29	factor	O	['N']	[29]
30	found	O	['N']	[30]
31	was	O	['N']	[31]
32	an	O	['N']	[32]
33	international	O	['N']	[33]
34	normalised	O	['N']	[34]
35	ratio	O	['N']	[35]
36	of	O	['N']	[36]
37	4.8	O	['N']	[37]
38	.	O	['N']	[38]
#1481
0	It	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	recognized	O	['N']	[3]
4	that	O	['N']	[4]
5	ibuprofen	O	['N']	[5]
6	may	O	['N']	[6]
7	be	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	salt	B	['N']	[10]
11	and	I	['N']	[11]
12	water	I	['N']	[12]
13	retention	I-Adverse_Effect	['N']	[13]
14	in	O	['N']	[14]
15	the	O	['N']	[15]
16	same	O	['N']	[16]
17	fashion	O	['N']	[17]
18	as	O	['N']	[18]
19	previously	O	['N']	[19]
20	described	O	['N']	[20]
21	with	O	['N']	[21]
22	phenylbutazone	O	['N']	[22]
23	and	O	['N']	[23]
24	indomethacin	B-Drug	['Causes']	[13]
25	.	O	['N']	[25]
#1482
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	with	O	['N']	[4]
5	congenital	O	['N']	[5]
6	toxoplasmosis	O	['N']	[6]
7	who	O	['N']	[7]
8	took	O	['N']	[8]
9	pyrimethamine	O	['N']	[9]
10	and	O	['N']	[10]
11	sulfadiazine	B-Drug	['Causes']	[16]
12	for	O	['N']	[12]
13	reactivated	O	['N']	[13]
14	chorioretinitis	O	['N']	[14]
15	developed	O	['N']	[15]
16	fever	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	severe	O	['N']	[18]
19	cutaneous	O	['N']	[19]
20	involvement	O	['N']	[20]
21	,	O	['N']	[21]
22	swelling	O	['N']	[22]
23	,	O	['N']	[23]
24	abdominal	O	['N']	[24]
25	pain	O	['N']	[25]
26	and	O	['N']	[26]
27	transaminitis	O	['N']	[27]
28	,	O	['N']	[28]
29	persisting	O	['N']	[29]
30	weeks	O	['N']	[30]
31	after	O	['N']	[31]
32	withholding	O	['N']	[32]
33	medicines	O	['N']	[33]
34	.	O	['N']	[34]
#1483
0	Dural	B	['N']	[0]
1	sinus	I	['N']	[1]
2	thrombosis	I-Adverse_Effect	['N']	[2]
3	developed	O	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	children	O	['N']	[6]
7	with	O	['N']	[7]
8	acute	O	['N']	[8]
9	lymphoblastic	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	during	O	['N']	[11]
12	induction	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	vincristine	O	['N']	[15]
16	sulfate	O	['N']	[16]
17	,	O	['N']	[17]
18	prednisone	B-Drug	['Causes']	[2]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	asparaginase	O	['N']	[21]
22	.	O	['N']	[22]
#1484
0	Ten	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	itraconazole	B-Drug	['Causes']	[10]
4	was	O	['N']	[4]
5	started	O	['N']	[5]
6	,	O	['N']	[6]
7	he	O	['N']	[7]
8	developed	O	['N']	[8]
9	paralytic	B	['N']	[9]
10	ileus	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	neurogenic	O	['N']	[12]
13	bladder	O	['N']	[13]
14	,	O	['N']	[14]
15	mild	O	['N']	[15]
16	left	O	['N']	[16]
17	ptosis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	absence	O	['N']	[20]
21	of	O	['N']	[21]
22	deep	O	['N']	[22]
23	reflexes	O	['N']	[23]
24	,	O	['N']	[24]
25	with	O	['N']	[25]
26	severe	O	['N']	[26]
27	paralysis	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	lower	O	['N']	[30]
31	extremities	O	['N']	[31]
32	and	O	['N']	[32]
33	mild	O	['N']	[33]
34	weakness	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	upper	O	['N']	[37]
38	extremities	O	['N']	[38]
39	.	O	['N']	[39]
#1485
0	Our	O	['N']	[0]
1	objective	O	['N']	[1]
2	is	O	['N']	[2]
3	to	O	['N']	[3]
4	present	O	['N']	[4]
5	a	O	['N']	[5]
6	retrospective	O	['N']	[6]
7	analysis	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	DWI	O	['N']	[10]
11	findings	O	['N']	[11]
12	in	O	['N']	[12]
13	four	O	['N']	[13]
14	patients	O	['N']	[14]
15	who	O	['N']	[15]
16	suffered	O	['N']	[16]
17	subacute	B	['N']	[17]
18	neurotoxicity	I-Adverse_Effect	['N']	[18]
19	after	O	['N']	[19]
20	intrathecal	O	['N']	[20]
21	MTX	B-Drug	['Causes']	[18]
22	.	O	['N']	[22]
#1486
0	Hypogammaglobulinemia	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	gold	B-Drug	['Causes']	[0]
4	therapy	O	['N']	[4]
5	:	O	['N']	[5]
6	evidence	O	['N']	[6]
7	for	O	['N']	[7]
8	a	O	['N']	[8]
9	partial	O	['N']	[9]
10	maturation	O	['N']	[10]
11	blockade	O	['N']	[11]
12	of	O	['N']	[12]
13	B	O	['N']	[13]
14	cells	O	['N']	[14]
15	.	O	['N']	[15]
#1487
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	queried	O	['N']	[3]
4	35	O	['N']	[4]
5	rheumatologists	O	['N']	[5]
6	at	O	['N']	[6]
7	the	O	['N']	[7]
8	Robert	O	['N']	[8]
9	Breck	O	['N']	[9]
10	Brigham	O	['N']	[10]
11	Arthritis	O	['N']	[11]
12	Center	O	['N']	[12]
13	to	O	['N']	[13]
14	determine	O	['N']	[14]
15	if	O	['N']	[15]
16	weight	B	['N']	[16]
17	loss	I-Adverse_Effect	['N']	[17]
18	had	O	['N']	[18]
19	occurred	O	['N']	[19]
20	as	O	['N']	[20]
21	an	O	['N']	[21]
22	adverse	O	['N']	[22]
23	event	O	['N']	[23]
24	in	O	['N']	[24]
25	patients	O	['N']	[25]
26	treated	O	['N']	[26]
27	with	O	['N']	[27]
28	leflunomide	B-Drug	['Causes']	[17]
29	between	O	['N']	[29]
30	November	O	['N']	[30]
31	1998	O	['N']	[31]
32	and	O	['N']	[32]
33	January	O	['N']	[33]
34	2000	O	['N']	[34]
35	.	O	['N']	[35]
#1488
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	paper	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	report	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	primary	O	['N']	[9]
10	anti	O	['N']	[10]
11	-	O	['N']	[11]
12	phospholipid	O	['N']	[12]
13	syndrome	O	['N']	[13]
14	treated	O	['N']	[14]
15	by	O	['N']	[15]
16	corticosteroid	B-Drug	['Causes']	[21]
17	,	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	disseminated	B	['N']	[20]
21	nocardiosis	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1489
0	Cisplatin	B-Drug	['Causes']	[9]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	of	O	['N']	[4]
5	inappropriate	O	['N']	[5]
6	antidiuretic	O	['N']	[6]
7	hormone	O	['N']	[7]
8	(	O	['N']	[8]
9	SIADH	B-Adverse_Effect	['N']	[9]
10	)	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	neuroendocrine	O	['N']	[15]
16	tumor	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	cervix	O	['N']	[19]
20	:	O	['N']	[20]
21	a	O	['N']	[21]
22	case	O	['N']	[22]
23	report	O	['N']	[23]
24	and	O	['N']	[24]
25	review	O	['N']	[25]
26	of	O	['N']	[26]
27	the	O	['N']	[27]
28	literature	O	['N']	[28]
29	.	O	['N']	[29]
#1490
0	Inadvertent	O	['N']	[0]
1	subsequent	O	['N']	[1]
2	rechallenge	O	['N']	[2]
3	with	O	['N']	[3]
4	celiprolol	B-Drug	['Causes']	[10]
5	led	O	['N']	[5]
6	to	O	['N']	[6]
7	recurrence	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	pneumonitis	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	10	O	['N']	[12]
13	weeks	O	['N']	[13]
14	after	O	['N']	[14]
15	drug	O	['N']	[15]
16	readministration	O	['N']	[16]
17	.	O	['N']	[17]
#1491
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	B-Drug	['Causes']	[45]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	B-Adverse_Effect	['N']	[45]
46	.	O	['N']	[46]
#1492
0	The	O	['N']	[0]
1	findings	O	['N']	[1]
2	were	O	['N']	[2]
3	judged	O	['N']	[3]
4	to	O	['N']	[4]
5	be	O	['N']	[5]
6	consistent	O	['N']	[6]
7	with	O	['N']	[7]
8	soft	O	['N']	[8]
9	-	O	['N']	[9]
10	tissue	O	['N']	[10]
11	injury	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	intravenous	O	['N']	[14]
15	administration	O	['N']	[15]
16	of	O	['N']	[16]
17	phenytoin	B-Drug	['Causes']	[23]
18	,	O	['N']	[18]
19	also	O	['N']	[19]
20	termed	O	['N']	[20]
21	purple	B	['N']	[21]
22	glove	I	['N']	[22]
23	syndrome	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#1493
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	present	O	['N']	[2]
3	paper	O	['N']	[3]
4	,	O	['N']	[4]
5	we	O	['N']	[5]
6	discuss	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	Japanese	O	['N']	[9]
10	vivax	O	['N']	[10]
11	malaria	O	['N']	[11]
12	patient	O	['N']	[12]
13	whose	O	['N']	[13]
14	QT	B	['N']	[14]
15	interval	I	['N']	[15]
16	was	I	['N']	[16]
17	prolonged	I-Adverse_Effect	['N']	[17]
18	after	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	halofantrine	B-Drug	['Causes']	[17]
22	.	O	['N']	[22]
#1494
0	Ketanserin	O	['N']	[0]
1	in	O	['N']	[1]
2	the	O	['N']	[2]
3	treatment	O	['N']	[3]
4	of	O	['N']	[4]
5	protamine	B-Drug	['Causes']	[9]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	pulmonary	B	['N']	[8]
9	hypertension	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#1495
0	Three	O	['N']	[0]
1	male	O	['N']	[1]
2	patients	O	['N']	[2]
3	aged	O	['N']	[3]
4	78	O	['N']	[4]
5	-	O	['N']	[5]
6	83	O	['N']	[6]
7	years	O	['N']	[7]
8	are	O	['N']	[8]
9	presented	O	['N']	[9]
10	,	O	['N']	[10]
11	in	O	['N']	[11]
12	whom	O	['N']	[12]
13	severe	B	['N']	[13]
14	hepatotoxic	I	['N']	[14]
15	reactions	I-Adverse_Effect	['N']	[15]
16	emerged	O	['N']	[16]
17	after	O	['N']	[17]
18	CPA	B-Drug	['Causes']	[15]
19	administration	O	['N']	[19]
20	.	O	['N']	[20]
#1496
0	The	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	two	O	['N']	[3]
4	asthmatic	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	became	O	['N']	[7]
8	hypokalemic	B-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	inhalation	O	['N']	[10]
11	of	O	['N']	[11]
12	normal	O	['N']	[12]
13	doses	O	['N']	[13]
14	of	O	['N']	[14]
15	albuterol	B-Drug	['Causes']	[8]
16	are	O	['N']	[16]
17	presented	O	['N']	[17]
18	.	O	['N']	[18]
#1497
0	Five	O	['N']	[0]
1	cases	O	['N']	[1]
2	(	O	['N']	[2]
3	four	O	['N']	[3]
4	from	O	['N']	[4]
5	the	O	['N']	[5]
6	literature	O	['N']	[6]
7	and	O	['N']	[7]
8	one	O	['N']	[8]
9	new	O	['N']	[9]
10	case	O	['N']	[10]
11	)	O	['N']	[11]
12	are	O	['N']	[12]
13	presented	O	['N']	[13]
14	in	O	['N']	[14]
15	which	O	['N']	[15]
16	patients	O	['N']	[16]
17	unsuspected	O	['N']	[17]
18	of	O	['N']	[18]
19	having	O	['N']	[19]
20	vitamin	O	['N']	[20]
21	B12	O	['N']	[21]
22	deficiency	O	['N']	[22]
23	developed	O	['N']	[23]
24	subacute	B	['N']	[24]
25	combined	I	['N']	[25]
26	degeneration	I	['N']	[26]
27	of	I	['N']	[27]
28	the	I	['N']	[28]
29	spinal	I	['N']	[29]
30	cord	I-Adverse_Effect	['N']	[30]
31	following	O	['N']	[31]
32	nitrous	B	['N']	[32]
33	oxide	I-Drug	['Causes']	[30]
34	anesthesia	O	['N']	[34]
35	.	O	['N']	[35]
#1498
0	Management	O	['N']	[0]
1	and	O	['N']	[1]
2	successful	O	['N']	[2]
3	desensitization	O	['N']	[3]
4	in	O	['N']	[4]
5	methotrexate	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	anaphylaxis	B-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#1499
0	This	O	['N']	[0]
1	progressed	O	['N']	[1]
2	to	O	['N']	[2]
3	tracheal	B	['N']	[3]
4	compression	I-Adverse_Effect	['N']	[4]
5	with	O	['N']	[5]
6	stridor	O	['N']	[6]
7	after	O	['N']	[7]
8	he	O	['N']	[8]
9	had	O	['N']	[9]
10	taken	O	['N']	[10]
11	some	O	['N']	[11]
12	aspirin	B-Drug	['Causes']	[4]
13	for	O	['N']	[13]
14	relief	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	neck	O	['N']	[17]
18	pain	O	['N']	[18]
19	.	O	['N']	[19]
#1500
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	child	O	['N']	[6]
7	with	O	['N']	[7]
8	neurodevelopmental	O	['N']	[8]
9	delay	O	['N']	[9]
10	with	O	['N']	[10]
11	chronic	O	['N']	[11]
12	constipation	O	['N']	[12]
13	and	O	['N']	[13]
14	a	O	['N']	[14]
15	history	O	['N']	[15]
16	of	O	['N']	[16]
17	chronic	O	['N']	[17]
18	mineral	B	['N']	[18]
19	oil	I-Drug	['Causes']	[26]
20	ingestion	O	['N']	[20]
21	presenting	O	['N']	[21]
22	as	O	['N']	[22]
23	asymptomatic	O	['N']	[23]
24	exogenous	B	['N']	[24]
25	lipoid	I	['N']	[25]
26	pneumonia	I-Adverse_Effect	['N']	[26]
27	(	O	['N']	[27]
28	ELP	O	['N']	[28]
29	)	O	['N']	[29]
30	.	O	['N']	[30]
#1501
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	valvular	B	['N']	[6]
7	heart	I	['N']	[7]
8	disease	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	48-year	O	['N']	[11]
12	-	O	['N']	[12]
13	old	O	['N']	[13]
14	woman	O	['N']	[14]
15	receiving	O	['N']	[15]
16	benfluorex	B-Drug	['Causes']	[8]
17	(	O	['N']	[17]
18	150	O	['N']	[18]
19	mg	O	['N']	[19]
20	t.i.d	O	['N']	[20]
21	.	O	['N']	[21]
22	for	O	['N']	[22]
23	8	O	['N']	[23]
24	years	O	['N']	[24]
25	)	O	['N']	[25]
26	and	O	['N']	[26]
27	leading	O	['N']	[27]
28	to	O	['N']	[28]
29	surgical	O	['N']	[29]
30	mitral	O	['N']	[30]
31	valve	O	['N']	[31]
32	replacement	O	['N']	[32]
33	.	O	['N']	[33]
#1502
0	Although	O	['N']	[0]
1	this	O	['N']	[1]
2	type	O	['N']	[2]
3	of	O	['N']	[3]
4	hyperpigmentation	B-Adverse_Effect	['N']	[4]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	previously	O	['N']	[7]
8	seen	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	cancer	O	['N']	[12]
13	who	O	['N']	[13]
14	are	O	['N']	[14]
15	receiving	O	['N']	[15]
16	bleomycin	B-Drug	['Causes']	[4]
17	,	O	['N']	[17]
18	this	O	['N']	[18]
19	is	O	['N']	[19]
20	,	O	['N']	[20]
21	to	O	['N']	[21]
22	our	O	['N']	[22]
23	knowledge	O	['N']	[23]
24	,	O	['N']	[24]
25	the	O	['N']	[25]
26	first	O	['N']	[26]
27	reported	O	['N']	[27]
28	case	O	['N']	[28]
29	of	O	['N']	[29]
30	bleomycin	O	['N']	[30]
31	-	O	['N']	[31]
32	induced	O	['N']	[32]
33	hyperpigmentation	O	['N']	[33]
34	in	O	['N']	[34]
35	an	O	['N']	[35]
36	AIDS	O	['N']	[36]
37	patient	O	['N']	[37]
38	and	O	['N']	[38]
39	should	O	['N']	[39]
40	be	O	['N']	[40]
41	added	O	['N']	[41]
42	to	O	['N']	[42]
43	the	O	['N']	[43]
44	growing	O	['N']	[44]
45	list	O	['N']	[45]
46	of	O	['N']	[46]
47	cutaneous	O	['N']	[47]
48	eruptions	O	['N']	[48]
49	seen	O	['N']	[49]
50	in	O	['N']	[50]
51	these	O	['N']	[51]
52	patients	O	['N']	[52]
53	.	O	['N']	[53]
#1503
0	The	O	['N']	[0]
1	sulfonamides	B-Drug	['Causes']	[16]
2	are	O	['N']	[2]
3	the	O	['N']	[3]
4	best	O	['N']	[4]
5	verified	O	['N']	[5]
6	drug	O	['N']	[6]
7	-	O	['N']	[7]
8	trigger	O	['N']	[8]
9	for	O	['N']	[9]
10	erythema	O	['N']	[10]
11	multiforme	O	['N']	[11]
12	and	O	['N']	[12]
13	Stevens	B	['N']	[13]
14	-	I	['N']	[14]
15	Johnson	I	['N']	[15]
16	syndrome	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#1504
0	She	O	['N']	[0]
1	died	O	['N']	[1]
2	within	O	['N']	[2]
3	six	O	['N']	[3]
4	weeks	O	['N']	[4]
5	of	O	['N']	[5]
6	developing	O	['N']	[6]
7	congestive	O	['N']	[7]
8	heart	O	['N']	[8]
9	failure	O	['N']	[9]
10	coupled	O	['N']	[10]
11	with	O	['N']	[11]
12	liver	O	['N']	[12]
13	failure	O	['N']	[13]
14	due	O	['N']	[14]
15	to	O	['N']	[15]
16	haemosiderosis	B-Adverse_Effect	['N']	[16]
17	despite	O	['N']	[17]
18	regular	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	desferrioxamine	B-Drug	['Causes']	[16]
22	.	O	['N']	[22]
#1505
0	The	O	['N']	[0]
1	pathogenic	O	['N']	[1]
2	mechanisms	O	['N']	[2]
3	involved	O	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	development	O	['N']	[6]
7	of	O	['N']	[7]
8	adriamycin	B-Drug	['Causes']	[9]
9	cardiomyopathy	B-Adverse_Effect	['N']	[9]
10	are	O	['N']	[10]
11	reviewed	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	the	O	['N']	[14]
15	possible	O	['N']	[15]
16	synergistic	O	['N']	[16]
17	effect	O	['N']	[17]
18	of	O	['N']	[18]
19	other	O	['N']	[19]
20	antitumor	O	['N']	[20]
21	antibiotics	O	['N']	[21]
22	is	O	['N']	[22]
23	discussed	O	['N']	[23]
24	.	O	['N']	[24]
#1506
0	In	O	['N']	[0]
1	rare	O	['N']	[1]
2	cases	O	['N']	[2]
3	mitomycin	O	['N']	[3]
4	C	O	['N']	[4]
5	(	O	['N']	[5]
6	MMC	B-Drug	['Causes']	[22]
7	)	O	['N']	[7]
8	may	O	['N']	[8]
9	induce	O	['N']	[9]
10	cancer	O	['N']	[10]
11	-	O	['N']	[11]
12	associated	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	uremic	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	is	O	['N']	[18]
19	characterized	O	['N']	[19]
20	by	O	['N']	[20]
21	hemolytic	B	['N']	[21]
22	anemia	I-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	thrombocytopenia	O	['N']	[24]
25	and	O	['N']	[25]
26	progressive	O	['N']	[26]
27	renal	O	['N']	[27]
28	failure	O	['N']	[28]
29	.	O	['N']	[29]
#1507
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	an	O	['N']	[8]
9	anaphylactic	B	['N']	[9]
10	reaction	I-Adverse_Effect	['N']	[10]
11	during	O	['N']	[11]
12	the	O	['N']	[12]
13	intravenous	O	['N']	[13]
14	infusion	O	['N']	[14]
15	of	O	['N']	[15]
16	cyclosporine	B-Drug	['Causes']	[10]
17	.	O	['N']	[17]
#1508
0	A	O	['N']	[0]
1	57-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	developed	O	['N']	[5]
6	pulmonary	B	['N']	[6]
7	sarcoidosis	I-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	therapy	O	['N']	[9]
10	with	O	['N']	[10]
11	interferon	B	['N']	[11]
12	beta	I-Drug	['Causes']	[7]
13	for	O	['N']	[13]
14	advanced	O	['N']	[14]
15	renal	O	['N']	[15]
16	cell	O	['N']	[16]
17	carcinoma	O	['N']	[17]
18	metastatic	O	['N']	[18]
19	to	O	['N']	[19]
20	mediastinal	O	['N']	[20]
21	lymph	O	['N']	[21]
22	nodes	O	['N']	[22]
23	.	O	['N']	[23]
#1509
0	Pulmonary	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	mefloquine	B-Drug	['Causes']	[1]
4	.	O	['N']	[4]
#1510
0	Sodium	O	['N']	[0]
1	phenylbutyrate	O	['N']	[1]
2	was	O	['N']	[2]
3	added	O	['N']	[3]
4	to	O	['N']	[4]
5	treatment	O	['N']	[5]
6	with	O	['N']	[6]
7	HU	B-Drug	['Causes']	[24]
8	in	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	failed	O	['N']	[13]
14	to	O	['N']	[14]
15	produce	O	['N']	[15]
16	an	O	['N']	[16]
17	increase	O	['N']	[17]
18	in	O	['N']	[18]
19	total	O	['N']	[19]
20	Hb	O	['N']	[20]
21	despite	O	['N']	[21]
22	increasing	B	['N']	[22]
23	Hb	I	['N']	[23]
24	F	I-Adverse_Effect	['N']	[24]
25	levels	O	['N']	[25]
26	.	O	['N']	[26]
#1511
0	Since	O	['N']	[0]
1	the	O	['N']	[1]
2	thrombocyte	B	['N']	[2]
3	count	I	['N']	[3]
4	started	I	['N']	[4]
5	to	I	['N']	[5]
6	increase	I-Adverse_Effect	['N']	[6]
7	immediately	O	['N']	[7]
8	after	O	['N']	[8]
9	initiation	O	['N']	[9]
10	and	O	['N']	[10]
11	dropped	O	['N']	[11]
12	immediately	O	['N']	[12]
13	after	O	['N']	[13]
14	discontinuation	O	['N']	[14]
15	of	O	['N']	[15]
16	ciprofloxacin	O	['N']	[16]
17	and	O	['N']	[17]
18	tazobactam	O	['N']	[18]
19	/	O	['N']	[19]
20	piperacillin	B-Drug	['Causes']	[6]
21	and	O	['N']	[21]
22	all	O	['N']	[22]
23	other	O	['N']	[23]
24	drugs	O	['N']	[24]
25	were	O	['N']	[25]
26	discontinued	O	['N']	[26]
27	already	O	['N']	[27]
28	before	O	['N']	[28]
29	or	O	['N']	[29]
30	were	O	['N']	[30]
31	started	O	['N']	[31]
32	after	O	['N']	[32]
33	the	O	['N']	[33]
34	nadir	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	thrombocyte	O	['N']	[37]
38	count	O	['N']	[38]
39	,	O	['N']	[39]
40	these	O	['N']	[40]
41	two	O	['N']	[41]
42	antibiotics	O	['N']	[42]
43	were	O	['N']	[43]
44	regarded	O	['N']	[44]
45	causative	O	['N']	[45]
46	.	O	['N']	[46]
#1512
0	Anastrozole	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	sclerosing	B	['N']	[3]
4	glomerulonephritis	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	breast	O	['N']	[9]
10	cancer	O	['N']	[10]
11	.	O	['N']	[11]
#1513
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	HUS	B-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	mitomycin	B	['N']	[10]
11	C	I-Drug	['Causes']	[6]
12	(	O	['N']	[12]
13	total	O	['N']	[13]
14	dose	O	['N']	[14]
15	144	O	['N']	[15]
16	mg	O	['N']	[16]
17	/	O	['N']	[17]
18	m2	O	['N']	[18]
19	)	O	['N']	[19]
20	due	O	['N']	[20]
21	to	O	['N']	[21]
22	a	O	['N']	[22]
23	carcinoma	O	['N']	[23]
24	of	O	['N']	[24]
25	the	O	['N']	[25]
26	ascending	O	['N']	[26]
27	colon	O	['N']	[27]
28	.	O	['N']	[28]
#1514
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	this	O	['N']	[4]
5	is	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	report	O	['N']	[8]
9	of	O	['N']	[9]
10	significant	O	['N']	[10]
11	hypotension	B-Adverse_Effect	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	intravenous	O	['N']	[14]
15	valproate	B-Drug	['Causes']	[11]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	treatment	O	['N']	[18]
19	of	O	['N']	[19]
20	status	O	['N']	[20]
21	epilepticus	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	pediatric	O	['N']	[24]
25	population	O	['N']	[25]
26	.	O	['N']	[26]
#1515
0	Acute	B	['N']	[0]
1	generalized	I	['N']	[1]
2	exanthematous	I	['N']	[2]
3	pustulosis	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	salazosulfapyridine	B-Drug	['Causes']	[3]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	ulcerative	O	['N']	[11]
12	colitis	O	['N']	[12]
13	.	O	['N']	[13]
#1516
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	urinary	B	['N']	[6]
7	incontinence	I-Adverse_Effect	['N']	[7]
8	(	O	['N']	[8]
9	UI	O	['N']	[9]
10	)	O	['N']	[10]
11	that	O	['N']	[11]
12	occurred	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	woman	O	['N']	[15]
16	after	O	['N']	[16]
17	administration	O	['N']	[17]
18	of	O	['N']	[18]
19	venlafaxine	B-Drug	['Causes']	[7]
20	.	O	['N']	[20]
#1517
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[27]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#1518
0	Abnormalities	B	['N']	[0]
1	of	I	['N']	[1]
2	the	I	['N']	[2]
3	pupil	I-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	visual	O	['N']	[5]
6	-	O	['N']	[6]
7	evoked	O	['N']	[7]
8	potential	O	['N']	[8]
9	in	O	['N']	[9]
10	quinine	B-Drug	['Causes']	[3]
11	amblyopia	O	['N']	[11]
12	.	O	['N']	[12]
#1519
0	Gemcitabine	B-Drug	['Causes']	[9]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	known	O	['N']	[3]
4	risk	O	['N']	[4]
5	factor	O	['N']	[5]
6	for	O	['N']	[6]
7	hemolytic	B	['N']	[7]
8	uremic	I	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	(	O	['N']	[10]
11	HUS	O	['N']	[11]
12	)	O	['N']	[12]
13	,	O	['N']	[13]
14	which	O	['N']	[14]
15	can	O	['N']	[15]
16	often	O	['N']	[16]
17	have	O	['N']	[17]
18	a	O	['N']	[18]
19	rapidly	O	['N']	[19]
20	fatal	O	['N']	[20]
21	clinical	O	['N']	[21]
22	course	O	['N']	[22]
23	despite	O	['N']	[23]
24	intervention	O	['N']	[24]
25	with	O	['N']	[25]
26	steroids	O	['N']	[26]
27	,	O	['N']	[27]
28	plasmapheresis	O	['N']	[28]
29	and	O	['N']	[29]
30	hemodialysis	O	['N']	[30]
31	.	O	['N']	[31]
#1520
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	40-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	fulminant	B	['N']	[12]
13	hepatic	I	['N']	[13]
14	failure	I-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	aplastic	O	['N']	[16]
17	anaemia	O	['N']	[17]
18	following	O	['N']	[18]
19	a	O	['N']	[19]
20	course	O	['N']	[20]
21	of	O	['N']	[21]
22	oral	O	['N']	[22]
23	flucloxacillin	B-Drug	['Causes']	[14]
24	.	O	['N']	[24]
#1521
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	test	O	['N']	[3]
4	the	O	['N']	[4]
5	hypothesis	O	['N']	[5]
6	that	O	['N']	[6]
7	tumor	O	['N']	[7]
8	necrosis	O	['N']	[8]
9	factor	O	['N']	[9]
10	(	O	['N']	[10]
11	TNF)-alpha	O	['N']	[11]
12	may	O	['N']	[12]
13	mediate	O	['N']	[13]
14	the	O	['N']	[14]
15	loss	O	['N']	[15]
16	and	O	['N']	[16]
17	the	O	['N']	[17]
18	dedifferentiation	O	['N']	[18]
19	of	O	['N']	[19]
20	subcutaneous	O	['N']	[20]
21	fat	O	['N']	[21]
22	tissue	O	['N']	[22]
23	in	O	['N']	[23]
24	the	O	['N']	[24]
25	insulin	B-Drug	['Causes']	[28]
26	-	O	['N']	[26]
27	induced	O	['N']	[27]
28	lipoatrophies	B-Adverse_Effect	['N']	[28]
29	of	O	['N']	[29]
30	a	O	['N']	[30]
31	diabetic	O	['N']	[31]
32	patient	O	['N']	[32]
33	who	O	['N']	[33]
34	presented	O	['N']	[34]
35	extensive	O	['N']	[35]
36	lesions	O	['N']	[36]
37	.	O	['N']	[37]
#1522
0	Here	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	Vogt	B	['N']	[7]
8	-	I	['N']	[8]
9	Koyanagi	I	['N']	[9]
10	-	I	['N']	[10]
11	Harada	I	['N']	[11]
12	disease	I-Adverse_Effect	['N']	[12]
13	occurring	O	['N']	[13]
14	4	O	['N']	[14]
15	months	O	['N']	[15]
16	after	O	['N']	[16]
17	the	O	['N']	[17]
18	start	O	['N']	[18]
19	of	O	['N']	[19]
20	interferon	B-Drug	['Causes']	[12]
21	alpha	O	['N']	[21]
22	treatment	O	['N']	[22]
23	,	O	['N']	[23]
24	probably	O	['N']	[24]
25	induced	O	['N']	[25]
26	by	O	['N']	[26]
27	the	O	['N']	[27]
28	immunomodulatory	O	['N']	[28]
29	effects	O	['N']	[29]
30	of	O	['N']	[30]
31	interferon	O	['N']	[31]
32	.	O	['N']	[32]
#1523
0	The	O	['N']	[0]
1	ocular	O	['N']	[1]
2	toxicity	O	['N']	[2]
3	of	O	['N']	[3]
4	DCF	B-Drug	['Causes']	[15]
5	,	O	['N']	[5]
6	previously	O	['N']	[6]
7	described	O	['N']	[7]
8	as	O	['N']	[8]
9	conjunctivitis	O	['N']	[9]
10	,	O	['N']	[10]
11	appears	O	['N']	[11]
12	to	O	['N']	[12]
13	be	O	['N']	[13]
14	a	O	['N']	[14]
15	keratitis	B-Adverse_Effect	['N']	[15]
16	of	O	['N']	[16]
17	moderate	O	['N']	[17]
18	severity	O	['N']	[18]
19	which	O	['N']	[19]
20	requires	O	['N']	[20]
21	further	O	['N']	[21]
22	study	O	['N']	[22]
23	.	O	['N']	[23]
#1524
0	Lithium	O	['N']	[0]
1	treatment	O	['N']	[1]
2	was	O	['N']	[2]
3	terminated	O	['N']	[3]
4	in	O	['N']	[4]
5	1975	O	['N']	[5]
6	because	O	['N']	[6]
7	of	O	['N']	[7]
8	lithium	B-Drug	['Causes']	[9]
9	intoxication	I-Adverse_Effect	['N']	[9]
10	with	O	['N']	[10]
11	a	O	['N']	[11]
12	diabetes	O	['N']	[12]
13	insipidus	O	['N']	[13]
14	-	O	['N']	[14]
15	like	O	['N']	[15]
16	syndrome	O	['N']	[16]
17	.	O	['N']	[17]
#1525
0	His	O	['N']	[0]
1	impaired	B	['N']	[1]
2	memory	I-Adverse_Effect	['N']	[2]
3	was	O	['N']	[3]
4	found	O	['N']	[4]
5	to	O	['N']	[5]
6	be	O	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	atenolol	B-Drug	['Causes']	[2]
11	he	O	['N']	[11]
12	was	O	['N']	[12]
13	on	O	['N']	[13]
14	and	O	['N']	[14]
15	he	O	['N']	[15]
16	made	O	['N']	[16]
17	a	O	['N']	[17]
18	complete	O	['N']	[18]
19	recovery	O	['N']	[19]
20	on	O	['N']	[20]
21	withdrawing	O	['N']	[21]
22	the	O	['N']	[22]
23	beta	O	['N']	[23]
24	-	O	['N']	[24]
25	blocker	O	['N']	[25]
26	.	O	['N']	[26]
#1526
0	Disseminated	O	['N']	[0]
1	muscular	O	['N']	[1]
2	cysticercosis	O	['N']	[2]
3	with	O	['N']	[3]
4	myositis	B-Adverse_Effect	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	praziquantel	B-Drug	['Causes']	[4]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#1527
0	There	O	['N']	[0]
1	are	O	['N']	[1]
2	,	O	['N']	[2]
3	however	O	['N']	[3]
4	,	O	['N']	[4]
5	case	O	['N']	[5]
6	studies	O	['N']	[6]
7	describing	O	['N']	[7]
8	patients	O	['N']	[8]
9	experiencing	O	['N']	[9]
10	recurrences	O	['N']	[10]
11	of	O	['N']	[11]
12	tics	B-Adverse_Effect	['N']	[12]
13	following	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	atomoxetine	B-Drug	['Causes']	[12]
17	.	O	['N']	[17]
#1528
0	Tegaserod	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	ischemic	B	['N']	[3]
4	colitis	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1529
0	Alternating	B	['N']	[0]
1	sinus	I	['N']	[1]
2	rhythm	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	intermittent	O	['N']	[4]
5	sinoatrial	O	['N']	[5]
6	block	O	['N']	[6]
7	induced	O	['N']	[7]
8	by	O	['N']	[8]
9	propranolol	B-Drug	['Causes']	[2]
10	.	O	['N']	[10]
#1530
0	Subglottic	B	['N']	[0]
1	stenosis	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	Wegener	O	['N']	[3]
4	's	O	['N']	[4]
5	granulomatosis	O	['N']	[5]
6	:	O	['N']	[6]
7	development	O	['N']	[7]
8	during	O	['N']	[8]
9	cyclophosphamide	B-Drug	['Causes']	[1]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	response	O	['N']	[12]
13	to	O	['N']	[13]
14	carbon	O	['N']	[14]
15	dioxide	O	['N']	[15]
16	laser	O	['N']	[16]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#1531
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	coccidioidal	O	['N']	[3]
4	meningitis	O	['N']	[4]
5	was	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	intrathecally	O	['N']	[8]
9	administered	O	['N']	[9]
10	amphotericin	B	['N']	[10]
11	B	I-Drug	['Causes']	[20]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	an	O	['N']	[14]
15	acute	O	['N']	[15]
16	toxic	O	['N']	[16]
17	delirium	O	['N']	[17]
18	with	O	['N']	[18]
19	EEG	B	['N']	[19]
20	abnormalities	I-Adverse_Effect	['N']	[20]
21	developed	O	['N']	[21]
22	.	O	['N']	[22]
#1532
0	The	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	"	O	['N']	[3]
4	sweet	O	['N']	[4]
5	spirits	O	['N']	[5]
6	of	O	['N']	[6]
7	nitre	O	['N']	[7]
8	"	O	['N']	[8]
9	(	O	['N']	[9]
10	4	B	['N']	[10]
11	%	I	['N']	[11]
12	ethyl	I	['N']	[12]
13	nitrite	I	['N']	[13]
14	CH3CH2ONO	I	['N']	[14]
15	in	I	['N']	[15]
16	70	I	['N']	[16]
17	%	I	['N']	[17]
18	ethyl	I	['N']	[18]
19	alcohol	I-Drug	['Causes']	[46]
20	)	O	['N']	[20]
21	was	O	['N']	[21]
22	followed	O	['N']	[22]
23	by	O	['N']	[23]
24	acute	O	['N']	[24]
25	methemoglobinemia	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	O	['N']	[27]
28	anoxic	O	['N']	[28]
29	metabolic	O	['N']	[29]
30	acidosis	O	['N']	[30]
31	in	O	['N']	[31]
32	infant	O	['N']	[32]
33	twins	O	['N']	[33]
34	,	O	['N']	[34]
35	Methylene	O	['N']	[35]
36	blue	O	['N']	[36]
37	administration	O	['N']	[37]
38	reversed	O	['N']	[38]
39	methemoglobinemia	O	['N']	[39]
40	in	O	['N']	[40]
41	both	O	['N']	[41]
42	,	O	['N']	[42]
43	but	O	['N']	[43]
44	one	O	['N']	[44]
45	twin	O	['N']	[45]
46	died	B-Adverse_Effect	['N']	[46]
47	from	O	['N']	[47]
48	the	O	['N']	[48]
49	consequences	O	['N']	[49]
50	of	O	['N']	[50]
51	hypoxemia	O	['N']	[51]
52	.	O	['N']	[52]
#1533
0	Angioedema	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	dysphagia	O	['N']	[2]
3	caused	O	['N']	[3]
4	by	O	['N']	[4]
5	contact	O	['N']	[5]
6	allergy	O	['N']	[6]
7	to	O	['N']	[7]
8	inhaled	O	['N']	[8]
9	budesonide	B-Drug	['Causes']	[0]
10	.	O	['N']	[10]
#1534
0	A	O	['N']	[0]
1	44-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	is	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	whom	O	['N']	[8]
9	amiodarone	O	['N']	[9]
10	,	O	['N']	[10]
11	disopyramide	B-Drug	['Causes']	[29]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	quinidine	O	['N']	[14]
15	,	O	['N']	[15]
16	administered	O	['N']	[16]
17	alone	O	['N']	[17]
18	separately	O	['N']	[18]
19	,	O	['N']	[19]
20	induced	O	['N']	[20]
21	atypical	O	['N']	[21]
22	ventricular	O	['N']	[22]
23	tachycardia	O	['N']	[23]
24	(	O	['N']	[24]
25	AVT	O	['N']	[25]
26	,	O	['N']	[26]
27	torsade	B	['N']	[27]
28	de	I	['N']	[28]
29	pointes	I-Adverse_Effect	['N']	[29]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#1535
0	A	O	['N']	[0]
1	21-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	patient	O	['N']	[4]
5	developed	O	['N']	[5]
6	rhabdomyolysis	B-Adverse_Effect	['N']	[6]
7	during	O	['N']	[7]
8	his	O	['N']	[8]
9	nineteenth	O	['N']	[9]
10	week	O	['N']	[10]
11	of	O	['N']	[11]
12	treatment	O	['N']	[12]
13	with	O	['N']	[13]
14	clozapine	B-Drug	['Causes']	[6]
15	for	O	['N']	[15]
16	drug	O	['N']	[16]
17	-	O	['N']	[17]
18	resistant	O	['N']	[18]
19	schizophrenia	O	['N']	[19]
20	.	O	['N']	[20]
#1536
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	postictal	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	lethargy	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	hyperammonemia	O	['N']	[11]
12	,	O	['N']	[12]
13	otherwise	O	['N']	[13]
14	normal	O	['N']	[14]
15	liver	O	['N']	[15]
16	function	O	['N']	[16]
17	tests	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	a	O	['N']	[20]
21	therapeutic	O	['N']	[21]
22	valproic	B	['N']	[22]
23	acid	I-Drug	['Causes']	[9]
24	level	O	['N']	[24]
25	.	O	['N']	[25]
#1537
0	This	O	['N']	[0]
1	profile	O	['N']	[1]
2	should	O	['N']	[2]
3	trigger	O	['N']	[3]
4	a	O	['N']	[4]
5	"	O	['N']	[5]
6	red	O	['N']	[6]
7	flag	O	['N']	[7]
8	"	O	['N']	[8]
9	as	O	['N']	[9]
10	to	O	['N']	[10]
11	the	O	['N']	[11]
12	possibility	O	['N']	[12]
13	of	O	['N']	[13]
14	phenobarbital	B-Drug	['Causes']	[23]
15	behavioral	O	['N']	[15]
16	side	O	['N']	[16]
17	effects	O	['N']	[17]
18	or	O	['N']	[18]
19	exacerbation	B	['N']	[19]
20	of	I	['N']	[20]
21	preexisting	I	['N']	[21]
22	maladaptive	I	['N']	[22]
23	behaviors	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#1538
0	Reversible	O	['N']	[0]
1	findings	O	['N']	[1]
2	of	O	['N']	[2]
3	restricted	O	['N']	[3]
4	diffusion	O	['N']	[4]
5	in	O	['N']	[5]
6	5-fluorouracil	B-Drug	['Causes']	[7]
7	neurotoxicity	B-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#1539
0	Torsades	B	['N']	[0]
1	de	I	['N']	[1]
2	Pointes	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	a	O	['N']	[5]
6	combination	O	['N']	[6]
7	of	O	['N']	[7]
8	garenoxacin	B-Drug	['Causes']	[2]
9	and	O	['N']	[9]
10	disopyramide	O	['N']	[10]
11	and	O	['N']	[11]
12	other	O	['N']	[12]
13	cytochrome	O	['N']	[13]
14	P450	O	['N']	[14]
15	,	O	['N']	[15]
16	family	O	['N']	[16]
17	3	O	['N']	[17]
18	,	O	['N']	[18]
19	subfamily	O	['N']	[19]
20	A	O	['N']	[20]
21	polypeptide-4-influencing	O	['N']	[21]
22	drugs	O	['N']	[22]
23	during	O	['N']	[23]
24	hypokalemia	O	['N']	[24]
25	due	O	['N']	[25]
26	to	O	['N']	[26]
27	licorice	O	['N']	[27]
28	.	O	['N']	[28]
#1540
0	Our	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	headache	B-Adverse_Effect	['N']	[3]
4	,	O	['N']	[4]
5	mild	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	nausea	O	['N']	[8]
9	,	O	['N']	[9]
10	vomiting	O	['N']	[10]
11	,	O	['N']	[11]
12	rash	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	eosinophilia	O	['N']	[15]
16	after	O	['N']	[16]
17	3	O	['N']	[17]
18	weeks	O	['N']	[18]
19	of	O	['N']	[19]
20	disulfiram	B-Drug	['Causes']	[3]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#1541
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	receiving	O	['N']	[2]
3	gold	B-Drug	['Causes']	[12]
4	salt	O	['N']	[4]
5	treatment	O	['N']	[5]
6	for	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	developed	O	['N']	[9]
10	severe	O	['N']	[10]
11	aplastic	B	['N']	[11]
12	anemia	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#1542
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	B	['N']	[26]
27	lymphadenopathy	I-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	-	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#1543
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	previously	O	['N']	[8]
9	prescribed	O	['N']	[9]
10	alendronate	B-Drug	['Causes']	[18]
11	(	O	['N']	[11]
12	Fosamax	O	['N']	[12]
13	)	O	['N']	[13]
14	and	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	postoperative	O	['N']	[17]
18	hypophosphatemia	B-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	hypocalcemic	O	['N']	[20]
21	tetany	O	['N']	[21]
22	after	O	['N']	[22]
23	bowel	O	['N']	[23]
24	preparation	O	['N']	[24]
25	with	O	['N']	[25]
26	Fleet	O	['N']	[26]
27	Phospho	O	['N']	[27]
28	-	O	['N']	[28]
29	Soda	O	['N']	[29]
30	.	O	['N']	[30]
#1544
0	Paraplegia	O	['N']	[0]
1	following	O	['N']	[1]
2	prophylactic	O	['N']	[2]
3	intrathecal	O	['N']	[3]
4	cytosine	B	['N']	[4]
5	arabinoside	I-Drug	['Dosage']	[29]
6	(	O	['N']	[6]
7	Ara	O	['N']	[7]
8	-	O	['N']	[8]
9	C	O	['N']	[9]
10	)	O	['N']	[10]
11	is	O	['N']	[11]
12	described	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	patient	O	['N']	[15]
16	with	O	['N']	[16]
17	acute	O	['N']	[17]
18	myelogenous	O	['N']	[18]
19	leukemia	O	['N']	[19]
20	in	O	['N']	[20]
21	remission	O	['N']	[21]
22	who	O	['N']	[22]
23	received	O	['N']	[23]
24	doses	O	['N']	[24]
25	of	O	['N']	[25]
26	100	B	['N']	[26]
27	mg	I	['N']	[27]
28	/	I	['N']	[28]
29	m2/d	I-Dose	['N']	[29]
30	for	O	['N']	[30]
31	5	O	['N']	[31]
32	consecutive	O	['N']	[32]
33	days	O	['N']	[33]
34	.	O	['N']	[34]
#1545
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	disseminated	O	['N']	[3]
4	herpes	O	['N']	[4]
5	zoster	O	['N']	[5]
6	developed	O	['N']	[6]
7	a	O	['N']	[7]
8	syndrome	B	['N']	[8]
9	of	I	['N']	[9]
10	inappropriate	I	['N']	[10]
11	antidiuretic	I	['N']	[11]
12	hormone	I-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	profound	O	['N']	[14]
15	hyponatremia	O	['N']	[15]
16	secondary	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	administration	O	['N']	[19]
20	of	O	['N']	[20]
21	adenine	B	['N']	[21]
22	arabinoside	I-Drug	['Causes']	[12]
23	.	O	['N']	[23]
#1546
0	Neurological	B	['N']	[0]
1	side	I	['N']	[1]
2	effects	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	receiving	O	['N']	[6]
7	gold	B-Drug	['Causes']	[2]
8	injections	O	['N']	[8]
9	for	O	['N']	[9]
10	rheumatoid	O	['N']	[10]
11	arthritis	O	['N']	[11]
12	.	O	['N']	[12]
#1547
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	vincristine	B-Drug	['Causes']	[15]
4	and	O	['N']	[4]
5	actinomycin	O	['N']	[5]
6	D	O	['N']	[6]
7	were	O	['N']	[7]
8	the	O	['N']	[8]
9	cause	O	['N']	[9]
10	of	O	['N']	[10]
11	this	O	['N']	[11]
12	rare	O	['N']	[12]
13	from	O	['N']	[13]
14	of	O	['N']	[14]
15	hepatotoxicity	B-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	that	O	['N']	[17]
18	chemotherapy	O	['N']	[18]
19	for	O	['N']	[19]
20	the	O	['N']	[20]
21	underlying	O	['N']	[21]
22	malignant	O	['N']	[22]
23	disease	O	['N']	[23]
24	could	O	['N']	[24]
25	be	O	['N']	[25]
26	given	O	['N']	[26]
27	safely	O	['N']	[27]
28	after	O	['N']	[28]
29	clinical	O	['N']	[29]
30	recovery	O	['N']	[30]
31	.	O	['N']	[31]
#1548
0	Piritrexim	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pulmonary	B	['N']	[3]
4	toxicity	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1549
0	CASE	O	['N']	[0]
1	PRESENTATION	O	['N']	[1]
2	:	O	['N']	[2]
3	Three	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	Leishmania	O	['N']	[6]
7	infantum	O	['N']	[7]
8	leishmaniasis	O	['N']	[8]
9	in	O	['N']	[9]
10	corticosteroid	B-Drug	['Causes']	[20]
11	(	O	['N']	[11]
12	CS)-treated	O	['N']	[12]
13	patients	O	['N']	[13]
14	are	O	['N']	[14]
15	reported	O	['N']	[15]
16	:	O	['N']	[16]
17	an	O	['N']	[17]
18	isolated	O	['N']	[18]
19	lingual	B	['N']	[19]
20	leishmaniasis	I-Adverse_Effect	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	farmer	O	['N']	[23]
24	treated	O	['N']	[24]
25	with	O	['N']	[25]
26	CS	O	['N']	[26]
27	for	O	['N']	[27]
28	asthma	O	['N']	[28]
29	,	O	['N']	[29]
30	a	O	['N']	[30]
31	severe	O	['N']	[31]
32	visceral	O	['N']	[32]
33	leishmaniasis	O	['N']	[33]
34	associated	O	['N']	[34]
35	with	O	['N']	[35]
36	cutaneous	O	['N']	[36]
37	lesions	O	['N']	[37]
38	in	O	['N']	[38]
39	a	O	['N']	[39]
40	woman	O	['N']	[40]
41	with	O	['N']	[41]
42	myasthenia	O	['N']	[42]
43	gravis	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	a	O	['N']	[46]
47	visceral	O	['N']	[47]
48	involvement	O	['N']	[48]
49	after	O	['N']	[49]
50	cutaneous	O	['N']	[50]
51	leishmaniasis	O	['N']	[51]
52	in	O	['N']	[52]
53	a	O	['N']	[53]
54	man	O	['N']	[54]
55	receiving	O	['N']	[55]
56	CS	O	['N']	[56]
57	.	O	['N']	[57]
#1550
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	infectious	B	['N']	[3]
4	toxicities	I-Adverse_Effect	['N']	[4]
5	experienced	O	['N']	[5]
6	by	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	in	O	['N']	[11]
12	our	O	['N']	[12]
13	institution	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	dexamethasone	B-Drug	['Causes']	[4]
17	(	O	['N']	[17]
18	10	O	['N']	[18]
19	mg	O	['N']	[19]
20	/	O	['N']	[20]
21	m(2)/day	O	['N']	[21]
22	for	O	['N']	[22]
23	4	O	['N']	[23]
24	weeks	O	['N']	[24]
25	with	O	['N']	[25]
26	gradual	O	['N']	[26]
27	tapering	O	['N']	[27]
28	)	O	['N']	[28]
29	during	O	['N']	[29]
30	induction	O	['N']	[30]
31	according	O	['N']	[31]
32	to	O	['N']	[32]
33	the	O	['N']	[33]
34	dexamethasone	O	['N']	[34]
35	arm	O	['N']	[35]
36	of	O	['N']	[36]
37	BFM	O	['N']	[37]
38	2000	O	['N']	[38]
39	and	O	['N']	[39]
40	review	O	['N']	[40]
41	the	O	['N']	[41]
42	relevant	O	['N']	[42]
43	literature	O	['N']	[43]
44	that	O	['N']	[44]
45	suggests	O	['N']	[45]
46	an	O	['N']	[46]
47	increased	O	['N']	[47]
48	risk	O	['N']	[48]
49	of	O	['N']	[49]
50	infectious	O	['N']	[50]
51	complications	O	['N']	[51]
52	with	O	['N']	[52]
53	dexamethasone	O	['N']	[53]
54	.	O	['N']	[54]
#1551
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	study	O	['N']	[2]
3	describes	O	['N']	[3]
4	an	O	['N']	[4]
5	atypical	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	refractory	O	['N']	[8]
9	,	O	['N']	[9]
10	sodium	B	['N']	[10]
11	warfarin	I-Drug	['Causes']	[17]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	necrotizing	O	['N']	[14]
15	fasciitis	O	['N']	[15]
16	and	O	['N']	[16]
17	myonecrosis	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#1552
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Amphotericin	B	['N']	[2]
3	B	I	['N']	[3]
4	deoxycholate	I-Drug	['Causes']	[18]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	reported	O	['N']	[7]
8	to	O	['N']	[8]
9	produce	O	['N']	[9]
10	significant	O	['N']	[10]
11	cardiac	O	['N']	[11]
12	toxicity	O	['N']	[12]
13	,	O	['N']	[13]
14	with	O	['N']	[14]
15	ventricular	O	['N']	[15]
16	arrhythmias	O	['N']	[16]
17	and	O	['N']	[17]
18	bradycardia	B-Adverse_Effect	['N']	[18]
19	reported	O	['N']	[19]
20	in	O	['N']	[20]
21	overdoses	O	['N']	[21]
22	in	O	['N']	[22]
23	children	O	['N']	[23]
24	and	O	['N']	[24]
25	in	O	['N']	[25]
26	adults	O	['N']	[26]
27	with	O	['N']	[27]
28	preexisting	O	['N']	[28]
29	cardiac	O	['N']	[29]
30	disease	O	['N']	[30]
31	,	O	['N']	[31]
32	even	O	['N']	[32]
33	when	O	['N']	[33]
34	administered	O	['N']	[34]
35	in	O	['N']	[35]
36	conventional	O	['N']	[36]
37	dosages	O	['N']	[37]
38	and	O	['N']	[38]
39	infusion	O	['N']	[39]
40	rates	O	['N']	[40]
41	.	O	['N']	[41]
#1553
0	CASE	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	severe	O	['N']	[10]
11	human	O	['N']	[11]
12	insulin	O	['N']	[12]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	lipoatrophy	B-Adverse_Effect	['N']	[15]
16	who	O	['N']	[16]
17	has	O	['N']	[17]
18	been	O	['N']	[18]
19	treated	O	['N']	[19]
20	exclusively	O	['N']	[20]
21	with	O	['N']	[21]
22	recombinant	B	['N']	[22]
23	DNA	I	['N']	[23]
24	human	I	['N']	[24]
25	insulin	I-Drug	['Causes']	[15]
26	since	O	['N']	[26]
27	the	O	['N']	[27]
28	onset	O	['N']	[28]
29	of	O	['N']	[29]
30	IDDM	O	['N']	[30]
31	.	O	['N']	[31]
#1554
0	Transient	O	['N']	[0]
1	left	O	['N']	[1]
2	homonymous	O	['N']	[2]
3	hemianopsia	O	['N']	[3]
4	and	O	['N']	[4]
5	encephalopathy	B-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	testicular	O	['N']	[9]
10	carcinoma	O	['N']	[10]
11	with	O	['N']	[11]
12	cisplatinum	B-Drug	['Causes']	[5]
13	,	O	['N']	[13]
14	vinblastine	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	bleomycin	O	['N']	[17]
18	.	O	['N']	[18]
#1555
0	Nephrogenic	O	['N']	[0]
1	diabetes	O	['N']	[1]
2	insipidus	O	['N']	[2]
3	and	O	['N']	[3]
4	renal	B	['N']	[4]
5	tubular	I	['N']	[5]
6	acidosis	I-Adverse_Effect	['N']	[6]
7	secondary	O	['N']	[7]
8	to	O	['N']	[8]
9	foscarnet	B-Drug	['Causes']	[6]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#1556
0	A	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	patient	O	['N']	[5]
6	presented	O	['N']	[6]
7	with	O	['N']	[7]
8	jaundice	O	['N']	[8]
9	followed	O	['N']	[9]
10	2	O	['N']	[10]
11	days	O	['N']	[11]
12	later	O	['N']	[12]
13	by	O	['N']	[13]
14	severe	B	['N']	[14]
15	dyspnea	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	tachypnea	O	['N']	[17]
18	which	O	['N']	[18]
19	worsened	O	['N']	[19]
20	when	O	['N']	[20]
21	patient	O	['N']	[21]
22	was	O	['N']	[22]
23	lying	O	['N']	[23]
24	flat	O	['N']	[24]
25	,	O	['N']	[25]
26	1	O	['N']	[26]
27	week	O	['N']	[27]
28	after	O	['N']	[28]
29	the	O	['N']	[29]
30	fourth	O	['N']	[30]
31	dose	O	['N']	[31]
32	of	O	['N']	[32]
33	adalimumab	B-Drug	['Causes']	[15]
34	.	O	['N']	[34]
#1557
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	clozapine	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	seizures	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	with	O	['N']	[12]
13	treatment	O	['N']	[13]
14	-	O	['N']	[14]
15	resistant	O	['N']	[15]
16	schizophrenia	O	['N']	[16]
17	.	O	['N']	[17]
#1558
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	second	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	lactic	B	['N']	[6]
7	acidosis	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	on	O	['N']	[11]
12	stavudine	B-Drug	['Causes']	[7]
13	and	O	['N']	[13]
14	lamivudine	O	['N']	[14]
15	.	O	['N']	[15]
#1559
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	typical	O	['N']	[5]
6	symptoms	O	['N']	[6]
7	of	O	['N']	[7]
8	Charles	B	['N']	[8]
9	-	I	['N']	[9]
10	Bonnet	I	['N']	[10]
11	syndrome	I-Adverse_Effect	['N']	[11]
12	(	O	['N']	[12]
13	CBS	O	['N']	[13]
14	)	O	['N']	[14]
15	in	O	['N']	[15]
16	patients	O	['N']	[16]
17	with	O	['N']	[17]
18	severe	O	['N']	[18]
19	AMD	O	['N']	[19]
20	after	O	['N']	[20]
21	intravitreal	O	['N']	[21]
22	Avastin	B-Drug	['Causes']	[11]
23	-	O	['N']	[23]
24	injections	O	['N']	[24]
25	.	O	['N']	[25]
#1560
0	Cholelithiasis	O	['N']	[0]
1	and	O	['N']	[1]
2	thrombosis	B	['N']	[2]
3	of	I	['N']	[3]
4	the	I	['N']	[4]
5	central	I	['N']	[5]
6	retinal	I	['N']	[6]
7	vein	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	renal	O	['N']	[10]
11	transplant	O	['N']	[11]
12	recipient	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	cyclosporin	B-Drug	['Causes']	[7]
16	.	O	['N']	[16]
#1561
0	This	O	['N']	[0]
1	unusual	O	['N']	[1]
2	pattern	O	['N']	[2]
3	of	O	['N']	[3]
4	low	B	['N']	[4]
5	-	I	['N']	[5]
6	grade	I	['N']	[6]
7	endometrial	I	['N']	[7]
8	carcinoma	I-Adverse_Effect	['N']	[8]
9	adds	O	['N']	[9]
10	to	O	['N']	[10]
11	the	O	['N']	[11]
12	spectrum	O	['N']	[12]
13	of	O	['N']	[13]
14	uterine	O	['N']	[14]
15	neoplasia	O	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	tamoxifen	B-Drug	['Causes']	[8]
19	therapy	O	['N']	[19]
20	.	O	['N']	[20]
#1562
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	catatonic	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	occurring	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	receiving	O	['N']	[13]
14	disulfiram	B-Drug	['Causes']	[8]
15	treatment	O	['N']	[15]
16	.	O	['N']	[16]
#1563
0	Docetaxel	B-Drug	['Causes']	[6]
1	induced	O	['N']	[1]
2	Meibomian	B	['N']	[2]
3	duct	I	['N']	[3]
4	inflammation	I	['N']	[4]
5	and	I	['N']	[5]
6	blockage	I-Adverse_Effect	['N']	[6]
7	is	O	['N']	[7]
8	the	O	['N']	[8]
9	likely	O	['N']	[9]
10	cause	O	['N']	[10]
11	of	O	['N']	[11]
12	this	O	['N']	[12]
13	presentation	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	with	O	['N']	[17]
18	no	O	['N']	[18]
19	history	O	['N']	[19]
20	of	O	['N']	[20]
21	eyelid	O	['N']	[21]
22	masses	O	['N']	[22]
23	in	O	['N']	[23]
24	the	O	['N']	[24]
25	past	O	['N']	[25]
26	.	O	['N']	[26]
#1564
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	bilateral	B	['N']	[4]
5	corneal	I	['N']	[5]
6	endothelial	I	['N']	[6]
7	dysfunction	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	Parkinson	O	['N']	[12]
13	disease	O	['N']	[13]
14	who	O	['N']	[14]
15	was	O	['N']	[15]
16	treated	O	['N']	[16]
17	with	O	['N']	[17]
18	long	O	['N']	[18]
19	-	O	['N']	[19]
20	term	O	['N']	[20]
21	amantadine	B-Drug	['Causes']	[7]
22	.	O	['N']	[22]
#1565
0	Jaundice	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	streptokinase	B-Drug	['Causes']	[0]
4	.	O	['N']	[4]
#1566
0	Painful	B-Adverse_Effect	['N']	[0]
1	neutrophilic	O	['N']	[1]
2	skin	O	['N']	[2]
3	lesions	O	['N']	[3]
4	were	O	['N']	[4]
5	observed	O	['N']	[5]
6	in	O	['N']	[6]
7	two	O	['N']	[7]
8	children	O	['N']	[8]
9	receiving	O	['N']	[9]
10	granulocyte	B	['N']	[10]
11	colony	I	['N']	[11]
12	-	I	['N']	[12]
13	stimulating	I	['N']	[13]
14	factor	I-Drug	['Causes']	[0]
15	(	O	['N']	[15]
16	G	O	['N']	[16]
17	-	O	['N']	[17]
18	CSF	O	['N']	[18]
19	)	O	['N']	[19]
20	for	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	idiopathic	O	['N']	[23]
24	neutropenia	O	['N']	[24]
25	.	O	['N']	[25]
#1567
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	of	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	probable	O	['N']	[7]
8	cisplatin	B-Drug	['Causes']	[13]
9	and	O	['N']	[9]
10	bleomycin	O	['N']	[10]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	TMA	B-Adverse_Effect	['N']	[13]
14	is	O	['N']	[14]
15	presented	O	['N']	[15]
16	.	O	['N']	[16]
#1568
0	Quetiapine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	leucopenia	B-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	thrombocytopenia	O	['N']	[5]
6	.	O	['N']	[6]
#1569
0	Here	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	angio	B	['N']	[7]
8	-	I	['N']	[8]
9	oedema	I-Adverse_Effect	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	VRC	B-Drug	['Causes']	[9]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#1570
0	Vincristine	B-Drug	['Causes']	[3]
1	induced	O	['N']	[1]
2	cranial	B	['N']	[2]
3	polyneuropathy	I-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#1571
0	After	O	['N']	[0]
1	rechallenge	O	['N']	[1]
2	with	O	['N']	[2]
3	monotherapy	O	['N']	[3]
4	pegvisomant	B-Drug	['Causes']	[11]
5	,	O	['N']	[5]
6	however	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	hepatic	B	['N']	[9]
10	enzyme	I	['N']	[10]
11	disturbances	I-Adverse_Effect	['N']	[11]
12	reappeared	O	['N']	[12]
13	within	O	['N']	[13]
14	a	O	['N']	[14]
15	few	O	['N']	[15]
16	weeks	O	['N']	[16]
17	,	O	['N']	[17]
18	indicating	O	['N']	[18]
19	that	O	['N']	[19]
20	most	O	['N']	[20]
21	likely	O	['N']	[21]
22	pegvisomant	O	['N']	[22]
23	alone	O	['N']	[23]
24	and	O	['N']	[24]
25	not	O	['N']	[25]
26	the	O	['N']	[26]
27	long	O	['N']	[27]
28	-	O	['N']	[28]
29	acting	O	['N']	[29]
30	somatostatin	O	['N']	[30]
31	analog	O	['N']	[31]
32	or	O	['N']	[32]
33	the	O	['N']	[33]
34	combination	O	['N']	[34]
35	of	O	['N']	[35]
36	these	O	['N']	[36]
37	two	O	['N']	[37]
38	drugs	O	['N']	[38]
39	was	O	['N']	[39]
40	responsible	O	['N']	[40]
41	for	O	['N']	[41]
42	this	O	['N']	[42]
43	case	O	['N']	[43]
44	of	O	['N']	[44]
45	drug	O	['N']	[45]
46	-	O	['N']	[46]
47	induced	O	['N']	[47]
48	hepatitis	O	['N']	[48]
49	.	O	['N']	[49]
#1572
0	Heparin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	thrombocytopenia	B-Adverse_Effect	['N']	[3]
4	complicated	O	['N']	[4]
5	with	O	['N']	[5]
6	massive	O	['N']	[6]
7	thrombosis	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	inferior	O	['N']	[10]
11	vena	O	['N']	[11]
12	cava	O	['N']	[12]
13	after	O	['N']	[13]
14	filter	O	['N']	[14]
15	placement	O	['N']	[15]
16	.	O	['N']	[16]
#1573
0	A	O	['N']	[0]
1	35-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	presented	O	['N']	[5]
6	with	O	['N']	[6]
7	neurotoxicity	O	['N']	[7]
8	correlated	O	['N']	[8]
9	to	O	['N']	[9]
10	an	O	['N']	[10]
11	i.v	O	['N']	[11]
12	.	O	['N']	[12]
13	regimen	O	['N']	[13]
14	of	O	['N']	[14]
15	5-fluorouracil	B-Drug	['Causes']	[21]
16	as	O	['N']	[16]
17	episodes	O	['N']	[17]
18	of	O	['N']	[18]
19	acute	B	['N']	[19]
20	confusional	I	['N']	[20]
21	state	I-Adverse_Effect	['N']	[21]
22	and	O	['N']	[22]
23	abnormalities	O	['N']	[23]
24	of	O	['N']	[24]
25	symmetrically	O	['N']	[25]
26	restricted	O	['N']	[26]
27	diffusion	O	['N']	[27]
28	in	O	['N']	[28]
29	the	O	['N']	[29]
30	periventricular	O	['N']	[30]
31	white	O	['N']	[31]
32	matter	O	['N']	[32]
33	and	O	['N']	[33]
34	corpus	O	['N']	[34]
35	callosum	O	['N']	[35]
36	.	O	['N']	[36]
#1574
0	Minocycline	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	autoimmune	B	['N']	[3]
4	hepatitis	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	usually	O	['N']	[6]
7	identical	O	['N']	[7]
8	to	O	['N']	[8]
9	sporadic	O	['N']	[9]
10	autoimmune	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	.	O	['N']	[12]
#1575
0	Abrupt	O	['N']	[0]
1	,	O	['N']	[1]
2	accidental	O	['N']	[2]
3	withdrawal	O	['N']	[3]
4	of	O	['N']	[4]
5	trihexyphenidyl	B-Drug	['Causes']	[16]
6	triggered	O	['N']	[6]
7	severe	O	['N']	[7]
8	exacerbation	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	cranial	O	['N']	[11]
12	dystonia	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	inspiratory	B	['N']	[15]
16	stridor	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	acute	O	['N']	[18]
19	respiratory	O	['N']	[19]
20	difficulties	O	['N']	[20]
21	,	O	['N']	[21]
22	prompting	O	['N']	[22]
23	emergency	O	['N']	[23]
24	admission	O	['N']	[24]
25	.	O	['N']	[25]
#1576
0	Mitomycin	O	['N']	[0]
1	C	O	['N']	[1]
2	(	O	['N']	[2]
3	MMC	B-Drug	['Causes']	[19]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	an	O	['N']	[6]
7	alkylating	O	['N']	[7]
8	agent	O	['N']	[8]
9	that	O	['N']	[9]
10	has	O	['N']	[10]
11	been	O	['N']	[11]
12	recently	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	hemolytic	B	['N']	[16]
17	-	I	['N']	[17]
18	uremic	I	['N']	[18]
19	syndrome	I-Adverse_Effect	['N']	[19]
20	(	O	['N']	[20]
21	HUS	O	['N']	[21]
22	)	O	['N']	[22]
23	.	O	['N']	[23]
#1577
0	Circulating	O	['N']	[0]
1	anticoagulant	O	['N']	[1]
2	in	O	['N']	[2]
3	the	O	['N']	[3]
4	procainamide	B-Drug	['Causes']	[8]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	lupus	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#1578
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	four	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	encephalopathy	O	['N']	[5]
6	coincident	O	['N']	[6]
7	with	O	['N']	[7]
8	elevated	B	['N']	[8]
9	aluminum	I	['N']	[9]
10	levels	I-Adverse_Effect	['N']	[10]
11	as	O	['N']	[11]
12	well	O	['N']	[12]
13	as	O	['N']	[13]
14	one	O	['N']	[14]
15	patient	O	['N']	[15]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	seizures	O	['N']	[18]
19	while	O	['N']	[19]
20	receiving	O	['N']	[20]
21	continuous	O	['N']	[21]
22	bladder	O	['N']	[22]
23	irrigations	O	['N']	[23]
24	with	O	['N']	[24]
25	alum	O	['N']	[25]
26	.	O	['N']	[26]
#1579
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	B	['N']	[31]
32	lymphocytosis	I-Adverse_Effect	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	B-Drug	['Causes']	[32]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#1580
0	Four	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	intravenous	O	['N']	[3]
4	Zoledronic	B	['N']	[4]
5	acid	I-Drug	['Causes']	[17]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	presented	O	['N']	[9]
10	to	O	['N']	[10]
11	emergency	O	['N']	[11]
12	room	O	['N']	[12]
13	with	O	['N']	[13]
14	complaints	O	['N']	[14]
15	of	O	['N']	[15]
16	carpopedal	B	['N']	[16]
17	spasm	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	bronchospasm	O	['N']	[19]
20	.	O	['N']	[20]
#1581
0	Various	O	['N']	[0]
1	case	O	['N']	[1]
2	reports	O	['N']	[2]
3	concerning	O	['N']	[3]
4	dapsone	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	agranulocytosis	B-Adverse_Effect	['N']	[7]
8	are	O	['N']	[8]
9	reviewed	O	['N']	[9]
10	.	O	['N']	[10]
#1582
0	Immobilization	O	['N']	[0]
1	,	O	['N']	[1]
2	while	O	['N']	[2]
3	Paget	O	['N']	[3]
4	's	O	['N']	[4]
5	bone	O	['N']	[5]
6	disease	O	['N']	[6]
7	was	O	['N']	[7]
8	present	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	perhaps	O	['N']	[11]
12	enhanced	O	['N']	[12]
13	activation	O	['N']	[13]
14	of	O	['N']	[14]
15	dihydrotachysterol	B-Drug	['Causes']	[26]
16	by	O	['N']	[16]
17	rifampicin	O	['N']	[17]
18	,	O	['N']	[18]
19	could	O	['N']	[19]
20	have	O	['N']	[20]
21	led	O	['N']	[21]
22	to	O	['N']	[22]
23	increased	B	['N']	[23]
24	calcium	I	['N']	[24]
25	-	I	['N']	[25]
26	release	I-Adverse_Effect	['N']	[26]
27	into	O	['N']	[27]
28	the	O	['N']	[28]
29	circulation	O	['N']	[29]
30	.	O	['N']	[30]
#1583
0	Thus	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	eosinophilia	B	['N']	[3]
4	myalgia	I	['N']	[4]
5	syndrome	I-Adverse_Effect	['N']	[5]
6	can	O	['N']	[6]
7	be	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	parenteral	O	['N']	[10]
11	tryptophan	B-Drug	['Causes']	[5]
12	administration	O	['N']	[12]
13	.	O	['N']	[13]
#1584
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	1	O	['N']	[2]
3	)	O	['N']	[3]
4	To	O	['N']	[4]
5	describe	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	rheumatoid	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	receiving	O	['N']	[11]
12	adalimumab	B-Drug	['Causes']	[15]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	fever	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	pancytopenia	O	['N']	[17]
18	,	O	['N']	[18]
19	splenomegaly	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	extreme	O	['N']	[22]
23	hyperferritinemia	O	['N']	[23]
24	.	O	['N']	[24]
#1585
0	Cefoxitin	B-Drug	['Causes']	[9]
1	therapy	O	['N']	[1]
2	for	O	['N']	[2]
3	Mycobacterium	O	['N']	[3]
4	fortuitum	O	['N']	[4]
5	bacteremia	O	['N']	[5]
6	with	O	['N']	[6]
7	associated	O	['N']	[7]
8	granulomatous	B	['N']	[8]
9	hepatitis	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#1586
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	male	O	['N']	[3]
4	patients	O	['N']	[4]
5	,	O	['N']	[5]
6	a	O	['N']	[6]
7	49-year	O	['N']	[7]
8	-	O	['N']	[8]
9	old	O	['N']	[9]
10	with	O	['N']	[10]
11	psoriatic	O	['N']	[11]
12	arthritis	O	['N']	[12]
13	and	O	['N']	[13]
14	impaired	O	['N']	[14]
15	renal	O	['N']	[15]
16	function	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	43-year	O	['N']	[19]
20	-	O	['N']	[20]
21	old	O	['N']	[21]
22	renal	O	['N']	[22]
23	transplant	O	['N']	[23]
24	recipient	O	['N']	[24]
25	,	O	['N']	[25]
26	who	O	['N']	[26]
27	both	O	['N']	[27]
28	sustained	O	['N']	[28]
29	a	O	['N']	[29]
30	marked	O	['N']	[30]
31	decline	B	['N']	[31]
32	in	I	['N']	[32]
33	glomerular	I	['N']	[33]
34	filtration	I	['N']	[34]
35	rate	I-Adverse_Effect	['N']	[35]
36	in	O	['N']	[36]
37	conjunction	O	['N']	[37]
38	with	O	['N']	[38]
39	a	O	['N']	[39]
40	selective	O	['N']	[40]
41	inhibitor	O	['N']	[41]
42	of	O	['N']	[42]
43	cyclooxygenase-2	O	['N']	[43]
44	(	O	['N']	[44]
45	COX-2	O	['N']	[45]
46	)	O	['N']	[46]
47	,	O	['N']	[47]
48	rofecoxib	B-Drug	['Causes']	[35]
49	.	O	['N']	[49]
#1587
0	Reversal	O	['N']	[0]
1	of	O	['N']	[1]
2	ergotamine	B-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	arteriospasm	B-Adverse_Effect	['N']	[5]
6	by	O	['N']	[6]
7	mechanical	O	['N']	[7]
8	intra	O	['N']	[8]
9	-	O	['N']	[9]
10	arterial	O	['N']	[10]
11	dilatation	O	['N']	[11]
12	.	O	['N']	[12]
#1588
0	He	O	['N']	[0]
1	was	O	['N']	[1]
2	later	O	['N']	[2]
3	skin	O	['N']	[3]
4	tested	O	['N']	[4]
5	to	O	['N']	[5]
6	confirm	O	['N']	[6]
7	allergy	B-Adverse_Effect	['N']	[7]
8	to	O	['N']	[8]
9	MTX	B-Drug	['Causes']	[7]
10	.	O	['N']	[10]
#1589
0	Based	O	['N']	[0]
1	upon	O	['N']	[1]
2	the	O	['N']	[2]
3	observed	O	['N']	[3]
4	fall	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	filtration	O	['N']	[7]
8	fraction	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	rise	O	['N']	[11]
12	in	O	['N']	[12]
13	the	O	['N']	[13]
14	relative	O	['N']	[14]
15	clearance	O	['N']	[15]
16	of	O	['N']	[16]
17	99Tc	O	['N']	[17]
18	-	O	['N']	[18]
19	dimercaptosuccinic	O	['N']	[19]
20	acid	O	['N']	[20]
21	and	O	['N']	[21]
22	the	O	['N']	[22]
23	increase	B	['N']	[23]
24	in	I	['N']	[24]
25	proteinuria	I-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	we	O	['N']	[27]
28	suggest	O	['N']	[28]
29	that	O	['N']	[29]
30	in	O	['N']	[30]
31	this	O	['N']	[31]
32	case	O	['N']	[32]
33	the	O	['N']	[33]
34	tubules	O	['N']	[34]
35	and/or	O	['N']	[35]
36	interstitium	O	['N']	[36]
37	are	O	['N']	[37]
38	the	O	['N']	[38]
39	main	O	['N']	[39]
40	targets	O	['N']	[40]
41	for	O	['N']	[41]
42	cyclosporine	B	['N']	[42]
43	A	I-Drug	['Causes']	[25]
44	nephrotoxicity	O	['N']	[44]
45	.	O	['N']	[45]
#1590
0	Phenylpropanolamine	O	['N']	[0]
1	(	O	['N']	[1]
2	PPA	B-Drug	['Causes']	[17]
3	)	O	['N']	[3]
4	recently	O	['N']	[4]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	publicly	O	['N']	[7]
8	implicated	O	['N']	[8]
9	as	O	['N']	[9]
10	a	O	['N']	[10]
11	cause	O	['N']	[11]
12	of	O	['N']	[12]
13	stroke	O	['N']	[13]
14	and	O	['N']	[14]
15	other	O	['N']	[15]
16	neurologic	B	['N']	[16]
17	events	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#1591
0	DLST	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	good	O	['N']	[3]
4	diagnostic	O	['N']	[4]
5	tool	O	['N']	[5]
6	for	O	['N']	[6]
7	AZA	B-Drug	['Causes']	[8]
8	allergy	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	especially	O	['N']	[10]
11	for	O	['N']	[11]
12	severe	O	['N']	[12]
13	drug	O	['N']	[13]
14	allergy	O	['N']	[14]
15	cases	O	['N']	[15]
16	.	O	['N']	[16]
#1592
0	After	O	['N']	[0]
1	induction	O	['N']	[1]
2	of	O	['N']	[2]
3	general	O	['N']	[3]
4	anesthesia	O	['N']	[4]
5	and	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	standard	O	['N']	[9]
10	dose	O	['N']	[10]
11	of	O	['N']	[11]
12	intravenous	O	['N']	[12]
13	esmolol	B	['N']	[13]
14	hydrochloride	I-Drug	['Causes']	[21]
15	,	O	['N']	[15]
16	her	O	['N']	[16]
17	cardiac	O	['N']	[17]
18	rhythm	O	['N']	[18]
19	progressed	O	['N']	[19]
20	to	O	['N']	[20]
21	asystole	B-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1593
0	The	O	['N']	[0]
1	cause	O	['N']	[1]
2	of	O	['N']	[2]
3	his	O	['N']	[3]
4	bleeding	O	['N']	[4]
5	was	O	['N']	[5]
6	a	O	['N']	[6]
7	severe	B	['N']	[7]
8	thrombocytopoaenia	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	induced	O	['N']	[10]
11	by	O	['N']	[11]
12	chronic	O	['N']	[12]
13	ingestion	O	['N']	[13]
14	of	O	['N']	[14]
15	quinine	B-Drug	['Causes']	[8]
16	.	O	['N']	[16]
#1594
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	44-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	taking	O	['N']	[7]
8	naproxen	O	['N']	[8]
9	for	O	['N']	[9]
10	chronic	O	['N']	[10]
11	low	O	['N']	[11]
12	back	O	['N']	[12]
13	pain	O	['N']	[13]
14	and	O	['N']	[14]
15	a	O	['N']	[15]
16	20-year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	woman	O	['N']	[19]
20	on	O	['N']	[20]
21	oxaprozin	B-Drug	['Causes']	[28]
22	for	O	['N']	[22]
23	rheumatoid	O	['N']	[23]
24	arthritis	O	['N']	[24]
25	presented	O	['N']	[25]
26	with	O	['N']	[26]
27	tense	B	['N']	[27]
28	bullae	I-Adverse_Effect	['N']	[28]
29	and	O	['N']	[29]
30	cutaneous	O	['N']	[30]
31	fragility	O	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	face	O	['N']	[34]
35	and	O	['N']	[35]
36	the	O	['N']	[36]
37	back	O	['N']	[37]
38	of	O	['N']	[38]
39	the	O	['N']	[39]
40	hands	O	['N']	[40]
41	.	O	['N']	[41]
#1595
0	Leiomyosarcoma	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	urinary	O	['N']	[2]
3	bladder	O	['N']	[3]
4	after	O	['N']	[4]
5	cyclophosphamide	B-Drug	['Causes']	[0]
6	therapy	O	['N']	[6]
7	for	O	['N']	[7]
8	retinoblastoma	O	['N']	[8]
9	and	O	['N']	[9]
10	review	O	['N']	[10]
11	of	O	['N']	[11]
12	bladder	O	['N']	[12]
13	sarcomas	O	['N']	[13]
14	.	O	['N']	[14]
#1596
0	Ampicillin	B-Drug	['Causes']	[5]
1	increased	O	['N']	[1]
2	the	O	['N']	[2]
3	preexisting	O	['N']	[3]
4	electrical	B	['N']	[4]
5	decrement	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	three	O	['N']	[7]
8	rabbits	O	['N']	[8]
9	with	O	['N']	[9]
10	experimental	O	['N']	[10]
11	autoimmune	O	['N']	[11]
12	myasthenia	O	['N']	[12]
13	gravis	O	['N']	[13]
14	while	O	['N']	[14]
15	the	O	['N']	[15]
16	drug	O	['N']	[16]
17	had	O	['N']	[17]
18	no	O	['N']	[18]
19	deleterious	O	['N']	[19]
20	effects	O	['N']	[20]
21	in	O	['N']	[21]
22	less	O	['N']	[22]
23	affected	O	['N']	[23]
24	or	O	['N']	[24]
25	normal	O	['N']	[25]
26	animals	O	['N']	[26]
27	.	O	['N']	[27]
#1597
0	The	O	['N']	[0]
1	rash	B-Adverse_Effect	['N']	[1]
2	seen	O	['N']	[2]
3	in	O	['N']	[3]
4	this	O	['N']	[4]
5	patient	O	['N']	[5]
6	,	O	['N']	[6]
7	who	O	['N']	[7]
8	was	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	cephalexin	B-Drug	['Causes']	[1]
12	,	O	['N']	[12]
13	may	O	['N']	[13]
14	be	O	['N']	[14]
15	similar	O	['N']	[15]
16	to	O	['N']	[16]
17	the	O	['N']	[17]
18	rash	O	['N']	[18]
19	seen	O	['N']	[19]
20	with	O	['N']	[20]
21	ampicillin	O	['N']	[21]
22	treatment	O	['N']	[22]
23	of	O	['N']	[23]
24	patients	O	['N']	[24]
25	with	O	['N']	[25]
26	infectious	O	['N']	[26]
27	mononucleosis	O	['N']	[27]
28	.	O	['N']	[28]
#1598
0	We	O	['N']	[0]
1	described	O	['N']	[1]
2	the	O	['N']	[2]
3	occurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	L	B	['N']	[5]
6	-	I	['N']	[6]
7	dopa	I-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	myoclonus	B-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	seizures	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	case	O	['N']	[15]
16	of	O	['N']	[16]
17	parkinsonism	O	['N']	[17]
18	with	O	['N']	[18]
19	its	O	['N']	[19]
20	SEPs	O	['N']	[20]
21	findings	O	['N']	[21]
22	.	O	['N']	[22]
#1599
0	Skin	B	['N']	[0]
1	manifestations	I-Adverse_Effect	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	phenylbutazone	B-Drug	['Causes']	[1]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	serum	O	['N']	[9]
10	sickness	O	['N']	[10]
11	-	O	['N']	[11]
12	like	O	['N']	[12]
13	reactions	O	['N']	[13]
14	.	O	['N']	[14]
#1600
0	An	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	granulocytopenia	O	['N']	[3]
4	,	O	['N']	[4]
5	eosinophilia	B-Adverse_Effect	['N']	[5]
6	,	O	['N']	[6]
7	skin	O	['N']	[7]
8	reaction	O	['N']	[8]
9	and	O	['N']	[9]
10	hepatitis	O	['N']	[10]
11	during	O	['N']	[11]
12	propylthiouracil	O	['N']	[12]
13	(	O	['N']	[13]
14	PTU	B-Drug	['Causes']	[5]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	thyrotoxicosis	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	47	O	['N']	[21]
22	year	O	['N']	[22]
23	old	O	['N']	[23]
24	black	O	['N']	[24]
25	female	O	['N']	[25]
26	is	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#1601
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	follow	O	['N']	[2]
3	-	O	['N']	[3]
4	up	O	['N']	[4]
5	revealed	O	['N']	[5]
6	that	O	['N']	[6]
7	gestational	B	['N']	[7]
8	diabetes	I-Adverse_Effect	['N']	[8]
9	when	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	norethisterone	B-Drug	['Causes']	[8]
13	had	O	['N']	[13]
14	a	O	['N']	[14]
15	lesser	O	['N']	[15]
16	risk	O	['N']	[16]
17	of	O	['N']	[17]
18	emerging	O	['N']	[18]
19	diabetes	O	['N']	[19]
20	mellitus	O	['N']	[20]
21	and	O	['N']	[21]
22	impaired	O	['N']	[22]
23	glucose	O	['N']	[23]
24	tolerance	O	['N']	[24]
25	.	O	['N']	[25]
#1602
0	Peripheral	B	['N']	[0]
1	neuropathy	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	capecitabine	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#1603
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	next	O	['N']	[2]
3	day	O	['N']	[3]
4	,	O	['N']	[4]
5	after	O	['N']	[5]
6	a	O	['N']	[6]
7	total	O	['N']	[7]
8	dose	O	['N']	[8]
9	of	O	['N']	[9]
10	only	O	['N']	[10]
11	600	O	['N']	[11]
12	mg	O	['N']	[12]
13	of	O	['N']	[13]
14	danazol	B-Drug	['Causes']	[17]
15	,	O	['N']	[15]
16	gingival	B	['N']	[16]
17	bleeding	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	purpura	O	['N']	[19]
20	occurred	O	['N']	[20]
21	.	O	['N']	[21]
#1604
0	Patient	O	['N']	[0]
1	1	O	['N']	[1]
2	presented	O	['N']	[2]
3	bilateral	B	['N']	[3]
4	ballism	I-Adverse_Effect	['N']	[4]
5	1	O	['N']	[5]
6	week	O	['N']	[6]
7	after	O	['N']	[7]
8	intravenous	O	['N']	[8]
9	heroin	B-Drug	['Causes']	[4]
10	injection	O	['N']	[10]
11	.	O	['N']	[11]
#1605
0	High	O	['N']	[0]
1	-	O	['N']	[1]
2	dose	O	['N']	[2]
3	methylprednisolone	B-Drug	['Causes']	[14]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	pregnant	O	['N']	[6]
7	woman	O	['N']	[7]
8	with	O	['N']	[8]
9	Crohn	O	['N']	[9]
10	's	O	['N']	[10]
11	disease	O	['N']	[11]
12	and	O	['N']	[12]
13	adrenal	B	['N']	[13]
14	suppression	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	her	O	['N']	[16]
17	newborn	O	['N']	[17]
18	.	O	['N']	[18]
#1606
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	pneumonitis	B-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	local	O	['N']	[7]
8	administration	O	['N']	[8]
9	of	O	['N']	[9]
10	methotrexate	B-Drug	['Causes']	[5]
11	for	O	['N']	[11]
12	nonsurgical	O	['N']	[12]
13	termination	O	['N']	[13]
14	of	O	['N']	[14]
15	an	O	['N']	[15]
16	ectopic	O	['N']	[16]
17	pregnancy	O	['N']	[17]
18	.	O	['N']	[18]
#1607
0	Clozapine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	akathisia	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	children	O	['N']	[5]
6	with	O	['N']	[6]
7	schizophrenia	O	['N']	[7]
8	.	O	['N']	[8]
#1608
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	severe	B	['N']	[5]
6	anemia	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	which	O	['N']	[8]
9	responded	O	['N']	[9]
10	well	O	['N']	[10]
11	to	O	['N']	[11]
12	steroid	O	['N']	[12]
13	therapy	O	['N']	[13]
14	,	O	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	receiving	O	['N']	[18]
19	IL-2	O	['N']	[19]
20	plus	O	['N']	[20]
21	IFN	B	['N']	[21]
22	-	I	['N']	[22]
23	alpha	I-Drug	['Causes']	[6]
24	for	O	['N']	[24]
25	metastatic	O	['N']	[25]
26	renal	O	['N']	[26]
27	cell	O	['N']	[27]
28	carcinoma	O	['N']	[28]
29	.	O	['N']	[29]
#1609
0	A	O	['N']	[0]
1	61-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	clinical	B	['N']	[6]
7	lupus	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	positive	O	['N']	[10]
11	antinuclear	O	['N']	[11]
12	antibody	O	['N']	[12]
13	,	O	['N']	[13]
14	positive	O	['N']	[14]
15	lupus	O	['N']	[15]
16	erythematosus	O	['N']	[16]
17	(	O	['N']	[17]
18	LE	O	['N']	[18]
19	)	O	['N']	[19]
20	cell	O	['N']	[20]
21	preparation	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	diffuse	O	['N']	[24]
25	proliferative	O	['N']	[25]
26	glomerulonephritis	O	['N']	[26]
27	following	O	['N']	[27]
28	26	O	['N']	[28]
29	months	O	['N']	[29]
30	of	O	['N']	[30]
31	procainamide	B-Drug	['Causes']	[8]
32	therapy	O	['N']	[32]
33	.	O	['N']	[33]
#1610
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	unique	O	['N']	[3]
4	autopsy	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	hepatocellular	B	['N']	[7]
8	carcinoma	I-Adverse_Effect	['N']	[8]
9	closely	O	['N']	[9]
10	related	O	['N']	[10]
11	to	O	['N']	[11]
12	diethylstilbestrol	B-Drug	['Causes']	[8]
13	(	O	['N']	[13]
14	DES	O	['N']	[14]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	prostatic	O	['N']	[18]
19	cancer	O	['N']	[19]
20	.	O	['N']	[20]
#1611
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	illustrates	O	['N']	[3]
4	the	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	continuous	O	['N']	[7]
8	high	O	['N']	[8]
9	-	O	['N']	[9]
10	dose	O	['N']	[10]
11	intracoronary	O	['N']	[11]
12	nitroglycerin	O	['N']	[12]
13	infusion	O	['N']	[13]
14	through	O	['N']	[14]
15	a	O	['N']	[15]
16	6	O	['N']	[16]
17	French	O	['N']	[17]
18	coronary	O	['N']	[18]
19	guiding	O	['N']	[19]
20	catheter	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	treatment	O	['N']	[23]
24	of	O	['N']	[24]
25	a	O	['N']	[25]
26	patient	O	['N']	[26]
27	with	O	['N']	[27]
28	cocaine	B-Drug	['Causes']	[33]
29	-	O	['N']	[29]
30	induced	O	['N']	[30]
31	refractory	B	['N']	[31]
32	coronary	I	['N']	[32]
33	vasospasm	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#1612
0	An	O	['N']	[0]
1	83-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	receiving	O	['N']	[5]
6	glipizide	O	['N']	[6]
7	10	O	['N']	[7]
8	mg	O	['N']	[8]
9	bid	O	['N']	[9]
10	developed	O	['N']	[10]
11	symptomatic	B	['N']	[11]
12	hypoglycemia	I-Adverse_Effect	['N']	[12]
13	within	O	['N']	[13]
14	three	O	['N']	[14]
15	days	O	['N']	[15]
16	of	O	['N']	[16]
17	adding	O	['N']	[17]
18	trimethoprim	O	['N']	[18]
19	/	O	['N']	[19]
20	sulfamethoxazole	O	['N']	[20]
21	(	O	['N']	[21]
22	TMP	O	['N']	[22]
23	/	O	['N']	[23]
24	SMX	B-Drug	['Causes']	[12]
25	)	O	['N']	[25]
26	to	O	['N']	[26]
27	his	O	['N']	[27]
28	regimen	O	['N']	[28]
29	.	O	['N']	[29]
#1613
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	ELBW	O	['N']	[3]
4	infants	O	['N']	[4]
5	affected	O	['N']	[5]
6	by	O	['N']	[6]
7	hyperkalaemia	O	['N']	[7]
8	,	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	Kayexalate	B-Drug	['Causes']	[16]
12	,	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	serious	O	['N']	[15]
16	hypernatraemia	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	that	O	['N']	[18]
19	has	O	['N']	[19]
20	never	O	['N']	[20]
21	been	O	['N']	[21]
22	reported	O	['N']	[22]
23	before	O	['N']	[23]
24	in	O	['N']	[24]
25	preterm	O	['N']	[25]
26	infants	O	['N']	[26]
27	.	O	['N']	[27]
#1614
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	diagnosed	O	['N']	[2]
3	with	O	['N']	[3]
4	Epstein	B	['N']	[4]
5	-	I	['N']	[5]
6	Barr	I	['N']	[6]
7	virus	I	['N']	[7]
8	-	I	['N']	[8]
9	associated	I	['N']	[9]
10	polymorphic	I	['N']	[10]
11	lymphoproliferative	I	['N']	[11]
12	disorder	I-Adverse_Effect	['N']	[12]
13	(	O	['N']	[13]
14	LPD	O	['N']	[14]
15	)	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	immunodeficiency	O	['N']	[18]
19	caused	O	['N']	[19]
20	by	O	['N']	[20]
21	MTX	B-Drug	['Causes']	[12]
22	administration	O	['N']	[22]
23	.	O	['N']	[23]
#1615
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	occurrence	O	['N']	[5]
6	of	O	['N']	[6]
7	ocular	B	['N']	[7]
8	hypertension	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	four	O	['N']	[10]
11	patients	O	['N']	[11]
12	following	O	['N']	[12]
13	injection	O	['N']	[13]
14	of	O	['N']	[14]
15	ranibizumab	B-Drug	['Causes']	[8]
16	intravitreally	O	['N']	[16]
17	.	O	['N']	[17]
#1616
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	cutaneous	B	['N']	[5]
6	leucocytoclastic	I	['N']	[6]
7	vasculitis	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	which	O	['N']	[9]
10	amphotericin	B	['N']	[10]
11	B	I-Drug	['Causes']	[7]
12	might	O	['N']	[12]
13	presumably	O	['N']	[13]
14	be	O	['N']	[14]
15	the	O	['N']	[15]
16	aetiological	O	['N']	[16]
17	factor	O	['N']	[17]
18	.	O	['N']	[18]
#1617
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	liver	B	['N']	[3]
4	damage	I-Adverse_Effect	['N']	[4]
5	following	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	Danazol	B-Drug	['Causes']	[4]
9	for	O	['N']	[9]
10	fibrocystic	O	['N']	[10]
11	breast	O	['N']	[11]
12	disease	O	['N']	[12]
13	is	O	['N']	[13]
14	reported	O	['N']	[14]
15	.	O	['N']	[15]
#1618
0	MR	O	['N']	[0]
1	findings	O	['N']	[1]
2	in	O	['N']	[2]
3	methotrexate	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	CNS	B	['N']	[6]
7	abnormalities	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#1619
0	Clinical	O	['N']	[0]
1	course	O	['N']	[1]
2	of	O	['N']	[2]
3	macular	B	['N']	[3]
4	edema	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	two	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	interferon	B-Drug	['Causes']	[4]
10	-	O	['N']	[10]
11	associated	O	['N']	[11]
12	retinopathy	O	['N']	[12]
13	observed	O	['N']	[13]
14	by	O	['N']	[14]
15	optical	O	['N']	[15]
16	coherence	O	['N']	[16]
17	tomography	O	['N']	[17]
18	.	O	['N']	[18]
#1620
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	O	['N']	[24]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	O	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	O	['N']	[42]
43	-	O	['N']	[43]
44	reaction	O	['N']	[44]
45	to	O	['N']	[45]
46	promethazine	B-Drug	['Causes']	[54]
47	,	O	['N']	[47]
48	decreased	B	['N']	[48]
49	MED	I	['N']	[49]
50	to	I	['N']	[50]
51	both	I	['N']	[51]
52	UVA	I	['N']	[52]
53	and	I	['N']	[53]
54	UVB	I-Adverse_Effect	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	photosensitivity	O	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#1621
0	Generalized	B	['N']	[0]
1	maculopapular	I	['N']	[1]
2	and	I	['N']	[2]
3	papular	I	['N']	[3]
4	purpuric	I	['N']	[4]
5	eruptions	I-Adverse_Effect	['N']	[5]
6	are	O	['N']	[6]
7	perhaps	O	['N']	[7]
8	the	O	['N']	[8]
9	most	O	['N']	[9]
10	common	O	['N']	[10]
11	thionamide	B-Drug	['Causes']	[5]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	reactions	O	['N']	[14]
15	.	O	['N']	[15]
#1622
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	aseptic	O	['N']	[9]
10	meningitis	O	['N']	[10]
11	,	O	['N']	[11]
12	hemolytic	O	['N']	[12]
13	anemia	O	['N']	[13]
14	,	O	['N']	[14]
15	hepatitis	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	orthostatic	O	['N']	[18]
19	hypotension	O	['N']	[19]
20	simultaneously	O	['N']	[20]
21	during	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	trimethoprim	O	['N']	[24]
25	-	O	['N']	[25]
26	sulfamethoxazole	B-Drug	['Causes']	[15]
27	is	O	['N']	[27]
28	described	O	['N']	[28]
29	.	O	['N']	[29]
#1623
0	Cerebrovascular	B	['N']	[0]
1	complications	I-Adverse_Effect	['N']	[1]
2	of	O	['N']	[2]
3	L	B	['N']	[3]
4	-	I	['N']	[4]
5	asparaginase	I-Drug	['Causes']	[1]
6	therapy	O	['N']	[6]
7	in	O	['N']	[7]
8	children	O	['N']	[8]
9	with	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	:	O	['N']	[11]
12	aphasia	O	['N']	[12]
13	and	O	['N']	[13]
14	other	O	['N']	[14]
15	neuropsychological	O	['N']	[15]
16	deficits	O	['N']	[16]
17	.	O	['N']	[17]
#1624
0	Vancomycin	B-Drug	['Causes']	[50]
1	is	O	['N']	[1]
2	widely	O	['N']	[2]
3	used	O	['N']	[3]
4	against	O	['N']	[4]
5	methicillin	O	['N']	[5]
6	-	O	['N']	[6]
7	resistant	O	['N']	[7]
8	Staphylococcus	O	['N']	[8]
9	aureus	O	['N']	[9]
10	infections	O	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	it	O	['N']	[13]
14	is	O	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	many	O	['N']	[17]
18	adverse	O	['N']	[18]
19	effects	O	['N']	[19]
20	such	O	['N']	[20]
21	as	O	['N']	[21]
22	nephrotoxicity	O	['N']	[22]
23	,	O	['N']	[23]
24	ototoxicity	O	['N']	[24]
25	,	O	['N']	[25]
26	gastrointestinal	O	['N']	[26]
27	disturbances	O	['N']	[27]
28	,	O	['N']	[28]
29	blood	O	['N']	[29]
30	disorders	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	two	O	['N']	[33]
34	types	O	['N']	[34]
35	of	O	['N']	[35]
36	hypersensitivity	O	['N']	[36]
37	reactions	O	['N']	[37]
38	-	O	['N']	[38]
39	an	O	['N']	[39]
40	anaphylactoid	O	['N']	[40]
41	reaction	O	['N']	[41]
42	known	O	['N']	[42]
43	as	O	['N']	[43]
44	"	O	['N']	[44]
45	red	O	['N']	[45]
46	man	O	['N']	[46]
47	syndrome	O	['N']	[47]
48	"	O	['N']	[48]
49	and	O	['N']	[49]
50	anaphylaxis	B-Adverse_Effect	['N']	[50]
51	.	O	['N']	[51]
#1625
0	Reversible	O	['N']	[0]
1	sirolimus	B-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	associated	O	['N']	[3]
4	pneumonitis	B-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	heart	O	['N']	[6]
7	transplantation	O	['N']	[7]
8	.	O	['N']	[8]
#1626
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	report	O	['N']	[3]
4	describes	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	probable	O	['N']	[9]
10	interaction	O	['N']	[10]
11	between	O	['N']	[11]
12	topical	O	['N']	[12]
13	econazole	B-Drug	['Causes']	[29]
14	lotion	O	['N']	[14]
15	1	O	['N']	[15]
16	%	O	['N']	[16]
17	and	O	['N']	[17]
18	acenocoumarol	O	['N']	[18]
19	that	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	overanticoagulation	O	['N']	[22]
23	and	O	['N']	[23]
24	a	O	['N']	[24]
25	life	O	['N']	[25]
26	-	O	['N']	[26]
27	threatening	O	['N']	[27]
28	laryngeal	B	['N']	[28]
29	hematoma	I-Adverse_Effect	['N']	[29]
30	in	O	['N']	[30]
31	this	O	['N']	[31]
32	elderly	O	['N']	[32]
33	patient	O	['N']	[33]
34	.	O	['N']	[34]
#1627
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	sulfadiazine	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	crystalluria	B-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	renal	O	['N']	[10]
11	failure	O	['N']	[11]
12	in	O	['N']	[12]
13	patients	O	['N']	[13]
14	with	O	['N']	[14]
15	acquired	O	['N']	[15]
16	immunodeficiency	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	,	O	['N']	[18]
19	review	O	['N']	[19]
20	the	O	['N']	[20]
21	pertinent	O	['N']	[21]
22	literature	O	['N']	[22]
23	,	O	['N']	[23]
24	and	O	['N']	[24]
25	discuss	O	['N']	[25]
26	the	O	['N']	[26]
27	pathogenesis	O	['N']	[27]
28	.	O	['N']	[28]
#1628
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	patient	O	['N']	[2]
3	developed	O	['N']	[3]
4	mild	O	['N']	[4]
5	nitritoid	O	['N']	[5]
6	symptoms	O	['N']	[6]
7	and	O	['N']	[7]
8	pain	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	band	O	['N']	[11]
12	-	O	['N']	[12]
13	like	O	['N']	[13]
14	distribution	O	['N']	[14]
15	,	O	['N']	[15]
16	corresponding	O	['N']	[16]
17	to	O	['N']	[17]
18	T10-T12	O	['N']	[18]
19	dermatomes	O	['N']	[19]
20	,	O	['N']	[20]
21	shortly	O	['N']	[21]
22	after	O	['N']	[22]
23	gold	B	['N']	[23]
24	sodium	I	['N']	[24]
25	thiomalate	I-Drug	['Causes']	[8]
26	(	O	['N']	[26]
27	GSTM	O	['N']	[27]
28	)	O	['N']	[28]
29	injection	O	['N']	[29]
30	.	O	['N']	[30]
#1629
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	for	O	['N']	[2]
3	diabetic	O	['N']	[3]
4	coma	O	['N']	[4]
5	with	O	['N']	[5]
6	insulin	B-Drug	['Causes']	[34]
7	(	O	['N']	[7]
8	containing	O	['N']	[8]
9	the	O	['N']	[9]
10	preservative	O	['N']	[10]
11	cresol	O	['N']	[11]
12	)	O	['N']	[12]
13	and	O	['N']	[13]
14	electrolyte	O	['N']	[14]
15	solutions	O	['N']	[15]
16	was	O	['N']	[16]
17	started	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	complained	O	['N']	[21]
22	of	O	['N']	[22]
23	increasing	O	['N']	[23]
24	myalgia	O	['N']	[24]
25	,	O	['N']	[25]
26	developed	O	['N']	[26]
27	a	O	['N']	[27]
28	high	O	['N']	[28]
29	fever	O	['N']	[29]
30	and	O	['N']	[30]
31	respiratory	B	['N']	[31]
32	and	I	['N']	[32]
33	metabolic	I	['N']	[33]
34	acidosis	I-Adverse_Effect	['N']	[34]
35	and	O	['N']	[35]
36	lost	O	['N']	[36]
37	consciousness	O	['N']	[37]
38	.	O	['N']	[38]
#1630
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	who	O	['N']	[2]
3	received	O	['N']	[3]
4	clindamycin	B-Drug	['Causes']	[14]
5	had	O	['N']	[5]
6	liver	O	['N']	[6]
7	biopsy	O	['N']	[7]
8	findings	O	['N']	[8]
9	of	O	['N']	[9]
10	marked	O	['N']	[10]
11	cholestasis	O	['N']	[11]
12	,	O	['N']	[12]
13	portal	B	['N']	[13]
14	inflammation	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	bile	O	['N']	[16]
17	duct	O	['N']	[17]
18	injury	O	['N']	[18]
19	and	O	['N']	[19]
20	bile	O	['N']	[20]
21	duct	O	['N']	[21]
22	paucity	O	['N']	[22]
23	(	O	['N']	[23]
24	ductopenia	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#1631
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	this	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	intrathecal	O	['N']	[8]
9	diamorphine	B-Drug	['Causes']	[11]
10	causing	O	['N']	[10]
11	anaphylaxis	B-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#1632
0	Itch	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	skin	O	['N']	[2]
3	rash	O	['N']	[3]
4	from	O	['N']	[4]
5	chocolate	O	['N']	[5]
6	during	O	['N']	[6]
7	fluoxetine	B-Drug	['Causes']	[0]
8	and	O	['N']	[8]
9	sertraline	O	['N']	[9]
10	treatment	O	['N']	[10]
11	:	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	.	O	['N']	[14]
#1633
0	INTRODUCTION	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	neurointensive	O	['N']	[5]
6	care	O	['N']	[6]
7	(	O	['N']	[7]
8	NIC	O	['N']	[8]
9	)	O	['N']	[9]
10	management	O	['N']	[10]
11	of	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	severe	O	['N']	[15]
16	cerebral	O	['N']	[16]
17	swelling	O	['N']	[17]
18	and	O	['N']	[18]
19	raised	B	['N']	[19]
20	intracranial	I	['N']	[20]
21	pressure	I-Adverse_Effect	['N']	[21]
22	(	O	['N']	[22]
23	ICP	O	['N']	[23]
24	)	O	['N']	[24]
25	after	O	['N']	[25]
26	severe	O	['N']	[26]
27	sodium	O	['N']	[27]
28	valproic	O	['N']	[28]
29	acid	O	['N']	[29]
30	(	O	['N']	[30]
31	VPA	B-Drug	['Causes']	[21]
32	)	O	['N']	[32]
33	intoxication	O	['N']	[33]
34	.	O	['N']	[34]
#1634
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	B-Drug	['Causes']	[27]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	O	['N']	[34]
35	.	O	['N']	[35]
#1635
0	Gemcitabine	B-Drug	['Causes']	[8]
1	therapy	O	['N']	[1]
2	has	O	['N']	[2]
3	been	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	radiation	B	['N']	[6]
7	recall	I	['N']	[7]
8	reactions	I-Adverse_Effect	['N']	[8]
9	when	O	['N']	[9]
10	used	O	['N']	[10]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	treatment	O	['N']	[13]
14	of	O	['N']	[14]
15	carcinoma	O	['N']	[15]
16	.	O	['N']	[16]
#1636
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	demonstrates	O	['N']	[2]
3	that	O	['N']	[3]
4	hypersensitivity	O	['N']	[4]
5	reaction	O	['N']	[5]
6	to	O	['N']	[6]
7	pranlukast	B-Drug	['Causes']	[10]
8	and	O	['N']	[8]
9	resultant	O	['N']	[9]
10	ATIN	B-Adverse_Effect	['N']	[10]
11	is	O	['N']	[11]
12	possible	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	that	O	['N']	[15]
16	periodic	O	['N']	[16]
17	urine	O	['N']	[17]
18	testing	O	['N']	[18]
19	in	O	['N']	[19]
20	patients	O	['N']	[20]
21	receiving	O	['N']	[21]
22	pranlukast	O	['N']	[22]
23	should	O	['N']	[23]
24	be	O	['N']	[24]
25	considered	O	['N']	[25]
26	.	O	['N']	[26]
#1637
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	4	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	2	O	['N']	[5]
6	on	O	['N']	[6]
7	methylphenidate	B-Drug	['Causes']	[16]
8	and	O	['N']	[8]
9	2	O	['N']	[9]
10	on	O	['N']	[10]
11	dextroamphetamine	O	['N']	[11]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	acral	B	['N']	[15]
16	cyanosis	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	livedo	O	['N']	[18]
19	reticularis	O	['N']	[19]
20	,	O	['N']	[20]
21	or	O	['N']	[21]
22	Raynaud	O	['N']	[22]
23	phenomenon	O	['N']	[23]
24	.	O	['N']	[24]
#1638
0	Olanzapine	B-Drug	['Causes']	[8]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hyperglycaemic	O	['N']	[3]
4	coma	O	['N']	[4]
5	and	O	['N']	[5]
6	neuroleptic	B	['N']	[6]
7	malignant	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	:	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	and	O	['N']	[12]
13	review	O	['N']	[13]
14	of	O	['N']	[14]
15	literature	O	['N']	[15]
16	.	O	['N']	[16]
#1639
0	The	O	['N']	[0]
1	goal	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	study	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	describe	O	['N']	[7]
8	three	O	['N']	[8]
9	patients	O	['N']	[9]
10	diagnosed	O	['N']	[10]
11	with	O	['N']	[11]
12	migraine	O	['N']	[12]
13	and	O	['N']	[13]
14	epilepsy	O	['N']	[14]
15	(	O	['N']	[15]
16	both	O	['N']	[16]
17	under	O	['N']	[17]
18	control	O	['N']	[18]
19	)	O	['N']	[19]
20	who	O	['N']	[20]
21	evolved	O	['N']	[21]
22	into	O	['N']	[22]
23	status	B	['N']	[23]
24	migrainosus	I-Adverse_Effect	['N']	[24]
25	after	O	['N']	[25]
26	the	O	['N']	[26]
27	introduction	O	['N']	[27]
28	of	O	['N']	[28]
29	oxcarbazepine	B-Drug	['Causes']	[24]
30	(	O	['N']	[30]
31	OXC	O	['N']	[31]
32	)	O	['N']	[32]
33	,	O	['N']	[33]
34	as	O	['N']	[34]
35	part	O	['N']	[35]
36	of	O	['N']	[36]
37	a	O	['N']	[37]
38	switch	O	['N']	[38]
39	off	O	['N']	[39]
40	from	O	['N']	[40]
41	carbamazepine	O	['N']	[41]
42	(	O	['N']	[42]
43	CBZ	O	['N']	[43]
44	)	O	['N']	[44]
45	.	O	['N']	[45]
#1640
0	Pemphigus	B	['N']	[0]
1	foliaceus	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	seen	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	pulmonary	O	['N']	[8]
9	tuberculosis	O	['N']	[9]
10	during	O	['N']	[10]
11	rifampicin	B-Drug	['Causes']	[1]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#1641
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	Case	O	['N']	[2]
3	analysis	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	poly	O	['N']	[6]
7	-	O	['N']	[7]
8	drug	O	['N']	[8]
9	overdose	O	['N']	[9]
10	(	O	['N']	[10]
11	venlafaxine	O	['N']	[11]
12	,	O	['N']	[12]
13	topiramate	O	['N']	[13]
14	,	O	['N']	[14]
15	divalproex	B	['N']	[15]
16	sodium	I-Drug	['Causes']	[26]
17	,	O	['N']	[17]
18	risperidone	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	carbamazepine	O	['N']	[21]
22	)	O	['N']	[22]
23	presenting	O	['N']	[23]
24	with	O	['N']	[24]
25	mixed	O	['N']	[25]
26	SS	B-Adverse_Effect	['N']	[26]
27	/	O	['N']	[27]
28	NMS	O	['N']	[28]
29	features	O	['N']	[29]
30	and	O	['N']	[30]
31	whose	O	['N']	[31]
32	clinical	O	['N']	[32]
33	management	O	['N']	[33]
34	suggests	O	['N']	[34]
35	a	O	['N']	[35]
36	practical	O	['N']	[36]
37	algorithm	O	['N']	[37]
38	for	O	['N']	[38]
39	treatment	O	['N']	[39]
40	of	O	['N']	[40]
41	undifferentiated	O	['N']	[41]
42	SS	O	['N']	[42]
43	/	O	['N']	[43]
44	NMS	O	['N']	[44]
45	in	O	['N']	[45]
46	critical	O	['N']	[46]
47	care	O	['N']	[47]
48	settings	O	['N']	[48]
49	.	O	['N']	[49]
#1642
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	trimethoprim	O	['N']	[4]
5	-	O	['N']	[5]
6	sulfamethoxazole	B-Drug	['Causes']	[28]
7	for	O	['N']	[7]
8	approximately	O	['N']	[8]
9	eight	O	['N']	[9]
10	days	O	['N']	[10]
11	when	O	['N']	[11]
12	he	O	['N']	[12]
13	revisited	O	['N']	[13]
14	his	O	['N']	[14]
15	family	O	['N']	[15]
16	physician	O	['N']	[16]
17	,	O	['N']	[17]
18	complaining	O	['N']	[18]
19	of	O	['N']	[19]
20	headaches	O	['N']	[20]
21	,	O	['N']	[21]
22	dizziness	O	['N']	[22]
23	,	O	['N']	[23]
24	difficulty	O	['N']	[24]
25	with	O	['N']	[25]
26	speech	O	['N']	[26]
27	,	O	['N']	[27]
28	weakness	B-Adverse_Effect	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	itching	O	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	trunk	O	['N']	[34]
35	of	O	['N']	[35]
36	his	O	['N']	[36]
37	body	O	['N']	[37]
38	and	O	['N']	[38]
39	legs	O	['N']	[39]
40	,	O	['N']	[40]
41	where	O	['N']	[41]
42	a	O	['N']	[42]
43	maculopapular	O	['N']	[43]
44	rash	O	['N']	[44]
45	was	O	['N']	[45]
46	noted	O	['N']	[46]
47	.	O	['N']	[47]
#1643
0	The	O	['N']	[0]
1	potential	O	['N']	[1]
2	for	O	['N']	[2]
3	progressive	O	['N']	[3]
4	brain	B	['N']	[4]
5	injury	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	subsequent	O	['N']	[7]
8	disability	O	['N']	[8]
9	related	O	['N']	[9]
10	to	O	['N']	[10]
11	intraventricular	O	['N']	[11]
12	IL-2	B-Drug	['Causes']	[5]
13	therapy	O	['N']	[13]
14	is	O	['N']	[14]
15	discussed	O	['N']	[15]
16	.	O	['N']	[16]
#1644
0	ADH	O	['N']	[0]
1	hypersecretion	O	['N']	[1]
2	in	O	['N']	[2]
3	relation	O	['N']	[3]
4	to	O	['N']	[4]
5	plasma	O	['N']	[5]
6	osmolality	O	['N']	[6]
7	was	O	['N']	[7]
8	reversed	O	['N']	[8]
9	by	O	['N']	[9]
10	mizoribin	O	['N']	[10]
11	withdrawal	O	['N']	[11]
12	,	O	['N']	[12]
13	suggesting	O	['N']	[13]
14	that	O	['N']	[14]
15	bredinin	B-Drug	['Causes']	[19]
16	might	O	['N']	[16]
17	adversely	O	['N']	[17]
18	induce	O	['N']	[18]
19	SIADH	B-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#1645
0	Clinicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	vigilant	O	['N']	[3]
4	when	O	['N']	[4]
5	monitoring	O	['N']	[5]
6	for	O	['N']	[6]
7	cardiotoxicity	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	receiving	O	['N']	[10]
11	pentamidine	B-Drug	['Causes']	[7]
12	throughout	O	['N']	[12]
13	the	O	['N']	[13]
14	duration	O	['N']	[14]
15	of	O	['N']	[15]
16	therapy	O	['N']	[16]
17	.	O	['N']	[17]
#1646
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	found	O	['N']	[3]
4	to	O	['N']	[4]
5	have	O	['N']	[5]
6	no	O	['N']	[6]
7	motile	O	['N']	[7]
8	sperm	O	['N']	[8]
9	with	O	['N']	[9]
10	a	O	['N']	[10]
11	normal	O	['N']	[11]
12	sperm	O	['N']	[12]
13	count	O	['N']	[13]
14	,	O	['N']	[14]
15	while	O	['N']	[15]
16	taking	O	['N']	[16]
17	a	O	['N']	[17]
18	dose	O	['N']	[18]
19	of	O	['N']	[19]
20	400	B	['N']	[20]
21	mg	I	['N']	[21]
22	/	I	['N']	[22]
23	day	I-Dose	['N']	[23]
24	of	O	['N']	[24]
25	carbamazepine	B-Drug	['Dosage']	[23]
26	.	O	['N']	[26]
#1647
0	Patient	O	['N']	[0]
1	A	O	['N']	[1]
2	reported	O	['N']	[2]
3	right	B	['N']	[3]
4	leg	I	['N']	[4]
5	weakness	I-Adverse_Effect	['N']	[5]
6	(	O	['N']	[6]
7	foot	O	['N']	[7]
8	drop	O	['N']	[8]
9	)	O	['N']	[9]
10	during	O	['N']	[10]
11	week	O	['N']	[11]
12	4	O	['N']	[12]
13	of	O	['N']	[13]
14	CAP	B	['N']	[14]
15	-	I	['N']	[15]
16	XRT	I-Drug	['Causes']	[5]
17	(	O	['N']	[17]
18	1600	O	['N']	[18]
19	mg	O	['N']	[19]
20	/	O	['N']	[20]
21	m2	O	['N']	[21]
22	)	O	['N']	[22]
23	.	O	['N']	[23]
#1648
0	Flucloxacillin	B-Drug	['Causes']	[7]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	aplastic	O	['N']	[3]
4	anaemia	O	['N']	[4]
5	and	O	['N']	[5]
6	liver	B	['N']	[6]
7	failure	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#1649
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	course	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	caffeine	B-Drug	['Causes']	[19]
6	,	O	['N']	[6]
7	which	O	['N']	[7]
8	is	O	['N']	[8]
9	present	O	['N']	[9]
10	in	O	['N']	[10]
11	oolong	O	['N']	[11]
12	tea	O	['N']	[12]
13	,	O	['N']	[13]
14	was	O	['N']	[14]
15	mainly	O	['N']	[15]
16	responsible	O	['N']	[16]
17	for	O	['N']	[17]
18	the	O	['N']	[18]
19	rhabdomyolysis	B-Adverse_Effect	['N']	[19]
20	as	O	['N']	[20]
21	well	O	['N']	[21]
22	as	O	['N']	[22]
23	the	O	['N']	[23]
24	delirium	O	['N']	[24]
25	,	O	['N']	[25]
26	although	O	['N']	[26]
27	severe	O	['N']	[27]
28	hyponatremia	O	['N']	[28]
29	has	O	['N']	[29]
30	been	O	['N']	[30]
31	reported	O	['N']	[31]
32	to	O	['N']	[32]
33	cause	O	['N']	[33]
34	rhabdomyolysis	O	['N']	[34]
35	on	O	['N']	[35]
36	rare	O	['N']	[36]
37	occasions	O	['N']	[37]
38	.	O	['N']	[38]
#1650
0	Transfusion	B	['N']	[0]
1	haemosiderosis	I-Adverse_Effect	['N']	[1]
2	inspite	O	['N']	[2]
3	of	O	['N']	[3]
4	regular	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	desferrioxamine	B-Drug	['Causes']	[1]
8	:	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#1651
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[47]
15	with	O	['N']	[15]
16	folinic	O	['N']	[16]
17	acid	O	['N']	[17]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	B	['N']	[45]
46	renal	I	['N']	[46]
47	impairment	I-Adverse_Effect	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#1652
0	Torsade	B	['N']	[0]
1	de	I	['N']	[1]
2	pointes	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	moxifloxacin	B-Drug	['Causes']	[2]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	rare	O	['N']	[8]
9	but	O	['N']	[9]
10	potentially	O	['N']	[10]
11	fatal	O	['N']	[11]
12	adverse	O	['N']	[12]
13	event	O	['N']	[13]
14	.	O	['N']	[14]
#1653
0	A	O	['N']	[0]
1	fatal	B	['N']	[1]
2	pancytopenia	I-Adverse_Effect	['N']	[2]
3	occurred	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	an	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	depression	O	['N']	[11]
12	with	O	['N']	[12]
13	hypomanic	O	['N']	[13]
14	rebounds	O	['N']	[14]
15	,	O	['N']	[15]
16	admitted	O	['N']	[16]
17	for	O	['N']	[17]
18	a	O	['N']	[18]
19	manic	O	['N']	[19]
20	episode	O	['N']	[20]
21	and	O	['N']	[21]
22	treated	O	['N']	[22]
23	with	O	['N']	[23]
24	levomepromazine	O	['N']	[24]
25	,	O	['N']	[25]
26	diazepam	O	['N']	[26]
27	and	O	['N']	[27]
28	lithium	B	['N']	[28]
29	carbonate	I-Drug	['Causes']	[2]
30	.	O	['N']	[30]
#1654
0	Peculiar	O	['N']	[0]
1	nail	B	['N']	[1]
2	-	I	['N']	[2]
3	changes	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	70-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	rheumatoid	O	['N']	[11]
12	arthritis	O	['N']	[12]
13	occurring	O	['N']	[13]
14	after	O	['N']	[14]
15	approximately	O	['N']	[15]
16	1	O	['N']	[16]
17	year	O	['N']	[17]
18	of	O	['N']	[18]
19	penicillamine	B-Drug	['Causes']	[3]
20	treatment	O	['N']	[20]
21	are	O	['N']	[21]
22	described	O	['N']	[22]
23	.	O	['N']	[23]
#1655
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	Case	O	['N']	[2]
3	analysis	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	poly	O	['N']	[6]
7	-	O	['N']	[7]
8	drug	O	['N']	[8]
9	overdose	O	['N']	[9]
10	(	O	['N']	[10]
11	venlafaxine	B-Drug	['Causes']	[26]
12	,	O	['N']	[12]
13	topiramate	O	['N']	[13]
14	,	O	['N']	[14]
15	divalproex	O	['N']	[15]
16	sodium	O	['N']	[16]
17	,	O	['N']	[17]
18	risperidone	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	carbamazepine	O	['N']	[21]
22	)	O	['N']	[22]
23	presenting	O	['N']	[23]
24	with	O	['N']	[24]
25	mixed	O	['N']	[25]
26	SS	B-Adverse_Effect	['N']	[26]
27	/	O	['N']	[27]
28	NMS	O	['N']	[28]
29	features	O	['N']	[29]
30	and	O	['N']	[30]
31	whose	O	['N']	[31]
32	clinical	O	['N']	[32]
33	management	O	['N']	[33]
34	suggests	O	['N']	[34]
35	a	O	['N']	[35]
36	practical	O	['N']	[36]
37	algorithm	O	['N']	[37]
38	for	O	['N']	[38]
39	treatment	O	['N']	[39]
40	of	O	['N']	[40]
41	undifferentiated	O	['N']	[41]
42	SS	O	['N']	[42]
43	/	O	['N']	[43]
44	NMS	O	['N']	[44]
45	in	O	['N']	[45]
46	critical	O	['N']	[46]
47	care	O	['N']	[47]
48	settings	O	['N']	[48]
49	.	O	['N']	[49]
#1656
0	The	O	['N']	[0]
1	failure	O	['N']	[1]
2	of	O	['N']	[2]
3	therapy	O	['N']	[3]
4	with	O	['N']	[4]
5	disopyramide	O	['N']	[5]
6	and	O	['N']	[6]
7	mexiletine	O	['N']	[7]
8	to	O	['N']	[8]
9	reproduce	O	['N']	[9]
10	this	O	['N']	[10]
11	observation	O	['N']	[11]
12	suggests	O	['N']	[12]
13	either	O	['N']	[13]
14	a	O	['N']	[14]
15	previously	O	['N']	[15]
16	unreported	O	['N']	[16]
17	electrophysiologic	B	['N']	[17]
18	effect	I-Adverse_Effect	['N']	[18]
19	of	O	['N']	[19]
20	,	O	['N']	[20]
21	or	O	['N']	[21]
22	idiosyncratic	O	['N']	[22]
23	response	O	['N']	[23]
24	to	O	['N']	[24]
25	,	O	['N']	[25]
26	procainamide	B-Drug	['Causes']	[18]
27	.	O	['N']	[27]
#1657
0	We	O	['N']	[0]
1	hypothesize	O	['N']	[1]
2	that	O	['N']	[2]
3	capecitabine	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	headache	B-Adverse_Effect	['N']	[6]
7	is	O	['N']	[7]
8	vascular	O	['N']	[8]
9	in	O	['N']	[9]
10	nature	O	['N']	[10]
11	.	O	['N']	[11]
#1658
0	Amphotericin	B	['N']	[0]
1	B	I-Drug	['Causes']	[23]
2	(	O	['N']	[2]
3	AmB	O	['N']	[3]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	effective	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	its	O	['N']	[9]
10	use	O	['N']	[10]
11	is	O	['N']	[11]
12	limited	O	['N']	[12]
13	by	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	:	O	['N']	[15]
16	renal	O	['N']	[16]
17	impairment	O	['N']	[17]
18	,	O	['N']	[18]
19	anaemia	O	['N']	[19]
20	,	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	malaise	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hypokalaemia	O	['N']	[26]
27	are	O	['N']	[27]
28	common	O	['N']	[28]
29	.	O	['N']	[29]
#1659
0	He	O	['N']	[0]
1	developed	O	['N']	[1]
2	a	O	['N']	[2]
3	late	O	['N']	[3]
4	secondary	B	['N']	[4]
5	infection	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	some	O	['N']	[7]
8	sites	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	imiquimod	B-Drug	['Causes']	[5]
12	.	O	['N']	[12]
#1660
0	A	O	['N']	[0]
1	26-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Japanese	O	['N']	[4]
5	man	O	['N']	[5]
6	,	O	['N']	[6]
7	who	O	['N']	[7]
8	had	O	['N']	[8]
9	been	O	['N']	[9]
10	receiving	O	['N']	[10]
11	medical	O	['N']	[11]
12	attention	O	['N']	[12]
13	for	O	['N']	[13]
14	ulcerative	O	['N']	[14]
15	colitis	O	['N']	[15]
16	for	O	['N']	[16]
17	one	O	['N']	[17]
18	year	O	['N']	[18]
19	,	O	['N']	[19]
20	presented	O	['N']	[20]
21	with	O	['N']	[21]
22	diffuse	B	['N']	[22]
23	erythema	I-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	pustules	O	['N']	[25]
26	on	O	['N']	[26]
27	his	O	['N']	[27]
28	face	O	['N']	[28]
29	and	O	['N']	[29]
30	trunk	O	['N']	[30]
31	,	O	['N']	[31]
32	malaise	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	fever	O	['N']	[35]
36	up	O	['N']	[36]
37	to	O	['N']	[37]
38	39	O	['N']	[38]
39	degrees	O	['N']	[39]
40	C	O	['N']	[40]
41	one	O	['N']	[41]
42	day	O	['N']	[42]
43	after	O	['N']	[43]
44	the	O	['N']	[44]
45	administration	O	['N']	[45]
46	of	O	['N']	[46]
47	salazosulfapyridine	B-Drug	['Causes']	[23]
48	.	O	['N']	[48]
#1661
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	B-Drug	['Causes']	[21]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#1662
0	Acute	B	['N']	[0]
1	sensorineural	I	['N']	[1]
2	hearing	I	['N']	[2]
3	loss	I-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	intravenous	O	['N']	[5]
6	ketoralac	B-Drug	['Causes']	[3]
7	administration	O	['N']	[7]
8	.	O	['N']	[8]
#1663
0	A	O	['N']	[0]
1	51-yr	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	nonsmoking	O	['N']	[4]
5	male	O	['N']	[5]
6	patient	O	['N']	[6]
7	without	O	['N']	[7]
8	any	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	previous	O	['N']	[11]
12	allergies	O	['N']	[12]
13	,	O	['N']	[13]
14	asthma	O	['N']	[14]
15	,	O	['N']	[15]
16	hay	O	['N']	[16]
17	fever	O	['N']	[17]
18	,	O	['N']	[18]
19	or	O	['N']	[19]
20	urticaria	O	['N']	[20]
21	developed	O	['N']	[21]
22	attacks	B	['N']	[22]
23	of	I	['N']	[23]
24	asthma	I-Adverse_Effect	['N']	[24]
25	when	O	['N']	[25]
26	captopril	O	['N']	[26]
27	was	O	['N']	[27]
28	added	O	['N']	[28]
29	to	O	['N']	[29]
30	the	O	['N']	[30]
31	nadolol	B-Drug	['Causes']	[24]
32	and	O	['N']	[32]
33	dyazide	O	['N']	[33]
34	treatment	O	['N']	[34]
35	for	O	['N']	[35]
36	his	O	['N']	[36]
37	high	O	['N']	[37]
38	blood	O	['N']	[38]
39	pressure	O	['N']	[39]
40	.	O	['N']	[40]
#1664
0	Severe	B	['N']	[0]
1	osteomalacia	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	present	O	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	epileptic	O	['N']	[6]
7	patients	O	['N']	[7]
8	who	O	['N']	[8]
9	were	O	['N']	[9]
10	under	O	['N']	[10]
11	long	O	['N']	[11]
12	-	O	['N']	[12]
13	term	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	congeners	O	['N']	[16]
17	of	O	['N']	[17]
18	phenytoin	B-Drug	['Causes']	[1]
19	,	O	['N']	[19]
20	phenobarbital	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	acetazolamide	O	['N']	[23]
24	.	O	['N']	[24]
#1665
0	Protease	O	['N']	[0]
1	inhibitors	O	['N']	[1]
2	(	O	['N']	[2]
3	ritonavir	O	['N']	[3]
4	and	O	['N']	[4]
5	saquinavir	B-Drug	['Causes']	[21]
6	)	O	['N']	[6]
7	were	O	['N']	[7]
8	added	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	treatment	O	['N']	[11]
12	and	O	['N']	[12]
13	the	O	['N']	[13]
14	patient	O	['N']	[14]
15	developed	O	['N']	[15]
16	progressive	O	['N']	[16]
17	ataxia	O	['N']	[17]
18	related	O	['N']	[18]
19	to	O	['N']	[19]
20	carbamazepine	B	['N']	[20]
21	toxicity	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1666
0	Amphotericin	O	['N']	[0]
1	B	O	['N']	[1]
2	(	O	['N']	[2]
3	AmB	B-Drug	['Causes']	[26]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	effective	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	its	O	['N']	[9]
10	use	O	['N']	[10]
11	is	O	['N']	[11]
12	limited	O	['N']	[12]
13	by	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	:	O	['N']	[15]
16	renal	O	['N']	[16]
17	impairment	O	['N']	[17]
18	,	O	['N']	[18]
19	anaemia	O	['N']	[19]
20	,	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	malaise	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hypokalaemia	B-Adverse_Effect	['N']	[26]
27	are	O	['N']	[27]
28	common	O	['N']	[28]
29	.	O	['N']	[29]
#1667
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	risk	O	['N']	[3]
4	of	O	['N']	[4]
5	drug	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	rhabdomyolysis	B-Adverse_Effect	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	the	O	['N']	[11]
12	potential	O	['N']	[12]
13	interaction	O	['N']	[13]
14	between	O	['N']	[14]
15	lovastatin	B-Drug	['Causes']	[8]
16	and	O	['N']	[16]
17	azithromycin	O	['N']	[17]
18	or	O	['N']	[18]
19	clarithromycin	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	considered	O	['N']	[22]
23	before	O	['N']	[23]
24	the	O	['N']	[24]
25	concomitant	O	['N']	[25]
26	use	O	['N']	[26]
27	of	O	['N']	[27]
28	these	O	['N']	[28]
29	agents	O	['N']	[29]
30	.	O	['N']	[30]
#1668
0	Although	O	['N']	[0]
1	there	O	['N']	[1]
2	have	O	['N']	[2]
3	been	O	['N']	[3]
4	numerous	O	['N']	[4]
5	reports	O	['N']	[5]
6	of	O	['N']	[6]
7	effusions	O	['N']	[7]
8	,	O	['N']	[8]
9	none	O	['N']	[9]
10	have	O	['N']	[10]
11	provided	O	['N']	[11]
12	complete	O	['N']	[12]
13	pleural	O	['N']	[13]
14	fluid	O	['N']	[14]
15	analysis	O	['N']	[15]
16	;	O	['N']	[16]
17	therefore	O	['N']	[17]
18	,	O	['N']	[18]
19	we	O	['N']	[19]
20	report	O	['N']	[20]
21	2	O	['N']	[21]
22	patients	O	['N']	[22]
23	with	O	['N']	[23]
24	dasatinib	B-Drug	['Causes']	[28]
25	-	O	['N']	[25]
26	induced	O	['N']	[26]
27	pleural	B	['N']	[27]
28	effusion	I-Adverse_Effect	['N']	[28]
29	with	O	['N']	[29]
30	complete	O	['N']	[30]
31	pleural	O	['N']	[31]
32	fluid	O	['N']	[32]
33	analysis	O	['N']	[33]
34	.	O	['N']	[34]
#1669
0	Pulmonary	B	['N']	[0]
1	hypertension	I-Adverse_Effect	['N']	[1]
2	during	O	['N']	[2]
3	lithium	B-Drug	['Causes']	[1]
4	therapy	O	['N']	[4]
5	:	O	['N']	[5]
6	clinical	O	['N']	[6]
7	case	O	['N']	[7]
8	study	O	['N']	[8]
9	.	O	['N']	[9]
#1670
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	fulminant	B	['N']	[5]
6	hepatic	I	['N']	[6]
7	failure	I-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	didanosine	B-Drug	['Causes']	[7]
11	and	O	['N']	[11]
12	masquerading	O	['N']	[12]
13	as	O	['N']	[13]
14	a	O	['N']	[14]
15	surgical	O	['N']	[15]
16	abdomen	O	['N']	[16]
17	and	O	['N']	[17]
18	compare	O	['N']	[18]
19	the	O	['N']	[19]
20	clinical	O	['N']	[20]
21	,	O	['N']	[21]
22	biologic	O	['N']	[22]
23	,	O	['N']	[23]
24	histologic	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	ultrastructural	O	['N']	[27]
28	findings	O	['N']	[28]
29	with	O	['N']	[29]
30	reports	O	['N']	[30]
31	described	O	['N']	[31]
32	previously	O	['N']	[32]
33	.	O	['N']	[33]
#1671
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	possible	O	['N']	[9]
10	interaction	O	['N']	[10]
11	between	O	['N']	[11]
12	propafenone	O	['N']	[12]
13	and	O	['N']	[13]
14	citalopram	B-Drug	['Causes']	[32]
15	,	O	['N']	[15]
16	which	O	['N']	[16]
17	caused	O	['N']	[17]
18	propafenone	O	['N']	[18]
19	adverse	O	['N']	[19]
20	effects	O	['N']	[20]
21	(	O	['N']	[21]
22	eg	O	['N']	[22]
23	,	O	['N']	[23]
24	dizziness	O	['N']	[24]
25	,	O	['N']	[25]
26	falls	O	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	mimicked	O	['N']	[29]
30	coronary	B	['N']	[30]
31	artery	I	['N']	[31]
32	disease	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#1672
0	Nephrogenic	B	['N']	[0]
1	diabetes	I	['N']	[1]
2	insipidus	I-Adverse_Effect	['N']	[2]
3	(	O	['N']	[3]
4	NDI	O	['N']	[4]
5	)	O	['N']	[5]
6	is	O	['N']	[6]
7	a	O	['N']	[7]
8	well	O	['N']	[8]
9	-	O	['N']	[9]
10	documented	O	['N']	[10]
11	complication	O	['N']	[11]
12	of	O	['N']	[12]
13	lithium	B-Drug	['Causes']	[2]
14	use	O	['N']	[14]
15	.	O	['N']	[15]
#1673
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	21-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	dapsone	B-Drug	['Causes']	[14]
13	hypersensitivity	B	['N']	[13]
14	syndrome	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#1674
0	PATIENT	O	['N']	[0]
1	AND	O	['N']	[1]
2	METHOD	O	['N']	[2]
3	:	O	['N']	[3]
4	A	O	['N']	[4]
5	34-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	chronic	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	C	O	['N']	[12]
13	,	O	['N']	[13]
14	genotype	O	['N']	[14]
15	3	O	['N']	[15]
16	,	O	['N']	[16]
17	receiving	O	['N']	[17]
18	pegylated	O	['N']	[18]
19	interferon	O	['N']	[19]
20	alpha-2a	O	['N']	[20]
21	and	O	['N']	[21]
22	ribavirin	B-Drug	['Causes']	[29]
23	for	O	['N']	[23]
24	6	O	['N']	[24]
25	months	O	['N']	[25]
26	,	O	['N']	[26]
27	developed	O	['N']	[27]
28	progressive	B	['N']	[28]
29	malaise	I-Adverse_Effect	['N']	[29]
30	and	O	['N']	[30]
31	anemia	O	['N']	[31]
32	6	O	['N']	[32]
33	months	O	['N']	[33]
34	after	O	['N']	[34]
35	the	O	['N']	[35]
36	end	O	['N']	[36]
37	of	O	['N']	[37]
38	treatment	O	['N']	[38]
39	.	O	['N']	[39]
#1675
0	A	O	['N']	[0]
1	new	O	['N']	[1]
2	type	O	['N']	[2]
3	of	O	['N']	[3]
4	minocycline	B-Drug	['Causes']	[8]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	cutaneous	B	['N']	[7]
8	hyperpigmentation	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#1676
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	pulmonary	O	['N']	[8]
9	hypertension	O	['N']	[9]
10	and	O	['N']	[10]
11	undifferentiated	O	['N']	[11]
12	connective	O	['N']	[12]
13	tissue	O	['N']	[13]
14	disease	O	['N']	[14]
15	who	O	['N']	[15]
16	,	O	['N']	[16]
17	after	O	['N']	[17]
18	2	O	['N']	[18]
19	months	O	['N']	[19]
20	of	O	['N']	[20]
21	treatment	O	['N']	[21]
22	with	O	['N']	[22]
23	epoprostenol	B-Drug	['Causes']	[33]
24	,	O	['N']	[24]
25	presented	O	['N']	[25]
26	with	O	['N']	[26]
27	rapidly	O	['N']	[27]
28	progressive	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	scaling	O	['N']	[31]
32	,	O	['N']	[32]
33	nausea	B-Adverse_Effect	['N']	[33]
34	and	O	['N']	[34]
35	vomiting	O	['N']	[35]
36	,	O	['N']	[36]
37	and	O	['N']	[37]
38	fever	O	['N']	[38]
39	.	O	['N']	[39]
#1677
0	Erythromycin	B-Drug	['Causes']	[14]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	macrolide	O	['N']	[3]
4	antibiotic	O	['N']	[4]
5	that	O	['N']	[5]
6	may	O	['N']	[6]
7	increase	O	['N']	[7]
8	the	O	['N']	[8]
9	risk	O	['N']	[9]
10	of	O	['N']	[10]
11	lovastatin	O	['N']	[11]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	rhabdomyolysis	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#1678
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	aseptic	B	['N']	[3]
4	pleuropericarditis	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	chronic	O	['N']	[9]
10	plaque	O	['N']	[10]
11	psoriasis	O	['N']	[11]
12	under	O	['N']	[12]
13	methotrexate	B-Drug	['Causes']	[4]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#1679
0	Only	O	['N']	[0]
1	one	O	['N']	[1]
2	report	O	['N']	[2]
3	links	O	['N']	[3]
4	phenylpropanolamine	B-Drug	['Causes']	[9]
5	consumption	O	['N']	[5]
6	to	O	['N']	[6]
7	an	O	['N']	[7]
8	intracerebral	B	['N']	[8]
9	hemorrhage	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	with	O	['N']	[13]
14	an	O	['N']	[14]
15	AVM	O	['N']	[15]
16	.	O	['N']	[16]
#1680
0	The	O	['N']	[0]
1	site	O	['N']	[1]
2	of	O	['N']	[2]
3	thrombosis	O	['N']	[3]
4	and	O	['N']	[4]
5	the	O	['N']	[5]
6	chronological	O	['N']	[6]
7	relationship	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	IIR	O	['N']	[10]
11	implicates	O	['N']	[11]
12	a	O	['N']	[12]
13	hypersensitivity	B-Adverse_Effect	['N']	[13]
14	to	O	['N']	[14]
15	infliximab	B-Drug	['Causes']	[13]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	causation	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	venous	O	['N']	[21]
22	thrombosis	O	['N']	[22]
23	in	O	['N']	[23]
24	this	O	['N']	[24]
25	case	O	['N']	[25]
26	.	O	['N']	[26]
#1681
0	A	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	,	O	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	intensive	O	['N']	[8]
9	care	O	['N']	[9]
10	unit	O	['N']	[10]
11	because	O	['N']	[11]
12	of	O	['N']	[12]
13	septic	O	['N']	[13]
14	shock	O	['N']	[14]
15	and	O	['N']	[15]
16	acute	O	['N']	[16]
17	renal	O	['N']	[17]
18	failure	O	['N']	[18]
19	,	O	['N']	[19]
20	had	O	['N']	[20]
21	a	O	['N']	[21]
22	small	B	['N']	[22]
23	-	I	['N']	[23]
24	bowel	I	['N']	[24]
25	obstruction	I-Adverse_Effect	['N']	[25]
26	due	O	['N']	[26]
27	to	O	['N']	[27]
28	Amphojel	B-Drug	['Causes']	[25]
29	concretions	O	['N']	[29]
30	.	O	['N']	[30]
#1682
0	Fluphenazine	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	neuroleptic	B	['N']	[3]
4	malignant	I	['N']	[4]
5	syndrome	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	schizophrenic	O	['N']	[8]
9	patient	O	['N']	[9]
10	.	O	['N']	[10]
#1683
0	A	O	['N']	[0]
1	56-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	male	O	['N']	[4]
5	parkinsonian	O	['N']	[5]
6	patient	O	['N']	[6]
7	developed	O	['N']	[7]
8	a	O	['N']	[8]
9	unique	O	['N']	[9]
10	behavioral	B	['N']	[10]
11	change	I-Adverse_Effect	['N']	[11]
12	following	O	['N']	[12]
13	the	O	['N']	[13]
14	oral	O	['N']	[14]
15	administration	O	['N']	[15]
16	of	O	['N']	[16]
17	cinepazide	B-Drug	['Causes']	[11]
18	,	O	['N']	[18]
19	a	O	['N']	[19]
20	cerebral	O	['N']	[20]
21	vasodilator	O	['N']	[21]
22	.	O	['N']	[22]
#1684
0	Amphotericin	O	['N']	[0]
1	B	O	['N']	[1]
2	(	O	['N']	[2]
3	AmB	B-Drug	['Causes']	[21]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	effective	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	its	O	['N']	[9]
10	use	O	['N']	[10]
11	is	O	['N']	[11]
12	limited	O	['N']	[12]
13	by	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	:	O	['N']	[15]
16	renal	O	['N']	[16]
17	impairment	O	['N']	[17]
18	,	O	['N']	[18]
19	anaemia	O	['N']	[19]
20	,	O	['N']	[20]
21	fever	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	malaise	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hypokalaemia	O	['N']	[26]
27	are	O	['N']	[27]
28	common	O	['N']	[28]
29	.	O	['N']	[29]
#1685
0	Hepato	B	['N']	[0]
1	-	I	['N']	[1]
2	biliary	I	['N']	[2]
3	abnormalities	I-Adverse_Effect	['N']	[3]
4	secondary	O	['N']	[4]
5	to	O	['N']	[5]
6	ceftriaxone	B-Drug	['Causes']	[3]
7	use	O	['N']	[7]
8	:	O	['N']	[8]
9	a	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	.	O	['N']	[12]
#1686
0	Acute	B	['N']	[0]
1	renal	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	lisinopril	B-Drug	['Causes']	[2]
5	and	O	['N']	[5]
6	losartan	O	['N']	[6]
7	therapy	O	['N']	[7]
8	for	O	['N']	[8]
9	proteinuria	O	['N']	[9]
10	.	O	['N']	[10]
#1687
0	A	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[15]
2	hypersensitivity	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	,	O	['N']	[4]
5	consisting	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	nausea	O	['N']	[11]
12	,	O	['N']	[12]
13	vomiting	O	['N']	[13]
14	,	O	['N']	[14]
15	lymphadenopathy	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	,	O	['N']	[18]
19	hemolysis	O	['N']	[19]
20	,	O	['N']	[20]
21	leukopenia	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	mononucleosis	O	['N']	[24]
25	,	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	for	O	['N']	[35]
36	leprosy	O	['N']	[36]
37	.	O	['N']	[37]
#1688
0	Lovastatin	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	rhabdomyolysis	B-Adverse_Effect	['N']	[3]
4	possibly	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	clarithromycin	B-Drug	['Causes']	[3]
8	and	O	['N']	[8]
9	azithromycin	O	['N']	[9]
10	.	O	['N']	[10]
#1689
0	Nail	B	['N']	[0]
1	staining	I-Adverse_Effect	['N']	[1]
2	from	O	['N']	[2]
3	hydroquinone	B-Drug	['Causes']	[1]
4	cream	O	['N']	[4]
5	.	O	['N']	[5]
#1690
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	suffering	O	['N']	[2]
3	from	O	['N']	[3]
4	heparin	B-Drug	['Causes']	[13]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	thrombocytopenia	O	['N']	[7]
8	(	O	['N']	[8]
9	HAT	O	['N']	[9]
10	)	O	['N']	[10]
11	,	O	['N']	[11]
12	recurrent	B	['N']	[12]
13	arteriothromboses	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	acute	O	['N']	[16]
17	renal	O	['N']	[17]
18	failure	O	['N']	[18]
19	after	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	standard	O	['N']	[22]
23	heparin	O	['N']	[23]
24	is	O	['N']	[24]
25	described	O	['N']	[25]
26	.	O	['N']	[26]
#1691
0	The	O	['N']	[0]
1	time	O	['N']	[1]
2	course	O	['N']	[2]
3	of	O	['N']	[3]
4	events	O	['N']	[4]
5	suggested	O	['N']	[5]
6	that	O	['N']	[6]
7	amphotericin	B	['N']	[7]
8	B	I-Drug	['Causes']	[14]
9	was	O	['N']	[9]
10	the	O	['N']	[10]
11	cause	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	seizures	B-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	this	O	['N']	[16]
17	AIDS	O	['N']	[17]
18	patient	O	['N']	[18]
19	.	O	['N']	[19]
#1692
0	A	O	['N']	[0]
1	25-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	sought	O	['N']	[5]
6	medical	O	['N']	[6]
7	attention	O	['N']	[7]
8	because	O	['N']	[8]
9	of	O	['N']	[9]
10	iliocaval	O	['N']	[10]
11	manifestations	O	['N']	[11]
12	of	O	['N']	[12]
13	retroperitoneal	B	['N']	[13]
14	fibrosis	I-Adverse_Effect	['N']	[14]
15	while	O	['N']	[15]
16	she	O	['N']	[16]
17	was	O	['N']	[17]
18	taking	O	['N']	[18]
19	methysergide	B-Drug	['Causes']	[14]
20	.	O	['N']	[20]
#1693
0	Phenytoin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hypersensitivity	B	['N']	[3]
4	reactions	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1694
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	cae	O	['N']	[3]
4	of	O	['N']	[4]
5	paranoid	O	['N']	[5]
6	psychosis	O	['N']	[6]
7	following	O	['N']	[7]
8	use	O	['N']	[8]
9	of	O	['N']	[9]
10	a	O	['N']	[10]
11	decongestant	O	['N']	[11]
12	containing	O	['N']	[12]
13	PPA	B-Drug	['Causes']	[23]
14	and	O	['N']	[14]
15	summarize	O	['N']	[15]
16	the	O	['N']	[16]
17	case	O	['N']	[17]
18	report	O	['N']	[18]
19	literature	O	['N']	[19]
20	of	O	['N']	[20]
21	psychiatric	B	['N']	[21]
22	adverse	I	['N']	[22]
23	effects	I-Adverse_Effect	['N']	[23]
24	to	O	['N']	[24]
25	PPA	O	['N']	[25]
26	in	O	['N']	[26]
27	which	O	['N']	[27]
28	doses	O	['N']	[28]
29	were	O	['N']	[29]
30	known	O	['N']	[30]
31	and	O	['N']	[31]
32	stated	O	['N']	[32]
33	to	O	['N']	[33]
34	be	O	['N']	[34]
35	within	O	['N']	[35]
36	recommended	O	['N']	[36]
37	guidelines	O	['N']	[37]
38	.	O	['N']	[38]
#1695
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	patient	O	['N']	[2]
3	developed	O	['N']	[3]
4	both	O	['N']	[4]
5	autoimmune	B	['N']	[5]
6	thyroid	I	['N']	[6]
7	disease	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	a	O	['N']	[9]
10	refractory	O	['N']	[10]
11	pre	O	['N']	[11]
12	-	O	['N']	[12]
13	patellar	O	['N']	[13]
14	bursitis	O	['N']	[14]
15	after	O	['N']	[15]
16	50	O	['N']	[16]
17	months	O	['N']	[17]
18	of	O	['N']	[18]
19	IFN	B	['N']	[19]
20	-	I	['N']	[20]
21	beta	I-Drug	['Causes']	[7]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#1696
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	'	O	['N']	[2]
3	results	O	['N']	[3]
4	suggest	O	['N']	[4]
5	that	O	['N']	[5]
6	L	B	['N']	[6]
7	-	I	['N']	[7]
8	dopa	I-Drug	['Causes']	[12]
9	may	O	['N']	[9]
10	cause	O	['N']	[10]
11	daytime	B	['N']	[11]
12	somnolence	I-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	some	O	['N']	[14]
15	patients	O	['N']	[15]
16	with	O	['N']	[16]
17	Parkinson	O	['N']	[17]
18	's	O	['N']	[18]
19	disease	O	['N']	[19]
20	.	O	['N']	[20]
#1697
0	Theophylline	O	['N']	[0]
1	intoxication	O	['N']	[1]
2	following	O	['N']	[2]
3	viloxazine	B-Drug	['Causes']	[7]
4	induced	O	['N']	[4]
5	decrease	B	['N']	[5]
6	in	I	['N']	[6]
7	clearance	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#1698
0	Flecainide	B-Drug	['Causes']	[8]
1	overdose	O	['N']	[1]
2	can	O	['N']	[2]
3	rapidly	O	['N']	[3]
4	result	O	['N']	[4]
5	in	O	['N']	[5]
6	profound	O	['N']	[6]
7	cardiovascular	B	['N']	[7]
8	collapse	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	is	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	relatively	O	['N']	[15]
16	high	O	['N']	[16]
17	mortality	O	['N']	[17]
18	.	O	['N']	[18]
#1699
0	An	O	['N']	[0]
1	83-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	receiving	O	['N']	[5]
6	glipizide	O	['N']	[6]
7	10	B	['N']	[7]
8	mg	I-Dose	['N']	[8]
9	bid	O	['N']	[9]
10	developed	O	['N']	[10]
11	symptomatic	O	['N']	[11]
12	hypoglycemia	O	['N']	[12]
13	within	O	['N']	[13]
14	three	O	['N']	[14]
15	days	O	['N']	[15]
16	of	O	['N']	[16]
17	adding	O	['N']	[17]
18	trimethoprim	B-Drug	['Dosage']	[8]
19	/	O	['N']	[19]
20	sulfamethoxazole	O	['N']	[20]
21	(	O	['N']	[21]
22	TMP	O	['N']	[22]
23	/	O	['N']	[23]
24	SMX	O	['N']	[24]
25	)	O	['N']	[25]
26	to	O	['N']	[26]
27	his	O	['N']	[27]
28	regimen	O	['N']	[28]
29	.	O	['N']	[29]
#1700
0	Myasthenic	O	['N']	[0]
1	patients	O	['N']	[1]
2	receiving	O	['N']	[2]
3	ampicillin	B-Drug	['Causes']	[11]
4	should	O	['N']	[4]
5	be	O	['N']	[5]
6	closely	O	['N']	[6]
7	monitored	O	['N']	[7]
8	for	O	['N']	[8]
9	possible	O	['N']	[9]
10	acute	B	['N']	[10]
11	exacerbations	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#1701
0	All	O	['N']	[0]
1	developed	O	['N']	[1]
2	mucocutaneous	B	['N']	[2]
3	side	I	['N']	[3]
4	effects	I-Adverse_Effect	['N']	[4]
5	within	O	['N']	[5]
6	20	O	['N']	[6]
7	weeks	O	['N']	[7]
8	of	O	['N']	[8]
9	beginning	O	['N']	[9]
10	i	O	['N']	[10]
11	m	O	['N']	[11]
12	gold	B-Drug	['Causes']	[4]
13	therapy	O	['N']	[13]
14	,	O	['N']	[14]
15	at	O	['N']	[15]
16	a	O	['N']	[16]
17	time	O	['N']	[17]
18	when	O	['N']	[18]
19	RA	O	['N']	[19]
20	had	O	['N']	[20]
21	improved	O	['N']	[21]
22	markedly	O	['N']	[22]
23	compared	O	['N']	[23]
24	to	O	['N']	[24]
25	pretreatment	O	['N']	[25]
26	status	O	['N']	[26]
27	.	O	['N']	[27]
#1702
0	Drug	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	psychosis	B-Adverse_Effect	['N']	[3]
4	resulted	O	['N']	[4]
5	from	O	['N']	[5]
6	the	O	['N']	[6]
7	administration	O	['N']	[7]
8	of	O	['N']	[8]
9	quinacrine	B	['N']	[9]
10	hydrochloride	I-Drug	['Causes']	[3]
11	at	O	['N']	[11]
12	a	O	['N']	[12]
13	dosage	O	['N']	[13]
14	of	O	['N']	[14]
15	100	O	['N']	[15]
16	mg	O	['N']	[16]
17	twice	O	['N']	[17]
18	daily	O	['N']	[18]
19	for	O	['N']	[19]
20	the	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	discoid	O	['N']	[23]
24	lupus	O	['N']	[24]
25	.	O	['N']	[25]
#1703
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	niacin	B-Drug	['Causes']	[10]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	visual	O	['N']	[6]
7	symptoms	O	['N']	[7]
8	had	O	['N']	[8]
9	cystoid	B	['N']	[9]
10	maculopathy	I-Adverse_Effect	['N']	[10]
11	without	O	['N']	[11]
12	leakage	O	['N']	[12]
13	on	O	['N']	[13]
14	fluorescein	O	['N']	[14]
15	angiography	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	fourth	O	['N']	[19]
20	patient	O	['N']	[20]
21	with	O	['N']	[21]
22	no	O	['N']	[22]
23	fundus	O	['N']	[23]
24	abnormality	O	['N']	[24]
25	experienced	O	['N']	[25]
26	cessation	O	['N']	[26]
27	of	O	['N']	[27]
28	visual	O	['N']	[28]
29	symptoms	O	['N']	[29]
30	upon	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	niacin	O	['N']	[33]
34	.	O	['N']	[34]
#1704
0	Use	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	probability	O	['N']	[4]
5	scale	O	['N']	[5]
6	determined	O	['N']	[6]
7	the	O	['N']	[7]
8	association	O	['N']	[8]
9	between	O	['N']	[9]
10	cephalosporin	B-Drug	['Causes']	[13]
11	use	O	['N']	[11]
12	and	O	['N']	[12]
13	leukopenia	B-Adverse_Effect	['N']	[13]
14	to	O	['N']	[14]
15	be	O	['N']	[15]
16	probable	O	['N']	[16]
17	.	O	['N']	[17]
#1705
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Ethambutol	B-Drug	['Causes']	[21]
3	,	O	['N']	[3]
4	and	O	['N']	[4]
5	to	O	['N']	[5]
6	a	O	['N']	[6]
7	lesser	O	['N']	[7]
8	extent	O	['N']	[8]
9	isoniazid	O	['N']	[9]
10	,	O	['N']	[10]
11	are	O	['N']	[11]
12	both	O	['N']	[12]
13	implicated	O	['N']	[13]
14	in	O	['N']	[14]
15	the	O	['N']	[15]
16	development	B	['N']	[16]
17	of	I	['N']	[17]
18	visually	I	['N']	[18]
19	related	I	['N']	[19]
20	side	I	['N']	[20]
21	effects	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1706
0	Neutrophilic	B	['N']	[0]
1	dermatoses	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	children	O	['N']	[4]
5	with	O	['N']	[5]
6	idiopathic	O	['N']	[6]
7	neutropenia	O	['N']	[7]
8	:	O	['N']	[8]
9	association	O	['N']	[9]
10	with	O	['N']	[10]
11	granulocyte	B	['N']	[11]
12	colony	I	['N']	[12]
13	-	I	['N']	[13]
14	stimulating	I	['N']	[14]
15	factor	I-Drug	['Causes']	[1]
16	(	O	['N']	[16]
17	G	O	['N']	[17]
18	-	O	['N']	[18]
19	CSF	O	['N']	[19]
20	)	O	['N']	[20]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#1707
0	In	O	['N']	[0]
1	four	O	['N']	[1]
2	patients	O	['N']	[2]
3	,	O	['N']	[3]
4	spasm	O	['N']	[4]
5	occurred	O	['N']	[5]
6	spontaneous	O	['N']	[6]
7	and	O	['N']	[7]
8	in	O	['N']	[8]
9	one	O	['N']	[9]
10	patient	O	['N']	[10]
11	after	O	['N']	[11]
12	0.05	B	['N']	[12]
13	mg	I-Dose	['N']	[13]
14	of	O	['N']	[14]
15	ergonovine	B-Drug	['Dosage']	[13]
16	.	O	['N']	[16]
#1708
0	Well	O	['N']	[0]
1	-	O	['N']	[1]
2	known	O	['N']	[2]
3	signs	O	['N']	[3]
4	of	O	['N']	[4]
5	methotrexate	B-Drug	['Causes']	[15]
6	toxicity	O	['N']	[6]
7	include	O	['N']	[7]
8	bone	O	['N']	[8]
9	marrow	O	['N']	[9]
10	suppression	O	['N']	[10]
11	and	O	['N']	[11]
12	oral	B	['N']	[12]
13	and	I	['N']	[13]
14	gastrointestinal	I	['N']	[14]
15	ulceration	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#1709
0	Gold	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pneumonitis	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#1710
0	Acute	O	['N']	[0]
1	myocardial	O	['N']	[1]
2	infarction	O	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	coronary	B	['N']	[5]
6	spasm	I-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	L	B	['N']	[9]
10	-	I	['N']	[10]
11	thyroxine	I-Drug	['Causes']	[6]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#1711
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	female	O	['N']	[2]
3	with	O	['N']	[3]
4	acute	O	['N']	[4]
5	lymphoblastic	O	['N']	[5]
6	leukemia	O	['N']	[6]
7	,	O	['N']	[7]
8	inadvertent	O	['N']	[8]
9	doxorubicin	B-Drug	['Causes']	[25]
10	administration	O	['N']	[10]
11	intrathecally	O	['N']	[11]
12	caused	O	['N']	[12]
13	severe	O	['N']	[13]
14	,	O	['N']	[14]
15	life	O	['N']	[15]
16	-	O	['N']	[16]
17	threatening	O	['N']	[17]
18	,	O	['N']	[18]
19	acute	O	['N']	[19]
20	encephalopathy	O	['N']	[20]
21	with	O	['N']	[21]
22	high	B	['N']	[22]
23	-	I	['N']	[23]
24	pressure	I	['N']	[24]
25	hydrocephalus	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#1712
0	Acute	B	['N']	[0]
1	dystonia	I-Adverse_Effect	['N']	[1]
2	during	O	['N']	[2]
3	pegylated	B	['N']	[3]
4	interferon	I	['N']	[4]
5	alpha	I-Drug	['Causes']	[1]
6	therapy	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	case	O	['N']	[9]
10	with	O	['N']	[10]
11	chronic	O	['N']	[11]
12	hepatitis	O	['N']	[12]
13	B	O	['N']	[13]
14	infection	O	['N']	[14]
15	.	O	['N']	[15]
#1713
0	Pneumocystis	O	['N']	[0]
1	pneumonia	O	['N']	[1]
2	should	O	['N']	[2]
3	be	O	['N']	[3]
4	considered	O	['N']	[4]
5	in	O	['N']	[5]
6	asthmatic	O	['N']	[6]
7	patients	O	['N']	[7]
8	taking	O	['N']	[8]
9	methotrexate	B-Drug	['Causes']	[13]
10	who	O	['N']	[10]
11	present	O	['N']	[11]
12	with	O	['N']	[12]
13	fever	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	pulmonary	O	['N']	[15]
16	infiltrates	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	hypoxia	O	['N']	[19]
20	.	O	['N']	[20]
#1714
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	sirolimus	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	pneumonitis	B-Adverse_Effect	['N']	[6]
7	have	O	['N']	[7]
8	been	O	['N']	[8]
9	reported	O	['N']	[9]
10	after	O	['N']	[10]
11	cardiac	O	['N']	[11]
12	transplantation	O	['N']	[12]
13	.	O	['N']	[13]
#1715
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	who	O	['N']	[2]
3	developed	O	['N']	[3]
4	decreased	B	['N']	[4]
5	visual	I	['N']	[5]
6	acuity	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	several	O	['N']	[8]
9	months	O	['N']	[9]
10	of	O	['N']	[10]
11	ethambutol	B-Drug	['Causes']	[6]
12	treatment	O	['N']	[12]
13	for	O	['N']	[13]
14	Mycobacterium	O	['N']	[14]
15	avium	O	['N']	[15]
16	-	O	['N']	[16]
17	intracellulare	O	['N']	[17]
18	infection	O	['N']	[18]
19	had	O	['N']	[19]
20	bitemporal	O	['N']	[20]
21	visual	O	['N']	[21]
22	field	O	['N']	[22]
23	defects	O	['N']	[23]
24	that	O	['N']	[24]
25	suggested	O	['N']	[25]
26	optic	O	['N']	[26]
27	chiasm	O	['N']	[27]
28	damage	O	['N']	[28]
29	.	O	['N']	[29]
#1716
0	The	O	['N']	[0]
1	NZ	O	['N']	[1]
2	Pharmacovigilance	O	['N']	[2]
3	Centre	O	['N']	[3]
4	has	O	['N']	[4]
5	received	O	['N']	[5]
6	7	O	['N']	[6]
7	additional	O	['N']	[7]
8	reports	O	['N']	[8]
9	of	O	['N']	[9]
10	severe	B	['N']	[10]
11	infections	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	patients	O	['N']	[13]
14	with	O	['N']	[14]
15	RA	O	['N']	[15]
16	taking	O	['N']	[16]
17	leflunomide	B-Drug	['Causes']	[11]
18	.	O	['N']	[18]
#1717
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	present	O	['N']	[3]
4	findings	O	['N']	[4]
5	suggest	O	['N']	[5]
6	that	O	['N']	[6]
7	fluvoxamine	B-Drug	['Causes']	[11]
8	can	O	['N']	[8]
9	cause	O	['N']	[9]
10	increased	B	['N']	[10]
11	libido	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	some	O	['N']	[13]
14	patients	O	['N']	[14]
15	.	O	['N']	[15]
#1718
0	Acute	B	['N']	[0]
1	psychosis	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	levetiracetam	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#1719
0	Controversy	O	['N']	[0]
1	concerning	O	['N']	[1]
2	the	O	['N']	[2]
3	nephrotoxicity	B-Adverse_Effect	['N']	[3]
4	of	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[3]
6	is	O	['N']	[6]
7	discussed	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	recommendations	O	['N']	[10]
11	for	O	['N']	[11]
12	the	O	['N']	[12]
13	evaluation	O	['N']	[13]
14	of	O	['N']	[14]
15	renal	O	['N']	[15]
16	failure	O	['N']	[16]
17	during	O	['N']	[17]
18	lithium	O	['N']	[18]
19	therapy	O	['N']	[19]
20	are	O	['N']	[20]
21	provided	O	['N']	[21]
22	.	O	['N']	[22]
#1720
0	Ischaemia	B-Adverse_Effect	['N']	[0]
1	following	O	['N']	[1]
2	selfadministered	O	['N']	[2]
3	intra	O	['N']	[3]
4	-	O	['N']	[4]
5	arterial	O	['N']	[5]
6	injection	O	['N']	[6]
7	of	O	['N']	[7]
8	methylphenidate	B-Drug	['Causes']	[0]
9	and	O	['N']	[9]
10	diamorphine	O	['N']	[10]
11	.	O	['N']	[11]
#1721
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Zidovudine	B-Drug	['Causes']	[11]
6	induced	O	['N']	[6]
7	anaemia	O	['N']	[7]
8	and	O	['N']	[8]
9	bone	B	['N']	[9]
10	marrow	I	['N']	[10]
11	aplasia	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	patient	O	['N']	[14]
15	infected	O	['N']	[15]
16	with	O	['N']	[16]
17	HIV	O	['N']	[17]
18	.	O	['N']	[18]
#1722
0	Levofloxacin	B-Drug	['Causes']	[4]
1	induced	O	['N']	[1]
2	polymorphic	B	['N']	[2]
3	ventricular	I	['N']	[3]
4	tachycardia	I-Adverse_Effect	['N']	[4]
5	with	O	['N']	[5]
6	normal	O	['N']	[6]
7	QT	O	['N']	[7]
8	interval	O	['N']	[8]
9	.	O	['N']	[9]
#1723
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	Case	O	['N']	[2]
3	analysis	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	poly	O	['N']	[6]
7	-	O	['N']	[7]
8	drug	O	['N']	[8]
9	overdose	O	['N']	[9]
10	(	O	['N']	[10]
11	venlafaxine	O	['N']	[11]
12	,	O	['N']	[12]
13	topiramate	O	['N']	[13]
14	,	O	['N']	[14]
15	divalproex	O	['N']	[15]
16	sodium	O	['N']	[16]
17	,	O	['N']	[17]
18	risperidone	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	carbamazepine	B-Drug	['Causes']	[28]
22	)	O	['N']	[22]
23	presenting	O	['N']	[23]
24	with	O	['N']	[24]
25	mixed	O	['N']	[25]
26	SS	O	['N']	[26]
27	/	O	['N']	[27]
28	NMS	B-Adverse_Effect	['N']	[28]
29	features	O	['N']	[29]
30	and	O	['N']	[30]
31	whose	O	['N']	[31]
32	clinical	O	['N']	[32]
33	management	O	['N']	[33]
34	suggests	O	['N']	[34]
35	a	O	['N']	[35]
36	practical	O	['N']	[36]
37	algorithm	O	['N']	[37]
38	for	O	['N']	[38]
39	treatment	O	['N']	[39]
40	of	O	['N']	[40]
41	undifferentiated	O	['N']	[41]
42	SS	O	['N']	[42]
43	/	O	['N']	[43]
44	NMS	O	['N']	[44]
45	in	O	['N']	[45]
46	critical	O	['N']	[46]
47	care	O	['N']	[47]
48	settings	O	['N']	[48]
49	.	O	['N']	[49]
#1724
0	Lethargy	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	a	O	['N']	[2]
3	newborn	O	['N']	[3]
4	:	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[0]
6	toxicity	O	['N']	[6]
7	or	O	['N']	[7]
8	lab	O	['N']	[8]
9	error	O	['N']	[9]
10	?	O	['N']	[10]
#1725
0	Oral	O	['N']	[0]
1	intake	O	['N']	[1]
2	and	O	['N']	[2]
3	acarbose	B-Drug	['Causes']	[8]
4	were	O	['N']	[4]
5	withheld	O	['N']	[5]
6	and	O	['N']	[6]
7	the	O	['N']	[7]
8	ileus	B-Adverse_Effect	['N']	[8]
9	spontaneously	O	['N']	[9]
10	resolved	O	['N']	[10]
11	after	O	['N']	[11]
12	2	O	['N']	[12]
13	days	O	['N']	[13]
14	.	O	['N']	[14]
#1726
0	Based	O	['N']	[0]
1	on	O	['N']	[1]
2	the	O	['N']	[2]
3	history	O	['N']	[3]
4	and	O	['N']	[4]
5	clinical	O	['N']	[5]
6	features	O	['N']	[6]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	diagnosis	O	['N']	[9]
10	of	O	['N']	[10]
11	insulin	B-Drug	['Causes']	[14]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	lipohypertrophy	B-Adverse_Effect	['N']	[14]
15	was	O	['N']	[15]
16	made	O	['N']	[16]
17	.	O	['N']	[17]
#1727
0	Infliximab	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	lupus	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	Crohn	O	['N']	[5]
6	's	O	['N']	[6]
7	disease	O	['N']	[7]
8	:	O	['N']	[8]
9	a	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	.	O	['N']	[12]
#1728
0	Case	O	['N']	[0]
1	report	O	['N']	[1]
2	of	O	['N']	[2]
3	withdrawal	O	['N']	[3]
4	dyskinesia	B-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	amoxapine	B-Drug	['Causes']	[4]
8	.	O	['N']	[8]
#1729
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	is	O	['N']	[2]
3	presented	O	['N']	[3]
4	with	O	['N']	[4]
5	typical	O	['N']	[5]
6	hyperthyroidism	O	['N']	[6]
7	,	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	a	O	['N']	[10]
11	severe	O	['N']	[11]
12	proximal	O	['N']	[12]
13	muscle	O	['N']	[13]
14	weakness	O	['N']	[14]
15	and	O	['N']	[15]
16	a	O	['N']	[16]
17	raised	O	['N']	[17]
18	creatine	O	['N']	[18]
19	phosphokinase	O	['N']	[19]
20	after	O	['N']	[20]
21	treatment	O	['N']	[21]
22	for	O	['N']	[22]
23	hyperthyroidism	O	['N']	[23]
24	with	O	['N']	[24]
25	propylthiouracil	B-Drug	['Dosage']	[34]
26	(	O	['N']	[26]
27	100	B	['N']	[27]
28	mg	I	['N']	[28]
29	orally	I	['N']	[29]
30	,	I	['N']	[30]
31	three	I	['N']	[31]
32	times	I	['N']	[32]
33	a	I	['N']	[33]
34	day	I-Dose	['N']	[34]
35	)	O	['N']	[35]
36	.	O	['N']	[36]
#1730
0	Following	O	['N']	[0]
1	the	O	['N']	[1]
2	institution	O	['N']	[2]
3	of	O	['N']	[3]
4	intravenous	O	['N']	[4]
5	therapy	O	['N']	[5]
6	with	O	['N']	[6]
7	acyclovir	B-Drug	['Causes']	[12]
8	,	O	['N']	[8]
9	the	O	['N']	[9]
10	patient	O	['N']	[10]
11	developed	O	['N']	[11]
12	fever	B-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	hemoptysis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	a	O	['N']	[17]
18	pleural	O	['N']	[18]
19	friction	O	['N']	[19]
20	rub	O	['N']	[20]
21	.	O	['N']	[21]
#1731
0	It	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	emphasized	O	['N']	[3]
4	that	O	['N']	[4]
5	the	O	['N']	[5]
6	recurrence	O	['N']	[6]
7	of	O	['N']	[7]
8	nephrotic	B	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	was	O	['N']	[10]
11	observed	O	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	following	O	['N']	[14]
15	chemotherapy	O	['N']	[15]
16	,	O	['N']	[16]
17	including	O	['N']	[17]
18	M	B	['N']	[18]
19	-	I	['N']	[19]
20	CSF	I-Drug	['Causes']	[9]
21	,	O	['N']	[21]
22	whereas	O	['N']	[22]
23	the	O	['N']	[23]
24	bone	O	['N']	[24]
25	marrow	O	['N']	[25]
26	still	O	['N']	[26]
27	remained	O	['N']	[27]
28	completely	O	['N']	[28]
29	remitted	O	['N']	[29]
30	.	O	['N']	[30]
#1732
0	An	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	granulocytopenia	O	['N']	[3]
4	,	O	['N']	[4]
5	eosinophilia	B-Adverse_Effect	['N']	[5]
6	,	O	['N']	[6]
7	skin	O	['N']	[7]
8	reaction	O	['N']	[8]
9	and	O	['N']	[9]
10	hepatitis	O	['N']	[10]
11	during	O	['N']	[11]
12	propylthiouracil	B-Drug	['Causes']	[5]
13	(	O	['N']	[13]
14	PTU	O	['N']	[14]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	thyrotoxicosis	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	47	O	['N']	[21]
22	year	O	['N']	[22]
23	old	O	['N']	[23]
24	black	O	['N']	[24]
25	female	O	['N']	[25]
26	is	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#1733
0	Despite	O	['N']	[0]
1	a	O	['N']	[1]
2	response	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	meningeal	O	['N']	[5]
6	tumor	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	developed	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	third	O	['N']	[12]
13	week	O	['N']	[13]
14	of	O	['N']	[14]
15	MTX	B-Drug	['Causes']	[20]
16	treatment	O	['N']	[16]
17	a	O	['N']	[17]
18	progressive	B	['N']	[18]
19	visual	I	['N']	[19]
20	loss	I-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	loss	O	['N']	[22]
23	of	O	['N']	[23]
24	consciousness	O	['N']	[24]
25	which	O	['N']	[25]
26	worsened	O	['N']	[26]
27	during	O	['N']	[27]
28	subsequent	O	['N']	[28]
29	Ara	O	['N']	[29]
30	-	O	['N']	[30]
31	C	O	['N']	[31]
32	treatment	O	['N']	[32]
33	and	O	['N']	[33]
34	led	O	['N']	[34]
35	to	O	['N']	[35]
36	death	O	['N']	[36]
37	within	O	['N']	[37]
38	3	O	['N']	[38]
39	weeks	O	['N']	[39]
40	.	O	['N']	[40]
#1734
0	Clinicians	O	['N']	[0]
1	have	O	['N']	[1]
2	been	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[20]
6	toxicity	O	['N']	[6]
7	for	O	['N']	[7]
8	many	O	['N']	[8]
9	years	O	['N']	[9]
10	and	O	['N']	[10]
11	traditionally	O	['N']	[11]
12	have	O	['N']	[12]
13	administered	O	['N']	[13]
14	thiazide	O	['N']	[14]
15	diuretics	O	['N']	[15]
16	for	O	['N']	[16]
17	lithium	O	['N']	[17]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	polyuria	B-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	nephrogenic	O	['N']	[22]
23	diabetes	O	['N']	[23]
24	insipidus	O	['N']	[24]
25	.	O	['N']	[25]
#1735
0	Treatment	O	['N']	[0]
1	of	O	['N']	[1]
2	chronic	O	['N']	[2]
3	hepatitis	O	['N']	[3]
4	C	O	['N']	[4]
5	with	O	['N']	[5]
6	interferon	B	['N']	[6]
7	alpha	I-Drug	['Causes']	[27]
8	(	O	['N']	[8]
9	IFN	O	['N']	[9]
10	-	O	['N']	[10]
11	alpha	O	['N']	[11]
12	)	O	['N']	[12]
13	is	O	['N']	[13]
14	relatively	O	['N']	[14]
15	contraindicated	O	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	with	O	['N']	[18]
19	psychiatric	O	['N']	[19]
20	disorders	O	['N']	[20]
21	because	O	['N']	[21]
22	of	O	['N']	[22]
23	possible	O	['N']	[23]
24	severe	O	['N']	[24]
25	psychiatric	B	['N']	[25]
26	side	I	['N']	[26]
27	effects	I-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#1736
0	Arrhythmias	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	cardiac	O	['N']	[2]
3	arrest	O	['N']	[3]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	reported	O	['N']	[6]
7	during	O	['N']	[7]
8	amphotericin	B	['N']	[8]
9	B	I-Drug	['Causes']	[0]
10	administration	O	['N']	[10]
11	but	O	['N']	[11]
12	no	O	['N']	[12]
13	effective	O	['N']	[13]
14	technique	O	['N']	[14]
15	has	O	['N']	[15]
16	been	O	['N']	[16]
17	described	O	['N']	[17]
18	to	O	['N']	[18]
19	prevent	O	['N']	[19]
20	them	O	['N']	[20]
21	.	O	['N']	[21]
#1737
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	Growth	B	['N']	[2]
3	retardation	I-Adverse_Effect	['N']	[3]
4	was	O	['N']	[4]
5	observed	O	['N']	[5]
6	in	O	['N']	[6]
7	six	O	['N']	[7]
8	severely	O	['N']	[8]
9	asthmatic	O	['N']	[9]
10	children	O	['N']	[10]
11	after	O	['N']	[11]
12	introduction	O	['N']	[12]
13	of	O	['N']	[13]
14	high	O	['N']	[14]
15	-	O	['N']	[15]
16	dose	O	['N']	[16]
17	fluticasone	B	['N']	[17]
18	propionate	I-Drug	['Causes']	[3]
19	treatment	O	['N']	[19]
20	(	O	['N']	[20]
21	dry	O	['N']	[21]
22	powder	O	['N']	[22]
23	)	O	['N']	[23]
24	.	O	['N']	[24]
#1738
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	87-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	white	O	['N']	[9]
10	woman	O	['N']	[10]
11	with	O	['N']	[11]
12	myasthenia	O	['N']	[12]
13	gravis	O	['N']	[13]
14	who	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	nausea	O	['N']	[17]
18	,	O	['N']	[18]
19	shortness	O	['N']	[19]
20	of	O	['N']	[20]
21	breath	O	['N']	[21]
22	,	O	['N']	[22]
23	azotemia	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hyperkalemia	B-Adverse_Effect	['N']	[26]
27	shortly	O	['N']	[27]
28	after	O	['N']	[28]
29	completing	O	['N']	[29]
30	a	O	['N']	[30]
31	course	O	['N']	[31]
32	of	O	['N']	[32]
33	intravenous	O	['N']	[33]
34	immunoglobulin	O	['N']	[34]
35	(	O	['N']	[35]
36	IVIG	B-Drug	['Causes']	[26]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#1739
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	who	O	['N']	[2]
3	were	O	['N']	[3]
4	receiving	O	['N']	[4]
5	Tolazoline	B-Drug	['Causes']	[10]
6	by	O	['N']	[6]
7	infusion	O	['N']	[7]
8	developed	O	['N']	[8]
9	duodenal	B	['N']	[9]
10	ulceration	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	subsequent	O	['N']	[12]
13	intestinal	O	['N']	[13]
14	perforation	O	['N']	[14]
15	.	O	['N']	[15]
#1740
0	The	O	['N']	[0]
1	potential	O	['N']	[1]
2	development	O	['N']	[2]
3	of	O	['N']	[3]
4	SJS	O	['N']	[4]
5	/	O	['N']	[5]
6	TEN	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	severe	O	['N']	[9]
10	life	O	['N']	[10]
11	-	O	['N']	[11]
12	threatening	O	['N']	[12]
13	illness	O	['N']	[13]
14	,	O	['N']	[14]
15	emphasizes	O	['N']	[15]
16	the	O	['N']	[16]
17	need	O	['N']	[17]
18	for	O	['N']	[18]
19	judicious	O	['N']	[19]
20	use	O	['N']	[20]
21	of	O	['N']	[21]
22	TMP	B	['N']	[22]
23	-	I	['N']	[23]
24	Sx	I-Drug	['Causes']	[6]
25	and	O	['N']	[25]
26	close	O	['N']	[26]
27	monitoring	O	['N']	[27]
28	and	O	['N']	[28]
29	follow	O	['N']	[29]
30	-	O	['N']	[30]
31	up	O	['N']	[31]
32	for	O	['N']	[32]
33	patients	O	['N']	[33]
34	who	O	['N']	[34]
35	were	O	['N']	[35]
36	given	O	['N']	[36]
37	TMP	O	['N']	[37]
38	-	O	['N']	[38]
39	Sx	O	['N']	[39]
40	for	O	['N']	[40]
41	SSTIs	O	['N']	[41]
42	.	O	['N']	[42]
#1741
0	RTA	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	one	O	['N']	[2]
3	type	O	['N']	[3]
4	of	O	['N']	[4]
5	nephrotoxicity	O	['N']	[5]
6	induced	O	['N']	[6]
7	by	O	['N']	[7]
8	FK506	B-Drug	['Causes']	[0]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	it	O	['N']	[11]
12	is	O	['N']	[12]
13	reversible	O	['N']	[13]
14	in	O	['N']	[14]
15	mild	O	['N']	[15]
16	cases	O	['N']	[16]
17	when	O	['N']	[17]
18	appropriately	O	['N']	[18]
19	treated	O	['N']	[19]
20	.	O	['N']	[20]
#1742
0	After	O	['N']	[0]
1	treatment	O	['N']	[1]
2	with	O	['N']	[2]
3	a	O	['N']	[3]
4	beta	O	['N']	[4]
5	-	O	['N']	[5]
6	sympathomimetic	O	['N']	[6]
7	drug	O	['N']	[7]
8	(	O	['N']	[8]
9	Partusisten	B-Drug	['Causes']	[15]
10	)	O	['N']	[10]
11	one	O	['N']	[11]
12	fetus	O	['N']	[12]
13	developed	O	['N']	[13]
14	supraventricular	B	['N']	[14]
15	tachycardia	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#1743
0	Ischaemia	B-Adverse_Effect	['N']	[0]
1	following	O	['N']	[1]
2	selfadministered	O	['N']	[2]
3	intra	O	['N']	[3]
4	-	O	['N']	[4]
5	arterial	O	['N']	[5]
6	injection	O	['N']	[6]
7	of	O	['N']	[7]
8	methylphenidate	O	['N']	[8]
9	and	O	['N']	[9]
10	diamorphine	B-Drug	['Causes']	[0]
11	.	O	['N']	[11]
#1744
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	placed	O	['N']	[2]
3	on	O	['N']	[3]
4	adjuvant	O	['N']	[4]
5	Adriamycin	B-Drug	['Causes']	[15]
6	(	O	['N']	[6]
7	doxorubicin	O	['N']	[7]
8	)	O	['N']	[8]
9	chemotherapy	O	['N']	[9]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	6	O	['N']	[12]
13	months	O	['N']	[13]
14	later	O	['N']	[14]
15	died	B-Adverse_Effect	['N']	[15]
16	of	O	['N']	[16]
17	Adriamycin	O	['N']	[17]
18	toxicity	O	['N']	[18]
19	.	O	['N']	[19]
#1745
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	woman	O	['N']	[3]
4	receiving	O	['N']	[4]
5	enoxaparin	B-Drug	['Causes']	[14]
6	every	O	['N']	[6]
7	12	O	['N']	[7]
8	hours	O	['N']	[8]
9	developed	O	['N']	[9]
10	signs	O	['N']	[10]
11	and	O	['N']	[11]
12	symptoms	O	['N']	[12]
13	of	O	['N']	[13]
14	hepatotoxicity	B-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	the	O	['N']	[16]
17	second	O	['N']	[17]
18	dose	O	['N']	[18]
19	.	O	['N']	[19]
#1746
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	childhood	O	['N']	[3]
4	-	O	['N']	[4]
5	onset	O	['N']	[5]
6	schizophrenia	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	clozapine	B-Drug	['Causes']	[12]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	akathisia	B-Adverse_Effect	['N']	[12]
13	responsive	O	['N']	[13]
14	to	O	['N']	[14]
15	beta	O	['N']	[15]
16	-	O	['N']	[16]
17	blocker	O	['N']	[17]
18	treatment	O	['N']	[18]
19	are	O	['N']	[19]
20	described	O	['N']	[20]
21	.	O	['N']	[21]
#1747
0	Thus	O	['N']	[0]
1	,	O	['N']	[1]
2	tacrolimus	B-Drug	['Causes']	[11]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	HUS	O	['N']	[5]
6	is	O	['N']	[6]
7	a	O	['N']	[7]
8	rare	O	['N']	[8]
9	cause	O	['N']	[9]
10	of	O	['N']	[10]
11	ARF	B-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	nephrotic	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	.	O	['N']	[15]
#1748
0	Myoclonus	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	seizures	O	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	parkinsonism	O	['N']	[7]
8	:	O	['N']	[8]
9	induction	O	['N']	[9]
10	by	O	['N']	[10]
11	levodopa	B-Drug	['Causes']	[0]
12	and	O	['N']	[12]
13	its	O	['N']	[13]
14	confirmation	O	['N']	[14]
15	on	O	['N']	[15]
16	SEPs	O	['N']	[16]
17	.	O	['N']	[17]
#1749
0	Reversible	B	['N']	[0]
1	corneal	I	['N']	[1]
2	keratinization	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	trabeculectomy	O	['N']	[4]
5	and	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	5-fluorouracil	B-Drug	['Causes']	[2]
9	.	O	['N']	[9]
#1750
0	over	O	['N']	[0]
1	the	O	['N']	[1]
2	past	O	['N']	[2]
3	3	O	['N']	[3]
4	years	O	['N']	[4]
5	there	O	['N']	[5]
6	have	O	['N']	[6]
7	been	O	['N']	[7]
8	several	O	['N']	[8]
9	reports	O	['N']	[9]
10	of	O	['N']	[10]
11	uveitis	B-Adverse_Effect	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	rifabutin	B-Drug	['Causes']	[11]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#1751
0	A	O	['N']	[0]
1	73-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	presented	O	['N']	[5]
6	with	O	['N']	[6]
7	fever	B-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	cough	O	['N']	[9]
10	2	O	['N']	[10]
11	weeks	O	['N']	[11]
12	after	O	['N']	[12]
13	completing	O	['N']	[13]
14	the	O	['N']	[14]
15	third	O	['N']	[15]
16	cycle	O	['N']	[16]
17	of	O	['N']	[17]
18	fludarabine	B-Drug	['Causes']	[7]
19	for	O	['N']	[19]
20	chronic	O	['N']	[20]
21	lymphocytic	O	['N']	[21]
22	leukemia	O	['N']	[22]
23	(	O	['N']	[23]
24	CLL	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#1752
0	After	O	['N']	[0]
1	the	O	['N']	[1]
2	first	O	['N']	[2]
3	oral	O	['N']	[3]
4	dose	O	['N']	[4]
5	of	O	['N']	[5]
6	propranolol	B-Drug	['Causes']	[8]
7	,	O	['N']	[7]
8	syncope	B-Adverse_Effect	['N']	[8]
9	developed	O	['N']	[9]
10	together	O	['N']	[10]
11	with	O	['N']	[11]
12	atrioventricular	O	['N']	[12]
13	block	O	['N']	[13]
14	.	O	['N']	[14]
#1753
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	Genetic	O	['N']	[3]
4	deficiencies	O	['N']	[4]
5	in	O	['N']	[5]
6	DPD	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	rate	O	['N']	[9]
10	-	O	['N']	[10]
11	limiting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	responsible	O	['N']	[13]
14	for	O	['N']	[14]
15	5-FU	B-Drug	['Causes']	[46]
16	catabolism	O	['N']	[16]
17	,	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	in	O	['N']	[20]
21	3	O	['N']	[21]
22	%	O	['N']	[22]
23	or	O	['N']	[23]
24	more	O	['N']	[24]
25	of	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	cancer	O	['N']	[28]
29	putting	O	['N']	[29]
30	them	O	['N']	[30]
31	at	O	['N']	[31]
32	increased	O	['N']	[32]
33	risk	O	['N']	[33]
34	for	O	['N']	[34]
35	unusually	O	['N']	[35]
36	severe	O	['N']	[36]
37	adverse	O	['N']	[37]
38	reactions	O	['N']	[38]
39	(	O	['N']	[39]
40	e.g.	O	['N']	[40]
41	,	O	['N']	[41]
42	diarrhea	O	['N']	[42]
43	,	O	['N']	[43]
44	stomatitis	O	['N']	[44]
45	,	O	['N']	[45]
46	mucositis	B-Adverse_Effect	['N']	[46]
47	,	O	['N']	[47]
48	myelosuppression	O	['N']	[48]
49	,	O	['N']	[49]
50	neurotoxicity	O	['N']	[50]
51	)	O	['N']	[51]
52	to	O	['N']	[52]
53	standard	O	['N']	[53]
54	doses	O	['N']	[54]
55	of	O	['N']	[55]
56	5-FU	O	['N']	[56]
57	.	O	['N']	[57]
#1754
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	cae	O	['N']	[3]
4	of	O	['N']	[4]
5	paranoid	B	['N']	[5]
6	psychosis	I-Adverse_Effect	['N']	[6]
7	following	O	['N']	[7]
8	use	O	['N']	[8]
9	of	O	['N']	[9]
10	a	O	['N']	[10]
11	decongestant	O	['N']	[11]
12	containing	O	['N']	[12]
13	PPA	B-Drug	['Causes']	[6]
14	and	O	['N']	[14]
15	summarize	O	['N']	[15]
16	the	O	['N']	[16]
17	case	O	['N']	[17]
18	report	O	['N']	[18]
19	literature	O	['N']	[19]
20	of	O	['N']	[20]
21	psychiatric	O	['N']	[21]
22	adverse	O	['N']	[22]
23	effects	O	['N']	[23]
24	to	O	['N']	[24]
25	PPA	O	['N']	[25]
26	in	O	['N']	[26]
27	which	O	['N']	[27]
28	doses	O	['N']	[28]
29	were	O	['N']	[29]
30	known	O	['N']	[30]
31	and	O	['N']	[31]
32	stated	O	['N']	[32]
33	to	O	['N']	[33]
34	be	O	['N']	[34]
35	within	O	['N']	[35]
36	recommended	O	['N']	[36]
37	guidelines	O	['N']	[37]
38	.	O	['N']	[38]
#1755
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	described	O	['N']	[2]
3	in	O	['N']	[3]
4	this	O	['N']	[4]
5	paper	O	['N']	[5]
6	was	O	['N']	[6]
7	a	O	['N']	[7]
8	78-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	diabetic	O	['N']	[11]
12	man	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	oral	B	['N']	[15]
16	lesions	I	['N']	[16]
17	of	I	['N']	[17]
18	PV	I-Adverse_Effect	['N']	[18]
19	following	O	['N']	[19]
20	institution	O	['N']	[20]
21	of	O	['N']	[21]
22	glibenclamide	B-Drug	['Causes']	[18]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#1756
0	Both	O	['N']	[0]
1	PAN	O	['N']	[1]
2	and	O	['N']	[2]
3	methotrexate	B-Drug	['Causes']	[12]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	independently	O	['N']	[6]
7	demonstrated	O	['N']	[7]
8	to	O	['N']	[8]
9	cause	O	['N']	[9]
10	sensorineural	B	['N']	[10]
11	hearing	I	['N']	[11]
12	loss	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#1757
0	Because	O	['N']	[0]
1	psoralens	B-Drug	['Causes']	[10]
2	sensitize	O	['N']	[2]
3	skin	O	['N']	[3]
4	to	O	['N']	[4]
5	ultraviolet	O	['N']	[5]
6	A	O	['N']	[6]
7	light	O	['N']	[7]
8	,	O	['N']	[8]
9	phototoxic	B	['N']	[9]
10	reactions	I-Adverse_Effect	['N']	[10]
11	are	O	['N']	[11]
12	the	O	['N']	[12]
13	most	O	['N']	[13]
14	frequent	O	['N']	[14]
15	adverse	O	['N']	[15]
16	effect	O	['N']	[16]
17	of	O	['N']	[17]
18	this	O	['N']	[18]
19	treatment	O	['N']	[19]
20	.	O	['N']	[20]
#1758
0	Alopecia	O	['N']	[0]
1	,	O	['N']	[1]
2	nausea	B-Adverse_Effect	['N']	[2]
3	,	O	['N']	[3]
4	and	O	['N']	[4]
5	vomiting	O	['N']	[5]
6	were	O	['N']	[6]
7	attributed	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	cyclophosphamide	B-Drug	['Causes']	[2]
11	component	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#1759
0	Spectral	O	['N']	[0]
1	-	O	['N']	[1]
2	domain	O	['N']	[2]
3	optical	O	['N']	[3]
4	coherence	O	['N']	[4]
5	tomography	O	['N']	[5]
6	and	O	['N']	[6]
7	adaptive	O	['N']	[7]
8	optics	O	['N']	[8]
9	may	O	['N']	[9]
10	detect	O	['N']	[10]
11	hydroxychloroquine	B-Drug	['Causes']	[13]
12	retinal	B	['N']	[12]
13	toxicity	I-Adverse_Effect	['N']	[13]
14	before	O	['N']	[14]
15	symptomatic	O	['N']	[15]
16	vision	O	['N']	[16]
17	loss	O	['N']	[17]
18	.	O	['N']	[18]
#1760
0	There	O	['N']	[0]
1	have	O	['N']	[1]
2	been	O	['N']	[2]
3	more	O	['N']	[3]
4	than	O	['N']	[4]
5	20	O	['N']	[5]
6	observations	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	appearance	O	['N']	[9]
10	or	O	['N']	[10]
11	aggravation	O	['N']	[11]
12	of	O	['N']	[12]
13	this	O	['N']	[13]
14	granulomatosis	B-Adverse_Effect	['N']	[14]
15	with	O	['N']	[15]
16	interferon	O	['N']	[16]
17	alfa	O	['N']	[17]
18	and	O	['N']	[18]
19	more	O	['N']	[19]
20	recently	O	['N']	[20]
21	with	O	['N']	[21]
22	the	O	['N']	[22]
23	combination	O	['N']	[23]
24	of	O	['N']	[24]
25	interferon	O	['N']	[25]
26	alfa	O	['N']	[26]
27	plus	O	['N']	[27]
28	ribavirin	B-Drug	['Causes']	[14]
29	.	O	['N']	[29]
#1761
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Sweet	B	['N']	[5]
6	's	I	['N']	[6]
7	syndrome	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	association	O	['N']	[9]
10	with	O	['N']	[10]
11	sargramostim	B-Drug	['Causes']	[7]
12	treatment	O	['N']	[12]
13	following	O	['N']	[13]
14	chemotherapy	O	['N']	[14]
15	for	O	['N']	[15]
16	acute	O	['N']	[16]
17	myelogenous	O	['N']	[17]
18	leukemia	O	['N']	[18]
19	.	O	['N']	[19]
#1762
0	Acute	B	['N']	[0]
1	endophthalmitis	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	intravitreal	O	['N']	[3]
4	bevacizumab	O	['N']	[4]
5	(	O	['N']	[5]
6	Avastin	B-Drug	['Causes']	[1]
7	)	O	['N']	[7]
8	injection	O	['N']	[8]
9	.	O	['N']	[9]
#1763
0	TREATMENT	O	['N']	[0]
1	/	O	['N']	[1]
2	OUTCOME	O	['N']	[2]
3	:	O	['N']	[3]
4	Standard	O	['N']	[4]
5	anti	O	['N']	[5]
6	-	O	['N']	[6]
7	tuberculosis	O	['N']	[7]
8	therapy	O	['N']	[8]
9	was	O	['N']	[9]
10	administered	O	['N']	[10]
11	but	O	['N']	[11]
12	was	O	['N']	[12]
13	complicated	O	['N']	[13]
14	by	O	['N']	[14]
15	interaction	O	['N']	[15]
16	with	O	['N']	[16]
17	cyclosporine	B-Drug	['Causes']	[22]
18	and	O	['N']	[18]
19	drug	O	['N']	[19]
20	-	O	['N']	[20]
21	induced	O	['N']	[21]
22	cholestasis	B-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#1764
0	ARA	B	['N']	[0]
1	-	I	['N']	[1]
2	C	I-Drug	['Causes']	[8]
3	is	O	['N']	[3]
4	frequently	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	dermatologic	B	['N']	[7]
8	toxicity	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	but	O	['N']	[10]
11	this	O	['N']	[11]
12	is	O	['N']	[12]
13	only	O	['N']	[13]
14	the	O	['N']	[14]
15	second	O	['N']	[15]
16	case	O	['N']	[16]
17	of	O	['N']	[17]
18	toxic	O	['N']	[18]
19	epidermal	O	['N']	[19]
20	necrolysis	O	['N']	[20]
21	described	O	['N']	[21]
22	in	O	['N']	[22]
23	connection	O	['N']	[23]
24	with	O	['N']	[24]
25	this	O	['N']	[25]
26	drug	O	['N']	[26]
27	.	O	['N']	[27]
#1765
0	An	O	['N']	[0]
1	objective	O	['N']	[1]
2	causality	O	['N']	[2]
3	assessment	O	['N']	[3]
4	by	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	Naranjo	O	['N']	[8]
9	probability	O	['N']	[9]
10	scale	O	['N']	[10]
11	revealed	O	['N']	[11]
12	that	O	['N']	[12]
13	NCSE	B-Adverse_Effect	['N']	[13]
14	due	O	['N']	[14]
15	to	O	['N']	[15]
16	ifosfamide	B-Drug	['Causes']	[13]
17	was	O	['N']	[17]
18	probable	O	['N']	[18]
19	.	O	['N']	[19]
#1766
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	subacute	O	['N']	[6]
7	methanol	B-Drug	['Causes']	[21]
8	toxicity	O	['N']	[8]
9	with	O	['N']	[9]
10	associated	O	['N']	[10]
11	diffuse	O	['N']	[11]
12	brain	O	['N']	[12]
13	involvement	O	['N']	[13]
14	,	O	['N']	[14]
15	including	O	['N']	[15]
16	bilateral	O	['N']	[16]
17	putaminal	O	['N']	[17]
18	necrosis	O	['N']	[18]
19	and	O	['N']	[19]
20	cerebral	B	['N']	[20]
21	edema	I-Adverse_Effect	['N']	[21]
22	with	O	['N']	[22]
23	ventricular	O	['N']	[23]
24	compression	O	['N']	[24]
25	.	O	['N']	[25]
#1767
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	these	O	['N']	[4]
5	cases	O	['N']	[5]
6	are	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	published	O	['N']	[9]
10	reports	O	['N']	[10]
11	of	O	['N']	[11]
12	lovastatin	O	['N']	[12]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	rhabdomyolysis	B-Adverse_Effect	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	azithromycin	B-Drug	['Causes']	[15]
19	and	O	['N']	[19]
20	clarithromycin	O	['N']	[20]
21	.	O	['N']	[21]
#1768
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	he	O	['N']	[2]
3	developed	O	['N']	[3]
4	acute	O	['N']	[4]
5	renal	O	['N']	[5]
6	failure	O	['N']	[6]
7	,	O	['N']	[7]
8	hyperkalemia	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	hyperuricemia	B-Adverse_Effect	['N']	[11]
12	30	O	['N']	[12]
13	d	O	['N']	[13]
14	after	O	['N']	[14]
15	receiving	O	['N']	[15]
16	the	O	['N']	[16]
17	sorafenib	B-Drug	['Causes']	[11]
18	treatment	O	['N']	[18]
19	.	O	['N']	[19]
#1769
0	After	O	['N']	[0]
1	three	O	['N']	[1]
2	weeks	O	['N']	[2]
3	of	O	['N']	[3]
4	carbamazepine	B-Drug	['Causes']	[22]
5	therapy	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	arrived	O	['N']	[9]
10	at	O	['N']	[10]
11	the	O	['N']	[11]
12	emergency	O	['N']	[12]
13	department	O	['N']	[13]
14	(	O	['N']	[14]
15	ED	O	['N']	[15]
16	)	O	['N']	[16]
17	with	O	['N']	[17]
18	severe	O	['N']	[18]
19	agitation	O	['N']	[19]
20	and	O	['N']	[20]
21	aggressive	B	['N']	[21]
22	behavior	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#1770
0	The	O	['N']	[0]
1	pharmaceutical	O	['N']	[1]
2	company	O	['N']	[2]
3	producing	O	['N']	[3]
4	Halfan	O	['N']	[4]
5	has	O	['N']	[5]
6	reported	O	['N']	[6]
7	8	O	['N']	[7]
8	cardiac	O	['N']	[8]
9	arrests	O	['N']	[9]
10	,	O	['N']	[10]
11	leading	O	['N']	[11]
12	to	O	['N']	[12]
13	6	O	['N']	[13]
14	deaths	O	['N']	[14]
15	,	O	['N']	[15]
16	when	O	['N']	[16]
17	a	O	['N']	[17]
18	higher	B-Dose	['N']	[18]
19	dose	O	['N']	[19]
20	than	O	['N']	[20]
21	recommended	O	['N']	[21]
22	was	O	['N']	[22]
23	used	O	['N']	[23]
24	,	O	['N']	[24]
25	there	O	['N']	[25]
26	was	O	['N']	[26]
27	recent	O	['N']	[27]
28	or	O	['N']	[28]
29	concomitant	O	['N']	[29]
30	treatment	O	['N']	[30]
31	with	O	['N']	[31]
32	mefloquine	B-Drug	['Dosage']	[18]
33	,	O	['N']	[33]
34	there	O	['N']	[34]
35	was	O	['N']	[35]
36	pre	O	['N']	[36]
37	-	O	['N']	[37]
38	existing	O	['N']	[38]
39	prolongation	O	['N']	[39]
40	of	O	['N']	[40]
41	the	O	['N']	[41]
42	QT	O	['N']	[42]
43	interval	O	['N']	[43]
44	or	O	['N']	[44]
45	the	O	['N']	[45]
46	patient	O	['N']	[46]
47	had	O	['N']	[47]
48	a	O	['N']	[48]
49	thiamine	O	['N']	[49]
50	deficiency	O	['N']	[50]
51	.	O	['N']	[51]
#1771
0	Rapid	O	['N']	[0]
1	onset	O	['N']	[1]
2	of	O	['N']	[2]
3	muscle	B	['N']	[3]
4	weakness	I-Adverse_Effect	['N']	[4]
5	(	O	['N']	[5]
6	rhabdomyolysis	O	['N']	[6]
7	)	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	combined	O	['N']	[11]
12	use	O	['N']	[12]
13	of	O	['N']	[13]
14	simvastatin	O	['N']	[14]
15	and	O	['N']	[15]
16	colchicine	B-Drug	['Causes']	[4]
17	.	O	['N']	[17]
#1772
0	After	O	['N']	[0]
1	identification	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	index	O	['N']	[4]
5	patient	O	['N']	[5]
6	,	O	['N']	[6]
7	additional	O	['N']	[7]
8	inquiry	O	['N']	[8]
9	revealed	O	['N']	[9]
10	that	O	['N']	[10]
11	the	O	['N']	[11]
12	patient	O	['N']	[12]
13	's	O	['N']	[13]
14	mother	O	['N']	[14]
15	was	O	['N']	[15]
16	hospitalized	O	['N']	[16]
17	previously	O	['N']	[17]
18	for	O	['N']	[18]
19	overwhelming	O	['N']	[19]
20	sepsis	B-Adverse_Effect	['N']	[20]
21	associated	O	['N']	[21]
22	with	O	['N']	[22]
23	metamizole	B-Drug	['Causes']	[20]
24	use	O	['N']	[24]
25	.	O	['N']	[25]
#1773
0	Aseptic	O	['N']	[0]
1	meningitis	O	['N']	[1]
2	,	O	['N']	[2]
3	hemolytic	B	['N']	[3]
4	anemia	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	orthostatic	O	['N']	[9]
10	hypotension	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	trimethoprim	O	['N']	[16]
17	-	O	['N']	[17]
18	sulfamethoxazole	B-Drug	['Causes']	[4]
19	.	O	['N']	[19]
#1774
0	Does	O	['N']	[0]
1	acyclovir	B-Drug	['Causes']	[5]
2	increase	B	['N']	[2]
3	serum	I	['N']	[3]
4	lithium	I	['N']	[4]
5	levels	I-Adverse_Effect	['N']	[5]
6	?	O	['N']	[6]
#1775
0	Previous	O	['N']	[0]
1	studies	O	['N']	[1]
2	have	O	['N']	[2]
3	demonstrated	O	['N']	[3]
4	the	O	['N']	[4]
5	interaction	O	['N']	[5]
6	of	O	['N']	[6]
7	MTX	B-Drug	['Causes']	[48]
8	and	O	['N']	[8]
9	a	O	['N']	[9]
10	variety	O	['N']	[10]
11	of	O	['N']	[11]
12	non	O	['N']	[12]
13	-	O	['N']	[13]
14	steroidal	O	['N']	[14]
15	,	O	['N']	[15]
16	anti	O	['N']	[16]
17	-	O	['N']	[17]
18	inflammatory	O	['N']	[18]
19	drugs	O	['N']	[19]
20	(	O	['N']	[20]
21	NSAIDs	O	['N']	[21]
22	)	O	['N']	[22]
23	with	O	['N']	[23]
24	various	O	['N']	[24]
25	clinical	O	['N']	[25]
26	manifestations	O	['N']	[26]
27	including	O	['N']	[27]
28	acute	O	['N']	[28]
29	renal	O	['N']	[29]
30	failure	O	['N']	[30]
31	,	O	['N']	[31]
32	pancytopenia	O	['N']	[32]
33	,	O	['N']	[33]
34	vomiting	O	['N']	[34]
35	,	O	['N']	[35]
36	diarrhea	O	['N']	[36]
37	,	O	['N']	[37]
38	elevated	O	['N']	[38]
39	liver	O	['N']	[39]
40	transaminases	O	['N']	[40]
41	,	O	['N']	[41]
42	jaundice	O	['N']	[42]
43	,	O	['N']	[43]
44	mucosal	O	['N']	[44]
45	ulcerations	O	['N']	[45]
46	,	O	['N']	[46]
47	and	O	['N']	[47]
48	pyrexia	B-Adverse_Effect	['N']	[48]
49	.	O	['N']	[49]
#1776
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Evidence	O	['N']	[2]
3	of	O	['N']	[3]
4	neurological	O	['N']	[4]
5	improvement	O	['N']	[5]
6	and	O	['N']	[6]
7	rehabilitation	O	['N']	[7]
8	potential	O	['N']	[8]
9	after	O	['N']	[9]
10	severe	B	['N']	[10]
11	myelopathy	I-Adverse_Effect	['N']	[11]
12	due	O	['N']	[12]
13	to	O	['N']	[13]
14	intrathecal	O	['N']	[14]
15	injection	O	['N']	[15]
16	of	O	['N']	[16]
17	doxorubicin	B-Drug	['Causes']	[11]
18	.	O	['N']	[18]
#1777
0	A	O	['N']	[0]
1	55-yr	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	prolonged	O	['N']	[6]
7	jaundice	O	['N']	[7]
8	and	O	['N']	[8]
9	sicca	B	['N']	[9]
10	complex	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	a	O	['N']	[12]
13	course	O	['N']	[13]
14	of	O	['N']	[14]
15	thiabendazole	B-Drug	['Causes']	[10]
16	therapy	O	['N']	[16]
17	.	O	['N']	[17]
#1778
0	Thoracoscopic	O	['N']	[0]
1	biopsy	O	['N']	[1]
2	to	O	['N']	[2]
3	confirm	O	['N']	[3]
4	metastasis	O	['N']	[4]
5	revealed	O	['N']	[5]
6	instead	O	['N']	[6]
7	fibrotic	B	['N']	[7]
8	lesions	I-Adverse_Effect	['N']	[8]
9	apparently	O	['N']	[9]
10	attributable	O	['N']	[10]
11	to	O	['N']	[11]
12	bleomycin	B-Drug	['Causes']	[8]
13	or	O	['N']	[13]
14	cyclophosphamide	O	['N']	[14]
15	.	O	['N']	[15]
#1779
0	The	O	['N']	[0]
1	latter	O	['N']	[1]
2	form	O	['N']	[2]
3	(	O	['N']	[3]
4	Macrodantin	B-Drug	['Causes']	[27]
5	)	O	['N']	[5]
6	is	O	['N']	[6]
7	reported	O	['N']	[7]
8	to	O	['N']	[8]
9	engender	O	['N']	[9]
10	less	O	['N']	[10]
11	gastrointestinal	O	['N']	[11]
12	intolerance	O	['N']	[12]
13	but	O	['N']	[13]
14	it	O	['N']	[14]
15	can	O	['N']	[15]
16	produce	O	['N']	[16]
17	the	O	['N']	[17]
18	same	O	['N']	[18]
19	adverse	O	['N']	[19]
20	effects	O	['N']	[20]
21	as	O	['N']	[21]
22	the	O	['N']	[22]
23	conventional	O	['N']	[23]
24	form	O	['N']	[24]
25	--	O	['N']	[25]
26	liver	B	['N']	[26]
27	damage	I-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	acute	O	['N']	[29]
30	and	O	['N']	[30]
31	chronic	O	['N']	[31]
32	pulmonary	O	['N']	[32]
33	reactions	O	['N']	[33]
34	,	O	['N']	[34]
35	peripheral	O	['N']	[35]
36	neuropathy	O	['N']	[36]
37	,	O	['N']	[37]
38	blood	O	['N']	[38]
39	dyscrasias	O	['N']	[39]
40	and	O	['N']	[40]
41	allergic	O	['N']	[41]
42	reactions	O	['N']	[42]
43	--	O	['N']	[43]
44	and	O	['N']	[44]
45	does	O	['N']	[45]
46	so	O	['N']	[46]
47	just	O	['N']	[47]
48	as	O	['N']	[48]
49	rapidly	O	['N']	[49]
50	and	O	['N']	[50]
51	floridly	O	['N']	[51]
52	;	O	['N']	[52]
53	one	O	['N']	[53]
54	such	O	['N']	[54]
55	case	O	['N']	[55]
56	is	O	['N']	[56]
57	reported	O	['N']	[57]
58	here	O	['N']	[58]
59	.	O	['N']	[59]
#1780
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	lung	O	['N']	[6]
7	cancer	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	bronquiloalveolar	O	['N']	[10]
11	carcinoma	O	['N']	[11]
12	(	O	['N']	[12]
13	BAC	O	['N']	[13]
14	)	O	['N']	[14]
15	presenting	O	['N']	[15]
16	with	O	['N']	[16]
17	BOOP	O	['N']	[17]
18	after	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	with	O	['N']	[20]
21	docetaxel	O	['N']	[21]
22	and	O	['N']	[22]
23	gemcitabine	B-Drug	['Causes']	[35]
24	producing	O	['N']	[24]
25	severe	O	['N']	[25]
26	respiratory	O	['N']	[26]
27	insufficiency	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	simulating	O	['N']	[30]
31	a	O	['N']	[31]
32	progression	B	['N']	[32]
33	of	I	['N']	[33]
34	the	I	['N']	[34]
35	tumor	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#1781
0	Paroxysmal	B	['N']	[0]
1	supraventricular	I	['N']	[1]
2	tachycardia	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	cisplatin	O	['N']	[6]
7	and	O	['N']	[7]
8	etoposide	B-Drug	['Causes']	[2]
9	combination	O	['N']	[9]
10	.	O	['N']	[10]
#1782
0	Pravastatin	B-Drug	['Causes']	[4]
1	is	O	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	myotonia	B-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	animals	O	['N']	[6]
7	.	O	['N']	[7]
#1783
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	43-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	man	O	['N']	[9]
10	with	O	['N']	[10]
11	ITP	O	['N']	[11]
12	refractory	O	['N']	[12]
13	to	O	['N']	[13]
14	steroids	O	['N']	[14]
15	and	O	['N']	[15]
16	intravenous	O	['N']	[16]
17	immunoglobulin	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	acute	O	['N']	[20]
21	respiratory	O	['N']	[21]
22	distress	O	['N']	[22]
23	syndrome	O	['N']	[23]
24	(	O	['N']	[24]
25	ARDS	B-Adverse_Effect	['N']	[25]
26	)	O	['N']	[26]
27	after	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	infusion	O	['N']	[30]
31	of	O	['N']	[31]
32	rituximab	B-Drug	['Causes']	[25]
33	.	O	['N']	[33]
#1784
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	relatively	O	['N']	[3]
4	healthy	O	['N']	[4]
5	,	O	['N']	[5]
6	9-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	boy	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	a	O	['N']	[12]
13	CA	O	['N']	[13]
14	-	O	['N']	[14]
15	MRSA	O	['N']	[15]
16	skin	O	['N']	[16]
17	and	O	['N']	[17]
18	soft	B	['N']	[18]
19	tissue	I	['N']	[19]
20	infection	I-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	was	O	['N']	[22]
23	treated	O	['N']	[23]
24	with	O	['N']	[24]
25	TMP	B	['N']	[25]
26	-	I	['N']	[26]
27	SMX	I-Drug	['Causes']	[20]
28	.	O	['N']	[28]
#1785
0	Esophageal	O	['N']	[0]
1	spasm	O	['N']	[1]
2	following	O	['N']	[2]
3	propranolol	B-Drug	['Dosage']	[4]
4	overdose	B-Dose	['N']	[4]
5	relieved	O	['N']	[5]
6	by	O	['N']	[6]
7	glucagon	O	['N']	[7]
8	.	O	['N']	[8]
#1786
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	AILD	O	['N']	[5]
6	in	O	['N']	[6]
7	an	O	['N']	[7]
8	80-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	male	O	['N']	[11]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	a	O	['N']	[15]
16	generalized	O	['N']	[16]
17	pruritic	O	['N']	[17]
18	maculopapular	O	['N']	[18]
19	eruption	O	['N']	[19]
20	and	O	['N']	[20]
21	fever	B-Adverse_Effect	['N']	[21]
22	following	O	['N']	[22]
23	doxycycline	B-Drug	['Causes']	[21]
24	administration	O	['N']	[24]
25	.	O	['N']	[25]
#1787
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	14-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	with	O	['N']	[10]
11	acute	O	['N']	[11]
12	promyelocytic	O	['N']	[12]
13	leukemia	O	['N']	[13]
14	who	O	['N']	[14]
15	developed	O	['N']	[15]
16	symptomatic	B	['N']	[16]
17	cardiomyopathy	I-Adverse_Effect	['N']	[17]
18	only	O	['N']	[18]
19	4	O	['N']	[19]
20	months	O	['N']	[20]
21	into	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	a	O	['N']	[24]
25	combination	O	['N']	[25]
26	of	O	['N']	[26]
27	daunomycin	O	['N']	[27]
28	and	O	['N']	[28]
29	all	B	['N']	[29]
30	-	I	['N']	[30]
31	trans	I	['N']	[31]
32	retinoic	I	['N']	[32]
33	acid	I-Drug	['Causes']	[17]
34	(	O	['N']	[34]
35	ATRA	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#1788
0	Our	O	['N']	[0]
1	case	O	['N']	[1]
2	points	O	['N']	[2]
3	to	O	['N']	[3]
4	the	O	['N']	[4]
5	need	O	['N']	[5]
6	for	O	['N']	[6]
7	increased	O	['N']	[7]
8	awareness	O	['N']	[8]
9	by	O	['N']	[9]
10	the	O	['N']	[10]
11	general	O	['N']	[11]
12	pediatricians	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	potential	B	['N']	[15]
16	hazards	I-Adverse_Effect	['N']	[16]
17	of	O	['N']	[17]
18	mineral	B	['N']	[18]
19	oil	I-Drug	['Causes']	[16]
20	use	O	['N']	[20]
21	for	O	['N']	[21]
22	chronic	O	['N']	[22]
23	constipation	O	['N']	[23]
24	.	O	['N']	[24]
#1789
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	B	['N']	[32]
33	gait	I-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[33]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#1790
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	trimethoprim	B-Drug	['Causes']	[20]
5	-	O	['N']	[5]
6	sulfamethoxazole	O	['N']	[6]
7	for	O	['N']	[7]
8	approximately	O	['N']	[8]
9	eight	O	['N']	[9]
10	days	O	['N']	[10]
11	when	O	['N']	[11]
12	he	O	['N']	[12]
13	revisited	O	['N']	[13]
14	his	O	['N']	[14]
15	family	O	['N']	[15]
16	physician	O	['N']	[16]
17	,	O	['N']	[17]
18	complaining	O	['N']	[18]
19	of	O	['N']	[19]
20	headaches	B-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	dizziness	O	['N']	[22]
23	,	O	['N']	[23]
24	difficulty	O	['N']	[24]
25	with	O	['N']	[25]
26	speech	O	['N']	[26]
27	,	O	['N']	[27]
28	weakness	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	itching	O	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	trunk	O	['N']	[34]
35	of	O	['N']	[35]
36	his	O	['N']	[36]
37	body	O	['N']	[37]
38	and	O	['N']	[38]
39	legs	O	['N']	[39]
40	,	O	['N']	[40]
41	where	O	['N']	[41]
42	a	O	['N']	[42]
43	maculopapular	O	['N']	[43]
44	rash	O	['N']	[44]
45	was	O	['N']	[45]
46	noted	O	['N']	[46]
47	.	O	['N']	[47]
#1791
0	Fever	O	['N']	[0]
1	,	O	['N']	[1]
2	lymphadenopathy	O	['N']	[2]
3	,	O	['N']	[3]
4	eosinophilia	O	['N']	[4]
5	,	O	['N']	[5]
6	lymphocytosis	O	['N']	[6]
7	,	O	['N']	[7]
8	hepatitis	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	dermatitis	B-Adverse_Effect	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	severe	O	['N']	[14]
15	adverse	O	['N']	[15]
16	reaction	O	['N']	[16]
17	to	O	['N']	[17]
18	minocycline	B-Drug	['Causes']	[11]
19	.	O	['N']	[19]
#1792
0	After	O	['N']	[0]
1	the	O	['N']	[1]
2	dose	O	['N']	[2]
3	of	O	['N']	[3]
4	methylprednisolone	B-Drug	['Causes']	[34]
5	was	O	['N']	[5]
6	reduced	O	['N']	[6]
7	from	O	['N']	[7]
8	40	O	['N']	[8]
9	mg	O	['N']	[9]
10	to	O	['N']	[10]
11	20	O	['N']	[11]
12	mg	O	['N']	[12]
13	i.v	O	['N']	[13]
14	.	O	['N']	[14]
15	q6h	O	['N']	[15]
16	and	O	['N']	[16]
17	shifted	O	['N']	[17]
18	to	O	['N']	[18]
19	other	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	asthma	O	['N']	[22]
23	treatment	O	['N']	[23]
24	by	O	['N']	[24]
25	procaterol	O	['N']	[25]
26	metered	O	['N']	[26]
27	dose	O	['N']	[27]
28	inhaler	O	['N']	[28]
29	via	O	['N']	[29]
30	spacer	O	['N']	[30]
31	,	O	['N']	[31]
32	the	O	['N']	[32]
33	psychotic	B	['N']	[33]
34	reaction	I-Adverse_Effect	['N']	[34]
35	disappeared	O	['N']	[35]
36	a	O	['N']	[36]
37	few	O	['N']	[37]
38	hours	O	['N']	[38]
39	later	O	['N']	[39]
40	.	O	['N']	[40]
#1793
0	An	O	['N']	[0]
1	apparent	O	['N']	[1]
2	link	O	['N']	[2]
3	is	O	['N']	[3]
4	described	O	['N']	[4]
5	between	O	['N']	[5]
6	the	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	MMF	B-Drug	['Causes']	[23]
10	with	O	['N']	[10]
11	prednisone	O	['N']	[11]
12	to	O	['N']	[12]
13	treat	O	['N']	[13]
14	pemphigus	O	['N']	[14]
15	vulgaris	O	['N']	[15]
16	and	O	['N']	[16]
17	the	O	['N']	[17]
18	development	O	['N']	[18]
19	of	O	['N']	[19]
20	red	B	['N']	[20]
21	blood	I	['N']	[21]
22	cell	I	['N']	[22]
23	anemia	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#1794
0	Four	O	['N']	[0]
1	years	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	beginning	O	['N']	[4]
5	of	O	['N']	[5]
6	IFN	B-Drug	['Causes']	[13]
7	therapy	O	['N']	[7]
8	,	O	['N']	[8]
9	he	O	['N']	[9]
10	acutely	O	['N']	[10]
11	developed	O	['N']	[11]
12	moderate	B	['N']	[12]
13	hyperglycemia	I-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	severe	O	['N']	[15]
16	ketonuria	O	['N']	[16]
17	with	O	['N']	[17]
18	positive	O	['N']	[18]
19	islet	O	['N']	[19]
20	cell	O	['N']	[20]
21	antibody	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	then	O	['N']	[24]
25	28	O	['N']	[25]
26	units	O	['N']	[26]
27	/	O	['N']	[27]
28	day	O	['N']	[28]
29	of	O	['N']	[29]
30	insulin	O	['N']	[30]
31	injection	O	['N']	[31]
32	was	O	['N']	[32]
33	started	O	['N']	[33]
34	.	O	['N']	[34]
#1795
0	Although	O	['N']	[0]
1	its	O	['N']	[1]
2	side	O	['N']	[2]
3	effects	O	['N']	[3]
4	are	O	['N']	[4]
5	few	O	['N']	[5]
6	,	O	['N']	[6]
7	tamoxifen	B-Drug	['Causes']	[16]
8	increases	O	['N']	[8]
9	the	O	['N']	[9]
10	incidence	O	['N']	[10]
11	of	O	['N']	[11]
12	proliferative	B	['N']	[12]
13	lesions	I	['N']	[13]
14	of	I	['N']	[14]
15	the	I	['N']	[15]
16	endometrium	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	which	O	['N']	[18]
19	theoretically	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	preventable	O	['N']	[22]
23	with	O	['N']	[23]
24	progestational	O	['N']	[24]
25	agents	O	['N']	[25]
26	.	O	['N']	[26]
#1796
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	2	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	maculopapular	O	['N']	[5]
6	eruption	O	['N']	[6]
7	and	O	['N']	[7]
8	fever	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	infected	O	['N']	[11]
12	with	O	['N']	[12]
13	human	O	['N']	[13]
14	immunodeficiency	O	['N']	[14]
15	virus	O	['N']	[15]
16	(	O	['N']	[16]
17	HIV	O	['N']	[17]
18	)	O	['N']	[18]
19	on	O	['N']	[19]
20	the	O	['N']	[20]
21	2nd	O	['N']	[21]
22	day	O	['N']	[22]
23	of	O	['N']	[23]
24	first	O	['N']	[24]
25	administration	O	['N']	[25]
26	of	O	['N']	[26]
27	ritonavir	B-Drug	['Causes']	[8]
28	,	O	['N']	[28]
29	a	O	['N']	[29]
30	protease	O	['N']	[30]
31	inhibitor	O	['N']	[31]
32	.	O	['N']	[32]
#1797
0	CASE	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	present	O	['N']	[3]
4	an	O	['N']	[4]
5	11-year	O	['N']	[5]
6	old	O	['N']	[6]
7	male	O	['N']	[7]
8	with	O	['N']	[8]
9	Budd	O	['N']	[9]
10	-	O	['N']	[10]
11	Chiari	O	['N']	[11]
12	syndrome	O	['N']	[12]
13	who	O	['N']	[13]
14	experienced	O	['N']	[14]
15	profound	O	['N']	[15]
16	worsening	B	['N']	[16]
17	of	I	['N']	[17]
18	chronic	I	['N']	[18]
19	aphthous	I	['N']	[19]
20	ulcers	I-Adverse_Effect	['N']	[20]
21	after	O	['N']	[21]
22	immunosuppressive	O	['N']	[22]
23	therapy	O	['N']	[23]
24	was	O	['N']	[24]
25	changed	O	['N']	[25]
26	from	O	['N']	[26]
27	tacrolimus	B-Drug	['Causes']	[20]
28	to	O	['N']	[28]
29	sirolimus	O	['N']	[29]
30	.	O	['N']	[30]
#1798
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	56-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	female	O	['N']	[7]
8	who	O	['N']	[8]
9	exhibited	O	['N']	[9]
10	drug	O	['N']	[10]
11	refractory	O	['N']	[11]
12	paroxysmal	O	['N']	[12]
13	atrial	O	['N']	[13]
14	fibrillation	O	['N']	[14]
15	,	O	['N']	[15]
16	in	O	['N']	[16]
17	which	O	['N']	[17]
18	marked	O	['N']	[18]
19	prolongation	B	['N']	[19]
20	of	I	['N']	[20]
21	the	I	['N']	[21]
22	QT	I	['N']	[22]
23	interval	I-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	T	O	['N']	[25]
26	wave	O	['N']	[26]
27	inversion	O	['N']	[27]
28	on	O	['N']	[28]
29	electrocardiogram	O	['N']	[29]
30	was	O	['N']	[30]
31	demonstrated	O	['N']	[31]
32	reproducibly	O	['N']	[32]
33	shortly	O	['N']	[33]
34	after	O	['N']	[34]
35	the	O	['N']	[35]
36	administration	O	['N']	[36]
37	of	O	['N']	[37]
38	oral	O	['N']	[38]
39	pirmenol	B-Drug	['Causes']	[23]
40	therapy	O	['N']	[40]
41	.	O	['N']	[41]
#1799
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	value	O	['N']	[3]
4	of	O	['N']	[4]
5	multihormonal	O	['N']	[5]
6	therapy	O	['N']	[6]
7	in	O	['N']	[7]
8	breast	O	['N']	[8]
9	carcinoma	B-Adverse_Effect	['N']	[9]
10	is	O	['N']	[10]
11	not	O	['N']	[11]
12	established	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	the	O	['N']	[15]
16	addition	O	['N']	[16]
17	of	O	['N']	[17]
18	progestogens	O	['N']	[18]
19	to	O	['N']	[19]
20	tamoxifen	B-Drug	['Causes']	[9]
21	may	O	['N']	[21]
22	not	O	['N']	[22]
23	reduce	O	['N']	[23]
24	of	O	['N']	[24]
25	developing	O	['N']	[25]
26	endometrial	O	['N']	[26]
27	lesions	O	['N']	[27]
28	,	O	['N']	[28]
29	including	O	['N']	[29]
30	carcinoma	O	['N']	[30]
31	.	O	['N']	[31]
#1800
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	traumatic	B	['N']	[7]
8	flap	I	['N']	[8]
9	dehiscence	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	Enterobacter	O	['N']	[11]
12	keratitis	O	['N']	[12]
13	34	O	['N']	[13]
14	months	O	['N']	[14]
15	after	O	['N']	[15]
16	LASIK	B-Drug	['Causes']	[9]
17	.	O	['N']	[17]
#1801
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	main	O	['N']	[3]
4	adverse	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	leflunomide	B-Drug	['Causes']	[12]
8	consist	O	['N']	[8]
9	of	O	['N']	[9]
10	diarrhea	O	['N']	[10]
11	,	O	['N']	[11]
12	nausea	B-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	liver	O	['N']	[14]
15	enzyme	O	['N']	[15]
16	elevation	O	['N']	[16]
17	,	O	['N']	[17]
18	hypertension	O	['N']	[18]
19	,	O	['N']	[19]
20	alopecia	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	allergic	O	['N']	[23]
24	skin	O	['N']	[24]
25	reactions	O	['N']	[25]
26	.	O	['N']	[26]
#1802
0	We	O	['N']	[0]
1	observed	O	['N']	[1]
2	2	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	hepatotoxicity	B-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	a	O	['N']	[7]
8	high	O	['N']	[8]
9	-	O	['N']	[9]
10	dose	O	['N']	[10]
11	methylprednisolone	B-Drug	['Causes']	[5]
12	treatment	O	['N']	[12]
13	of	O	['N']	[13]
14	a	O	['N']	[14]
15	demyelinating	O	['N']	[15]
16	disease	O	['N']	[16]
17	and	O	['N']	[17]
18	evaluated	O	['N']	[18]
19	the	O	['N']	[19]
20	potential	O	['N']	[20]
21	relationship	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	light	O	['N']	[24]
25	of	O	['N']	[25]
26	available	O	['N']	[26]
27	evidence	O	['N']	[27]
28	.	O	['N']	[28]
#1803
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	45-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	Chinese	O	['N']	[6]
7	man	O	['N']	[7]
8	with	O	['N']	[8]
9	CML	O	['N']	[9]
10	and	O	['N']	[10]
11	chronic	O	['N']	[11]
12	hepatitis	O	['N']	[12]
13	B	O	['N']	[13]
14	virus	O	['N']	[14]
15	infection	O	['N']	[15]
16	,	O	['N']	[16]
17	on	O	['N']	[17]
18	imatinib	B-Drug	['Causes']	[28]
19	treatment	O	['N']	[19]
20	,	O	['N']	[20]
21	presenting	O	['N']	[21]
22	with	O	['N']	[22]
23	herpetic	O	['N']	[23]
24	rash	O	['N']	[24]
25	and	O	['N']	[25]
26	acute	B	['N']	[26]
27	liver	I	['N']	[27]
28	failure	I-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#1804
0	Linezolid	B-Drug	['Causes']	[13]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	acute	O	['N']	[3]
4	interstitial	O	['N']	[4]
5	nephritis	O	['N']	[5]
6	and	O	['N']	[6]
7	drug	B	['N']	[7]
8	rash	I	['N']	[8]
9	with	I	['N']	[9]
10	eosinophilia	I	['N']	[10]
11	and	I	['N']	[11]
12	systemic	I	['N']	[12]
13	symptoms	I-Adverse_Effect	['N']	[13]
14	(	O	['N']	[14]
15	DRESS	O	['N']	[15]
16	)	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	.	O	['N']	[18]
#1805
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	fifth	O	['N']	[2]
3	day	O	['N']	[3]
4	after	O	['N']	[4]
5	administration	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	high	B-Dose	['N']	[8]
9	dose	O	['N']	[9]
10	of	O	['N']	[10]
11	ARA	B	['N']	[11]
12	-	I	['N']	[12]
13	C	I-Drug	['Dosage']	[8]
14	(	O	['N']	[14]
15	2	O	['N']	[15]
16	g	O	['N']	[16]
17	/	O	['N']	[17]
18	m2	O	['N']	[18]
19	intravenously	O	['N']	[19]
20	every	O	['N']	[20]
21	12	O	['N']	[21]
22	hours	O	['N']	[22]
23	)	O	['N']	[23]
24	,	O	['N']	[24]
25	she	O	['N']	[25]
26	developed	O	['N']	[26]
27	bullous	O	['N']	[27]
28	lesions	O	['N']	[28]
29	on	O	['N']	[29]
30	the	O	['N']	[30]
31	hands	O	['N']	[31]
32	and	O	['N']	[32]
33	soles	O	['N']	[33]
34	that	O	['N']	[34]
35	disseminated	O	['N']	[35]
36	,	O	['N']	[36]
37	evolving	O	['N']	[37]
38	to	O	['N']	[38]
39	necrosis	O	['N']	[39]
40	,	O	['N']	[40]
41	sepsis	O	['N']	[41]
42	,	O	['N']	[42]
43	and	O	['N']	[43]
44	death	O	['N']	[44]
45	on	O	['N']	[45]
46	the	O	['N']	[46]
47	22nd	O	['N']	[47]
48	day	O	['N']	[48]
49	.	O	['N']	[49]
#1806
0	Pulmonary	B	['N']	[0]
1	gold	B-Drug	['Causes']	[2]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	.	O	['N']	[3]
#1807
0	Albuterol	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hypokalemia	B-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	its	O	['N']	[5]
6	potential	O	['N']	[6]
7	cardiac	O	['N']	[7]
8	toxicity	O	['N']	[8]
9	are	O	['N']	[9]
10	discussed	O	['N']	[10]
11	briefly	O	['N']	[11]
12	.	O	['N']	[12]
#1808
0	The	O	['N']	[0]
1	most	O	['N']	[1]
2	commonly	O	['N']	[2]
3	recognized	O	['N']	[3]
4	toxic	O	['N']	[4]
5	effect	O	['N']	[5]
6	of	O	['N']	[6]
7	ethambutol	B-Drug	['Causes']	[10]
8	is	O	['N']	[8]
9	optic	B	['N']	[9]
10	neuropathy	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	generally	O	['N']	[13]
14	is	O	['N']	[14]
15	considered	O	['N']	[15]
16	uncommon	O	['N']	[16]
17	and	O	['N']	[17]
18	reversible	O	['N']	[18]
19	in	O	['N']	[19]
20	medical	O	['N']	[20]
21	literature	O	['N']	[21]
22	.	O	['N']	[22]
#1809
0	A	O	['N']	[0]
1	combination	O	['N']	[1]
2	of	O	['N']	[2]
3	behavioural	O	['N']	[3]
4	and	O	['N']	[4]
5	cognitive	O	['N']	[5]
6	adverse	O	['N']	[6]
7	effects	O	['N']	[7]
8	is	O	['N']	[8]
9	illustrated	O	['N']	[9]
10	in	O	['N']	[10]
11	this	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	of	O	['N']	[14]
15	a	O	['N']	[15]
16	recurrent	O	['N']	[16]
17	triazolam	B-Drug	['Causes']	[21]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	eating	B	['N']	[20]
21	disorder	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1810
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	for	O	['N']	[2]
3	diabetic	O	['N']	[3]
4	coma	O	['N']	[4]
5	with	O	['N']	[5]
6	insulin	B-Drug	['Causes']	[37]
7	(	O	['N']	[7]
8	containing	O	['N']	[8]
9	the	O	['N']	[9]
10	preservative	O	['N']	[10]
11	cresol	O	['N']	[11]
12	)	O	['N']	[12]
13	and	O	['N']	[13]
14	electrolyte	O	['N']	[14]
15	solutions	O	['N']	[15]
16	was	O	['N']	[16]
17	started	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	complained	O	['N']	[21]
22	of	O	['N']	[22]
23	increasing	O	['N']	[23]
24	myalgia	O	['N']	[24]
25	,	O	['N']	[25]
26	developed	O	['N']	[26]
27	a	O	['N']	[27]
28	high	O	['N']	[28]
29	fever	O	['N']	[29]
30	and	O	['N']	[30]
31	respiratory	O	['N']	[31]
32	and	O	['N']	[32]
33	metabolic	O	['N']	[33]
34	acidosis	O	['N']	[34]
35	and	O	['N']	[35]
36	lost	B	['N']	[36]
37	consciousness	I-Adverse_Effect	['N']	[37]
38	.	O	['N']	[38]
#1811
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	cholestatic	B	['N']	[3]
4	hepatitis	I-Adverse_Effect	['N']	[4]
5	while	O	['N']	[5]
6	being	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	nitrofurantoin	B-Drug	['Causes']	[4]
10	.	O	['N']	[10]
#1812
0	In	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	swallowing	B	['N']	[3]
4	dysfunction	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	pneumonia	O	['N']	[6]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	mineral	B	['N']	[11]
12	oil	I-Drug	['Causes']	[4]
13	use	O	['N']	[13]
14	should	O	['N']	[14]
15	be	O	['N']	[15]
16	obtained	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	diagnosis	O	['N']	[19]
20	of	O	['N']	[20]
21	ELP	O	['N']	[21]
22	should	O	['N']	[22]
23	be	O	['N']	[23]
24	considered	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	differential	O	['N']	[27]
28	diagnoses	O	['N']	[28]
29	if	O	['N']	[29]
30	mineral	O	['N']	[30]
31	oil	O	['N']	[31]
32	use	O	['N']	[32]
33	has	O	['N']	[33]
34	occurred	O	['N']	[34]
35	.	O	['N']	[35]
#1813
0	The	O	['N']	[0]
1	diagnosis	O	['N']	[1]
2	was	O	['N']	[2]
3	based	O	['N']	[3]
4	on	O	['N']	[4]
5	the	O	['N']	[5]
6	rapid	O	['N']	[6]
7	onset	O	['N']	[7]
8	of	O	['N']	[8]
9	renal	O	['N']	[9]
10	failure	O	['N']	[10]
11	,	O	['N']	[11]
12	presence	O	['N']	[12]
13	of	O	['N']	[13]
14	eosinophilia	O	['N']	[14]
15	,	O	['N']	[15]
16	skin	B	['N']	[16]
17	rash	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	characteristic	O	['N']	[20]
21	renal	O	['N']	[21]
22	biopsy	O	['N']	[22]
23	finding	O	['N']	[23]
24	,	O	['N']	[24]
25	following	O	['N']	[25]
26	the	O	['N']	[26]
27	administration	O	['N']	[27]
28	of	O	['N']	[28]
29	ampicillin	B-Drug	['Causes']	[17]
30	.	O	['N']	[30]
#1814
0	Vocal	B	['N']	[0]
1	cord	I	['N']	[1]
2	paralysis	I-Adverse_Effect	['N']	[2]
3	as	O	['N']	[3]
4	a	O	['N']	[4]
5	consequence	O	['N']	[5]
6	of	O	['N']	[6]
7	peritonsillar	O	['N']	[7]
8	infiltration	O	['N']	[8]
9	with	O	['N']	[9]
10	bupivacaine	B-Drug	['Causes']	[2]
11	.	O	['N']	[11]
#1815
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	present	O	['N']	[2]
3	an	O	['N']	[3]
4	elderly	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	mixed	O	['N']	[7]
8	dementia	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	TD	O	['N']	[11]
12	at	O	['N']	[12]
13	multiple	O	['N']	[13]
14	sites	O	['N']	[14]
15	,	O	['N']	[15]
16	(	O	['N']	[16]
17	including	O	['N']	[17]
18	respiratory	O	['N']	[18]
19	dyskinesia	O	['N']	[19]
20	[	O	['N']	[20]
21	RD	O	['N']	[21]
22	]	O	['N']	[22]
23	,	O	['N']	[23]
24	limb	O	['N']	[24]
25	dyskinesia	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	orofacial	B	['N']	[28]
29	dyskinesia	I-Adverse_Effect	['N']	[29]
30	)	O	['N']	[30]
31	following	O	['N']	[31]
32	abrupt	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	of	O	['N']	[34]
35	risperidone	B-Drug	['Causes']	[29]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#1816
0	A	O	['N']	[0]
1	macrophage	O	['N']	[1]
2	activation	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	,	O	['N']	[4]
5	possibly	O	['N']	[5]
6	related	O	['N']	[6]
7	to	O	['N']	[7]
8	methotrexate	B-Drug	['Causes']	[9]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	developed	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	boy	O	['N']	[14]
15	with	O	['N']	[15]
16	systemic	O	['N']	[16]
17	juvenile	O	['N']	[17]
18	rheumatoid	O	['N']	[18]
19	arthritis	O	['N']	[19]
20	.	O	['N']	[20]
#1817
0	Hypoxia	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	predisposing	O	['N']	[3]
4	factor	O	['N']	[4]
5	for	O	['N']	[5]
6	premature	O	['N']	[6]
7	ductal	O	['N']	[7]
8	closure	O	['N']	[8]
9	and	O	['N']	[9]
10	often	O	['N']	[10]
11	occurs	O	['N']	[11]
12	after	O	['N']	[12]
13	maternal	O	['N']	[13]
14	indomethacin	B-Drug	['Causes']	[0]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#1818
0	Physicians	O	['N']	[0]
1	treating	O	['N']	[1]
2	patients	O	['N']	[2]
3	with	O	['N']	[3]
4	methotrexate	B-Drug	['Causes']	[16]
5	for	O	['N']	[5]
6	juvenile	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	must	O	['N']	[9]
10	be	O	['N']	[10]
11	aware	O	['N']	[11]
12	of	O	['N']	[12]
13	this	O	['N']	[13]
14	extraarticular	B	['N']	[14]
15	side	I	['N']	[15]
16	effect	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#1819
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	patient	O	['N']	[5]
6	had	O	['N']	[6]
7	sulfasalazine	B-Drug	['Causes']	[19]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	lupus	O	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	manifested	O	['N']	[13]
14	with	O	['N']	[14]
15	serositis	O	['N']	[15]
16	and	O	['N']	[16]
17	pulmonary	B	['N']	[17]
18	parenchymal	I	['N']	[18]
19	involvement	I-Adverse_Effect	['N']	[19]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	absence	O	['N']	[22]
23	of	O	['N']	[23]
24	joint	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	.	O	['N']	[26]
#1820
0	Acute	O	['N']	[0]
1	abdomen	O	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	endometriosis	B-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	premenopausal	O	['N']	[7]
8	woman	O	['N']	[8]
9	taking	O	['N']	[9]
10	tamoxifen	B-Drug	['Causes']	[4]
11	.	O	['N']	[11]
#1821
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	O	['N']	[24]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	O	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	O	['N']	[42]
43	-	O	['N']	[43]
44	reaction	O	['N']	[44]
45	to	O	['N']	[45]
46	promethazine	B-Drug	['Causes']	[60]
47	,	O	['N']	[47]
48	decreased	O	['N']	[48]
49	MED	O	['N']	[49]
50	to	O	['N']	[50]
51	both	O	['N']	[51]
52	UVA	O	['N']	[52]
53	and	O	['N']	[53]
54	UVB	O	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	B	['N']	[57]
58	of	I	['N']	[58]
59	the	I	['N']	[59]
60	photosensitivity	I-Adverse_Effect	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#1822
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	subtle	O	['N']	[6]
7	,	O	['N']	[7]
8	mild	O	['N']	[8]
9	hypothermia	B-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	54-year	O	['N']	[12]
13	old	O	['N']	[13]
14	female	O	['N']	[14]
15	patient	O	['N']	[15]
16	receiving	O	['N']	[16]
17	risperidone	B-Drug	['Causes']	[9]
18	for	O	['N']	[18]
19	schizophrenia	O	['N']	[19]
20	.	O	['N']	[20]
#1823
0	Pneumonitis	B-Adverse_Effect	['N']	[0]
1	with	O	['N']	[1]
2	pleural	O	['N']	[2]
3	and	O	['N']	[3]
4	pericardial	O	['N']	[4]
5	effusion	O	['N']	[5]
6	and	O	['N']	[6]
7	neuropathy	O	['N']	[7]
8	during	O	['N']	[8]
9	amiodarone	B-Drug	['Causes']	[0]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#1824
0	Hypoglycemia	O	['N']	[0]
1	can	O	['N']	[1]
2	be	O	['N']	[2]
3	a	O	['N']	[3]
4	serious	O	['N']	[4]
5	side	O	['N']	[5]
6	effect	O	['N']	[6]
7	of	O	['N']	[7]
8	etanercept	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	already	O	['N']	[11]
12	on	O	['N']	[12]
13	antidiabetic	O	['N']	[13]
14	medications	O	['N']	[14]
15	known	O	['N']	[15]
16	to	O	['N']	[16]
17	cause	O	['N']	[17]
18	hypoglycemia	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	such	O	['N']	[20]
21	as	O	['N']	[21]
22	sulfonylureas	O	['N']	[22]
23	,	O	['N']	[23]
24	meglitinides	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	insulin	B-Drug	['Causes']	[18]
28	.	O	['N']	[28]
#1825
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	to	O	['N']	[2]
3	its	O	['N']	[3]
4	known	O	['N']	[4]
5	effect	O	['N']	[5]
6	on	O	['N']	[6]
7	gallbladder	O	['N']	[7]
8	stasis	O	['N']	[8]
9	,	O	['N']	[9]
10	octreotide	B-Drug	['Causes']	[20]
11	alters	O	['N']	[11]
12	bile	O	['N']	[12]
13	acid	O	['N']	[13]
14	composition	O	['N']	[14]
15	and	O	['N']	[15]
16	may	O	['N']	[16]
17	thus	O	['N']	[17]
18	hasten	B	['N']	[18]
19	intrahepatic	I	['N']	[19]
20	sludge	I-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	stone	O	['N']	[22]
23	formation	O	['N']	[23]
24	.	O	['N']	[24]
#1826
0	A	O	['N']	[0]
1	chronic	O	['N']	[1]
2	reaction	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	long	O	['N']	[5]
6	-	O	['N']	[6]
7	term	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	nitrofurantoin	B-Drug	['Causes']	[19]
11	has	O	['N']	[11]
12	also	O	['N']	[12]
13	been	O	['N']	[13]
14	reported	O	['N']	[14]
15	and	O	['N']	[15]
16	causes	O	['N']	[16]
17	irreversible	O	['N']	[17]
18	pulmonary	B	['N']	[18]
19	fibrosis	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#1827
0	Thus	O	['N']	[0]
1	,	O	['N']	[1]
2	an	O	['N']	[2]
3	immunological	O	['N']	[3]
4	mechanism	O	['N']	[4]
5	might	O	['N']	[5]
6	be	O	['N']	[6]
7	involved	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	mechanism	O	['N']	[10]
11	of	O	['N']	[11]
12	pirmenol	B-Drug	['Causes']	[16]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	QT	B	['N']	[15]
16	prolongation	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	T	O	['N']	[18]
19	wave	O	['N']	[19]
20	inversion	O	['N']	[20]
21	on	O	['N']	[21]
22	the	O	['N']	[22]
23	electrocardiogram	O	['N']	[23]
24	.	O	['N']	[24]
#1828
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	represents	O	['N']	[2]
3	the	O	['N']	[3]
4	third	O	['N']	[4]
5	example	O	['N']	[5]
6	of	O	['N']	[6]
7	erythroid	B	['N']	[7]
8	aplasia	I-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	an	O	['N']	[11]
12	anti	O	['N']	[12]
13	-	O	['N']	[13]
14	inflammatory	O	['N']	[14]
15	agent	O	['N']	[15]
16	and	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	instance	O	['N']	[19]
20	due	O	['N']	[20]
21	to	O	['N']	[21]
22	fenoprofen	B-Drug	['Causes']	[8]
23	.	O	['N']	[23]
#1829
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	two	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	acute	B	['N']	[7]
8	myelocytic	I	['N']	[8]
9	leukemia	I-Adverse_Effect	['N']	[9]
10	only	O	['N']	[10]
11	after	O	['N']	[11]
12	exposure	O	['N']	[12]
13	to	O	['N']	[13]
14	cyclophosphamide	O	['N']	[14]
15	,	O	['N']	[15]
16	methotrexate	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	5-fluorouracil	B-Drug	['Causes']	[9]
20	adjuvant	O	['N']	[20]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#1830
0	Type	O	['N']	[0]
1	I	O	['N']	[1]
2	second	O	['N']	[2]
3	-	O	['N']	[3]
4	degree	O	['N']	[4]
5	AV	O	['N']	[5]
6	block	O	['N']	[6]
7	(	O	['N']	[7]
8	Mobitz	O	['N']	[8]
9	type	O	['N']	[9]
10	I	O	['N']	[10]
11	,	O	['N']	[11]
12	Wenckebach	B	['N']	[12]
13	AV	I	['N']	[13]
14	block	I-Adverse_Effect	['N']	[14]
15	)	O	['N']	[15]
16	during	O	['N']	[16]
17	ritodrine	B-Drug	['Causes']	[14]
18	therapy	O	['N']	[18]
19	for	O	['N']	[19]
20	preterm	O	['N']	[20]
21	labor	O	['N']	[21]
22	.	O	['N']	[22]
#1831
0	She	O	['N']	[0]
1	continued	O	['N']	[1]
2	to	O	['N']	[2]
3	receive	O	['N']	[3]
4	regular	O	['N']	[4]
5	insulin	B-Drug	['Dosage']	[9]
6	4	B	['N']	[6]
7	times	I	['N']	[7]
8	per	I	['N']	[8]
9	day	I-Dose	['N']	[9]
10	over	O	['N']	[10]
11	the	O	['N']	[11]
12	following	O	['N']	[12]
13	3	O	['N']	[13]
14	years	O	['N']	[14]
15	with	O	['N']	[15]
16	only	O	['N']	[16]
17	occasional	O	['N']	[17]
18	hives	O	['N']	[18]
19	.	O	['N']	[19]
#1832
0	Prenatal	O	['N']	[0]
1	cytomegalovirus	O	['N']	[1]
2	(	O	['N']	[2]
3	CMV	O	['N']	[3]
4	)	O	['N']	[4]
5	infection	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	severe	O	['N']	[8]
9	brain	B	['N']	[9]
10	damage	I-Adverse_Effect	['N']	[10]
11	was	O	['N']	[11]
12	detected	O	['N']	[12]
13	in	O	['N']	[13]
14	an	O	['N']	[14]
15	infant	O	['N']	[15]
16	whose	O	['N']	[16]
17	mother	O	['N']	[17]
18	had	O	['N']	[18]
19	been	O	['N']	[19]
20	treated	O	['N']	[20]
21	with	O	['N']	[21]
22	prednisolone	B-Drug	['Causes']	[10]
23	and	O	['N']	[23]
24	azathioprine	O	['N']	[24]
25	for	O	['N']	[25]
26	systemic	O	['N']	[26]
27	lupus	O	['N']	[27]
28	erythematosus	O	['N']	[28]
29	(	O	['N']	[29]
30	SLE	O	['N']	[30]
31	)	O	['N']	[31]
32	.	O	['N']	[32]
#1833
0	An	O	['N']	[0]
1	unusual	O	['N']	[1]
2	cause	O	['N']	[2]
3	of	O	['N']	[3]
4	burn	B	['N']	[4]
5	injury	I-Drug	['Causes']	[13]
6	:	O	['N']	[6]
7	unsupervised	O	['N']	[7]
8	use	O	['N']	[8]
9	of	O	['N']	[9]
10	drugs	O	['N']	[10]
11	that	O	['N']	[11]
12	contain	O	['N']	[12]
13	psoralens	B-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#1834
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	interstitial	B	['N']	[5]
6	pulmonary	I	['N']	[6]
7	disease	I-Adverse_Effect	['N']	[7]
8	that	O	['N']	[8]
9	occurred	O	['N']	[9]
10	together	O	['N']	[10]
11	with	O	['N']	[11]
12	lymphocytic	O	['N']	[12]
13	colitis	O	['N']	[13]
14	during	O	['N']	[14]
15	treatment	O	['N']	[15]
16	with	O	['N']	[16]
17	ticlopidine	B-Drug	['Causes']	[7]
18	.	O	['N']	[18]
#1835
0	With	O	['N']	[0]
1	the	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	optical	O	['N']	[4]
5	coherence	O	['N']	[5]
6	tomography	O	['N']	[6]
7	(	O	['N']	[7]
8	OCT	O	['N']	[8]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	two	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	IFN	B-Drug	['Causes']	[26]
15	-	O	['N']	[15]
16	associated	O	['N']	[16]
17	retinopathy	O	['N']	[17]
18	who	O	['N']	[18]
19	had	O	['N']	[19]
20	developed	O	['N']	[20]
21	macular	O	['N']	[21]
22	edema	O	['N']	[22]
23	and	O	['N']	[23]
24	reduced	B	['N']	[24]
25	visual	I	['N']	[25]
26	acuity	I-Adverse_Effect	['N']	[26]
27	during	O	['N']	[27]
28	the	O	['N']	[28]
29	clinical	O	['N']	[29]
30	course	O	['N']	[30]
31	of	O	['N']	[31]
32	IFN	O	['N']	[32]
33	therapy	O	['N']	[33]
34	were	O	['N']	[34]
35	observed	O	['N']	[35]
36	.	O	['N']	[36]
#1836
0	Although	O	['N']	[0]
1	the	O	['N']	[1]
2	literature	O	['N']	[2]
3	on	O	['N']	[3]
4	the	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	risperidone	B-Drug	['Causes']	[48]
8	in	O	['N']	[8]
9	elderly	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	dementia	O	['N']	[12]
13	consists	O	['N']	[13]
14	largely	O	['N']	[14]
15	of	O	['N']	[15]
16	uncontrolled	O	['N']	[16]
17	trials	O	['N']	[17]
18	,	O	['N']	[18]
19	case	O	['N']	[19]
20	reports	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	chart	O	['N']	[23]
24	reviews	O	['N']	[24]
25	,	O	['N']	[25]
26	it	O	['N']	[26]
27	appears	O	['N']	[27]
28	that	O	['N']	[28]
29	this	O	['N']	[29]
30	agent	O	['N']	[30]
31	is	O	['N']	[31]
32	effective	O	['N']	[32]
33	for	O	['N']	[33]
34	managing	O	['N']	[34]
35	agitation	O	['N']	[35]
36	in	O	['N']	[36]
37	this	O	['N']	[37]
38	population	O	['N']	[38]
39	and	O	['N']	[39]
40	does	O	['N']	[40]
41	so	O	['N']	[41]
42	with	O	['N']	[42]
43	a	O	['N']	[43]
44	low	O	['N']	[44]
45	frequency	O	['N']	[45]
46	of	O	['N']	[46]
47	extrapyramidal	B	['N']	[47]
48	symptoms	I-Adverse_Effect	['N']	[48]
49	(	O	['N']	[49]
50	EPS	O	['N']	[50]
51	)	O	['N']	[51]
52	.	O	['N']	[52]
#1837
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	Balint	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	with	O	['N']	[8]
9	irreversible	O	['N']	[9]
10	posterior	B	['N']	[10]
11	leukoencephalopathy	I-Adverse_Effect	['N']	[11]
12	on	O	['N']	[12]
13	MRI	O	['N']	[13]
14	following	O	['N']	[14]
15	intrathecal	O	['N']	[15]
16	methotrexate	B-Drug	['Causes']	[11]
17	and	O	['N']	[17]
18	cytarabine	O	['N']	[18]
19	.	O	['N']	[19]
#1838
0	Isotretinoin	B-Drug	['Causes']	[17]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	drug	O	['N']	[3]
4	used	O	['N']	[4]
5	for	O	['N']	[5]
6	the	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	acne	O	['N']	[9]
10	,	O	['N']	[10]
11	has	O	['N']	[11]
12	been	O	['N']	[12]
13	shown	O	['N']	[13]
14	to	O	['N']	[14]
15	have	O	['N']	[15]
16	teratogenic	B	['N']	[16]
17	effects	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#1839
0	Myoclonus	O	['N']	[0]
1	and	O	['N']	[1]
2	seizures	B-Adverse_Effect	['N']	[2]
3	disappeared	O	['N']	[3]
4	after	O	['N']	[4]
5	discontinuation	O	['N']	[5]
6	of	O	['N']	[6]
7	L	B	['N']	[7]
8	-	I	['N']	[8]
9	dopa	I-Drug	['Causes']	[2]
10	and	O	['N']	[10]
11	the	O	['N']	[11]
12	introduction	O	['N']	[12]
13	of	O	['N']	[13]
14	valproate	O	['N']	[14]
15	sodium	O	['N']	[15]
16	(	O	['N']	[16]
17	VPA	O	['N']	[17]
18	)	O	['N']	[18]
19	.	O	['N']	[19]
#1840
0	Quinine	B-Drug	['Causes']	[2]
1	induced	O	['N']	[1]
2	coagulopathy	B-Adverse_Effect	['N']	[2]
3	--	O	['N']	[3]
4	a	O	['N']	[4]
5	near	O	['N']	[5]
6	fatal	O	['N']	[6]
7	experience	O	['N']	[7]
8	.	O	['N']	[8]
#1841
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	histories	O	['N']	[4]
5	of	O	['N']	[5]
6	identical	O	['N']	[6]
7	twin	O	['N']	[7]
8	brothers	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	concordant	O	['N']	[11]
12	acute	O	['N']	[12]
13	lymphoblastic	O	['N']	[13]
14	leukemia	O	['N']	[14]
15	at	O	['N']	[15]
16	the	O	['N']	[16]
17	age	O	['N']	[17]
18	of	O	['N']	[18]
19	4	O	['N']	[19]
20	years	O	['N']	[20]
21	and	O	['N']	[21]
22	who	O	['N']	[22]
23	later	O	['N']	[23]
24	developed	O	['N']	[24]
25	leukoencephalopathy	O	['N']	[25]
26	and	O	['N']	[26]
27	hydrocephalus	B-Adverse_Effect	['N']	[27]
28	related	O	['N']	[28]
29	to	O	['N']	[29]
30	central	O	['N']	[30]
31	nervous	O	['N']	[31]
32	system	O	['N']	[32]
33	prophylaxis	O	['N']	[33]
34	by	O	['N']	[34]
35	,	O	['N']	[35]
36	in	O	['N']	[36]
37	the	O	['N']	[37]
38	first	O	['N']	[38]
39	case	O	['N']	[39]
40	intrathecally	O	['N']	[40]
41	administered	O	['N']	[41]
42	methotrexate	B-Drug	['Causes']	[27]
43	and	O	['N']	[43]
44	,	O	['N']	[44]
45	in	O	['N']	[45]
46	the	O	['N']	[46]
47	second	O	['N']	[47]
48	by	O	['N']	[48]
49	intrathecally	O	['N']	[49]
50	administered	O	['N']	[50]
51	methotrexate	O	['N']	[51]
52	and	O	['N']	[52]
53	cranial	O	['N']	[53]
54	irradiation	O	['N']	[54]
55	.	O	['N']	[55]
#1842
0	After	O	['N']	[0]
1	having	O	['N']	[1]
2	received	O	['N']	[2]
3	gemcitabine	B-Drug	['Causes']	[19]
4	on	O	['N']	[4]
5	day	O	['N']	[5]
6	1	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	second	O	['N']	[9]
10	course	O	['N']	[10]
11	,	O	['N']	[11]
12	the	O	['N']	[12]
13	patient	O	['N']	[13]
14	developed	O	['N']	[14]
15	dry	O	['N']	[15]
16	cough	O	['N']	[16]
17	,	O	['N']	[17]
18	subfebrile	B	['N']	[18]
19	temperatures	I-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	dyspnea	O	['N']	[21]
22	within	O	['N']	[22]
23	48	O	['N']	[23]
24	h.	O	['N']	[24]
#1843
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	seen	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	terminal	O	['N']	[6]
7	malignant	O	['N']	[7]
8	melanoma	O	['N']	[8]
9	in	O	['N']	[9]
10	which	O	['N']	[10]
11	clinical	O	['N']	[11]
12	manifestations	O	['N']	[12]
13	,	O	['N']	[13]
14	indicative	O	['N']	[14]
15	of	O	['N']	[15]
16	anterior	O	['N']	[16]
17	spinal	O	['N']	[17]
18	artery	O	['N']	[18]
19	syndrome	O	['N']	[19]
20	,	O	['N']	[20]
21	developed	O	['N']	[21]
22	following	O	['N']	[22]
23	the	O	['N']	[23]
24	injection	O	['N']	[24]
25	of	O	['N']	[25]
26	0.3	B	['N']	[26]
27	ml	I-Dose	['N']	[27]
28	of	O	['N']	[28]
29	10	O	['N']	[29]
30	%	O	['N']	[30]
31	phenol	B	['N']	[31]
32	-	I	['N']	[32]
33	glycerine	I-Drug	['Dosage']	[27]
34	into	O	['N']	[34]
35	the	O	['N']	[35]
36	cervical	O	['N']	[36]
37	subarachnoid	O	['N']	[37]
38	space	O	['N']	[38]
39	at	O	['N']	[39]
40	the	O	['N']	[40]
41	C4	O	['N']	[41]
42	-	O	['N']	[42]
43	-C5	O	['N']	[43]
44	level	O	['N']	[44]
45	for	O	['N']	[45]
46	the	O	['N']	[46]
47	control	O	['N']	[47]
48	of	O	['N']	[48]
49	severe	O	['N']	[49]
50	right	O	['N']	[50]
51	arm	O	['N']	[51]
52	pain	O	['N']	[52]
53	.	O	['N']	[53]
#1844
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	three	O	['N']	[3]
4	observations	O	['N']	[4]
5	of	O	['N']	[5]
6	parkinsonian	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	levo	B	['N']	[9]
10	-	I	['N']	[10]
11	dopa	I-Drug	['Causes']	[15]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	diphasic	B	['N']	[14]
15	dyskinesias	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	who	O	['N']	[17]
18	received	O	['N']	[18]
19	subcutaneous	O	['N']	[19]
20	apomorphine	O	['N']	[20]
21	to	O	['N']	[21]
22	reduce	O	['N']	[22]
23	the	O	['N']	[23]
24	duration	O	['N']	[24]
25	of	O	['N']	[25]
26	abnormal	O	['N']	[26]
27	movements	O	['N']	[27]
28	.	O	['N']	[28]
#1845
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	use	O	['N']	[3]
4	of	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[24]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	avoided	O	['N']	[8]
9	with	O	['N']	[9]
10	any	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	is	O	['N']	[13]
14	purging	O	['N']	[14]
15	,	O	['N']	[15]
16	since	O	['N']	[16]
17	it	O	['N']	[17]
18	may	O	['N']	[18]
19	exacerbate	O	['N']	[19]
20	the	O	['N']	[20]
21	loss	B	['N']	[21]
22	of	I	['N']	[22]
23	intracellular	I	['N']	[23]
24	potassium	I-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	thereby	O	['N']	[26]
27	increasing	O	['N']	[27]
28	the	O	['N']	[28]
29	risk	O	['N']	[29]
30	of	O	['N']	[30]
31	cardiac	O	['N']	[31]
32	toxicity	O	['N']	[32]
33	.	O	['N']	[33]
#1846
0	After	O	['N']	[0]
1	infliximab	B-Drug	['Causes']	[15]
2	treatment	O	['N']	[2]
3	,	O	['N']	[3]
4	additional	O	['N']	[4]
5	sleep	O	['N']	[5]
6	studies	O	['N']	[6]
7	revealed	O	['N']	[7]
8	an	O	['N']	[8]
9	increase	B	['N']	[9]
10	in	I	['N']	[10]
11	the	I	['N']	[11]
12	number	I	['N']	[12]
13	of	I	['N']	[13]
14	apneic	I	['N']	[14]
15	events	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	SaO2	O	['N']	[17]
18	dips	O	['N']	[18]
19	suggesting	O	['N']	[19]
20	that	O	['N']	[20]
21	TNFalpha	O	['N']	[21]
22	plays	O	['N']	[22]
23	an	O	['N']	[23]
24	important	O	['N']	[24]
25	role	O	['N']	[25]
26	in	O	['N']	[26]
27	the	O	['N']	[27]
28	pathophysiology	O	['N']	[28]
29	of	O	['N']	[29]
30	sleep	O	['N']	[30]
31	apnea	O	['N']	[31]
32	.	O	['N']	[32]
#1847
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Significant	O	['N']	[2]
3	ocular	O	['N']	[3]
4	complications	O	['N']	[4]
5	such	O	['N']	[5]
6	as	O	['N']	[6]
7	an	O	['N']	[7]
8	irreversible	B	['N']	[8]
9	decrease	I	['N']	[9]
10	of	I	['N']	[10]
11	visual	I	['N']	[11]
12	acuity	I-Adverse_Effect	['N']	[12]
13	may	O	['N']	[13]
14	develop	O	['N']	[14]
15	in	O	['N']	[15]
16	patients	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	pegylated	B	['N']	[19]
20	interferon	I-Drug	['Causes']	[12]
21	.	O	['N']	[21]
#1848
0	Immunosuppression	O	['N']	[0]
1	elicited	O	['N']	[1]
2	by	O	['N']	[2]
3	the	O	['N']	[3]
4	extensive	O	['N']	[4]
5	administration	O	['N']	[5]
6	of	O	['N']	[6]
7	prednisolone	B-Drug	['Causes']	[17]
8	was	O	['N']	[8]
9	suspected	O	['N']	[9]
10	for	O	['N']	[10]
11	the	O	['N']	[11]
12	initiation	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	generalized	O	['N']	[15]
16	mite	B	['N']	[16]
17	infestation	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#1849
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	antiphospholipid	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	who	O	['N']	[8]
9	had	O	['N']	[9]
10	skin	B	['N']	[10]
11	necrosis	I-Adverse_Effect	['N']	[11]
12	develop	O	['N']	[12]
13	from	O	['N']	[13]
14	low	B	['N']	[14]
15	-	I	['N']	[15]
16	molecular	I	['N']	[16]
17	weight	I	['N']	[17]
18	heparin	I-Drug	['Causes']	[11]
19	therapy	O	['N']	[19]
20	at	O	['N']	[20]
21	sites	O	['N']	[21]
22	distant	O	['N']	[22]
23	from	O	['N']	[23]
24	injection	O	['N']	[24]
25	sites	O	['N']	[25]
26	.	O	['N']	[26]
#1850
0	Pneumonitis	O	['N']	[0]
1	with	O	['N']	[1]
2	pleural	O	['N']	[2]
3	and	O	['N']	[3]
4	pericardial	O	['N']	[4]
5	effusion	O	['N']	[5]
6	and	O	['N']	[6]
7	neuropathy	B-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	amiodarone	B-Drug	['Causes']	[7]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#1851
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	lung	O	['N']	[6]
7	cancer	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	bronquiloalveolar	O	['N']	[10]
11	carcinoma	O	['N']	[11]
12	(	O	['N']	[12]
13	BAC	O	['N']	[13]
14	)	O	['N']	[14]
15	presenting	O	['N']	[15]
16	with	O	['N']	[16]
17	BOOP	B-Adverse_Effect	['N']	[17]
18	after	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	with	O	['N']	[20]
21	docetaxel	B-Drug	['Causes']	[17]
22	and	O	['N']	[22]
23	gemcitabine	O	['N']	[23]
24	producing	O	['N']	[24]
25	severe	O	['N']	[25]
26	respiratory	O	['N']	[26]
27	insufficiency	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	simulating	O	['N']	[30]
31	a	O	['N']	[31]
32	progression	O	['N']	[32]
33	of	O	['N']	[33]
34	the	O	['N']	[34]
35	tumor	O	['N']	[35]
36	.	O	['N']	[36]
#1852
0	Ten	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	itraconazole	B-Drug	['Causes']	[13]
4	was	O	['N']	[4]
5	started	O	['N']	[5]
6	,	O	['N']	[6]
7	he	O	['N']	[7]
8	developed	O	['N']	[8]
9	paralytic	O	['N']	[9]
10	ileus	O	['N']	[10]
11	,	O	['N']	[11]
12	neurogenic	B	['N']	[12]
13	bladder	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	mild	O	['N']	[15]
16	left	O	['N']	[16]
17	ptosis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	absence	O	['N']	[20]
21	of	O	['N']	[21]
22	deep	O	['N']	[22]
23	reflexes	O	['N']	[23]
24	,	O	['N']	[24]
25	with	O	['N']	[25]
26	severe	O	['N']	[26]
27	paralysis	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	lower	O	['N']	[30]
31	extremities	O	['N']	[31]
32	and	O	['N']	[32]
33	mild	O	['N']	[33]
34	weakness	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	upper	O	['N']	[37]
38	extremities	O	['N']	[38]
39	.	O	['N']	[39]
#1853
0	Teicoplanin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	agranulocytosis	B-Adverse_Effect	['N']	[3]
4	that	O	['N']	[4]
5	followed	O	['N']	[5]
6	vancomycin	O	['N']	[6]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	agranulocytosis	O	['N']	[9]
10	suggests	O	['N']	[10]
11	a	O	['N']	[11]
12	possible	O	['N']	[12]
13	cross	O	['N']	[13]
14	-	O	['N']	[14]
15	reactivity	O	['N']	[15]
16	between	O	['N']	[16]
17	the	O	['N']	[17]
18	2	O	['N']	[18]
19	drugs	O	['N']	[19]
20	.	O	['N']	[20]
#1854
0	Fulminant	B	['N']	[0]
1	liver	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	clarithromycin	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#1855
0	A	O	['N']	[0]
1	71-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	paroxysmal	O	['N']	[6]
7	atrial	O	['N']	[7]
8	fibrillation	O	['N']	[8]
9	who	O	['N']	[9]
10	had	O	['N']	[10]
11	a	O	['N']	[11]
12	previous	O	['N']	[12]
13	anterior	O	['N']	[13]
14	myocardial	O	['N']	[14]
15	infarction	O	['N']	[15]
16	exhibited	O	['N']	[16]
17	granulocytopenia	B-Adverse_Effect	['N']	[17]
18	8	O	['N']	[18]
19	days	O	['N']	[19]
20	following	O	['N']	[20]
21	the	O	['N']	[21]
22	administration	O	['N']	[22]
23	of	O	['N']	[23]
24	oral	O	['N']	[24]
25	sustained	O	['N']	[25]
26	-	O	['N']	[26]
27	release	O	['N']	[27]
28	procainamide	B-Drug	['Causes']	[17]
29	(	O	['N']	[29]
30	750	O	['N']	[30]
31	mg	O	['N']	[31]
32	/	O	['N']	[32]
33	day	O	['N']	[33]
34	)	O	['N']	[34]
35	.	O	['N']	[35]
#1856
0	During	O	['N']	[0]
1	dose	O	['N']	[1]
2	-	O	['N']	[2]
3	finding	O	['N']	[3]
4	studies	O	['N']	[4]
5	for	O	['N']	[5]
6	intravenous	O	['N']	[6]
7	proton	O	['N']	[7]
8	pump	O	['N']	[8]
9	inhibitors	O	['N']	[9]
10	omeprazole	O	['N']	[10]
11	and	O	['N']	[11]
12	pantoprazole	B-Drug	['Causes']	[31]
13	,	O	['N']	[13]
14	three	O	['N']	[14]
15	of	O	['N']	[15]
16	six	O	['N']	[16]
17	young	O	['N']	[17]
18	female	O	['N']	[18]
19	volunteers	O	['N']	[19]
20	receiving	O	['N']	[20]
21	omeprazole	O	['N']	[21]
22	and	O	['N']	[22]
23	two	O	['N']	[23]
24	young	O	['N']	[24]
25	female	O	['N']	[25]
26	volunteers	O	['N']	[26]
27	receiving	O	['N']	[27]
28	pantoprazole	O	['N']	[28]
29	developed	O	['N']	[29]
30	peripheral	B	['N']	[30]
31	edema	I-Adverse_Effect	['N']	[31]
32	within	O	['N']	[32]
33	8	O	['N']	[33]
34	hr	O	['N']	[34]
35	when	O	['N']	[35]
36	high	O	['N']	[36]
37	doses	O	['N']	[37]
38	of	O	['N']	[38]
39	the	O	['N']	[39]
40	proton	O	['N']	[40]
41	pump	O	['N']	[41]
42	inhibitors	O	['N']	[42]
43	were	O	['N']	[43]
44	applied	O	['N']	[44]
45	by	O	['N']	[45]
46	continuous	O	['N']	[46]
47	infusion	O	['N']	[47]
48	together	O	['N']	[48]
49	with	O	['N']	[49]
50	large	O	['N']	[50]
51	volumes	O	['N']	[51]
52	of	O	['N']	[52]
53	fluid	O	['N']	[53]
54	.	O	['N']	[54]
#1857
0	The	O	['N']	[0]
1	following	O	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	report	O	['N']	[5]
6	analysis	O	['N']	[6]
7	intended	O	['N']	[7]
8	to	O	['N']	[8]
9	draw	O	['N']	[9]
10	attention	O	['N']	[10]
11	to	O	['N']	[11]
12	the	O	['N']	[12]
13	need	O	['N']	[13]
14	for	O	['N']	[14]
15	better	O	['N']	[15]
16	care	O	['N']	[16]
17	coordination	O	['N']	[17]
18	by	O	['N']	[18]
19	describing	O	['N']	[19]
20	the	O	['N']	[20]
21	observed	O	['N']	[21]
22	relationship	O	['N']	[22]
23	of	O	['N']	[23]
24	olanzapine	B-Drug	['Causes']	[32]
25	to	O	['N']	[25]
26	metabolic	O	['N']	[26]
27	changes	O	['N']	[27]
28	manifested	O	['N']	[28]
29	as	O	['N']	[29]
30	uncontrolled	B	['N']	[30]
31	diabetes	I	['N']	[31]
32	mellitus	I-Adverse_Effect	['N']	[32]
33	and	O	['N']	[33]
34	weight	O	['N']	[34]
35	gain	O	['N']	[35]
36	.	O	['N']	[36]
#1858
0	Acute	B	['N']	[0]
1	coronary	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	capecitabine	B-Drug	['Causes']	[2]
6	therapy	O	['N']	[6]
7	.	O	['N']	[7]
#1859
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	hemolytic	B	['N']	[5]
6	-	I	['N']	[6]
7	uremic	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	developed	O	['N']	[10]
11	during	O	['N']	[11]
12	the	O	['N']	[12]
13	4th	O	['N']	[13]
14	cycle	O	['N']	[14]
15	of	O	['N']	[15]
16	combination	O	['N']	[16]
17	chemotherapy	O	['N']	[17]
18	with	O	['N']	[18]
19	oxaliplatin	O	['N']	[19]
20	,	O	['N']	[20]
21	5-fluorouracil	B-Drug	['Causes']	[8]
22	and	O	['N']	[22]
23	leucovorin	O	['N']	[23]
24	.	O	['N']	[24]
#1860
0	A	O	['N']	[0]
1	64	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	recurrent	O	['N']	[6]
7	metastatic	O	['N']	[7]
8	squamous	O	['N']	[8]
9	cell	O	['N']	[9]
10	carcinoma	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	head	O	['N']	[13]
14	and	O	['N']	[14]
15	neck	O	['N']	[15]
16	developed	O	['N']	[16]
17	severe	O	['N']	[17]
18	skin	O	['N']	[18]
19	rash	O	['N']	[19]
20	and	O	['N']	[20]
21	bone	O	['N']	[21]
22	marrow	O	['N']	[22]
23	aplasia	O	['N']	[23]
24	4	O	['N']	[24]
25	and	O	['N']	[25]
26	7	O	['N']	[26]
27	days	O	['N']	[27]
28	,	O	['N']	[28]
29	respectively	O	['N']	[29]
30	,	O	['N']	[30]
31	following	O	['N']	[31]
32	a	O	['N']	[32]
33	single	O	['N']	[33]
34	dose	O	['N']	[34]
35	of	O	['N']	[35]
36	40	B	['N']	[36]
37	mg	I	['N']	[37]
38	/	I	['N']	[38]
39	m2	I-Dose	['N']	[39]
40	methotrexate	O	['N']	[40]
41	(	O	['N']	[41]
42	MTX	B-Drug	['Dosage']	[39]
43	)	O	['N']	[43]
44	.	O	['N']	[44]
#1861
0	Priapism	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	olanzapine	B-Drug	['Causes']	[0]
4	.	O	['N']	[4]
#1862
0	Thrombocytopenia	B-Adverse_Effect	['N']	[0]
1	with	O	['N']	[1]
2	or	O	['N']	[2]
3	without	O	['N']	[3]
4	microangiopathy	O	['N']	[4]
5	following	O	['N']	[5]
6	quinine	B-Drug	['Causes']	[0]
7	is	O	['N']	[7]
8	often	O	['N']	[8]
9	referred	O	['N']	[9]
10	to	O	['N']	[10]
11	as	O	['N']	[11]
12	quinine	O	['N']	[12]
13	"	O	['N']	[13]
14	hypersensitivity	O	['N']	[14]
15	.	O	['N']	[15]
16	"	O	['N']	[16]
17	When	O	['N']	[17]
18	schistocytes	O	['N']	[18]
19	are	O	['N']	[19]
20	present	O	['N']	[20]
21	it	O	['N']	[21]
22	is	O	['N']	[22]
23	frequently	O	['N']	[23]
24	termed	O	['N']	[24]
25	"	O	['N']	[25]
26	quinine	O	['N']	[26]
27	-	O	['N']	[27]
28	associated	O	['N']	[28]
29	TTP	O	['N']	[29]
30	/	O	['N']	[30]
31	HUS	O	['N']	[31]
32	.	O	['N']	[32]
33	"	O	['N']	[33]
34	A	O	['N']	[34]
35	severe	O	['N']	[35]
36	deficiency	O	['N']	[36]
37	of	O	['N']	[37]
38	the	O	['N']	[38]
39	vWF	O	['N']	[39]
40	-	O	['N']	[40]
41	cleaving	O	['N']	[41]
42	protease	O	['N']	[42]
43	,	O	['N']	[43]
44	ADAMTS13	O	['N']	[44]
45	,	O	['N']	[45]
46	is	O	['N']	[46]
47	associated	O	['N']	[47]
48	with	O	['N']	[48]
49	idiopathic	O	['N']	[49]
50	TTP	O	['N']	[50]
51	.	O	['N']	[51]
#1863
0	Experience	O	['N']	[0]
1	with	O	['N']	[1]
2	five	O	['N']	[2]
3	patients	O	['N']	[3]
4	in	O	['N']	[4]
5	whom	O	['N']	[5]
6	impaired	B	['N']	[6]
7	renal	I	['N']	[7]
8	function	I-Adverse_Effect	['N']	[8]
9	developed	O	['N']	[9]
10	early	O	['N']	[10]
11	during	O	['N']	[11]
12	amphotericin	B	['N']	[12]
13	B	I-Drug	['Causes']	[8]
14	therapy	O	['N']	[14]
15	is	O	['N']	[15]
16	reported	O	['N']	[16]
17	.	O	['N']	[17]
#1864
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	positive	O	['N']	[3]
4	for	O	['N']	[4]
5	antibody	O	['N']	[5]
6	against	O	['N']	[6]
7	complexes	O	['N']	[7]
8	of	O	['N']	[8]
9	heparin	B-Drug	['Causes']	[25]
10	and	O	['N']	[10]
11	platelet	O	['N']	[11]
12	factor	O	['N']	[12]
13	4	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	was	O	['N']	[16]
17	diagnosed	O	['N']	[17]
18	as	O	['N']	[18]
19	heparin	O	['N']	[19]
20	-	O	['N']	[20]
21	induced	O	['N']	[21]
22	thrombocytopenia	O	['N']	[22]
23	with	O	['N']	[23]
24	thrombosis	B	['N']	[24]
25	syndrome	I-Adverse_Effect	['N']	[25]
26	(	O	['N']	[26]
27	HITTS	O	['N']	[27]
28	)	O	['N']	[28]
29	.	O	['N']	[29]
#1865
0	Acute	B	['N']	[0]
1	abdomen	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	endometriosis	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	premenopausal	O	['N']	[7]
8	woman	O	['N']	[8]
9	taking	O	['N']	[9]
10	tamoxifen	B-Drug	['Causes']	[1]
11	.	O	['N']	[11]
#1866
0	This	O	['N']	[0]
1	paper	O	['N']	[1]
2	reports	O	['N']	[2]
3	on	O	['N']	[3]
4	a	O	['N']	[4]
5	6.9-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	autistic	O	['N']	[8]
9	male	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	repeated	O	['N']	[12]
13	episodes	O	['N']	[13]
14	of	O	['N']	[14]
15	acute	B	['N']	[15]
16	dystonic	I	['N']	[16]
17	reactions	I-Adverse_Effect	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	pimozide	B-Drug	['Causes']	[17]
21	administration	O	['N']	[21]
22	at	O	['N']	[22]
23	the	O	['N']	[23]
24	doses	O	['N']	[24]
25	of	O	['N']	[25]
26	0.096	O	['N']	[26]
27	mg	O	['N']	[27]
28	/	O	['N']	[28]
29	kg	O	['N']	[29]
30	/	O	['N']	[30]
31	day	O	['N']	[31]
32	and	O	['N']	[32]
33	0.032	O	['N']	[33]
34	mg	O	['N']	[34]
35	/	O	['N']	[35]
36	kg	O	['N']	[36]
37	/	O	['N']	[37]
38	day	O	['N']	[38]
39	and	O	['N']	[39]
40	32	O	['N']	[40]
41	hours	O	['N']	[41]
42	following	O	['N']	[42]
43	pimozide	O	['N']	[43]
44	withdrawal	O	['N']	[44]
45	,	O	['N']	[45]
46	as	O	['N']	[46]
47	well	O	['N']	[47]
48	as	O	['N']	[48]
49	during	O	['N']	[49]
50	subsequent	O	['N']	[50]
51	thioridazine	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#1867
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	87-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	white	O	['N']	[9]
10	woman	O	['N']	[10]
11	with	O	['N']	[11]
12	myasthenia	O	['N']	[12]
13	gravis	O	['N']	[13]
14	who	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	nausea	B-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	shortness	O	['N']	[19]
20	of	O	['N']	[20]
21	breath	O	['N']	[21]
22	,	O	['N']	[22]
23	azotemia	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hyperkalemia	O	['N']	[26]
27	shortly	O	['N']	[27]
28	after	O	['N']	[28]
29	completing	O	['N']	[29]
30	a	O	['N']	[30]
31	course	O	['N']	[31]
32	of	O	['N']	[32]
33	intravenous	O	['N']	[33]
34	immunoglobulin	B-Drug	['Causes']	[17]
35	(	O	['N']	[35]
36	IVIG	O	['N']	[36]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#1868
0	ADR	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	drug	O	['N']	[3]
4	treatment	O	['N']	[4]
5	can	O	['N']	[5]
6	be	O	['N']	[6]
7	a	O	['N']	[7]
8	side	O	['N']	[8]
9	effect	O	['N']	[9]
10	of	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	antipsychotic	O	['N']	[13]
14	drugs	O	['N']	[14]
15	and	O	['N']	[15]
16	other	O	['N']	[16]
17	drugs	O	['N']	[17]
18	;	O	['N']	[18]
19	however	O	['N']	[19]
20	,	O	['N']	[20]
21	there	O	['N']	[21]
22	have	O	['N']	[22]
23	been	O	['N']	[23]
24	no	O	['N']	[24]
25	reports	O	['N']	[25]
26	of	O	['N']	[26]
27	lamivudine	B-Drug	['Causes']	[0]
28	-	O	['N']	[28]
29	induced	O	['N']	[29]
30	ADR	O	['N']	[30]
31	in	O	['N']	[31]
32	the	O	['N']	[32]
33	English	O	['N']	[33]
34	literature	O	['N']	[34]
35	.	O	['N']	[35]
#1869
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	B-Drug	['Causes']	[41]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	B-Adverse_Effect	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#1870
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	aim	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	study	O	['N']	[6]
7	was	O	['N']	[7]
8	to	O	['N']	[8]
9	report	O	['N']	[9]
10	on	O	['N']	[10]
11	the	O	['N']	[11]
12	possible	O	['N']	[12]
13	development	O	['N']	[13]
14	of	O	['N']	[14]
15	corneal	B	['N']	[15]
16	endothelial	I	['N']	[16]
17	deposits	I-Adverse_Effect	['N']	[17]
18	resulting	O	['N']	[18]
19	from	O	['N']	[19]
20	the	O	['N']	[20]
21	use	O	['N']	[21]
22	of	O	['N']	[22]
23	rifabutin	B-Drug	['Causes']	[17]
24	.	O	['N']	[24]
#1871
0	We	O	['N']	[0]
1	presented	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	a	O	['N']	[9]
10	cutaneous	B	['N']	[10]
11	reaction	I-Adverse_Effect	['N']	[11]
12	induced	O	['N']	[12]
13	by	O	['N']	[13]
14	captopril	B-Drug	['Causes']	[11]
15	with	O	['N']	[15]
16	positive	O	['N']	[16]
17	patch	O	['N']	[17]
18	test	O	['N']	[18]
19	.	O	['N']	[19]
#1872
0	Failure	O	['N']	[0]
1	of	O	['N']	[1]
2	plasmapheresis	O	['N']	[2]
3	,	O	['N']	[3]
4	corticosteroids	O	['N']	[4]
5	and	O	['N']	[5]
6	thionamides	O	['N']	[6]
7	to	O	['N']	[7]
8	ameliorate	O	['N']	[8]
9	a	O	['N']	[9]
10	case	O	['N']	[10]
11	of	O	['N']	[11]
12	protracted	O	['N']	[12]
13	amiodarone	B-Drug	['Causes']	[16]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	thyroiditis	B-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#1873
0	In	O	['N']	[0]
1	both	O	['N']	[1]
2	cases	O	['N']	[2]
3	,	O	['N']	[3]
4	high	B	['N']	[4]
5	fever	I-Adverse_Effect	['N']	[5]
6	,	O	['N']	[6]
7	skin	O	['N']	[7]
8	rash	O	['N']	[8]
9	,	O	['N']	[9]
10	liver	O	['N']	[10]
11	dysfunction	O	['N']	[11]
12	and	O	['N']	[12]
13	atypical	O	['N']	[13]
14	lymphocytosis	O	['N']	[14]
15	developed	O	['N']	[15]
16	3	O	['N']	[16]
17	weeks	O	['N']	[17]
18	after	O	['N']	[18]
19	initiating	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	SASP	B-Drug	['Causes']	[5]
23	.	O	['N']	[23]
#1874
0	INTRODUCTION	O	['N']	[0]
1	-	O	['N']	[1]
2	The	O	['N']	[2]
3	aim	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	is	O	['N']	[8]
9	to	O	['N']	[9]
10	present	O	['N']	[10]
11	a	O	['N']	[11]
12	15-year	O	['N']	[12]
13	follow	O	['N']	[13]
14	-	O	['N']	[14]
15	up	O	['N']	[15]
16	of	O	['N']	[16]
17	a	O	['N']	[17]
18	patient	O	['N']	[18]
19	with	O	['N']	[19]
20	phenytoin	O	['N']	[20]
21	(	O	['N']	[21]
22	PHT	B-Drug	['Causes']	[28]
23	)	O	['N']	[23]
24	intoxication	O	['N']	[24]
25	with	O	['N']	[25]
26	unilateral	B	['N']	[26]
27	gingival	I	['N']	[27]
28	hyperplasia	I-Adverse_Effect	['N']	[28]
29	(	O	['N']	[29]
30	GH	O	['N']	[30]
31	)	O	['N']	[31]
32	.	O	['N']	[32]
#1875
0	CCBs	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	considered	O	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	5-FU	O	['N']	[8]
9	or	O	['N']	[9]
10	capecitabine	B-Drug	['Causes']	[13]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	headaches	B-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#1876
0	Secondary	B	['N']	[0]
1	leukemia	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	child	O	['N']	[4]
5	with	O	['N']	[5]
6	neuroblastoma	O	['N']	[6]
7	while	O	['N']	[7]
8	on	O	['N']	[8]
9	oral	O	['N']	[9]
10	etoposide	B-Drug	['Causes']	[1]
11	:	O	['N']	[11]
12	what	O	['N']	[12]
13	is	O	['N']	[13]
14	the	O	['N']	[14]
15	cause	O	['N']	[15]
16	?	O	['N']	[16]
#1877
0	These	O	['N']	[0]
1	observations	O	['N']	[1]
2	indicate	O	['N']	[2]
3	that	O	['N']	[3]
4	submassive	B	['N']	[4]
5	hepatic	I	['N']	[5]
6	necrosis	I-Adverse_Effect	['N']	[6]
7	may	O	['N']	[7]
8	result	O	['N']	[8]
9	from	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	propylthiouracil	B-Drug	['Causes']	[6]
13	and	O	['N']	[13]
14	are	O	['N']	[14]
15	consistent	O	['N']	[15]
16	with	O	['N']	[16]
17	the	O	['N']	[17]
18	notion	O	['N']	[18]
19	that	O	['N']	[19]
20	sensitization	O	['N']	[20]
21	mechanisms	O	['N']	[21]
22	may	O	['N']	[22]
23	be	O	['N']	[23]
24	responsible	O	['N']	[24]
25	for	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatic	O	['N']	[27]
28	injury	O	['N']	[28]
29	induced	O	['N']	[29]
30	by	O	['N']	[30]
31	this	O	['N']	[31]
32	drug	O	['N']	[32]
33	.	O	['N']	[33]
#1878
0	Transient	O	['N']	[0]
1	leucopenia	B-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	thrombocytopenia	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	sodium	B	['N']	[6]
7	nitroprusside	I-Drug	['Causes']	[1]
8	infusion	O	['N']	[8]
9	.	O	['N']	[9]
#1879
0	Severe	B	['N']	[0]
1	hepatotoxicity	I-Adverse_Effect	['N']	[1]
2	from	O	['N']	[2]
3	phenobarbital	B-Drug	['Causes']	[1]
4	occurred	O	['N']	[4]
5	in	O	['N']	[5]
6	an	O	['N']	[6]
7	infant	O	['N']	[7]
8	boy	O	['N']	[8]
9	who	O	['N']	[9]
10	had	O	['N']	[10]
11	a	O	['N']	[11]
12	complicated	O	['N']	[12]
13	illness	O	['N']	[13]
14	with	O	['N']	[14]
15	chronic	O	['N']	[15]
16	bilateral	O	['N']	[16]
17	subdural	O	['N']	[17]
18	hematomas	O	['N']	[18]
19	and	O	['N']	[19]
20	sepsis	O	['N']	[20]
21	.	O	['N']	[21]
#1880
0	Ten	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	itraconazole	B-Drug	['Causes']	[23]
4	was	O	['N']	[4]
5	started	O	['N']	[5]
6	,	O	['N']	[6]
7	he	O	['N']	[7]
8	developed	O	['N']	[8]
9	paralytic	O	['N']	[9]
10	ileus	O	['N']	[10]
11	,	O	['N']	[11]
12	neurogenic	O	['N']	[12]
13	bladder	O	['N']	[13]
14	,	O	['N']	[14]
15	mild	O	['N']	[15]
16	left	O	['N']	[16]
17	ptosis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	absence	B	['N']	[20]
21	of	I	['N']	[21]
22	deep	I	['N']	[22]
23	reflexes	I-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	with	O	['N']	[25]
26	severe	O	['N']	[26]
27	paralysis	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	lower	O	['N']	[30]
31	extremities	O	['N']	[31]
32	and	O	['N']	[32]
33	mild	O	['N']	[33]
34	weakness	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	upper	O	['N']	[37]
38	extremities	O	['N']	[38]
39	.	O	['N']	[39]
#1881
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	potential	O	['N']	[6]
7	for	O	['N']	[7]
8	developing	O	['N']	[8]
9	a	O	['N']	[9]
10	gemcitabine	B-Drug	['Causes']	[21]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	radiation	O	['N']	[13]
14	recall	O	['N']	[14]
15	reaction	O	['N']	[15]
16	resulting	O	['N']	[16]
17	in	O	['N']	[17]
18	hemodynamically	O	['N']	[18]
19	significant	O	['N']	[19]
20	pericardial	B	['N']	[20]
21	effusion	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1882
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	believe	O	['N']	[3]
4	this	O	['N']	[4]
5	to	O	['N']	[5]
6	be	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	reported	O	['N']	[9]
10	case	O	['N']	[10]
11	of	O	['N']	[11]
12	rhGH	B-Drug	['Causes']	[15]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	hypercalcemia	B-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	an	O	['N']	[17]
18	HIV	O	['N']	[18]
19	-	O	['N']	[19]
20	infected	O	['N']	[20]
21	patient	O	['N']	[21]
22	.	O	['N']	[22]
#1883
0	Sodium	B	['N']	[0]
1	phenylbutyrate	I-Drug	['Causes']	[24]
2	was	O	['N']	[2]
3	added	O	['N']	[3]
4	to	O	['N']	[4]
5	treatment	O	['N']	[5]
6	with	O	['N']	[6]
7	HU	O	['N']	[7]
8	in	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	failed	O	['N']	[13]
14	to	O	['N']	[14]
15	produce	O	['N']	[15]
16	an	O	['N']	[16]
17	increase	O	['N']	[17]
18	in	O	['N']	[18]
19	total	O	['N']	[19]
20	Hb	O	['N']	[20]
21	despite	O	['N']	[21]
22	increasing	B	['N']	[22]
23	Hb	I	['N']	[23]
24	F	I-Adverse_Effect	['N']	[24]
25	levels	O	['N']	[25]
26	.	O	['N']	[26]
#1884
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	details	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	bilateral	B	['N']	[6]
7	avascular	I	['N']	[7]
8	necrosis	I	['N']	[8]
9	of	I	['N']	[9]
10	the	I	['N']	[10]
11	femoral	I	['N']	[11]
12	heads	I-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	patient	O	['N']	[15]
16	receiving	O	['N']	[16]
17	'	O	['N']	[17]
18	standard	O	['N']	[18]
19	'	O	['N']	[19]
20	doses	O	['N']	[20]
21	of	O	['N']	[21]
22	dexamethasone	B-Drug	['Causes']	[12]
23	as	O	['N']	[23]
24	part	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	antiemetic	O	['N']	[27]
28	regimen	O	['N']	[28]
29	used	O	['N']	[29]
30	in	O	['N']	[30]
31	cisplatin	O	['N']	[31]
32	-	O	['N']	[32]
33	based	O	['N']	[33]
34	combination	O	['N']	[34]
35	chemotherapy	O	['N']	[35]
36	.	O	['N']	[36]
#1885
0	Elevated	B	['N']	[0]
1	serum	I	['N']	[1]
2	triglycerides	I-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	clozapine	B-Drug	['Causes']	[2]
5	resolved	O	['N']	[5]
6	with	O	['N']	[6]
7	risperidone	O	['N']	[7]
8	in	O	['N']	[8]
9	four	O	['N']	[9]
10	patients	O	['N']	[10]
11	.	O	['N']	[11]
#1886
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	in	O	['N']	[4]
5	whom	O	['N']	[5]
6	the	O	['N']	[6]
7	anti	O	['N']	[7]
8	-	O	['N']	[8]
9	depressant	O	['N']	[9]
10	trazodone	B	['N']	[10]
11	hydrochloride	I-Drug	['Causes']	[27]
12	(	O	['N']	[12]
13	Molipaxin	O	['N']	[13]
14	,	O	['N']	[14]
15	Roussel	O	['N']	[15]
16	)	O	['N']	[16]
17	,	O	['N']	[17]
18	a	O	['N']	[18]
19	serotonin	O	['N']	[19]
20	antagonist	O	['N']	[20]
21	,	O	['N']	[21]
22	provoked	O	['N']	[22]
23	generalized	O	['N']	[23]
24	pustular	O	['N']	[24]
25	psoriasis	O	['N']	[25]
26	(	O	['N']	[26]
27	GPP	B-Adverse_Effect	['N']	[27]
28	)	O	['N']	[28]
29	.	O	['N']	[29]
#1887
0	His	O	['N']	[0]
1	fever	O	['N']	[1]
2	resolved	O	['N']	[2]
3	,	O	['N']	[3]
4	but	O	['N']	[4]
5	he	O	['N']	[5]
6	developed	O	['N']	[6]
7	symptoms	O	['N']	[7]
8	consistent	O	['N']	[8]
9	with	O	['N']	[9]
10	those	O	['N']	[10]
11	of	O	['N']	[11]
12	chloroquine	B-Drug	['Causes']	[13]
13	toxicity	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#1888
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Fluoxetine	B-Drug	['Causes']	[17]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	highly	O	['N']	[5]
6	specific	O	['N']	[6]
7	serotonin	O	['N']	[7]
8	reuptake	O	['N']	[8]
9	inhibitor	O	['N']	[9]
10	,	O	['N']	[10]
11	has	O	['N']	[11]
12	been	O	['N']	[12]
13	reported	O	['N']	[13]
14	to	O	['N']	[14]
15	cause	O	['N']	[15]
16	sexual	B	['N']	[16]
17	dysfunction	I-Adverse_Effect	['N']	[17]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	minority	O	['N']	[20]
21	of	O	['N']	[21]
22	patients	O	['N']	[22]
23	.	O	['N']	[23]
#1889
0	A	O	['N']	[0]
1	high	O	['N']	[1]
2	dose	O	['N']	[2]
3	of	O	['N']	[3]
4	cotrimoxazole	B-Drug	['Causes']	[38]
5	induced	O	['N']	[5]
6	hyperkalaemia	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	elevation	O	['N']	[9]
10	of	O	['N']	[10]
11	serum	O	['N']	[11]
12	creatinine	O	['N']	[12]
13	and	O	['N']	[13]
14	blood	O	['N']	[14]
15	urea	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	increased	O	['N']	[18]
19	urinary	O	['N']	[19]
20	N	O	['N']	[20]
21	-	O	['N']	[21]
22	acetyl	O	['N']	[22]
23	glucosaminase	O	['N']	[23]
24	after	O	['N']	[24]
25	several	O	['N']	[25]
26	days	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	drug	O	['N']	[29]
30	administration	O	['N']	[30]
31	in	O	['N']	[31]
32	these	O	['N']	[32]
33	patients	O	['N']	[33]
34	;	O	['N']	[34]
35	one	B	['N']	[35]
36	patient	I	['N']	[36]
37	became	I	['N']	[37]
38	unconscious	I-Adverse_Effect	['N']	[38]
39	.	O	['N']	[39]
#1890
0	Bulbar	O	['N']	[0]
1	and	O	['N']	[1]
2	pseudobulbar	B	['N']	[2]
3	palsy	I-Adverse_Effect	['N']	[3]
4	complicating	O	['N']	[4]
5	therapy	O	['N']	[5]
6	with	O	['N']	[6]
7	high	O	['N']	[7]
8	-	O	['N']	[8]
9	dose	O	['N']	[9]
10	cytosine	B	['N']	[10]
11	arabinoside	I-Drug	['Causes']	[3]
12	in	O	['N']	[12]
13	children	O	['N']	[13]
14	with	O	['N']	[14]
15	leukemia	O	['N']	[15]
16	.	O	['N']	[16]
#1891
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	,	O	['N']	[5]
6	to	O	['N']	[6]
7	our	O	['N']	[7]
8	knowledge	O	['N']	[8]
9	,	O	['N']	[9]
10	of	O	['N']	[10]
11	rituximab	B-Drug	['Causes']	[16]
12	-	O	['N']	[12]
13	related	O	['N']	[13]
14	autoimmune	B	['N']	[14]
15	hemolytic	I	['N']	[15]
16	anemia	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#1892
0	Although	O	['N']	[0]
1	dyspnea	O	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	verapamil	B-Drug	['Causes']	[27]
5	administration	O	['N']	[5]
6	has	O	['N']	[6]
7	been	O	['N']	[7]
8	reported	O	['N']	[8]
9	,	O	['N']	[9]
10	this	O	['N']	[10]
11	is	O	['N']	[11]
12	the	O	['N']	[12]
13	first	O	['N']	[13]
14	report	O	['N']	[14]
15	of	O	['N']	[15]
16	an	O	['N']	[16]
17	elderly	O	['N']	[17]
18	asymptomatic	O	['N']	[18]
19	asthmatic	O	['N']	[19]
20	patient	O	['N']	[20]
21	with	O	['N']	[21]
22	hypertension	O	['N']	[22]
23	who	O	['N']	[23]
24	developed	O	['N']	[24]
25	an	O	['N']	[25]
26	acute	B	['N']	[26]
27	asthma	I-Adverse_Effect	['N']	[27]
28	attack	O	['N']	[28]
29	following	O	['N']	[29]
30	sustained	O	['N']	[30]
31	-	O	['N']	[31]
32	release	O	['N']	[32]
33	verapamil	O	['N']	[33]
34	administration	O	['N']	[34]
35	.	O	['N']	[35]
#1893
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	trimethoprim	O	['N']	[4]
5	-	O	['N']	[5]
6	sulfamethoxazole	B-Drug	['Causes']	[34]
7	for	O	['N']	[7]
8	approximately	O	['N']	[8]
9	eight	O	['N']	[9]
10	days	O	['N']	[10]
11	when	O	['N']	[11]
12	he	O	['N']	[12]
13	revisited	O	['N']	[13]
14	his	O	['N']	[14]
15	family	O	['N']	[15]
16	physician	O	['N']	[16]
17	,	O	['N']	[17]
18	complaining	O	['N']	[18]
19	of	O	['N']	[19]
20	headaches	O	['N']	[20]
21	,	O	['N']	[21]
22	dizziness	O	['N']	[22]
23	,	O	['N']	[23]
24	difficulty	O	['N']	[24]
25	with	O	['N']	[25]
26	speech	O	['N']	[26]
27	,	O	['N']	[27]
28	weakness	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	itching	B	['N']	[31]
32	on	I	['N']	[32]
33	the	I	['N']	[33]
34	trunk	I-Adverse_Effect	['N']	[34]
35	of	O	['N']	[35]
36	his	O	['N']	[36]
37	body	O	['N']	[37]
38	and	O	['N']	[38]
39	legs	O	['N']	[39]
40	,	O	['N']	[40]
41	where	O	['N']	[41]
42	a	O	['N']	[42]
43	maculopapular	O	['N']	[43]
44	rash	O	['N']	[44]
45	was	O	['N']	[45]
46	noted	O	['N']	[46]
47	.	O	['N']	[47]
#1894
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	73-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	serious	O	['N']	[9]
10	systemic	O	['N']	[10]
11	vasculitis	O	['N']	[11]
12	with	O	['N']	[12]
13	associated	O	['N']	[13]
14	thrombocytopenia	B-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	course	O	['N']	[17]
18	of	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	cladribine	B-Drug	['Causes']	[14]
22	.	O	['N']	[22]
#1895
0	Posthypoglycemic	B	['N']	[0]
1	hyperglycemia	I-Adverse_Effect	['N']	[1]
2	(	O	['N']	[2]
3	rebound	O	['N']	[3]
4	hyperglycemia	O	['N']	[4]
5	)	O	['N']	[5]
6	after	O	['N']	[6]
7	overdosing	O	['N']	[7]
8	of	O	['N']	[8]
9	insulin	B-Drug	['Causes']	[1]
10	was	O	['N']	[10]
11	diagnosed	O	['N']	[11]
12	in	O	['N']	[12]
13	6	O	['N']	[13]
14	cats	O	['N']	[14]
15	with	O	['N']	[15]
16	diabetes	O	['N']	[16]
17	mellitus	O	['N']	[17]
18	.	O	['N']	[18]
#1896
0	As	O	['N']	[0]
1	far	O	['N']	[1]
2	as	O	['N']	[2]
3	we	O	['N']	[3]
4	know	O	['N']	[4]
5	,	O	['N']	[5]
6	this	O	['N']	[6]
7	is	O	['N']	[7]
8	the	O	['N']	[8]
9	first	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	of	O	['N']	[12]
13	acute	O	['N']	[13]
14	hemorrhagic	O	['N']	[14]
15	gastritis	O	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	AZ	B-Drug	['Causes']	[19]
19	intoxication	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#1897
0	Therefore	O	['N']	[0]
1	,	O	['N']	[1]
2	it	O	['N']	[2]
3	is	O	['N']	[3]
4	reasonable	O	['N']	[4]
5	to	O	['N']	[5]
6	conclude	O	['N']	[6]
7	that	O	['N']	[7]
8	:	O	['N']	[8]
9	1	O	['N']	[9]
10	)	O	['N']	[10]
11	2-CdA	B-Drug	['Causes']	[42]
12	can	O	['N']	[12]
13	induce	O	['N']	[13]
14	durable	O	['N']	[14]
15	complete	O	['N']	[15]
16	remission	O	['N']	[16]
17	in	O	['N']	[17]
18	MCD	O	['N']	[18]
19	patients	O	['N']	[19]
20	but	O	['N']	[20]
21	unfortunately	O	['N']	[21]
22	it	O	['N']	[22]
23	can	O	['N']	[23]
24	not	O	['N']	[24]
25	cure	O	['N']	[25]
26	the	O	['N']	[26]
27	disease	O	['N']	[27]
28	;	O	['N']	[28]
29	2	O	['N']	[29]
30	)	O	['N']	[30]
31	the	O	['N']	[31]
32	possibility	O	['N']	[32]
33	that	O	['N']	[33]
34	2-CdA	O	['N']	[34]
35	may	O	['N']	[35]
36	accelerate	O	['N']	[36]
37	the	O	['N']	[37]
38	transformation	B	['N']	[38]
39	of	I	['N']	[39]
40	MCD	I	['N']	[40]
41	to	I	['N']	[41]
42	NHL	I-Adverse_Effect	['N']	[42]
43	can	O	['N']	[43]
44	not	O	['N']	[44]
45	be	O	['N']	[45]
46	ruled	O	['N']	[46]
47	out	O	['N']	[47]
48	.	O	['N']	[48]
#1898
0	Disseminated	B	['N']	[0]
1	tuberculous	I	['N']	[1]
2	lesions	I-Adverse_Effect	['N']	[2]
3	post	O	['N']	[3]
4	intravesical	O	['N']	[4]
5	BCG	B-Drug	['Causes']	[2]
6	therapy	O	['N']	[6]
7	are	O	['N']	[7]
8	rare	O	['N']	[8]
9	but	O	['N']	[9]
10	need	O	['N']	[10]
11	to	O	['N']	[11]
12	be	O	['N']	[12]
13	identified	O	['N']	[13]
14	and	O	['N']	[14]
15	treated	O	['N']	[15]
16	quickly	O	['N']	[16]
17	.	O	['N']	[17]
#1899
0	Interestingly	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	use	O	['N']	[3]
4	of	O	['N']	[4]
5	carboplatin	O	['N']	[5]
6	(	O	['N']	[6]
7	CBDCA	O	['N']	[7]
8	)	O	['N']	[8]
9	and	O	['N']	[9]
10	VDS	O	['N']	[10]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	subsequent	O	['N']	[13]
14	treatment	O	['N']	[14]
15	course	O	['N']	[15]
16	was	O	['N']	[16]
17	well	O	['N']	[17]
18	tolerated	O	['N']	[18]
19	indicating	O	['N']	[19]
20	that	O	['N']	[20]
21	the	O	['N']	[21]
22	SIADH	B-Adverse_Effect	['N']	[22]
23	was	O	['N']	[23]
24	most	O	['N']	[24]
25	likely	O	['N']	[25]
26	to	O	['N']	[26]
27	have	O	['N']	[27]
28	been	O	['N']	[28]
29	induced	O	['N']	[29]
30	by	O	['N']	[30]
31	administration	O	['N']	[31]
32	of	O	['N']	[32]
33	CDDP	B-Drug	['Causes']	[22]
34	.	O	['N']	[34]
#1900
0	Only	O	['N']	[0]
1	one	O	['N']	[1]
2	case	O	['N']	[2]
3	of	O	['N']	[3]
4	severe	B	['N']	[4]
5	symptomatic	I	['N']	[5]
6	hepatitis	I-Adverse_Effect	['N']	[6]
7	occurring	O	['N']	[7]
8	after	O	['N']	[8]
9	pulse	O	['N']	[9]
10	therapy	O	['N']	[10]
11	with	O	['N']	[11]
12	itraconazole	B-Drug	['Causes']	[6]
13	for	O	['N']	[13]
14	onychomycosis	O	['N']	[14]
15	and	O	['N']	[15]
16	requiring	O	['N']	[16]
17	transplantation	O	['N']	[17]
18	has	O	['N']	[18]
19	been	O	['N']	[19]
20	reported	O	['N']	[20]
21	previously	O	['N']	[21]
22	.	O	['N']	[22]
#1901
0	Neutropenia	O	['N']	[0]
1	and	O	['N']	[1]
2	agranulocytosis	B-Adverse_Effect	['N']	[2]
3	are	O	['N']	[3]
4	risks	O	['N']	[4]
5	known	O	['N']	[5]
6	to	O	['N']	[6]
7	occur	O	['N']	[7]
8	with	O	['N']	[8]
9	phenothiazines	B-Drug	['Causes']	[2]
10	and	O	['N']	[10]
11	clozapine	O	['N']	[11]
12	.	O	['N']	[12]
#1902
0	We	O	['N']	[0]
1	hypothesize	O	['N']	[1]
2	that	O	['N']	[2]
3	caffeine	B-Drug	['Causes']	[22]
4	toxicity	O	['N']	[4]
5	injured	O	['N']	[5]
6	the	O	['N']	[6]
7	muscle	O	['N']	[7]
8	cells	O	['N']	[8]
9	,	O	['N']	[9]
10	which	O	['N']	[10]
11	were	O	['N']	[11]
12	fragile	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	potassium	O	['N']	[16]
17	depletion	O	['N']	[17]
18	induced	O	['N']	[18]
19	by	O	['N']	[19]
20	the	O	['N']	[20]
21	coexisting	B	['N']	[21]
22	hyponatremia	I-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	to	O	['N']	[24]
25	result	O	['N']	[25]
26	in	O	['N']	[26]
27	unusually	O	['N']	[27]
28	severe	O	['N']	[28]
29	rhabdomyolysis	O	['N']	[29]
30	.	O	['N']	[30]
#1903
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	neuroleptic	O	['N']	[7]
8	malignant	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	(	O	['N']	[10]
11	NMS	B-Adverse_Effect	['N']	[11]
12	)	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	fluphenazine	B-Drug	['Causes']	[11]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	schizophrenic	O	['N']	[18]
19	patient	O	['N']	[19]
20	and	O	['N']	[20]
21	review	O	['N']	[21]
22	the	O	['N']	[22]
23	literature	O	['N']	[23]
24	related	O	['N']	[24]
25	to	O	['N']	[25]
26	this	O	['N']	[26]
27	condition	O	['N']	[27]
28	.	O	['N']	[28]
#1904
0	We	O	['N']	[0]
1	highlight	O	['N']	[1]
2	two	O	['N']	[2]
3	instances	O	['N']	[3]
4	of	O	['N']	[4]
5	systemic	B	['N']	[5]
6	allergic	I	['N']	[6]
7	reaction	I-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	discuss	O	['N']	[10]
11	the	O	['N']	[11]
12	potential	O	['N']	[12]
13	side	O	['N']	[13]
14	effects	O	['N']	[14]
15	of	O	['N']	[15]
16	local	O	['N']	[16]
17	aprotinin	B-Drug	['Causes']	[7]
18	injections	O	['N']	[18]
19	in	O	['N']	[19]
20	the	O	['N']	[20]
21	orthopaedic	O	['N']	[21]
22	setting	O	['N']	[22]
23	as	O	['N']	[23]
24	well	O	['N']	[24]
25	as	O	['N']	[25]
26	the	O	['N']	[26]
27	evidence	O	['N']	[27]
28	base	O	['N']	[28]
29	for	O	['N']	[29]
30	its	O	['N']	[30]
31	use	O	['N']	[31]
32	.	O	['N']	[32]
#1905
0	Treatment	O	['N']	[0]
1	with	O	['N']	[1]
2	infliximab	B-Drug	['Causes']	[20]
3	is	O	['N']	[3]
4	known	O	['N']	[4]
5	to	O	['N']	[5]
6	produce	O	['N']	[6]
7	an	O	['N']	[7]
8	increase	O	['N']	[8]
9	of	O	['N']	[9]
10	autoantibodies	O	['N']	[10]
11	(	O	['N']	[11]
12	antinuclear	O	['N']	[12]
13	antibodies	O	['N']	[13]
14	,	O	['N']	[14]
15	anti	B	['N']	[15]
16	-	I	['N']	[16]
17	double	I	['N']	[17]
18	-	I	['N']	[18]
19	stranded	I	['N']	[19]
20	DNA	I-Adverse_Effect	['N']	[20]
21	)	O	['N']	[21]
22	,	O	['N']	[22]
23	but	O	['N']	[23]
24	not	O	['N']	[24]
25	clinical	O	['N']	[25]
26	disease	O	['N']	[26]
27	.	O	['N']	[27]
#1906
0	Horner	B	['N']	[0]
1	's	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	demyelinating	O	['N']	[4]
5	peripheral	O	['N']	[5]
6	neuropathy	O	['N']	[6]
7	caused	O	['N']	[7]
8	by	O	['N']	[8]
9	high	O	['N']	[9]
10	-	O	['N']	[10]
11	dose	O	['N']	[11]
12	cytosine	B	['N']	[12]
13	arabinoside	I-Drug	['Causes']	[2]
14	.	O	['N']	[14]
#1907
0	Trazodone	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	transient	B	['N']	[3]
4	hypomanic	I	['N']	[4]
5	symptoms	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	their	O	['N']	[7]
8	management	O	['N']	[8]
9	.	O	['N']	[9]
#1908
0	Fibrosis	B	['N']	[0]
1	of	I	['N']	[1]
2	corpus	I	['N']	[2]
3	cavernosum	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	intracavernous	O	['N']	[5]
6	injection	O	['N']	[6]
7	of	O	['N']	[7]
8	phentolamine	O	['N']	[8]
9	/	O	['N']	[9]
10	papaverine	B-Drug	['Causes']	[3]
11	.	O	['N']	[11]
#1909
0	The	O	['N']	[0]
1	pharmacology	O	['N']	[1]
2	and	O	['N']	[2]
3	toxicology	O	['N']	[3]
4	of	O	['N']	[4]
5	chloral	B	['N']	[5]
6	hydrate	I-Drug	['Dosage']	[20]
7	are	O	['N']	[7]
8	discussed	O	['N']	[8]
9	with	O	['N']	[9]
10	particular	O	['N']	[10]
11	reference	O	['N']	[11]
12	to	O	['N']	[12]
13	the	O	['N']	[13]
14	cardiac	O	['N']	[14]
15	arrhythmias	O	['N']	[15]
16	that	O	['N']	[16]
17	are	O	['N']	[17]
18	seen	O	['N']	[18]
19	with	O	['N']	[19]
20	overdosage	B-Dose	['N']	[20]
21	.	O	['N']	[21]
#1910
0	Scleroderma	B	['N']	[0]
1	-	I	['N']	[1]
2	like	I	['N']	[2]
3	reaction	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	uracil	O	['N']	[6]
7	-	O	['N']	[7]
8	tegafur	O	['N']	[8]
9	(	O	['N']	[9]
10	UFT	B-Drug	['Causes']	[3]
11	)	O	['N']	[11]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	second	O	['N']	[14]
15	-	O	['N']	[15]
16	generation	O	['N']	[16]
17	anticancer	O	['N']	[17]
18	agent	O	['N']	[18]
19	.	O	['N']	[19]
#1911
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	B-Drug	['Causes']	[31]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	B-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	O	['N']	[34]
35	.	O	['N']	[35]
#1912
0	Severe	O	['N']	[0]
1	abdominal	O	['N']	[1]
2	pain	O	['N']	[2]
3	in	O	['N']	[3]
4	low	B-Dose	['N']	[4]
5	dosage	O	['N']	[5]
6	clofazimine	B-Drug	['Dosage']	[4]
7	.	O	['N']	[7]
#1913
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	three	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	IFN	B	['N']	[5]
6	beta	I-Drug	['Causes']	[8]
7	induced	O	['N']	[7]
8	hepatitis	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	MS	O	['N']	[10]
11	and	O	['N']	[11]
12	discuss	O	['N']	[12]
13	the	O	['N']	[13]
14	pathology	O	['N']	[14]
15	findings	O	['N']	[15]
16	and	O	['N']	[16]
17	possible	O	['N']	[17]
18	mechanisms	O	['N']	[18]
19	of	O	['N']	[19]
20	drug	O	['N']	[20]
21	-	O	['N']	[21]
22	induced	O	['N']	[22]
23	liver	O	['N']	[23]
24	injury	O	['N']	[24]
25	.	O	['N']	[25]
#1914
0	Aggressive	O	['N']	[0]
1	management	O	['N']	[1]
2	of	O	['N']	[2]
3	doxorubicin	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	cardiomyopathy	B-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	'	O	['N']	[9]
10	low	O	['N']	[10]
11	'	O	['N']	[11]
12	doses	O	['N']	[12]
13	of	O	['N']	[13]
14	doxorubicin	O	['N']	[14]
15	.	O	['N']	[15]
#1915
0	Patients	O	['N']	[0]
1	with	O	['N']	[1]
2	vitamin	O	['N']	[2]
3	B12	O	['N']	[3]
4	deficiency	O	['N']	[4]
5	are	O	['N']	[5]
6	exceedingly	O	['N']	[6]
7	sensitive	O	['N']	[7]
8	to	O	['N']	[8]
9	neurologic	B	['N']	[9]
10	deterioration	I-Adverse_Effect	['N']	[10]
11	following	O	['N']	[11]
12	nitrous	B	['N']	[12]
13	oxide	I-Drug	['Causes']	[10]
14	anesthesia	O	['N']	[14]
15	.	O	['N']	[15]
#1916
0	This	O	['N']	[0]
1	compound	O	['N']	[1]
2	,	O	['N']	[2]
3	used	O	['N']	[3]
4	by	O	['N']	[4]
5	adults	O	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	child	O	['N']	[8]
9	's	O	['N']	[9]
10	home	O	['N']	[10]
11	,	O	['N']	[11]
12	had	O	['N']	[12]
13	caused	O	['N']	[13]
14	accidental	O	['N']	[14]
15	theophylline	B-Drug	['Causes']	[16]
16	poisoning	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	mimicking	O	['N']	[18]
19	diabetic	O	['N']	[19]
20	ketoacidosis	O	['N']	[20]
21	.	O	['N']	[21]
#1917
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	chronic	O	['N']	[3]
4	myeloid	O	['N']	[4]
5	leukaemia	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	busulphan	B-Drug	['Causes']	[22]
9	for	O	['N']	[9]
10	4	O	['N']	[10]
11	-	O	['N']	[11]
12	5	O	['N']	[12]
13	years	O	['N']	[13]
14	,	O	['N']	[14]
15	developed	O	['N']	[15]
16	signs	O	['N']	[16]
17	of	O	['N']	[17]
18	busulphan	O	['N']	[18]
19	toxicity	O	['N']	[19]
20	and	O	['N']	[20]
21	portal	B	['N']	[21]
22	hypertension	I-Adverse_Effect	['N']	[22]
23	with	O	['N']	[23]
24	ascites	O	['N']	[24]
25	,	O	['N']	[25]
26	oesophageal	O	['N']	[26]
27	varices	O	['N']	[27]
28	and	O	['N']	[28]
29	jaundice	O	['N']	[29]
30	.	O	['N']	[30]
#1918
0	Although	O	['N']	[0]
1	they	O	['N']	[1]
2	had	O	['N']	[2]
3	only	O	['N']	[3]
4	a	O	['N']	[4]
5	few	O	['N']	[5]
6	nodules	B-Adverse_Effect	['N']	[6]
7	at	O	['N']	[7]
8	diagnosis	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	nodules	O	['N']	[11]
12	increased	O	['N']	[12]
13	in	O	['N']	[13]
14	number	O	['N']	[14]
15	and	O	['N']	[15]
16	size	O	['N']	[16]
17	3	O	['N']	[17]
18	to	O	['N']	[18]
19	4	O	['N']	[19]
20	months	O	['N']	[20]
21	after	O	['N']	[21]
22	the	O	['N']	[22]
23	start	O	['N']	[23]
24	of	O	['N']	[24]
25	methotrexate	B-Drug	['Causes']	[6]
26	therapy	O	['N']	[26]
27	in	O	['N']	[27]
28	both	O	['N']	[28]
29	patients	O	['N']	[29]
30	.	O	['N']	[30]
#1919
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	Two	O	['N']	[3]
4	children	O	['N']	[4]
5	with	O	['N']	[5]
6	attention	O	['N']	[6]
7	deficit	O	['N']	[7]
8	disorder	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	methylphenidate	B-Drug	['Causes']	[22]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	simple	O	['N']	[14]
15	drug	O	['N']	[15]
16	developed	O	['N']	[16]
17	fixed	B	['N']	[17]
18	drug	I	['N']	[18]
19	eruption	I	['N']	[19]
20	of	I	['N']	[20]
21	the	I	['N']	[21]
22	scrotum	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#1920
0	Paradoxical	O	['N']	[0]
1	seizures	B-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	phenytoin	B-Drug	['Causes']	[1]
4	toxicity	O	['N']	[4]
5	.	O	['N']	[5]
#1921
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	O	['N']	[14]
15	with	O	['N']	[15]
16	folinic	B	['N']	[16]
17	acid	I-Drug	['Causes']	[37]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	B-Adverse_Effect	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#1922
0	Radiation	B	['N']	[0]
1	recall	I-Adverse_Effect	['N']	[1]
2	from	O	['N']	[2]
3	gemcitabine	B-Drug	['Causes']	[1]
4	is	O	['N']	[4]
5	rare	O	['N']	[5]
6	,	O	['N']	[6]
7	but	O	['N']	[7]
8	can	O	['N']	[8]
9	potentially	O	['N']	[9]
10	arise	O	['N']	[10]
11	in	O	['N']	[11]
12	any	O	['N']	[12]
13	site	O	['N']	[13]
14	that	O	['N']	[14]
15	has	O	['N']	[15]
16	been	O	['N']	[16]
17	previously	O	['N']	[17]
18	irradiated	O	['N']	[18]
19	.	O	['N']	[19]
#1923
0	When	O	['N']	[0]
1	SASP	O	['N']	[1]
2	was	O	['N']	[2]
3	changed	O	['N']	[3]
4	to	O	['N']	[4]
5	5-aminosalicylic	B	['N']	[5]
6	acid	I-Drug	['Causes']	[41]
7	(	O	['N']	[7]
8	5-ASA	O	['N']	[8]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	his	O	['N']	[11]
12	skin	O	['N']	[12]
13	eruptions	O	['N']	[13]
14	were	O	['N']	[14]
15	resolved	O	['N']	[15]
16	,	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	he	O	['N']	[19]
20	developed	O	['N']	[20]
21	weakness	O	['N']	[21]
22	and	O	['N']	[22]
23	atrophy	O	['N']	[23]
24	in	O	['N']	[24]
25	his	O	['N']	[25]
26	right	O	['N']	[26]
27	arm	O	['N']	[27]
28	as	O	['N']	[28]
29	well	O	['N']	[29]
30	as	O	['N']	[30]
31	progressive	O	['N']	[31]
32	worsening	O	['N']	[32]
33	of	O	['N']	[33]
34	the	O	['N']	[34]
35	dysesthesia	O	['N']	[35]
36	in	O	['N']	[36]
37	his	O	['N']	[37]
38	legs	O	['N']	[38]
39	and	O	['N']	[39]
40	gait	B	['N']	[40]
41	disturbance	I-Adverse_Effect	['N']	[41]
42	.	O	['N']	[42]
#1924
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	young	O	['N']	[4]
5	adolescent	O	['N']	[5]
6	with	O	['N']	[6]
7	benign	B	['N']	[7]
8	intracranial	I	['N']	[8]
9	hypertension	I-Adverse_Effect	['N']	[9]
10	which	O	['N']	[10]
11	we	O	['N']	[11]
12	attribute	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	use	O	['N']	[15]
16	of	O	['N']	[16]
17	minocycline	B-Drug	['Causes']	[9]
18	for	O	['N']	[18]
19	acne	O	['N']	[19]
20	.	O	['N']	[20]
#1925
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	20-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	originally	O	['N']	[10]
11	from	O	['N']	[11]
12	Cameroon	O	['N']	[12]
13	who	O	['N']	[13]
14	was	O	['N']	[14]
15	infected	O	['N']	[15]
16	by	O	['N']	[16]
17	the	O	['N']	[17]
18	L.	O	['N']	[18]
19	loa	O	['N']	[19]
20	parasite	O	['N']	[20]
21	and	O	['N']	[21]
22	developed	O	['N']	[22]
23	severe	B	['N']	[23]
24	hepatitis	I-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	identified	O	['N']	[26]
27	1	O	['N']	[27]
28	month	O	['N']	[28]
29	after	O	['N']	[29]
30	a	O	['N']	[30]
31	single	O	['N']	[31]
32	dose	O	['N']	[32]
33	of	O	['N']	[33]
34	ivermectin	B-Drug	['Causes']	[24]
35	.	O	['N']	[35]
#1926
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	these	O	['N']	[4]
5	cases	O	['N']	[5]
6	represent	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	reports	O	['N']	[9]
10	of	O	['N']	[10]
11	TDF	B-Drug	['Causes']	[18]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	irreversible	O	['N']	[14]
15	renal	O	['N']	[15]
16	failure	O	['N']	[16]
17	and	O	['N']	[17]
18	rickets	B-Adverse_Effect	['N']	[18]
19	in	O	['N']	[19]
20	pediatric	O	['N']	[20]
21	patients	O	['N']	[21]
22	.	O	['N']	[22]
#1927
0	Histological	O	['N']	[0]
1	examination	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	dacryolith	B-Adverse_Effect	['N']	[4]
5	suggested	O	['N']	[5]
6	its	O	['N']	[6]
7	derivation	O	['N']	[7]
8	from	O	['N']	[8]
9	breakdown	O	['N']	[9]
10	products	O	['N']	[10]
11	of	O	['N']	[11]
12	adrenaline	B-Drug	['Causes']	[4]
13	.	O	['N']	[13]
#1928
0	Atypical	B	['N']	[0]
1	ventricular	I	['N']	[1]
2	tachycardia	I-Adverse_Effect	['N']	[2]
3	(	O	['N']	[3]
4	torsade	O	['N']	[4]
5	de	O	['N']	[5]
6	pointes	O	['N']	[6]
7	)	O	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	amiodarone	B-Drug	['Causes']	[2]
11	:	O	['N']	[11]
12	arrhythmia	O	['N']	[12]
13	previously	O	['N']	[13]
14	induced	O	['N']	[14]
15	by	O	['N']	[15]
16	quinidine	O	['N']	[16]
17	and	O	['N']	[17]
18	disopyramide	O	['N']	[18]
19	.	O	['N']	[19]
#1929
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Alendronate	B-Drug	['Causes']	[6]
3	led	O	['N']	[3]
4	to	O	['N']	[4]
5	nodular	O	['N']	[5]
6	scleritis	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	rechallenge	O	['N']	[8]
9	caused	O	['N']	[9]
10	recurrence	O	['N']	[10]
11	of	O	['N']	[11]
12	scleritis	O	['N']	[12]
13	.	O	['N']	[13]
#1930
0	Rapid	O	['N']	[0]
1	onset	O	['N']	[1]
2	of	O	['N']	[2]
3	quetiapine	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	diabetic	B	['N']	[6]
7	ketoacidosis	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	an	O	['N']	[9]
10	elderly	O	['N']	[10]
11	patient	O	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	case	O	['N']	[14]
15	report	O	['N']	[15]
16	.	O	['N']	[16]
#1931
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	picture	O	['N']	[2]
3	was	O	['N']	[3]
4	identical	O	['N']	[4]
5	to	O	['N']	[5]
6	that	O	['N']	[6]
7	of	O	['N']	[7]
8	chloroquine	O	['N']	[8]
9	and	O	['N']	[9]
10	hydroxychloroquine	B-Drug	['Causes']	[11]
11	maculopathy	B-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#1932
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	osteosarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	normal	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	manifested	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	impending	O	['N']	[15]
16	renal	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	and	O	['N']	[18]
19	extreme	O	['N']	[19]
20	elevation	O	['N']	[20]
21	of	O	['N']	[21]
22	aspartate	O	['N']	[22]
23	aminotrasferase	O	['N']	[23]
24	and	O	['N']	[24]
25	alanine	O	['N']	[25]
26	aminotransferase	O	['N']	[26]
27	within	O	['N']	[27]
28	2	O	['N']	[28]
29	hours	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	completion	O	['N']	[32]
33	of	O	['N']	[33]
34	a	O	['N']	[34]
35	4-hour	O	['N']	[35]
36	infusion	O	['N']	[36]
37	of	O	['N']	[37]
38	high	O	['N']	[38]
39	-	O	['N']	[39]
40	dose	O	['N']	[40]
41	methotrexate	B-Drug	['Dosage']	[49]
42	(	O	['N']	[42]
43	MTX	O	['N']	[43]
44	)	O	['N']	[44]
45	(	O	['N']	[45]
46	12	B	['N']	[46]
47	g	I	['N']	[47]
48	/	I	['N']	[48]
49	m2	I-Dose	['N']	[49]
50	)	O	['N']	[50]
51	,	O	['N']	[51]
52	and	O	['N']	[52]
53	went	O	['N']	[53]
54	on	O	['N']	[54]
55	to	O	['N']	[55]
56	develop	O	['N']	[56]
57	acute	O	['N']	[57]
58	renal	O	['N']	[58]
59	failure	O	['N']	[59]
60	with	O	['N']	[60]
61	life	O	['N']	[61]
62	-	O	['N']	[62]
63	threatening	O	['N']	[63]
64	hyperkalemia	O	['N']	[64]
65	29	O	['N']	[65]
66	hours	O	['N']	[66]
67	later	O	['N']	[67]
68	.	O	['N']	[68]
#1933
0	Chronic	O	['N']	[0]
1	myelogenous	O	['N']	[1]
2	leukemia	O	['N']	[2]
3	(	O	['N']	[3]
4	CML	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	hepatitis	O	['N']	[7]
8	C	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	interferon	O	['N']	[11]
12	alpha	O	['N']	[12]
13	(	O	['N']	[13]
14	IFNalpha	B-Drug	['Causes']	[22]
15	)	O	['N']	[15]
16	have	O	['N']	[16]
17	all	O	['N']	[17]
18	been	O	['N']	[18]
19	associated	O	['N']	[19]
20	with	O	['N']	[20]
21	renal	B	['N']	[21]
22	dysfunction	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#1934
0	A	O	['N']	[0]
1	53	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	Greenlandic	O	['N']	[4]
5	male	O	['N']	[5]
6	was	O	['N']	[6]
7	admitted	O	['N']	[7]
8	twice	O	['N']	[8]
9	over	O	['N']	[9]
10	a	O	['N']	[10]
11	period	O	['N']	[11]
12	of	O	['N']	[12]
13	4	O	['N']	[13]
14	years	O	['N']	[14]
15	with	O	['N']	[15]
16	a	O	['N']	[16]
17	new	O	['N']	[17]
18	complete	O	['N']	[18]
19	right	B	['N']	[19]
20	bundle	I	['N']	[20]
21	branch	I	['N']	[21]
22	block	I-Adverse_Effect	['N']	[22]
23	after	O	['N']	[23]
24	ingestion	O	['N']	[24]
25	of	O	['N']	[25]
26	10	O	['N']	[26]
27	g	O	['N']	[27]
28	and	O	['N']	[28]
29	4	O	['N']	[29]
30	g	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	B-Drug	['Causes']	[22]
33	respectively	O	['N']	[33]
34	.	O	['N']	[34]
#1935
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	received	O	['N']	[2]
3	respectively	O	['N']	[3]
4	190	B	['N']	[4]
5	mg	I-Dose	['N']	[5]
6	,	O	['N']	[6]
7	175	O	['N']	[7]
8	mg	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	196	O	['N']	[11]
12	mg	O	['N']	[12]
13	of	O	['N']	[13]
14	methotrexate	B-Drug	['Dosage']	[5]
15	and	O	['N']	[15]
16	developed	O	['N']	[16]
17	bilateral	O	['N']	[17]
18	pulmonary	O	['N']	[18]
19	infiltrates	O	['N']	[19]
20	without	O	['N']	[20]
21	evidence	O	['N']	[21]
22	of	O	['N']	[22]
23	peripheral	O	['N']	[23]
24	blood	O	['N']	[24]
25	eosinophilia	O	['N']	[25]
26	.	O	['N']	[26]
#1936
0	Currently	O	['N']	[0]
1	the	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	zidovudine	B-Drug	['Causes']	[35]
5	is	O	['N']	[5]
6	one	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	few	O	['N']	[9]
10	specific	O	['N']	[10]
11	measures	O	['N']	[11]
12	available	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	as	O	['N']	[15]
16	a	O	['N']	[16]
17	potentially	O	['N']	[17]
18	teratogenic	O	['N']	[18]
19	and	O	['N']	[19]
20	fetotoxic	O	['N']	[20]
21	agent	O	['N']	[21]
22	,	O	['N']	[22]
23	any	O	['N']	[23]
24	decision	O	['N']	[24]
25	for	O	['N']	[25]
26	its	O	['N']	[26]
27	use	O	['N']	[27]
28	requires	O	['N']	[28]
29	evaluation	O	['N']	[29]
30	of	O	['N']	[30]
31	the	O	['N']	[31]
32	potential	O	['N']	[32]
33	for	O	['N']	[33]
34	fetal	B	['N']	[34]
35	damage	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#1937
0	The	O	['N']	[0]
1	azathioprine	B-Drug	['Causes']	[12]
2	dose	O	['N']	[2]
3	was	O	['N']	[3]
4	low	O	['N']	[4]
5	(	O	['N']	[5]
6	1	O	['N']	[6]
7	mg	O	['N']	[7]
8	/	O	['N']	[8]
9	kg	O	['N']	[9]
10	)	O	['N']	[10]
11	and	O	['N']	[11]
12	pancytopenia	B-Adverse_Effect	['N']	[12]
13	occurred	O	['N']	[13]
14	after	O	['N']	[14]
15	56	O	['N']	[15]
16	days	O	['N']	[16]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#1938
0	Four	O	['N']	[0]
1	Chinese	O	['N']	[1]
2	female	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	suffered	O	['N']	[5]
6	from	O	['N']	[6]
7	manic	O	['N']	[7]
8	-	O	['N']	[8]
9	depressive	O	['N']	[9]
10	disorder	O	['N']	[10]
11	and	O	['N']	[11]
12	underlying	O	['N']	[12]
13	autoimmune	O	['N']	[13]
14	thyroiditis	O	['N']	[14]
15	developed	O	['N']	[15]
16	transient	O	['N']	[16]
17	episodes	O	['N']	[17]
18	of	O	['N']	[18]
19	thyrotoxicosis	B-Adverse_Effect	['N']	[19]
20	during	O	['N']	[20]
21	maintenance	O	['N']	[21]
22	lithium	B-Drug	['Causes']	[19]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#1939
0	The	O	['N']	[0]
1	disease	O	['N']	[1]
2	-	O	['N']	[2]
3	modifying	O	['N']	[3]
4	drugs	O	['N']	[4]
5	he	O	['N']	[5]
6	was	O	['N']	[6]
7	taking	O	['N']	[7]
8	,	O	['N']	[8]
9	cyclosporin	B-Drug	['Causes']	[18]
10	and	O	['N']	[10]
11	methotrexate	O	['N']	[11]
12	,	O	['N']	[12]
13	were	O	['N']	[13]
14	stopped	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	the	O	['N']	[17]
18	lymphoma	B-Adverse_Effect	['N']	[18]
19	resolved	O	['N']	[19]
20	spontaneously	O	['N']	[20]
21	without	O	['N']	[21]
22	the	O	['N']	[22]
23	use	O	['N']	[23]
24	of	O	['N']	[24]
25	chemotherapy	O	['N']	[25]
26	.	O	['N']	[26]
#1940
0	A	O	['N']	[0]
1	70-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	was	O	['N']	[5]
6	admitted	O	['N']	[6]
7	to	O	['N']	[7]
8	our	O	['N']	[8]
9	hospital	O	['N']	[9]
10	because	O	['N']	[10]
11	of	O	['N']	[11]
12	dyspnea	B-Adverse_Effect	['N']	[12]
13	after	O	['N']	[13]
14	taking	O	['N']	[14]
15	an	O	['N']	[15]
16	antihistaminic	O	['N']	[16]
17	agent	O	['N']	[17]
18	(	O	['N']	[18]
19	homochlorcyclizine	B	['N']	[19]
20	hydrochloride	I-Drug	['Causes']	[12]
21	)	O	['N']	[21]
22	for	O	['N']	[22]
23	itching	O	['N']	[23]
24	.	O	['N']	[24]
#1941
0	An	O	['N']	[0]
1	11-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	who	O	['N']	[5]
6	was	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	relatively	O	['N']	[10]
11	high	O	['N']	[11]
12	dose	O	['N']	[12]
13	of	O	['N']	[13]
14	methotrimeprazine	O	['N']	[14]
15	meleate	O	['N']	[15]
16	(	O	['N']	[16]
17	Levemepromazine	B-Drug	['Causes']	[36]
18	)	O	['N']	[18]
19	a	O	['N']	[19]
20	phenothiazine	O	['N']	[20]
21	antipsychotic	O	['N']	[21]
22	drug	O	['N']	[22]
23	,	O	['N']	[23]
24	was	O	['N']	[24]
25	admitted	O	['N']	[25]
26	to	O	['N']	[26]
27	the	O	['N']	[27]
28	pediatric	O	['N']	[28]
29	intensive	O	['N']	[29]
30	care	O	['N']	[30]
31	unit	O	['N']	[31]
32	suffering	O	['N']	[32]
33	from	O	['N']	[33]
34	respiratory	B	['N']	[34]
35	distress	I	['N']	[35]
36	syndrome	I-Adverse_Effect	['N']	[36]
37	.	O	['N']	[37]
#1942
0	A	O	['N']	[0]
1	twelve	O	['N']	[1]
2	year	O	['N']	[2]
3	-	O	['N']	[3]
4	old	O	['N']	[4]
5	-	O	['N']	[5]
6	girl	O	['N']	[6]
7	with	O	['N']	[7]
8	idiopathic	O	['N']	[8]
9	partial	O	['N']	[9]
10	epilepsy	O	['N']	[10]
11	with	O	['N']	[11]
12	secondary	O	['N']	[12]
13	generalization	O	['N']	[13]
14	,	O	['N']	[14]
15	developed	O	['N']	[15]
16	acute	B	['N']	[16]
17	psychosis	I-Adverse_Effect	['N']	[17]
18	10	O	['N']	[18]
19	days	O	['N']	[19]
20	after	O	['N']	[20]
21	the	O	['N']	[21]
22	administration	O	['N']	[22]
23	of	O	['N']	[23]
24	levetiracetam	B-Drug	['Causes']	[17]
25	.	O	['N']	[25]
#1943
0	Captopril	B-Drug	['Causes']	[8]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	(	O	['N']	[3]
4	and	O	['N']	[4]
5	-induced	O	['N']	[5]
6	?	O	['N']	[6]
7	)	O	['N']	[7]
8	asthma	B-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#1944
0	INTRODUCTION	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	neurointensive	O	['N']	[5]
6	care	O	['N']	[6]
7	(	O	['N']	[7]
8	NIC	O	['N']	[8]
9	)	O	['N']	[9]
10	management	O	['N']	[10]
11	of	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	severe	O	['N']	[15]
16	cerebral	O	['N']	[16]
17	swelling	O	['N']	[17]
18	and	O	['N']	[18]
19	raised	B	['N']	[19]
20	intracranial	I	['N']	[20]
21	pressure	I-Adverse_Effect	['N']	[21]
22	(	O	['N']	[22]
23	ICP	O	['N']	[23]
24	)	O	['N']	[24]
25	after	O	['N']	[25]
26	severe	O	['N']	[26]
27	sodium	B	['N']	[27]
28	valproic	I	['N']	[28]
29	acid	I-Drug	['Causes']	[21]
30	(	O	['N']	[30]
31	VPA	O	['N']	[31]
32	)	O	['N']	[32]
33	intoxication	O	['N']	[33]
34	.	O	['N']	[34]
#1945
0	We	O	['N']	[0]
1	reviewed	O	['N']	[1]
2	the	O	['N']	[2]
3	literature	O	['N']	[3]
4	in	O	['N']	[4]
5	an	O	['N']	[5]
6	attempt	O	['N']	[6]
7	to	O	['N']	[7]
8	characterize	O	['N']	[8]
9	the	O	['N']	[9]
10	pattern	O	['N']	[10]
11	and	O	['N']	[11]
12	predictors	O	['N']	[12]
13	of	O	['N']	[13]
14	TMP	B-Drug	['Causes']	[20]
15	/	O	['N']	[15]
16	SMX	O	['N']	[16]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	aseptic	B	['N']	[19]
20	meningitis	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#1946
0	Hepatitis	B-Adverse_Effect	['N']	[0]
1	following	O	['N']	[1]
2	cimetidine	B-Drug	['Causes']	[0]
3	administration	O	['N']	[3]
4	.	O	['N']	[4]
#1947
0	The	O	['N']	[0]
1	diagnosis	O	['N']	[1]
2	was	O	['N']	[2]
3	based	O	['N']	[3]
4	on	O	['N']	[4]
5	the	O	['N']	[5]
6	rapid	O	['N']	[6]
7	onset	O	['N']	[7]
8	of	O	['N']	[8]
9	renal	B	['N']	[9]
10	failure	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	presence	O	['N']	[12]
13	of	O	['N']	[13]
14	eosinophilia	O	['N']	[14]
15	,	O	['N']	[15]
16	skin	O	['N']	[16]
17	rash	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	characteristic	O	['N']	[20]
21	renal	O	['N']	[21]
22	biopsy	O	['N']	[22]
23	finding	O	['N']	[23]
24	,	O	['N']	[24]
25	following	O	['N']	[25]
26	the	O	['N']	[26]
27	administration	O	['N']	[27]
28	of	O	['N']	[28]
29	ampicillin	B-Drug	['Causes']	[10]
30	.	O	['N']	[30]
#1948
0	Vancomycin	B-Drug	['Causes']	[47]
1	is	O	['N']	[1]
2	widely	O	['N']	[2]
3	used	O	['N']	[3]
4	against	O	['N']	[4]
5	methicillin	O	['N']	[5]
6	-	O	['N']	[6]
7	resistant	O	['N']	[7]
8	Staphylococcus	O	['N']	[8]
9	aureus	O	['N']	[9]
10	infections	O	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	it	O	['N']	[13]
14	is	O	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	many	O	['N']	[17]
18	adverse	O	['N']	[18]
19	effects	O	['N']	[19]
20	such	O	['N']	[20]
21	as	O	['N']	[21]
22	nephrotoxicity	O	['N']	[22]
23	,	O	['N']	[23]
24	ototoxicity	O	['N']	[24]
25	,	O	['N']	[25]
26	gastrointestinal	O	['N']	[26]
27	disturbances	O	['N']	[27]
28	,	O	['N']	[28]
29	blood	O	['N']	[29]
30	disorders	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	two	O	['N']	[33]
34	types	O	['N']	[34]
35	of	O	['N']	[35]
36	hypersensitivity	O	['N']	[36]
37	reactions	O	['N']	[37]
38	-	O	['N']	[38]
39	an	O	['N']	[39]
40	anaphylactoid	O	['N']	[40]
41	reaction	O	['N']	[41]
42	known	O	['N']	[42]
43	as	O	['N']	[43]
44	"	O	['N']	[44]
45	red	B	['N']	[45]
46	man	I	['N']	[46]
47	syndrome	I-Adverse_Effect	['N']	[47]
48	"	O	['N']	[48]
49	and	O	['N']	[49]
50	anaphylaxis	O	['N']	[50]
51	.	O	['N']	[51]
#1949
0	Interference	B	['N']	[0]
1	with	I	['N']	[1]
2	the	I	['N']	[2]
3	cortisol	I	['N']	[3]
4	axis	I-Adverse_Effect	['N']	[4]
5	by	O	['N']	[5]
6	the	O	['N']	[6]
7	microtubule	O	['N']	[7]
8	antagonist	O	['N']	[8]
9	,	O	['N']	[9]
10	CPH82	B-Drug	['Causes']	[4]
11	.	O	['N']	[11]
#1950
0	While	O	['N']	[0]
1	both	O	['N']	[1]
2	amiodarone	B-Drug	['Causes']	[9]
3	and	O	['N']	[3]
4	digoxin	O	['N']	[4]
5	can	O	['N']	[5]
6	cause	O	['N']	[6]
7	permanent	O	['N']	[7]
8	visual	B	['N']	[8]
9	changes	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	the	O	['N']	[11]
12	ocular	O	['N']	[12]
13	effects	O	['N']	[13]
14	are	O	['N']	[14]
15	often	O	['N']	[15]
16	reversible	O	['N']	[16]
17	.	O	['N']	[17]
#1951
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	,	O	['N']	[2]
3	ethambutol	B-Drug	['Causes']	[7]
4	rarely	O	['N']	[4]
5	causes	O	['N']	[5]
6	visual	B	['N']	[6]
7	loss	I-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	the	O	['N']	[9]
10	early	O	['N']	[10]
11	period	O	['N']	[11]
12	or	O	['N']	[12]
13	when	O	['N']	[13]
14	given	O	['N']	[14]
15	at	O	['N']	[15]
16	lower	O	['N']	[16]
17	doses	O	['N']	[17]
18	.	O	['N']	[18]
#1952
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	bullous	B	['N']	[6]
7	lichenoid	I	['N']	[7]
8	eruption	I-Adverse_Effect	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	the	O	['N']	[11]
12	intake	O	['N']	[12]
13	of	O	['N']	[13]
14	captopril	B-Drug	['Causes']	[8]
15	.	O	['N']	[15]
#1953
0	We	O	['N']	[0]
1	concluded	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	colonic	O	['N']	[4]
5	ulcer	O	['N']	[5]
6	and	O	['N']	[6]
7	the	O	['N']	[7]
8	sigmoidovesical	B	['N']	[8]
9	fistula	I-Adverse_Effect	['N']	[9]
10	had	O	['N']	[10]
11	been	O	['N']	[11]
12	caused	O	['N']	[12]
13	by	O	['N']	[13]
14	the	O	['N']	[14]
15	administration	O	['N']	[15]
16	of	O	['N']	[16]
17	calcium	B	['N']	[17]
18	polystyrene	I	['N']	[18]
19	sulfonate	I-Drug	['Causes']	[9]
20	and	O	['N']	[20]
21	sorbitol	O	['N']	[21]
22	.	O	['N']	[22]
#1954
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	anemia	B-Adverse_Effect	['N']	[4]
5	can	O	['N']	[5]
6	occur	O	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	MMF	O	['N']	[9]
10	,	O	['N']	[10]
11	in	O	['N']	[11]
12	particular	O	['N']	[12]
13	when	O	['N']	[13]
14	it	O	['N']	[14]
15	is	O	['N']	[15]
16	given	O	['N']	[16]
17	with	O	['N']	[17]
18	prednisone	O	['N']	[18]
19	,	O	['N']	[19]
20	a	O	['N']	[20]
21	side	O	['N']	[21]
22	effect	O	['N']	[22]
23	well	O	['N']	[23]
24	documented	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	transplantation	O	['N']	[27]
28	literature	O	['N']	[28]
29	when	O	['N']	[29]
30	the	O	['N']	[30]
31	triple	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	MMF	O	['N']	[34]
35	,	O	['N']	[35]
36	cyclosporine	B-Drug	['Causes']	[4]
37	and	O	['N']	[37]
38	prednisone	O	['N']	[38]
39	is	O	['N']	[39]
40	used	O	['N']	[40]
41	.	O	['N']	[41]
#1955
0	A	O	['N']	[0]
1	36-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	being	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	cisplatinum	O	['N']	[8]
9	,	O	['N']	[9]
10	vinblastine	B-Drug	['Causes']	[24]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	bleomycin	O	['N']	[13]
14	for	O	['N']	[14]
15	testicular	O	['N']	[15]
16	carcinoma	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	dense	O	['N']	[19]
20	left	O	['N']	[20]
21	homonymous	O	['N']	[21]
22	hemianopsia	O	['N']	[22]
23	,	O	['N']	[23]
24	encephalopathy	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	a	O	['N']	[27]
28	partial	O	['N']	[28]
29	nondominant	O	['N']	[29]
30	parietal	O	['N']	[30]
31	lobe	O	['N']	[31]
32	syndrome	O	['N']	[32]
33	.	O	['N']	[33]
#1956
0	Treatment	O	['N']	[0]
1	of	O	['N']	[1]
2	chronic	O	['N']	[2]
3	hepatitis	O	['N']	[3]
4	C	O	['N']	[4]
5	with	O	['N']	[5]
6	interferon	O	['N']	[6]
7	alpha	O	['N']	[7]
8	(	O	['N']	[8]
9	IFN	B	['N']	[9]
10	-	I	['N']	[10]
11	alpha	I-Drug	['Causes']	[27]
12	)	O	['N']	[12]
13	is	O	['N']	[13]
14	relatively	O	['N']	[14]
15	contraindicated	O	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	with	O	['N']	[18]
19	psychiatric	O	['N']	[19]
20	disorders	O	['N']	[20]
21	because	O	['N']	[21]
22	of	O	['N']	[22]
23	possible	O	['N']	[23]
24	severe	O	['N']	[24]
25	psychiatric	B	['N']	[25]
26	side	I	['N']	[26]
27	effects	I-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#1957
0	Valproate	B-Drug	['Causes']	[1]
1	embryopathy	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	three	O	['N']	[3]
4	sets	O	['N']	[4]
5	of	O	['N']	[5]
6	siblings	O	['N']	[6]
7	:	O	['N']	[7]
8	further	O	['N']	[8]
9	proof	O	['N']	[9]
10	of	O	['N']	[10]
11	hereditary	O	['N']	[11]
12	susceptibility	O	['N']	[12]
13	.	O	['N']	[13]
#1958
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	acute	B	['N']	[4]
5	renal	I	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	our	O	['N']	[8]
9	patient	O	['N']	[9]
10	was	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	anastrozole	B-Drug	['Causes']	[6]
14	.	O	['N']	[14]
#1959
0	Mean	O	['N']	[0]
1	time	O	['N']	[1]
2	between	O	['N']	[2]
3	initiation	O	['N']	[3]
4	of	O	['N']	[4]
5	gemcitabine	B-Drug	['Causes']	[10]
6	therapy	O	['N']	[6]
7	and	O	['N']	[7]
8	onset	O	['N']	[8]
9	of	O	['N']	[9]
10	HUS	B-Adverse_Effect	['N']	[10]
11	was	O	['N']	[11]
12	7.4	O	['N']	[12]
13	+	O	['N']	[13]
14	/-	O	['N']	[14]
15	3.5	O	['N']	[15]
16	months	O	['N']	[16]
17	,	O	['N']	[17]
18	or	O	['N']	[18]
19	21.9	O	['N']	[19]
20	+	O	['N']	[20]
21	/-	O	['N']	[21]
22	10.9	O	['N']	[22]
23	doses	O	['N']	[23]
24	of	O	['N']	[24]
25	gemcitabine	O	['N']	[25]
26	.	O	['N']	[26]
#1960
0	Hepatotoxicity	O	['N']	[0]
1	after	O	['N']	[1]
2	high	B	['N']	[2]
3	-	I	['N']	[3]
4	dose	I-Dose	['N']	[4]
5	methylprednisolone	B-Drug	['Dosage']	[4]
6	for	O	['N']	[6]
7	demyelinating	O	['N']	[7]
8	disease	O	['N']	[8]
9	.	O	['N']	[9]
#1961
0	The	O	['N']	[0]
1	possible	O	['N']	[1]
2	effects	O	['N']	[2]
3	of	O	['N']	[3]
4	tamoxifen	B-Drug	['Causes']	[25]
5	upon	O	['N']	[5]
6	the	O	['N']	[6]
7	uterus	O	['N']	[7]
8	are	O	['N']	[8]
9	discussed	O	['N']	[9]
10	in	O	['N']	[10]
11	this	O	['N']	[11]
12	article	O	['N']	[12]
13	,	O	['N']	[13]
14	in	O	['N']	[14]
15	view	O	['N']	[15]
16	of	O	['N']	[16]
17	reports	O	['N']	[17]
18	of	O	['N']	[18]
19	tamoxifen	O	['N']	[19]
20	associated	O	['N']	[20]
21	with	O	['N']	[21]
22	endometrial	O	['N']	[22]
23	carcinoma	O	['N']	[23]
24	and	O	['N']	[24]
25	endometriosis	B-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#1962
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	hereby	O	['N']	[4]
5	report	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	radiation	O	['N']	[9]
10	recall	O	['N']	[10]
11	dermatitis	O	['N']	[11]
12	and	O	['N']	[12]
13	myositis	B-Adverse_Effect	['N']	[13]
14	occurring	O	['N']	[14]
15	on	O	['N']	[15]
16	gemcitabine	B-Drug	['Causes']	[13]
17	monotherapy	O	['N']	[17]
18	,	O	['N']	[18]
19	five	O	['N']	[19]
20	months	O	['N']	[20]
21	after	O	['N']	[21]
22	completing	O	['N']	[22]
23	chemoradiation	O	['N']	[23]
24	for	O	['N']	[24]
25	locally	O	['N']	[25]
26	advanced	O	['N']	[26]
27	pancreatic	O	['N']	[27]
28	cancer	O	['N']	[28]
29	.	O	['N']	[29]
#1963
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	patient	O	['N']	[2]
3	experienced	O	['N']	[3]
4	mild	B	['N']	[4]
5	nitritoid	I	['N']	[5]
6	symptoms	I-Adverse_Effect	['N']	[6]
7	following	O	['N']	[7]
8	several	O	['N']	[8]
9	GSTM	B-Drug	['Causes']	[6]
10	injections	O	['N']	[10]
11	prior	O	['N']	[11]
12	experiencing	O	['N']	[12]
13	a	O	['N']	[13]
14	cerebrovascular	O	['N']	[14]
15	accident	O	['N']	[15]
16	within	O	['N']	[16]
17	several	O	['N']	[17]
18	hours	O	['N']	[18]
19	of	O	['N']	[19]
20	her	O	['N']	[20]
21	next	O	['N']	[21]
22	injection	O	['N']	[22]
23	.	O	['N']	[23]
#1964
0	Acute	B	['N']	[0]
1	eosinophilic	I	['N']	[1]
2	pneumonia	I-Adverse_Effect	['N']	[2]
3	caused	O	['N']	[3]
4	by	O	['N']	[4]
5	calcium	B	['N']	[5]
6	stearate	I-Drug	['Causes']	[2]
7	,	O	['N']	[7]
8	an	O	['N']	[8]
9	additive	O	['N']	[9]
10	agent	O	['N']	[10]
11	for	O	['N']	[11]
12	an	O	['N']	[12]
13	oral	O	['N']	[13]
14	antihistaminic	O	['N']	[14]
15	medication	O	['N']	[15]
16	.	O	['N']	[16]
#1965
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	occurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	renal	O	['N']	[5]
6	failure	O	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	cholesterol	B	['N']	[9]
10	crystal	I	['N']	[10]
11	embolization	I-Adverse_Effect	['N']	[11]
12	following	O	['N']	[12]
13	thrombolytic	O	['N']	[13]
14	therapy	O	['N']	[14]
15	with	O	['N']	[15]
16	intravenous	O	['N']	[16]
17	recombinant	O	['N']	[17]
18	tissue	O	['N']	[18]
19	-	O	['N']	[19]
20	type	O	['N']	[20]
21	plasminogen	O	['N']	[21]
22	activator	O	['N']	[22]
23	(	O	['N']	[23]
24	t	B	['N']	[24]
25	-	I	['N']	[25]
26	PA	I-Drug	['Causes']	[11]
27	)	O	['N']	[27]
28	.	O	['N']	[28]
#1966
0	Lithium	B-Drug	['Causes']	[13]
1	therapy	O	['N']	[1]
2	was	O	['N']	[2]
3	discontinued	O	['N']	[3]
4	because	O	['N']	[4]
5	of	O	['N']	[5]
6	poor	O	['N']	[6]
7	compliance	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	medication	O	['N']	[10]
11	and	O	['N']	[11]
12	intolerable	O	['N']	[12]
13	polyuria	B-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#1967
0	Marked	O	['N']	[0]
1	elevation	B	['N']	[1]
2	of	I	['N']	[2]
3	serum	I	['N']	[3]
4	creatine	I	['N']	[4]
5	kinase	I-Adverse_Effect	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	olanzapine	B-Drug	['Causes']	[5]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#1968
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	drug	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	Kaposi	B	['N']	[8]
9	's	I	['N']	[9]
10	sarcoma	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	KS	O	['N']	[12]
13	)	O	['N']	[13]
14	on	O	['N']	[14]
15	the	O	['N']	[15]
16	sole	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	right	O	['N']	[19]
20	foot	O	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	71-year	O	['N']	[23]
24	-	O	['N']	[24]
25	old	O	['N']	[25]
26	man	O	['N']	[26]
27	,	O	['N']	[27]
28	treated	O	['N']	[28]
29	for	O	['N']	[29]
30	6	O	['N']	[30]
31	months	O	['N']	[31]
32	with	O	['N']	[32]
33	corticosteroid	O	['N']	[33]
34	therapy	O	['N']	[34]
35	(	O	['N']	[35]
36	prednisolone	B-Drug	['Causes']	[10]
37	25	O	['N']	[37]
38	mg	O	['N']	[38]
39	/	O	['N']	[39]
40	day	O	['N']	[40]
41	)	O	['N']	[41]
42	for	O	['N']	[42]
43	pericardial	O	['N']	[43]
44	effusion	O	['N']	[44]
45	.	O	['N']	[45]
#1969
0	A	O	['N']	[0]
1	review	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	literature	O	['N']	[4]
5	found	O	['N']	[5]
6	11	O	['N']	[6]
7	children	O	['N']	[7]
8	and	O	['N']	[8]
9	2	O	['N']	[9]
10	adults	O	['N']	[10]
11	in	O	['N']	[11]
12	whom	O	['N']	[12]
13	intranasal	O	['N']	[13]
14	desmopressin	B-Drug	['Causes']	[18]
15	was	O	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	hyponatremia	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	all	O	['N']	[20]
21	of	O	['N']	[21]
22	whom	O	['N']	[22]
23	experienced	O	['N']	[23]
24	seizures	O	['N']	[24]
25	or	O	['N']	[25]
26	altered	O	['N']	[26]
27	mental	O	['N']	[27]
28	status	O	['N']	[28]
29	.	O	['N']	[29]
#1970
0	Herein	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	AIDS	O	['N']	[7]
8	who	O	['N']	[8]
9	presented	O	['N']	[9]
10	to	O	['N']	[10]
11	medical	O	['N']	[11]
12	attention	O	['N']	[12]
13	with	O	['N']	[13]
14	pancytopenia	B-Adverse_Effect	['N']	[14]
15	48	O	['N']	[15]
16	months	O	['N']	[16]
17	postchemotherapy	O	['N']	[17]
18	with	O	['N']	[18]
19	etoposide	O	['N']	[19]
20	,	O	['N']	[20]
21	prednisone	O	['N']	[21]
22	,	O	['N']	[22]
23	vincristine	O	['N']	[23]
24	,	O	['N']	[24]
25	cyclophosphamide	O	['N']	[25]
26	,	O	['N']	[26]
27	doxorubicin	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	rituximab	B-Drug	['Causes']	[14]
31	(	O	['N']	[31]
32	R	O	['N']	[32]
33	-	O	['N']	[33]
34	EPOCH	O	['N']	[34]
35	)	O	['N']	[35]
36	for	O	['N']	[36]
37	diffuse	O	['N']	[37]
38	large	O	['N']	[38]
39	B	O	['N']	[39]
40	-	O	['N']	[40]
41	cell	O	['N']	[41]
42	lymphoma	O	['N']	[42]
43	.	O	['N']	[43]
#1971
0	Severe	O	['N']	[0]
1	steroid	B-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	glaucoma	B-Adverse_Effect	['N']	[4]
5	following	O	['N']	[5]
6	intravitreal	O	['N']	[6]
7	injection	O	['N']	[7]
8	of	O	['N']	[8]
9	triamcinolone	O	['N']	[9]
10	acetonide	O	['N']	[10]
11	.	O	['N']	[11]
#1972
0	Our	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	both	O	['N']	[3]
4	nephrogenic	B	['N']	[4]
5	diabetes	I	['N']	[5]
6	insipidus	I-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	renal	O	['N']	[8]
9	tubular	O	['N']	[9]
10	acidosis	O	['N']	[10]
11	with	O	['N']	[11]
12	a	O	['N']	[12]
13	temporal	O	['N']	[13]
14	pattern	O	['N']	[14]
15	that	O	['N']	[15]
16	demonstrated	O	['N']	[16]
17	a	O	['N']	[17]
18	link	O	['N']	[18]
19	between	O	['N']	[19]
20	foscarnet	B-Drug	['Causes']	[6]
21	therapy	O	['N']	[21]
22	and	O	['N']	[22]
23	these	O	['N']	[23]
24	abnormalities	O	['N']	[24]
25	.	O	['N']	[25]
#1973
0	Epstein	B	['N']	[0]
1	-	I	['N']	[1]
2	Barr	I	['N']	[2]
3	virus	I	['N']	[3]
4	-	I	['N']	[4]
5	associated	I	['N']	[5]
6	lymphoproliferative	I	['N']	[6]
7	disorder	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	on	O	['N']	[14]
15	methotrexate	O	['N']	[15]
16	and	O	['N']	[16]
17	rofecoxib	B-Drug	['Causes']	[7]
18	:	O	['N']	[18]
19	idiosyncratic	O	['N']	[19]
20	reaction	O	['N']	[20]
21	or	O	['N']	[21]
22	pharmacogenetics	O	['N']	[22]
23	?	O	['N']	[23]
#1974
0	A	O	['N']	[0]
1	retrospective	O	['N']	[1]
2	review	O	['N']	[2]
3	of	O	['N']	[3]
4	TTP	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	quinine	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	associated	O	['N']	[9]
10	thrombotic	B	['N']	[10]
11	microangiopathy	I-Adverse_Effect	['N']	[11]
12	(	O	['N']	[12]
13	TMA	O	['N']	[13]
14	)	O	['N']	[14]
15	for	O	['N']	[15]
16	whom	O	['N']	[16]
17	ADAMTS13	O	['N']	[17]
18	was	O	['N']	[18]
19	measured	O	['N']	[19]
20	before	O	['N']	[20]
21	plasma	O	['N']	[21]
22	exchange	O	['N']	[22]
23	was	O	['N']	[23]
24	performed	O	['N']	[24]
25	.	O	['N']	[25]
#1975
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	case	O	['N']	[3]
4	illustrates	O	['N']	[4]
5	a	O	['N']	[5]
6	potential	O	['N']	[6]
7	link	O	['N']	[7]
8	between	O	['N']	[8]
9	dermatologic	B	['N']	[9]
10	and	I	['N']	[10]
11	ocular	I	['N']	[11]
12	5-FU	B-Drug	['Causes']	[13]
13	toxicities	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#1976
0	Three	O	['N']	[0]
1	distinct	O	['N']	[1]
2	types	O	['N']	[2]
3	of	O	['N']	[3]
4	minocycline	B-Drug	['Causes']	[8]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	cutaneous	B	['N']	[7]
8	pigmentation	I-Adverse_Effect	['N']	[8]
9	have	O	['N']	[9]
10	been	O	['N']	[10]
11	described	O	['N']	[11]
12	.	O	['N']	[12]
#1977
0	This	O	['N']	[0]
1	article	O	['N']	[1]
2	describes	O	['N']	[2]
3	two	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	aplastic	O	['N']	[6]
7	anemia	O	['N']	[7]
8	,	O	['N']	[8]
9	at	O	['N']	[9]
10	least	O	['N']	[10]
11	one	O	['N']	[11]
12	of	O	['N']	[12]
13	which	O	['N']	[13]
14	was	O	['N']	[14]
15	almost	O	['N']	[15]
16	certainly	O	['N']	[16]
17	induced	O	['N']	[17]
18	by	O	['N']	[18]
19	the	O	['N']	[19]
20	use	O	['N']	[20]
21	of	O	['N']	[21]
22	methazolamide	B-Drug	['Causes']	[28]
23	,	O	['N']	[23]
24	and	O	['N']	[24]
25	one	O	['N']	[25]
26	case	O	['N']	[26]
27	of	O	['N']	[27]
28	agranulocytosis	B-Adverse_Effect	['N']	[28]
29	related	O	['N']	[29]
30	to	O	['N']	[30]
31	the	O	['N']	[31]
32	use	O	['N']	[32]
33	of	O	['N']	[33]
34	methazolamide	O	['N']	[34]
35	.	O	['N']	[35]
#1978
0	Case	O	['N']	[0]
1	report	O	['N']	[1]
2	:	O	['N']	[2]
3	dapsone	B-Drug	['Causes']	[5]
4	hypersensitivity	B	['N']	[4]
5	syndrome	I-Adverse_Effect	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	treatment	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	bite	O	['N']	[11]
12	of	O	['N']	[12]
13	a	O	['N']	[13]
14	brown	O	['N']	[14]
15	recluse	O	['N']	[15]
16	spider	O	['N']	[16]
17	.	O	['N']	[17]
#1979
0	The	O	['N']	[0]
1	gynecomastia	B-Adverse_Effect	['N']	[1]
2	regressed	O	['N']	[2]
3	when	O	['N']	[3]
4	the	O	['N']	[4]
5	theophylline	B-Drug	['Causes']	[1]
6	was	O	['N']	[6]
7	discontinued	O	['N']	[7]
8	.	O	['N']	[8]
#1980
0	Levofloxacin	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	delirium	B	['N']	[3]
4	with	I	['N']	[4]
5	psychotic	I	['N']	[5]
6	features	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#1981
0	Dipyrone	B-Drug	['Causes']	[29]
1	,	O	['N']	[1]
2	also	O	['N']	[2]
3	known	O	['N']	[3]
4	as	O	['N']	[4]
5	metamizole	O	['N']	[5]
6	,	O	['N']	[6]
7	is	O	['N']	[7]
8	an	O	['N']	[8]
9	analgesic	O	['N']	[9]
10	and	O	['N']	[10]
11	antipyretic	O	['N']	[11]
12	drug	O	['N']	[12]
13	that	O	['N']	[13]
14	was	O	['N']	[14]
15	banned	O	['N']	[15]
16	by	O	['N']	[16]
17	the	O	['N']	[17]
18	United	O	['N']	[18]
19	States	O	['N']	[19]
20	Food	O	['N']	[20]
21	and	O	['N']	[21]
22	Drug	O	['N']	[22]
23	Administration	O	['N']	[23]
24	because	O	['N']	[24]
25	of	O	['N']	[25]
26	its	O	['N']	[26]
27	association	O	['N']	[27]
28	with	O	['N']	[28]
29	agranulocytosis	B-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#1982
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Similar	O	['N']	[2]
3	to	O	['N']	[3]
4	previous	O	['N']	[4]
5	findings	O	['N']	[5]
6	of	O	['N']	[6]
7	drug	O	['N']	[7]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	vortex	B	['N']	[10]
11	keratopathy	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	atovaquone	B-Drug	['Causes']	[11]
14	vortex	O	['N']	[14]
15	keratopathy	O	['N']	[15]
16	is	O	['N']	[16]
17	presumably	O	['N']	[17]
18	caused	O	['N']	[18]
19	by	O	['N']	[19]
20	its	O	['N']	[20]
21	lipophilic	O	['N']	[21]
22	properties	O	['N']	[22]
23	.	O	['N']	[23]
#1983
0	Cefoxitin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	renal	B	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1984
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	think	O	['N']	[2]
3	that	O	['N']	[3]
4	although	O	['N']	[4]
5	lamivudine	B-Drug	['Causes']	[16]
6	is	O	['N']	[6]
7	widely	O	['N']	[7]
8	used	O	['N']	[8]
9	and	O	['N']	[9]
10	well	O	['N']	[10]
11	tolerated	O	['N']	[11]
12	,	O	['N']	[12]
13	it	O	['N']	[13]
14	can	O	['N']	[14]
15	cause	O	['N']	[15]
16	ADRs	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	which	O	['N']	[18]
19	are	O	['N']	[19]
20	reversible	O	['N']	[20]
21	after	O	['N']	[21]
22	drug	O	['N']	[22]
23	withdrawal	O	['N']	[23]
24	.	O	['N']	[24]
#1985
0	A	O	['N']	[0]
1	62-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	pranlukast	B-Drug	['Causes']	[17]
8	for	O	['N']	[8]
9	2	O	['N']	[9]
10	months	O	['N']	[10]
11	developed	O	['N']	[11]
12	interstitial	O	['N']	[12]
13	pneumonitis	O	['N']	[13]
14	with	O	['N']	[14]
15	a	O	['N']	[15]
16	high	B	['N']	[16]
17	fever	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#1986
0	Triazolam	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	nocturnal	O	['N']	[3]
4	bingeing	O	['N']	[4]
5	with	O	['N']	[5]
6	amnesia	B-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#1987
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	hydroxyurea	B-Drug	['Causes']	[11]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	acute	B	['N']	[9]
10	interstitial	I	['N']	[10]
11	pneumonitis	I-Adverse_Effect	['N']	[11]
12	reported	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	literature	O	['N']	[15]
16	.	O	['N']	[16]
#1988
0	The	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	"	O	['N']	[3]
4	sweet	O	['N']	[4]
5	spirits	O	['N']	[5]
6	of	O	['N']	[6]
7	nitre	O	['N']	[7]
8	"	O	['N']	[8]
9	(	O	['N']	[9]
10	4	B	['N']	[10]
11	%	I	['N']	[11]
12	ethyl	I	['N']	[12]
13	nitrite	I	['N']	[13]
14	CH3CH2ONO	I	['N']	[14]
15	in	I	['N']	[15]
16	70	I	['N']	[16]
17	%	I	['N']	[17]
18	ethyl	I	['N']	[18]
19	alcohol	I-Drug	['Causes']	[25]
20	)	O	['N']	[20]
21	was	O	['N']	[21]
22	followed	O	['N']	[22]
23	by	O	['N']	[23]
24	acute	B	['N']	[24]
25	methemoglobinemia	I-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	severe	O	['N']	[27]
28	anoxic	O	['N']	[28]
29	metabolic	O	['N']	[29]
30	acidosis	O	['N']	[30]
31	in	O	['N']	[31]
32	infant	O	['N']	[32]
33	twins	O	['N']	[33]
34	,	O	['N']	[34]
35	Methylene	O	['N']	[35]
36	blue	O	['N']	[36]
37	administration	O	['N']	[37]
38	reversed	O	['N']	[38]
39	methemoglobinemia	O	['N']	[39]
40	in	O	['N']	[40]
41	both	O	['N']	[41]
42	,	O	['N']	[42]
43	but	O	['N']	[43]
44	one	O	['N']	[44]
45	twin	O	['N']	[45]
46	died	O	['N']	[46]
47	from	O	['N']	[47]
48	the	O	['N']	[48]
49	consequences	O	['N']	[49]
50	of	O	['N']	[50]
51	hypoxemia	O	['N']	[51]
52	.	O	['N']	[52]
#1989
0	A	O	['N']	[0]
1	58-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	rheumatoid	O	['N']	[6]
7	arthritis	O	['N']	[7]
8	(	O	['N']	[8]
9	RA	O	['N']	[9]
10	)	O	['N']	[10]
11	developed	O	['N']	[11]
12	fever	O	['N']	[12]
13	,	O	['N']	[13]
14	skin	O	['N']	[14]
15	eruptions	O	['N']	[15]
16	,	O	['N']	[16]
17	leukocytopenia	B-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	thrombocytopenia	O	['N']	[20]
21	,	O	['N']	[21]
22	3	O	['N']	[22]
23	weeks	O	['N']	[23]
24	after	O	['N']	[24]
25	treatment	O	['N']	[25]
26	with	O	['N']	[26]
27	sulfasalazine	B-Drug	['Causes']	[17]
28	.	O	['N']	[28]
#1990
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	sustained	B	['N']	[6]
7	monomorphic	I	['N']	[7]
8	ventricular	I	['N']	[8]
9	tachycardia	I-Adverse_Effect	['N']	[9]
10	following	O	['N']	[10]
11	adenosine	B-Drug	['Causes']	[9]
12	infusion	O	['N']	[12]
13	.	O	['N']	[13]
#1991
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	case	O	['N']	[2]
3	concerns	O	['N']	[3]
4	a	O	['N']	[4]
5	70-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	man	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	severe	O	['N']	[11]
12	aplastic	O	['N']	[12]
13	anemia	O	['N']	[13]
14	7	O	['N']	[14]
15	weeks	O	['N']	[15]
16	after	O	['N']	[16]
17	treatment	O	['N']	[17]
18	with	O	['N']	[18]
19	500	B	['N']	[19]
20	mg	I-Dose	['N']	[20]
21	of	O	['N']	[21]
22	ticlopidine	B-Drug	['Dosage']	[20]
23	daily	O	['N']	[23]
24	.	O	['N']	[24]
#1992
0	We	O	['N']	[0]
1	observed	O	['N']	[1]
2	2	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	hepatotoxicity	O	['N']	[5]
6	after	O	['N']	[6]
7	a	O	['N']	[7]
8	high	B	['N']	[8]
9	-	I	['N']	[9]
10	dose	I-Dose	['N']	[10]
11	methylprednisolone	B-Drug	['Dosage']	[10]
12	treatment	O	['N']	[12]
13	of	O	['N']	[13]
14	a	O	['N']	[14]
15	demyelinating	O	['N']	[15]
16	disease	O	['N']	[16]
17	and	O	['N']	[17]
18	evaluated	O	['N']	[18]
19	the	O	['N']	[19]
20	potential	O	['N']	[20]
21	relationship	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	light	O	['N']	[24]
25	of	O	['N']	[25]
26	available	O	['N']	[26]
27	evidence	O	['N']	[27]
28	.	O	['N']	[28]
#1993
0	Massive	O	['N']	[0]
1	prolapse	B	['N']	[1]
2	of	I	['N']	[2]
3	the	I	['N']	[3]
4	urethral	I	['N']	[4]
5	mucosa	I-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	periurethral	O	['N']	[7]
8	injection	O	['N']	[8]
9	of	O	['N']	[9]
10	calcium	B	['N']	[10]
11	hydroxylapatite	I-Drug	['Causes']	[5]
12	for	O	['N']	[12]
13	stress	O	['N']	[13]
14	urinary	O	['N']	[14]
15	incontinence	O	['N']	[15]
16	.	O	['N']	[16]
#1994
0	Their	O	['N']	[0]
1	parkinsonism	B-Adverse_Effect	['N']	[1]
2	improved	O	['N']	[2]
3	on	O	['N']	[3]
4	discontinuation	O	['N']	[4]
5	of	O	['N']	[5]
6	metoclopramide	B-Drug	['Causes']	[1]
7	therapy	O	['N']	[7]
8	.	O	['N']	[8]
#1995
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	occurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	spontaneous	O	['N']	[5]
6	intracranial	B	['N']	[6]
7	bleeding	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	an	O	['N']	[9]
10	human	O	['N']	[10]
11	immunodeficiency	O	['N']	[11]
12	virus	O	['N']	[12]
13	(	O	['N']	[13]
14	HIV)-infected	O	['N']	[14]
15	adolescent	O	['N']	[15]
16	with	O	['N']	[16]
17	hemophilia	O	['N']	[17]
18	A	O	['N']	[18]
19	who	O	['N']	[19]
20	was	O	['N']	[20]
21	receiving	O	['N']	[21]
22	amprenavir	B-Drug	['Causes']	[7]
23	(	O	['N']	[23]
24	APV	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#1996
0	Aripiprazole	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hiccups	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	.	O	['N']	[8]
#1997
0	Itraconazole	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	increased	O	['N']	[3]
4	vincristine	B	['N']	[4]
5	neurotoxicity	I-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	case	O	['N']	[7]
8	report	O	['N']	[8]
9	and	O	['N']	[9]
10	review	O	['N']	[10]
11	of	O	['N']	[11]
12	literature	O	['N']	[12]
13	.	O	['N']	[13]
#1998
0	Hypercalcemia	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	an	O	['N']	[2]
3	AIDS	O	['N']	[3]
4	patient	O	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	growth	B	['N']	[7]
8	hormone	I-Drug	['Causes']	[0]
9	.	O	['N']	[9]
#1999
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	congestive	B	['N']	[3]
4	heart	I	['N']	[4]
5	failure	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	child	O	['N']	[8]
9	with	O	['N']	[9]
10	Wilms	O	['N']	[10]
11	'	O	['N']	[11]
12	tumor	O	['N']	[12]
13	treated	O	['N']	[13]
14	Adriamycin	B-Drug	['Causes']	[5]
15	is	O	['N']	[15]
16	presented	O	['N']	[16]
17	and	O	['N']	[17]
18	discussed	O	['N']	[18]
19	.	O	['N']	[19]
#2000
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	Genetic	O	['N']	[3]
4	deficiencies	O	['N']	[4]
5	in	O	['N']	[5]
6	DPD	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	rate	O	['N']	[9]
10	-	O	['N']	[10]
11	limiting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	responsible	O	['N']	[13]
14	for	O	['N']	[14]
15	5-FU	B-Drug	['Causes']	[48]
16	catabolism	O	['N']	[16]
17	,	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	in	O	['N']	[20]
21	3	O	['N']	[21]
22	%	O	['N']	[22]
23	or	O	['N']	[23]
24	more	O	['N']	[24]
25	of	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	cancer	O	['N']	[28]
29	putting	O	['N']	[29]
30	them	O	['N']	[30]
31	at	O	['N']	[31]
32	increased	O	['N']	[32]
33	risk	O	['N']	[33]
34	for	O	['N']	[34]
35	unusually	O	['N']	[35]
36	severe	O	['N']	[36]
37	adverse	O	['N']	[37]
38	reactions	O	['N']	[38]
39	(	O	['N']	[39]
40	e.g.	O	['N']	[40]
41	,	O	['N']	[41]
42	diarrhea	O	['N']	[42]
43	,	O	['N']	[43]
44	stomatitis	O	['N']	[44]
45	,	O	['N']	[45]
46	mucositis	O	['N']	[46]
47	,	O	['N']	[47]
48	myelosuppression	B-Adverse_Effect	['N']	[48]
49	,	O	['N']	[49]
50	neurotoxicity	O	['N']	[50]
51	)	O	['N']	[51]
52	to	O	['N']	[52]
53	standard	O	['N']	[53]
54	doses	O	['N']	[54]
55	of	O	['N']	[55]
56	5-FU	O	['N']	[56]
57	.	O	['N']	[57]
#2001
0	Hypersensitivity	B-Adverse_Effect	['N']	[0]
1	to	O	['N']	[1]
2	carboplatin	B-Drug	['Causes']	[0]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	rare	O	['N']	[5]
6	but	O	['N']	[6]
7	real	O	['N']	[7]
8	complication	O	['N']	[8]
9	of	O	['N']	[9]
10	therapy	O	['N']	[10]
11	and	O	['N']	[11]
12	should	O	['N']	[12]
13	be	O	['N']	[13]
14	considered	O	['N']	[14]
15	in	O	['N']	[15]
16	patients	O	['N']	[16]
17	presenting	O	['N']	[17]
18	with	O	['N']	[18]
19	hyperacute	O	['N']	[19]
20	changes	O	['N']	[20]
21	on	O	['N']	[21]
22	ECG	O	['N']	[22]
23	whilst	O	['N']	[23]
24	receiving	O	['N']	[24]
25	carboplatin	O	['N']	[25]
26	therapy	O	['N']	[26]
27	.	O	['N']	[27]
#2002
0	Self	B	['N']	[0]
1	-	I	['N']	[1]
2	limited	I	['N']	[2]
3	edema	I-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	well	O	['N']	[6]
7	-	O	['N']	[7]
8	recognized	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	insulin	B-Drug	['Causes']	[3]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#2003
0	Ten	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	itraconazole	B-Drug	['Causes']	[17]
4	was	O	['N']	[4]
5	started	O	['N']	[5]
6	,	O	['N']	[6]
7	he	O	['N']	[7]
8	developed	O	['N']	[8]
9	paralytic	O	['N']	[9]
10	ileus	O	['N']	[10]
11	,	O	['N']	[11]
12	neurogenic	O	['N']	[12]
13	bladder	O	['N']	[13]
14	,	O	['N']	[14]
15	mild	B	['N']	[15]
16	left	I	['N']	[16]
17	ptosis	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	absence	O	['N']	[20]
21	of	O	['N']	[21]
22	deep	O	['N']	[22]
23	reflexes	O	['N']	[23]
24	,	O	['N']	[24]
25	with	O	['N']	[25]
26	severe	O	['N']	[26]
27	paralysis	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	lower	O	['N']	[30]
31	extremities	O	['N']	[31]
32	and	O	['N']	[32]
33	mild	O	['N']	[33]
34	weakness	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	upper	O	['N']	[37]
38	extremities	O	['N']	[38]
39	.	O	['N']	[39]
#2004
0	Phenylpropanolamine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	psychosis	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#2005
0	Pulmonary	B	['N']	[0]
1	leukostasis	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	all	B	['N']	[4]
5	-	I	['N']	[5]
6	trans	I	['N']	[6]
7	retinoic	I	['N']	[7]
8	acid	I-Drug	['Causes']	[1]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	treatment	O	['N']	[11]
12	of	O	['N']	[12]
13	acute	O	['N']	[13]
14	promyelocytic	O	['N']	[14]
15	leukemia	O	['N']	[15]
16	in	O	['N']	[16]
17	first	O	['N']	[17]
18	relapse	O	['N']	[18]
19	.	O	['N']	[19]
#2006
0	Skin	O	['N']	[0]
1	rash	O	['N']	[1]
2	began	O	['N']	[2]
3	after	O	['N']	[3]
4	2	O	['N']	[4]
5	weeks	O	['N']	[5]
6	of	O	['N']	[6]
7	treatment	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	signs	O	['N']	[10]
11	of	O	['N']	[11]
12	hepatocellular	B	['N']	[12]
13	failure	I-Adverse_Effect	['N']	[13]
14	developed	O	['N']	[14]
15	3	O	['N']	[15]
16	weeks	O	['N']	[16]
17	after	O	['N']	[17]
18	phenobarbital	B-Drug	['Causes']	[13]
19	had	O	['N']	[19]
20	been	O	['N']	[20]
21	started	O	['N']	[21]
22	.	O	['N']	[22]
#2007
0	Multiple	B	['N']	[0]
1	sclerosis	I	['N']	[1]
2	-	I	['N']	[2]
3	like	I	['N']	[3]
4	disease	I-Adverse_Effect	['N']	[4]
5	secondary	O	['N']	[5]
6	to	O	['N']	[6]
7	alpha	B	['N']	[7]
8	interferon	I-Drug	['Causes']	[4]
9	.	O	['N']	[9]
#2008
0	Progressive	B	['N']	[0]
1	hypokalemia	I-Adverse_Effect	['N']	[1]
2	developed	O	['N']	[2]
3	during	O	['N']	[3]
4	phosphate	B-Drug	['Causes']	[1]
5	treatment	O	['N']	[5]
6	.	O	['N']	[6]
#2009
0	Pheripheral	B	['N']	[0]
1	edema	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	in	O	['N']	[4]
5	five	O	['N']	[5]
6	female	O	['N']	[6]
7	patients	O	['N']	[7]
8	after	O	['N']	[8]
9	taking	O	['N']	[9]
10	proton	O	['N']	[10]
11	pump	O	['N']	[11]
12	inhibitors	O	['N']	[12]
13	omeprazole	B-Drug	['Causes']	[1]
14	,	O	['N']	[14]
15	lansoprazole	O	['N']	[15]
16	,	O	['N']	[16]
17	or	O	['N']	[17]
18	pantoprazole	O	['N']	[18]
19	for	O	['N']	[19]
20	7	O	['N']	[20]
21	-	O	['N']	[21]
22	15	O	['N']	[22]
23	days	O	['N']	[23]
24	for	O	['N']	[24]
25	peptic	O	['N']	[25]
26	acid	O	['N']	[26]
27	diseases	O	['N']	[27]
28	in	O	['N']	[28]
29	recommended	O	['N']	[29]
30	standard	O	['N']	[30]
31	doses	O	['N']	[31]
32	.	O	['N']	[32]
#2010
0	After	O	['N']	[0]
1	the	O	['N']	[1]
2	patient	O	['N']	[2]
3	discontinued	O	['N']	[3]
4	rifampicin	B-Drug	['Causes']	[8]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	skin	B	['N']	[7]
8	lesions	I-Adverse_Effect	['N']	[8]
9	cleared	O	['N']	[9]
10	completely	O	['N']	[10]
11	within	O	['N']	[11]
12	5	O	['N']	[12]
13	weeks	O	['N']	[13]
14	without	O	['N']	[14]
15	any	O	['N']	[15]
16	systemic	O	['N']	[16]
17	medication	O	['N']	[17]
18	.	O	['N']	[18]
#2011
0	Phenytoin	B-Drug	['Causes']	[1]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	concomitant	O	['N']	[4]
5	antituberculosis	O	['N']	[5]
6	therapy	O	['N']	[6]
7	.	O	['N']	[7]
#2012
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	intravenous	O	['N']	[2]
3	nitroglycerin	B-Drug	['Causes']	[25]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	idiopathic	O	['N']	[8]
9	pulmonary	O	['N']	[9]
10	hypertension	O	['N']	[10]
11	resulted	O	['N']	[11]
12	in	O	['N']	[12]
13	an	O	['N']	[13]
14	increase	O	['N']	[14]
15	in	O	['N']	[15]
16	pulmonary	O	['N']	[16]
17	artery	O	['N']	[17]
18	pressure	O	['N']	[18]
19	associated	O	['N']	[19]
20	with	O	['N']	[20]
21	a	O	['N']	[21]
22	decrease	B	['N']	[22]
23	in	I	['N']	[23]
24	blood	I	['N']	[24]
25	flow	I-Adverse_Effect	['N']	[25]
26	that	O	['N']	[26]
27	is	O	['N']	[27]
28	best	O	['N']	[28]
29	explained	O	['N']	[29]
30	by	O	['N']	[30]
31	an	O	['N']	[31]
32	increase	O	['N']	[32]
33	in	O	['N']	[33]
34	pulmonary	O	['N']	[34]
35	vascular	O	['N']	[35]
36	resistance	O	['N']	[36]
37	.	O	['N']	[37]
#2013
0	INH	B-Drug	['Causes']	[9]
1	,	O	['N']	[1]
2	which	O	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	leading	O	['N']	[5]
6	cause	O	['N']	[6]
7	of	O	['N']	[7]
8	drug	B	['N']	[8]
9	eruptions	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	above	O	['N']	[12]
13	group	O	['N']	[13]
14	of	O	['N']	[14]
15	drugs	O	['N']	[15]
16	was	O	['N']	[16]
17	withdrawn	O	['N']	[17]
18	.	O	['N']	[18]
#2014
0	Two	O	['N']	[0]
1	other	O	['N']	[1]
2	patients	O	['N']	[2]
3	who	O	['N']	[3]
4	did	O	['N']	[4]
5	not	O	['N']	[5]
6	receive	O	['N']	[6]
7	prochlorperazine	O	['N']	[7]
8	,	O	['N']	[8]
9	developed	O	['N']	[9]
10	retinal	B	['N']	[10]
11	problems	I-Adverse_Effect	['N']	[11]
12	which	O	['N']	[12]
13	later	O	['N']	[13]
14	improved	O	['N']	[14]
15	,	O	['N']	[15]
16	one	O	['N']	[16]
17	after	O	['N']	[17]
18	only	O	['N']	[18]
19	15	O	['N']	[19]
20	g	O	['N']	[20]
21	of	O	['N']	[21]
22	desferrioxamine	B-Drug	['Causes']	[11]
23	.	O	['N']	[23]
#2015
0	A	O	['N']	[0]
1	22-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	black	O	['N']	[4]
5	man	O	['N']	[5]
6	developed	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	chills	O	['N']	[9]
10	,	O	['N']	[10]
11	fatigue	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	night	O	['N']	[13]
14	sweats	O	['N']	[14]
15	,	O	['N']	[15]
16	tender	O	['N']	[16]
17	lymphadenopathy	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	a	O	['N']	[20]
21	generalized	O	['N']	[21]
22	,	O	['N']	[22]
23	pruritic	O	['N']	[23]
24	,	O	['N']	[24]
25	macular	O	['N']	[25]
26	eruption	O	['N']	[26]
27	3	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	starting	O	['N']	[30]
31	minocycline	B-Drug	['Causes']	[11]
32	therapy	O	['N']	[32]
33	for	O	['N']	[33]
34	acne	O	['N']	[34]
35	.	O	['N']	[35]
#2016
0	Dexamethasone	O	['N']	[0]
1	treatment	O	['N']	[1]
2	of	O	['N']	[2]
3	amiodarone	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	thyrotoxicosis	B-Adverse_Effect	['N']	[6]
7	(	O	['N']	[7]
8	AIT	O	['N']	[8]
9	)	O	['N']	[9]
10	with	O	['N']	[10]
11	or	O	['N']	[11]
12	without	O	['N']	[12]
13	persistent	O	['N']	[13]
14	administration	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	drug	O	['N']	[17]
18	.	O	['N']	[18]
#2017
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	report	O	['N']	[2]
3	illustrates	O	['N']	[3]
4	a	O	['N']	[4]
5	rare	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	refractory	O	['N']	[8]
9	akathisia	B-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	interferon	B	['N']	[11]
12	-	I	['N']	[12]
13	alpha	I-Drug	['Causes']	[9]
14	treatment	O	['N']	[14]
15	and	O	['N']	[15]
16	also	O	['N']	[16]
17	that	O	['N']	[17]
18	levodopa	O	['N']	[18]
19	treatment	O	['N']	[19]
20	would	O	['N']	[20]
21	be	O	['N']	[21]
22	theoretically	O	['N']	[22]
23	and	O	['N']	[23]
24	practically	O	['N']	[24]
25	useful	O	['N']	[25]
26	in	O	['N']	[26]
27	reducing	O	['N']	[27]
28	the	O	['N']	[28]
29	neurotoxicity	O	['N']	[29]
30	associated	O	['N']	[30]
31	with	O	['N']	[31]
32	interferon	O	['N']	[32]
33	-	O	['N']	[33]
34	alpha	O	['N']	[34]
35	.	O	['N']	[35]
#2018
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	with	O	['N']	[4]
5	congenital	O	['N']	[5]
6	toxoplasmosis	O	['N']	[6]
7	who	O	['N']	[7]
8	took	O	['N']	[8]
9	pyrimethamine	O	['N']	[9]
10	and	O	['N']	[10]
11	sulfadiazine	B-Drug	['Causes']	[20]
12	for	O	['N']	[12]
13	reactivated	O	['N']	[13]
14	chorioretinitis	O	['N']	[14]
15	developed	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	severe	B	['N']	[18]
19	cutaneous	I	['N']	[19]
20	involvement	I-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	swelling	O	['N']	[22]
23	,	O	['N']	[23]
24	abdominal	O	['N']	[24]
25	pain	O	['N']	[25]
26	and	O	['N']	[26]
27	transaminitis	O	['N']	[27]
28	,	O	['N']	[28]
29	persisting	O	['N']	[29]
30	weeks	O	['N']	[30]
31	after	O	['N']	[31]
32	withholding	O	['N']	[32]
33	medicines	O	['N']	[33]
34	.	O	['N']	[34]
#2019
0	Gemcitabine	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	hemolytic	B	['N']	[3]
4	-	I	['N']	[4]
5	uremic	I	['N']	[5]
6	syndrome	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#2020
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	treated	O	['N']	[2]
3	with	O	['N']	[3]
4	5-fluorouracil	B-Drug	['Causes']	[16]
5	(	O	['N']	[5]
6	5-FU	O	['N']	[6]
7	)	O	['N']	[7]
8	for	O	['N']	[8]
9	disseminated	O	['N']	[9]
10	adenocarcinoma	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	colon	O	['N']	[13]
14	developed	O	['N']	[14]
15	cerebellar	B	['N']	[15]
16	dysfunction	I-Adverse_Effect	['N']	[16]
17	typical	O	['N']	[17]
18	of	O	['N']	[18]
19	5-FU	O	['N']	[19]
20	neurotoxicity	O	['N']	[20]
21	.	O	['N']	[21]
#2021
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	fatal	B	['N']	[5]
6	pulmonary	I	['N']	[6]
7	toxicity	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	advanced	O	['N']	[12]
13	non	O	['N']	[13]
14	-	O	['N']	[14]
15	small	O	['N']	[15]
16	cell	O	['N']	[16]
17	lung	O	['N']	[17]
18	cancer	O	['N']	[18]
19	who	O	['N']	[19]
20	received	O	['N']	[20]
21	erlotinib	B-Drug	['Causes']	[7]
22	.	O	['N']	[22]
#2022
0	An	O	['N']	[0]
1	adverse	O	['N']	[1]
2	reaction	O	['N']	[2]
3	to	O	['N']	[3]
4	IFN	B-Drug	['Causes']	[12]
5	was	O	['N']	[5]
6	strongly	O	['N']	[6]
7	suspected	O	['N']	[7]
8	as	O	['N']	[8]
9	the	O	['N']	[9]
10	cause	O	['N']	[10]
11	of	O	['N']	[11]
12	CHF	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#2023
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	BH	B	['N']	[4]
5	-	I	['N']	[5]
6	AC	I-Drug	['Causes']	[27]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	derivative	O	['N']	[9]
10	of	O	['N']	[10]
11	cytosine	O	['N']	[11]
12	arabinoside	O	['N']	[12]
13	(	O	['N']	[13]
14	1-beta	O	['N']	[14]
15	-	O	['N']	[15]
16	D	O	['N']	[16]
17	-	O	['N']	[17]
18	arabinofuranosylcytosine	O	['N']	[18]
19	)	O	['N']	[19]
20	could	O	['N']	[20]
21	be	O	['N']	[21]
22	a	O	['N']	[22]
23	cause	O	['N']	[23]
24	of	O	['N']	[24]
25	reversible	O	['N']	[25]
26	encephalopathy	B	['N']	[26]
27	syndrome	I-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#2024
0	Cushing	B	['N']	[0]
1	's	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	persisted	O	['N']	[3]
4	more	O	['N']	[4]
5	than	O	['N']	[5]
6	6	O	['N']	[6]
7	months	O	['N']	[7]
8	while	O	['N']	[8]
9	TCA	B-Drug	['Causes']	[2]
10	concentrations	O	['N']	[10]
11	remained	O	['N']	[11]
12	detectable	O	['N']	[12]
13	for	O	['N']	[13]
14	at	O	['N']	[14]
15	least	O	['N']	[15]
16	80	O	['N']	[16]
17	days	O	['N']	[17]
18	.	O	['N']	[18]
#2025
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	had	O	['N']	[8]
9	undergone	O	['N']	[9]
10	cholecystectomy	O	['N']	[10]
11	previously	O	['N']	[11]
12	,	O	['N']	[12]
13	but	O	['N']	[13]
14	in	O	['N']	[14]
15	whom	O	['N']	[15]
16	morphine	B-Drug	['Causes']	[23]
17	given	O	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	Emergency	O	['N']	[20]
21	Department	O	['N']	[21]
22	precipitated	O	['N']	[22]
23	pain	B-Adverse_Effect	['N']	[23]
24	consistent	O	['N']	[24]
25	with	O	['N']	[25]
26	biliary	O	['N']	[26]
27	colic	O	['N']	[27]
28	;	O	['N']	[28]
29	the	O	['N']	[29]
30	pain	O	['N']	[30]
31	resolved	O	['N']	[31]
32	promptly	O	['N']	[32]
33	after	O	['N']	[33]
34	administration	O	['N']	[34]
35	of	O	['N']	[35]
36	naloxone	O	['N']	[36]
37	.	O	['N']	[37]
#2026
0	Sudden	B	['N']	[0]
1	cardiac	I	['N']	[1]
2	death	I-Adverse_Effect	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	hypersensitivity	O	['N']	[5]
6	myocarditis	O	['N']	[6]
7	during	O	['N']	[7]
8	clozapine	B-Drug	['Causes']	[2]
9	treatment	O	['N']	[9]
10	.	O	['N']	[10]
#2027
0	Pulmonary	O	['N']	[0]
1	hemorrhage	O	['N']	[1]
2	is	O	['N']	[2]
3	an	O	['N']	[3]
4	uncommon	O	['N']	[4]
5	feature	O	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	HUS	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	seems	O	['N']	[11]
12	to	O	['N']	[12]
13	appear	O	['N']	[13]
14	especially	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	HUS	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	MMC	B-Drug	['Causes']	[8]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#2028
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Colchicine	B-Drug	['Causes']	[10]
3	has	O	['N']	[3]
4	a	O	['N']	[4]
5	known	O	['N']	[5]
6	adverse	B	['N']	[6]
7	effect	I	['N']	[7]
8	on	I	['N']	[8]
9	wound	I	['N']	[9]
10	healing	I-Adverse_Effect	['N']	[10]
11	through	O	['N']	[11]
12	its	O	['N']	[12]
13	inhibitory	O	['N']	[13]
14	effect	O	['N']	[14]
15	on	O	['N']	[15]
16	tubulin	O	['N']	[16]
17	-	O	['N']	[17]
18	dependent	O	['N']	[18]
19	cell	O	['N']	[19]
20	functions	O	['N']	[20]
21	and	O	['N']	[21]
22	through	O	['N']	[22]
23	collagenase	O	['N']	[23]
24	activation	O	['N']	[24]
25	.	O	['N']	[25]
#2029
0	Quetiapine	B-Drug	['Causes']	[7]
1	and	O	['N']	[1]
2	obsessive	O	['N']	[2]
3	-	O	['N']	[3]
4	compulsive	O	['N']	[4]
5	symptoms	O	['N']	[5]
6	(	O	['N']	[6]
7	OCS	B-Adverse_Effect	['N']	[7]
8	)	O	['N']	[8]
9	:	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	and	O	['N']	[12]
13	review	O	['N']	[13]
14	of	O	['N']	[14]
15	atypical	O	['N']	[15]
16	antipsychotic	O	['N']	[16]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	OCS	O	['N']	[19]
20	.	O	['N']	[20]
#2030
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	gemcitabine	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	LABD	B-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#2031
0	Large	B	['N']	[0]
1	cerebral	I	['N']	[1]
2	infarction	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	praziquantel	B-Drug	['Causes']	[2]
5	therapy	O	['N']	[5]
6	in	O	['N']	[6]
7	neurocysticercosis	O	['N']	[7]
8	.	O	['N']	[8]
#2032
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Topiramate	B-Drug	['Causes']	[21]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	ciliochoroidal	O	['N']	[7]
8	effusion	O	['N']	[8]
9	with	O	['N']	[9]
10	forward	O	['N']	[10]
11	displacement	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	lens	O	['N']	[14]
15	-	O	['N']	[15]
16	iris	O	['N']	[16]
17	diaphragm	O	['N']	[17]
18	and	O	['N']	[18]
19	anterior	B	['N']	[19]
20	chamber	I	['N']	[20]
21	shallowing	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	resulting	O	['N']	[23]
24	in	O	['N']	[24]
25	acute	O	['N']	[25]
26	myopia	O	['N']	[26]
27	and	O	['N']	[27]
28	angle	O	['N']	[28]
29	-	O	['N']	[29]
30	closure	O	['N']	[30]
31	glaucoma	O	['N']	[31]
32	.	O	['N']	[32]
#2033
0	The	O	['N']	[0]
1	fetal	B	['N']	[1]
2	valproate	B-Drug	['Causes']	[3]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	(	O	['N']	[4]
5	FVS	O	['N']	[5]
6	)	O	['N']	[6]
7	is	O	['N']	[7]
8	characterized	O	['N']	[8]
9	by	O	['N']	[9]
10	distinctive	O	['N']	[10]
11	facial	O	['N']	[11]
12	appearance	O	['N']	[12]
13	,	O	['N']	[13]
14	major	O	['N']	[14]
15	and	O	['N']	[15]
16	minor	O	['N']	[16]
17	malformations	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	developmental	O	['N']	[20]
21	delay	O	['N']	[21]
22	.	O	['N']	[22]
#2034
0	Though	O	['N']	[0]
1	hypotension	B-Adverse_Effect	['N']	[1]
2	,	O	['N']	[2]
3	dry	O	['N']	[3]
4	mouth	O	['N']	[4]
5	,	O	['N']	[5]
6	and	O	['N']	[6]
7	constipation	O	['N']	[7]
8	are	O	['N']	[8]
9	well	O	['N']	[9]
10	-	O	['N']	[10]
11	documented	O	['N']	[11]
12	possible	O	['N']	[12]
13	adverse	O	['N']	[13]
14	effects	O	['N']	[14]
15	,	O	['N']	[15]
16	the	O	['N']	[16]
17	possibility	O	['N']	[17]
18	of	O	['N']	[18]
19	clonidine	B-Drug	['Causes']	[1]
20	-	O	['N']	[20]
21	induced	O	['N']	[21]
22	bradycardia	O	['N']	[22]
23	is	O	['N']	[23]
24	less	O	['N']	[24]
25	well	O	['N']	[25]
26	recognized	O	['N']	[26]
27	and	O	['N']	[27]
28	is	O	['N']	[28]
29	rare	O	['N']	[29]
30	.	O	['N']	[30]
#2035
0	Aminoglutethimide	B-Drug	['Causes']	[10]
1	was	O	['N']	[1]
2	discontinued	O	['N']	[2]
3	until	O	['N']	[3]
4	completion	O	['N']	[4]
5	of	O	['N']	[5]
6	radiotherapy	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	the	O	['N']	[9]
10	rash	B-Adverse_Effect	['N']	[10]
11	resolved	O	['N']	[11]
12	.	O	['N']	[12]
#2036
0	Pulmonary	O	['N']	[0]
1	eosinophilia	O	['N']	[1]
2	or	O	['N']	[2]
3	granulomas	B-Adverse_Effect	['N']	[3]
4	,	O	['N']	[4]
5	classically	O	['N']	[5]
6	seen	O	['N']	[6]
7	in	O	['N']	[7]
8	previously	O	['N']	[8]
9	reported	O	['N']	[9]
10	cases	O	['N']	[10]
11	of	O	['N']	[11]
12	methotrexate	B-Drug	['Causes']	[3]
13	pneumonitis	O	['N']	[13]
14	,	O	['N']	[14]
15	were	O	['N']	[15]
16	not	O	['N']	[16]
17	observed	O	['N']	[17]
18	.	O	['N']	[18]
#2037
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	our	O	['N']	[4]
5	report	O	['N']	[5]
6	is	O	['N']	[6]
7	one	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	first	O	['N']	[10]
11	on	O	['N']	[11]
12	shock	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	angio	O	['N']	[14]
15	-	O	['N']	[15]
16	oedema	O	['N']	[16]
17	from	O	['N']	[17]
18	irbesartan	B-Drug	['Causes']	[12]
19	.	O	['N']	[19]
#2038
0	Unexpected	O	['N']	[0]
1	severe	O	['N']	[1]
2	reversible	O	['N']	[2]
3	cyclosporine	B	['N']	[3]
4	A	I-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	nephrotoxicity	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	systemic	O	['N']	[12]
13	lupus	O	['N']	[13]
14	erythematosus	O	['N']	[14]
15	and	O	['N']	[15]
16	tubulointerstitial	O	['N']	[16]
17	renal	O	['N']	[17]
18	disease	O	['N']	[18]
19	.	O	['N']	[19]
#2039
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	O	['N']	[9]
10	mg	O	['N']	[10]
11	sertraline	O	['N']	[11]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	O	['N']	[17]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	lamotrigine	B-Drug	['Causes']	[33]
28	blood	O	['N']	[28]
29	level	O	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	B	['N']	[31]
32	of	I	['N']	[32]
33	toxicity	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#2040
0	Cholestatic	B	['N']	[0]
1	liver	I	['N']	[1]
2	disease	I-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	ductopenia	O	['N']	[4]
5	(	O	['N']	[5]
6	vanishing	O	['N']	[6]
7	bile	O	['N']	[7]
8	duct	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	)	O	['N']	[10]
11	after	O	['N']	[11]
12	administration	O	['N']	[12]
13	of	O	['N']	[13]
14	clindamycin	O	['N']	[14]
15	and	O	['N']	[15]
16	trimethoprim	B	['N']	[16]
17	-	I	['N']	[17]
18	sulfamethoxazole	I-Drug	['Causes']	[2]
19	.	O	['N']	[19]
#2041
0	There	O	['N']	[0]
1	is	O	['N']	[1]
2	documentation	O	['N']	[2]
3	of	O	['N']	[3]
4	ocular	B	['N']	[4]
5	toxicity	I-Adverse_Effect	['N']	[5]
6	with	O	['N']	[6]
7	ethambutol	B-Drug	['Causes']	[5]
8	when	O	['N']	[8]
9	administered	O	['N']	[9]
10	at	O	['N']	[10]
11	dosages	O	['N']	[11]
12	generally	O	['N']	[12]
13	pronounced	O	['N']	[13]
14	as	O	['N']	[14]
15	being	O	['N']	[15]
16	safe	O	['N']	[16]
17	.	O	['N']	[17]
#2042
0	While	O	['N']	[0]
1	on	O	['N']	[1]
2	a	O	['N']	[2]
3	maximal	O	['N']	[3]
4	dose	O	['N']	[4]
5	of	O	['N']	[5]
6	phenylephrine	B-Drug	['Causes']	[12]
7	she	O	['N']	[7]
8	developed	O	['N']	[8]
9	prominent	O	['N']	[9]
10	positive	B	['N']	[10]
11	U	I	['N']	[11]
12	waves	I-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	which	O	['N']	[14]
15	disappeared	O	['N']	[15]
16	with	O	['N']	[16]
17	the	O	['N']	[17]
18	cessation	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	drug	O	['N']	[21]
22	.	O	['N']	[22]
#2043
0	A	O	['N']	[0]
1	retrospective	O	['N']	[1]
2	epidemiological	O	['N']	[2]
3	study	O	['N']	[3]
4	of	O	['N']	[4]
5	deaths	O	['N']	[5]
6	from	O	['N']	[6]
7	hepatic	B	['N']	[7]
8	angiosarcoma	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	HAS	O	['N']	[10]
11	)	O	['N']	[11]
12	in	O	['N']	[12]
13	the	O	['N']	[13]
14	U.S.	O	['N']	[14]
15	showed	O	['N']	[15]
16	that	O	['N']	[16]
17	during	O	['N']	[17]
18	1964	O	['N']	[18]
19	-	O	['N']	[19]
20	-74	O	['N']	[20]
21	there	O	['N']	[21]
22	were	O	['N']	[22]
23	168	O	['N']	[23]
24	such	O	['N']	[24]
25	cases	O	['N']	[25]
26	,	O	['N']	[26]
27	of	O	['N']	[27]
28	which	O	['N']	[28]
29	37	O	['N']	[29]
30	(	O	['N']	[30]
31	22	O	['N']	[31]
32	%	O	['N']	[32]
33	)	O	['N']	[33]
34	were	O	['N']	[34]
35	associated	O	['N']	[35]
36	with	O	['N']	[36]
37	previously	O	['N']	[37]
38	known	O	['N']	[38]
39	causes	O	['N']	[39]
40	(	O	['N']	[40]
41	vinyl	B	['N']	[41]
42	chloride	I-Drug	['Causes']	[8]
43	,	O	['N']	[43]
44	'	O	['N']	[44]
45	Thorotrast	O	['N']	[45]
46	'	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	inorganic	O	['N']	[49]
50	arsenic	O	['N']	[50]
51	)	O	['N']	[51]
52	and	O	['N']	[52]
53	4	O	['N']	[53]
54	(	O	['N']	[54]
55	3.1	O	['N']	[55]
56	%	O	['N']	[56]
57	)	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	remaining	O	['N']	[60]
61	131	O	['N']	[61]
62	cases	O	['N']	[62]
63	with	O	['N']	[63]
64	the	O	['N']	[64]
65	use	O	['N']	[65]
66	of	O	['N']	[66]
67	androgenic	O	['N']	[67]
68	-	O	['N']	[68]
69	anabolic	O	['N']	[69]
70	steroids	O	['N']	[70]
71	.	O	['N']	[71]
#2044
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	following	O	['N']	[2]
3	case	O	['N']	[3]
4	report	O	['N']	[4]
5	,	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	developed	O	['N']	[8]
9	acute	O	['N']	[9]
10	interstitial	O	['N']	[10]
11	nephritis	O	['N']	[11]
12	with	O	['N']	[12]
13	renal	B	['N']	[13]
14	failure	I-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	exfoliative	O	['N']	[16]
17	dermatitis	O	['N']	[17]
18	following	O	['N']	[18]
19	ampicillin	B-Drug	['Causes']	[14]
20	therapy	O	['N']	[20]
21	.	O	['N']	[21]
#2045
0	Hypernatraemia	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	sodium	B	['N']	[3]
4	polystyrene	I	['N']	[4]
5	sulphonate	I-Drug	['Causes']	[0]
6	(	O	['N']	[6]
7	Kayexalate	O	['N']	[7]
8	)	O	['N']	[8]
9	in	O	['N']	[9]
10	two	O	['N']	[10]
11	extremely	O	['N']	[11]
12	low	O	['N']	[12]
13	birth	O	['N']	[13]
14	weight	O	['N']	[14]
15	newborns	O	['N']	[15]
16	.	O	['N']	[16]
#2046
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	spontaneous	B	['N']	[6]
7	splenic	I	['N']	[7]
8	infarction	I-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	the	O	['N']	[10]
11	use	O	['N']	[11]
12	of	O	['N']	[12]
13	sumatriptan	B-Drug	['Causes']	[8]
14	for	O	['N']	[14]
15	the	O	['N']	[15]
16	treatment	O	['N']	[16]
17	of	O	['N']	[17]
18	migraine	O	['N']	[18]
19	headache	O	['N']	[19]
20	.	O	['N']	[20]
#2047
0	Dihydropyrimidine	O	['N']	[0]
1	dehydrogenase	O	['N']	[1]
2	deficiency	O	['N']	[2]
3	:	O	['N']	[3]
4	a	O	['N']	[4]
5	pharmacogenetic	O	['N']	[5]
6	defect	O	['N']	[6]
7	causing	O	['N']	[7]
8	severe	B	['N']	[8]
9	adverse	I	['N']	[9]
10	reactions	I-Adverse_Effect	['N']	[10]
11	to	O	['N']	[11]
12	5-fluorouracil	B-Drug	['Causes']	[10]
13	-	O	['N']	[13]
14	based	O	['N']	[14]
15	chemotherapy	O	['N']	[15]
16	.	O	['N']	[16]
#2048
0	A	O	['N']	[0]
1	56-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	scleroderma	O	['N']	[6]
7	developed	O	['N']	[7]
8	rapidly	O	['N']	[8]
9	progressive	O	['N']	[9]
10	glomerulonephritis	O	['N']	[10]
11	with	O	['N']	[11]
12	epithelial	O	['N']	[12]
13	crescents	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	hemoptysis	O	['N']	[16]
17	after	O	['N']	[17]
18	27	O	['N']	[18]
19	months	O	['N']	[19]
20	of	O	['N']	[20]
21	D	B	['N']	[21]
22	-	I	['N']	[22]
23	penicillamine	I-Drug	['N']	[23]
24	therapy	O	['N']	[24]
25	and	O	['N']	[25]
26	a	O	['N']	[26]
27	cumulative	O	['N']	[27]
28	dose	O	['N']	[28]
29	of	O	['N']	[29]
30	1,200	-	['N']	[30]
31	g.	-	['N']	[31]
#2049
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	young	O	['N']	[6]
7	healthy	O	['N']	[7]
8	woman	O	['N']	[8]
9	who	O	['N']	[9]
10	presented	O	['N']	[10]
11	an	O	['N']	[11]
12	early	O	['N']	[12]
13	overanticoagulation	B-Adverse_Effect	['N']	[13]
14	when	O	['N']	[14]
15	receiving	O	['N']	[15]
16	acenocoumarol	B-Drug	['Causes']	[13]
17	for	O	['N']	[17]
18	a	O	['N']	[18]
19	first	O	['N']	[19]
20	thromboembolic	O	['N']	[20]
21	episode	O	['N']	[21]
22	.	O	['N']	[22]
#2050
0	Conversely	O	['N']	[0]
1	,	O	['N']	[1]
2	diffuse	B	['N']	[2]
3	interstitial	I	['N']	[3]
4	pulmonary	I	['N']	[4]
5	fibrosis	I-Adverse_Effect	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	considered	O	['N']	[8]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	differential	O	['N']	[11]
12	diagnosis	O	['N']	[12]
13	of	O	['N']	[13]
14	patients	O	['N']	[14]
15	receiving	O	['N']	[15]
16	methotrexate	B-Drug	['Causes']	[5]
17	who	O	['N']	[17]
18	develop	O	['N']	[18]
19	bilateral	O	['N']	[19]
20	pulmonary	O	['N']	[20]
21	infiltrates	O	['N']	[21]
22	seen	O	['N']	[22]
23	on	O	['N']	[23]
24	chest	O	['N']	[24]
25	roentgenograms	O	['N']	[25]
26	.	O	['N']	[26]
#2051
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	31-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	with	O	['N']	[8]
9	obsessive	O	['N']	[9]
10	-	O	['N']	[10]
11	compulsive	O	['N']	[11]
12	disorder	O	['N']	[12]
13	developed	O	['N']	[13]
14	RBD	B-Adverse_Effect	['N']	[14]
15	soon	O	['N']	[15]
16	after	O	['N']	[16]
17	starting	O	['N']	[17]
18	fluoxetine	B-Drug	['Causes']	[14]
19	therapy	O	['N']	[19]
20	,	O	['N']	[20]
21	which	O	['N']	[21]
22	persisted	O	['N']	[22]
23	at	O	['N']	[23]
24	PSG	O	['N']	[24]
25	study	O	['N']	[25]
26	19	O	['N']	[26]
27	months	O	['N']	[27]
28	after	O	['N']	[28]
29	fluoxetine	O	['N']	[29]
30	discontinuation	O	['N']	[30]
31	.	O	['N']	[31]
#2052
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	cyclosporine	B-Drug	['Causes']	[10]
3	dependency	O	['N']	[3]
4	is	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	the	O	['N']	[7]
8	risk	O	['N']	[8]
9	of	O	['N']	[9]
10	nephrotoxicity	B-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#2053
0	Ocular	B	['N']	[0]
1	ethambutol	B-Drug	['Causes']	[2]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	.	O	['N']	[3]
#2054
0	Captopril	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pulmonary	B	['N']	[3]
4	infiltrates	I	['N']	[4]
5	with	I	['N']	[5]
6	eosinophilia	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	an	O	['N']	[8]
9	infant	O	['N']	[9]
10	with	O	['N']	[10]
11	congenital	O	['N']	[11]
12	heart	O	['N']	[12]
13	disease	O	['N']	[13]
14	.	O	['N']	[14]
#2055
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	three	O	['N']	[2]
3	cases	O	['N']	[3]
4	from	O	['N']	[4]
5	the	O	['N']	[5]
6	Provincial	O	['N']	[6]
7	Toxicology	O	['N']	[7]
8	Center	O	['N']	[8]
9	of	O	['N']	[9]
10	British	O	['N']	[10]
11	Columbia	O	['N']	[11]
12	,	O	['N']	[12]
13	Canada	O	['N']	[13]
14	in	O	['N']	[14]
15	which	O	['N']	[15]
16	suicidal	B	['N']	[16]
17	overdose	I	['N']	[17]
18	deaths	I-Adverse_Effect	['N']	[18]
19	were	O	['N']	[19]
20	associated	O	['N']	[20]
21	with	O	['N']	[21]
22	quetiapine	B-Drug	['Causes']	[18]
23	.	O	['N']	[23]
#2056
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	series	O	['N']	[2]
3	of	O	['N']	[3]
4	104	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	intentional	O	['N']	[7]
8	or	O	['N']	[8]
9	inadvertent	O	['N']	[9]
10	use	O	['N']	[10]
11	of	O	['N']	[11]
12	zidovudine	B-Drug	['Causes']	[36]
13	at	O	['N']	[13]
14	differing	O	['N']	[14]
15	gestations	O	['N']	[15]
16	in	O	['N']	[16]
17	pregnancy	O	['N']	[17]
18	,	O	['N']	[18]
19	there	O	['N']	[19]
20	were	O	['N']	[20]
21	eight	O	['N']	[21]
22	spontaneous	O	['N']	[22]
23	first	O	['N']	[23]
24	trimester	O	['N']	[24]
25	abortions	O	['N']	[25]
26	,	O	['N']	[26]
27	eight	O	['N']	[27]
28	therapeutic	O	['N']	[28]
29	terminations	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	eight	O	['N']	[32]
33	cases	O	['N']	[33]
34	of	O	['N']	[34]
35	fetal	B	['N']	[35]
36	abnormality	I-Adverse_Effect	['N']	[36]
37	occurring	O	['N']	[37]
38	among	O	['N']	[38]
39	a	O	['N']	[39]
40	total	O	['N']	[40]
41	of	O	['N']	[41]
42	88	O	['N']	[42]
43	cases	O	['N']	[43]
44	where	O	['N']	[44]
45	the	O	['N']	[45]
46	pregnancy	O	['N']	[46]
47	progressed	O	['N']	[47]
48	.	O	['N']	[48]
#2057
0	A	O	['N']	[0]
1	28	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	white	O	['N']	[4]
5	schizophrenic	O	['N']	[5]
6	male	O	['N']	[6]
7	has	O	['N']	[7]
8	been	O	['N']	[8]
9	under	O	['N']	[9]
10	risperidone	B-Drug	['Causes']	[20]
11	monotherapy	O	['N']	[11]
12	for	O	['N']	[12]
13	about	O	['N']	[13]
14	one	O	['N']	[14]
15	year	O	['N']	[15]
16	when	O	['N']	[16]
17	he	O	['N']	[17]
18	developed	O	['N']	[18]
19	dyskinetic	B	['N']	[19]
20	movements	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#2058
0	Soon	O	['N']	[0]
1	after	O	['N']	[1]
2	introduction	O	['N']	[2]
3	of	O	['N']	[3]
4	insulin	B-Drug	['Causes']	[20]
5	therapy	O	['N']	[5]
6	,	O	['N']	[6]
7	she	O	['N']	[7]
8	developed	O	['N']	[8]
9	severe	O	['N']	[9]
10	anasarca	O	['N']	[10]
11	,	O	['N']	[11]
12	including	O	['N']	[12]
13	marked	O	['N']	[13]
14	peripheral	O	['N']	[14]
15	oedema	O	['N']	[15]
16	,	O	['N']	[16]
17	ascites	O	['N']	[17]
18	and	O	['N']	[18]
19	pleural	B	['N']	[19]
20	effusion	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#2059
0	Warfarin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	bleeding	B-Adverse_Effect	['N']	[3]
4	generally	O	['N']	[4]
5	is	O	['N']	[5]
6	considered	O	['N']	[6]
7	deleterious	O	['N']	[7]
8	;	O	['N']	[8]
9	however	O	['N']	[9]
10	,	O	['N']	[10]
11	in	O	['N']	[11]
12	our	O	['N']	[12]
13	patient	O	['N']	[13]
14	it	O	['N']	[14]
15	unmasked	O	['N']	[15]
16	an	O	['N']	[16]
17	early	O	['N']	[17]
18	stage	O	['N']	[18]
19	of	O	['N']	[19]
20	colon	O	['N']	[20]
21	cancer	O	['N']	[21]
22	and	O	['N']	[22]
23	thus	O	['N']	[23]
24	may	O	['N']	[24]
25	have	O	['N']	[25]
26	saved	O	['N']	[26]
27	the	O	['N']	[27]
28	patient	O	['N']	[28]
29	's	O	['N']	[29]
30	life	O	['N']	[30]
31	.	O	['N']	[31]
#2060
0	A	O	['N']	[0]
1	sixty	O	['N']	[1]
2	-	O	['N']	[2]
3	year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	advanced	O	['N']	[8]
9	breast	O	['N']	[9]
10	cancer	O	['N']	[10]
11	,	O	['N']	[11]
12	previously	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	cisplatin	O	['N']	[15]
16	,	O	['N']	[16]
17	developed	O	['N']	[17]
18	an	O	['N']	[18]
19	irreversible	O	['N']	[19]
20	lethal	O	['N']	[20]
21	renal	O	['N']	[21]
22	failure	O	['N']	[22]
23	with	O	['N']	[23]
24	anuria	O	['N']	[24]
25	,	O	['N']	[25]
26	the	O	['N']	[26]
27	day	O	['N']	[27]
28	after	O	['N']	[28]
29	5	B	['N']	[29]
30	g	I	['N']	[30]
31	/	I	['N']	[31]
32	m2	I-Dose	['N']	[32]
33	bolus	O	['N']	[33]
34	ifosfamide	B-Drug	['Dosage']	[32]
35	.	O	['N']	[35]
#2061
0	Pneumocystis	O	['N']	[0]
1	pneumonia	O	['N']	[1]
2	should	O	['N']	[2]
3	be	O	['N']	[3]
4	considered	O	['N']	[4]
5	in	O	['N']	[5]
6	asthmatic	O	['N']	[6]
7	patients	O	['N']	[7]
8	taking	O	['N']	[8]
9	methotrexate	B-Drug	['Causes']	[19]
10	who	O	['N']	[10]
11	present	O	['N']	[11]
12	with	O	['N']	[12]
13	fever	O	['N']	[13]
14	,	O	['N']	[14]
15	pulmonary	O	['N']	[15]
16	infiltrates	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	hypoxia	B-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#2062
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	believed	O	['N']	[2]
3	that	O	['N']	[3]
4	this	O	['N']	[4]
5	is	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	reported	O	['N']	[8]
9	case	O	['N']	[9]
10	of	O	['N']	[10]
11	reversible	O	['N']	[11]
12	azathioprine	B-Drug	['Causes']	[15]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	cholestasis	B-Adverse_Effect	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	histological	O	['N']	[18]
19	evidence	O	['N']	[19]
20	of	O	['N']	[20]
21	bile	O	['N']	[21]
22	duct	O	['N']	[22]
23	injury	O	['N']	[23]
24	.	O	['N']	[24]
#2063
0	IV	O	['N']	[0]
1	propranolol	B-Drug	['Causes']	[26]
2	was	O	['N']	[2]
3	used	O	['N']	[3]
4	as	O	['N']	[4]
5	the	O	['N']	[5]
6	initial	O	['N']	[6]
7	treatment	O	['N']	[7]
8	for	O	['N']	[8]
9	his	O	['N']	[9]
10	hyperadrenergic	O	['N']	[10]
11	state	O	['N']	[11]
12	,	O	['N']	[12]
13	resulting	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	decrease	O	['N']	[16]
17	in	O	['N']	[17]
18	heart	O	['N']	[18]
19	rate	O	['N']	[19]
20	but	O	['N']	[20]
21	a	O	['N']	[21]
22	paroxsymal	B	['N']	[22]
23	increase	I	['N']	[23]
24	in	I	['N']	[24]
25	blood	I	['N']	[25]
26	pressure	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#2064
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[34]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	B-Adverse_Effect	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#2065
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	risk	O	['N']	[6]
7	of	O	['N']	[7]
8	severe	O	['N']	[8]
9	AIHA	B-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	CLL	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	history	O	['N']	[15]
16	of	O	['N']	[16]
17	AIHA	O	['N']	[17]
18	or	O	['N']	[18]
19	positivation	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	DAT	O	['N']	[22]
23	during	O	['N']	[23]
24	previous	O	['N']	[24]
25	fludarabine	B-Drug	['Causes']	[9]
26	administration	O	['N']	[26]
27	,	O	['N']	[27]
28	or	O	['N']	[28]
29	in	O	['N']	[29]
30	case	O	['N']	[30]
31	of	O	['N']	[31]
32	secondary	O	['N']	[32]
33	fixation	O	['N']	[33]
34	of	O	['N']	[34]
35	complement	O	['N']	[35]
36	to	O	['N']	[36]
37	the	O	['N']	[37]
38	red	O	['N']	[38]
39	cell	O	['N']	[39]
40	membrane	O	['N']	[40]
41	occurring	O	['N']	[41]
42	during	O	['N']	[42]
43	fludarabine	O	['N']	[43]
44	treatment	O	['N']	[44]
45	.	O	['N']	[45]
#2066
0	A	O	['N']	[0]
1	young	O	['N']	[1]
2	woman	O	['N']	[2]
3	with	O	['N']	[3]
4	epilepsy	O	['N']	[4]
5	had	O	['N']	[5]
6	tonic	B	['N']	[6]
7	-	I	['N']	[7]
8	clonic	I	['N']	[8]
9	seizures	I-Adverse_Effect	['N']	[9]
10	during	O	['N']	[10]
11	antineoplastic	O	['N']	[11]
12	therapy	O	['N']	[12]
13	with	O	['N']	[13]
14	adriamycin	B-Drug	['Causes']	[9]
15	and	O	['N']	[15]
16	cisplatin	O	['N']	[16]
17	.	O	['N']	[17]
#2067
0	STUDY	O	['N']	[0]
1	DESIGN	O	['N']	[1]
2	:	O	['N']	[2]
3	Case	O	['N']	[3]
4	reports	O	['N']	[4]
5	are	O	['N']	[5]
6	presented	O	['N']	[6]
7	of	O	['N']	[7]
8	three	O	['N']	[8]
9	premature	O	['N']	[9]
10	infants	O	['N']	[10]
11	(	O	['N']	[11]
12	mean	O	['N']	[12]
13	gestational	O	['N']	[13]
14	age	O	['N']	[14]
15	27	O	['N']	[15]
16	weeks	O	['N']	[16]
17	)	O	['N']	[17]
18	cared	O	['N']	[18]
19	for	O	['N']	[19]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	intensive	O	['N']	[22]
23	care	O	['N']	[23]
24	nursery	O	['N']	[24]
25	in	O	['N']	[25]
26	whom	O	['N']	[26]
27	clinically	O	['N']	[27]
28	significant	O	['N']	[28]
29	septal	O	['N']	[29]
30	hypertrophy	O	['N']	[30]
31	and	O	['N']	[31]
32	left	B	['N']	[32]
33	ventricular	I	['N']	[33]
34	outflow	I	['N']	[34]
35	tract	I	['N']	[35]
36	obstruction	I-Adverse_Effect	['N']	[36]
37	developed	O	['N']	[37]
38	during	O	['N']	[38]
39	dexamethasone	B-Drug	['Causes']	[36]
40	treatment	O	['N']	[40]
41	for	O	['N']	[41]
42	bronchopulmonary	O	['N']	[42]
43	dysplasia	O	['N']	[43]
44	.	O	['N']	[44]
#2068
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	O	['N']	[24]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	B-Adverse_Effect	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	O	['N']	[42]
43	-	O	['N']	[43]
44	reaction	O	['N']	[44]
45	to	O	['N']	[45]
46	promethazine	B-Drug	['Causes']	[39]
47	,	O	['N']	[47]
48	decreased	O	['N']	[48]
49	MED	O	['N']	[49]
50	to	O	['N']	[50]
51	both	O	['N']	[51]
52	UVA	O	['N']	[52]
53	and	O	['N']	[53]
54	UVB	O	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	photosensitivity	O	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#2069
0	Prolongation	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	QT	O	['N']	[3]
4	interval	O	['N']	[4]
5	and	O	['N']	[5]
6	ventricular	B	['N']	[6]
7	tachyarrhymias	I-Adverse_Effect	['N']	[7]
8	have	O	['N']	[8]
9	been	O	['N']	[9]
10	described	O	['N']	[10]
11	in	O	['N']	[11]
12	patients	O	['N']	[12]
13	on	O	['N']	[13]
14	amiodarone	B-Drug	['Causes']	[7]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#2070
0	Although	O	['N']	[0]
1	praziquantel	B-Drug	['Causes']	[23]
2	administration	O	['N']	[2]
3	may	O	['N']	[3]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	effective	O	['N']	[6]
7	in	O	['N']	[7]
8	killing	O	['N']	[8]
9	the	O	['N']	[9]
10	parasite	O	['N']	[10]
11	in	O	['N']	[11]
12	both	O	['N']	[12]
13	patients	O	['N']	[13]
14	,	O	['N']	[14]
15	we	O	['N']	[15]
16	are	O	['N']	[16]
17	concerned	O	['N']	[17]
18	about	O	['N']	[18]
19	the	O	['N']	[19]
20	production	O	['N']	[20]
21	of	O	['N']	[21]
22	marked	O	['N']	[22]
23	inflammation	B-Adverse_Effect	['N']	[23]
24	as	O	['N']	[24]
25	a	O	['N']	[25]
26	result	O	['N']	[26]
27	of	O	['N']	[27]
28	treatment	O	['N']	[28]
29	.	O	['N']	[29]
#2071
0	The	O	['N']	[0]
1	interval	O	['N']	[1]
2	between	O	['N']	[2]
3	initiating	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	interferon	B-Drug	['Causes']	[24]
7	alfa	O	['N']	[7]
8	and	O	['N']	[8]
9	onset	O	['N']	[9]
10	of	O	['N']	[10]
11	anterior	O	['N']	[11]
12	ischemic	O	['N']	[12]
13	optic	O	['N']	[13]
14	neuropathy	O	['N']	[14]
15	was	O	['N']	[15]
16	similar	O	['N']	[16]
17	to	O	['N']	[17]
18	that	O	['N']	[18]
19	of	O	['N']	[19]
20	interferon	O	['N']	[20]
21	-	O	['N']	[21]
22	associated	O	['N']	[22]
23	vascular	B	['N']	[23]
24	retinopathy	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#2072
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	this	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	myocardial	B	['N']	[8]
9	infarction	I-Adverse_Effect	['N']	[9]
10	due	O	['N']	[10]
11	to	O	['N']	[11]
12	coronary	O	['N']	[12]
13	spasm	O	['N']	[13]
14	,	O	['N']	[14]
15	demonstrated	O	['N']	[15]
16	by	O	['N']	[16]
17	angiography	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	L	B	['N']	[20]
21	-	I	['N']	[21]
22	thyroxine	I-Drug	['Causes']	[9]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#2073
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	osteosarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	normal	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	manifested	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	impending	O	['N']	[15]
16	renal	B	['N']	[16]
17	toxicity	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	extreme	O	['N']	[19]
20	elevation	O	['N']	[20]
21	of	O	['N']	[21]
22	aspartate	O	['N']	[22]
23	aminotrasferase	O	['N']	[23]
24	and	O	['N']	[24]
25	alanine	O	['N']	[25]
26	aminotransferase	O	['N']	[26]
27	within	O	['N']	[27]
28	2	O	['N']	[28]
29	hours	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	completion	O	['N']	[32]
33	of	O	['N']	[33]
34	a	O	['N']	[34]
35	4-hour	O	['N']	[35]
36	infusion	O	['N']	[36]
37	of	O	['N']	[37]
38	high	O	['N']	[38]
39	-	O	['N']	[39]
40	dose	O	['N']	[40]
41	methotrexate	O	['N']	[41]
42	(	O	['N']	[42]
43	MTX	B-Drug	['Causes']	[17]
44	)	O	['N']	[44]
45	(	O	['N']	[45]
46	12	O	['N']	[46]
47	g	O	['N']	[47]
48	/	O	['N']	[48]
49	m2	O	['N']	[49]
50	)	O	['N']	[50]
51	,	O	['N']	[51]
52	and	O	['N']	[52]
53	went	O	['N']	[53]
54	on	O	['N']	[54]
55	to	O	['N']	[55]
56	develop	O	['N']	[56]
57	acute	O	['N']	[57]
58	renal	O	['N']	[58]
59	failure	O	['N']	[59]
60	with	O	['N']	[60]
61	life	O	['N']	[61]
62	-	O	['N']	[62]
63	threatening	O	['N']	[63]
64	hyperkalemia	O	['N']	[64]
65	29	O	['N']	[65]
66	hours	O	['N']	[66]
67	later	O	['N']	[67]
68	.	O	['N']	[68]
#2074
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	administered	O	['N']	[2]
3	metoclopramide	B-Drug	['Causes']	[14]
4	because	O	['N']	[4]
5	of	O	['N']	[5]
6	nausea	O	['N']	[6]
7	and	O	['N']	[7]
8	,	O	['N']	[8]
9	within	O	['N']	[9]
10	2	O	['N']	[10]
11	hours	O	['N']	[11]
12	,	O	['N']	[12]
13	developed	O	['N']	[13]
14	agitation	B-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	dysarthria	O	['N']	[16]
17	,	O	['N']	[17]
18	diaphoresis	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	a	O	['N']	[21]
22	movement	O	['N']	[22]
23	disorder	O	['N']	[23]
24	.	O	['N']	[24]
#2075
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	high	B	['N']	[3]
4	-	I	['N']	[4]
5	grade	I	['N']	[5]
6	endometrial	I	['N']	[6]
7	stromal	I	['N']	[7]
8	sarcoma	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	confined	O	['N']	[10]
11	into	O	['N']	[11]
12	an	O	['N']	[12]
13	intrauterine	O	['N']	[13]
14	polypoid	O	['N']	[14]
15	growth	O	['N']	[15]
16	,	O	['N']	[16]
17	in	O	['N']	[17]
18	a	O	['N']	[18]
19	woman	O	['N']	[19]
20	with	O	['N']	[20]
21	a	O	['N']	[21]
22	history	O	['N']	[22]
23	of	O	['N']	[23]
24	breast	O	['N']	[24]
25	cancer	O	['N']	[25]
26	who	O	['N']	[26]
27	was	O	['N']	[27]
28	treated	O	['N']	[28]
29	with	O	['N']	[29]
30	adjuvant	O	['N']	[30]
31	tamoxifen	B-Drug	['Causes']	[8]
32	.	O	['N']	[32]
#2076
0	Vanishing	B	['N']	[0]
1	bile	I	['N']	[1]
2	duct	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	Stevens	O	['N']	[4]
5	-	O	['N']	[5]
6	Johnson	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	ciprofloxacin	B-Drug	['Causes']	[2]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	tacrolimus	O	['N']	[13]
14	.	O	['N']	[14]
#2077
0	Fever	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	maculopapular	O	['N']	[2]
3	rashes	O	['N']	[3]
4	appeared	O	['N']	[4]
5	at	O	['N']	[5]
6	10	O	['N']	[6]
7	days	O	['N']	[7]
8	after	O	['N']	[8]
9	phenytoin	B-Drug	['Causes']	[0]
10	initiation	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	then	O	['N']	[13]
14	the	O	['N']	[14]
15	drug	O	['N']	[15]
16	was	O	['N']	[16]
17	discontinued	O	['N']	[17]
18	.	O	['N']	[18]
#2078
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	It	O	['N']	[2]
3	is	O	['N']	[3]
4	probable	O	['N']	[4]
5	that	O	['N']	[5]
6	foscarnet	B-Drug	['Causes']	[11]
7	contributed	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	electrolyte	B	['N']	[10]
11	disorders	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	symptomatology	O	['N']	[13]
14	in	O	['N']	[14]
15	this	O	['N']	[15]
16	patient	O	['N']	[16]
17	.	O	['N']	[17]
#2079
0	With	O	['N']	[0]
1	itraconazole	B-Drug	['Causes']	[3]
2	,	O	['N']	[2]
3	hepatotoxic	B-Adverse_Effect	['N']	[3]
4	reactions	O	['N']	[4]
5	have	O	['N']	[5]
6	only	O	['N']	[6]
7	very	O	['N']	[7]
8	rarely	O	['N']	[8]
9	been	O	['N']	[9]
10	reported	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	histologic	O	['N']	[13]
14	data	O	['N']	[14]
15	are	O	['N']	[15]
16	lacking	O	['N']	[16]
17	.	O	['N']	[17]
#2080
0	Symptoms	O	['N']	[0]
1	and	O	['N']	[1]
2	signs	O	['N']	[2]
3	of	O	['N']	[3]
4	augmentation	B-Adverse_Effect	['N']	[4]
5	were	O	['N']	[5]
6	related	O	['N']	[6]
7	to	O	['N']	[7]
8	low	O	['N']	[8]
9	plasma	O	['N']	[9]
10	levodopa	B-Drug	['Causes']	[4]
11	levels	O	['N']	[11]
12	,	O	['N']	[12]
13	abating	O	['N']	[13]
14	75	O	['N']	[14]
15	minutes	O	['N']	[15]
16	after	O	['N']	[16]
17	oral	O	['N']	[17]
18	levodopa	O	['N']	[18]
19	administration	O	['N']	[19]
20	and	O	['N']	[20]
21	reappearing	O	['N']	[21]
22	after	O	['N']	[22]
23	3	O	['N']	[23]
24	hours	O	['N']	[24]
25	,	O	['N']	[25]
26	closely	O	['N']	[26]
27	mirroring	O	['N']	[27]
28	the	O	['N']	[28]
29	rapid	O	['N']	[29]
30	rise	O	['N']	[30]
31	and	O	['N']	[31]
32	fall	O	['N']	[32]
33	of	O	['N']	[33]
34	plasma	O	['N']	[34]
35	levodopa	O	['N']	[35]
36	concentration	O	['N']	[36]
37	.	O	['N']	[37]
#2081
0	Methotrexate	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	papular	B	['N']	[3]
4	eruption	I-Adverse_Effect	['N']	[4]
5	following	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	psoriasis	O	['N']	[8]
9	.	O	['N']	[9]
#2082
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Optic	O	['N']	[2]
3	neuritis	O	['N']	[3]
4	in	O	['N']	[4]
5	combination	O	['N']	[5]
6	with	O	['N']	[6]
7	other	O	['N']	[7]
8	neurological	B	['N']	[8]
9	signs	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	simulating	O	['N']	[11]
12	multiple	O	['N']	[12]
13	sclerosis	O	['N']	[13]
14	,	O	['N']	[14]
15	should	O	['N']	[15]
16	be	O	['N']	[16]
17	included	O	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	list	O	['N']	[20]
21	of	O	['N']	[21]
22	adverse	O	['N']	[22]
23	effects	O	['N']	[23]
24	of	O	['N']	[24]
25	recombinant	O	['N']	[25]
26	and	O	['N']	[26]
27	natural	O	['N']	[27]
28	interferon	B	['N']	[28]
29	alpha	I-Drug	['Causes']	[9]
30	administration	O	['N']	[30]
31	.	O	['N']	[31]
#2083
0	A	O	['N']	[0]
1	56-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	scleroderma	O	['N']	[6]
7	developed	O	['N']	[7]
8	rapidly	O	['N']	[8]
9	progressive	O	['N']	[9]
10	glomerulonephritis	O	['N']	[10]
11	with	O	['N']	[11]
12	epithelial	B	['N']	[12]
13	crescents	I-Adverse_Effect	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	hemoptysis	O	['N']	[16]
17	after	O	['N']	[17]
18	27	O	['N']	[18]
19	months	O	['N']	[19]
20	of	O	['N']	[20]
21	D	B	['N']	[21]
22	-	I	['N']	[22]
23	penicillamine	I-Drug	['Causes']	[13]
24	therapy	O	['N']	[24]
25	and	O	['N']	[25]
26	a	O	['N']	[26]
27	cumulative	O	['N']	[27]
28	dose	O	['N']	[28]
29	of	O	['N']	[29]
30	1,200	O	['N']	[30]
31	g.	O	['N']	[31]
#2084
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	carboplatin	O	['N']	[5]
6	(	O	['N']	[6]
7	CBDCA	B-Drug	['N']	[7]
8	)	O	['N']	[8]
9	hypersensitivity	O	['N']	[9]
10	after	O	['N']	[10]
11	weekly	O	['N']	[11]
12	low	O	['N']	[12]
13	-	O	['N']	[13]
14	dose	O	['N']	[14]
15	paclitaxel	O	['N']	[15]
16	(	O	['N']	[16]
17	60	-	['N']	[17]
18	mg	-	['N']	[18]
19	/	-	['N']	[19]
20	m2)/CBDCA	-	['N']	[20]
21	(	O	['N']	[21]
22	area	O	['N']	[22]
23	under	O	['N']	[23]
24	the	O	['N']	[24]
25	concentration	O	['N']	[25]
26	curve	O	['N']	[26]
27	=	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	therapy	O	['N']	[30]
31	in	O	['N']	[31]
32	patients	O	['N']	[32]
33	with	O	['N']	[33]
34	recurrent	O	['N']	[34]
35	ovarian	O	['N']	[35]
36	cancer	O	['N']	[36]
37	receiving	O	['N']	[37]
38	multiple	O	['N']	[38]
39	platinum	O	['N']	[39]
40	-	O	['N']	[40]
41	based	O	['N']	[41]
42	chemotherapy	O	['N']	[42]
43	.	O	['N']	[43]
#2085
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	ciprofloxacin	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	SJS	B-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	acute	O	['N']	[13]
14	onset	O	['N']	[14]
15	of	O	['N']	[15]
16	VBDS	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	reviewed	O	['N']	[19]
20	the	O	['N']	[20]
21	related	O	['N']	[21]
22	literature	O	['N']	[22]
23	.	O	['N']	[23]
#2086
0	Nitrofurantoin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	lung	B	['N']	[3]
4	disease	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	two	O	['N']	[6]
7	cases	O	['N']	[7]
8	demonstrating	O	['N']	[8]
9	resolution	O	['N']	[9]
10	of	O	['N']	[10]
11	apparently	O	['N']	[11]
12	irreversible	O	['N']	[12]
13	CT	O	['N']	[13]
14	abnormalities	O	['N']	[14]
15	.	O	['N']	[15]
#2087
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	unusual	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	simultaneous	O	['N']	[6]
7	transitional	B	['N']	[7]
8	cell	I	['N']	[8]
9	carcinoma	I	['N']	[9]
10	of	I	['N']	[10]
11	the	I	['N']	[11]
12	renal	I	['N']	[12]
13	pelvis	I-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	distal	O	['N']	[15]
16	ureter	O	['N']	[16]
17	without	O	['N']	[17]
18	transitional	O	['N']	[18]
19	cell	O	['N']	[19]
20	carcinoma	O	['N']	[20]
21	of	O	['N']	[21]
22	the	O	['N']	[22]
23	bladder	O	['N']	[23]
24	occurring	O	['N']	[24]
25	after	O	['N']	[25]
26	chronic	O	['N']	[26]
27	cyclophosphamide	B-Drug	['Causes']	[13]
28	therapy	O	['N']	[28]
29	for	O	['N']	[29]
30	nonHodgkin	O	['N']	[30]
31	's	O	['N']	[31]
32	lymphoma	O	['N']	[32]
33	.	O	['N']	[33]
#2088
0	This	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	sequential	O	['N']	[3]
4	symptoms	O	['N']	[4]
5	including	O	['N']	[5]
6	alternative	O	['N']	[6]
7	hemiparesis	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	dysarthria	O	['N']	[9]
10	and	O	['N']	[10]
11	altered	O	['N']	[11]
12	consciousness	O	['N']	[12]
13	5	O	['N']	[13]
14	days	O	['N']	[14]
15	after	O	['N']	[15]
16	the	O	['N']	[16]
17	second	O	['N']	[17]
18	course	O	['N']	[18]
19	of	O	['N']	[19]
20	HD	B	['N']	[20]
21	-	I	['N']	[21]
22	MTX	I-Drug	['Causes']	[7]
23	(	O	['N']	[23]
24	8	O	['N']	[24]
25	gm	O	['N']	[25]
26	/	O	['N']	[26]
27	m2	O	['N']	[27]
28	by	O	['N']	[28]
29	6	O	['N']	[29]
30	h	O	['N']	[30]
31	continuous	O	['N']	[31]
32	infusion	O	['N']	[32]
33	)	O	['N']	[33]
34	with	O	['N']	[34]
35	leucovorin	O	['N']	[35]
36	rescue	O	['N']	[36]
37	.	O	['N']	[37]
#2089
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	the	O	['N']	[3]
4	first	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	bucillamine	B-Drug	['Causes']	[12]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	giant	B	['N']	[10]
11	mammary	I	['N']	[11]
12	hyperplasia	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#2090
0	The	O	['N']	[0]
1	epivodes	O	['N']	[1]
2	of	O	['N']	[2]
3	NMS	B-Adverse_Effect	['N']	[3]
4	occured	O	['N']	[4]
5	under	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	clozapine	O	['N']	[8]
9	,	O	['N']	[9]
10	risperidone	B-Drug	['Causes']	[3]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	amisulpride	O	['N']	[13]
14	.	O	['N']	[14]
#2091
0	Epstein	B	['N']	[0]
1	-	I	['N']	[1]
2	Barr	I	['N']	[2]
3	virus	I	['N']	[3]
4	-	I	['N']	[4]
5	associated	I	['N']	[5]
6	lymphoproliferative	I	['N']	[6]
7	disorder	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	on	O	['N']	[14]
15	methotrexate	B-Drug	['Causes']	[7]
16	and	O	['N']	[16]
17	rofecoxib	O	['N']	[17]
18	:	O	['N']	[18]
19	idiosyncratic	O	['N']	[19]
20	reaction	O	['N']	[20]
21	or	O	['N']	[21]
22	pharmacogenetics	O	['N']	[22]
23	?	O	['N']	[23]
#2092
0	A	O	['N']	[0]
1	potential	O	['N']	[1]
2	role	O	['N']	[2]
3	for	O	['N']	[3]
4	renal	O	['N']	[4]
5	and	O	['N']	[5]
6	hepatic	O	['N']	[6]
7	impairment	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	observed	O	['N']	[10]
11	protracted	O	['N']	[11]
12	course	O	['N']	[12]
13	of	O	['N']	[13]
14	amiodarone	B-Drug	['Causes']	[17]
15	-	O	['N']	[15]
16	induced	O	['N']	[16]
17	thyrotoxicosis	B-Adverse_Effect	['N']	[17]
18	is	O	['N']	[18]
19	suggested	O	['N']	[19]
20	.	O	['N']	[20]
#2093
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	68-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	developed	O	['N']	[7]
8	intense	B	['N']	[8]
9	conjunctival	I	['N']	[9]
10	hyperemia	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	cystoid	O	['N']	[12]
13	macula	O	['N']	[13]
14	edema	O	['N']	[14]
15	after	O	['N']	[15]
16	switching	O	['N']	[16]
17	from	O	['N']	[17]
18	latanoprost	O	['N']	[18]
19	to	O	['N']	[19]
20	bimatoprost	B-Drug	['Causes']	[10]
21	9	O	['N']	[21]
22	months	O	['N']	[22]
23	after	O	['N']	[23]
24	cataract	O	['N']	[24]
25	surgery	O	['N']	[25]
26	in	O	['N']	[26]
27	an	O	['N']	[27]
28	eye	O	['N']	[28]
29	at	O	['N']	[29]
30	low	O	['N']	[30]
31	-	O	['N']	[31]
32	risk	O	['N']	[32]
33	for	O	['N']	[33]
34	this	O	['N']	[34]
35	cystoid	O	['N']	[35]
36	macular	O	['N']	[36]
37	edema	O	['N']	[37]
38	.	O	['N']	[38]
#2094
0	The	O	['N']	[0]
1	treatment	O	['N']	[1]
2	for	O	['N']	[2]
3	acidosis	O	['N']	[3]
4	and	O	['N']	[4]
5	hyperkalaemia	O	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	started	O	['N']	[8]
9	as	O	['N']	[9]
10	soon	O	['N']	[10]
11	as	O	['N']	[11]
12	RTA	B-Adverse_Effect	['N']	[12]
13	is	O	['N']	[13]
14	diagnosed	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	the	O	['N']	[17]
18	dosage	O	['N']	[18]
19	of	O	['N']	[19]
20	FK506	B-Drug	['Causes']	[12]
21	should	O	['N']	[21]
22	also	O	['N']	[22]
23	be	O	['N']	[23]
24	reduced	O	['N']	[24]
25	if	O	['N']	[25]
26	possible	O	['N']	[26]
27	.	O	['N']	[27]
#2095
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	development	O	['N']	[3]
4	of	O	['N']	[4]
5	scrotal	B	['N']	[5]
6	ulcer	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	acute	O	['N']	[11]
12	promyleocytic	O	['N']	[12]
13	leukemia	O	['N']	[13]
14	(	O	['N']	[14]
15	APL	O	['N']	[15]
16	)	O	['N']	[16]
17	within	O	['N']	[17]
18	10	O	['N']	[18]
19	days	O	['N']	[19]
20	of	O	['N']	[20]
21	treatment	O	['N']	[21]
22	with	O	['N']	[22]
23	ATRA	B-Drug	['Causes']	[6]
24	at	O	['N']	[24]
25	a	O	['N']	[25]
26	dose	O	['N']	[26]
27	of	O	['N']	[27]
28	40	O	['N']	[28]
29	mg	O	['N']	[29]
30	orally	O	['N']	[30]
31	twice	O	['N']	[31]
32	daily	O	['N']	[32]
33	.	O	['N']	[33]
#2096
0	He	O	['N']	[0]
1	developed	O	['N']	[1]
2	fever	O	['N']	[2]
3	,	O	['N']	[3]
4	nausea	B-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	diarrhea	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	malaise	O	['N']	[9]
10	and	O	['N']	[10]
11	stopped	O	['N']	[11]
12	taking	O	['N']	[12]
13	on	O	['N']	[13]
14	the	O	['N']	[14]
15	third	O	['N']	[15]
16	day	O	['N']	[16]
17	after	O	['N']	[17]
18	commencing	O	['N']	[18]
19	Pentasa	B-Drug	['Causes']	[4]
20	.	O	['N']	[20]
#2097
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	nonatopic	O	['N']	[6]
7	17-year	O	['N']	[7]
8	-	O	['N']	[8]
9	old	O	['N']	[9]
10	girl	O	['N']	[10]
11	with	O	['N']	[11]
12	bronchial	O	['N']	[12]
13	asthma	O	['N']	[13]
14	and	O	['N']	[14]
15	aspirin	O	['N']	[15]
16	intolerance	O	['N']	[16]
17	who	O	['N']	[17]
18	developed	O	['N']	[18]
19	a	O	['N']	[19]
20	dramatic	O	['N']	[20]
21	anaphylactic	B	['N']	[21]
22	reaction	I-Adverse_Effect	['N']	[22]
23	to	O	['N']	[23]
24	oral	O	['N']	[24]
25	prednisone	B-Drug	['Causes']	[22]
26	.	O	['N']	[26]
#2098
0	Young	O	['N']	[0]
1	children	O	['N']	[1]
2	undergoing	O	['N']	[2]
3	cisplatin	B-Drug	['Causes']	[15]
4	chemotherapy	O	['N']	[4]
5	are	O	['N']	[5]
6	known	O	['N']	[6]
7	to	O	['N']	[7]
8	be	O	['N']	[8]
9	at	O	['N']	[9]
10	risk	O	['N']	[10]
11	for	O	['N']	[11]
12	progressive	B	['N']	[12]
13	sensorineural	I	['N']	[13]
14	hearing	I	['N']	[14]
15	loss	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#2099
0	We	O	['N']	[0]
1	observed	O	['N']	[1]
2	transient	O	['N']	[2]
3	panhypogammaglobulinaemia	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	neuropsychiatric	O	['N']	[8]
9	SLE	O	['N']	[9]
10	after	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	prednisolone	B-Drug	['Causes']	[3]
14	and	O	['N']	[14]
15	cyclophosphamide	O	['N']	[15]
16	.	O	['N']	[16]
#2100
0	Prenatal	B	['N']	[0]
1	cytomegalovirus	I	['N']	[1]
2	(	I	['N']	[2]
3	CMV	I	['N']	[3]
4	)	I	['N']	[4]
5	infection	I-Adverse_Effect	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	severe	O	['N']	[8]
9	brain	O	['N']	[9]
10	damage	O	['N']	[10]
11	was	O	['N']	[11]
12	detected	O	['N']	[12]
13	in	O	['N']	[13]
14	an	O	['N']	[14]
15	infant	O	['N']	[15]
16	whose	O	['N']	[16]
17	mother	O	['N']	[17]
18	had	O	['N']	[18]
19	been	O	['N']	[19]
20	treated	O	['N']	[20]
21	with	O	['N']	[21]
22	prednisolone	B-Drug	['Causes']	[5]
23	and	O	['N']	[23]
24	azathioprine	O	['N']	[24]
25	for	O	['N']	[25]
26	systemic	O	['N']	[26]
27	lupus	O	['N']	[27]
28	erythematosus	O	['N']	[28]
29	(	O	['N']	[29]
30	SLE	O	['N']	[30]
31	)	O	['N']	[31]
32	.	O	['N']	[32]
#2101
0	Posterior	B	['N']	[0]
1	leukoencephalopathy	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	cisplatin	O	['N']	[3]
4	,	O	['N']	[4]
5	bleomycin	O	['N']	[5]
6	and	O	['N']	[6]
7	vinblastine	B-Drug	['Causes']	[1]
8	therapy	O	['N']	[8]
9	for	O	['N']	[9]
10	germ	O	['N']	[10]
11	cell	O	['N']	[11]
12	tumor	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	ovary	O	['N']	[15]
16	.	O	['N']	[16]
#2102
0	The	O	['N']	[0]
1	risk	O	['N']	[1]
2	of	O	['N']	[2]
3	developing	O	['N']	[3]
4	sAML	B-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	estimated	O	['N']	[6]
7	to	O	['N']	[7]
8	be	O	['N']	[8]
9	between	O	['N']	[9]
10	1	O	['N']	[10]
11	%	O	['N']	[11]
12	and	O	['N']	[12]
13	5	O	['N']	[13]
14	%	O	['N']	[14]
15	,	O	['N']	[15]
16	2	O	['N']	[16]
17	-	O	['N']	[17]
18	20	O	['N']	[18]
19	years	O	['N']	[19]
20	after	O	['N']	[20]
21	exposure	O	['N']	[21]
22	to	O	['N']	[22]
23	etoposide	B-Drug	['Causes']	[4]
24	but	O	['N']	[24]
25	may	O	['N']	[25]
26	also	O	['N']	[26]
27	be	O	['N']	[27]
28	related	O	['N']	[28]
29	to	O	['N']	[29]
30	cumulative	O	['N']	[30]
31	drug	O	['N']	[31]
32	doses	O	['N']	[32]
33	,	O	['N']	[33]
34	treatment	O	['N']	[34]
35	schedules	O	['N']	[35]
36	,	O	['N']	[36]
37	host	O	['N']	[37]
38	factors	O	['N']	[38]
39	and	O	['N']	[39]
40	co	O	['N']	[40]
41	-	O	['N']	[41]
42	administration	O	['N']	[42]
43	of	O	['N']	[43]
44	other	O	['N']	[44]
45	antineoplastic	O	['N']	[45]
46	agents	O	['N']	[46]
47	.	O	['N']	[47]
#2103
0	Metformin	O	['N']	[0]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	lactic	B	['N']	[3]
4	acidosis	I-Adverse_Effect	['N']	[4]
5	(	O	['N']	[5]
6	MALA	O	['N']	[6]
7	)	O	['N']	[7]
8	is	O	['N']	[8]
9	a	O	['N']	[9]
10	serious	O	['N']	[10]
11	metabolic	O	['N']	[11]
12	complication	O	['N']	[12]
13	that	O	['N']	[13]
14	occurs	O	['N']	[14]
15	because	O	['N']	[15]
16	of	O	['N']	[16]
17	metformin	B-Drug	['Causes']	[4]
18	accumulation	O	['N']	[18]
19	in	O	['N']	[19]
20	patients	O	['N']	[20]
21	who	O	['N']	[21]
22	become	O	['N']	[22]
23	dehydrated	O	['N']	[23]
24	or	O	['N']	[24]
25	developed	O	['N']	[25]
26	acute	O	['N']	[26]
27	renal	O	['N']	[27]
28	failure	O	['N']	[28]
29	.	O	['N']	[29]
#2104
0	Recovery	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	tubular	B	['N']	[3]
4	dysfunction	I-Adverse_Effect	['N']	[4]
5	took	O	['N']	[5]
6	15	O	['N']	[6]
7	days	O	['N']	[7]
8	following	O	['N']	[8]
9	cessation	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	offending	O	['N']	[12]
13	drug	O	['N']	[13]
14	,	O	['N']	[14]
15	Amikacin	B-Drug	['Causes']	[4]
16	.	O	['N']	[16]
#2105
0	Five	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	fourth	O	['N']	[4]
5	dose	O	['N']	[5]
6	of	O	['N']	[6]
7	vincristine	B-Drug	['Causes']	[13]
8	,	O	['N']	[8]
9	she	O	['N']	[9]
10	presented	O	['N']	[10]
11	with	O	['N']	[11]
12	bilateral	B	['N']	[12]
13	ptosis	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#2106
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	normotensive	O	['N']	[3]
4	scleroderma	O	['N']	[4]
5	renal	O	['N']	[5]
6	crisis	O	['N']	[6]
7	after	O	['N']	[7]
8	high	B-Dose	['N']	[8]
9	-	O	['N']	[9]
10	dose	O	['N']	[10]
11	methylprednisolone	B-Drug	['Dosage']	[8]
12	treatment	O	['N']	[12]
13	.	O	['N']	[13]
#2107
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	paradoxical	B-Drug	['Causes']	[14]
7	,	O	['N']	[7]
8	intravenous	O	['N']	[8]
9	valproic	O	['N']	[9]
10	acid	O	['N']	[10]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	seizure	B	['N']	[13]
14	exacerbation	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	child	O	['N']	[17]
18	with	O	['N']	[18]
19	juvenile	O	['N']	[19]
20	absence	O	['N']	[20]
21	epilepsy	O	['N']	[21]
22	,	O	['N']	[22]
23	documented	O	['N']	[23]
24	by	O	['N']	[24]
25	video	O	['N']	[25]
26	-	O	['N']	[26]
27	electroencephalography	O	['N']	[27]
28	.	O	['N']	[28]
#2108
0	Following	O	['N']	[0]
1	7	O	['N']	[1]
2	days	O	['N']	[2]
3	of	O	['N']	[3]
4	tigecycline	B-Drug	['Causes']	[13]
5	she	O	['N']	[5]
6	developed	O	['N']	[6]
7	severe	O	['N']	[7]
8	abdominal	O	['N']	[8]
9	pain	O	['N']	[9]
10	and	O	['N']	[10]
11	elevated	B	['N']	[11]
12	pancreatic	I	['N']	[12]
13	enzymes	I-Adverse_Effect	['N']	[13]
14	suggesting	O	['N']	[14]
15	acute	O	['N']	[15]
16	pancreatitis	O	['N']	[16]
17	.	O	['N']	[17]
#2109
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	71-year	O	['N']	[3]
4	male	O	['N']	[4]
5	with	O	['N']	[5]
6	castration	O	['N']	[6]
7	-	O	['N']	[7]
8	resistant	O	['N']	[8]
9	metastatic	O	['N']	[9]
10	prostate	O	['N']	[10]
11	cancer	O	['N']	[11]
12	who	O	['N']	[12]
13	was	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	weekly	O	['N']	[16]
17	docetaxel	B-Drug	['Causes']	[27]
18	for	O	['N']	[18]
19	12	O	['N']	[19]
20	weeks	O	['N']	[20]
21	and	O	['N']	[21]
22	developed	O	['N']	[22]
23	significant	O	['N']	[23]
24	eye	B	['N']	[24]
25	irritation	I	['N']	[25]
26	and	I	['N']	[26]
27	dryness	I-Adverse_Effect	['N']	[27]
28	during	O	['N']	[28]
29	treatment	O	['N']	[29]
30	.	O	['N']	[30]
#2110
0	Thus	O	['N']	[0]
1	,	O	['N']	[1]
2	tardive	B	['N']	[2]
3	seizures	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	our	O	['N']	[5]
6	cases	O	['N']	[6]
7	are	O	['N']	[7]
8	thought	O	['N']	[8]
9	to	O	['N']	[9]
10	be	O	['N']	[10]
11	related	O	['N']	[11]
12	to	O	['N']	[12]
13	piperacillin	B-Drug	['Causes']	[3]
14	and	O	['N']	[14]
15	cefotiam	O	['N']	[15]
16	.	O	['N']	[16]
#2111
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	55-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	became	O	['N']	[7]
8	stuporous	B-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	overdose	O	['N']	[10]
11	with	O	['N']	[11]
12	lamotrigine	O	['N']	[12]
13	(	O	['N']	[13]
14	LTG	O	['N']	[14]
15	)	O	['N']	[15]
16	and	O	['N']	[16]
17	valproic	O	['N']	[17]
18	acid	O	['N']	[18]
19	(	O	['N']	[19]
20	VPA	B-Drug	['Causes']	[8]
21	)	O	['N']	[21]
22	tablets	O	['N']	[22]
23	.	O	['N']	[23]
#2112
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	risk	O	['N']	[3]
4	of	O	['N']	[4]
5	drug	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	rhabdomyolysis	B-Adverse_Effect	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	the	O	['N']	[11]
12	potential	O	['N']	[12]
13	interaction	O	['N']	[13]
14	between	O	['N']	[14]
15	lovastatin	O	['N']	[15]
16	and	O	['N']	[16]
17	azithromycin	B-Drug	['Causes']	[8]
18	or	O	['N']	[18]
19	clarithromycin	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	considered	O	['N']	[22]
23	before	O	['N']	[23]
24	the	O	['N']	[24]
25	concomitant	O	['N']	[25]
26	use	O	['N']	[26]
27	of	O	['N']	[27]
28	these	O	['N']	[28]
29	agents	O	['N']	[29]
30	.	O	['N']	[30]
#2113
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	third	O	['N']	[2]
3	child	O	['N']	[3]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	tics	B-Adverse_Effect	['N']	[6]
7	ceased	O	['N']	[7]
8	after	O	['N']	[8]
9	CBZ	B-Drug	['Causes']	[6]
10	discontinuation	O	['N']	[10]
11	.	O	['N']	[11]
#2114
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	occurrence	O	['N']	[5]
6	of	O	['N']	[6]
7	anterior	B	['N']	[7]
8	ischemic	I	['N']	[8]
9	optic	I	['N']	[9]
10	neuropathy	I-Adverse_Effect	['N']	[10]
11	as	O	['N']	[11]
12	a	O	['N']	[12]
13	complication	O	['N']	[13]
14	of	O	['N']	[14]
15	treatment	O	['N']	[15]
16	with	O	['N']	[16]
17	interferon	B	['N']	[17]
18	alfa	I-Drug	['Causes']	[10]
19	and	O	['N']	[19]
20	to	O	['N']	[20]
21	consider	O	['N']	[21]
22	the	O	['N']	[22]
23	possible	O	['N']	[23]
24	underlying	O	['N']	[24]
25	mechanisms	O	['N']	[25]
26	for	O	['N']	[26]
27	this	O	['N']	[27]
28	association	O	['N']	[28]
29	.	O	['N']	[29]
#2115
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	for	O	['N']	[2]
3	diabetic	O	['N']	[3]
4	coma	O	['N']	[4]
5	with	O	['N']	[5]
6	insulin	B-Drug	['Causes']	[24]
7	(	O	['N']	[7]
8	containing	O	['N']	[8]
9	the	O	['N']	[9]
10	preservative	O	['N']	[10]
11	cresol	O	['N']	[11]
12	)	O	['N']	[12]
13	and	O	['N']	[13]
14	electrolyte	O	['N']	[14]
15	solutions	O	['N']	[15]
16	was	O	['N']	[16]
17	started	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	complained	O	['N']	[21]
22	of	O	['N']	[22]
23	increasing	B	['N']	[23]
24	myalgia	I-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	developed	O	['N']	[26]
27	a	O	['N']	[27]
28	high	O	['N']	[28]
29	fever	O	['N']	[29]
30	and	O	['N']	[30]
31	respiratory	O	['N']	[31]
32	and	O	['N']	[32]
33	metabolic	O	['N']	[33]
34	acidosis	O	['N']	[34]
35	and	O	['N']	[35]
36	lost	O	['N']	[36]
37	consciousness	O	['N']	[37]
38	.	O	['N']	[38]
#2116
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	receiving	O	['N']	[2]
3	vancomycin	B-Drug	['Causes']	[40]
4	for	O	['N']	[4]
5	a	O	['N']	[5]
6	serious	O	['N']	[6]
7	staphylococcal	O	['N']	[7]
8	infection	O	['N']	[8]
9	had	O	['N']	[9]
10	a	O	['N']	[10]
11	lupus	O	['N']	[11]
12	-	O	['N']	[12]
13	like	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	characterized	O	['N']	[15]
16	by	O	['N']	[16]
17	a	O	['N']	[17]
18	malar	O	['N']	[18]
19	rash	O	['N']	[19]
20	,	O	['N']	[20]
21	pain	O	['N']	[21]
22	and	O	['N']	[22]
23	erythema	O	['N']	[23]
24	of	O	['N']	[24]
25	the	O	['N']	[25]
26	cartilage	O	['N']	[26]
27	of	O	['N']	[27]
28	both	O	['N']	[28]
29	ears	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	tender	O	['N']	[32]
33	erythematous	O	['N']	[33]
34	and	O	['N']	[34]
35	hemorrhagic	B	['N']	[35]
36	lesions	I	['N']	[36]
37	of	I	['N']	[37]
38	the	I	['N']	[38]
39	finger	I	['N']	[39]
40	tips	I-Adverse_Effect	['N']	[40]
41	.	O	['N']	[41]
#2117
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	recurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	urticaria	O	['N']	[5]
6	and	O	['N']	[6]
7	angioedema	B-Adverse_Effect	['N']	[7]
8	a	O	['N']	[8]
9	year	O	['N']	[9]
10	and	O	['N']	[10]
11	a	O	['N']	[11]
12	half	O	['N']	[12]
13	later	O	['N']	[13]
14	,	O	['N']	[14]
15	at	O	['N']	[15]
16	which	O	['N']	[16]
17	point	O	['N']	[17]
18	the	O	['N']	[18]
19	NPH	B-Drug	['Causes']	[7]
20	was	O	['N']	[20]
21	stopped	O	['N']	[21]
22	and	O	['N']	[22]
23	she	O	['N']	[23]
24	was	O	['N']	[24]
25	desensitized	O	['N']	[25]
26	to	O	['N']	[26]
27	regular	O	['N']	[27]
28	insulin	O	['N']	[28]
29	.	O	['N']	[29]
#2118
0	Hydroxyurea	O	['N']	[0]
1	(	O	['N']	[1]
2	HU	O	['N']	[2]
3	)	O	['N']	[3]
4	and	O	['N']	[4]
5	sodium	B	['N']	[5]
6	phenylbutyrate	I-Drug	['Causes']	[16]
7	(	O	['N']	[7]
8	SPB	O	['N']	[8]
9	)	O	['N']	[9]
10	have	O	['N']	[10]
11	been	O	['N']	[11]
12	shown	O	['N']	[12]
13	to	O	['N']	[13]
14	increase	B	['N']	[14]
15	fetal	I	['N']	[15]
16	hemoglobin	I-Adverse_Effect	['N']	[16]
17	(	O	['N']	[17]
18	Hb	O	['N']	[18]
19	F	O	['N']	[19]
20	)	O	['N']	[20]
21	levels	O	['N']	[21]
22	in	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	thalassemia	O	['N']	[25]
26	intermedia	O	['N']	[26]
27	.	O	['N']	[27]
#2119
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	43-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	sore	O	['N']	[9]
10	throat	O	['N']	[10]
11	,	O	['N']	[11]
12	swelling	B	['N']	[12]
13	of	I	['N']	[13]
14	the	I	['N']	[14]
15	lips	I	['N']	[15]
16	and	I	['N']	[16]
17	oral	I	['N']	[17]
18	cavity	I-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	dysphagia	O	['N']	[20]
21	,	O	['N']	[21]
22	2	O	['N']	[22]
23	weeks	O	['N']	[23]
24	after	O	['N']	[24]
25	the	O	['N']	[25]
26	use	O	['N']	[26]
27	of	O	['N']	[27]
28	budesonide	O	['N']	[28]
29	spray	O	['N']	[29]
30	(	O	['N']	[30]
31	Budefat	B-Drug	['Causes']	[18]
32	)	O	['N']	[32]
33	for	O	['N']	[33]
34	treatment	O	['N']	[34]
35	of	O	['N']	[35]
36	bronchial	O	['N']	[36]
37	asthma	O	['N']	[37]
38	.	O	['N']	[38]
#2120
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	report	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	clarithromycin	O	['N']	[5]
6	coadministration	O	['N']	[6]
7	induces	O	['N']	[7]
8	increased	B	['N']	[8]
9	plasma	I	['N']	[9]
10	carbamazepine	B-Drug	['N']	[10]
11	concentrations	O	['N']	[11]
12	,	O	['N']	[12]
13	which	O	['N']	[13]
14	may	O	['N']	[14]
15	result	O	['N']	[15]
16	in	O	['N']	[16]
17	carbamazepine	O	['N']	[17]
18	toxicity	O	['N']	[18]
19	.	O	['N']	[19]
#2121
0	Hemolytic	B	['N']	[0]
1	uremic	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	on	O	['N']	[6]
7	cis	O	['N']	[7]
8	-	O	['N']	[8]
9	platinum	O	['N']	[9]
10	,	O	['N']	[10]
11	vinblastine	O	['N']	[11]
12	and	O	['N']	[12]
13	bleomycin	B-Drug	['Causes']	[2]
14	.	O	['N']	[14]
#2122
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	is	O	['N']	[2]
3	presented	O	['N']	[3]
4	with	O	['N']	[4]
5	typical	O	['N']	[5]
6	hyperthyroidism	O	['N']	[6]
7	,	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	a	O	['N']	[10]
11	severe	B	['N']	[11]
12	proximal	I	['N']	[12]
13	muscle	I	['N']	[13]
14	weakness	I-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	a	O	['N']	[16]
17	raised	O	['N']	[17]
18	creatine	O	['N']	[18]
19	phosphokinase	O	['N']	[19]
20	after	O	['N']	[20]
21	treatment	O	['N']	[21]
22	for	O	['N']	[22]
23	hyperthyroidism	O	['N']	[23]
24	with	O	['N']	[24]
25	propylthiouracil	B-Drug	['Causes']	[14]
26	(	O	['N']	[26]
27	100	O	['N']	[27]
28	mg	O	['N']	[28]
29	orally	O	['N']	[29]
30	,	O	['N']	[30]
31	three	O	['N']	[31]
32	times	O	['N']	[32]
33	a	O	['N']	[33]
34	day	O	['N']	[34]
35	)	O	['N']	[35]
36	.	O	['N']	[36]
#2123
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	sertraline	B-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	rhabdomyolysis	B-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	an	O	['N']	[12]
13	elderly	O	['N']	[13]
14	patient	O	['N']	[14]
15	with	O	['N']	[15]
16	dementia	O	['N']	[16]
17	and	O	['N']	[17]
18	comorbidities	O	['N']	[18]
19	.	O	['N']	[19]
#2124
0	It	O	['N']	[0]
1	was	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	ANCA	B-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	closely	O	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	pathogenesis	O	['N']	[10]
11	of	O	['N']	[11]
12	crescentic	O	['N']	[12]
13	glomerulonephritis	O	['N']	[13]
14	and	O	['N']	[14]
15	that	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	PTU	B-Drug	['Causes']	[4]
19	appeared	O	['N']	[19]
20	to	O	['N']	[20]
21	induce	O	['N']	[21]
22	ANCA	O	['N']	[22]
23	.	O	['N']	[23]
#2125
0	Isoniazid	B-Drug	['Causes']	[8]
1	and	O	['N']	[1]
2	ethambutol	O	['N']	[2]
3	as	O	['N']	[3]
4	a	O	['N']	[4]
5	cause	O	['N']	[5]
6	of	O	['N']	[6]
7	optic	B	['N']	[7]
8	neuropathy	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#2126
0	After	O	['N']	[0]
1	39	O	['N']	[1]
2	hours	O	['N']	[2]
3	on	O	['N']	[3]
4	argatroban	B-Drug	['Causes']	[12]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	infusion	O	['N']	[7]
8	was	O	['N']	[8]
9	stopped	O	['N']	[9]
10	when	O	['N']	[10]
11	minor	O	['N']	[11]
12	bleeding	B-Adverse_Effect	['N']	[12]
13	was	O	['N']	[13]
14	observed	O	['N']	[14]
15	with	O	['N']	[15]
16	a	O	['N']	[16]
17	concurrent	O	['N']	[17]
18	activated	O	['N']	[18]
19	partial	O	['N']	[19]
20	thromboplastin	O	['N']	[20]
21	time	O	['N']	[21]
22	(	O	['N']	[22]
23	aPTT	O	['N']	[23]
24	)	O	['N']	[24]
25	of	O	['N']	[25]
26	100	O	['N']	[26]
27	seconds	O	['N']	[27]
28	.	O	['N']	[28]
#2127
0	We	O	['N']	[0]
1	introduce	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	sixty	O	['N']	[6]
7	years	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	several	O	['N']	[11]
12	previous	O	['N']	[12]
13	episodes	O	['N']	[13]
14	of	O	['N']	[14]
15	rhinitis	O	['N']	[15]
16	,	O	['N']	[16]
17	conjunctivitis	O	['N']	[17]
18	and	O	['N']	[18]
19	perspiration	B-Adverse_Effect	['N']	[19]
20	immediately	O	['N']	[20]
21	after	O	['N']	[21]
22	the	O	['N']	[22]
23	administration	O	['N']	[23]
24	of	O	['N']	[24]
25	salmon	O	['N']	[25]
26	calcitonin	B-Drug	['Causes']	[19]
27	with	O	['N']	[27]
28	nasal	O	['N']	[28]
29	spray	O	['N']	[29]
30	or	O	['N']	[30]
31	intramuscular	O	['N']	[31]
32	administration	O	['N']	[32]
33	(	O	['N']	[33]
34	Calsynar	O	['N']	[34]
35	)	O	['N']	[35]
36	.	O	['N']	[36]
#2128
0	We	O	['N']	[0]
1	consider	O	['N']	[1]
2	asterixis	O	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	an	O	['N']	[5]
6	easily	O	['N']	[6]
7	overlooked	O	['N']	[7]
8	sign	O	['N']	[8]
9	of	O	['N']	[9]
10	neurotoxicity	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	may	O	['N']	[13]
14	occur	O	['N']	[14]
15	even	O	['N']	[15]
16	at	O	['N']	[16]
17	low	O	['N']	[17]
18	or	O	['N']	[18]
19	moderate	O	['N']	[19]
20	dosage	O	['N']	[20]
21	levels	O	['N']	[21]
22	,	O	['N']	[22]
23	if	O	['N']	[23]
24	certain	O	['N']	[24]
25	drugs	O	['N']	[25]
26	as	O	['N']	[26]
27	lithium	O	['N']	[27]
28	or	O	['N']	[28]
29	clozapine	O	['N']	[29]
30	are	O	['N']	[30]
31	used	O	['N']	[31]
32	in	O	['N']	[32]
33	combination	O	['N']	[33]
34	with	O	['N']	[34]
35	CBZ	B-Drug	['Causes']	[10]
36	.	O	['N']	[36]
#2129
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	11-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	boy	O	['N']	[9]
10	who	O	['N']	[10]
11	experienced	O	['N']	[11]
12	an	O	['N']	[12]
13	anaphylactic	B	['N']	[13]
14	reaction	I-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	administration	O	['N']	[16]
17	of	O	['N']	[17]
18	bacitracin	B-Drug	['Causes']	[14]
19	ointment	O	['N']	[19]
20	.	O	['N']	[20]
